

Evidence-based GUIDELINE: Premature ovarian insufficiency 2024

DRAFT FOR STAKEHOLDER REVIEW April 2024



EVIEN

Disclaimer

The European Society of Human Reproduction and Embryology (hereinafter referred to as 'ESHRE') developed the current clinical practice guideline, to provide clinical recommendations to improve the quality of healthcare delivery within the European field of human reproduction and embryology. This guideline represents the views of ESHRE, which were achieved after careful consideration of the scientific evidence available at the time of preparation. In the absence of scientific evidence on certain aspects, a consensus between the relevant ESHRE stakeholders has been obtained.

The aim of clinical practice guidelines is to aid healthcare professionals in everyday clinical decisions about appropriate and effective care of their patients.

However, adherence to these clinical practice guidelines does not guarantee a successful or specific outcome, nor does it establish a standard of care. Clinical practice guidelines do not override the healthcare professional's clinical judgment in the diagnosis and treatment of particular patients. Ultimately, healthcare professionals must make their own clinical decisions on a case-by-case basis, using their clinical judgment, knowledge, and expertise, and taking into account the condition, circumstances, and wishes of the individual patient, in consultation with that patient and/or the guardian or carer.

ESHRE makes no warranty, express or implied, regarding the clinical practice guidelines and specifically excludes any warranties of merchantability and fitness for a particular use or purpose. ESHRE shall not be liable for direct, indirect, special, incidental, or consequential damages related to the use of the information contained herein. While ESHRE makes every effort to compile accurate information and to keep it up to date, it cannot, however, guarantee the correctness, completeness, and accuracy of the guideline in every respect. In any event, these clinical practice guidelines do not necessarily represent the views of all clinicians that are a member of ESHRE.

The information provided in this document does not constitute business, medical, or other professional advice, and is subject to change.



Acknowledgements

We gratefully acknowledge the contribution of our engaged, funding, partner and collaborating organisations:

- ESHRE
- Our partner organisations which co-funded the guideline: American Society for Reproductive Medicine (ASRM), International Menopause Society (IMS), and The Australian National Health and Medical Research Council (NHMRC) through the funded Centre for Research Excellence in Women's Health in Reproductive Life (CRE WHIRL)
- Our collaborating and engaged societies and consumer groups.

branch



Table of Contents

INTRODUCTION	8
Clinical need	8
Guideline scope	8
Guideline development	8
Target users of the guideline	9
Patient population	9
Terminology Previous versions	9 10
LIST OF ALL RECOMMENDATIONS	10
PART A: INTRODUCTION TO POI	20
I. PREMATURE OVARIAN INSUFFICIENCY (POI)	20
I.1. POI Nomenclature	20
I.2. Definition of POI	20
POI versus diminished ovarian reserve	23
I.3. Prevalence of POI	23
Epidemiological data	23
latrogenic POI	25
I.4. Risk factors for POI.	25
Genetic	26
Family history and demographic factors	26
Ethnicity	26
Early life factors Reproductive factors	26 27
Body Mass Index	27
Socio-economic status	28
Smoking	28
Alcohol	28
Infectious causes	29
Coexisting medical conditions Chemical exposures	29 29
Vaccines	30
Circulating factors as POI biomarkers	30
PART B: DIAGNOSIS OF POI	32
II. SYMPTOMS, DIAGNOSIS, AND INITIAL ASSESSMENT	32
II.1. Symptoms	32
II.2. Diagnosis	34
Measurement of AMH in women with POI	35
II.3 The causes of POI	38
latrogenic POI	38
Genetic background of POI Autoimmune causes of POI	39 48
II.4 Care for women with POI after diagnosis	54
III. IMPLICATIONS FOR RELATIVES OF WOMEN WITH POI	56
Chances of relatives developing POI	56
Follow-up of relatives of women with POI	57
Guideline POI – DRAFT FOR REVIEW	4



Family planning and fertility preservation	57
PART C: SEQUELAE OF POI	60
IV. POI AND LIFE EXPECTANCY	60
	60
Bilateral oophorectomy and mortality Non-iatrogenic POI and mortality	60
Interaction of POI with other risk factors	62
Hormone therapy in POI	62
V. POI, FERTILITY, AND PREGNANCY	64
V.1. Fertility and fertility treatments	64
What is the chance of natural pregnancy with a diagnosis of POI?	64
Treatments to increase natural pregnancy rate in women with POI.	65
Oocyte donation to achieve pregnancy in women with POI.	66
V.2. Fertility preservation	68
V.3. Pregnancy	69
After idiopathic POI	69
After cancer treatment	69
For oocyte donated pregnancies	71
In women with Turner Syndrome (TS) (see also Table IV)	71
Other issues	74
Specific investigations are indicated according to the cause of POI.	76
VI. POI AND MUSCULOSKELETAL HEALTH	79
VI.1. Skeletal health	79
Bone mineral density (BMD)	80
Prevalence of low bone mass and osteoporosis	81
Fracture Risk factors for reduced BMD and fracture.	82 83
Other Bone assessment modalities	83
VI.2 Bone protection and improvement	85
Non-pharmacological approaches	85
Hormone therapy	86
Testosterone	87
Pharmacological approaches	87
VI.3. Monitoring of skeletal health	89
VI.4. Muscle health	92
VI.5.Muscle protection and improvement	94
VI.6. Monitoring of muscle health VII. POI AND CARDIOMETABOLIC HEALTH	95 97
VII.1. Impact of POI on cardiometabolic health	97
-	
Cardiovascular effects of spontaneous and surgical POI Turner Syndrome	98 99
VII.2 Hormone treatment for cardiovascular health	100
Spontaneous and surgical POI	100
Turner Syndrome	101
VII.3. Monitoring of cardiovascular risk factors	102
Spontaneous and surgical POI	102
Turner Syndrome	102
VIII. POI AND PSYCHOLOGICAL WELLBEING	104
	_



VIII.1. Impact of POI on psychological wellbeing	104
General aspects	104
Quality of Life and menopausal symptoms	105
Quality of Life and psychological wellbeing	105
Quality of Life and fertility concerns	107
VIII.2. Management options	109
Medical interventions Psychological interventions	110 111
IX. POI AND SEXUALITY	113
IX.1. Impact of POI on sexuality	113
General aspects	113
Common clinical conditions associated with sexual problems.	113
Sexual function in women with POI	114
IX.2. Management options	116
General aspects	116
Systemic Estrogens	117
Systemic Testosterone and other androgenic compounds	118
Psychosexual management	119
IX.3. Treatment of genital-urinary symptoms	121
General aspects	121
Systemic therapy	122
Local therapies	122
Physical therapy	124
Lasers and other thermal energies	124
Other local approaches	124
X. POI AND NEUROLOGICAL FUNCTION	126
X.1. Impact of POI on neurological function	126
XI. POI TREATMENT: HORMONE THERAPY	132
XI.1. Hormone therapy in POI – Principles and indications	132
Principles of HT	132
Pragmatic aspects	132
Indications for HT in POL	132
XI.2. Risks of hormone therapy	134
Risk of breast cancer	134
Risk of endometrial cancer and endometrial hyperplasia	136
Risk of stroke Risk of thromboembolic disease	137
POI patients with potential higher risks of HT linked to comorbidities.	137 138
XI.3. HT – treatment options	138
Type of preparations: Estrogens and progestogens	141
HT Regimens	141
Route of administration	144
Dose	146
XI.3.e Duration	146
XI.3. Adherence to therapy	147
XI.4.Monitoring HT	150
Mammography	150



Bone density assessment Cardiovascular health	150 150
XI.5. Testosterone Therapy	152
Indications Risks of androgen therapy Routes of administration, dose, duration, monitoring	152 153 154
XI.6. HT in women with latrogenic POI	156
Breast Cancer Gynaecological Cancers Surgical Menopause Risk reducing bilateral oophorectomy. Hematopoietic stem cell transplantation	156 156 157 157 158
XII. POI TREATMENT: NON-HORMONAL TREATMENTS, COMPLEMENTARY TREATME	NTS, AND
LIFESTYLE INTERVENTIONS	161
XII.1. Non-hormonal therapies Women with POI Pharmacologic therapies for vasomotor symptoms Non-pharmacological therapies for vasomotor symptoms Non-hormonal therapies and the effect on other symptoms or quality of life	161 161 163 165
XII.2. Complementary therapies	167
Chinese herbal medicine (CHM) Acupuncture and moxibustion. Nutrients	167 169 170
XII.3. Lifestyle management options	173
Menopause symptoms Quality of life Cardiovascular health	173 173 174
XIII. PUBERTY INDUCTION	178
When to start estrogens? What preparations, mode of delivery and doses of estrogen should be used? Effects of estrogen therapy	178 178 180
REFERENCES	183
ANNEX 1 GUIDELINE GROUP.	220
ANNEX 2 ABBREVIATIONS.	221
ANNEX 3 LIST OF RESEARCH RECOMMENDATIONS.	222
ANNEX 4 METHODOLOGY.	224
Guideline development Key Questions	224 224
Evidence search and synthesis.	224
Recommendations	225
Implications of recommendations	225
Review of the Guideline draft	226
Guideline Implementation strategy	226
Schedule for updating the guideline.	226



1 Introduction

2 Clinical need

3 This guideline provides an update of the ESHRE Guideline of the Management of women with premature 4 ovarian insufficiency, published in December 2015 (Webber et al., 2016). While regular revision and 5 updating of guidelines is part of the methodology and essential to ensure up-to-date clinical guidance, 6 the need for this update is underscored by several external key factors. Firstly, studies, such as that 7 conducted by Gameiro et al. (2019), have identified a concerning trend of low uptake of the original 8 guideline (Gameiro et al., 2019). Additionally, an audit conducted at a prominent UK teaching hospital, 9 as reported by Richardson et al. (2018), revealed inconsistent adherence to recommended investigation 10 and treatment protocols, with care variation observed across different clinical specialties (Richardson et al., 2018). These findings highlight a critical gap between guideline recommendations and their 11 12 implementation in clinical practice, which may significantly impact the quality of care and outcomes for 13 women with POI.

The current update of the 2015 guideline as well as the planned implementation and translation resources for this guideline will be imperative to support high quality and evidence-based care for women with POI.

17 Guideline scope

18 This guideline offers best practice advice on the care of women with premature/primary ovarian 19 insufficiency (POI), both primary and secondary. The first chapters of this guideline will elaborate on the 20 nomenclature and definition of POI.

21 Furthermore, this clinical guideline provides recommendations on the initial assessment and management of women with POI. The initial assessment includes diagnosis, assessment of causation, 22 23 and basic assessment. The management includes hormonal treatment. Since POI has consequences for health apart from gynaecological issues, these are also described. Consequences of POI and treatment 24 25 options are included in the following domains: fertility and contraception, musculoskeletal health, cardiovascular issues, psychosexual function, psychological function, and neurological function. Other 26 27 topics discussed are puberty induction, life expectancy, and implications for relatives of women with 28 POI.

- This guideline is limited to POI and does not apply to women with low ovarian reserve. Reference to early menopause is included where evidence is available but was not the focus of the key questions.
- While the care for women with Turner Syndrome, as a subgroup of POI, is covered, the reader is referred to other guidelines specifically addressing Tuner Syndrome for more in depth clinical guidance (Gravholt, 2024).

34 **Guideline development**

While the previous version of the guideline on the Management of women with premature ovarian insufficiency (Webber *et al.*, 2016) was developed by ESHRE only, the current version was developed by ESHRE in partnership with the Centre For Research Excellence In Women's Health In Reproductive Life (CRE-WHIRL), the American Society For Reproductive Medicine (ASRM) and the International Menopause Society (IMS). The four partners were represented in the guideline development group. An ESHRE research specialist supported the guideline development. The members of the guideline



- 41 development group, representing experts in the various topics covered in the guideline, are listed in42 Annex 1.
- 43 The guideline was developed according to the published methodology (Vermeulen *et al.*, 2020). More
- 44 details on the methodology are included in Annex 4.

45 **Target users of the guideline**

The guideline covers the care provided by health care providers who have direct contact with, and make decisions concerning the care of, women with POI. ESHRE guidelines are mainly focussed on gynaecologists. However, women with POI suffer health problems that require multi-disciplinary care and are not limited to the field of gynaecology. Therefore, this guideline is also targeted at health care providers of other disciplines (e.g. general practitioners, endocrinologists, oncologists, geneticists, paediatricians, internists). During the review phase and in development of tools for implementation, specific attention will be given to these health care providers.

- se specific attention will be given to these health care providers.
- 53 This guideline is of relevance to health care providers and women with POI globally. For the benefit of
- 54 patient education and shared decision making, a patient version of this guideline will be developed.
- 55 Translation and resource development will be led by CRE WHiRL and modelled on the example of the
- 56 international PCOS guideline (<u>https://www.monash.edu/medicine/mchri/pcos/guideline</u>).

57 **Patient population**

- 58 The current guideline focusses on women with POI, both primary and secondary. The patient population
- 59 comprises women younger than 40 years (which includes Turner Syndrome patients) and women older
- 60 than 40 years, but with disease onset before age 40. Reference to women with early menopause
- 61 (menopause occurring between the ages of 40 and 45) is included where the evidence is available but
- 62 was not a focus of the key questions or search strategy.
- In this guideline, in line with published research, the terminology and discussion focus on women. The guideline group recognises that there are individuals living with POI who are transgender or who do
- not identify with the terms used in the literature. For the purpose of this guideline, we use the term
- 66 "women with POI". The terminology, however, is not intended to isolate, exclude, or diminish any
- 67 individual's experience nor to discriminate against any group.

68 **Terminology**

- 69 Apart from the term POI, which is discussed in depth in section I.1. POI Nomenclature, several other
- terms have been variably used throughout the literature, sometimes with regional preferences. For the
- sake of clarity, the Guideline group opted for consistent use of a single term throughout the guidelineTable I).

73 Table I Terminology used in this document

Term used in this document	Definition	Other terms used in literature/other sources		
Non-iatrogenic POI	POI not caused by a medical intervention (i.e. iatrogenic POI)	Spontaneous POI, natural POI		
Natural pregnancy	Pregnancy occurring through intercourse (to differentiate from pregnancy after ART)	Spontaneous pregnancy, un- assisted pregnancy		



Usual age menopause / age at usual menopause	Menopause at age 45 to 55 years	Normal menopause, natural menopause (age at natural menopause is still used for epidemiological studies)
Hot flushes		Hot flashes
Hormone therapy	As an overarching term, including HRT and the COC	Menopausal hormone therapy
Risk reducing bilateral salpingo-oophorectomy (RRBSO)	BSO performed for reducing risk of breast/ovarian cancer (e.g. in women with a BRCA ¹ / ₂ mutation)	Prophylactic BSO
Sequential		Cyclical

Previous versions 74

- This guideline provides an update of the ESHRE Guideline of the Management of women with premature ., 2016). 75
- ovarian insufficiency, published in December 2015 (Webber et al., 2016). 76
- 77

Guideline POI – DRAFT FOR REVIEW



78 List of all recommendations

Nr	Recommendation	Evidence level	Strength ¹
	PART A: Introduction to POI		
	Key Question: What should this condition be called?		
1	The guideline group recommends that the term "premature ovarian insufficiency" is used to describe this condition in research and clinical practice.		GPP
	Key Question: How should POI be defined?		
2	Premature ovarian insufficiency is a condition defined by loss of ovarian activity before the age of 40 years. POI is characterised by amenorrhea or oligomenorrhea with elevated gonadotropins and low estradiol. In this guideline, cessation of ovarian function in women aged between 40 and less than 45 (age 40-44 years) will be termed early menopause. Even if this group is outside the scope of the current guideline, the evidence and recommendations may still be relevant to women with early menopause.	Ņ	gdg Statement
	Key Question: What is the prevalence of POI in the general population?		
3	The reported prevalence of non-iatrogenic POI varies from approximately 1% in older studies to 3,5% in recent publications Population characteristics such as ethnicity may affect the prevalence of non-iatrogenic POI.		gdg Statement
	PICO Question: What are the risk factors for POI?		
4	The guideline group recommends that in view of the long-term health consequences of POI, efforts should be made to reduce the risk of POI. Modifiable factors may include: - gynaecological surgical practice - lifestyle such as smoking cessation - modified treatment regimens for malignant and chronic diseases.		GPP
5	The guideline group recommends that women with risk factors for POI are counselled regarding the potential for prevention of POI, such as stopping smoking, and fertility preservation. PART B: Diagnosis of POI		GPP
	PICO Question: What are the symptoms of POI?		
6	The guideline group recommends that HCPs enquire about symptoms of estrogen deficiency in women presenting with oligomenorrhea or amenorrhea.		GPP
7	The guideline group recommends HCPs consider and exclude the diagnosis of POI in women aged less than 40 years who have amenorrhea/oligomenorrhea or estrogen-deficiency symptoms.		GPP
	PICO Question: What investigations should be performed for diagnosis of POI?		
8	HCPs should diagnose POI based on the presence of amenorrhea or oligomenorrhea and biochemical confirmation.	$\oplus \oplus \bigcirc \bigcirc$	STRONG
9	Although proper diagnostic accuracy in POI is lacking, the guideline group recommends the following diagnostic criteria: amenorrhea or oligomenorrhea for at least 4 months, and an elevated FSH level > 25 IU/I. FSH assessment should be repeated after > 4 weeks if there is diagnostic uncertainty.		GPP
	PICO Question: What is the role of AMH to predict/ diagnose POI?		



10	AMH testing could be considered in the diagnosis of POI where there is diagnostic uncertainty. However, it has not been shown to have benefit over existing FSH-based diagnostic testing.	€000	CONDITIONAL
11	The guideline group recommends that AMH tests are interpreted within the clinical context. Further research is required to determine diagnostic thresholds for POI.		GPP
	PICO Question: What are the known causes of non-iatrogenic POI and how should they be investigated?		
12	The guideline group recommends that HCPs should inform women with POI of the different causes of POI, the limitations of current knowledge and testing for causes of POI and that an exact cause may not be determined		GPP
13	The guideline group recommends that HCPs treating women with medical or surgical intervention that may cause POI should discuss the risk of POI as part of the consent process.		GPP
14	Chromosomal analysis and Fragile X premutation testing is recommended for all women with non-iatrogenic POI	$\oplus \oplus \bigcirc \bigcirc$	STRONG
15	Where available and after comprehensive genetic counselling, additional genetic testing (e.g. NGS) can be offered to identify other potential genes that may cause POI.	⊕⊕000	CONDITIONAL
16	The guideline group recommends that the age of a woman with POI should not be used to restrict access to genetic testing.		GPP
17	Screening for 210H-Abs should be performed in women with POI of unknown cause.	€000	STRONG
18	Screening for anti-ovarian autoantibodies should not be used to diagnose autoimmune POI.	$\odot OOO$	STRONG
19	Thyroid function should be assessed by measuring TSH at diagnosis. TSH measurement should be repeated every 5 years or when symptoms arise.	$\odot OOO$	STRONG
20	The guideline group recommends that HCPs do not perform thyroid peroxidase (TPO) antibody screening as part of testing for autoimmune causes of POI due to the high prevalence of positive TPO antibodies in the general community.		GPP
	PICO Question: How often should tests for autoantibodies be repeated?		
21	Women with POI and positive 21OH-Ab should be referred to an endocrinologist for testing of adrenal function.	€000	STRONG
22	If 21OH-Abs are negative in women with POI, there is no indication for re-testing later in life, unless signs or symptoms of adrenal insufficiency develop.	€000	STRONG
23	Women with POI with abnormal TSH levels should be referred to an endocrinologist for evaluation and treatment for thyroid hormone disorders.	⊕0000	STRONG
	Care for women with POI at diagnosis		
24	The guideline group recommends that HCPs convey the diagnosis of POI in a compassionate and sensitive manner, provide personalised evidence-based information about the condition and ensure enough time for the women to ask questions.		GPP
25	The guideline group recommends shared decision making and support for continuity of care in managing POI.		GPP
26	The guideline group recommends referral of women with POI to appropriate support groups and mental health care.		GPP
	PICO Question: What are the implications for relatives of women with POI?		
27	The guideline group recommends that relatives of women with the Fragile X premutation or other identified genetic causes of POI should be offered genetic counselling and testing.		"GPP



28	Female relatives (such as sisters or daughters) of women with non- iatrogenic POI should be counselled that they are at increased risk of developing POI themselves	⊕⊕⊖⊖	STRONG
29	The guideline group recommends that female relatives (such as sisters or daughters) of women with non-iatrogenic POI are offered support regarding their increased risk of POI		GPP
30	The guideline group recommends that female relatives (such as sisters or daughters) of women with non-iatrogenic POI should be informed of the signs and symptoms of POI and should promptly seek medical advice if this occurs.		GPP
31	The guideline group recommends that female relatives (such as sisters or daughters) of women with non-iatrogenic POI should be informed that there are no established methods for predicting or preventing POI. Some relatives may wish to consider family planning and fertility preservation options.		GPP
	PART C: Sequelae of POI		
	PICO Question: What are the consequences of POI for life expectancy?		
32	Women with POI should be informed that POI without hormone therapy is associated with reduced life expectancy, largely due to cardiovascular disease.	@@ ()()	STRONG
33	Women with POI should be offered hormone therapy at least until the usual age of menopause as primary prevention to reduce risk of overall morbidity and mortality.	€000	STRONG
34	The guideline group recommends that, in addition to hormone therapy, women with POI are advised to reduce cardiovascular risk by avoidance of smoking, healthy diet, regular exercise, and maintaining a healthy weight range		GPP
	PICO Question: What are the consequences of POI for fertility?		
35	Women with non-surgical POI should be informed that ovarian activity may occur. This is associated with a chance of natural conception.	$\oplus OOO$	STRONG
36	Women with non-surgical POI should be advised to use contraception if they wish to avoid pregnancy.	€000	STRONG
	PICO Question: What fertility interventions are effective?		
37	Women with POI should be informed that there are no interventions that have been reliably shown to increase ovarian activity and natural conception rates.	⊕⊕⊕⊖	STRONG
38	Women with POI should be informed that oocyte donation is an established option to achieve pregnancy after a diagnosis of POI	$\oplus \oplus \bigcirc \bigcirc$	STRONG
39	Women with non-iatrogenic POI considering oocyte donation from sisters should be informed that this includes shared genetic risk and carries a higher risk of ovarian stimulation cycle cancellation.	⊕⊕⊖⊖	STRONG
	PICO Question: What therapies are effective for fertility preservation and /or prevention of POI?		
40	The guideline group recommends that fertility preservation is discussed with women at risk of POI. In women with established POI, the opportunity for fertility preservation has passed.		GPP
	PICO Question: What are the obstetric risks associated with POI?		
41	Women should be reassured that natural pregnancies after idiopathic POI or most forms of chemotherapy do not show any higher obstetric or neonatal risk than in the general population.	⊕⊕⊕⊖	STRONG
42	Oocyte donation pregnancies are high risk and should be managed in an appropriate obstetric unit. Women and their partners should be encouraged to disclose the origin of their pregnancy with their obstetric team.	⊕⊕⊖⊖	STRONG



43	Pregnancies after radiation to the uterus are at high risk of obstetric complications and should be managed in an appropriate obstetric unit.	$\oplus \oplus \bigcirc \bigcirc$	STRONG
44	Pregnancies in women with Turner Syndrome are at high risk of obstetric and non-obstetric complications and should be managed in an appropriate obstetric unit with cardiologist involvement.	\$ \$ 00	STRONG
45	A cardiologist should be involved in care of pregnant women who have received anthracyclines and/or cardiac irradiation.	$\odot OOO$	STRONG
	PICO Question: How should fitness for pregnancy be assessed in women with POI?		
46	Women presenting for oocyte donation who are suspected of having POI should be fully investigated prior to oocyte donation, including thyroid and adrenal function as well as genetic testing.	$\oplus \oplus \bigcirc \bigcirc$	STRONG
47	Women previously exposed to anthracyclines, high dose cyclophosphamide or mediastinal irradiation should have an echocardiogram prior to pregnancy, and referral to a cardiologist if indicated.	⊕000	STRONG
48	Thorough cardiac screening and appropriate counselling by maternal– foetal medicine specialists and cardiologists with expertise in managing women with Turner Syndrome is recommended prior to planning a pregnancy, especially if oocyte or embryo donation is considered	@@ 00	STRONG
49	Women with POI should have their cardiometabolic and thyroid function assessed prior to pregnancy.	€000	STRONG
50	Pregnancy in some women can be of such high risk that clinicians may consider oocyte donation pregnancy to be life threatening and therefore inappropriate.	000	STRONG
	PICO Question: What are the consequences of POI for skeletal health?		
51	Women with POI and HCPs should be aware that POI is associated with abnormal bone microarchitecture and reduced bone mineral density (BMD)	⊕⊕⊖⊖	STRONG
52	It is suggested that HCPs inform women that POI may be associated with an increased risk of fracture later in life, although this has not been adequately demonstrated	⊕0000	CONDITIONAL
	PICO Question: What are the treatment options for bone protection and improvement?		
53	The guideline group recommends that HCPs advise women with POI regarding bone health.		GPP
54	The guideline group recommends that osteoporosis risk factors should be identified in women with POI.		GPP
55	The guideline group recommends that women with POI should be advised to maintain a healthy lifestyle, involving weight-bearing exercise, avoidance of smoking, and maintenance of normal body weight to optimize bone health.		GPP
56	Dietary supplementation of calcium and vitamin D may be required in women with inadequate vitamin D status and/or calcium intake and may be of value in women with low BMD.	$\oplus \oplus \bigcirc \bigcirc$	CONDITIONAL
57	Estrogen replacement is recommended to maintain bone health and prevent osteoporosis; it is plausible that it will reduce the risk of fracture.	$\oplus \oplus \bigcirc \bigcirc$	STRONG
58	A daily dose of HT containing at least 2 mg oral estradiol or 100 µg transdermal estradiol or equivalent is suggested to optimise bone density.	€000	CONDITIONAL
59	Delayed initiation and non-adherence of estrogen replacement should be avoided.	$\oplus OOO$	STRONG
60	The combined oral contraceptive pill may be appropriate for some women. A continuous or extended regimen is recommended.	€€00	CONDITIONAL



61	Other pharmacological treatments, including bisphosphonates, should only be considered with advice from an osteoporosis specialist. Particular caution applies to women desiring pregnancy.	$\oplus \oplus \bigcirc \bigcirc$	STRONG
	PICO QUESTION: How should skeletal health be monitored in women with POI?		
62	It is important to consider bone health at diagnosis of POI, and during ongoing care. Osteoporosis risk factors should be identified and addressed.	⊕ 000	STRONG
63	Where available, measurement of BMD at initial diagnosis of POI is recommended for all women.	$\oplus \oplus \bigcirc \bigcirc$	STRONG
64	In case of a diagnosis of osteoporosis or low bone mass in women with POI, BMD measurement should be repeated within 5 years. A decrease in BMD should prompt review of estrogen replacement therapy and of other potential factors. Review by a specialist in osteoporosis may be appropriate.	⊕000	STRONG
65	If BMD is normal and adequate systemic estrogen replacement is commenced, the value of repeated DXA scan within 5 years is low.	⊕000	STRONG
66	Assessment of bone turnover markers can be considered as it may be useful in monitoring response and adherence to therapy.	0000	CONDITIONAL
~7	PICO Question: what are the consequences of POI for muscle health?		
67	Women with POI and HCPs should be aware that POI is associated with lower muscle mass, strength, and performance.	$\oplus \oplus \bigcirc \bigcirc$	STRONG
68	The guideline group recommends that HCPs be aware that POI may be associated with an increased risk of sarcopenia.		GPP
	PICO Question: What are the treatment options for muscle protection		
	and improvement?		
69	The guideline group recommends that HCPs consider informing women with POI about muscle health.		GPP
70	HCPs should identify modifiable risk factors for muscle health in women with POI. Maintaining a healthy lifestyle, involving adequate nutrition, regular exercise, avoidance of smoking, and maintenance of normal body weight is likely to benefit muscle health	⊕000	STRONG
71	Dietary supplementation of calcium and vitamin D may be required in women with inadequate vitamin D status and/or calcium intake and may benefit muscle health.	$\oplus \oplus \bigcirc \bigcirc$	CONDITIONAL
72	Resistance training can be considered as it increases muscle mass, strength and performance in other populations and is likely to be of benefit in POL	⊕0000	CONDITIONAL
73	The effect of HT on muscle parameters in women with POI is uncertain but treatment may be of benefit and can be offered.	$\odot OOO$	CONDITIONAL
74	The effect of other therapies, including testosterone, on muscle health in women with POI is uncertain and they should not be offered.	⊕000	STRONG
	PICO Question: how should muscle health be monitored in women with POI?		
75	The guideline group recommends that HCPs consider assessment for		CPD
	sarcopenia at POI diagnosis.		GPP
	PICO Question: What are the consequences of POI for the cardiovascular system?		
76	HCPs should be aware that women with POI are at increased risk of cardiovascular disease, including coronary artery disease, heart failure and stroke.	⊕⊕⊖⊖	STRONG
77	The guideline group recommends that women with POI should be advised of cardiovascular risk factors that they can modify through behavioural change (e.g. by avoidance of smoking, heart healthy diet, regular exercise, and maintenance of normal body weight).		GPP



78	All women diagnosed with Turner Syndrome should be evaluated by a cardiologist with expertise in congenital heart disease, especially prior to and during pregnancy.	⊕⊕⊖⊖	STRONG
	PICO Question: Is estrogen replacement cardio-protective?		
79	Despite a lack of data from randomised controlled trials, hormone therapy with early initiation is recommended in women with POI to control future risk of cardiovascular disease. HT should be continued at least until the usual age of menopause.	⊕⊕⊖⊖	STRONG
	PICO Question: Should cardiovascular risk factors be monitored?		
80	The guideline group recommends that cardiovascular risk should be assessed in women diagnosed with POI.		GPP
81	The guideline group recommends that all women with POI should have annual monitoring of blood pressure, weight and smoking status, and where available blood tests for lipid profile and diabetes screening. Other tests for assessing cardiovascular risk can be performed upon indication.		GPP
	PICO Question: What are the consequences of POI on psychological wellbeing and quality of life?		
82	HCPs should be aware that a diagnosis of POI can have a significant impact on psychological wellbeing and quality of life	€0000	STRONG
83	The guideline group recommends offering assessment of psychological health and quality of life to all women with POI.		GPP
	PICO Question: What are the management options for reduced quality of life associated with POI?		
84	Personalised care, including psychological support, should be accessible to women with POI	0000	STRONG
	PICO Question: What are the consequences of POI for sexuality?		
85	HCPs should be aware that a diagnosis of POI can have a significant	⊕⊕⊖⊖	STRONG
86	impact on sexual wellbeing and function The guideline group recommends that HCPs routinely enquire about		311/01/0
00	sexual wellbeing and sexual function in women with POI.		GPP
	PICO Question: What are the management options for the effects of POI on sexuality?		
87	The guideline group recommends personalised management using the biopsychosocial model for the effects of POI on sexuality .		GPP
88	Where available, transdermal testosterone therapy at physiological premenopausal levels can be considered as it may improve HSDD and sexual function.	⊕⊕⊖⊖	CONDITIONAL
89	HCPs should be aware that although short term treatment with transdermal testosterone at physiological premenopausal levels is safe, longer term safety data are lacking	⊕⊕⊖⊖	STRONG
90	HCPs should be aware that HT prescribed to women with POI for other indications may improve sexual function, although the effect is generally small.	000	STRONG
	PICO Question: What treatments are available for genital-urinary symptoms in POI?		
91	HCPs should offer local estrogen therapy (LET) to improve genital, sexual and urinary GSM symptoms.	€000	STRONG
92	Women with POI may be offered local estrogen therapy (LET) if GSM is not fully relieved by using systemic HT.	\odot	CONDITIONAL
93	Vaginal lubricants and moisturizers can be used for treatment of vaginal discomfort and dyspareunia in women with POI and can be combined with other treatments.	€000	CONDITIONAL
94	The guideline group recommends that laser or thermal energy is not currently considered standard care for GSM due to the lack of clear benefit in RCTs		GPP



 PICO Question: What are the consequences of POI on cognition/neurological function? 95 HCPs should be aware that earlier age of menopause is associated with an increased risk of dementia. 96 The guideline group recommends that HCPs implement appropriate preventive actions for the consequences of POI on neurological function 97 The possible detrimental effect on cognition and the increased risk of dementia, parkinsonism, and other neurologic diseases should be discussed when planning a bilateral oophorectomy under the age of 45 years, especially for women at average risk of ovarian cancer. PICO Question: What are the management options for the effect of POI on cognition/neurological function? 98 Hormone replacement therapy to reduce the possible risk of cognitive impairment and the risk of dementia, parkinsonism and other neurologic diseases is recommended in women with POI at least until the usual age of menopause. 99 Hormone replacement therapy may be recommended for neurological function even in the absence of menopausal symptoms, as HRT is for cardiovascular and bone health. 100 The guideline group recommends that women with POI should be advised to maintain a healthy lifestyle, involving exercise, healthy diet avoidance of smoking, and maintenance of normal body weight to reduce possible risks for cognitive impairment. Hormone therapy in POI – Principles and indications 101 Women with POI should be advised that hormone therapy is recommended for the preservation of bone, cardiovascular and brain health. 102 Women with POI should be advised that hormone therapy is recommended for the treatment of symptoms due to low estrogen. 103 HT should be continued until at least the usual age of menopause ⊕ ⊕ ◯ STROM for the start of the treatment of symptoms due to low estrogen. 104 It is suggested that women with POI be informed that hormone therapy does not appear to increase the risk of hormone thera	IG
95 HCPs should be aware that earlier age of menopause is associated with an increased risk of dementia. 96 The guideline group recommends that HCPs implement appropriate preventive actions for the consequences of POI on neurological function GPP 97 The possible detrimental effect on cognition and the increased risk of dementia, parkinsonism, and other neurologic diseases should be discussed when planning a bilateral oophorectomy under the age of 45 years, especially for women at average risk of ovarian cancer. <i>Φ Φ Φ Φ Φ Φ Φ</i> 98 Hormone replacement therapy to reduce the possible risk of cognitive impairment and the risk of dementia, parkinsonism and other neurologic diseases is recommended in women with POI at least until the usual age of menopause. <i>Φ Φ Φ Φ Φ Φ</i> 99 Hormone replacement therapy may be recommended for neurological function? <i>Φ Φ Φ Φ Φ Φ</i> 99 Hormone replacement therapy may be recommended for neurological function even in the absence of menopausal symptoms, as HRT is for cardiovascular and bone health. <i>Φ Φ Φ Φ Φ Φ Φ Φ Φ Φ Φ Φ</i> 100 The guideline group recommends that women with POI should be advised to maintain a healthy lifestyle, involving exercise, healthy diet, avoidance of smoking, and maintenance of normal body weight to reduce possible risks for cognitive impairment.	IG
 an increased risk of dementia. an increased risk of demential effect on cognition and the increased risk of dementia, parkinsonism, and other neurologic diseases should be discussed when planning a bilateral oophorectomy under the age of 45 years, especially for women at average risk of ovarian cancer. PICO Question: What are the management options for the effect of POI on cognition/neurological function? 98 Hormone replacement therapy to reduce the possible risk of cognitive impairment and the risk of dementia, parkinsonism and other neurologic diseases is recommended in women with POI at least until the usual age of menopause. 99 Hormone replacement therapy may be recommended for neurological function even in the absence of menopausal symptoms, as HRT is for cardiovascular and bone health. 100 The guideline group recommends that women with POI should be advised to maintain a healthy lifestyle, involving exercise, healthy diet avoidance of smoking, and maintenance of normal body weight to reduce possible risks for cognitive impairment. Hormone therapy in POI – Principles and indications 101 Women with POI should be advised that hormone therapy is recommended for the treatment of symptoms due to low estrogen. 102 Women with POI should be advised that hormone therapy is PICO Question: What are the risks of hormone therapy? 104 It is suggested that women with POI in the same age group. 105 Women with POI should be informed that hormone therapy is generally 106 Women with POI should be informed that hormone therapy is generally 107 Women with POI should be informed that hormone therapy is generally 108 Women with POI should be informed that hormone therapy 109 Women with POI should be informed that hormone therapy 	IG
 preventive actions for the consequences of POI on neurological function 97 The possible detrimental effect on cognition and the increased risk of dementia, parkinsonism, and other neurologic diseases should be discussed when planning a bilateral oophorectomy under the age of 45 years, especially for women at average risk of ovarian cancer. PICO Question: What are the management options for the effect of POI on cognition/neurological function? 98 Hormone replacement therapy to reduce the possible risk of cognitive impairment and the risk of dementia, parkinsonism and other neurologic diseases is recommended in women with POI at least until the usual age of menopause. 99 Hormone replacement therapy may be recommended for neurological function even in the absence of menopausal symptoms, as HRT is for cardiovascular and bone health. 100 The guideline group recommends that women with POI should be advised to maintain a healthy lifestyle, involving exercise, healthy diet, avoidance of smoking, and maintenance of normal body weight to reduce possible risks for cognitive impairment. Hormone therapy in POI – Principles and indications 101 Women with POI should be advised that hormone therapy is recommended for the preservation of bone, cardiovascular and brain health. 102 Women with POI should be advised that hormone therapy is recommended for the treatment of symptoms due to low estrogen. 103 HT should be continued until at least the usual age of menopause. 99 PICO Question: What are the risks of hormone therapy? 104 It is suggested that women with POI be informed that hormone therapy does not appear to increase the risk of hormone therapy is generally does not appear to increase the risk of hormone therapy is generally does not appear to increase the risk of hormone therapy is generally does not appear to increase the risk of hormone therapy is generally does not appear to increase the risk of hormone therapy i	IG
 preventive actions for the consequences of POI on neurological function 97 The possible detrimental effect on cognition and the increased risk of dementia, parkinsonism, and other neurologic diseases should be discussed when planning a bilateral oophorectomy under the age of 45 years, especially for women at average risk of ovarian cancer. PICO Question: What are the management options for the effect of POI on cognition/neurological function? 98 Hormone replacement therapy to reduce the possible risk of cognitive impairment and the risk of dementia, parkinsonism and other neurologic diseases is recommended in women with POI at least until the usual age of menopause. 99 Hormone replacement therapy may be recommended for neurological function even in the absence of menopausal symptoms, as HRT is for cardiovascular and bone health. 100 The guideline group recommends that women with POI should be advised to maintain a healthy lifestyle, involving exercise, healthy diet avoidance of smoking, and maintenance of normal body weight to reduce possible risks for cognitive impairment. Hormone therapy in POI – Principles and indications 101 Women with POI should be advised that hormone therapy is recommended for the preservation of bone, cardiovascular and brain mealth. 102 Women with POI should be advised that hormone therapy is recommended for the treatment of symptoms due to low estrogen. 103 HT should be continued until at least the usual age of menopause. 94 CO Question: What are the risks of hormone therapy? 104 It is suggested that women with POI be informed that hormone therapy does not appear to increase the risk of preast cancer before the usual age of menopause. 95 CO Question: What are the risks of hormone therapy is generally does not appear to increase the risk of preast cancer before the usual age of menopause. 96 CO Question: What are the risks of hormone therapy is generally does n	IG
 dementia, parkinsonism, and other neurologic diseases should be discussed when planning a bilateral oophorectomy under the age of 45 years, especially for women at average risk of ovarian cancer. PICO Question: What are the management options for the effect of POI on cognition/neurological function? 98 Hormone replacement therapy to reduce the possible risk of cognitive impairment and the risk of dementia, parkinsonism and other neurologic diseases is recommended in women with POI at least until the usual age of menopause. 99 Hormone replacement therapy may be recommended for neurological function even in the absence of menopausal symptoms, as HRT is for cardiovascular and bone health. 100 The guideline group recommends that women with POI should be advised to maintain a healthy lifestyle, involving exercise, healthy diet, avoidance of smoking, and maintenance of normal body weight to reduce possible risks for cognitive impairment. Hormone therapy in POI – Principles and indications 101 Women with POI should be advised that hormone therapy is recommended for the preservation of bone, cardiovascular and brain health. 102 Women with POI should be advised that hormone therapy is recommended for the treatment of symptoms due to low estrogen. 103 HT should be continued until at least the usual age of menopause PICO Question: What are the risks of hormone therapy? 104 It is suggested that women with POI be informed that hormone therapy does not appear to increase the risk of hormone therapy is generally does not appear to increase the risk of hormone therapy is generally PICO Question: What are the risk of hormone therapy is generally PICO Question: What are the risk of hormone therapy is generally PICO Question: What are the risk of hormone therapy is generally PICO Question: What are the risk of hormone therapy is generally PICO Question: What are the risk of hormone thera	IG
 discussed when planning a bilateral oophorectomy under the age of 45 years, especially for women at average risk of ovarian cancer. PICO Question: What are the management options for the effect of POI on cognition/neurological function? 98 Hormone replacement therapy to reduce the possible risk of cognitive impairment and the risk of dementia, parkinsonism and other neurologic diseases is recommended in women with POI at least until the usual age of menopause. 99 Hormone replacement therapy may be recommended for neurological function even in the absence of menopausal symptoms, as HRT is for cardiovascular and bone health. 100 The guideline group recommends that women with POI should be advised to maintain a healthy lifestyle, involving exercise, healthy diet, avoidance of smoking, and maintenance of normal body weight to reduce possible risks for cognitive impairment. Hormone therapy in POI – Principles and indications 101 Women with POI should be advised that hormone therapy is recommended for the preservation of bone, cardiovascular and brain health. 102 Women with POI should be advised that hormone therapy is recommended for the treatment of symptoms due to low estrogen. 103 HT should be continued until at least the usual age of menopause PICO Question: What are the risks of hormone therapy? 104 It is suggested that women with POI be informed that hormone therapy does not appear to increase the risk of breast cancer before the usual age of menopause group. 105 Women with POI should be informed that hormone therapy is generally \$\$\P\$(\$	IG
 years, especially for women at average risk of ovarian cancer. PICO Question: What are the management options for the effect of POI on cognition/neurological function? 98 Hormone replacement therapy to reduce the possible risk of cognitive impairment and the risk of dementia, parkinsonism and other neurologic diseases is recommended in women with POI at least until the usual age of menopause. 99 Hormone replacement therapy may be recommended for neurological function even in the absence of menopausal symptoms, as HRT is for cardiovascular and bone health. 100 The guideline group recommends that women with POI should be advised to maintain a healthy lifestyle, involving exercise, healthy diet, avoidance of smoking, and maintenance of normal body weight to reduce possible risks for cognitive impairment. Hormone therapy in POI – Principles and indications 101 Women with POI should be advised that hormone therapy is recommended for the preservation of bone, cardiovascular and brain health. 102 Women with POI should be advised that hormone therapy is recommended for the treatment of symptoms due to low estrogen. 103 HT should be continued until at least the usual age of menopause PICO Question: What are the risks of hormone therapy? 104 It is suggested that women with POI be informed that hormone therapy is of menopause compared to women with vol in the same age group. 105 Women with POI should be informed that hormone therapy is generally does not appear to increase the risk of breast cancer before the usual age of menopause of menopause compared to women with vol in the same age group. 105 Women with POI should be informed that hormone therapy is generally does not appear to increase the risk of breast cancer before the usual age of menopause. 	_
 PICO Question: What are the management options for the effect of POI on cognition/neurological function? 98 Hormone replacement therapy to reduce the possible risk of cognitive impairment and the risk of dementia, parkinsonism and other neurologic diseases is recommended in women with POI at least until the usual age of menopause. 99 Hormone replacement therapy may be recommended for neurological function even in the absence of menopausal symptoms, as HRT is for cardiovascular and bone health. 100 The guideline group recommends that women with POI should be advised to maintain a healthy lifestyle, involving exercise, healthy diet, avoidance of smoking, and maintenance of normal body weight to reduce possible risks for cognitive impairment. Hormone therapy in POI – Principles and indications 101 Women with POI should be advised that hormone therapy is recommended for the preservation of bone, cardiovascular and brain health. 102 Women with POI should be advised that hormone therapy is recommended for the treatment of symptoms due to low estrogen. 103 HT should be continued until at least the usual age of menopause 94000 STROM 9700 STROM 98 Hormone therapy is of menopause 99 (104 It is suggested that women with POI is the assence of menopause compared to women with POI is the assence of menopause of menopause compared to women with POI is the assence of menopause of menopause compared to women with POI is the assence of menopause of menopause of menopause compared to women with POI in the same age group. 105 Women with POI should be informed that hormone therapy is generally 90 (000 STROM 	_
 on cognition/neurological function? 98 Hormone replacement therapy to reduce the possible risk of cognitive impairment and the risk of dementia, parkinsonism and other neurologic diseases is recommended in women with POI at least until the usual age of menopause. 99 Hormone replacement therapy may be recommended for neurological function even in the absence of menopausal symptoms, as HRT is for cardiovascular and bone health. 100 The guideline group recommends that women with POI should be advised to maintain a healthy lifestyle, involving exercise, healthy diet, avoidance of smoking, and maintenance of normal body weight to reduce possible risks for cognitive impairment. Hormone therapy in POI – Principles and indications 101 Women with POI should be advised that hormone therapy is recommended for the preservation of bone, cardiovascular and brain health. 102 Women with POI should be advised that hormone therapy is recommended for the treatment of symptoms due to low estrogen. 103 HT should be continued until at least the usual age of menopause PICO Question: What are the risks of hormone therapy? 104 It is suggested that women with POI in the same age group. 105 Women with POI should be informed that hormone therapy is generally (CONDITIONE) 	_
 98 Hormone replacement therapy to reduce the possible risk of cognitive impairment and the risk of dementia, parkinsonism and other neurologic diseases is recommended in women with POI at least until the usual age of menopause. 99 Hormone replacement therapy may be recommended for neurological function even in the absence of menopausal symptoms, as HRT is for cardiovascular and bone health. 100 The guideline group recommends that women with POI should be advised to maintain a healthy lifestyle, involving exercise, healthy diet, avoidance of smoking, and maintenance of normal body weight to reduce possible risks for cognitive impairment. Hormone therapy in POI – Principles and indications 101 Women with POI should be advised that hormone therapy is recommended for the preservation of bone, cardiovascular and brain health. 102 Women with POI should be advised that hormone therapy is recommended for the treatment of symptoms due to low estrogen. 103 HT should be continued until at least the usual age of menopause PICO Question: What are the risks of hormone therapy? 104 It is suggested that women with POI in the same age group. 105 Women with POI should be informed that hormone therapy is generally ⊕⊕⊕⊕ STRON 	_
 impairment and the risk of dementia, parkinsonism and other neurologic diseases is recommended in women with POI at least until the usual age of menopause. 99 Hormone replacement therapy may be recommended for neurological function even in the absence of menopausal symptoms, as HRT is for cardiovascular and bone health. 100 The guideline group recommends that women with POI should be advised to maintain a healthy lifestyle, involving exercise, healthy diet, avoidance of smoking, and maintenance of normal body weight to reduce possible risks for cognitive impairment. Hormone therapy in POI – Principles and indications 101 Women with POI should be advised that hormone therapy is recommended for the preservation of bone, cardiovascular and brain health. 102 Women with POI should be advised that hormone therapy is recommended for the treatment of symptoms due to low estrogen. 103 HT should be continued until at least the usual age of menopause PICO Question: What are the risks of hormone therapy? 104 It is suggested that women with POI be informed that hormone therapy does not appear to increase the risk of breast cancer before the usual age of menopause compared to women without POI in the same age group. 105 Women with POI should be informed that hormone therapy is generally () () () () () () () () () () () () () (_
 diseases is recommended in women with POI at least until the usual age of menopause. 99 Hormone replacement therapy may be recommended for neurological function even in the absence of menopausal symptoms, as HRT is for cardiovascular and bone health. 100 The guideline group recommends that women with POI should be advised to maintain a healthy lifestyle, involving exercise, healthy diet, avoidance of smoking, and maintenance of normal body weight to reduce possible risks for cognitive impairment. Hormone therapy in POI – Principles and indications 101 Women with POI should be advised that hormone therapy is recommended for the preservation of bone, cardiovascular and brain health. 102 Women with POI should be advised that hormone therapy is recommended for the treatment of symptoms due to low estrogen. 103 HT should be continued until at least the usual age of menopause ⊕⊕⊖○○ STROM PICO Question: What are the risks of hormone therapy? 104 It is suggested that women with POI be informed that hormone therapy does not appear to increase the risk of breast cancer before the usual age of menopause compared to women with POI in the same age group. 105 Women with POI should be informed that hormone therapy is generally ⊕⊕⊕○ STROM 	_
 of menopause. 99 Hormone replacement therapy may be recommended for neurological function even in the absence of menopausal symptoms, as HRT is for cardiovascular and bone health. 100 The guideline group recommends that women with POI should be advised to maintain a healthy lifestyle, involving exercise, healthy diet, avoidance of smoking, and maintenance of normal body weight to reduce possible risks for cognitive impairment. Hormone therapy in POI – Principles and indications 101 Women with POI should be advised that hormone therapy is recommended for the preservation of bone, cardiovascular and brain health. 102 Women with POI should be advised that hormone therapy is recommended for the treatment of symptoms due to low estrogen. 103 HT should be continued until at least the usual age of menopause ⊕⊕⊖○ STROM PICO Question: What are the risks of hormone therapy? 104 It is suggested that women with POI be informed that hormone therapy does not appear to increase the risk of breast cancer before the usual age of menopause compared to women with POI in the same age group. 105 Women with POI should be informed that hormone therapy is generally ⊕⊕⊕○ STROM)NAL
 99 Hormone replacement therapy may be recommended for neurological function even in the absence of menopausal symptoms, as HRT is for cardiovascular and bone health. 100 The guideline group recommends that women with POI should be advised to maintain a healthy lifestyle, involving exercise, healthy diet, avoidance of smoking, and maintenance of normal body weight to reduce possible risks for cognitive impairment. Hormone therapy in POI – Principles and indications 101 Women with POI should be advised that hormone therapy is recommended for the preservation of bone, cardiovascular and brain health. 102 Women with POI should be advised that hormone therapy is recommended for the treatment of symptoms due to low estrogen. 103 HT should be continued until at least the usual age of menopause ⊕€€€€ STRON PICO Question: What are the risks of hormone therapy? 104 It is suggested that women with POI be informed that hormone therapy does not appear to increase the risk of breast cancer before the usual age of menopause compared to women without POI in the same age group. 105 Women with POI should be informed that hormone therapy is generally ⊕⊕€€ STRON 	DNAL
 function even in the absence of menopausal symptoms, as HRT is for ⊕⊕⊕ CONDITION cardiovascular and bone health. 100 The guideline group recommends that women with POI should be advised to maintain a healthy lifestyle, involving exercise, healthy diet, avoidance of smoking, and maintenance of normal body weight to reduce possible risks for cognitive impairment. Hormone therapy in POI – Principles and indications 101 Women with POI should be advised that hormone therapy is recommended for the preservation of bone, cardiovascular and brain health. 102 Women with POI should be advised that hormone therapy is recommended for the treatment of symptoms due to low estrogen. 103 HT should be continued until at least the usual age of menopause ⊕⊕⊖○ STROM PICO Question: What are the risks of hormone therapy? 104 It is suggested that women with POI be informed that hormone therapy does not appear to increase the risk of breast cancer before the usual age of menopause compared to women without POI in the same age group. 105 Women with POI should be informed that hormone therapy is generally ⊕⊕⊕○ STROM 	DNAL
 cardiovascular and bone health. 100 The guideline group recommends that women with POI should be advised to maintain a healthy lifestyle, involving exercise, healthy diet, avoidance of smoking, and maintenance of normal body weight to reduce possible risks for cognitive impairment. Hormone therapy in POI – Principles and indications 101 Women with POI should be advised that hormone therapy is recommended for the preservation of bone, cardiovascular and brain health. 102 Women with POI should be advised that hormone therapy is recommended for the treatment of symptoms due to low estrogen. 103 HT should be continued until at least the usual age of menopause ⊕⊕◯◯ STROM PICO Question: What are the risks of hormone therapy? 104 It is suggested that women with POI be informed that hormone therapy does not appear to increase the risk of breast cancer before the usual age of menopause compared to women without POI in the same age group. 105 Women with POI should be informed that hormone therapy is generally ⊕⊕⊕◯ STROM 	
 advised to maintain a healthy lifestyle, involving exercise, healthy diet, avoidance of smoking, and maintenance of normal body weight to reduce possible risks for cognitive impairment. Hormone therapy in POI – Principles and indications 101 Women with POI should be advised that hormone therapy is recommended for the preservation of bone, cardiovascular and brain ⊕⊕⊕ STRON health. 102 Women with POI should be advised that hormone therapy is recommended for the treatment of symptoms due to low estrogen. 103 HT should be continued until at least the usual age of menopause ⊕⊕⊖ STRON PICO Question: What are the risks of hormone therapy? 104 It is suggested that women with POI be informed that hormone therapy does not appear to increase the risk of breast cancer before the usual age of menopause compared to women without POI in the same age group. 105 Women with POI should be informed that hormone therapy is generally ⊕⊕⊕ STRON 	
 avoidance of smoking, and maintenance of normal body weight to reduce possible risks for cognitive impairment. Hormone therapy in POI – Principles and indications 101 Women with POI should be advised that hormone therapy is recommended for the preservation of bone, cardiovascular and brain health. 102 Women with POI should be advised that hormone therapy is recommended for the treatment of symptoms due to low estrogen. 103 HT should be continued until at least the usual age of menopause ⊕ ⊕ ⊕ STRON PICO Question: What are the risks of hormone therapy? 104 It is suggested that women with POI be informed that hormone therapy is of menopause compared to women without POI in the same age group. 105 Women with POI should be informed that hormone therapy is generally ⊕ ⊕ ⊕ STRON 	
 avoidance of smoking, and maintenance of normal body weight to reduce possible risks for cognitive impairment. Hormone therapy in POI – Principles and indications 101 Women with POI should be advised that hormone therapy is recommended for the preservation of bone, cardiovascular and brain health. 102 Women with POI should be advised that hormone therapy is recommended for the treatment of symptoms due to low estrogen. 103 HT should be continued until at least the usual age of menopause ⊕⊕⊖○ STRON PICO Question: What are the risks of hormone therapy? 104 It is suggested that women with POI be informed that hormone therapy does not appear to increase the risk of breast cancer before the usual age of menopause compared to women without POI in the same age group. 105 Women with POI should be informed that hormone therapy is generally ⊕⊕⊕○ STRON 	
 Hormone therapy in POI – Principles and indications 101 Women with POI should be advised that hormone therapy is recommended for the preservation of bone, cardiovascular and brain ⊕⊕⊕● STRON health. 102 Women with POI should be advised that hormone therapy is recommended for the treatment of symptoms due to low estrogen. 103 HT should be continued until at least the usual age of menopause ⊕⊕⊕● STRON PICO Question: What are the risks of hormone therapy? 104 It is suggested that women with POI be informed that hormone therapy does not appear to increase the risk of breast cancer before the usual age of menopause ⊕⊕●● CONDITION of menopause compared to women with POI in the same age group. 105 Women with POI should be informed that hormone therapy is generally ⊕⊕⊕● STRON 	
 101 Women with POI should be advised that hormone therapy is recommended for the preservation of bone, cardiovascular and brain ⊕⊕⊕○○ STRON health. 102 Women with POI should be advised that hormone therapy is recommended for the treatment of symptoms due to low estrogen. 103 HT should be continued until at least the usual age of menopause ⊕⊕○○ STRON PICO Question: What are the risks of hormone therapy? 104 It is suggested that women with POI be informed that hormone therapy does not appear to increase the risk of breast cancer before the usual age of menopause ⊕⊕○○ CONDITION to menopause compared to women without POI in the same age group. 105 Women with POI should be informed that hormone therapy is generally ⊕⊕⊕○ STRON 	
 recommended for the preservation of bone, cardiovascular and brain ⊕⊕ STRON health. 102 Women with POI should be advised that hormone therapy is recommended for the treatment of symptoms due to low estrogen. 103 HT should be continued until at least the usual age of menopause ⊕⊕ STRON STRON PICO Question: What are the risks of hormone therapy? 104 It is suggested that women with POI be informed that hormone therapy does not appear to increase the risk of breast cancer before the usual age of menopause ⊕⊕ CONDITION CONDITION (PICO QUESTION PICO PICO QUESTION WOMEN WITH POI be informed that hormone therapy does not appear to increase the risk of breast cancer before the usual age of menopause compared to women without POI in the same age group. 105 Women with POI should be informed that hormone therapy is generally ⊕⊕ O STRON 	
health. 102 Women with POI should be advised that hormone therapy is recommended for the treatment of symptoms due to low estrogen. ⊕⊕⊖○○ STROM 103 HT should be continued until at least the usual age of menopause ⊕⊕⊖○○ STROM PICO Question: What are the risks of hormone therapy? 104 It is suggested that women with POI be informed that hormone therapy does not appear to increase the risk of breast cancer before the usual age of menopause compared to women without POI in the same age group. 105 Women with POI should be informed that hormone therapy is generally 105 STROM 105 Women with POI should be informed that hormone therapy is generally	
 102 Women with POI should be advised that hormone therapy is recommended for the treatment of symptoms due to low estrogen. 103 HT should be continued until at least the usual age of menopause ⊕⊕⊕○○ STRON PICO Question: What are the risks of hormone therapy? 104 It is suggested that women with POI be informed that hormone therapy does not appear to increase the risk of breast cancer before the usual age of menopause ⊕⊕⊕○○ CONDITION 105 Women with POI should be informed that hormone therapy is generally ⊕⊕⊕○○ STRON 	iG
recommended for the treatment of symptoms due to low estrogen. 103 HT should be continued until at least the usual age of menopause ⊕⊕⊕◯◯ STROM PICO Question: What are the risks of hormone therapy? 104 It is suggested that women with POI be informed that hormone therapy does not appear to increase the risk of breast cancer before the usual age of menopause compared to women without POI in the same age group. ⊕⊕⊖◯ CONDITION 105 Women with POI should be informed that hormone therapy is generally ⊕⊕⊕◯ STROM	
 103 HT should be continued until at least the usual age of menopause ⊕ ⊕ ⊕ ○ STROM PICO Question: What are the risks of hormone therapy? 104 It is suggested that women with POI be informed that hormone therapy does not appear to increase the risk of breast cancer before the usual age of menopause compared to women without POI in the same age group. 105 Women with POI should be informed that hormone therapy is generally ⊕ ⊕ ⊕ ○ STROM 	IG
 PICO Question: What are the risks of hormone therapy? 104 It is suggested that women with POI be informed that hormone therapy does not appear to increase the risk of breast cancer before the usual age of menopause compared to women without POI in the same age group. 105 Women with POI should be informed that hormone therapy is generally ⊕⊕⊕O STRON 	
 104 It is suggested that women with POI be informed that hormone therapy does not appear to increase the risk of breast cancer before the usual age of menopause compared to women without POI in the same age group. 105 Women with POI should be informed that hormone therapy is generally ⊕⊕⊕O STRON 	0
 does not appear to increase the risk of breast cancer before the usual age ⊕⊕⊖○ CONDITION of menopause compared to women without POI in the same age group. 105 Women with POI should be informed that hormone therapy is generally ⊕⊕⊕○ STRON 	
of menopause compared to women without POI in the same age group. 105 Women with POI should be informed that hormone therapy is generally ⊕⊕⊕⊖ STRON	
105 Women with POI should be informed that hormone therapy is generally $\oplus \oplus \oplus \oplus \bigcirc$ STROP	JNAL
	iG
106 Women with BRCA1/2 mutations without a personal history of breast	
cancer should be advised that hormone therapy is an option after risk $\oplus \oplus \bigcirc \bigcirc$ STRON	G
reducing bilateral salpingo-oophorectomy.	
107 Women with POI should be advised that progestogen should be given in	
combination with estrogen therapy to protect the endometrium in all $\oplus \oplus \bigcirc \bigcirc$ STRON	IG
women with an intact uterus.	
108 It is suggested that the dose of progestogen is increased when higher $\bigcirc \bigcirc \bigcirc$	NAL
doses of estrogen therapy are used.	
109The guideline group recommends that HCPs treat women with a history of endometriosis after surgical menopause with combined estrogen-GPP	
progestogen at least until the usual age of menopause	
110 Migraine should not be seen as a contraindication to hormone therapy	
use by women with POI. $\oplus \oplus \oplus \oplus \oplus$ STRON	
111 HCPS should consider changing dose route of administration or regimen	IG
if migraine worsens during hormone therapy. $\oplus \oplus \bigcirc \bigcirc$ STRON	
112 Women with POI and migraine with aura should be advised to use	
transdermal estrogen as this may be the lowest-risk route of $\oplus \bigcirc \bigcirc \bigcirc$ STROM	
administration	IG
PICO Question: What are the options for hormone therapy?	IG



113	The guideline group recommends that women are advised that compounded "bio-identical" preparations of estrogen and progesterone are not recommended due to lack of data on efficacy and safety unless no alternative regimens are available.		GPP
114	Women with POI should be advised that estradiol has advantages over ethinylestradiol and conjugated equine estrogens when used for hormone therapy.	⊕⊕⊕⊖	STRONG
115	The guideline group recommends shared decision making when prescribing each component of hormone therapy with consideration of patient preference, contraceptive needs, and presence of co-morbidities.		GPP
116	Women with POI should be advised that adherence to hormone therapy is important to minimise long term health risks and therefore long term follow up is needed	$\oplus \oplus \bigcirc \bigcirc$	STRONG
	Monitoring hormone therapy		
117	Women with POI should be advised to have a clinical review at least annually, addressing individualised risk review (specifically cardiovascular and bone health) and adherence to therapy.	⊕⊕⊖⊖	STRONG
	PICO Question: What is the role of testosterone therapy in POI?		
118	Testosterone treatment should be considered in women with POI to manage hypoactive sexual desire disorder (HSDD) when other biopsychosocial aetiologies are excluded.	000®	STRONG
119	The guideline group recommends that women with POI are informed that there is limited data for androgen treatment for indications other than hypoactive sexual desire disorder (HSDD), and that long-term health effects are unknown.		GPP
	PICO Question: What are the specific considerations for hormone therapy in iatrogenic POI ?		
120	The guideline group recommends a personalised approach to risks and benefits of HT in women with iatrogenic POI after gynaecological/breast cancer		GPP
121	Hormone therapy does not increase the risk of recurrence of squamous cell carcinoma of the cervix and is recommended for women with iatrogenic POI due to treatment of squamous cell carcinoma.	⊕⊕⊕⊖	STRONG
122	Hormone therapy may be associated with a low risk of recurrence of cervical adenocarcinoma and a personalised approach considering individualised hormone therapy risk and benefits is recommended.	⊕⊕⊖⊖	STRONG
123	HCPs could consider use of hormone therapy in women with early-stage low-risk endometrioid adenocarcinoma, as there is a low risk of cancer recurrence with hormone therapy use	⊕⊕⊖⊖	CONDITIONAL
124	HCPs could consider hormone therapy in women with iatrogenic POI due to epithelial ovarian cancer.	$\oplus \oplus \oplus \bigcirc$	CONDITIONAL
125	The effect of hormone therapy on the risk of recurrence of non-epithelial ovarian cancer is unclear and it is suggested that HCPs use an individualised approach to prescribing hormone therapy including consideration of tumour hormone receptor status.	⊕ 0000	CONDITIONAL
126	Hormone therapy should be avoided in women with hormone dependent ovarian or uterine tumours including uterine sarcoma, endometrioid carcinoma, ovarian clear cell carcinoma, ovarian granulosa cell tumour, or sex cord-stromal tumours.	⊕⊕⊕⊖	STRONG
127	Women should be informed of the risks of iatrogenic POI and risks and benefits of hormone therapy before risk reducing bilateral salpingo- oophorectomy	⊕000	STRONG
128	It is recommended that individualised hormone therapy or pubertal induction be commenced in girls/women with POI following hematopoietic stem cell transplantation.	$\oplus \oplus \bigcirc \bigcirc$	STRONG
	PICO Question: What non-hormonal therapies are available for POI?		



129	Non-hormonal pharmacologic and non-pharmacologic therapies effective in peri-/postmenopausal women are likely to be helpful in women with POI although POI specific data is lacking	€000	CONDITIONAL
	PICO Question: What complementary treatments are effective for managing the sequelae of POI?		
130	The guideline group recommends that HCPs should enquire about use of complementary therapies, and incorporate individual patient values and preferences into shared decision making about their use		GPP
131	Complementary treatments do not prevent the long-term sequalae of POI and should therefore not be used to replace hormone therapy	$\oplus OOO$	STRONG
132	Women who are considering the use of Chinese herbal medicine for the management of menopausal symptoms and metabolic risk should be informed that the evidence for benefit is limited but the intervention does not appear to cause significant harm in the short term.	$\odot O O O$	STRONG
133	Women should be informed that there is limited evidence on the effectiveness of acupuncture for menopausal symptoms in POI and the evidence does not suggest a benefit from adding acupuncture to hormone therapy.	⊕OOO	STRONG
134	Women who are considering using nutrient supplements for improving reproductive parameters in POI should be informed that the evidence is very limited with only one intervention (Vitamin E and selenium) studied in randomised controlled trials.	0000	STRONG
135	Women who are considering using other nutrient supplements and herbal medicines should be informed that there is insufficient evidence to support its use.	⊕000	STRONG
	PICO Question: What are the lifestyle management options for POI?		
136	Women should be aware that a healthy lifestyle, including physical activity, has metabolic and heart benefits in the general population including postmenopausal women, although specific evidence on lifestyle interventions in POI is limited.	⊕⊕⊖⊖	STRONG
137	The guideline group recommends women with POI should be encouraged to adopt a healthy lifestyle to improve their overall well- being and mitigate the risk of potential complications.		GPP
	PICO Question: How should puberty be induced?		
138	Puberty should be induced or progressed with 17β -estradiol, starting with low dose at the age of 11 with a gradual increase over 2 to 3 years.	$\oplus \oplus \bigcirc \bigcirc$	STRONG
139	In cases of late diagnosis and for those girls in whom growth is not a concern, a modified regimen of estradiol can be considered.	$\oplus OOO$	CONDITIONAL
140	Evidence for the optimum mode of administration (oral or transdermal) is inconclusive. Transdermal estradiol may result in more physiological estrogen levels and may therefore be preferred.	0000	CONDITIONAL
141	The oral contraceptive pill should not be used for puberty induction.	$\oplus OOO$	STRONG
142	The guideline group recommends starting cyclical progestogens after about 2 years of estrogen therapy or when breakthrough bleeding occurs.		GPP

79

¹GDG, guideline development group; GPP, good practice point



PART A: Introduction to POI

I. PREMATURE OVARIAN INSUFFICIENCY (POI)

This chapter summarises the nomenclature for POI and formulates guidance on what this condition should be called in clinical practice and future research. Furthermore, the definition and prevalence of POI are discussed

84 POI are discussed.

85 I.1. POI Nomenclature

86 Key QUESTION: WHAT SHOULD THIS CONDITION BE CALLED?

The condition addressed in this guideline was first described as Primary Ovarian Insufficiency by Fuller Albright in 1942 (Albright *et al.*, 1942). Subsequently several terms have been used, with variation between specialities (e.g. gynaecology, endocrinology) and between countries (e.g. USA, UK).

90 The use of standard terminology is important to clarify information given to women, improve 91 communication between health professionals, facilitate data collection and audit, and aid future 92 research.

- 93 The ESHRE Guideline: management of women with premature ovarian insufficiency published in 94 2015/2016 recommended that the term "premature ovarian insufficiency" should be used to describe 95 the condition in research and clinical practice (Webber et al., 2016). This followed a workshop convened by ESHRE Special Interest Group for Reproductive Endocrinology (Utrecht, December 2013) for the 96 guideline development group, patient representatives, and the broader membership. It was felt that in 97 98 Europe the terms "primary" and "secondary" were widely used to classify amenorrhoea in relation to 99 menarche, and thus "primary ovarian insufficiency" would lead to confusion, as it was not synonymous 100 with primary amenorrhoea. Consensus was easily reached to recommend the term "insufficiency" 101 instead of "failure" as this more accurately describes the fluctuating nature of the condition and does 102 not carry the negative connotation of "failure".
- The uptake of the term "premature ovarian insufficiency" and the use of other terms can be assessed through a search of PUBMED, updated from Cooper and colleagues and the previous guideline (Cooper *et al.*, 2011, Webber *et al.*, 2016) (Table II). The results indicate that since the publication of the ESHRE Guideline: management of women with premature ovarian insufficiency, the term "premature ovarian insufficiency" has been increasingly used over the last decade, even if "Primary Ovarian Insufficiency" is still the most prevalent term in current research publications (Figure 1).
- A second source of information is the scoping survey performed as part of this guideline development process. This included 282 consumer and 473 healthcare professional responses, with international representation. 'Premature ovarian failure' was the term used by most consumer (40%) and health care professional (71%) respondents. 'Primary ovarian insufficiency' was used by approximately 15% of both consumer and healthcare professionals, predominately in North America. 'Premature ovarian failure' was the term used by 26% of consumer and 13% of healthcare professionals respectively (unpublished data).
- 116
- 117




118 TABLE II NUMBER OF PAPERS RETRIEVED IN PUBMED FOR THE DIFFERENT TERMS USED FOR POI, IN TOTAL AND

119 SINCE THE ESHRE RECOMMENDATION WAS PUBLISHED (MAY 2016)

	Number of papers retrieved in PUBMED	Number of papers retrieved in PUBMED, since May 2016
Primary Ovarian Insufficiency	3837	1647
Premature Ovarian Failure	2856	852
Gonadal dysgenesis	4268	598
Premature menopause	1779	553
Early menopause	1218	454
Hypergonadotropic	688	249
hypogonadism		
Premature Ovarian Insufficiency	1156	1011
Ovarian dysgenesis	276	52
Primary ovarian failure	220	50
Hypergonadotropic amenorrhea	62	4
Climacterium praecox	5	0
Menopause praecox	1	0
		V.

121 FIGURE 1 NUMBER OF PUBMED CITATIONS USING THE TERM "PREMATURE OVARIAN INSUFFICIENCY" AND





124 **Recommendation**

120

The guideline group recommends that the term "premature ovarian insufficiency" is used to describe this condition in research and clinical practice.

GPP

- 125 Justification
- 126 In developing an international guideline, the terminology used must be unambiguous and consistent,
- in order to ensure clarity. The guideline group encourages consistency in the terminology used inpublished studies and clinical practice.
- 129 The issue of terminology was discussed within the guideline development group and the advantages
- and disadvantages of the different terms used in the literature and clinical practice were weighed. The
- 131 Guideline Development Group acknowledges the preferences in terminology from individual authors,



- but also regional preferences, such as the preference in the USA to refer to 'primary ovarianinsufficiency'.
- 134 To ensure the terminology does not hinder implementation, the Guideline Development Group has 135 used the abbreviation "POI" throughout this guideline.

136 I.2. Definition of POI

137 Key QUESTION: HOW SHOULD POI BE DEFINED?

A definition of POI is important to differentiate women with menopause at usual age from women with POI, as these women have unique needs and management options. Women with POI may not only suffer from vasomotor symptoms and symptoms associated with estrogen deficiency, but they can also experience infertility and psychological problems with a significant impact on their quality of life and later health outcomes (see IV. POI and life expectancy).

POI is a clinical condition characterised by loss of ovarian function indicated by amenorrhoea, or oligomenorrhoea, for more than 4-6 months together with biochemical confirmation of ovarian insufficiency before the age of 40. It is a state of female hypergonadotropic hypogonadism. It can manifest as primary amenorrhea, with onset before menarche, or secondary amenorrhea.

147 The age of 40 years is set by convention but is supported by clinical observations.

The usual age of menopause is a first relevant point of relevance. A systematic review and meta-analysis 148 analysed 46 studies across 24 countries (Schoenaker et al., 2014). They calculated the overall mean age 149 of menopause is 48.78 years (95% CI 48.33 to 49.22). However, there was substantial heterogeneity 150 between studies, with mean age ranging from 46 to 52 years. There was a geographical variation in the 151 152 usual age of menopause across regions, see Figure 2. In addition to the regional variation, the authors 153 also highlighted general trends of increasing age of menopause (Schoenaker et al., 2014). This trend 154 was confirmed by an analysis in the USA that reported that over the last 6 decades, the usual age of menopause increased by 1.5 years (from 48.4 years in 1959-1962 to 49.9 years in 2015-2018)(Appiah et 155 al., 2021). Similar data were reported from a population study in Norway. In this study, the mean age of 156 menopause increased from 50.31 years (95% CI 50.25 to 50.37 years) among women born during 1936-157 1939 to 52.73 years (95% CI 52.64 to 52.82 years) among women born during 1960–1964 (Gottschalk et 158

- 159 *al.*, 2020).
- 160 FIGURE 2 USUAL AGE OF MENOPAUSE PER REGION, BASED ON DATA FROM (SCHOENAKER ET AL., 2014).





- 162 From a statistical point of view, the age limit of 40 is approximately two standard deviations (SD) below
- 163 the usual age of menopause (50 \pm 4 years). Conventionally, menopause occurring in the 40-44 age
- 164 group is referred to as 'early menopause'; although, this may include age 45 years in some studies.

165 POI versus diminished ovarian reserve

Loss of ovarian function in POI can be entangled with low ovarian reserve, although these need to be considered as separate entities in different patients, with different management needs. Low ovarian

- reserve is a condition in which the ovary loses its normal reproductive potential; it is characterized by
- 169 regular menses with alterations of ovarian reserve tests.
- 170 The term 'ovarian reserve' encompasses both the quantity and quality of primordial follicles. Women 171 with low ovarian reserve often respond poorly to ovarian stimulation resulting in retrieval of fewer
- 172 oocytes, producing poorer quality embryos and reduced implantation rates and pregnancy rates.
- 173 Incidence of poor ovarian response over all assisted conception cycles ranges from 5 to 35% (The ESHRE
- 174 Guideline Group On Ovarian Stimulation *et al.*, 2020).
- 175 It is important to distinguish between low ovarian reserve and POI, although they may lie on the same
- 176 spectrum, because women with POI face challenges much wider than fertility alone and will need
- 177 appropriate management options.

178 GDG statement

Premature ovarian insufficiency is a condition defined by loss of ovarian activity before the age of 40 years.

POI is characterised by amenorrhea or oligomenorrhea, with elevated gonadotropins and low estradiol.

In this guideline, cessation of ovarian function in women aged between 40 and less than 45 (age 40-44 years) will be termed early menopause. Even if this group is outside the scope of the current guideline, the evidence and recommendations may still be relevant to women with early menopause.

179

180 I.3. Prevalence of PO

181

182 Key QUESTION: WHAT IS THE PREVALENCE OF **POI** IN THE GENERAL POPULATION?


183 Epidemiological data

184 Earlier studies indicated that the prevalence of non-iatrogenic menopause before the age of 40 was 185 approximately 1% (Krailo and Pike, 1983, Coulam et al., 1986, Cramer and Xu, 1996, Luborsky et al., 2003). Coulam and colleagues established that the rate of non-iatrogenic menopause is ten times higher 186 in the 40 to 44 age group; conventionally this is called "early menopause", as compared to the 30 to 39 187 age group (Coulam et al., 1986) (Figure 3). However, more recent data suggest a higher prevalence. In 188 a large meta-analysis, the prevalence of non-iatrogenic menopause in women below 40 years old was 189 190 3.7% (95% CI 3.1 to 4.3) (Golezar et al., 2019). The authors also calculated the prevalence of menopause 191 in other age groups, and reported a prevalence of 12.2% (95% CI 10.5 to 14.0) in those between 40 and 45 years old, 78.1% (95% CI 75.9 to 80.3) in women between 45 and 55 years old (Usual age menopause), 192 193 and 7.2% (95% CI 4.5 to 10) in women above 55 years old (late menopause) (Golezar et al., 2019) (see 194 Figure 4). The meta-analysis. further reported that the prevalence of POI was greater in medium (4.9%),



- and low (23.8%) human development index (HDI) countries as opposed to high (3.6%) HDI countries
- 196 (Golezar *et al.*, 2019).


197 **FIGURE 3 DISTRIBUTION OF AGE OF MENOPAUSE.**



198

199

- 200 A similar global overall prevalence of POI of 3.5% was reported in a more recent systematic review and
- 201 meta-analysis (Li *et al.*, 2023a). The prevalence of POI differed between regions globally, as well as
- between developing and developed countries. In addition, the trend of prevalence of POI over the past
- 203 20 years appears to be on the rise (Li *et al.*, 2023a).
- FIGURE 4 DISTRIBUTION OF AGE OF MENOPAUSE AND PREVALENCE OF NON-IATROGENIC POI (BASED ON (GOLEZAR
 ET AL., 2019)).



206 207



208 *latrogenic POI*

- Historically, bilateral oophorectomy has been practised at the time of hysterectomy for benign gynaecological disease. Hysterectomy rates of about 20% by age 55 were estimated in a UK cohort in
- the early 1990s (Vessey et al., 1992, Kramer and Reiter, 1997, Hill et al., 2010, Pokoradi et al., 2011). A
- 212 large study on unilateral and bilateral oophorectomy trends in Minnesota (USA) concluded that there
- has been a notable decrease in the incidence of premenopausal oophorectomies over the 69-year study
- 214 period (1950 2018). These findings suggest a shift in clinical practice towards more conservative
- 215 approaches in managing ovarian health, particularly in women without a high genetic risk or ovarian
- indication for surgery (Erickson *et al.*, 2022). Still, bilateral oophorectomy is the most common cause of
- 217 POI in Western countries (Rocca *et al.*, 2023).
- 218 Of current concern is the rising incidence of iatrogenic POI in young cancer survivors, consequent on
- the increasing success of cancer therapy. A systematic review of 36 studies from 1990 to 2017 (sample
- size ranging from 15 to 3749) reported the prevalence of POI in female childhood or adolescent cancer
- survivors aged 0 to 24 years as 2.1% to 82.2% (Gargus et al., 2018, Giri and Vincent, 2020). A meta-
- analysis of 68 studies included 26 585 patients with breast cancer and reported an overall prevalence of
- chemotherapy-induced amenorrhea of 63.3% (16 927 patients) (Wang et al., 2022). The prevalence of
- chemotherapy-induced amenorrhea was lower in women below 40 years at the time of treatment and
- women with hormone receptor negative tumours. Incidence was further impacted by chemotherapy
- regimen. In women below 40, the incidence of chemotherapy-induced amenorrhea was 35.53%.
- 227 Iatrogenic POI may also arise from the increasing use of cytotoxic agents in treatment of serious non-
- 228 malignant disease such as cyclophosphamide for systemic lupus erythematosus (Huong et al., 2002,
- 229 Katsifis and Tzioufas, 2004), stem cell transplant for haemoglobinopathies (Rahal et al., 2018) or surgery
- for ovarian endometriosis (Coccia *et al.*, 2011).
- 231 All causes of POI, including associated diseases, are summarised in section II.3 Investigating the cause
- 232 for POI
- 233 GDG statement

The reported prevalence of non-iatrogenic POI varies from approximately 1% in older studies to 3,5% in recent publications Population characteristics such as ethnicity may affect the prevalence of non-iatrogenic POI.

234

235 I.4. Risk factors for POI.

Identifying risk factors for POI is crucial as it may allow for preventive measures both on a patient-level
 and on a public health level, facilitate early detection and diagnosis, and allow for decisions about
 fertility preservation. It is widely agreed that early diagnosis is important to prevent some consequences
 of POI.

240 **PICO QUESTION: WHAT ARE THE RISK FACTORS FOR POI?**

Risk factors for POI or early menopause include many but not all factors that influence age of natural menopause. Additionally, there is reported disparity regarding factors affecting early menopause versus POI risk which may reflect methodological rather than physiological differences. Risk factors for POI include both non-modifiable and modifiable. A recent position statement concluded that the following were predictors of POI: genetic abnormalities; family history of premature or early menopause; being a



child of multiple pregnancy, early menarche, nulliparity/low parity, cigarette smoking (dose–response effect), and being underweight (Mishra *et al.*, 2019). Specific factors are discussed in more detail below.

248 Genetic

Specific chromosomal abnormalities and genetic variants are associated with an increased risk of POI. In a registry study of 5011 women diagnosed with POI, 15.9% had at least one diagnostic code for a genetic disorder or congenital malformation. Documented congenital malformations among women ultimately diagnosed with POI included malformations of the ovary, fallopian tubes, and broad ligaments, skin and mammary gland anomalies, malformations of the nervous system, eye, ear, face, and neck, lip and cleft palate, and malformations of the digestive, urinary, and musculoskeletal systems (Silven *et al.*, 2023).

Specific chromosomal abnormalities and genetic variants are associated with an increased risk of POI.
 Genetic causes of POI, prevalence and genetic testing is discussed in section II.3.a POI and genetic
 causes .

259 *Family history and demographic factors*

Multiple studies have identified family history as a strong predictor of the age of menopause. Indeed, 260 hereditability estimates suggest that approximately 50% of interindividual variation in age of 261 menopause can be explained by genetic effects, with higher values associated with twin studies (Giri 262 and Vincent, 2020). The odds of early menopause (OR 6.1; 95% Cl 3.9 to 9.4) was increased with a family 263 264 history of early menopause affecting mother, sister, aunt, or grandmother in a USA case-control study 265 after adjusting for smoking, education, BMI, and parity (Cramer et al., 1995). Higher risks were observed with multiple family members affected or a family history of an affected sister; greatest risk observed in 266 association with an affected twin sister (Cramer et al., 1995, Morris et al., 2011, Silvén et al., 2022). More 267 recently, a US study using data linkage, reported that the risk of POI was increased 18-fold in first degree 268 relatives, 4-fold in second degree relatives and 2.7-fold in third degree relatives of women with POI 269 compared with controls (Verrilli et al., 2023). Among a cohort of 955 Chinese women with POI, 12.25% 270 of patients reported a family history of either POI or early menopause (Jiao et al., 2017). In another 271 cohort of 553 Han Chinese women, a family history of a relative with menstrual abnormalities was 272 273 strongly associated with a future diagnosis of POI (OR 28.12; 95% CI 8.84 to 89.46) (Wang et al., 2015).

274 Ethnicity

Usual age of menopause presents with a geographical variation as described previously, with the lower
age in African, Asian, Latin American, and Middle Eastern countries (Schoenaker *et al.*, 2014)(see I.3.
Prevalence of POI). As with usual age of menopause, the prevalence and thus potential risk of POI varies
with ethnicity. The Study of Women's Health Across the Nation (SWAN) identified lower prevalence of
POI in Asian women compared with Hispanic, African American or Caucasian. This may reflect both

280 genetic and non-genetic factors (Luborsky *et al.*, 2003).

281 Early life factors

Large cohort studies suggest a link between early life factors and the age of onset of natural menopause, but data specific to POI is lacking. A 2022 analysis investigated pooled data from two large prospective British birth cohort studies, the 1958 National Child Development Study (NCDS) and the 1970 British Cohort Study (BCS70), which followed a total of 17 614 women from birth through middle age. The study found multiple factors influencing the age of natural menopause across the lifespan and beginning during prenatal life. For example, women whose mothers smoked during pregnancy had 24% higher odds for early menopause as compared to women whose mothers did not smoke (OR 1.24; 95%

289 CI 1.03 to 1.49) (Peycheva et al., 2022). A UK biobank study identified that being part of a multiple birth



- is associated with an increased risk of early menopause after adjustment for confounders (OR 1.55; 95% CI 1.13 to 2.13) (Ruth *et al.*, 2016). Twin registry data indicated a higher prevalence of POI and early menopause in twins compared with the general population (Gosden *et al.*, 2007). One small study (n=151) observed an increased prevalence of POI in those born at gestation<37 weeks compared with controls (OR 4.66; 95% CI 1.3 to 16.7) (Sadrzadeh *et al.*, 2017). Association between low birth weight and earlier age at natural menopause is inconclusive (Sadrzadeh *et al.*, 2017).
- 296 Neonatal and early childhood factors which have been associated with an earlier age of menopause 297 include shorter duration of breastfeeding (<1 month, OR 1.30; 95% CI 1.05 to 1.60) (Peycheva *et al.*, 2022). Longer duration of breastfeeding was associated with a lower risk of early menopause in the 298 Nurses Health Study II cohort study (Langton *et al.*, 2020). Lower early childhood socioeconomic position 300 has also been associated with an early age of menopause (Peycheva *et al.*, 2022). Finally, higher 301 childhood cognitive ability in early childhood, as measured by reading comprehension and mathematics 302 test scores, is associated with a reduced risk for early menopause (OR 0.64; 95% CI 0.57 to 0.71).
- Adverse parenting or childhood experiences is associated with an earlier age of menopause; however, data specific to POI is lacking (Giri and Vincent, 2020).

305 *Reproductive factors*

- A 2020 meta-analysis observed that parous women had a later age at natural menopause (Roman Lay *et al.*, 2020). Consistent with this, data from the Nurses Health Study II indicated a lower risk of early menopause with one or more pregnancies (Langton *et al.*, 2020). A retrospective Norwegian population study of 310147 women reported lower age of menopause with lower parity (Gottschalk *et al.*, 2022). Data from the UK Biobank revealed that later age at first birth was associated with later age of menopause (Prince *et al.*, 2022). The INTERLACE study (n=51450) identified a 2.26-fold and 1.32-fold increased risk of POI and early menopause respectively, with nulliparity. Risk was further increased with
- 313 the combination of nulliparity and early menarche (Mishra *et al.*, 2017).
- 314 Data are conflicting regarding a possible association between POI or early menopause and earlier age
- at menarche. A 2020 meta-analysis also concluded that later age of menarche was associated with later
- age at natural menopause; however, a direct linear relationship was difficult to establish due to multiple
- potential confounders (Roman Lay *et al.*, 2020). In contrast to older or smaller studies (van Noord *et al.*,
- 1997, Otero *et al.*, 2010, Wang *et al.*, 2015, Whitcomb *et al.*, 2018a), The InterLACE study (n=51450)
 reported an association between POI or early menopause and earlier age at menarche (defined as age
- ≤ 11 years) compared to menarche at age 12-13 years, with risk ratios of 1.8 and 1.32 respectively
- 321 (Mishra *et al.*, 2017).
- Shorter menstrual cycle length<25 days was associated with a 70% higher risk of early menopause compared with cycle lengths of 26 to 31 days in the Nurses health Study II (Whitcomb *et al.*, 2018a). A meta-analysis including 17 observational studies, reported that previous/ever use of the combined oral contraceptive pill (COC) was associated with later age at natural menopause (Roman Lay *et al.*, 2020).
- 525 contraceptive pin (COC) was associated with later age at hatural menopause (Roman Lay et al., 2020).
- Finally, a case-control study of 553 women with POI and 400 controls reported an increased risk of POI associated with a history of pelvic surgery (OR 5.53; 95% CI 2.15 to 14.23) (Wang *et al.*, 2015).

328 Body Mass Index

- 329 Data from a 2015 meta-analysis indicated that lower body mass index (BMI) <18.5 was associated with
- an earlier age at natural menopause compared with women with normal BMI (HR 1.08; 95% CI 1.03 to
- 1.14) (Tao *et al.*, 2015). Consistent with this, findings from the Nurses Health II study and InterLACE study
- indicate a 30% and two-fold increase respectively in the risk of early menopause with low BMI (Szegda
- et al., 2017, Zhu et al., 2018b). Data specific to POI is lacking. However, obesity was associated with a



reduced risk of POI (HR 0.43; 95% CI 0.22 to 0.86) in a cohort of cancer survivors (Chemaitilly *et al.*, 2017).

336 Socio-economic status

337 Based on 11 studies, a 2014 meta-analysis reported that onset of menopause was later in women with 338 middle (higher school certificate/diploma) and higher (university or higher degree) education levels, 339 compared to in women with lower education (no formal gualifications); corresponding to one-third and two-thirds of a year respectively. Occupation had an effect comparable to education (Schoenaker et al., 340 341 2014). More recently, a Finnish study indicated that women with POI had lower socio-economic status 342 and levels of education compared with the general population (Silvén et al., 2022), while a 2022 pooled 343 analysis of the British NCDS and BCS70 studies found an increased odds for early menopause in women without paid employment (OR 1.43; 95% CI 1.13 to 1.81) (Peycheva et al., 2022). Indian women living in 344 345 rural areas were more likely to experience POI compared to those in urban areas. In addition, POI was associated with poorer wealth quintiles compared with richer (Jungari and Chauhan, 2017). 346 347 Confounding/ contributing factors could be early life experiences and lifestyle elements such as 348 smoking, BMI, early life factors, and nutrition.

349 Smoking

Multiple studies have linked smoking to an earlier age of natural menopause (Schoenaker, 2014 #3; Zhu, 350 2018 #62;Oboni, 2016 #63;Ruth, 2021 #64}(Kato et al., 1998), but not all (van Noord et al., 1997). Tobacco 351 smoke disrupts folliculogenesis and development, increases apoptosis and DNA damage, and disrupts 352 353 oocyte-granulosa cell communication (Giri and Vincent, 2020, Cui and Wang, 2024). Based on 15 studies, 354 smoking was found to be associated with an earlier mean age of menopause by almost a year 355 (Schoenaker et al., 2014). Another prospective cohort study of 5113 postmenopausal women found that 356 smokers in this study had a mean age of menopause of 45.6 years (SD 6.04 years) as compared to 46.9 years (SD 5.7 years) in non-smokers (Pokoradi et al., 2011). The same was observed in the Massachusetts 357 Women's Health Study and in the National Survey of Health and Development (McKinlay et al., 1985, 358 Hardy et al., 2000), as well as in an analysis of pooled data from the British NCDS and BCS70 studies (OR 359 1.69, 95% CI 1.28-2.23) (Peycheva et al., 2022). In a study of 244 menopausal Jordanian women, smoking 360 361 was the major risk factor for early menopausal age (OR 2.46; 95% CI 1.08 to 5.59; p<0.05) (Bustami et 362 al., 2021). This association was found in both current and former smokers, and a dose-response relationship was observed. Higher intensity, longer duration, higher cumulative dose, earlier age starting 363 364 smoking, and shorter time since quitting smoking have all been significantly associated with higher risk of early menopause (Whitcomb et al., 2018b, Zhu et al., 2018a). Passive smoking was not significantly 365 associated with POI or early menopause (Gold et al., 2013). 366

367 Alcohol

Alcohol consumption seems to be inversely associated with age at natural menopause. Data from a 368 369 large prospective study suggest a weak association of moderate alcohol intake (10.0-14.9 g/day) with 370 lower risk of early menopause (<45 years old), but high consumption was not related to lower risk of 371 early menopause (Freeman et al., 2021). A 2016 meta-analysis reported that low and moderate alcohol 372 consumption (more than one drink per week (RR 0.60; 95% CI 0.49 to 0.75) and three or fewer drinks 373 per week (RR 0.75; 95% CI 0.60 to 0.94) were associated with later menopause onset, compared to nondrinkers. The relative risk for earlier menopause onset was 0.95 (95% CI 0.91 to 0.98) when comparing 374 375 women who reported drinking alcohol versus women who did not (Taneri et al., 2016). Finally, a 2022 376 analysis of pooled data from two large British cohort studies found that alcohol intake 2-3 times per 377 month was inversely associated with age of menopause (OR 0.76; 95% CI 0.57 to 1.00) (Peycheva et al., 378 2022). While it has been suggested that the benefits observed with light to moderate alcohol use are 379 due to alterations in sex steroid hormone levels (Gill, 2000), others have argued that these results may



be confounded by inappropriate control groups (e.g. individuals who abstain from alcohol due to former
 heavy use or underlying long term health problems) (Peycheva *et al.*, 2022).

382 Infectious causes

POI has been reported following various infections, including mumps, HIV, herpes zoster, cytomegalovirus, tuberculosis, malaria, varicella, and shigella (Goswami and Conway, 2005, Kokcu, 2010). However, only mumps oophoritis has been considered a cause of POI, explaining 3 to 7% of women with POI (BROOKS, 1913, Morrison *et al.*, 1975). Among a cohort of Han Chinese women, a history of mumps conferred an increased odds of POI (OR 3.26; 95% CI 2.38 to 4.47) (Wang *et al.*, 2015).

388 A systematic review of six studies on the prevalence of early menopause and POI among women living with HIV reported an increased prevalence of both early menopause and POI among women living with 389 HIV (up to 26%, compared to as low as 2.3% among controls in studies including control women) (Van 390 391 Ommen et al., 2021). However, given that only one study included biochemical confirmation of 392 menopause, and several studies did not include control groups, the authors suggested that these 393 studies might overestimate the prevalence of POI by including women with prolonged amenorrhea. In 394 contrast, a 2022 study of 3059 US women living with or at risk of HIV reported a prevalence of POI and early menopause similar to that reported globally (Bullington et al., 2022). 395

396 *Coexisting medical conditions*

A recent population-based study of women with PCOS (n=7049) and women without PCOS (n=70490) 397 reported that the risk for POI was significantly higher in women with PCOS than controls (adjusted HR 398 399 8.31; 95% CI 7.05 to 9.81), with an even higher risk in women with PCOS who did not receive metformin treatment (adjusted HR 9.93; 95% CI 8.28 to 11.90), and was significantly reduced for women with PCOS 400 401 who received metformin treatment (adjusted HR 5.66; 95% CI 4.36 to 7.35) (Pan et al., 2017). Galactosemia is an inherited metabolic disorder that affects about 1 in 50000 live births in the United 402 States. In a recent cohort study of 102 post-pubertal girls and women with galactosemia, only 68% 403 achieved spontaneous menarche; fewer than 50% of these women were still cycling regularly after 3 404 years, and fewer than 15% were cycling regularly after 10 years (Frederick et al., 2018). 405

Autoimmune disease, especially Addison's disease, has also been associated with an increased risk of
 POI (see section II.3.b POI and autoimmune causes. The risk of POI associated with medical treatments
 and iatrogenic causes of POI are discussed in section II.3 latrogenic POI.

409 Chemical exposures

410 Exposure to endocrine disruptors also appears to impact the usual age of menopause. Examples of 411 endocrine disrupting chemicals (EDCs) include i) heavy metals such as cadmium, thallium, and arsenic, ii) persistent organic pollutants (POPs), a class of carbon-based organic chemicals including pesticides 412 413 and industrial chemicals which have long environmental half-lives, and iii) plasticizers, a class of additives incorporated into plastics which includes phthalates, perfluoroalkyl and polyfluoroalkyl 414 415 substances (PFASs), and bisphenol A (BPA). Studies in rodent and mouse models support a detrimental 416 effect of endocrine disruptors on ovarian follicle recruitment and growth, sex steroid hormone levels, 417 oocyte quality and markers of ovarian reserve (Zhu et al., 2024)

In a series of case-control studies comparing a group of Chinese women with POI (defined as age <40, oligomenorrhoea or amenorrhea for at least 4 months, and an elevated FSH level > 25 IU/L on two occasions > 4 weeks apart) to control women, serum and/or urinary levels of multiple EDCs were associated with significantly increased odds for POI (ORs ranging from 1.34 to 3.15). These exposures included heavy metals (thallium, cadmium, and arsenic), pesticides (including pyrethroids, DDT and DDT metabolites), plasticizers including PFAS, and POPs including PCBs and polycyclic aromatic



hydrocarbons (PAHs) (Pan et al., 2019Ye, 2020 #2438, Cao et al., 2020, Pan et al., 2020, Pan et al., 2021, 424 425 Ma et al., 2022). Findings are mixed regarding the association between BPA exposure and POI risk (Li et 426 al., 2018, Li et al., 2021a). Another case-control study of a group of Chinese women found that high 427 plasma PFAS levels were positively associated with POI (OR 2.81-6.63 for various PFAS chemicals) (Zhang 428 et al., 2018). Finally, a 2024 systematic review and meta-analysis of 10 studies investigating the effect of 429 environmental pollutants on female fertility found an increased pooled odds ratio for POI (OR 2.33; 95% Cl 1.97 to 2.68). Pooled exposures in this study included heavy metals (thallium, copper, selenium), 430 431 plasticizers (PFASs and BPA), and POPs (PCBs, DDT, and pyrethroids) (Zhu et al., 2024).

In the United States, a cross-sectional survey of National Health and Nutrition Examination Survey 432 433 (NHANES) data, which included 31,575 women gathered between 1999-2008, found that women with 434 high serum or urinary concentrations of certain organochloride pesticides, phthalates, or 435 polychlorinated biphenyls (PCBs, a class of POPs which are widely distributed in the environment) had 436 mean ages of menopause 1.9 to 3.8 years earlier than women with lower levels of these chemicals. 437 (Agency for Toxic Substances and Disease Registry (ATSDR). 2000, Grindler et al., 2015). The SWAN study reported a 63% higher risk of earlier menopause, equivalent to 2 years earlier median time to 438 439 menopause, associated with high concentrations of perfluorinated compounds (a class of POPs) (Ding 440 et al., 2020). More studies are required to evaluate the effects of EDC exposures on reproductive health 441 and to clarify potential dose-response effects.

442 Vaccines

While the mean number of reported POI events increased after the first human papillomavirus (HPV) vaccine launch in 2006 with (22.2 POI cases/year up from 1.4 POI cases/year pre-launch) (Tatang *et al.*, 2022), a 2023 meta-analysis, which included four studies and a total of 1 253 758 female children and adolescents, found no increased risk for POI after quadrivalent HPV vaccination (RR 0.47; 95% CI 0.14 to 1.5), as well as no increased risk with quadrivalent HPV vaccines relative to bivalent (RR 0.93; 95% CI 0.33 to 2.64) and 9-valent (RR 0.93; 95% CI 0.33 to 2.64) vaccines (Torella *et al.*, 2023).

A review of women with POI reported to the Vaccine Adverse Event Reporting System (VAERS) [a United 449 450 States vaccine surveillance system] using the ACOG definition for POI, found 19 reports of POI over a 451 span of 27 years (1990 – 2017). Of these 19 reports, only three met ACOG diagnostic criteria for POI and did not have another underlying cause identified. The authors concluded that, while POI is rarely 452 reported to VAERS and most reports contained limited diagnostic information, results did not suggest 453 a safety concern (Patricia Wodi et al., 2023). Cohort studies have also found no association between POI 454 455 and other vaccines, including the tetanus, diphtheria, and pertussis (Tdap), inactivated influenza, and 456 meningococcal vaccines (Naleway et al., 2018).

457 Circulating factors as POI biomarkers

Various circulating factors have been shown to be altered in women with POI in small studies, including vitamin E (Ma *et al.*, 2021), trace elements (Verma *et al.*, 2018), co-enzyme Q10 (Ma *et al.*, 2023), certain gut microbiota (Wu *et al.*, 2021), CD4+ T-cells (Kobayashi *et al.*, 2019), neutrophil to lymphocyte ratios (Yldrm *et al.*, 2015, Ağaçayak *et al.*, 2016), inducible nitric oxide synthase (Tokmak *et al.*, 2015), insulinlike peptide 3 (Zhu *et al.*, 2021), and IFN-γ (Xiong *et al.*, 2020). However, whether these circulating factors are relevant to the pathogenesis of POI, or can serve as novel biomarkers, has not been established.

464 Recommendations



The guideline group recommends that in view of the long-term health consequences of POI, efforts should be made to reduce the risk of POI. Modifiable factors may include:

GPP

- gynaecological surgical practice
- lifestyle such as smoking cessation
- modified treatment regimens for malignant and chronic diseases.

465

The guideline group recommends that women with risk factors for POI are counselled regarding potential for prevention of POI, such as stopping smoking, and fertility preservation.

GPP

466

467 Justification

- 468 POI and early menopause are associated with both modifiable and non-modifiable risk factors including
- 469 family history, early life, reproductive, socio-economic, co-existing illness, lifestyle, and environmental
- 470 factors. Identification of risk factors for POI, especially about family history, is important to identify those
- 471 at risk of POI thereby facilitating potential POI prevention strategies and fertility preservation.

472 Research recommendation.

- 473 Further research is required to (i) identify and clarify risk factors for POI, in addition to those related to
- 474 early menopause, especially the role of socio-economic factors, lifestyle and environmental chemicals; and
- 475 (ii) identify and quantify strategies that may mitigate modifiable risk factors.

RAFT

476



477 PART B: Diagnosis of POI

II. Symptoms, diagnosis, and initial assessment

This chapter explores the symptoms of POI, the diagnostic criteria as well as investigations to establishthe causation of POI.

481 II.1. Symptoms

482 **PICO QUESTION: WHAT ARE THE SYMPTOMS OF POI?**

483 The clinical presentation of POI is guite variable. In a cohort of 955 women with overt POI, 86% presented with secondary amenorrhea and 14% with primary amenorrhea (Jiao et al., 2017). More than 484 50% of women developed amenorrhea within 1 year after irregularity occurred (69.18%, 568/821) (Jiao 485 et al., 2017), although amenorrhea is not required for a diagnosis of POI. Menstrual cycle irregularities 486 may be followed by symptoms related to estrogen deficiency, such as hot flushes and night sweats 487 (Conway, 2000) and vaginal symptoms such as dyspareunia and dryness (Davis 2011). Other symptoms 488 include sleep disturbance, mood changes, poor concentration, stiffness, dry eyes (Smith et al., 2004), 489 altered urinary frequency, low libido, and lack of energy (Conway, 2000). In a cross-sectional study of 490 491 293 Chinese women with POI, the most prevalent symptoms were mood swings (73.4%), insomnia (58.7%), sexual problems (58.7%), and fatigue (57.3%). Other symptoms - with varying severity -492 reported by the women with POI include hot flushes/sweating (49.5 %), melancholia (44.4%), headaches 493 (37.5%), vertigo (36.3%), muscle/joint pain (36.2%), palpitations (32.1), formication¹ (20.1%), urinary tract 494 infection (19.1%) and paraesthesia (17.7%) (Huang et al., 2021). In another study of 160 women with 495 496 POI, women reported a number of menopausal symptoms, including mood swings and mental fog (>75% reporting); hair loss, dry eyes, cold intolerance, and joint clicking (>50% reporting); tingling in 497 limbs(Allshouse et al., 2015). These symptoms can represent a significant source of distress for patients 498 (Davis and Jane, 2011). 499


POI-related symptoms may be transient or intermittent and can vary in severity, reflecting the 500 fluctuations in ovarian activity that occur after the onset of non-iatrogenic POI (Welt, 2008, Knauff et al., 501 502 2009). Some women with POI may not experience any symptoms. Young women with primary 503 amenorrhea due to POI are less likely to experience symptoms related to estrogen deficiency at 504 presentation. In a cohort of women with primary and secondary amenorrhea, symptoms of intermittent 505 estrogen deficiency were reported in 85.6% of those with secondary amenorrhea, while only 22.2% of 506 women with primary amenorrhea reported symptoms (p<0.001) (Rebar and Connolly, 1990). These 507 findings suggest that the onset of these symptoms is due to estrogen withdrawal rather than estrogen deficiency. In contrast, women experiencing surgical menopause usually have severe and persistent 508 509 symptoms. Women may also experience sudden severe symptoms upon cessation of the contraceptive 510 pill. Symptoms have also been reported to vary according to the type of POI (iatrogenic or non-511 iatrogenic) and the underlying cause (Deeks et al., 2011, Gibson-Helm et al., 2014).

- 512 More information on the impact of POI on psychosocial wellbeing and sexuality is available in in section
- 513 VIII.1. Impact of POI on psychological wellbeing and IX.1. Impact of POI on sexuality, respectively.

¹ Formication is an acutely distressing sensation of ants or other insects crawling on the skin (cfr APA Dictionary of Psychology).



514 FIGURE 5. SYMPTOMS OF POI (SYMPTOMS IN BOLD ARE MOST COMMON/IMPORTANT)



519



520 II.2. Diagnosis

521 The diagnosis of POI is confirmed in women < 40 years by a combination of a 4-to-6-month period of 522 disordered menses (including amenorrhea or irregular menses) and measurement of elevated follicle 523 stimulating hormone (FSH). The value of FSH, and other tests used to make the diagnosis of POI, are 524 explored in this chapter.

525 The second part of the diagnostic work-up is to establish a cause for POI. Establishing causation may 526 have implications for the management options for symptoms associated with POI, and/or associated

527 conditions. Finally, autoantibody tests used in POI are further explored, including what clinicians should

- 528 do in case of a positive antibody test result, and when to repeat the test in case of a negative result.
- 529

530 **PICO QUESTION: WHAT INVESTIGATIONS SHOULD BE PERFORMED FOR DIAGNOSIS OF POI?**

POI is characterised by menstrual disturbance, raised gonadotropins, and low estradiol. However, 531 standardized diagnostic criteria have not been established by any professional organization. The 2015 532 533 National Institute for Health and Care Excellence (NICE) guidelines recommend making a diagnosis of 534 POI in women under 40 based on a combination of menopausal symptoms (including amenorrhea or infrequent periods, with consideration of whether the woman has a uterus) and elevated serum FSH 535 536 twice, at least 4-6 weeks apart (NICE, 2015, NICE, 2019). Women presenting with amenorrhea should be 537 directly questioned about symptoms, as they may not volunteer these, or indeed be aware that their symptoms are related to menstrual disturbance. Other aetiologies of amenorrhea (e.g. pregnancy, 538 polycystic ovary syndrome (PCOS), thyroid dysfunction, hyperprolactinemia) should be ruled out before 539 540 assigning a diagnosis of POI. FSH levels are used as the gold standard in establishing a diagnosis of POI 541 but there is insufficient high-quality evidence to propose definitive cut-off levels. Indeed, ovarian function decline can be intermittent and erratic, and POI can still be characterized by periods of low FSH 542 concentrations and vaginal bleeding (De Vos et al., 2010). As such, FSH thresholds to diagnose POI vary 543 in the literature, with suggested cut-off levels ranging from >15 (Gordon et al., 2017) to >40 (2014) or 544 545 >50 (Ishizuka, 2021). Nelson et al proposed using criteria as defined by the reporting laboratory (FSH level in the menopausal range) (Nelson, 2009). 546

547 Histological evaluation of ovarian biopsies from women with primary amenorrhea found no follicles 548 when FSH levels were above 33 mIU/ml, while in women with secondary amenorrhea no follicles were 549 found when the FSH was >40 mIU/ml (Goldenberg et al., 1973). However, some women with POI express 550 FSH levels lower than these values, particularly women with autoantibodies. La Marca found that women with POI due to steroidogenic cell autoimmunity had significantly lower FSH levels (n=26; median 37 551 552 mIU/ml; range 26-64 mIU/ml) compared with idiopathic POI (median 99 mIU/ml; range 61-166 mIU/ml; p=0.001) (La Marca et al., 2009). As such, the previous guideline group proposed a cut off level of FSH 553 554 > 25 IU/I to diagnose POI, as this is above the physiological range for FSH even at the pre-ovulatory 555 peak and even in women with autoimmune POI (Webber et al., 2016). No new evidence exists to alter 556 this proposed cutoff. While estradiol alone should not be used to make the diagnosis of POI, estradiol 557 levels of less than 50 pg/mL (183.6 pmol/L) indicate hypoestrogenism (ACOG, 2014).

If the clinical presentation and initial biochemical testing (high FSH/low estradiol) are consistent, then the diagnosis of POI should be made. A second test may be required if the first set of results are inconclusive, and the index of clinical suspicion is high. Given the sometimes-fluctuant nature of the condition, menses may return, and FSH/estradiol levels normalise, thus a second test may paradoxically confuse the situation.



563 **Recommendations**

HCPs should diagnose POI based on the presence of amenorrhea or oligomenorrhea and biochemical confirmation.

 $\oplus \oplus \bigcirc \bigcirc$ STRONG

564

Although proper diagnostic accuracy in POI is lacking, the guideline group recommends the following diagnostic criteria: amenorrhea or oligomenorrhea for at least 4 months, and an elevated FSH level >25 IU/I.

GPP

FSH assessment should be repeated after >4 weeks if there is diagnostic uncertainty.

565 Justification

POI is characterised by oligo/amenorrhoea, raised gonadotropins, and low estradiol. In the absence of 566

- 567 new data, the previous diagnostic criteria were accepted by the Guideline development group. An
- elevated FSH> 25 IU represents a value greater than the physiological peak observed in premenopausal 568
- 569 women and will encompass women with POI due to autoimmune causes. Often, the diagnosis is clear
- after a single biochemical test. Repeat FSH and estradiol testing is indicated where there is uncertainty: 570 571
- as discussed below, AMH may sometimes be of value. As fluctuating ovarian function may occur with
- 572 POI, FSH concentrations may also vary considerably, including into the normal range.
- **Research Recommendation** 573
- Further research is required to establish the optimal FSH criteria for the diagnosis of POI or a sensitive and 574
- specific alternative biomarker that is readily available. 575
- Measurement of AMH in women with POI 576
- 577

PICO QUESTION: WHAT IS THE ROLE OF AMH TO PREDICT/ DIAGNOSE POI? 578

AMH now has an established role as a clinically useful predictor of the ovarian response to stimulation 579 in IVF (The ESHRE Guideline Group On Ovarian Stimulation et al., 2020). This reflects its known main 580 source of production, which is predominantly the population of small antral follicles in the ovary. It is 581 582 produced by ovarian follicles when they start to grow, i.e. from the primary stage onwards but their 583 relatively small size and thus small number of granulosa cells compared to the much larger small antral 584 follicles means that the latter is the predominant source of AMH in circulation. This is important in the context of its potential use in POI as it means that AMH will be detectable within the serum of women 585 586 with a very small number of antral follicles, even when the population of primordial and early growing follicles is extremely depleted. Diagnostic accuracy will also be impacted by the fluctuant ovarian 587 588 function that is characteristic of POI, but particularly in the initial years (see section V. POI, fertility and pregnancy), all confounding the simplistic assumption that AMH will be undetectable or nearly so in 589 women with POI. 590

591 The value of AMH in both prediction and diagnosis of both usual age menopause and POI has recently 592 been subject of a systematic review (Nelson et al., 2023) which evaluated 11 publications that 593 investigated the use of AMH in the context of POI. This excludes women treated for cancer, also the subject of a recent specific systematic review (Anderson et al., 2022a). Another more general review of 594 595 the use of AMH also included POI as a specific diagnosis of evaluation (Iwase et al., 2024). In summary,



these studies confirm that AMH levels are markedly reduced in women with POI, and it does, therefore, 596 have diagnostic value. This is particularly the case to distinguish POI from the common alternative 597 598 diagnosis of PCOS in a woman with amenorrhea, where AMH levels are high, and in women with hypothalamic amenorrhea, where AMH levels are normal or only mildly reduced. While longitudinal 599 studies are lacking, cross-sectional studies do suggest an increase in the likelihood of very low or 600 undetectable AMH levels in women with developing POI. While these studies are subject to enrichment 601 bias, there may be clinical value in women with a known risk factor for POI, such as those with Turner 602 603 syndrome. Studies assessing the formal diagnostic accuracy of AMH for the diagnosis of POI have, 604 however, shown very good sensitivity and specificity. The largest such study, including 410 women with 605 clinical presentations including early and established POI, found that a diagnostic threshold of less than 606 0.25 ng per mL (1.78 pmol/L) gave an optimum combination for the diagnosis of POI with sensitivity 607 92.5% and specificity 90%. However, there is no evidence for an advantage over current FSH-based 608 diagnostic testing. Further studies are required to confirm and refine the potential value, particularly 609 identifying more clearly populations of women with some aetiologies of POI who have relatively 610 maintained AMH levels. This particularly appears to be associated with women with developing autoimmune POI where the pathological stage of follicle loss occurs relatively late in folliculogenesis, 611 but this remains to be established in adequately sized and designed studies. 612

In the context of POI after cancer treatment, the possibility of post-treatment recovery of ovarian 613 614 function in many women resulted in their exclusion from characterization and diagnostic recommendations in the Stages of Reproductive Aging in Women analysis (Harlow et al., 2012). 615 However, the diagnostic accuracy of AMH for the diagnosis of POI after chemotherapy for breast cancer 616 has been demonstrated to have very high sensitivity and specificity when assessed approximately 2 617 vears after completion of treatment (in the absence of confounding endocrine treatment) (Anderson et 618 al., 2017b). Early assessment after completion of treatment also shows good accuracy, but particularly 619 in women over the age of 40 (Anderson et al., 2022c) and thus is of less clear value in the population of 620 women to whom the term POI pertains. While it seems likely that AMH will have similar value for the 621 diagnosis of POI after treatment of other cancers, this has not been formally tested. 622

623 **Recommendations**

AMH testing could be considered in the diagnosis of POI where there is diagnostic uncertainty. However, it has not been shown to have benefit OOOO CONDITIONAL over existing FSH-based diagnostic testing.

624

The guideline group recommends that AMH tests are interpreted within the clinical context. Further research is required to determine diagnostic thresholds for POI.

GPP


625 Justification

- As AMH is a direct product of the small growing follicles of the ovary, it has theoretical value as a diagnostic test in POI. However, the evidence at present does not support its value over the existing,
- 628 FSH-based, approach. It may become of value in identifying women at risk of POI, where a risk factor is
- 629 identified, but this is not clearly supported by current evidence. In some contexts, there may be reasons
- 630 not to perform an AMH test, for example when a low result risks limiting access to fertility treatment.
- 631 Availability of the test, particularly in primary care, remains limited.

632



633 Figure 6 Algorithm for the diagnosis of POI (Created with BioRender.com)



Guideline POI – DRAFT FOR REVIEW



637 II.3 The causes of POI

POI is a complex, multifactorial condition and its aetiology remains poorly understood in many cases
(Rahman and Panay, 2021). A combination of different factors (see I.4. Risk factors for POI), may
ultimately precipitate the disorder (Panay *et al.*, 2020).

641 In broad terms, POI can be iatrogenic or spontaneous (Nash and Davies, 2024). The proportion of 642 women with different causes of POI has not been established overall, as it varies by patient population 643 and clinical setting. (Nash and Davies, 2024)

In a proportion of women with non-iatrogenic POI, a genetic cause, such as chromosomal defects, 644 645 Fragile X syndrome, or autosomal gene defects, or a genetic predisposition can be identified. Other women with POI could be linked to autoimmune conditions. Testing for genetic causes and autoimmune 646 647 causes after a diagnosis of POI is discussed in this chapter. Other causes and risk factors, such as infection, mumps oophoritis, toxins, galactosemia, (Panay et al., 2020, Rahman and Panay, 2021, Nash 648 649 and Davies, 2024) are usually not tested in clinical practice, due to low prevalence, and lack of evidence 650 of causation, and limited relevance for clinical management of POI, and hence are not discussed in 651 detail.

- 652 It has been estimated that the aetiology of non-iatrogenic POI is unknown in 70–90% of diagnosed
- women (Nelson, 2009) and for these women, the term idiopathic POI is appropriate. However, improved
- 654 genetic testing is likely to reduce the proportion of women designated as having 'idiopathic' POI (see
- also Figure 7 Summary of testing to establish a cause for POI).
- 656 **Recommendation**

The guideline group recommends that HCPs should inform women with POI of the different causes of POI, the limitations of current knowledge and testing for causes of POI and that an exact cause may not be determined

657

658 *latrogenic POI*

In a subgroup analysis of a systematic review and meta-analysis, an iatrogenic etiology was determined in 11.2% of women with POI, followed by autoimmunity (10.5%) (Li *et al.*, 2023a).

latrogenic POI includes POI after i) chemotherapy; ii) pelvic field radiotherapy; iii) linked to ovarian
 pathology or pelvic surgery, e.g. endometriosis surgery, ovarian torsion, or surgery to remove large
 ovarian cysts; and iv) bilateral oophorectomy (Nash and Davies, 2024).

664 Chemotherapy, pelvic field radiotherapy and surgery for treatment of common cancers in younger 665 women will often cause ovarian damage, potentially inducing permanent menopause (Szabo *et al.*, 2019, 666 Hickey *et al.*, 2024). These common cancers include breast, gynaecological, haematological, and some 667 low colorectal cancers.

- 668 Chemotherapy-induced amenorrhea (often used as a surrogate marker of POI)is a common 669 complication observed in premenopausal women with breast cancer, and the incidence of 670 chemotherapy-induced amenorrhea ranges from 15% to 94% (5) in women with breast cancer after 671 receiving chemotherapy. Whether or not chemotherapy for breast cancer will result in POI is affected 672 by several factors. The meta-analysis by Wang reported that women treated before the age of 40 were 673 less likely to develop POI (pooled OR 0.136; 95% CI 0.104 to 0.177; p <0.001). In terms of chemotherapy
- treatments, the risk of POI was increased with the addition of taxanes to anthracycline-based treatments

GPP



- 675 (OR 0.699; 95% CI 0.608 to 0.803; p < 0.001 for anthracycline versus anthracycline-taxane), and with the 676 addition of tamoxifen treatment (OR 0.568; 95% CI 0.461 to 0.701; p < 0.001)(Wang *et al.*, 2022).
- 677 Gynaecological cancers (estimated 1.8 million diagnosis in women per year) are commonly treated with
- 678 bilateral oophorectomy, pelvic radiation and/or gonadotoxic chemotherapy, which all potentially induce
- 679 POI or early menopause (Brennan *et al.*, 2021).
- 680 Colorectal cancer diagnosis is increasing in younger women, particularly rectal and anal cancer, which 681 are commonly treated with pelvic irradiation that will induce POI (Sung *et al.*, 2021, Hickey *et al.*, 2024).
- Leukaemia and lymphomas comprise about 4% of all cancers in women younger than 50 years and are commonly treated with a stem-cell transplant (Sung *et al.*, 2021). Gonadotoxic chemotherapy before stem-cell transplantation will induce menopause in the majority of premenopausal women, depending
- on their age and nature of the conditioning regimen (Lee *et al.*, 2023b).
- A history of pelvic surgery was found associated with an increased risk of POI in a case-control study of 553 women with POI and 400 controls (OR 5.53; 95% CI 2.15 to 14.23) (Wang *et al.*, 2015). Both ovarian surgery for endometrioma and endometriosis as a disease seem to influence age of menopause, and
- the risk of POI(Coccia et al., 2011, Raffi et al., 2012, Somigliana et al., 2012).
- Finally, bilateral oophorectomy before the age of 40 will result in POI. Often, bilateral salpingooophorectomy is performed by age 35–40 years in women at elevated risk of ovarian cancer due to pathogenic gene variants such as BRCA1 or BRCA2, in line with international guidelines (Daly *et al.*,
- 693 2021).
- 694 Recommendation

The guideline group recommends that HCPs treating women with medical or surgical intervention that may cause POI should discuss the risk of POI as part of the consent process.

695

696 Genetic background of POI

The risk of POI is increased in female relatives of women with POI (RR 4.6; 95% CI 3.3 to 6.5) (Silvén et 697 al., 2022) (see also I.4. Risk factors for POI), and approximately 15-30% of women with POI have family 698 699 members who are also affected, pointing to an underlying genetic component (Bachelot, et al., 2009, 700 Panay, et al., 2020, van Kasteren, et al., 1999, Vegetti, et al., 1998). Twin studies have indicated a high 701 concordance of POI among monozygotic twins (Gosden, et al., 2007, Huhtaniemi, et al., 2018, Ruth, et 702 al., 2016). Genetic factors also explain a large proportion of the variability of the age of natural 703 menopause, ranging from 45 to 85% depending on the studies (McGrath, et al., 2021, Murabito, et al., 704 2005).

705 Genetic causes of POI are not restricted to X chromosome anomalies, variants linked to POI have been 706 identified across many of the chromosomes. The mode of transmission of POI is either recessive (and 707 the parents are not affected), dominant (and the mother can be affected), or X-linked, depending on 708 the gene involved. Some genetic causes are shared between female and male infertility (notably in the 709 case of the involvement of meiosis/DNA repair genes) and in such families, men with azoospermia can 710 be found as well as women with POI. Numerical and structural abnormalities on the X chromosome as 711 well as dysfunction in several genes that regulate ovarian development and function are strongly 712 associated with POI. Next-generation sequencing (NGS) of all coding genes (exome or genome studies) 713 has made it easier to reveal new pathogenic variants in genes already identified or newly related to POI thus increasing the frequency of a positive genetic diagnosis for women with POI which would otherwise 714

GPP



- be designated as "idiopathic" POI. International standards have been developed to ensure rigorous
 assessment of whether an identified genetic variant is truly causal for POI (Richards *et al.*, 2015).
- 717 The possible genetic cause of POI supports the collection of information on the patient and her family
- about fertility and other associated pathologies (developmental disorder, neurologic signs, mental
 retardation, sensorial symptoms, cardiovascular symptoms, endocrine or metabolic associated disorder,
- tumours, etc.) as well as drawing up a family tree.
- 721

PICO QUESTION: WHAT ARE THE KNOWN GENETIC CAUSES OF POI AND HOW SHOULD THEY BE INVESTIGATED?

724

725 Chromosomal anomalies

726 Large cohort studies and meta-analyses have found the frequency of chromosomal anomalies in women with POI to be approximately 10-13%, of which the majority are X chromosomal anomalies (X 727 728 aneuploidy or X structural abnormalities) (Chen, et al., 2023, Jiao, et al., 2012, Lakhal, et al., 2010). A large Finnish population-based study including 5011 women with POI, found an odds ratio (OR) for Turner 729 syndrome of 275 (95% CI 68.1 to 1110). For other sex chromosome abnormalities, the OR was 12.7 (95% 730 731 CI 4.1 to 39.1)(Silven et al., 2023). Abnormal karyotypes are more commonly diagnosed in women with primary amenorrhea (21%) than in those presenting with secondary amenorrhea (11%) (Jiao, et al., 2012, 732 733 Kalantari, et al., 2013). As chromosomal anomalies may result in more extreme phenotypes, including syndromic features, the incidence is higher at younger age of POI diagnosis (Gruber, et al., 2020, Jiao, 734 735 et al., 2017).

Normal germ cells carry two X chromosomes, of which one is initially inactivated during the early stages of oocyte formation in the foetal ovary. However, the presence of two transcriptionally active X chromosomes are essential for normal germ cell maturation and the second X chromosome is temporary reactivated at later stages of germ cell differentiation (Arnold, et al., 2016, Khan and Theunissen, 2023). Furthermore, approximately 20% of the genes on the inactivated X chromosomes escape inactivation and continue to be expressed in somatic cells, maintaining the dosage specific gene products, essential to the female phenotype (Loda, et al., 2022, Tukiainen, et al., 2017)(Fukami, 2023).

743

744 Chromosomal Aneuploidy

745 Turner syndrome (TS) is caused by the complete or partial loss of one X chromosome, i.e. 45,X karyotype, 746 and occurs in approximately 25-50 per 100 000 live female births (Rossetti, et al., 2017, Sybert and 747 McCauley, 2004)(Gravholt, 2024). Haploinsufficiency, when one copy of the X chromosome is missing, 748 leads to lack of required dosages of particular X-linked gene products causing accelerated loss of 749 primordial oocytes during female foetal development, resulting in streak gonads at birth (Castronovo 750 et al., 2014, Ibarra-Ramírez et al., 2023). Clinically, women with TS with complete 45,X karyotype are 751 characterized by primary amenorrhea and POI. Other characteristic phenotypic features of TS include 752 short stature, lymphedema, webbed neck, shield chest, wide-spaced nipples, cubitus valgus as well as 753 cardiac anomalies (coarctation or aortic anomalies) (Gravholt, et al., 2017, Sybert and McCauley, 2004). 754 Mosaicism with 45,X/46,XX karyotypes are found in 15-25% of women with TS (Gravholt, et al., 2023). 755 Other TS karyotypes include more complex forms of mosaicism such as 45,X/47,XXX, mosaicism with 3 756 or more different cell lines (e.g. 45,X/46,XX/47,XXX), or mosaicism with structural variants of the X 757 chromosome (Gravholt, et al., 2023). In women with mosaic TS, the severity of symptoms may vary, and

758 menarche and pregnancy can occur (Castronovo, et al., 2014, Tuke, et al., 2019).



759 Other numerical chromosome abnormalities are also associated with POI, including Triple X syndrome 760 (TXS), with the presence of an extra X chromosome resulting in a 47,XXX karyotype (Davis, et al., 2020, 761 Franić-Ivanišević, et al., 2016, Rafigue, et al., 2019). TXS affects approximately 1 in 1000-2000 live female births (Davis, et al., 2020). However, it is estimated that only 10% of women with TXS receive a diagnosis 762 763 and that many receive a delayed diagnosis (Berglund, et al., 2019, Tartaglia, et al., 2010). Although many 764 women are asymptomatic, a wide variety of clinical and psychological conditions are associated with TXS; the most common characteristics include tall stature, hypotonia in infancy, epicanthal folds, 765 766 clinodactyly, and constipation (Davis, et al., 2020, Sybert, 2002, Tartaglia, et al., 2010). Low AMH 767 concentrations in TXS women, indicating diminished ovarian reserves, have been demonstrated in two case-control studies (Davis, et al., 2020). Several case reports have illustrated that women with TXS are 768 769 at increased risk of early menopause and POI; however, available data on frequency TXS in POI are 770 limited (Rafigue, et al., 2019, Rogol, 2023). A case-control study of 269 women with POI found a 5-fold 771 increase of TXS compared to 46,XX women (Baronchelli et al., 2011). A similar frequency was noted in a 772 Chinese cohort of 531 women with POI (~0.6%) (Jiao, et al., 2012).

Y chromosome material may be present in some women, and confers an increased risk of gonadal 773 774 tumours (10-30%) (Gravholt, et al., 2000, Matsumoto, et al., 2020, Michala, et al., 2008, Steinmacher, et 775 al., 2021). Gonadoblastoma and dysgerminoma are the most common types of tumours found in these 776 patients (Matsumoto et al., 2020). In a study of 102 women with disorders of sex development (DSD) 777 and karyotypic Y chromosome or Y-derived sequences present, the total incidence of gonadoblastomas 778 was 17.6% (Liu, et al., 2014). In TS women with 45,X/46,XX mosaicism, Y chromosomal material was 779 present in 10% to 12% (Gravholt, 2024). Several small studies have found a high incidence of 780 gonadoblastomas in TS patients with Y chromosome material present, detected in 36.4% (4 of 11) and 781 18% (6 of 34) (Dendrinos et al., 2015, Matsumoto et al., 2020, Steinmacher et al., 2021). It is therefore important that women with TS have had an accurate karyotype, including investigation for low level Y 782 chromosome mosaicism (Gravholt, et al., 2017). 783

784 Structural X chromosome anomalies

785 Structural defects of the long Xq arm, especially deletions, duplications, inversions, isochromosomes and translocations affecting the critical regions Xq13-21 and Xq23-27 are associated with reduced 786 787 ovarian function (Rossetti, et al., 2017). A number of studies have established a relationship between 788 structural X chromosomal disorders and POI, with a frequency ranging from 4% to 12% (Ceylaner, et al., 789 2010, Chen, et al., 2023, Di-Battista, et al., 2020, Jiao, et al., 2012, Lakhal, et al., 2010, Toniolo, 2006). POL is observed in approximately 50% of translocations affecting the X chromosome, more often when 790 791 breakpoints fall in one of the two POI critical regions, while breakpoints outside these regions rarely 792 result in ovarian impairment (Di-Battista, et al., 2020).

Several mechanisms have been suggested to explain the association with structural defects in the POI critical regions, including gene disruption and/or down regulation of genes necessary for normal ovarian function in these regions, as well as implications on positioning effects resulting in meiosis error. Moreover, many POI candidate genes on the X chromosome have been identified by analyzing the X-autosome translocation breakpoints, pointing to these areas as important for ovarian function (Bestetti, et al., 2021, Di-Battista, et al., 2020, Tšuiko, et al., 2016).

799 Fragile X premutation

Premutation of the Fragile X mental-retardation 1 (*FMR1*) gene (55-200 trinucleotide repeats) is the most common single genetic disorder linked with POI (Cronister, et al., 1991, Schwartz, et al., 1994)(Tassone *et al.*, 2023). *FMR1* premutations are found to in 1 to 5% of women with sporadic POI and up to 13% in women with a positive family history of POI (Chen, et al., 2023, Conway, et al., 1998, Fink, et al., 2018, Murray, et al., 2014, Wittenberger, et al., 2007). In a large UK cohort population study

including more than 2000 women with POI or early menopause, the prevalence of *FMR1* premutation



was 2.0% in women with POI, 0.7% in early menopause, and 0.4% in controls, corresponding to OR of
5.4 (95% CI 1.7 to 17.4; p=0.004) for POI and 2.0 (95% CI 0.8 to 5.1; p=0.12) for early menopause (Murray,
et al., 2014). This association between *FMR1* premutation and POI was not found in a meta-analysis of
4 studies on POI in an Asian population (Tosh, et al., 2014). The *FMR1* premutation frequency is also
lower among Chinese women 0.49 to 1.6% (Guo, et al., 2014, Tang and Yu, 2020).

811 Women who carry the premutation of the FMR1 gene have a 20% increased risk of developing Fragile 812 X-associated POI (FXPOI) (Hunter JE., et al., 2019, Sherman, 2000, Wittenberger, et al., 2007). The exact 813 molecular mechanism by which the FMR1 premutation leads to ovarian failure and POI has not yet been fully elucidated but when CGG trinucleotide repeats of the FMR1 gene are duplicated to 55-200 repeats 814 815 the premutation becomes unstable and results in inadequate production of the FMR1 protein which is 816 likely to be important for normal follicle function (Lu, et al., 2012, Rosario, et al., 2022, Rossetti, et al., 2017). The age at development of POI in women with FMR1 premutations is variable. Background 817 818 modifier genes and environmental factors as well as the number of CGG repeats are related to the 819 severity of FXPOI (Allen, et al., 2007, Spath, et al., 2011, Tejada, et al., 2008, Trevino, et al., 2021). In a 820 recent meta-analysis involving 3394 women with idiopathic POI and 8461 controls, FMR1 premutation 821 was significantly associated with increased risks of POI (OR 8.13; 95% CI 4.35 to 15.19; p<0.00001) but also diminished ovarian reserve (characterised by subfertility, normal or slightly elevated FSH levels, low 822 anti-mullerian hormone (AMH), low antral follicle count) (OR 14.87; 95% CI 5.20 to 42.52; p<0.00001) 823 (Huang, et al., 2019). Other studies have demonstrated a bell-shaped relationship with CGG repeat 824 numbers of 80 to 100 CGG triplets, yielding the highest risk for FXPOI compared to repeat lengths of 59 825 to 79 or >100 (Allen, et al., 2007, Hipp, et al., 2016, Tassone, et al., 2023). No correlation is found between 826 the FMR1 CGG high normal intermediate repeat length (45-54 trinucleotide repeats) and FXPOI (Huang, 827 et al., 2019, Ruth, et al., 2016). The risk of developing FXPOI is also not increased in women with the full 828 mutation (>200 trinucleotide repeats) (Bennett, et al., 2010). 829

830 Clinically, FMR1 premutation carriers may exhibit a wide range of symptoms and phenotypes including 831 neuropsychological conditions (Coffey, et al., 2008, Tassone, et al., 2023). FMR1 premutation increases 832 the risk of Fragile X-associated tremor/ataxia syndrome (FXTAS), a neurological condition characterized by late-onset, progressive cerebellar ataxia and intention tremor followed by cognitive impairment. The 833 penetrance of FXTAS among adult FMR1 premutation carriers increases with age, exceeding 50% for 834 835 men aged 70-90 years. Females are also affected but severity and penetrance are less (16%-20%) (Jacquemont et al., 2007, Hagerman and Hagerman, 2013, Hunter JE. et al., 2019, Schneider et al., 2020). 836 Psychological difficulties have also been associated with FMR1 premutation. In a population-based 837 838 cohort of 20 000 patients, FMR1 genotyping demonstrated increased rates of anxiety conditions in both 839 female and male premutation carriers compared to non-carriers (Movaghar, et al., 2019).

FMR1 premutations can expand to a full mutation (>200 repeats) when transmitted to the next
 generation, causing Fragile X syndrome (FXS). The Fragile X syndrome is an X-linked inherited condition
 characterized by mental retardation, primarily affecting male offspring (Tassone, et al., 2023).

843 Other genetic causes of POI

844 The advent of next-generation sequencing (NGS) with whole exome (WES) and whole genome (WGS) 845 sequencing has provided the opportunity to simultaneously study a series of genes in large patient cohorts and allowed a leap in the identification of novel genes involved in POI in the last ten years 846 847 (Huhtaniemi, et al., 2018). Data from international studies with large cohorts and using strict criteria 848 have shown genetic causation with positive gene variants identified in 14 to 30% of women with POI 849 depending on the size of the gene panels used (Patiño et al., 2017, Jolly et al., 2019, Yang et al., 2019, 850 França et al., 2020, Bestetti et al., 2021, Eskenazi et al., 2021, Rossetti et al., 2021, Shen et al., França and 851 Mendonca, 2022, Heddar et al., 2022, Chen et al., 2023, Ke et al., 2023, Luo et al., 2023, Long et al., 2024, 852 Vogt et al., 2024). Higher gene variant positivity, for example up to 75% of women with POI (Rossetti et



al., 2021), has been reported in studies employing different methodologies including criteria in determining the causative importance of genes for POI when constructing a gene panel. Familial/consanguineous POI (30.5-36.7% patients (Jolly *et al.*, 2019, Heddar *et al.*, 2022) or syndromic POI (58.3% patients (Heddar *et al.*, 2022) is associated with higher gene variant positivity compared with sporadic POI (gene variants reported in 15-20% in Brazilian (França *et al.*, 2020), Chinese (Shen *et al.*, 2021) and Norwegian (Vogt *et al.*, 2024) cohorts.

859 Systematic reviews and standardized clinical validity assessment of genes involved in POI have been 860 performed (França and Mendonca, 2022, Volozonoka et al., 2022, Doulgeraki et al., 2023, Van Der Kelen et al., 2023). Pathologic variants in approximately 100 genes associated with POI, indicating a high 861 862 genetic heterogeneity, have been identified and the list is constantly expanding (Rossetti et al., 2021, 863 Ruth et al., 2021, Yang et al., 2021, França and Mendonca, 2022, Volozonoka et al., 2022, Doulgeraki et al., 2023, Ke et al., 2023, Van Der Kelen et al., 2023). Virtual POI gene panels and genetic variant 864 865 classifications based on continuously updated expert curated databases exist (e.g.: Genomic England, or PanelApp Australia). 866

As mentioned, approximately 100 monogenic causes of POI have been reported, where a single genetic 867 variant is sufficient to cause the POI phenotype. Apart from research on monogenic causes, there has 868 been focus on oligogenic inheritance with possible synergistic effects explaining the variance in 869 phenotype seen (Rossetti et al., 2021). A NGS study of 64 women with POI noted at least one POI gene 870 871 related variant in 48/64 and 2 or more variants in 34/64 patients where type and number of gene variants 872 influenced the severity of the POI clinical phenotype (Rossetti et al 2021). A study of a Chinese POI cohort (n=1030) identified pathogenic/likely pathogenic gene variants in 19% of women with POI 873 overall where 80% were monogenic and 7.3% had multiple variants identified in different genes (Ke et 874 al., 2023). A large cohort study investigating the presence of genetic variants for 105 genes associated 875 876 with POI in 104 733 women from the UK Biobank (1.14% with menopause before 40 years/POI), reported 877 that pathogenic variants in these genes were commonly found in the heterozygous state in women with 878 menopause within the normal age range (Shekari et al., 2023). These data provide evidence towards the 879 hypothesis that POI may be polygenic in nature in some cases, where women inherit a number of common alleles associated with earlier age of menopause that, when combined with other risk factors, 880 881 could push them into the extreme end of the phenotypic distribution (Shekari et al., 2023). However, 882 further studies are needed to clarify potential oligogenic/ polygenic contributions to the POI phenotype.

Categories of genes where the associated molecular defects, cellular dysfunction and disrupted pathways illustrate the range of causes of POI. Genes involved in DNA repair (37.4%) or follicular growth (35.4%) were the most common pathways identified in a study of 375 European women with POI (Heddar, et al., 2022). Similar findings were obtained in study of 1030 Chinese women with POI where genes involved in meiosis (48.7%) were most commonly affected (Ke *et al.*, 2023). These categories can be listed:

- Genes involved in DNA and meiosis repair. Mutations cause chromosomal fragility severe enough to impact meiosis with significant impact on fertility and increased susceptibility to tumorigenesis. Screening for and identifying variants in this class of genes should be considered in collaboration with multidisciplinary teams to facilitate presymptomatic co-morbidity screening and prevention.
 - Genes involved in metabolism and mitochondrial functions resulting in isolated or syndromic POI such as Perrault syndrome or galactosemia.
- Genes involved in follicle growth, coding for hormone receptors, such as *FSHR*, or oocyte growth factors, such as *GDF9* and *BMP15*.
- 898 Other gene families linked to POI include:

894



- Genes involved in ovarian or early follicle development may be associated with POI, and other organ defects if they play a role in development (for example, *SF1/NR5A1* gene, which is also involved in adrenal development).
 - Genes involved in follicular atresia. Very few genes in this family have been identified so far.
 - Genes involved in immune function such as NF-KB
 - Genes involved in RNA metabolism and translation such as FMR1.
- 904 905

902

903

POI is usually isolated (i.e. sporadic POI), with no associated clinical signs, but can also be syndromic, 906 associated with other more complex pathologies requiring multidisciplinary management. (see Table II 907 908 Syndromes associated with POI). The specific genes associated with syndromic POI can be screened 909 routinely in expert laboratories where available. A population-based register study in Finland including >5000 women with POI (1988-2017) showed that 15.9% of women had at least one other congenital 910 disorder (Silven, et al., 2023). In the cohort of Heddar et al, 44.8% of patients had, or were at risk to 911 912 develop, associated comorbidities, requiring a comprehensive assessment by a multidisciplinary team. 913 POI pathogenic variants of genes causing syndromic POI were identified in 8.5% of cases (Heddar et al., 2022). Symptoms of syndromic POI may include endocrine symptoms, neurosensorial symptoms, 914 cardiovascular symptoms, inborn errors of metabolisms, ovarioleukodystrophy, and susceptibility to 915 916 tumours/cancers when meiosis/DNA repair genes are involved (Huhtaniemi, 2018 #2885).

917

918 TABLE III SYNDROMES ASSOCIATED WITH POI (LIST BASED ON QIN 2015 AND HUHTANIEMI 2018, NOT 919 EXHAUSTIVE)

EXHAUSTIVE)			
Syndrome	OMIM	Gene(s)	Further information
Acromesomelic chondrodysplasia with genital anomalies	#609441	BMPR1B	Particular features: Severe brachydactyly with radial deviation of the fingers, ulnar deviation of the hands, fusion of the carpal/tarsal bones, aplasia of the fibula, bilateral clubfeet with small broad feet and short toes
Ataxia telangiectasia	#208900	ATM	Progressive cerebellar degeneration, telangiectasias, immunodeficiency, recurrent infections, insulin-resistant diabetes, premature aging, radiosensitivity, and high risk for epithelial cancers in surviving adults.
Autoimmune polyendocrine syndrome type I (APS-1)	#240300	AIRE	Rare autoimmune condition including chronic mucocutaneous candidiasis, hypoparathyroidism, and autoimmune adrenal failure. Some patients also present with POI. It results from mutations in the AIRE gene, with complex transmission: recessive autosomal in some variants, and dominant in others. Also called Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)
Blepharophimosis-ptosis- epicanthus inversus syndrome (BPES)	#110100	FOXL.2	Prevalence: ~1–9/100,000 Transmission: Autosomal dominant Rare congenital palpebral malformation It is in some cases associated with POI; in which case it is known as type-1 BPES.
Bloom syndrome	#210900	BLM	Chromosomal breakage leading to early onset of aging, short stature, and elevated rates of most cancers.
Fanconi anemia	#227650 #227645 #614082	FANCA FANCC FANCG	Particular features: Pancytopenia, small stature, microcephaly, ear anomalies, heart defects, kidney malformations, radial aplasia and thumb deformities, intellectual disability, café-au lait spots
Fragile X syndrome	#300624	FMR1	Attention deficits, hyperactivity, social deficits, anxiety disorder, deficits in cognitive flexibility.
Galactosemia	#230400	GALT	A metabolic disease related to abnormal glucose metabolism. The culprit gene in this form showing recessive autosomal transmission is GALT. The POI is due to accumulation of galactose in the ovaries, leading to oocyte apoptosis. Acute neonatal life-threatening symptoms are observed (e.g., vomiting, poor feeding, lethargy, metabolic acidosis, jaundice,



			abnormal clotting, liver failure) but adults are also affected in milder forms.
GAPO	#230740	ANTXR1	Particular features: Growth retardation, alopecia, pseudoanodontia, optic atrophy, high forehead, midface hypoplasia
Hutchinson-Gilford progeria	#176670	LMNA	Particular features: Progeria, short stature, low body weight, early loss of hair, lipodystrophy, scleroderma, decreased joint mobility, osteolysis, cardiomyopathy
Nijmegen breakage syndrome	#251260	NBN	Particular features: Prenatal growth retardation, progressive mental deterioration, microcephaly, recurrent infections, increased risk for neoplasias such as lymphoma
Perrault syndrome	#233400	HSD17B4	Associated with ovarian dysgenesis and sensorineural hearing
-	#614926	HARS2	loss. Like the hearing loss, the dysgenesis is extremely variable,
	#614129	LARS2	but systematic.
	#615300	CLPP	Identifying new candidate genes should shed light on the
	#616138	C10orf2	pathophysiology of the hearing loss and of POI in this syndrome
	#605608	CLDN14	
	#612425	SGO2	
	#609947	KIAA0391	
	#607435	ERAL1	
PMM2-CDG CDG-1 (a	#212065	PMM2	Cerebellar dysfunction (ataxia, dysarthria, dysmetria), non-
previously known as			progressive cognitive impairment, stroke-like episodes,
congenital disorder of			peripheral neuropathy with or without muscle wasting, absent
glycosylation type 1a)			puberty in females, small testes in males, retinitis pigmentosa,
			progressive scoliosis with truncal shortening, joint contractures,
	#157640	DOLC	and premature aging
Progressive external	#157640	POLG	Particular features: Ptosis, progressive external ophthalmoplegia,
ophthalmoplegia, PEO			sensorineural hearing loss, axonal neuropathy, muscle weakness, ataxia, dysarthria, dysphagia, and late onset Parkinsonism
Proximal symphalangism, SYM1	#185800	NOG	Ankylosis of the proximal interphalangeal joints. Particular features: symphalangism, hearing loss
Pseudohypopara thyroidism	#103580	GNAS	Particular features: Brachydactyly, short stature, hypocalcemia and hyperphosphatemia, hypothyroidism, obesity
Pseudohypoparathyroidism	#103580	GNAS	An endocrine disease characterized by resistance to parathyroid
type 1A (PHP 1A)			hormone and other hormones such as TSH and GnRH. Particular
			features: Brachydactyly, short stature, hypocalcemia and
			hyperphosphatemia, hypothyroidism, obesity
Retinal dystrophy with or without extraocular	#617175	RCBTB1	Particular features: Retinal dystrophy, goiter, intellectual disability, hypogonadism
anomalies			
Rothmund–Thomson	#268400	RECQL4	Cutaneous rash, sparse hair, small stature, skeletal and dental
syndrome, RTS		-	abnormalities, cataracts,
			premature aging, and an increased risk for cancer, especially
			malignancies originating from
•			bone and skin tissue.
SF1-related XX-DSD	#612964	NR5A1/SF1	Particular features: Adrenal insufficiency
Vanishing white matter	#603896	EIF2B	Neurological disorder characterized by involvement of the white
disease,	#615889	AARS2	matter of the central nervous system. When Leukodystrophies
ovarioleukodystrophy			associated with premature ovarian failure referred to as
			ovarioleukodystrophy.
Werner syndrome	#277700	WRN	Premature aging of the skin, vasculature, and bone and elevated
			rates of certain cancers,
			particularly sarcomas.
Woodhouse-Sakati syndrome	#241080	C2orf37	Particular features: Alopecia, deafness, hypogonadism, diabetes,
			intellectual disability
WT1-related XX-DSD	#194070	WT1	Particular features: Nephropathy, diaphragmatic hernia
XRCC4-related disorder	#616541	XRCC4	Particular features: Short stature, microcephaly, developmental delay, diabetes mellitus



921 Rationale for genetic testing

922 Identifying the genetic cause of POI can be helpful for patients and families by enabling (Heddar *et al.*,923 2022):

- 924 potential psychological benefits including providing a cause of POI rather than the term
 925 "idiopathic".
- better understanding of prognosis, including fertility, thus facilitating counselling and
 personalised management.
- 928 appropriate co-morbidity screening with involvement of multidisciplinary teams (e.g.
 929 oncogeneticists).
- family screening, including male siblings (Huhtaniemi, et al., 2018), facilitating fertility
 preservation and co-morbidity screening in members not yet affected.
- 932 development of novel prevention or treatment strategies (Heddar, et al., 2022, Ke, et al., 2023;
 933 Yang 2021).
- 934

935 **Clinical steps in identifying a genetic cause.**

936 Informed consent and genetic counselling

- 937 Information and written consent should be obtained from the patient and all family members tested
- 938 before genetic testing. The implications of the genetic testing including the implications of NGS analysis,
- should be explained to the patient before the genetic testing. Genetic counselling may be performed in
- a multidisciplinary team setting according to the gene altered.
- 941 Advancement of precision and personalised medicine have raised several ethical issues regarding 942 genetic testing, especially where novel gene variants are detected. As with other genetic diseases, there are issues regarding pathogenic accuracy, interpretation of variants, and potential variable expression. 943 Not everyone with a pathogenic genetic variant associated with POI develops the disease. This must be 944 considered both in diagnostic and predictive testing, especially regarding screening of healthy relatives. 945 On the other hand, information about the risk of POI can enable these women to make adjustments in 946 947 their lives in order to deal with potential fertility issues. Awareness of the implications and limitations of 948 genetic testing as well as clinical counselling is essential. Clinicians should have a clear understanding of the patients' phenotype, as well as the medical- and family histories of the women, to ensure 949
- 950 appropriate interpretation of variants in close collaboration with geneticists.
- 951 Genetic studies

952 Chromosomal analysis

953 Karyotyping using G-banded chromosome analysis is the gold standard for detecting numerical 954 anomalies, including mosaicism and Y chromosomal material, as well as larger structural chromosomal 955 abnormalities. Other methods such as chromosomal microarray (CMA) and other new technologies exist 956 and can be useful in detecting smaller copy number variants and mapping breakpoints of structural 957 chromosomal rearrangements. Use of molecular and cytomolecular techniques such as PCR 958 (polymerase chain reaction) and FISH (fluorescence in situ hybridization) can detect chromosome mosaicisms (Soares, et al., 2021). Recent observations have suggested chromosomal abnormalities are 959 960 underdiagnosed in POI in older women (Berglund, et al., 2019), thus an age cut-off limit for testing for 961 chromosomal abnormalities is not recommended, Women with Y chromosome material present should

be counselled about the risk of development of a gonadal tumour and gonadectomy should be advised.

963 FMR1 gene testing

The diagnosis of an *FMR1* disorder is established through the use of molecular genetic testing to detect and quantify the CGG trinucleotide repeat expansion in the 5' UTR of *FMR1*. In some cases, Southern



- blot analysis may be performed to confirm the results of PCR and to assess methylation status which might affect *FMR1* gene expression. It should be noted that typical multigene panels and NGS are not useful in detecting *FMR1* premutations (Hunter JE., et al., 2019). Genetic counselling for *FMR1* should include education about *FMR1*-related disorders and the possibility and implications for the patients and their families (Poteet, et al., 2023). Genetic screening of family members of women with *FMR1* premutations is recommended, not only for fertility assessment of female relatives but also because of the risk of passing on an unstable mutation to potential offspring resulting in full mutations and FXS.
- 973 This requires careful counselling before the test is performed.
- 974 Specific gene variant testing

975 If karyotype and *FMR1* gene testing is normal, the study of specific genes should be performed where 976 available in a specialised laboratory according to international best practice. Tailored NGS POI gene 977 panels can be useful in diagnostic testing of women affected, as well as in predictive genetic screening 978 of family members and women at risk of POI.

- 979 At present, extended testing using targeted NGS gene panels or virtual in silico panels based on 980 WES/WGS are not available as routine assessments for women with POI in most countries. NGS has however proven to be a powerful tool in unravelling an expanding number of genetic variants associated 981 with POI, thus increasing the possibilities to find underlying causes of POI (França and Mendonca, 2022) 982 especially in large cohorts of POI (Heddar et al., 2022, Ke et al., 2023). A dynamic evaluation of which 983 genes to include in disease specific NGS gene panels is important. Custom gene panels must be 984 consecutively modified and updated, allowing for the addition of novel genes found to be involved in 985 POI or the removal of genes that upon re-evaluation are found not be associated with POI. 986
- 987 These studies should be performed as recommended by both the European Society of Human Genetics 988 (Matthijs *et al.*, 2016) and the American College of Medical Genetics and Genomics (ACMG) (Rehm *et al.*, 2013) and strict ACMG/AMP criteria or similar should be used to interpret variants in a clinical setting 989 (Richards *et al.*, 2015). Analysis of gene copy number variations is not routinely performed due to the 989 absence or very low positivity observed.
- At present, there is a NGS approach for the diagnosis of rare endocrine disorders of sex development and maturation including POI across several European countries (www.endo-ern.eu) (Persani *et al.*, 2022). Additional genetic testing is available in France and a French position statement on the diagnosis and management of POI (except Turner syndrome) recommends gene panel or WGS analysis in all undiagnosed POI (Christin-Maitre *et al.*, 2021). It is likely that the availability of additional genetic testing will continue to increase globally with a resulting decrease in the costs.
- 998 **Recommendations**

Where available and after comprehensive genetic counselling, additional genetic testing (e.g. NGS) can be offered to identify other potential genes that may cause POI.	Chromosomal analysis and Fragile X premutation testing are recommended for all women with non-iatrogenic POI.	⊕⊕⊖⊖	STRONG
	additional genetic testing (e.g. NGS) can be offered to identify other	⊕⊕⊖⊖	CONDITIONAL

1000

999

The guideline group recommends that the age of a woman with POI should not be GPP used to restrict access to genetic testing.



1002 Justification

1003 Chromosomal anomalies are common among women with POI, affecting 10-13% of patients. These 1004 chromosomal anomalies include X chromosome aneuploids and mosaicisms as well as structural X 1005 chromosomal defects. Based on the significant prevalence of chromosomal anomalies in women with 1006 POI and the implications thereof, chromosomal analysis is recommended. A specific age cut-off limit for 1007 testing for chromosomal abnormalities is not recommended. Based on its prevalence and potentially 1008 severe implications, Fragile X testing is indicated in all women diagnosed with POI. Genetic counselling 1009 for FMR1 should include education about FMR1-related disorders and the possibility and implications 1010 for the patients and their families (Poteet, et al., 2023).Additional genetic testing (e.g. NGS) may be 1011 offered, based on the potential of such tests to uncover a genetic cause for POI which has psychological 1012 benefits for the patients and their family and allows genetic counselling and personalised patient care. 1013 Large cohorts of women with POI have been studied and shown diagnostic positivity in up to 30% using 1014 NGS (Heddar et al., 2022, Ke et al., 2023). However, there are prerequisites for genetic studies of POI in 1015 clinical practice. Only genes that are fully characterized and proven to cause POI should be used for 1016 clinical diagnostics. The availability of NGS tests in specialised laboratories and the associated costs are 1017 currently barriers to widespread use.

1018 Research recommendations.

- 1019 Ongoing research both in animal models and humans is required to identify additional genes involved in 1020 POI and to allow uncovering of molecular defects in non-coding regions of known genes, copy number 1021 variations and structural variations.
- 1022 Exploration of how genetic variants combine with environmental factors to determine the clinical
- phenotype is also needed. This will markedly enhance the positivity of genetic testing, availability of genetic
 testing and development of novel management strategies.
- 1025 Improvements in genetic sequencing techniques and interpretive approaches may provide a more precise
- 1026 determination of the mechanisms underlying ovarian dysfunction, facilitate screening, diagnosis, and cost-
- 1027 effectiveness.

1028 Autoimmune causes of POI

1029

1030 PICO QUESTION: WHAT ARE THE KNOWN AUTOIMMUNE CAUSES OF NON-IATROGENIC POI 1031 AND HOW SHOULD THEY BE INVESTIGATED?

1032 The ovaries have been shown to be a target of autoimmune attacks manifested by endocrine and 1033 reproductive dysfunction in POI. The uncertainty with regards to reported frequencies of autoimmune 1034 causes of POI (3–30%), probably reflects heterogenic study populations as well as use of variable 1035 diagnostic methods (Silva *et al.*, 2014, Kirshenbaum and Orvieto, 2019).

- 1036 Ovarian biopsies of subgroups of women with POI have demonstrated autoimmune oophoritis with 1037 mononuclear infiltrates of the theca cells in growing follicles, initially sparing the primordial, primary 1038 and preantral follicles (Irvine *et al.*, 1968, Bakalov *et al.*, 2005, Welt *et al.*, 2005). Immunohistochemical 1039 studies have revealed that the immune infiltrates contain both B- and T cells as well as polyclonal plasma 1040 cells, suggesting a complex immune system interplay (Sedmak *et al.*, 1987, Suh, 1992, Warren *et al.*, 1041 2014, Jacob and Koc, 2015).
- 1042 Clinically women with autoimmune oophoritis present with higher serum inhibin B and AMH levels 1043 compared to women with other causes of POI, reflecting the presence of functional intact granulosa 1044 cells within the quiescent follicles (Tsigkou *et al.*, 2008, La Marca *et al.*, 2009, Falorni *et al.*, 2012). On 1045 ultrasound, the ovaries can be of normal size or enlarged and follicles may have a cystic appearance



1046 due to gonadotropin stimulation (Bannatyne *et al.*, 1990, Welt *et al.*, 2005, Nelson, 2009). Autoimmune
1047 POI is rarely a dichotomous event and several years of fluctuating ovarian function may precede
1048 complete ovarian failure (Nelson, 2009).

1049 Markers of autoimmune oophoritis

- 1050 Diagnostic biopsies of the ovaries are not recommended as a routine investigation partly because of 1051 the general inaccessibility of the ovaries but also because studies have shown good correlation between 1052 histologically confirmed autoimmune oophoritis and autoantibodies (Khastgir *et al.*, 1994, Hoek *et al.*, 1053 1997, Bakalov *et al.*, 2005).
- 1054 To establish an autoimmune pathogenesis, it is common practice to evaluate the presence of disease-1055 specific autoantibody markers. Historically methods of indirect immunofluorescence have been used to 1056 detect autoantibodies against ovarian antigens, including anti-ovarian autoantibodies (AOA) and 1057 Steroid-cell autoantibodies (SCA) (Vallotton and Forbes, 1966, Blizzard et al., 1967 Sotsiou, 1980 #1761, Chen et al., 1996, Hoek et al., 1997, Falorni et al., 2002, Dal Pra et al., 2003, Bakalov et al., 2005, La Marca 1058 1059 et al., 2010, Gao et al., 2017). Multiple specific ovarian autoantigens have been identified as targets for 1060 AOAs, including the oocyte, gonadotropin receptors, β -subunit of FSH, zona pellucida, corpus luteum, 1061 heat shock proteins, alpha-enolase, beta-actin and NACHT leucine-rich-repeat protein 5 (NALP5) (Tang and Faiman, 1983, Moncayo et al., 1989, Forges et al., 2004, Ryan and Jones, 2004, Kelkar et al., 2005, 1062 Sundblad et al., 2006, Takamizawa et al., 2007, Pires and Khole, 2009, Otsuka et al., 2011). Despite 1063 1064 biopsy-confirmed autoimmune opphoritis being coherent with AOA in 100% of cases, the diagnostic 1065 significance of AOAs is questionable as 2/3 of all women with POI are positive. In addition, AOAs have been demonstrated in up to 1/3 of women with infertility of unknown cause (Coulam and Ryan, 1985, 1066 1067 Wheatcroft et al., 1994, Luborsky et al., 1999).
- 1068 Although SCAs are more specific than AOA, the diagnostic accuracy is low because of lack of 1069 standardization of methods and use of antigens from various steroid hormone producing tissues (testes, 1070 ovaries, placenta, or adrenal cortex) (Novosad *et al.*, 2003).
- 1071 Use of specific immunoprecipitation methods such as Radio-Ligand Binding Assay (RIA) and Enzymelinked immunosorbent assay (ELISA) have identified ovarian target antigens against several 1072 steroidogenic enzymes: 21-hydroxylase (21OH-Ab), cytochrome P450 side-chain cleavage enzyme 1073 1074 (P450SCC), 17α -hydroxylase (17α -OH) and 3β -hydroxysteroid dehydrogenase (3β HSD) (Wingvist *et al.*, 1075 1995, Chen et al., 1996, Arif et al., 1999, Falorni et al., 2002, Dal Pra et al., 2003, La Marca et al., 2009, 1076 Reato et al., 2011, Brozzetti et al., 2015). Approximately 3-5% of women with POI are positive for 21OH-1077 Ab, a frequency significantly higher than the expected in the general population (<0.6%) (Betterle et al., 1078 2005, Del Pilar Larosa et al., 2018, Vogt et al., 2022, Vogt et al., 2024). Antibodies against 21OH-Ab 1079 appear to be the marker with the highest diagnostic accuracy for autoimmune POI and is also the only 1080 one commercially available.

1081 Associated autoimmune disease.

- Autoimmune disorders are more frequent in women with POI than in the general population, and noniatrogenic POI is more frequent in women with certain autoimmune disorders. It is uncertain whether this association is due to an overlapping autoimmune process involving common antigens or if it is caused by a general immune dysregulation triggered by the complex interaction between hormones and the immune system impacted by estrogen withdrawal in POI.
- 1087 The clinically <u>most</u> important association is with autoimmune adrenal insufficiency (Addison's disease) 1088 and autoimmune polyendocrine syndrome (APS-1) (La Marca *et al.*, 2010, Kirshenbaum and Orvieto, 1089 2019, Panay *et al.*, 2020). Between 6-20% of women with autoimmune adrenal insufficiency have POI, 1090 while approximately 2-3% of women with POI develop adrenal autoimmunity. The diagnosis of POI most
- 1091 often precedes but can also manifest after adrenal insufficiency (1/3 of cases) (Bakalov *et al.*, 2005, Reato



1092 et al., 2011, Webber et al., 2016, Kirshenbaum and Orvieto, 2019, Vogt et al., 2021). This association 1093 might be a consequence of a common embryological adrenogonadal primordium and autoantibodies 1094 cross-reacting against antigens of steroid producing cells in both the adrenals and ovaries. The 1095 correlation with POI is strongest in the context of autoimmune APS-1, an autosomal recessive disease 1096 caused by mutation in the autoimmune regulator (AIRE) gene involved in negative selection of T cells 1097 in the thymus (Anderson et al., 2002, Husebye et al., 2018). APS-1 predominantly manifests as adrenal 1098 insufficiency, mucocutaneous candidiasis, hypoparathyroidism and 50-60% of these women develop 1099 POI (Saari et al., 2020, Garelli et al., 2021). Most women with autoimmune adrenal insufficiency will 1100 already have disease-associated 21OH-Ab and these can therefore not be used to diagnose 1101 autoimmune POI. Instead, autoantibodies against P450SCC can be used for screening (Vogt et al., 1102 2021).

1103 Autoimmune thyroid hormone disorders are common in women with POI affecting approximately 20% 1104 compared to 5-10% in the general female population (Coulam, 1983, Silva et al., 2014, Kirshenbaum and 1105 Orvieto, 2019, Grossmann et al., 2020, Hsieh and Ho, 2021, Chaker et al., 2022). Thyroid function and 1106 the gonadal axis are tightly intertwined through the hypothalamic-pituitary axes and the presence of 1107 thyroid hormone receptors in the ovaries, but the pathogenic mechanisms of how autoimmune thyroid disease can impair the ovarian reserve are still unclear (Poppe et al., 2008, Khizroeva et al., 2019). Thyroid 1108 peroxidase autoantibodies (TPO Abs) have been detected in ovarian follicles but have not been linked 1109 with immunological damage of ovarian tissue (Persani et al., 2009) (Monteleone et al., 2011, Osuka et 1110 1111 al., 2018). A recent meta-analysis confirmed a higher frequency of TPO-Ab positivity in women with POI (OR 2.26; 95% CI 1.31 to 3.92; p=0.004) (Li et al., 2022, Tańska et al., 2023). However, TPO abs are 1112 common in disease-free women, detectable in 15-20%, with increasing incidence with ageing (Hollowell 1113 1114 et al., 2002). TPO abs should therefore not be analysed for screening purposes in women with POI. As 1115 autoimmune thyroid hormone disorders are common in women with POI and some symptoms and clinical manifestations are similar, it is reasonable to screen newly diagnosed women with POI with TSH 1116 1117 measurement.

Type 1 diabetes mellitus has historically been associated with delayed menarche and menopause at a younger age (Dorman *et al.*, 2001, Brand *et al.*, 2015). Other reports have failed to find significant age difference at menopause in women with type 1 diabetes mellitus compared with healthy controls, (Sjöberg *et al.*, 2011, Kim *et al.*, 2014, Yarde *et al.*, 2015), probably reflecting better general health and glucose control in newer study populations (Stuenkel, 2017). Currently no significant data indicate the need for routine screening for concomitant type 1 diabetes mellitus in patients with POI (Thong *et al.*, 2020).

1125 Coeliac disease has been associated with a shorter reproductive period, early menopause, and infertility 1126 in women (Kotze, 2004). The mechanisms causing reproductive dysfunction in coeliac disease have been 1127 inadequately investigated to date. Very few studies have evaluated hormonal status and they have failed to show altered values of gonadotropins and sex hormones in women with coeliac disease (Cakmak et 1128 1129 al., 2018, Comba et al., 2020). According to several meta-analyses and large population-based reports 1130 there appears to be an increased risk of undiagnosed coeliac disease among women with infertility (Tata 1131 et al., 2005, Zugna et al., 2010, Lasa et al., 2014, Singh et al., 2016). Available data suggests no increased prevalence of infertility in women with diagnosed coeliac disease, implying that treatment of coeliac 1132 1133 disease may restore reproductive function, however prospective longitudinal studies are needed to 1134 confirm this. Existing data do not imply a direct association with POI (Walker et al., 2019).

POI may also be associated with other organ specific or systemic autoimmune disorders, such as systemic lupus erythematosus (SLE), rheumatoid arthritis, immune thrombocytopenic purpura, autoimmune haemolytic anaemia, pernicious anaemia, vitiligo, alopecia areata, inflammatory bowel diseases, primary biliary cirrhosis, glomerulonephritis, multiple sclerosis, and myasthenia gravis (Coulam,



1139 1983, Silva *et al.*, 2014, Kirshenbaum and Orvieto, 2019, Grossmann *et al.*, 2020). Testing for these conditions is however only indicated if symptoms of disease are present.

1141 Recommendations

 Screening for 210H-Abs should be performed in women with POI of unknown cause.
 Image: Constraint of the streen of the streen

1144

The guideline group recommends that HCPs do not perform TPO antibody screening as part of testing for autoimmune causes of POI due to the high prevalence of positive TPO antibodies in the general community.

1145 Justification

An autoimmune aetiology of POI should be considered in the presence of associated autoimmune disorders, the existence of POI associated autoantibodies or histologically verified lymphocytic oophoritis. Antibodies against 21OH-Ab are currently the marker with the highest diagnostic accuracy for autoimmune POI and should be analysed in women with idiopathic POI. Although currently there is no specific treatment option for autoimmune POI, identification of women with autoimmune POI is clinically relevant for diagnosing subclinical or latent autoimmune adrenal insufficiency.

1152 Untreated hypothyroidism can impact general health and quality of life. Furthermore, because of the 1153 detrimental effects on foetal neurocognitive development, it is important to treat hypothyroidism in 1154 women where pregnancy is desired (spontaneous or after oocyte donation). Therefore, screening for 1155 TSH should be performed in women with POI.

1156

1157 **PICO QUESTION: HOW OFTEN SHOULD TESTS FOR AUTOANTIBODIES BE REPEATED?**

POI may precede the diagnosis of autoimmune adrenal insufficiency (Vogt *et al.*, 2021). About 1 in 5 women with positive 21 OH autoantibodies develop overt autoimmune adrenal insufficiency within 10 years (Naletto *et al.*, 2019). Women with POI and positive 21 OH autoantibodies should be referred to an endocrinologist. Basal determination of morning cortisol and adrenocorticotropic hormone (ACTH) levels should be used as routine screening tools. Additionally, plasma renin activity and ACTH stimulation test at five yearly intervals should be considered if adrenal insufficiency is suspected (Husebye *et al.*, 2021).

There are no longitudinal studies available providing information on the natural history of autoimmunity in women with POI that have negative autoantibodies at initial screening. In women with POI and negative autoantibody tests and absence of clinical signs and symptoms of endocrine disease, followup should be applied as for the general population of women. There is no consensus for repeated analysis for autoantibody tests if the initial tests are negative.

GPP



1170 *Recommendations*

Women with POI and positive 210H-Ab should be referred to an endocrinologist for testing of adrenal function.

1171

If 21OH-Abs are negative in women with POI, there is no indication for re-testing later in life, unless signs or symptoms of adrenal $\bigcirc \bigcirc \bigcirc \bigcirc \bigcirc$ STRONG insufficiency develop.

1172


1173 Justification

- 1174 The evidence of association between positive 21 OH autoantibodies and autoimmune adrenal disease
- 1175 is substantial. As the consequence of adrenal insufficiency is potentially detrimental, endocrinological
- 1176 evaluation and follow-up of women with POI with increased risk is crucial. However, there is no evidence
- 1177 regarding the natural history of autoimmunity in women with POI who have negative autoantibodies at
- 1178 initial screening. Further autoantibody testing is only indicated if symptoms of disease are present.
- 1179

JRAFTEO









1185 **II.4 Care for women with POI after diagnosis**

The journey of a woman diagnosed with POI is one that necessitates comprehensive and compassionate care from HCPs. In addition, POI does not only affect the individual diagnosed; it can have ripple effects on family members and dynamics. HCPs are instrumental in helping women and their families understand and adapt to this diagnosis and should provide support and guidance. There is also a significant need for greater community awareness and education regarding POI to reduce the perceived impact, stigma, and marginalization of POI, improve patient outcomes, and better support patients (McDonald *et al.*, 2022, Vincent *et al.*, 2024).

- Dissatisfaction with care, related to multiple factors including unmet information needs, manner of delivery of the diagnosis, delayed diagnosis, discontinuity of care, negative clinical interactions, and perceived unsympathetic HCPs, has been reported and contributes to impaired quality of life (Alzubaidi *et al.*, 2002, Deeks *et al.*, 2011, McDonald *et al.*, 2022)(see Figure 11). A scoping review (McDonald *et al.*, 2022) identified factors including mental health counselling, compassionate HCPs, sensitive revelation of the diagnosis of POI, individualised care and continuity of care as positively influencing quality of life
- 1199 for women with POI.

As discussed, a diagnosis of POI can have a significant impact on psychological wellbeing and quality of life (see VIII. POI and psychological wellbeing). HCPs should use care both while delivering the diagnosis of POI, but also afterwards. Therefore, the guideline group has formulated the following recommendations for the organisation of care in POI (see also Figure 7).

- 1204 Care for family members of women with POI is addressed in III. Implications for relatives of women with 1205 POI.
- 1206 Recommendations

The guideline group recommends that HCPs convey the diagnosis of POI in a compassionate and sensitive manner, provide personalised evidence-based information about the condition and ensure enough time for the women to ask questions.

GPP

1207

The guideline group recommends shared decision making and support for continuity of care in managing POI.

1208


The guideline group recommends referral of women with POI to appropriate support groups and mental health care.

GPP

- 1210 Justification
- POI has a significant impact on multiple aspects of an individual's life requiring long-term medical management. Positive patient experience and outcomes are promoted by empathic, supportive HCPs and shared decision making.
- 1214
- 1215
- 1216



1217 FIGURE 8 SUPPORTIVE CARE FOR WOMEN WITH POI





1220 III. Implications for relatives of women with POI

1221 Non-iatrogenic POI can occur sporadically, but it has also been observed that women diagnosed with 1222 POI often have at least one (first-degree) relative with POI or early menopause. This risk is particularly 1223 heightened when multiple family members are affected. Research from various countries including the 1224 US, UK, Finland, and China has corroborated these findings, showing increased odds of POI and early 1225 menopause among relatives of women with POI. A recent USA study quantified the risks using data 1226 linkage. They reported that the risk of POI was increased 18-fold in first degree relatives, 4-fold in second 1227 degree relatives and 2.7-fold in third degree relatives of women with POI compared with controls (Verrilli 1228 et al., 2023). Data on this topic are discussed in section Family history and demographic factors.

1229 In families with two or more affected females, a genetic aetiology is suggested, but the genetic 1230 association with POI cannot always be identified (Barros *et al.*, 2020). Irrespective of a genetic 1231 background, women with POI may ask their HCPs questions on the implications of their diagnosis for 1232 their relatives (sisters, children), including the chances of their relatives developing POI, and measures 1233 for prevention and/or postponement of POI and infertility. Another aspect is intrafamilial egg donation, 1234 aspects of which are discussed in section Oocyte donation to achieve pregnancy in women with POI.


1235 **PICO QUESTION: WHAT ARE THE IMPLICATIONS FOR RELATIVES OF WOMEN WITH POI?**

1236 Chances of relatives developing POI

The relative risk of POI among relatives of women with POI was 4.6 (95% CI 3.3 to 6.5) compared to relatives of women without POI (Silvén *et al.*, 2022). A US study reported that the risk of POI was increased 18-fold in first degree relatives, 4-fold in second degree relatives and 2.7-fold in third degree relatives of women with POI compared to controls (Verrilli *et al.*, 2023).

- 1241 As mentioned before, the prevalence of POI was estimated around 3.5% in recent reviews (Golezar et
- 1242 *al.*, 2019, Li *et al.*, 2023a). This implies that the likelihood of POI under the age of 40 among the relatives 1243 of women with POI is approximately 15% (Figure 9).

1244 FIGURE 9 RISK OF POI IN RELATIVES OF WOMEN WITH POI AND IN THE GENERAL POPULATION.





1249

1250

- Relatives of women with POI who are concerned about their risk of developing POI should be informed(Webber *et al.*, 2016):
- 1248 They are at increased risk of developing POI.
 - There is currently no proven predictive test to identify women who will develop POI, unless a genetic mutation known to be related to POI is detected.
- There are no established methods for preventing or predicting POI.
- About the symptoms and signs of POI such as menstrual disturbance or symptoms of estrogen deficiency. They should also be advised that long term use of hormonal contraception may mask these symptoms and signs.
- Fertility preservation could be considered, although data remain limited (see V.2. Fertility preservation)
- Their potential risk of earlier menopause should be taken into account when planning a family.

1258 Follow-up of relatives of women with POI

- 1259 Awareness of the increased risk of POI among relatives of women with POI would improve the likelihood
- 1260 of diagnosing POI earlier, thereby preventing unfavourable health outcomes (Silvén et al., 2022), such
- as bone loss or other sequelae of POI that could have been prevented by prompt institution of HT.
- 1262 Family members of women with POI may require support to cope with their newfound risk of POI.
- 1263 The implications for relatives of women with POI with an underlying genetic cause, particularly a Fragile
- 1264 X premutation, are more extensive than reproductive issues. For these relatives, genetic counselling
- 1265 should be offered (see also II.3.b. Genetic background of POI).

1266 *Family planning and fertility preservation*

- While in women with established POI the opportunity for fertility preservation is missed, it is worth considering it for women who are at risk of developing POI, such as sisters of women with the condition. Additionally, for women at risk of POI, it may be advisable not to delay pregnancy, even if it needs to
- 1270 be acknowledged that the decision to start a family is complex and influenced by multiple factors.
- 1271 It has been suggested that close monitoring of these women and their ovarian reserve can guide fertility
- 1272 preservation and family planning (Jiao *et al.*, 2017, Martyn *et al.*, 2017, La Marca and Mastellari, 2021).
- 1273 However, assessment of AMH level has limitations for predicting fertility and menopause. This is further
- 1274 discussed in chapter V.2. Fertility preservation.
- 1275 Oocyte cryopreservation and/or embryo cryopreservation are established options for fertility 1276 preservation. However, data on the effectiveness of these techniques in women at risk of POI are not 1277 available (La Marca and Mastellari, 2021).
- 1278 **Recommendations**

The guideline group recommends that relatives of women with the Fragile X premutation or other identified genetic causes of POI should be offered genetic counselling and testing.

GPP

STRONG

1279

Female relatives (such as sisters or daughters) of women with noniatrogenic POI should be counselled that they are at increased risk of developing POI themselves



The guideline group recommends that female relatives (such as sisters or daughters) of women with non-iatrogenic POI are offered support regarding their increased risk of POI

GPP

1281

The guideline group recommends that female relatives (such as sisters or daughters) of women with non-iatrogenic POI should be informed of the signs and symptoms of POI and should promptly seek medical advice if this occurs.


1282

The guideline group recommends that female relatives (such as sisters or daughters) of women with non-iatrogenic POI should be informed that there are no established methods for predicting or preventing POI. Some relatives may wish to consider family planning and fertility preservation options.

1283 Justification

Although there seems to be a familial factor in POI and there is evidence of heritability of age of 1284 menopause, the specific genetic associations in POI have not been completely elucidated and more 1285 1286 research is needed. Women with at least one affected family member may be at increased risk of POI 1287 and should speak to their HCP about their options. While it is not currently possible to predict or prevent POI, ovarian assessment may be appropriate in some women. It may be appropriate for these women 1288 1289 not to postpone pregnancy, although the decision to start a family is multifactorial. Oocyte freezing 1290 may be an option for fertility preservation but there are legal restrictions in some countries. Egg and embryo freezing are well established methods of fertility preservation, however there are no studies on 1291 the effectiveness of oocyte freezing specifically in women with a familial link to POI. 1292

1293 FIGURE 10. SUMMARY OF INFORMATION FOR FAMILY MEMBERS OF WOMEN WITH POI





1295 Research recommendation.

Research into methods for reliable prediction of POI and monitoring of ovarian function in relatives of
women with non-iatrogenic POI is needed. Further research into the outcomes of fertility preservation in
the specific group of women with a family history of POI is indicated.

1299

brancher



1300 PART C: Sequelae of POI

1301 IV. POI and life expectancy

POI affects not only fertility, but also impacts bone health, cardiovascular health, and neurological function, as described in the relevant chapters. Awareness that these effects may have long-term consequences has led to the hypothesis that POI, and early menopause, may be associated with higher mortality rates. Furthermore, POI can be associated with a number of autoimmune diseases, can be caused by treatment for cancer, or by risk reducing bilateral oophorectomy in women with high risk of developing cancer, which again may largely affect mortality. This chapter reviews the available evidence and considers whether a diagnosis of POI has significant consequences for life expectancy.

1309

PICO QUESTION: WHAT ARE THE CONSEQUENCES OF POI FOR LIFE EXPECTANCY?

A recent study in a US population of approximately 160,000 people reported that among 36 women 1310 with POI, 32 (88.9%) had induced (iatrogenic) POI, and for 28 of them (77.8%) the cause was bilateral 1311 salpingo oophorectomy (Rocca et al., 2023). Remarkably, in this general population, bilateral salpingo 1312 oophorectomy was the most frequent cause of POI (Rocca et al., 2023). However, the distribution by 1313 causes of POI may vary across countries because of differences in gynaecologic practice. It is not 1314 1315 surprising that most of the evidence on long-term outcomes of POI comes from observational studies 1316 of women who have undergone bilateral oophorectomy, usually at the time of hysterectomy for a 1317 benign gynaecological disease (e.g., fibromas or excessive bleeding), or as a risk reducing surgery for 1318 familial cancer risk. Some more recent evidence comes from cohort studies of women with spontaneous (non-iatrogenic) POI. The outcomes in women who undergo oophorectomy may differ from the 1319 outcomes in women who have experienced non-iatrogenic POI, which typically has a gradual onset and 1320 1321 prolonged fluctuating course, compared to the immediate onset and profound estrogen-deficiency 1322 caused by surgical menopause.

1323 Bilateral oophorectomy and mortality

1324 A 2021 paper from Canada included a detailed review of 8 cohort studies on bilateral oophorectomy and mortality (Cusimano et al., 2021). The cohort studies differed in several methodologic details and 1325 were conducted in 4 countries (United States, United Kingdom, Australia, and Canada). The most 1326 important difference was the selection of the referent women that were compared to the women who 1327 1328 underwent bilateral oophorectomy. In 4 studies, the referent women were women who had not 1329 undergone bilateral oophorectomy (most women had no gynaecological surgery) (Rocca et al., 2006, Gierach et al., 2014, Wilson et al., 2019, Tuesley et al., 2020). In the remaining 4 studies, the referent 1330 1331 women were women who had undergone hysterectomy with ovarian conservation (Parker et al., 2009a, 1332 Jacoby et al., 2011, Parker et al., 2013, Mytton et al., 2017, Cusimano et al., 2021). Therefore, the question addressed in the two groups of studies was somewhat different (surgical management decision vs. 1333 1334 broader public health perspective). In addition, the age cut-off used to define premature or early 1335 menopause caused by bilateral oophorectomy differed across studies (e.g., <45; <50, <40; ≤45; 35-45; 1336 <35; 35-44 years). In any event, 7 of the 8 studies confirmed that bilateral oophorectomy at younger 1337 age was associated with an increased overall mortality. As an example of the magnitude of the effect, the Canadian study showed a hazard ratio (HR) of 1.31 (95% CI 1.18 to 1.45; p<0.001) for women aged 1338 45 years or younger at the time of surgery. The number needed to harm was 71 oophorectomies 1339 (measured at 20 years of follow-up) (Cusimano et al., 2021). Therefore, for every 71 women who 1340 1341 underwent bilateral oophorectomy, 1 additional death associated with bilateral oophorectomy was 1342 expected within 20 years of follow-up.



- 1343 Only the Women's Health Initiative Observational Study did not report a significant association between bilateral oophorectomy before age 40 years and mortality (Jacoby et al., 2011). However, women were 1344 1345 recruited at an average age of 63 years (approximately 20 or more years after the bilateral oophorectomy, which had occurred at or before 40 years of age) and followed for a short time (mean 1346 1347 7.6 years, SD 1.6). Therefore, women were relatively young at the end of follow-up (mean age 70.6 years). In addition, the analyses were adjusted for a number of cardiovascular risk factors and conditions 1348 1349 present at the time of recruitment in the study. Therefore, the cardiovascular risk factors and conditions 1350 were most likely mediating events in the chain of causality between the original oophorectomy and 1351 mortality, and they should not have been included in the model. In conclusion, the study by Jacoby and 1352 colleagues does not provide strong contradictory evidence.
- 1353 Specific causes of death were addressed in some of the 8 cohort studies considered above. For example, 1354 in the Mayo Clinic Cohort Study of Oophorectomy and Aging, bilateral oophorectomy before age 45 1355 years was associated with increased cardiovascular mortality, especially cardiac mortality (Rivera et al., 1356 2009a). In the same study, oophorectomy before age 45 years was also associated with increased mortality for neurological and mental diseases (Rivera et al., 2009b). In the Nurse's Health Study, 1357 1358 oophorectomy at age 50 years or younger was associated with reduced risk of ovarian cancer mortality 1359 but with increased risk of total cancer mortality. Cardiovascular disease mortality and coronary heart disease mortality were also increased (Parker et al., 2013). 1360
- A 2023 study from Denmark confirmed the higher risk of all-cause mortality after bilateral 1361 1362 oophorectomy before age 45 years compared to women who underwent hysterectomy with ovarian conservation. However, the differences at 10 and 20 years of follow-up were not statistically significant 1363 (Gottschau et al., 2023). Another 2023 study from Norway confirmed the higher risk of all-cause 1364 mortality or of cardiovascular mortality after bilateral oophorectomy before age 40 years compared to 1365 women with no gynaecologic surgery, but the differences were not statistically significant (Michelsen et 1366 1367 al., 2023). Finally, a 2023 systematic review confirmed the association of bilateral oophorectomy before 1368 age 50 years with all-cause mortality both using women with hysterectomy and ovarian conservation or 1369 women with no gynaecologic surgery as the referent group. However, there was substantial heterogeneity across studies (Hassan et al., 2024). In particular, the Women's Health Initiative 1370 Observational Study discussed above reported inconsistent findings (Jacoby et al., 2011). 1371

1372 Non-iatrogenic POI and mortality

We found 4 systematic reviews of studies on the association between non-iatrogenic POI and overall 1373 1374 mortality. Three reviews were published in 2016 and a more recent review in 2021 (Gong et al., 2016, 1375 Muka et al., 2016, Tao et al., 2016, Huan et al., 2021). The most recent review by Huan and colleagues 1376 included 16 studies and 321 233 women. The magnitude of the association was measured by relative 1377 risk (RR) or HR. In analyses comparing non-iatrogenic POI with spontaneous menopause at age 49-52 1378 years (reference category), the association with all-cause mortality was significant both including follow-1379 up intervals in the model (adjusted HR 1.10; 95% Cl 1.01 to 1.21; p=0.034) and not including follow-up 1380 intervals in the model (adjusted RR 1.34; 95% CI 1.08 to 1.66; p=0.007). Marginal significance was 1381 reported for cardiovascular mortality after including follow-up intervals in the model (HR 1.09; 95% CI 1382 1.00 to 1.19; p=0.045). Subgroup analyses indicated that geographic location and follow-up intervals 1383 were possible causes of heterogeneity across studies. There was an overall low probability of publication 1384 bias (Huan et al., 2021).

A 2022 study based on the UK Biobank reported an increased risk of cardiovascular mortality, but not of cancer mortality, when comparing POI with spontaneous menopause at age 50-52 years (Xu *et al.*, 2022). A 2023 study from the United States confirmed the association between POI (spontaneous or iatrogenic) and increased all-cause mortality compared to non-premature menopause (all other ages at



menopause). The association between age of menopause and all-cause mortality was not linear, and particularly strong for menopause before age 37.5 years (Xing *et al.*, 2023). Finally, a 2023 study from Korea confirmed the association between POI (spontaneous or iatrogenic) and increased all-cause mortality compared with menopause after age 49 years. The association was particularly strong for menopause at ages 30-34 years. The risk was also increased in women who underwent early menopause (age 40-45 years) (Lee *et al.*, 2023a).

1395 Interaction of POI with other risk factors

Evidence for possible interactions between POI and other risk factors for mortality such as obesity, smoking, or chronic diseases remains limited. For example, one study suggested a possible interaction between cardiovascular risk factors and early menopause in increasing mortality (Li *et al.*, 2021c). Another study showed that women who smoked and underwent early menopause were at particularly high risk of lung cancer or lung diseases (Zhai *et al.*, 2022).

1401 Hormone therapy in POI

There are no clinical trials examining the long-term effects of hormone therapy (HT) on mortality after 1402 1403 POI. The evidence available comes once again from observational studies of women who underwent 1404 bilateral oophorectomy and did or did not receive estrogen replacement therapy. For example, in the Mayo Clinic Cohort Study of Oophorectomy and Aging, increased overall mortality was observed mainly 1405 in women who had undergone bilateral oophorectomy before age 45 years and had not received 1406 estrogen replacement therapy (HR 1.93; 95% CI 1.25 to 2.96) compared to women who had received 1407 therapy up to age 45 years or longer (HR 1.27; 95% CI 0.67 to 2.39)(Rocca et al., 2006). In the Nurses' 1408 1409 Health Study, the increased overall mortality, lung cancer mortality, cardiovascular mortality, and 1410 coronary heart mortality were higher in women who did not receive estrogen replacement therapy 1411 compared to women who did (significant interaction tests) (Parker et al., 2013). Finally, in the Women's Health Initiative study, unopposed estrogen initiated at age 50-59 years in women who underwent 1412 bilateral oophorectomy and hysterectomy reduced overall mortality during a cumulative 18-year follow-1413 up period (HR 0.68; 95% CI 0.48 to 0.96). However, this randomized controlled trial was not designed to 1414 1415 test the effect of estrogen replacement therapy on POI (Manson et al., 2019). Therefore, the results 1416 should be interpreted with caution.

1417 *Recommendations*

Women with POI should be informed that POI without hormone therapy is associated with reduced life expectancy, largely due to cardiovascular disease.

1418

Women with POI should be offered hormone therapy at least until the		
usual age of menopause as primary prevention to reduce risk of overall	€000	STRONG
morbidity and mortality.		

1419

The guideline group recommends that, in addition to hormone therapy, women with POI are advised to reduce cardiovascular risk by avoidance of smoking, healthy diet, regular exercise, and maintaining a healthy weight range



1421 Justification

1422 Both spontaneous and iatrogenic POI are associated with increased risk of premature death. The risk 1423 may be worsened by contributory factors such as cardiovascular risk factors or smoking and may be 1424 ameliorated by hormone therapy, but the evidence is only observational.

Patients asking whether POI has an impact on their life expectancy can be informed about interventionsthat help reduce mortality in the general population.

Although the studies have important limitations, the evidence is adequate to support a
recommendation for hormone therapy. Unfortunately, the duration of treatment is also not well studied.
Some authors have suggested treating women up to the usual age of menopause. (Kaunitz *et al.*, 2021,

1430 Rocca and Faubion, 2022). However, some evidence suggests that the longer the replacement therapy

- 1431 is used, the better the outcomes. Therefore, women should be given the opportunity to take hormone
- 1432 therapy long-term, and not only for 10 years after the onset of POI.
- 1433

ORAFICRATION



1434 V. POI, fertility, and pregnancy

As POI is characterised by cessation of ovarian function, loss of fertility is one of the key accompanyingfeatures of the diagnosis.

1437 In the current chapter, the consequences of POI for fertility are described, and the options for women 1438 with POI wishing to achieve pregnancy. In the second part of this chapter, obstetric complications in 1439 women with POI, and the potential for mitigation of these complications by assessing fitness prior to 1440 pregnancy are explored. Additionally, the issue of fertility preservation in women with POI is covered.

1441 V.1. Fertility and fertility treatments

1442 **PICO QUESTION: WHAT ARE THE CONSEQUENCES OF POI FOR FERTILITY?**

1443 Much of the literature consists of case reports demonstrating the potential for natural pregnancy in 1444 women with POI related to specific aetiologies.

1445 What is the chance of natural pregnancy with a diagnosis of POI?

Information on this can be derived from the natural pregnancy rate of women with POI awaiting oocyte
donation. In an analysis of 200 consecutive women, 5 (2.5%) conceived within 2-8 years after diagnosis
(Sauer, 1995). A review of the literature up to 1999 showed marked differences in pregnancy rate
according to the design of the study, with 4.8% of women achieving pregnancy in observational studies
compared to 1.5% in controlled studies (van Kasteren and Schoemaker, 1999). Subsequent analyses
have reported pregnancy rates of between 2.2 and 14.2%, although mostly under 10% (Bachelot *et al.*,
2017, Fraison *et al.*, 2019, Cambray *et al.*, 2023).

- An analysis of 358 consecutive women with idiopathic POI revealed that 25% showed subsequent 1453 1454 evidence of ovarian function (at least 2 consecutive menstrual cycles or pregnancy), the great majority within 1 year of diagnosis. Pregnancy occurred in 4.8%. Predictive factors included markers of ovarian 1455 activity at diagnosis, a family history of POI and secondary amenorrhea (Bidet et al., 2011). A more recent 1456 1457 study showed a similar rate of resumption of ovarian activity (117/507; 23%), with 53% of these women 1458 continuing to have ovarian function at the end of the follow-up period, a mean of 3.4 years later. Women 1459 with resumption of ovarian activity had lower FSH levels at initial evaluation and were younger than those who did not. They also had a significantly higher pregnancy rate of 15.3%, vs 3.5% for the whole 1460 cohort (Bachelot et al., 2017). 1461
- 1462 Oocyte donation can significantly improve the pregnancy rate and live birth rate of women with POI. 1463 However, studies have shown that only women with POI with underlying genetic factors tend to choose 1464 oocyte donation, and women with idiopathic and iatrogenic POI prefer to use their own oocytes to 1465 obtain pregnancy (Cambray *et al.*, 2023).
- 1466 **Recommendations**

Women with non-surgical POI should be informed that ovarian activity may occur. This is associated with a chance of natural conception.

1467



1468 Justification

Ovarian activity may occur in women with non-surgical POI, especially early in the natural history of the condition. This gives the possibility for natural conception, which occurs in up to 15% in those women, although probably in <5% overall. The cause of POI should be considered in a woman who has a natural programmer in case it has implications for the programmer and child (e.g. EMB1 promutation).

- 1472 pregnancy, in case it has implications for the pregnancy and child (e.g. FMR1 premutation).
- 1473

1474 **PICO QUESTION: WHAT FERTILITY INTERVENTIONS ARE EFFECTIVE?**

1475 Treatments to increase natural pregnancy rate in women with POI.

1476 A range of treatments including estrogens, gonadotrophins, and corticosteroids have been explored as 1477 potential treatments to increase the chance of pregnancy. A review of 7 controlled trials of therapies in POI concluded that none showed a statistically significant increase in ovulation (the primary end point 1478 1479 in all) or pregnancy rates (van Kasteren et al., 1999). Meta-analysis was not possible due to 1480 heterogeneities in design, patient selection, and intervention. Only one study included a placebo group 1481 (Taylor et al., 1996). A more recent systematic review including two randomized controlled trials, two observational studies, and 11 interventional studies also concluded that no treatment had been shown 1482 1483 to increase the pregnancy rate in women with POI (Fraison et al., 2019). One of these RCTs has been 1484 withdrawn (Badawy et al., 2007).

The remaining RCT involved administration of ethinyl estradiol in the context of gonadotropin 1485 administration (Tartagni et al., 2007). They randomized 50 women with POI to 0.05 mg ethinylestradiol 1486 1487 (EE) versus placebo three times a day for 2 weeks before and during gonadotrophin treatment, with the 1488 main outcome being ovulation (Tartagni et al., 2007). Eight out of 25 women treated with EE ovulated and 4 of them conceived. None of the 25 women in the placebo group ovulated (p<0.005). Sub-analysis 1489 1490 demonstrated that ovulation only occurred in women with FSH<15IU/I during EE treatment. It seems 1491 likely that this subgroup had greater ovarian activity, reflecting the often-fluctuating nature of POI 1492 especially early in its natural history.

These data confirm the high rate of follicle development and potentially of ovulation in women with POI, especially with a shorter duration of amenorrhoea; this may also underline the apparent relationship between EE suppression of FSH and ovulation, the basis of which is unclear. Further RCTs are required to confirm the potential beneficial effect of gonadotrophin suppression (using either estrogen or GnRHa) pre-treatment and hormone replacement therapy, with pregnancy as the main outcome measure.

There have been many recent interventional studies of novel approaches aiming to enhance fertility in women with POI, but generally without appropriate study designs (notably the inclusion of controls) or with sufficient power to allow any conclusions. Many also include populations of women with reduced ovarian reserve as well as POI. Several recent reviews have been published providing more details on the proposed mechanisms and individual studies (Rosario and Anderson, 2021, Zhang *et al.*, 2021, Pellicer *et al.*, 2023). Most of these interventions fall into the following categories:

- 1505 1. In vitro activation of follicle growth in biopsied ovarian tissue.
- 1506 2. Administration of mesenchymal stem cells.
- 1507 3. Injection of platelet rich plasma into the ovary.

1508 In vitro activation (IVA) was originally described as a joint surgical/pharmacological treatment to activate 1509 the growth of remaining follicles in the ovaries of women with POI (Kawamura *et al.*, 2016), involving 1510 surgical removal of ovarian tissue, its fragmentation and pharmacological treatment, and surgical



- replacement. A pharmacological treatment-free version has also been described (Ferreri *et al.*, 2020), as has the surgical procedure in combination with administration of stem cells (Tinjić *et al.*, 2021).
- 1513 Stem cell-based treatments have used mesenchymal stem cells derived from bone marrow, placenta, 1514 and umbilical cord. Injection of platelet rich plasma has also been used in several studies, including one 1515 of 311 women (Cakiroglu *et al.*, 2020), generally without adequate control groups.

1516 A recent RCT of platelet rich plasma administration versus no intervention in women with diminished 1517 ovarian reserve has been presented in abstract form (Herlihy *et al.*, 2023); 83 women were randomised, 1518 with no differences in the number of metaphase II oocytes or blastocysts obtained after subsequent 1519 ovarian stimulation. Thus, at present none of the approaches can be recommended for women with 1520 POI.

1521 Oocyte donation to achieve pregnancy in women with POI.

1522 It is clear that oocyte donation is the most successful treatment for women with POI desiring pregnancy. 1523 Successful pregnancy was first reported in 1984 (Lutjen *et al.*, 1984) and since then it has become a 1524 'routine' treatment. The pregnancy rate from oocyte donation is not greatly affected by the recipient's 1525 age (Sauer *et al.*, 1994, Templeton *et al.*, 1996, Hogan *et al.*, 2019).

- 1526 Oocytes may be donated altruistically, or from a known donor (often a sister). A comparison of treatment 1527 cycles where 'egg-sharing' was used (i.e. the donor was an infertile woman undergoing IVF for her own 1528 treatment at the same time) with altruistic donors showed no difference in clinical pregnancy rate 1529 (n=352 cycles overall) (Overange et al. 2000)
- 1529 (n=353 cycles overall) (Oyesanya *et al.*, 2009).
- 1530 Sisters or other near relatives are often oocyte donors for women with POI. There are specific ethical
- 1531 considerations in sibling donation, and in addition, sisters will have a high genetic homology to the
- 1532 woman with POI, which may be of relevance if there is a possible genetic cause or component to the
- aetiology of the POI, which may not be clinically apparent in the donor sister. This is supported by an analysis of donation by sisters (n=13) with altruistic donors (n=66), which showed that sisters had a 5-
- analysis of donation by sisters (n=13) with altruistic donors (n=66), which showed that sisters had a 5fold increased risk of cycle cancellation (30.7% vs 6.1%). However, in completed cycles the number of
- 1536 oocytes obtained was similar, as were pregnancy and miscarriage rates (Sung *et al.*, 1997). These issues,
- 1537 including the sister's own plans for pregnancy, should be discussed with the potential donor sister
- 1538 before proceeding with donation.
 - Sex steroid replacement therapies are used to ensure endometrial development and receptivity at the time of embryo replacement. Most studies have investigated this in women without POI. One small RCT in women with POI (n=17 completed the study, with a range of aetiologies including idiopathic, post chemotherapy and TS) compared transdermal estradiol plus vaginal progesterone with oral ethinylestradiol plus norethisterone (O'Donnell *et al.*, 2012). Endometrial thickness was greater in the former group, with no significant differences in uterine volume or blood flow. The significance of this for establishment of pregnancy was not assessed.
 - However, while oocyte donation is a technically straightforward procedure for IVF clinics, oocyte
 donation pregnancies are associated with some obstetric risks, which may be related to maternal factors,
 particularly the cause of POI (*see section* V.3. Pregnancy).
 - Abnormal uterine function and thus the potential for early and late pregnancy complications is a wellestablished consideration in women who have received radiotherapy (including total body irradiation) to the uterus (*see section 6.3*). Radiotherapy in childhood causes failure of uterine growth and in some women reduced responsiveness to exogenous sex steroids (Critchley *et al.*, 1992). There may be a relationship between the risk of pregnancy complications and age at irradiation and uterine volume (Larsen *et al.*, 2000), but series of sufficient size on which to base clinical advice are lacking.
 - Guideline POI DRAFT FOR REVIEW



Special considerations apply in women with Turner Syndrome (TS) in relation to comorbidity (especially 1555 1556 cardiovascular), which results in high rates of complications in pregnancy (see section V.3. Pregnancy). 1557 Implantation and pregnancy rates in women with TS have been comparable to those in women with 1558 other POI aetiologies in most (Foudila et al., 1999, Bodri et al., 2006, Alvaro Mercadal et al., 2011), but not all series (Yaron et al., 1996). Women with TS may have higher rates of early pregnancy loss 1559 1560 compared to other groups with POI (early miscarriage 60% versus 8.7%), indicating reduced endometrial and uterine function (Yaron et al., 1996). A cohort study of 57 women having 124 pregnancies from a 1561 1562 population of 482 Swedish women with TS described a miscarriage rate of 45% in spontaneous 1563 pregnancies compared to 26% in oocyte donated pregnancies (Bryman et al., 2011).

1564 *Recommendation*

 Women with POI should be informed that there are no interventions that have been reliably shown to increase ovarian activity and natural conception rates.
 ⊕⊕⊕⊙
 STRONG

 Women with POI should be informed that oocyte donation is an ⊕⊕○○
 STRONG

established option to achieve pregnancy after a diagnosis of POI

1566

1565

1567

1568 Justification

There are no known treatments which reliably increase ovarian activity, ovulation rate, and the possibility of conception. Several novel approaches have been described, but study design precludes reliable interpretation, particularly in the light of the prevalence of resumption of ovarian activity in women with POI. Robust studies of these approaches are required so that if effective, they can be more widely used or if ineffective, not be offered to vulnerable women.

1574 Oocyte donation is the treatment of choice in women wishing to conceive (efficacy shown in 1575 observational studies). As pregnancies after oocyte donation are associated with obstetric 1576 complications, the guideline group strongly recommends that these pregnancies are followed with 1577 adequate obstetric involvement, although no studies have been performed showing the effect of 1578 obstetric care on complications in these patients.

1579 While there may be personal reasons why a sister (or other close relative) would be a suitable donor, 1580 sisters have a higher donation cycle cancellation rate due to low response to ovarian stimulation. This 1581 is likely to reflect that siblings may have a shared genetic risk of low ovarian reserve/POI.

1582 There are special considerations regarding oocyte donation in women with TS. While establishment of

- 1583 clinical pregnancy can be achieved, severe maternal morbidity and maternal mortality during and after 1584 pregnancy is a critical issue. This is discussed more fully in *section* V.3. Pregnancy.
- 1585



1586 V.2. Fertility preservation

1587 PICO QUESTION: WHAT THERAPIES ARE EFFECTIVE FOR FERTILITY PRESERVATION AND /OR 1588 PREVENTION OF POI?

1589 This aspect is reviewed in detail in the ESHRE Guideline 'Fertility Preservation in Women' (Anderson *et* 1590 *al.*, 2020) thus only a brief summary is given here.

The diagnosis of POI indicates the loss of the ovarian follicle pool; thus, fertility preservation 1591 1592 interventions (oocyte, embryo or ovarian tissue cryopreservation) would appear futile. However, the variable course of the condition, especially in its early course, indicate the potential for a window of 1593 opportunity for this approach. While this is advocated in reviews of the subject (Baker, 2011), there are 1594 no data available as to success rates. These considerations also apply to highly selected women with 1595 1596 Turner Syndrome (TS), who may have an opportunity during adolescence and early adulthood for fertility preservation treatments. Both oocyte and ovarian tissue cryopreservation (including IVM and 1597 1598 combining both approaches) have been described in case reports (Lau et al., 2009, Balen et al., 2010) (Gayete-Lafuente et al., 2023) and series (Borgstrom et al., 2009, Mamsen et al., 2018, Mamsen et al., 1599 1600 2019, Nadesapillai et al., 2023); while a clinical pregnancy has been reported after ovarian tissue cryopreservation and replacement, live birth was not achieved (Dunlop et al., 2023). 1601

1602 Women with auto-immune POI may show some preservation of antral follicle growth in the early stages 1603 of the condition. The possibility of aspiration of immature oocytes from such follicles, with in vitro 1604 maturation and cryopreservation and subsequently successful warming, fertilisation and pregnancy has 1605 been described (Grynberg *et al.*, 2020).

1606 Fertility preservation may also be considered for women at risk of POI, either because of a naturally low number of follicles in the ovary, or where it is low as a result of disease or medical treatment. These 1607 might include sisters of women with POI, women with Fragile X/TS and survivors of childhood and 1608 1609 adolescent cancer who have not yet developed POI, although data remain limited (Zajicek et al., 2023). While available biomarkers of ovarian reserve have some predictive value of time to menopause 1610 (e.g.(Broer et al., 2011, Freeman et al., 2012)), evidence linking reduced ovarian reserve in young women 1611 to fertility is limited, but indeed suggests that regularly cycling women with low AMH levels do not have 1612 1613 reduced fecundability (Hagen et al., 2012, Steiner et al., 2017). Many women will conceive naturally after treatment for childhood or young adult cancer (Chow et al., 2016, Anderson et al., 2022b). Some will 1614 1615 have low AMH levels after such treatment: the limited evidence suggests that such low AMH levels can 1616 be maintained over many years, indicating ongoing ovarian function and thus the potential for conception (Cameron et al., 2019, Su et al., 2020b). 1617

1618 Recommendation

The guideline group recommends that fertility preservation is discussed with women at risk of POI. In women with established POI, the opportunity for fertility preservation has passed.

GPP

1619 Justification

Where a risk of POI has been identified, there will be concern about the risk to fertility. This will be modified by age and imminent vs distant family intentions. Discussion of future fertility and the possibility of fertility preservation interventions is therefore appropriate, recognising the limitations of tests such as AMH that might predict POI (see section XI.2. Risks of hormone therapy). Where POI is established, there is complete or near-complete exhaustion of the follicle pool and fertility preservation

1625 interventions are not recommended.



1626 V.3. Pregnancy

1627 **PICO QUESTION: WHAT ARE THE OBSTETRIC RISKS ASSOCIATED WITH POI?**

Pregnancy-related risks are associated with the cause of POI and to some extent, whether the pregnancyis natural, or the result of oocyte/embryo donation.

1630 After idiopathic POI

1631 There are case reports of natural pregnancies occurring, but it is difficult to draw any detailed 1632 conclusions regarding the outcomes. The risk of miscarriage is probably the same as in women with 1633 normal ovarian function (van Kasteren *et al.*, 1999). A pilot study of 20 women and 20 age-matched 1634 controls, examining the aneuploidy rates in embryos from women with prematurely declining ovarian 1635 function (not POI) showed this to be the same as that for women with age-appropriate ovarian function 1636 (Weghofer *et al.*, 2007).

1637 *After cancer treatment*

1638 The obstetric risks associated with pregnancy after cancer treatment (chemotherapy/radiotherapy) –

- 1639 independent of POI were earlier summarized in the ESHRE Guideline on Female Fertility Preservation1640 (Anderson *et al.*, 2020).
- 1641 Reports from large registry data from the Scottish Cancer Registry (van der Kooi, et al., 2018), the North
- Carolina Central Cancer Registry (CCR) (Anderson et al., 2017a), the Finnish Cancer Registry (Madanat-1642 Harjuoja et al., 2013, Melin et al., 2019) and the Cancer registry of Norway (Fosså et al., 2005) concluded 1643 1644 that women previously treated for cancer had higher rates of postpartum haemorrhage, operative or assisted delivery, and preterm birth. Furthermore, their offspring were more likely to require monitoring 1645 1646 or care in a neonatal intensive care unit. The risks of early death or stillbirth were not increased after adjustment for prematurity, and there was no increased risk of congenital or chromosomal abnormality 1647 (Winther et al., 2012, Nielsen et al., 2018, van der Kooi et al., 2018, van der Kooi et al., 2019). Data from 1648 the Swedish Cancer Register (10 017 births in female cancer survivors) identified an increased risk of 1649 stillbirth within three years after the cancer diagnosis (OR 1.92; 95% CI 1.03 to 3.57). However, the risk 1650 of stillbirth and neonatal death was significantly decreased among second children as compared to the 1651 first born, suggesting that any adverse effect associated with cancer treatments may diminish with time 1652 1653 (Ji et al., 2016).
- 1654 A meta-analysis of data from cohort studies and registries came to similar conclusions (van der Kooi et 1655 al., 2019). Their calculations showed that cancer survivors had an increased risk of prematurity (RR 1.56; 1656 95% CI 1.37 to 1.77), low birth weight (RR 1.47; 95% CI 1.24 to 1.73), emergency caesarean section (RR 1657 1.22; 95% CI 1.15 to 1.30), elective caesarean section (RR 1.38; 95% CI 1.13 to 1.70), and postpartum haemorrhage (RR 1.18; 95% CI 1.02-1.36). They reported a non-significant difference in small-for-1658 1659 gestational-age-babies (RR 0.99; 95% CI 0.81 to 1.22), and antepartum haemorrhage (RR 1.06; 95% CI 1660 0.88-1.29). From this meta-analysis, they also concluded that the incidence of congenital abnormalities 1661 was not higher in children from cancer survivors, with an apparent increase due to the statistical artefact know as Simpson's paradox (van der Kooi et al., 2019). 1662
- 1663 Effect of chemotherapy

1664 No systematic reviews were found on the effect of different chemotherapy regimens in adult women 1665 on subsequent pregnancy. Chemotherapy has not been associated with adverse pregnancy outcomes 1666 (van Dorp *et al.*, 2018). Akhtar and colleagues retrospectively assessed 176 patients (age 14-40 years) 1667 who underwent high dose chemotherapy and autologous stem cell transplant without total body 1668 irradiation (TBI) for diffuse large B-cell lymphoma and Hodgkin lymphoma (Akhtar *et al.*, 2015). Twenty-1669 six patients (65%) became pregnant 50 times (range 1-6 times), resulting in 43 (86%) live births, 7 (14%)



miscarriages, including 1 still birth (at 28 weeks). There was a significantly higher incidence of successful
 pregnancies after autologous stem cell transplant in patients younger than 40 years. Other single studies
 were of very small patient groups, precluding accurate interpretation.

1673 Large prospective cohort and population-based studies have evaluated the effects of chemotherapy for 1674 childhood cancer on subsequent pregnancy outcomes, whereas data are more limited for adult cancer 1675 patients. One relevant publication reported outcomes of 4922 births to cancer survivors and concluded 1676 that women who conceived ≥ 1 year after starting chemotherapy without radiation or ≥ 2 years after 1677 chemotherapy with radiation did not have an increased risk of preterm birth (Hartnett et al., 2018). Women who conceived ≤ 1 year after starting chemotherapy had higher risks of preterm birth than 1678 1679 controls (chemotherapy alone: RR 1.9; 95% CI 1.3-2.7; chemotherapy with radiation: RR 2.4; 95% CI 1.6 1680 to 3.6).

- 1681 Anthracyclines (e.g. doxorubicin, daunorubicin) and mediastinal radiotherapy (including that for breast 1682 cancer, as the heart can fall within the area of scatter) are both associated with cardiomyopathy and
- 1683 heart failure. The risk is greatest when either is used at higher doses or in combination with each other.
- 1684 Anthracyclines can be cardiotoxic at all doses, and it is not entirely clear at what dosage the risk increases
- 1685 significantly, but it is likely to between a cumulative dose of 250 mg/m² (Scottish Intercollegiate
- 1686 Guidelines Network (SIGN), 2013) and 300 mg/m² (Hudson, 2010). The overall risks for heart failure are
- 1687 low (1.7%), most severely in those with pre-existing cardiac dysfunction (Nolan *et al.*, 2020).
- 1688 Effect of Pelvic radiotherapy
- 1689 There are robust data that radiotherapy to a field that includes the uterus is associated with adverse 1690 pregnancy outcomes in women who had been exposed during childhood and adolescence, but the data
- 1691 following adult exposure are much more limited. Females treated with pelvic radiation for childhood
- 1692 cancers have an increased rate of uterine dysfunction leading to pregnancy loss, preterm birth, and low
 1693 birth weight (Critchley and Wallace, 2005). These pregnancy-related complications are related with
 1694 reduced uterine volume, damage of uterine vessels, myometrial fibrosis, endometrial injury (Critchley
- and Wallace, 2005, Teh *et al.*, 2014). Doses of 14 to 30Gy can lead to irreversible uterine dysfunction in
 young female patients (Critchley and Wallace, 2005).
- A large retrospective cohort study, performed between 1970 and 1986, enrolled 1774 women younger 1697 1698 than 21 years at initial cancer diagnosis, who had survived for at least 5 years after diagnosis and who 1699 had received radiotherapy, found that high-dose pelvic irradiation can permanently impair growth and 1700 blood flow to the uterus resulting in a reduced uterine volume; these effects of radiation are dependent on age (Signorello et al., 2010). Sixty stillbirths or neonatal deaths, and 3077 live births were reported. 1701 1702 Uterine or ovarian irradiation with doses \geq 2.5 Gy greatly increased the risk of stillbirth or neonatal death 1703 (12-fold) in women treated before menarche. Therefore, careful management is warranted for pregnant 1704 women treated with high doses of pelvic irradiation particularly before they have reached puberty.
- 1705 In a study reporting on the effect of adulthood radiation effect on pregnancy, the incidence of 1706 spontaneous miscarriage (37% versus 7%) and preterm birth (63% versus 18%) were significantly higher 1707 in total body irradiation (TBI) recipients when compared to the chemotherapy-only group (Sanders *et* 1708 *al.*, 1996). The 13 preterm births resulted in 10 low birth weight (1.8 to 2.24kg) and three very low birth 1709 weight (\leq 1.36kg) infants, for an overall incidence of 25%, which is higher than the expected incidence 1710 of 6.5% for the general population. Four Gy appears to be the threshold dose.
- 1711 Radiotherapy-induced structural and functional changes to the uterus (> 5Gy) may adversely affect
 1712 implantation and maintenance of pregnancy increasing the risk of placental attachment disorders
 1713 (placenta accreta or placenta percreta), low birth weight (OR 3.64; 95% CI 1.33 to 9.96; in survivors after
- abdominopelvic radiation; OR 6.8; 95% CI 2.1 to 22.2); small for gestational age (OR 4.0; 95% CI 1.6 to



- 1715 9.8) ; preterm birth (OR 3.5; 95% CI 1.5 to 8.0); and perinatal death and foetal malposition (Tarín *et al.*,
 1716 2016).
- 1717 In conclusion, uterine exposure to radiotherapy during childhood reduces adult uterine volume and
 1718 leads to an increased risk of pregnancy complications and adverse pregnancy outcomes.
 1719 Preconceptional assessment and appropriate obstetric monitoring is warranted (van de Loo *et al.*, 2019).

1720 For oocyte donated pregnancies

1721 Oocyte (or embryo) donation is an established fertility treatment, and most IVF units report similar pregnancy, implantation, and live birth rates as their cycles using women's own oocytes when egg age 1722 1723 is similar. Pregnancies following oocyte donation (OD) are at increased risk for obstetrical and neonatal complications. In a large systemic review and meta-analysis (Storgaard et al., 2017) singleton OD 1724 1725 pregnancies, compared with singleton IVF pregnancies, had increased risk for hypertensive disorders of pregnancy (AOR 2.11; 95% CI 1.42 to 3.15), caesarean section (AOR 2.20; 95% CI 1.85 to 2.60), post-1726 1727 partum haemorrhage (AOR 2.40; 95% CI 1.49 to 3.88), preterm birth (AOR 1.75; 95% CI 1.39 to 2.20), 1728 and low birth weight (AOR 1.53; 95% CI 1.16 to 2.01). There was no increased risk for gestational 1729 diabetes.

- The greatest risk for oocyte donor cycles seems to be the risk for pre-eclampsia (PE). A large systemic 1730 1731 review and meta-analysis evaluated data from 27 studies and over 7000 donor cycles and 70 000 IVF cycles to establish risk (Keukens et al., 2022). The risk was 13.5 to 18% in OD pregnancies compared to 1732 5.9% in autologous IVF, with risk for severe PE of 6.8 to 12% vs. 3.3%, respectively. Interpretation of 1733 these data are complicated by the fact that a higher percentage of the OD pregnancies were multiples 1734 1735 compared with autologous IVF, and that the OD pregnancies were conceived in a medicated cycle. 1736 Recent data have suggested the absence of the corpus luteum in medicated cycles, compared with natural cycle, or transfer in a fresh egg retrieval cycle, increases PE risk (Conrad et al., 2022). Lastly, 1737 1738 women with POI, based on the cause of the POI, may have unique risk factors, such as prior abdominopelvic radiation, chemotherapy, and estrogen deficiency. 1739
- 1740 The risk of aneuploidy is related to the age of the donor, not the recipient, and should be taken into 1741 consideration during antenatal aneuploidy screening (Bowman and Saunders, 1994, Donnenfeld *et al.*, 1742 2002).

1743 In women with Turner Syndrome (TS) (see also Table IV)

1744 Pregnancies in women with TS are high risk due to the underlying increased morbidity and mortality of 1745 the condition. Although not common, spontaneous pregnancies can occur, especially in women with a 1746 mosaic karyotype rather than 45,X, and these may be lower risk than oocyte donated pregnancies 1747 (Hadnott et al., 2011). Hadnott and colleagues reported 7 spontaneous pregnancies in 5 women with 1748 spontaneous menses out of a population of 276 TS women (Hadnott et al., 2011). All 7 pregnancies 1749 resulted in live births without any maternal complications, although one of the offspring had cerebral 1750 palsy. None had congenital or karyotypic anomalies. A much larger cohort study of 57 women having 1751 124 pregnancies from a population of 482 Swedish women with TS described a miscarriage rate in 1752 spontaneous pregnancies of 45% compared to 26% in oocyte donated pregnancies (Bryman et al., 1753 2011). The higher miscarriage rate is consistent with a higher rate of karyotypic abnormalities in natural 1754 pregnancies (Birkebaek et al., 2002, Bernard et al., 2016). Assessment of anti-mullerian hormone (AMH) 1755 levels is a reliable marker of ovarian function in women with Turner syndrome to assess chances for 1756 natural pregnancy and/or options for fertility preservation (Kalra et al., 2019).



1757 TABLE IV THE PREVALENCE OF COMPLICATIONS IN PREGNANCIES IN WOMEN WITH TURNER SYNDROME

	Pregnancies with own oocytes				Pregnancies with donated oocytes					
	(Hadnott <i>et al.</i> , 2011)	(Bryman <i>et</i> <i>al</i> ., 2011).	(Bernard <i>et</i> <i>al.</i> , 2016)	(Birkebaek <i>et</i> <i>al.</i> , 2002)	(Hadnott <i>et al</i> ., 2011)	(Bryman <i>et</i> <i>al</i> ., 2011).	(Chevalier <i>et</i> <i>al.</i> , 2011)	(Foudila <i>et</i> <i>al</i> ., 1999)	(Bodri <i>et al</i> ., 2006)	(Hagman <i>et al</i> . 2013)
Nr of TS women	5	27	27	33 . ²	5	30		18	21	106
Unassisted / IVF / UIU	5/0	23 / 3 / 1	27	32 / 1						
Nr of Pregnancies	7	82	52	61	6	42	82	20	17	
Deliveries (children)	7 (7)	36 (37)	30 (30)	61 (64)	6 (7)	31 (31)	71	11 (12) (1 ongoing)	7 (8) (1 ongoing)	122 (131)
Pregnancy complication	ons									
Multiple pregnancy	0/7	1/82	0/52		1/6	0/42		1/20		13/122
Miscarriage		37/82 (45)	16/52 (30.8)		N	11/42 (26)		8/20 (40)	8/17 (47)	
Legal abortion		8/82 (10)	2/52 (3.8)			0				
Medical interruption			3/52 (5.8)	0						
Extrauterine pregnancy		1/82 (1.2)				0				
Intrauterine foetal death			1/52 (1.9)		•				1/17 (5.6)	
Stillbirth										1/131 (0.8)
Maternal complication	าร									
Aortic dissection	0	1	0/30		0		2/93 (2.2)			1/117 (0.8)
Other cardiovascular complications			X							1/117 (0.8). ³
⇒ Maternal death		0					2			0
Pregnancy-associated hypertensive disorders (PAHD)	0		4/30 (13.3)		0		31/82 (37.8)	6/18 (33)	5/8 (62.5)	17/117 (14.5)
Pre-eclampsia	0		2/30 (6.7) (included in PAHD)		1 (twin pregnancy)		17/82 (20.7) (included in PAHD)	2/18 (11) (included in PAHD)	3/8 (37.5) (included in PAHD)	24/117 (20.5)

² This includes 1 patient pregnant after Oocyte donation for which the results/data could not be excluded.

³ heart regurgitation and left ventricular dilatation.



Gestational diabetes	0		1/30 (3.3)		0/6		3/82 (3.6)			11/117 (9.4)
Intrahepatic cholestasis of pregnancy			1/30 (3.3)				1/82 (1.2)			8/117 (6.8)
C-section	4/7 (57.1)	17/27 (63)	14/30 (46.7)		6/6 (100)	24/30 (80)	58/71 (81.7)	11/11 (100)	7/7 (100)	100/122 (82.0)
Neonatal complication	s									
Placental complications								1 /11 (twin)		5/118 (4.2)
Perinatal mortality						7	1			3/131 (2.3)
Preterm delivery (<37wks)	0				2		28/73 (38.3). ⁴		4/8 (50)	15/122 (12.3)
Low birth weight (<2500g)	0				4/7					23/131 (17.6)
Chromosomal anomalies	0				0	7				
Birth defects	1/7.5	4. ⁶	0		0	1				8/131 (6.1%). ⁷
Abnormal Karyotype			2 TS /11 girls tested	6/25 tested. ⁸						
Other adverse neonatal outcomes				0			7/87			
		Ċ	RAF							

1758

⁴ ≤35 wg

⁵ cerebral palsy

⁶ five (7%) had a birth defect or a serious illness. These were cerebral paresis (n=1), neuropsychological disorder (n=1), coarctation of the aorta (n=1), cleft lip and palate (n=1), and congenital tumour (n=1). Four of these five children were born after spontaneous pregnancies.

⁷ Of which 5/131 (3.8) were considered serious birth defects

⁸ Two children had karyotype of 46,Xdel(X)(p22.1)mat, and one child a karyotype of 47XX,del(X)(p22.1)mat. All three were siblings. One child with congenital hydrocephalus had the karyotype 46,Xdel(X)(p21.2)mat. One child with ambiguous genitalia had the karyotype 45,X/ 46,XY, and one child had a normal variant.



Overall risk for death related to pregnancy for a patient with Turner Syndrome is ~1% (Bondy, 2014). Pregnancy increased the risk of aortic dissection by an estimated two to five times for women with TS while a recent systematic review found 14 reported cases of death from aortic dissection with a concurrent or recent pregnancy (Hynes *et al.*, 2020). Rates of death, and serious complications, have declined with good pre-pregnancy screening (excluding from pregnancy for those with high risk) and careful monitoring of those with lesser risk as aortic dissection can occur even with a normal prepregnancy cardiac evaluation.

1766 A cohort study of oocyte donated pregnancies in 106 TS women in 3 Nordic countries (1992-2011) 1767 similarly showed these pregnancies to be high risk (Hagman et al., 2013). Hypertensive disorders of 1768 pregnancy were the most common complication (35%). Life-threatening events occurred in 4 1769 pregnancies (3.3%), one of which was an aortic dissection, although there were no maternal mortalities. 1770 Neonatal complications appeared less common than suggested by previous studies; in singleton 1771 pregnancies the preterm birth rate was 8.0% with low birth weight in 8.8%. Perinatal mortality was 2.3% overall. It is not known how many women were declined treatment based on an unfavourable pre-1772 conception assessment and the same proportion of women was 45,X as in the Hadnott & Bondy review 1773 1774 (44%) (Hadnott et al., 2011). Only 63.5% of cases had a prior cardiac review (although 100% of the 1775 Swedish group - 31 deliveries) and only 48.7% of assessments were within 2 years of pregnancy (71% 1776 in Sweden).

1777 Other issues

A case report of post-partum depression in a woman with POI (Shea and Wolfman, 2017) raises the concern for the impact of rapid changes in hormones that occur post-partum and differential affect in women with chronic estrogen deficiency and potential sensitivity to mood alterations. Transdermal estrogen can be given post-partum without impact on lactation and may be of benefit (Moses-Kolko *et al.*, 2009, Wisner *et al.*, 2015). A recently approved medication, specifically for post-partum depression (zuranolone) may offer benefit but has not yet been tested in this population.

1784 **Recommendations**

	Women should be reassured that natural pregnancies after idiopathic POI or most forms of chemotherapy do not show any higher obstetric or neonatal risk than in the general population.	⊕⊕⊕⊖	STRONG
1785			
	Oocyte donation pregnancies are high risk and should be managed in an appropriate obstetric unit. Women and their partners should be encouraged to disclose the origin of their pregnancy with their obstetric team.	⊕⊕⊖⊖	STRONG
1786			
	Pregnancies after radiation to the uterus are at high risk of obstetric complications and should be managed in an appropriate obstetric unit.	⊕⊕⊖⊖	STRONG
1787			
	Pregnancies in women with Turner Syndrome are at high risk of obstetric and non-obstetric complications and should be managed in an appropriate obstetric unit with cardiologist involvement.	⊕⊕⊖⊖	STRONG



1788

A cardiologist should be involved in care of pregnant women who have received anthracyclines and/or cardiac irradiation.

1789 Justification

1790 Unassisted pregnancies after idiopathic POI or after most forms of chemotherapy are probably not any 1791 higher risk than the general population (moderate quality of evidence). Pelvic irradiation is associated 1792 with increased obstetric risks due to poor uterine function, especially when exposure occurred before 1793 menarche. Anthracycline chemotherapy and cardiac irradiation are associated with cardiac failure, which 1794 may become clinically apparent in pregnancy.

- 1795 Oocyte donated pregnancies, regardless of recipient's age, indication for treatment or ovarian function, 1796 are associated with pregnancy-induced hypertensive disorders, threatened miscarriage, caesarean 1797 section, and possibly postpartum haemorrhage. Fetal growth restriction may be more common in 1798 oocyte donated pregnancies in women with POI. Therefore, the guideline development group strongly 1799 recommends that these pregnancies are followed with adequate obstetric surveillance, although no 1800 studies have been performed showing the effect of obstetric care on complications in these patients. 1801 (Good practice point)
- 1802 Low dose aspirin (150mg) has been shown to reduce risk of pre-eclampsia (Duley et al., 2019). Aspirin is most effective if started prior to 16 weeks but can be started earlier based on proposed mechanism. 1803 1804 The recommendation is that 2 or more moderate risk factors, an example of which is first pregnancy, 1805 should be an indication for aspirin (NICE clinical Guideline, 2010). Although oocyte donation is not given 1806 as a specific risk factor, consideration of prescribing aspirin should be given in these pregnancies, especially when it is the first pregnancy or in a woman with Turner Syndrome. A recent randomized trial 1807 (Mendoza et al., 2023) suggests that stopping treatment at 24 - 28 weeks in those with a normal sFlt-1808 1:PIGF ratio does not negative impact pre-eclampsia risk. 1809
- Pregnancies in women with Turner Syndrome are high risk and may have a maternal mortality as high as 3.5%, with newer studies reporting lower risk. Reporting bias may make the true incidences of complications uncertain. Pre-conception screening, especially for cardiac risk factors, may help reduce maternal risks in pregnancy as well as identify those in whom pregnancy might be considered best avoided. Women with TS should be appropriately counselled regarding the risks of reproduction, and this should include contraceptive advice when pregnancy is considered contra-indicated, especially in those with spontaneous menses.
- 1817

1818

PICO QUESTION: How should fitness for pregnancy be assessed in women with **POI**?

1819 Women with POI seeking to embark on pregnancy should be given the same pre-conception advice as 1820 any woman with regard to ensuring immunity to rubella, varicella, and measles and, ideally, have 1821 optimized body mass index (BMI). Treatment of co-existing medical conditions should be optimized, 1822 any medication should be reviewed, and folic acid commenced. If either partner is a smoker, they should 1823 be advised to stop.

1824 No evidence of effectiveness or otherwise for any intervention prior to pregnancy in POI was identified, 1825 except for women with Turner Syndrome (TS). Given that oocyte donation pregnancies appear to be 1826 high risk (see section V.3. Pregnancy), it would be reasonable to consider a general assessment for all 1827 women prior to oocyte donation with measurement of blood pressure and renal function, starting with 1828 creatinine.



1829 Specific investigations are indicated according to the cause of POI.

1830 Co-existing endocrinopathies associated with autoimmune POI should be sought and treated as 1831 described in section II.3.3 Autoimmune causes of POI. Specifically, thyroid function should be tested, as 1832 should adrenal antibodies. Genetic analysis should also be performed, if not already known, in view of 1833 the significance of Turner Syndrome in pregnancy.

1834 Cardiotoxicity may result from prior treatment with anthracyclines, high dose cyclophosphamide or 1835 mediastinal irradiation, including chest wall irradiation for breast cancer, and the effects may be 1836 subclinical (see section V.3. Pregnancy). While risk for women without pre-existing, cardiac dysfunction 1837 is low (0.24%, 95% CI 0.00 to 0.81%), the risk with during pregnancy, and post-partum, with pre-existing 1838 disease is significantly increased (28.4%; 95% CI 15 to 44%) (Nolan et al., 2020). Therefore, 1839 echocardiogram and assessment of left ventricular ejaculatory function (LVEJ) is recommended pre-1840 pregnancy for all women exposed to anthracyclines or chest radiation (Bansal et al., 2022, Ehrhardt et 1841 al., 2023). Doxorubicin-induced cardiomyopathy was associated with a poor survival rate compared to 1842 other causes in a study of 1230 patients with cardiomyopathy, although these cases were not pregnancy 1843 related (Felker et al., 2000).

1844 Only one study was identified that considered pregnancy outcome in relation to myocardial function 1845 (Bar et al., 2003). Fractional shortening values of 30% or more pre-pregnancy in women treated with doxorubicin in childhood were associated with no deterioration in cardiac function during pregnancy. 1846 Those with lower fractional shortening had a non-significant decrease after pregnancy but more 1847 maternal admissions to the intensive care unit and neonatal admissions to the neonatal intensive care 1848 unit as well as a higher rate of induction of labour (Bar et al., 2003). However, it is not clear whether 1849 these differences were a result of clinical reaction to the known impaired cardiac function or were driven 1850 1851 by the deterioration.

Pregnancy in women with TS is high risk. Women with TS considering pregnancy (spontaneous or oocyte donation) should have a thorough medical assessment with special consideration paid to the cardiovascular system (Gravholt *et al.*, 2017). Thyroid and liver function should be updated and screening for diabetes performed (Gravholt *et al.*, 2017) (Bondy and Turner Syndrome Study Group, 2007, Cabanes *et al.*, 2010). Resting blood pressure must be measured, and Cabanes and colleagues suggest ambulatory monitoring in addition (Cabanes *et al.*, 2010).

Congenital and acquired cardiac abnormalities should be screened for using MRI and echocardiography 1858 1859 (Gravholt *et al.*, 2017). Women with a rtic size index (ASI) > 2.5 cm/m² should be advised against 1860 pregnancy. This is a conservative recommendation and may reflect publication bias (pregnancies with 1861 adverse outcomes being more likely to be reported). Additionally, in most of the reported case series, 1862 the proportion of women who had a cardiology assessment was relatively low and outcome may be improved when this is performed. Transthoracic echocardiography is recommended at least once during 1863 1864 pregnancy for those without observed risk and more frequently for those with ASI > 2 or other risk 1865 factors. CT/cardiac magnetic resonance should be performed during pregnancy for suspicion of disease 1866 of the distal ascending aorta, aortic arch, or descending aorta (Gravholt et al., 2017).

1867Aortic dissection occurred in 33% of TS women with an aortic root over 2.5 cm/m² in a series of 166 TS1868women with the average age of 36 years over a 3-year period (Matura *et al.*, 2007). The French review1869of practice recommends this as the cut-off above which pregnancy should be avoided or suggest a level1870of > 2.0cm/m² in those with additional risk factors including bicuspid aortic valve (BAV), coarctation of1871the aorta, elongated transverse arch, uncontrolled hypertension and/or liver disease (Fiot *et al.*, 2022).1872A previous ASRM guideline offered a more conservative recommendation with a cut-off value of 2.01873cm/m² (Practice Committee of American Society For Reproductive Medicine., 2012). The consensus is



- that aortic root measurement is best expressed as aortic size index (ASI) due to the short stature of theaffected women (Matura *et al.*, 2007).
- 1876 It is also recommended a renal ultrasound scan for structural abnormalities and, if hypertensive, for 1877 renal artery stenosis along with measurement of urea and electrolytes be performed (Cabanes *et al.*, 1878 2010).
- 1879 Recommendation see also Table V Summary assessing fitness for pregnancy in POI

Women presenting for oocyte donation who are suspected of having POI should be fully investigated prior to oocyte donation, including thyroid and adrenal function as well as genetic testing.

1880

Women previously exposed to anthracyclines, high dose cyclophosphamide or mediastinal irradiation should have an echocardiogram prior to pregnancy, and referral to a cardiologist if indicated.	⊕000	STRONG
--	------	--------

1881

Thorough cardiac screening and appropriate counselling by a maternal-foetal medicine specialists and cardiologists with expertise in managing women with Turner Syndrome is recommended prior to planning a pregnancy, especially if oocyte or embryo donation is considered.	⊕⊕⊖⊖	STRONG
---	------	--------

1882

Women with POI should have their cardiometabolic and thyroid function assessed prior to pregnancy.	€000	STRONG

1883

Pregnancy in some women can be of such high risk that clinicians may		
consider oocyte donation pregnancy to be life threatening and	$\oplus OOO$	STRONG
therefore inappropriate.		

1884 Justification

1885 Oocyte donation pregnancies appear to be at high risk of obstetric complications, especially in women
 1886 with POI and a history of chemotherapy and/or cardiac irradiation, or women with Turner syndrome.

- 1887 Although no evidence was found on the effectiveness of any intervention prior to pregnancy in POI, the
 1888 guideline development group recommends consideration of a general assessment for all women prior
- 1889 to oocyte donation, and a specific assessment based on additional risk factors, especially a history of 1890 chemotherapy and/or cardiac irradiation, or Turner syndrome patients.
- 1891 In addition to the assessment of fitness for pregnancy based obstetric risk factors, an oncology
 1892 assessment to rule out recurrence prior to pregnancy could be recommended in women with POI after
 1893 treatment for cancer.
- 1894



1895 TABLE V SUMMARY – ASSESSING FITNESS FOR PREGNANCY IN POI

	Idiopathic	Turner	Fragile X	POI after car	ncer treatment	POI after
	POI	Syndrome	premutation	chemotherapy only	chemotherapy + radiotherapy	surgery
Standard antenatal	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark
assessment						
Echocardiogram				√1	√ ²	
Evaluation by cardiologist		\checkmark				
Renal function	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark
Thyroid function	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark
Genetic evaluation ³	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark
Adrenal function			In case of oo	cyte donation		
Uterine doppler / MRI /					\checkmark	
EMBx					If Pelvic RT, esp. pre-pubertal	

1896 ¹ If exposed to anthracyclines or high dose cyclophosphamide.

1897 ² In case of mediastinal irradiation

³ Karyotype for all + WES when clinically available 1898

1899

JRAFF FOR REVIEW



1900 VI. POI and musculoskeletal health

Muscle and bone form an integrated locomotor unit and both menopause and aging impact 1901 1902 musculoskeletal health. During the menopausal transition and early post-menopause, rapid bone loss 1903 in the range of 2-5% per year occurs which then slows after approximately 10 years, and thereafter is 1904 similar to that of eugonadal age-matched men, i.e. bone loss is age-related rather than reflecting 1905 hormone deficiency after that time point (Eastell et al., 2016). Accelerated bone loss around menopause 1906 predominately affects trabecular bone; however, the subsequent age-related slower bone mass decline 1907 affects both cortical and trabecular bone. This is reflected in the onset of fragility fractures where spine fractures occur earlier than hip fractures (Eastell et al., 2016). Peak muscle mass and strength is attained 1908 1909 in young adulthood, being greater in men than women. The age-related decline in muscle mass 1910 accelerates after usual menopause reflecting the impact of estrogen deficiency, decreasing by 1911 approximately 1-2 % per year after age 50 and from the mid-seventies by about 0.7% per year (Cruz-1912 Jentoft and Sayer, 2019). A greater decline in muscle strength also occurs, decreasing 10-15% per decade to age 70 and then accelerating to 25-40% (Cruz-Jentoft and Sayer, 2019). 1913

The beneficial effects of estrogen on bone have long been recognized; however, it is increasingly 1914 recognised that estrogen is important for muscle mass and function as well. Estrogen is important for 1915 bone accrual during puberty/adolescence with attainment of peak bone mass during early adulthood 1916 (Samad *et al.*, 2020). Human and animal studies have shown that estrogen receptors α and β are 1917 1918 expressed in multiple cell types in both muscle and bone. Estrogen signals via both classical nuclear 1919 genomic and non-genomic membrane G-protein-coupled receptor pathways (Samad et al., 2020). However, the details remain unclear. Bone-muscle crosstalk via myokines and osteokines influence 1920 1921 musculoskeletal function, growth, and repair (Samad et al., 2020). Bone loss secondary to estrogen 1922 deficiency results from greater bone resorption versus formation due to decreased osteoblast function, 1923 decreased osteocyte mechano-sensing, increased osteoclast number and activity and increased T cell activation leading to increased cytokines and reactive oxygen species (Eastell et al., 2016). Estrogen 1924 deficiency is also associated with: (i) loss of muscle mass via increased muscle apoptosis and protein 1925 turnover; and (ii) loss of muscle strength via loss of type II (fast twitch) fibres, dysregulated muscle 1926 1927 metabolism, lipid infiltration and impaired myosin function (Samad et al., 2020). In addition, reduced 1928 hormones including, testosterone, insulin-like growth levels of other factor-1 and 1929 dehydroepiandrosterone, may also contribute to loss of muscle mass and function. Lower muscle mass 1930 and function is associated with bone microarchitecture abnormalities, decreased bone size, and bending 1931 strength (Kirk et al., 2020).

1932 Clinical consequences of these interacting musculoskeletal changes are an increased incidence of 1933 osteoporosis (low bone mass with deteriorated microarchitecture leading to fragility fractures (de Villiers 1934 and Goldstein, 2021), sarcopenia (loss of skeletal muscle mass and function) (Cruz-Jentoft and Sayer, 1935 2019) and osteosarcopenia (sarcopenia associated with bone loss) (de Villiers and Goldstein, 2021). 1936 Osteosarcopenia is associated with increased morbidity, including cardiometabolic disease, and 1937 mortality.

1938 VI.1. Skeletal health

1939 **PICO QUESTION: WHAT ARE THE CONSEQUENCES OF POI FOR SKELETAL HEALTH?**

1940 The effect of POI on skeletal or bone health is among the most clearly established adverse consequences 1941 of the condition and a key concern for women (Deeks *et al.*, 2011). Underlying mechanisms for POI 1942 associated low bone mass include: (i) reduced bone accrual and failure to achieve peak bone mass; (ii)



increased bone resorption associated with estrogen deficiency; (iii) presence of POI associated comorbidities that increase the risk of osteoporosis such as rheumatoid arthritis or coeliac disease; and (iv) factors specific to the cause of POI, for example Turner Syndrome (TS) (Gravholt and Backeljauw, 2017, Samad *et al.*, 2020). The relative contributions of reproductive (estrogen deficiency), socioeconomic, health behavioural, and genetic factors to bone health in POI must be considered and many details have yet to be determined.

1949 Bone mineral density (BMD)

1950 The World Health Organization (WHO) has defined 'osteoporosis' as a condition where BMD values fall 1951 by 2.5 standard deviations below those of young, healthy women (represented by a T-score <-2.5), 1952 whereas 'osteopenia' refers to T-score -1.0 to -2.5 (International Society for Clinical Densitometry, 2019, 1953 de Villiers and Goldstein, 2021). Using BMD to assess fracture risk in young adult populations, including 1954 those with POI, can be problematic since the correlation between BMD and fracture risk in such cohorts 1955 is not fully established. The International Clinical Densitometry Society has suggested avoiding the terms 1956 "osteopenia" and "osteoporosis" for premenopausal women under 50 years of age and instead use "low 1957 bone mass" when BMD is 2.0 standard deviations below age and sex-matched populations (Z-score ≤-2.0) (International Society for Clinical Densitometry, 2019). However, the International Osteoporosis 1958 1959 Foundation proposed that BMD T-score \leq -2.5 may be used to diagnose osteoporosis in young adults with chronic conditions known to influence bone metabolism as long as peak bone mass has been 1960 achieved (Ferrari et al., 2012). In addition, reduced height is characteristic of TS and BMD should be 1961 adjusted to allow for this as otherwise BMD would be underestimated. 1962

- 1963 Reduced BMD compared to reference populations has been established in many studies investigating 1964 women with POI of different aetiologies. This includes women with idiopathic POI, TS, galactosemia, 1965 Fragile X premutation, gonadal dysgenesis, iatrogenic POI and in populations of mixed aetiology 1966 (Gravholt and Backeljauw, 2017). However, the magnitude varies reflecting differences in POI aetiology, 1967 ethnicity, study design, reference population, duration of amenorrhoea, HRT use and presence of other 1968 osteoporosis risk factors.
- A 2023 systematic review of eight studies assessing the effect of HT on BMD in women with POI 1969 (including 977 women with idiopathic POI, 698 premenopausal controls, and 55 postmenopausal 1970 1971 controls) reported that women with POI had lower lumbar spine (mean difference ranged from 0.028 to 1972 0.43 g/cm²) and femoral neck (mean difference ranged from 0.025 to 0.047g/cm²) BMD than control 1973 subjects (Costa et al., 2023). African, American, and Asian women with POI were found to have a greater risk of having Z-score < -2.0 (Costa et al., 2023). Similar findings have been reported in other studies. A 1974 1975 study of 70 Indian women with non-iatrogenic POI reported 11.5%, 11.4%, and 9.1% lower mean BMD 1976 values at the lumbar spine, hip, and forearm respectively (p < 0.01) compared to 70 age-matched controls 1977 (Dhakate et al., 2023). A case-control study observed that mean lumbar spine and femoral BMD was 1978 lower in 240 Chinese women with spontaneous normal karyotype POI compared to 260 perimenopausal 1979 controls, but higher than 260 postmenopausal controls (Luo et al., 2018). A retrospective study of 162 1980 Italian women with POI of diverse causes observed lower BMD in primary versus secondary 1981 amenorrhoea (Bakhsh et al., 2015).
- Later induction of puberty was associated with lower BMD in women with POI including TS (Nakamura *et al.*, 2015, Gravholt and Backeljauw, 2017, Nguyen *et al.*, 2017, Cardona Attard *et al.*, 2019).

1984 Women with TS have increased prevalence and risk (OR 9.8; 95% CI 1.9 to 49.9 adjusted for height and 1985 BMI) of low bone mass compared to controls (Nguyen *et al.*, 2017). Lumbar spine BMD (but not total 1986 hip BMD) was significantly lower in 267 TS women compared to 67 women with POI (Cardona Attard *et 1987 al.*, 2019). TS women who have spontaneous menses have higher spine BMD than those with primary 1988 amenorrhoea (Nakamura *et al.*, 2015). Late initiation of HRT after 18 years or non-use of HRT was



- associated with lower lumbar spine BMD (Nakamura *et al.*, 2015). Although BMD does not appear to be associated with TS karyotype (Gravholt and Backeljauw, 2017), recent studies reported variation in femoral neck bone density with estrogen receptor 1 (ESR1) polymorphism pattern (Scalco *et al.*, 2019) and an association between low BMD and variants in the CYP27B1 gene (Barrientos-Rios *et al.*, 2019).
- Bilateral oophorectomy (BO) was associated with decreased lumbar spine BMD by up to 8% and at the hip by up to 5.7% within 2 years post-surgery in a prospective longitudinal study (Jiang *et al.*, 2021). Similar reductions in lumbar spine (7.8%) and hip (5.2%) BMD at 2 years follow-up were reported in women (mean age 42.8 years) with early surgical menopause secondary to risk reducing BO and not treated with HT (Jiang *et al.*, 2021).
- 1998 A substantial difference in BMD (8.3%) was reported between chemotherapy-associated POI (24 women 1999 treated for lymphoma) and age-matched controls (Ratcliffe et al., 1992). In a study of women with POI 2000 following chemotherapy for cancer assessed at a mean age of 37, 21% (7 of 33) had a Z-score of <-2 2001 for at least one of 4 skeletal sites surveyed, only 1 of whom was taking estrogen replacement (Howell 2002 et al., 1998). As BMD in a cohort of 26 women treated for lymphoma who did not have POI was similar 2003 to controls, the decreased BMD was not attributed to the drugs involved in treatment (Ratcliffe et al., 2004 1992), although there had been an interval of several years since treatment. However, in prospective analysis of changes in BMD during chemotherapy for early breast cancer and in relation to ovarian 2005 function, an adverse effect of the chemotherapy in addition to the effect of loss of ovarian function was 2006 2007 identified (Cameron et al., 2010).
- A study of 985 Serbian women, median age 64 years, reported that those with early menopause defined
- 2009 as \leq 45 years) reported lower median femoral neck BMD in both women with and without previous 2010 fracture compared to those with menopause after age 45 years (Minaković *et al.*, 2023).
- 2011 Prevalence of low bone mass and osteoporosis
- A higher prevalence of low bone mass.⁹ and osteoporosis.¹⁰ () is reported in women with POI; however, 2012 the extent and study quality varies according to study design, sample size, comparators, diagnostic 2013 2014 criteria used, presence of co-morbidities and cause of POI. A cohort study of Canadian women (n= 12329; mean age 65 years at follow-up) observed a higher rate of self-reported osteoporosis in women 2015 2016 with POI versus normal age menopause (21.9% versus 16.7%) (Shea et al., 2021). Similar findings were 2017 reported in an Australian prospective cohort of 5107 women; spontaneous menopause ≤40 years (mean 2018 age 38.2 years) was associated with the highest prevalence of osteoporosis (26.5%) at age 59-64 and an 2019 increased risk of osteoporosis (OR 2.54; 95% CI 2.63 to 3.96) compared to menopause at age 50-51 2020 years (Xu et al., 2020). Women with POI were more likely to have multiple co-morbidities, smoke, have 2021 low levels of physical activity and be less educated (Xu et al., 2020).
- 2022 The reported prevalence of DXA defined osteoporosis in spontaneous normal karvotype non-iatrogenic 2023 POI varies from 5-14% (Bachelot et al., 2009, Popat et al., 2009, Podfigurna et al., 2020, Beitl et al., 2021, 2024 Shea et al., 2021, Samad et al., 2022). A Canadian study of 374 women with POI indicated osteoporosis 2025 prevalence of 9.3% with a 69% increased risk of osteoporosis compared to women with usual age menopause (aOR 1.69; 95% Cl 1.07 to 2.66) (Shea et al., 2021). An osteoporosis prevalence of 2026 2027 approximately 17% associated with non-iatrogenic POI was observed in a Brazilian (n=72; excluding 2028 those with primary amenorrhoea)(Benetti-Pinto et al., 2015a) and a European cohort (n=195) (Vogt et 2029 al., 2022). The reported prevalence of low bone mass varied from 13% (Samad et al., 2022) to 85% in an 2030 Indian cohort (n=20) with 75% having vitamin D deficiency (Dutta et al., 2016). A higher prevalence of 2031 low bone mass was observed in women with non-iatrogenic POI compared with controls including

⁹ Low bone mass is defined as Z score <-2 unless otherwise indicated.

 $^{^{10}}$ Osteoporosis is defined as T score <-2.5 unless otherwise indicated.



lumbar spine (35.7% versus 11.4%; P<0.01), hip (20% versus 4.3%; P=0.01) and forearm (15.2% versus
0%; P < 0.01)(Dhakate *et al.*, 2023). The prevalence of self-reported osteoporosis was 26.4% in a cohort
of 87 women with Fragile X premutation POI (Allen *et al.*, 2020).

2035 A Danish national registry study (n=1156 women with TS and 115577 age matched controls) reported 2036 a seven-fold increased risk of osteoporosis after TS diagnosis compared to controls (incidence rate ratio 2037 6.6; 95% CI 4.4 to 9.9)(Viuff et al., 2020). A study of 150 women with TS (mean age 31 years) reported 2038 the prevalence of DXA defined osteoporosis as 12% and 52% had osteopenia (Freriks et al., 2011). A 2039 study of 26 women with TS treated with hormone therapy (HT) (mean age 23.5 years) reported 2040 osteoporosis in 10.4% (Faienza et al., 2015). Low lumbar spine bone mass was observed in 26% of TS 2041 participants in an Australian cohort (n=58, mean age 28.5 years) (Nguyen et al., 2018). In contrast, 89.5% 2042 of 19 Turkish adolescents with POI (predominately due to TS, mean age 14.2 years) had low bone mass 2043 (Özbek et al., 2016).

2044 The prevalence of osteoporosis in iatrogenic POI was 12.2% in a cross-sectional European study, lower 2045 than the prevalence in non-iatrogenic POI (p=0.034)(Vogt et al., 2022). The prevalence of osteoporosis 2046 was 18% in a study of 27 women with POI following bone marrow transplantation, mean age 31 years, of whom only one was taking estrogen replacement (Castaneda et al., 1997). A systematic review 2047 reported an osteoporosis prevalence of 9-13% in premenopausal women (although not confined to 2048 women under age 40 years) undergoing risk reducing BO (Gaba and Manchanda, 2020). Bilateral 2049 2050 oophorectomy and chemotherapy for gynaecological cancer has also been associated with a higher 2051 prevalence of low BMD in comparison to oophorectomy for benign indications (39% versus 15%; 2052 p=0.009) (Stavraka et al., 2013).

2053 Fracture

2054 There are substantial data linking low BMD to fracture risk in postmenopausal women (Eastell et al., 2055 2016) but there is limited data specifically assessing fracture in women with POI and findings are mixed. A 2019 systematic review assessing fracture risk and menopausal age reported no significant difference 2056 2057 in fracture risk or hip fracture incidence between women with POI compared with menopausal women 2058 over 45 or 50 years of age on the basis of two studies (Anagnostis et al., 2019). However, early 2059 menopause was associated with an increased fracture risk (OR 1.36; 95% CI 1.11 to 1.66; p<0.002) (14 studies included) and this finding persisted when only fragility fractures were included (OR 1.48, 95% CI 2060 2061 1.11 to 1.97; p=0.007) (Anagnostis et al., 2019). Consistent with this, a study of 985 Serbian women, median age 64 years, reported increased risk of hip fracture calculated by FRAX scores (OR 1.6; 95% CI 2062 2063 1.14 to 2.34) in women with early menopause (defined as \leq 45 years) compared to women with 2064 menopause occurring after age 45 years (Minaković et al., 2023). A recent Indian cohort study of 70 2065 women with non-iatrogenic POI observed a higher prevalence of vertebral fractures (15.7% versus 4.3%; 2066 P=0.045) compared to 70 controls (Dhakate et al., 2023).

2067 Women with TS have an increased risk of fracture (reported risk ratios ranging from 1.35 to 3.2) (Gravholt 2068 and Backeljauw, 2017, Viuff et al., 2020). Fracture risk is further increased in women aged >45 years, co-2069 existing hearing impairment, balance problems and low BMI, but reduced in those with spontaneous menstruation (Gravholt and Backeljauw, 2017, Wasserman et al., 2018, Cardona Attard et al., 2019). A 2070 2071 cross-sectional UK study assessing 267 women with TS and 67 karyotypically normal POI reported that 2072 women with TS had a higher prevalence of major osteoporotic fractures compared to those with normal 2073 karyotype POI (52.7% versus 30.2%; p=0.012) although the overall fracture prevalence was similar (30.7% 2074 versus 32.8%)(Cardona Attard et al., 2019). Overall self-reported fracture prevalence was similar in a USA 2075 study of 711 TS women compared to 231 controls (41.8% versus 29.4%; p>0.05); however, in those aged 2076 25 years or older, fracture prevalence was higher in TS women (57.7% versus 46.4%; p=0.03) (Wasserman



et al., 2018). Fracture prevalence was also higher in TS women aged 25 years or older who discontinued
HT compared to those who continue HT (67.4% versus 47.7%; p=0.003)(Wasserman *et al.*, 2018).

2079 Risk factors for reduced BMD and fracture.

2080 Identified risk factors for low BMD and osteoporosis in women with POI include: primary amenorrhoea, 2081 longer duration of amenorrhoea/ menopause, age <20 years at onset of irregular menses, >1 year delay 2082 in diagnosis, African or Asian ethnicity, low serum vitamin D concentrations, low dietary calcium intake, 2083 smoking, non-adherence or shorter duration of estrogen replacement, lower BMI and lack of exercise 2084 (Bachelot et al., 2009, Popat et al., 2009, Bakhsh et al., 2015, Nakamura et al., 2015, Nguyen et al., 2017, 2085 Wasserman et al., 2018, Cameron-Pimblett et al., 2019, Cardona Attard et al., 2019, Samad et al., 2020, 2086 Beitl et al., 2021, Costa et al., 2023, Dhakate et al., 2023, Minaković et al., 2023). Abnormal autoimmune 2087 screening was associated with a lower T score (p=0.01) in a study of idiopathic POI (n=76) (Beitl et al., 2088 2021) (see Figure 11).

2089 Other Bone assessment modalities

DXA derived BMD only provides a measure of 60-80% of bone strength. Other imaging techniques such as trabecular bone score, quantitative ultrasound (QUS), quantitative computed tomography (QCT) provide greater insights into bone geometry and microarchitecture. However, studies in POI are few and relevance to fracture risk is yet to be established.


2094 Trabecular bone score (TBS)

- Trabecular bone score (TBS) provides a DXA-derived analysis of the lumbar spine trabecular 2095 microarchitecture, is an independent predictor of fracture risk and is now incorporated into fracture risk 2096 tools (International Society for Clinical Densitometry, 2019). However, this tool is not recommended for 2097 2098 women younger than 20 years old or those with a BMI over 37 kg/m2 (International Society for Clinical Densitometry, 2019). A higher prevalence of degraded TBS is reported in women with POI of mixed 2099 causes including non-iatrogenic POI, iatrogenic POI and TS compared with controls (Nguyen et al., 2018, 2100 Samad et al., 2022, Dhakate et al., 2023). Fracture prevalence was greater in women with degraded TBS 2101 in women with TS or non-iatrogenic POI (Nguyen et al., 2018, Dhakate et al., 2023). TBS was a superior 2102 predictor of fracture in women with TS compared to BMD (Nguyen et al., 2018). Age, duration of 2103 2104 amenorrhea, and HRT use were significant predictors of TBS in women with POI (Nguyen et al., 2018, 2105 Dhakate et al., 2023).
- 2106 Quantitative CT Although not widely available, peripheral (pQCT) and high resolution QCT (HRQCT) have advantages over DXA as they provide three-dimensional measures of volumetric BMD, bone 2107 2108 geometry and morphometry of separate bone compartments, mechanical properties, and integral bone 2109 strength without being influenced by bone size (Samad et al., 2020). Studies involving pQCT and HR 2110 QCT have shown compromised microarchitecture and lower bone strength in women with TS (Hansen 2111 et al., 2012, Gravholt and Backeljauw, 2017). This may explain the increased fracture risk that is observed in TS women with 'normal' DXA defined areal BMD (Gravholt and Backeljauw, 2017). Significant 2112 2113 decreases in volumetric cortical BMD and bone strength measures were observed at 24 months follow-2114 up in women with early menopause following risk reducing BO who did not use HRT compared to HRT 2115 users or age matched controls (Jiang et al., 2021).



FIGURE 11 MANAGEMENT ALGORITHM FOR BONE HEALTH IN WOMEN WITH POI (REPRODUCED FROM (KIRIAKOVA

ET AL., 2019), PERMISSION PENDING)



2122

2124 2125



It is suggested that HCPs inform women that POI may be associated with an increased risk of fracture later in life, although this has not been adequately demonstrated

2131

2132 Justification

- 2133 The effect of POI on bone is among the most clearly established adverse consequences of the condition.
- Women with POI have been shown to have reduced BMD, abnormal bone microarchitecture and possibly an increased risk of fracture later in life.

2136 VI.2 Bone protection and improvement

2137 PICO QUESTION: WHAT ARE THE TREATMENT OPTIONS FOR BONE PROTECTION AND 2138 IMPROVEMENT?

A systematic appraisal of guidelines regarding management of bone health in women with POI reported variable quality and evidence and recommendation gaps (Kiriakova *et al.*, 2019).

2141 Non-pharmacological approaches

- Low serum Vitamin D, physical inactivity, low calcium intake and smoking have been identified as risk factors for low BMD in women with POI. A balanced diet, adequate calcium and vitamin D intake, weightbearing exercise, maintaining a healthy body weight and cessation of smoking and moderation of alcohol intake are primary goals in reducing fracture risk in postmenopausal women (Eastell *et al.*, 2019, Camacho *et al.*, 2020, de Villiers and Goldstein, 2021). While there are few data directly relating to women with POI, it is considered that the same beneficial effects will apply.
- An observational study of 70 Indian women with idiopathic POI reported that vitamin D deficiency increased vertebral fracture risk and fracture risk decreased 9% for every 2.5nmol increase in Vitamin D levels (OR 0.910; 95% CI 0.837 to 0.988; p=0.025) (Dhakate *et al.*, 2023). Addition of eldecalcitol, a vitamin D analogue, to HRT (0.625mg dose CEE or 0.72mg transdermal estradiol patch) increased spine bone density after 12 months compared to baseline (-2.37 \pm 0.57g/cm² versus -2.62 \pm 0.55 g/cm²; P<0.05) in
- an uncontrolled study of Japanese women with TS with vitamin D deficiency (Tsuburai et al., 2018).
- 2154 Although not specific to POI, a systematic review which included five cohort studies in Asian populations
- 2155 reported that higher consumption of soy containing foods was associated with a reduced risk of fracture
- 2156 in pre-and perimenopausal women and postmenopausal women within 10 years of menopause
- 2157 (Akhavan Zanjani *et al*., 2022).
- A randomised study involving 32 BRCA positive breast cancer survivors (not taking adjuvant endocrine therapy or HRT) with early surgical menopause investigating a commercially available online lifestyle
- 2160 program, which included strength training, assessed bone health as a secondary outcome and observed
- 2161 increased cortical volumetric bone density (+0.3mg/cm³ versus -0.4 g/cm³; P=0.02), but not total body
- 2162 BMD, compared to a waitlist control group at 12 months follow-up (Sturgeon et al., 2017).
- 2163 A survey of 316 women with POI/ EM indicated that osteoporosis knowledge, beliefs and self-efficacy
- 2164 predicted calcium intake, physical activity, and osteoporosis screening behaviours (Goh *et al.*, 2019).
- 2165 These findings indicate the importance of providing information regarding bone health to women and
- 2166 the codesigned consumer website/App 'Ask Early Menopause' was developed in response to this
- 2167 (<u>www.askearly</u>menopause.org).



2168 *Hormone therapy*

An extensive evidence base and guidelines exist for the role of HRT in management of osteoporosis in postmenopausal women (Zhu *et al.*, 2016, Eastell *et al.*, 2019, de Villiers and Goldstein, 2021). In contrast, studies of the effects of HRT on BMD in women with POI are heterogenous, many with small sample sizes and methodological limitations. No RCTs have fracture as a primary outcome. Non-use, delayed initiation, interrupted and/or shorter duration of estrogen therapy is associated with reduced BMD and increased risk of fracture.

2175 A 2022 systematic review of 14 studies (6 RCT and 8 cohort studies; n=4004, median age 31 years) investigating the effect of HRT on BMD in women with POI of diverse aetiologies reported that HRT 2176 2177 increased or maintained BMD (Gonçalves et al., 2022). In five studies, HRT was superior to non-2178 treatment, placebo, calcitriol or calcium supplementation and meta-analysis (4 studies; n= 197 women) 2179 reported 3.27% (95% CI 1.89 to 4.65) increase in mean difference lumbar spine BMD per year with HRT 2180 compared to controls (Gonçalves et al., 2022). An earlier systematic review of women with diverse POI aetiologies and some differences in the included studies, reported mixed findings with significant 2181 2182 increases reported in 3/6 studies with bone outcomes and otherwise no significant effect or inconclusive 2183 findings (Burgos et al., 2017). A recent observational study of 70 Indian women with non-iatrogenic POI 2184 reported higher prevalence of low bone mass in HRT non-users compared to users (51.9% vs. 25.6%; 2185 p=0.04) (Dhakate et al., 2023). Lumbar BMD and TBS increased with duration of HRT (p<0.001). However, 2186 in the stratified analysis there was no difference in frequency of vertebral fractures and TBS between women with or without HRT (Dhakate et al., 2023). A cross-sectional UK study indicated that women 2187 with POI using HRT had higher spine BMD than non-users (-1.1 g/cm²; 95% CI -4.3 to 2.7 versus -1.4 2188 g/cm²; 95% CI – 3.4 to 2.2; p=0.031)(Cardona Attard *et al.*, 2019). Follow-up (mean 7.4 years) of a French 2189 2190 cohort (n=162) with idiopathic POI observed a significant reduction in femoral BMD in women who had ceased their HRT for more than one year compared to women who continued HRT (-57 mg/cm² per 2191 2192 year versus -13 mg/cm² per year; P = 0.009)(Bachelot et al., 2016). Similarly, interrupted HRT use was associated with declines in femoral neck BMD (-0.020g/cm² per year,95% CI -0.037, 0.0030; P=0.025) 2193 and TBS (-0.0070 per year, 95% CI -0.011, -0.0020), P=0.007) (Samad et al., 2022). A lower risk of 2194 osteoporosis was observed with current (OR 0.65 (95% CI: 0.46 to 0.91) and past (OR 0.76 (95% CI: 0.63 2195 to 0.90) HRT use in a large cohort of Canadian women (Shea et al., 2021). 2196

A 2023 systematic review examined the effect of hormone preparation on BMD in women with 2197 2198 idiopathic POI (TS excluded) included 9 studies with varying HRT regimens including use of the 2199 combined oral contraceptive (COC). The authors reported increased femoral neck and lumbar spine 2200 BMD with regimens containing 2 mg estradiol, 1.25 mg CEE, 100 µg transdermal estradiol or continuous 2201 30 µg ethinyl estradiol COC: but not with lower doses of estradiol/ CEE, tibolone or non-continuous 2202 COC use (Costa et al., 2023). These findings are consistent with a 2022 meta-analysis (28 studies, 2203 n=4004) which reported that HRT use was associated with a greater BMD effect compared to non-2204 continuous COC (mean difference 1.95% per annum; 95% CI 0.48-3.43)(Gonçalves et al., 2022).

2205 A national registry study reported that HRT treatment in TS women was associated with a significantly 2206 lower risk of hospital admissions for osteoporotic fractures (HR 0.37; 95% CI 0.14 to 0.99) compared to 2207 those not treated with HRT and was similar to general population controls (HR 1.3; 95% Cl 0.7 to 2.4) 2208 (Viuff et al., 2020). A significant increase in lumbar spine BMD was reported with estradiol (mean 2209 difference 0.09 g/cm²; 95% CI 0.04 to 0.14), but not CEE or ethinyl estradiol, in a systematic review of studies (12 RCTs and 13 observational studies) involving women with TS aged under 40 years (Cintron 2210 2211 et al., 2017). Later age at initiation of estrogen and interrupted use of HRT is associated with lower BMD 2212 and TBS (Nguyen et al., 2018, Wasserman et al., 2018, Cardona Attard et al., 2019). A UK cohort of 799 2213 TS women showed that bone density T-scores of the hip and spine were negatively correlated with age 2214 at estrogen initiation (r = 20.20 and r = 20.22 respectively; $p \le 0.001$) (Cameron-Pimblett *et al.*, 2019).



Meta-analysis of 2 studies (n=52 adolescents) concluded that transdermal estrogen was associated with a greater increase in whole body BMD z-score that oral estrogens (Zaiem *et al.*, 2017, Cameron-Pimblett *et al.*, 2019). Increased BMD over time was observed in a five- year RCT involving 20 women with TS (mean age 19 years) with no difference between those randomised to 2 or 4 mg estradiol (Cleemann *et al.*, 2017).

2220 An observational Korean study of 234 females with POI post allogeneic hematopoietic stem cell 2221 transplantation, median age 30.8 years, reported that lumbar spine BMD gains was significantly greater 2222 in the HRT group (2 mg estradiol) compared with the non-HRT group, after the first (4.16 ± 4.39% versus 2223 $+2.61 \pm 7.50\%$, P =0.033) and second year of treatment (5.42 \pm 5.86% vs 3.80 \pm 6.00%; p=0.047) (Ha et 2224 al., 2020). No significant changes were observed in hip/ femoral BMD(Ha et al., 2020). At two years 2225 follow-up, early initiation within 12 months was associated with greater spine BMD (6.31±3.89% versus 2226 3.10±4.94%; p=0.013) and total hip BMD gains (3.35±3.99% versus 1.39±3.94%; p=0.002) compared to 2227 delayed HRT initiation (Ha et al., 2020). Similar findings were reported in 38 French women with POI 2228 secondary to chemo-radiotherapy for haematological malignancies treated with HRT (9–13-year follow-2229 up) where an increase in spine BMD (+0.015g/cm² per year; 95% CI 0.002 to 0.028) but not hip BMD 2230 was observed (Naessén et al., 2014). In contrast, an earlier Italian RCT, reported no significant change in 2231 spine or femoral BMD with HRT containing 2 mg estradiol in women with POI secondary to allogenic stem cell transplantation (Tauchmanovà et al., 2006). A prospective cohort study reported that HRT use 2232 2233 attenuated BMD loss in women with early menopause secondary to risk reducing bilateral salpingo 2234 oophorectomy (BSO)(Jiang et al., 2021).

No specific evidence was found regarding optimal progestogen regimen with POI in regard to bone
 health (see XI.3. HT – treatment options).

2237 Testosterone

Following non-iatrogenic and iatrogenic POI, ovarian testosterone production is low/lost, with a 50% 2238 reduction in testosterone levels (Soman et al., 2019). A recent systematic review concluded that 2239 testosterone replacement improves sexual function in postmenopausal women; however, the effect on 2240 2241 bone is mixed which may reflect small sample sizes and differing testosterone preparations used (Islam 2242 et al., 2019a). Limited data exists regarding androgen replacement and bone health in women with POI. No significant alteration in BMD gain was found with the addition of testosterone to HRT (mean 2243 2244 difference 0.05; 95% Cl -2.45 to +2.55) as reported in a meta-analysis of two studies involving 145 2245 women with non-iatrogenic POI and the other study including 15 women with TS (Gonçalves et al., 2246 2022). No studies were identified on DHEA treatment and bone density outcomes for surgically menopausal 2247 women or those with non-iatrogenic POI (see also XI.5. Testosterone Therapy).

2248 Pharmacological approaches

2249 Bone specific therapies including bisphosphonates, selective estrogen receptor modulator raloxifene, 2250 denosumab, romosozumab, teriparatide and abaloparetide reduce fracture risk in postmenopausal 2251 women (Eastell et al., 2019, Kanis et al., 2019, Camacho et al., 2020, de Villiers and Goldstein, 2021, North 2252 American Menopause Society, 2021). Combined calcium and vitamin D supplements in a daily dose of 2253 0.5–1.0 g and 400–800 IU, respectively, are generally recommended in patients receiving bone-specific 2254 therapy, since most randomised controlled trial evidence for the efficacy of interventions is based on 2255 co-administration with calcium and vitamin D supplements (Eastell et al., 2019, Kanis et al., 2019, 2256 Camacho et al., 2020, de Villiers and Goldstein, 2021).

A RCT involving women with POI secondary to chemotherapy for stem cell transplantation reported significant lumbar spine BMD gains at 12 months with weekly oral risedronate ($5.8\pm2.1\%$; p<0.05) and intravenous (a monthly infusion for three consecutive months) zoledronate ($8.6\pm7\%$; p<0.05) compared



2260 to HRT or calcium/ vitamin D supplementation alone (Tauchmanovà et al., 2006). Femoral neck BMD 2261 also increased with zoledronate (5.4±2.2%) but not risedronate therapy. Zoledronate is effective in 2262 preventing bone loss in premenopausal women with chemotherapy induced amenorrhoea and/or 2263 adjuvant endocrine therapy for breast cancer (Shapiro et al., 2011, Wagas et al., 2021, Ebeling et al., 2264 2022). A non-randomised clinical study of 86 Japanese women, mean age 42 years, with BSO for management of benign or malignant gynaecological disease, reported higher femoral neck and spine 2265 BMD at 12-, 24- and 36-month's follow-up in patients treated with the bisphosphonate, minodronic 2266 2267 acid (1mg/day) compared to no treatment (HT users were excluded) (Okumura et al., 2022). 2268 Bisphosphonates remain incorporated in bone for a long period of time, especially zoledronate, which 2269 has led to concern over use in young women, and particularly in relation to future pregnancy. There is 2270 no direct trial evidence, but it is regarded as prudent to withdraw oral bisphosphonate therapy prior to 2271 pregnancy. However, the recommended duration cited varies from three to twelve months 2272 (Stathopoulos et al., 2011, Schreiber et al., 2023). Bisphosphonate use was higher in women with TS 2273 compared to non-iatrogenic POI (9.8% versus 2.2%; p=0.006)(Cardona Attard et al., 2019).

There are no trials of other bone specific agents in women with POI. Selective estrogen receptor 2274 2275 modulators (SERMs) have mixed functional estrogen receptor agonist or antagonist activity, depending 2276 on the target tissue, and this varies between drugs. Conjugated estrogens (0.45mg) combined with bazedoxifene improves bone density in postmenopausal women (de Villiers and Goldstein, 2021, North 2277 2278 American Menopause Society, 2021) but has not been investigated in women with POI. Tamoxifen is 2279 beneficial for bone health in postmenopausal but not premenopausal women (Ebeling et al., 2022). Other bone specific agents have been used in small studies/ case reports of younger women with 2280 secondary hypogonadism with mixed results (Ebeling et al., 2022). 2281

2282 Recommendations

The guideline group recommends that HCPs advise women with POI regarding bone health.	GPP
The guideline group recommends that osteoporosis risk factors should be identified.	GPP
The guideline group recommends that women with POI should be advised to maintain a healthy lifestyle, involving weight-bearing exercise, avoidance of smoking, and maintenance of normal body weight to optimize bone health.	GPP
Dietary supplementation of calcium and vitamin D may be required in women with inadequate vitamin D status and/or calcium intake and $\oplus \oplus \oplus \bigcirc \bigcirc$ may be of value in women with low BMD.	CONDITIONAL
Estrogen replacement is recommended to maintain bone health and prevent osteoporosis; it is plausible that it will reduce the risk of $\oplus \oplus \odot \odot$	STRONG

2287

fracture.



A daily dose of HT containing at least 2mg oral estradiol or 100 µg transdermal estradiol or equivalent is suggested to optimise bone density.	⊕000	CONDITIONAL
Delayed initiation and non-adherence of estrogen replacement should be avoided.	⊕0000	STRONG
The combined oral contraceptive pill may be appropriate for some women. A continuous or extended regimen is recommended.	⊕⊕⊖⊖	CONDITIONAL
Other pharmacological treatments, including bisphosphonates, should only be considered with advice from an osteoporosis specialist. Particular caution applies to women desiring pregnancy.	€⊕⊖⊖	STRONG
<i>Justification</i> There are a number of modifiable risk factors associated with fracture risk that are relevant to women with POI and advice regarding these modifiable risk factors are relevant to momen with POI and advice regarding these modifiable risk factors are relevant to women with POI and advice regarding these modifiable risk factors are relevant to women with POI and advice regarding these modifiable risk factors are relevant to women with POI and advice regarding these modifiable risk factors are relevant to women with POI and advice regarding these modifiable risk factors are relevant to women with POI and advice regarding these modifiable risk factors are relevant to women with POI and advice regarding these modifiable risk factors are relevant to women with POI and advice regarding these modifiable risk factors are relevant to women with POI and advice regarding these modifiable risk factors are relevant to women with POI and advice regarding these modifiable risk factors are relevant to women with POI and advice regarding these modifiable risk factors are relevant to women with POI and advice regarding these modifiable risk factors are relevant to women with POI and advice regarding these modifiable risk factors are relevant to women with POI and advice regarding these modifiable risk factors are relevant to women with POI and advice regarding these modifiable risk factors are relevant to women with POI and advice regarding these modifiable risk factors are relevant to women with POI and advice regarding these modifiable risk factors are relevant to women with POI and advice regarding these modifiable risk factors are relevant to women with POI and advice regarding these modifiable risk factors are relevant to women with POI and advice regarding these modifiable risk factors are relevant to women with POI and advice regarding these modifiable risk factors are relevant to women with POI and advice regarding these modifiable risk factors are relevant to women with POI and advice regarding these women	tors should	be provided.
HRT in postmenopausal women increases BMD and reduces fracture risk. Estroy to have similar beneficial effects on BMD in POI of all causes although fracture of at least 2 mg estradiol or 100 µg transdermal patch is associated with suggests that sequential COC use is inferior to HRT with continuous estrogen a is the preferred option if the COC is used. Non-adherence to HRT is associated density and increased risk of osteoporosis. Current data suggests no benefit addition of testosterone therapy to HRT.	e data is lac gains in BM and that con I with reduct	king. A dose 1D. Evidence tinuous COC tions in bone
There is little data regarding the use of bone-specific therapies for osteoporos	sis in POI.	
VI.3. Monitoring of skeletal health		

2308 **PICO QUESTION: How should skeletal health be monitored in women with POI?**

Initial and ongoing assessment of bone health should identify and address modifiable risk factors(Kiriakova *et al.*, 2019).

Dual-Energy X-ray Absorptiometry (DXA) is the key investigation in the diagnosis and management of women with suspected osteoporosis (Eastell *et al.*, 2019, International Society for Clinical Densitometry,

- 2313 2019, Kanis et al., 2019, Camacho et al., 2020, de Villiers and Goldstein, 2021). While DXA is considered
- the 'gold standard' method of BMD measurement, it has limitations including (very low) use of ionizing



radiation, large size of the equipment, high cost, and limited availability in some regions. However, thereis a paucity of evidence regarding the use of other imaging techniques in POI.

2317 DXA scan is suggested by most guidelines to provide a baseline measurement at POI diagnosis 2318 (Kiriakova et al., 2019) especially in the setting of long duration of estrogen deficiency or other risk 2319 factors (e.g. history of low impact fractures). If a baseline DXA is performed, BMD is within the normal 2320 range and women are receiving adequate estrogen replacement, it is unclear when BMD measurement 2321 should be rechecked. DXA involves X-rays, which should be avoided unless there is a specific indication, 2322 although radiation exposure from DXA is very low. Postmenopausal osteoporosis guidelines vary 2323 regarding the interval at which repeat DXA measurement should be performed; ranging from every 1-2324 2 years (Camacho et al., 2020), 3 years (Eastell et al., 2019, North American Menopause Society, 2021) 2325 or 5 years (Kanis et al., 2019). Non-adherence or suspicion of continuing bone loss due to secondary 2326 factors e.g., antihormonal therapy in breast cancer patients or in the initial phase of treatment of women 2327 with moderate to severe osteoporosis, this time interval should be shortened.

FRAX® is a computer-based algorithm (http://www.shef.ac.uk/FRAX) that calculates the 10-year probability of a major fracture (hip, lumbar spine, humerus, or wrist fracture) and the 10-year probability of hip fracture from age, body mass index and dichotomized risk factors. BMD data can also be added to improve predictive accuracy. Because fracture probability differs markedly by geography, FRAX is calibrated to those countries where the epidemiology of fracture and death is known. An important consideration in POI is the lower age for which this tool is applicable is currently 40 years.

Biochemical markers of bone resorption (C-telopeptide (CTX) and urinary N-telopeptide (NTX)) and 2334 bone formation (procollagen type 1 N propeptide (PINP) and bone specific alkaline phosphatase (BSAP)) 2335 2336 are useful for the prediction of fractures and rapid bone loss and are recommended for monitoring the 2337 treatment of osteoporosis (adherence and response) (Eastell et al., 2019, Kanis et al., 2019, Camacho et 2338 al., 2020). The use of bone turnover markers to aid assessment of response to treatment is based on their more rapid response (typically within 3 months) than changes in BMD. However, assay variability 2339 2340 and poor standardization have limited the use of bone turnover markers in clinical practice. There is 2341 limited data regarding POI and bone turnover markers. In the RCT conducted by Cartwright et al., both P1NP and CTX declined after the administration of COC and HRT (2mg estradiol) for 6, 12, and 24 2342 2343 months when compared to the baseline levels in women with non-iatrogenic POI, with no significant 2344 difference between hormone therapies during follow-up (Cartwright et al., 2016). Three months after commencing HRT containing 100 µg estradiol patch, there was no difference in bone resorption marker 2345 2346 levels (CTX) between women with idiopathic POI and controls (Popat et al., 2014) however, the bone 2347 formation marker (BSAP) was significantly higher in women with idiopathic POI (12.6 versus 11.4 ng/ml; 2348 p=0.04)(Popat et al., 2014). Similar findings were observed in a randomised crossover study involving 2349 34 women with diverse causes of POI where a reduction in bone resorption markers was observed with 2350 12 months treatment with both the cyclic COC and HRT (100 µg estradiol patch) compared to baseline (Crofton et al., 2010). However, the pattern of bone formation marker response (P1NP and BSAP) varied 2351 2352 with significant increases observed with transdermal estradiol but decreases with COC use. These 2353 findings may help to explain the differences in BMD results observed between cyclic COC and HRT 2354 regimens (Costa et al., 2023).

2355 *Recommendations*

It is important to consider bone health at diagnosis of POI, and during ongoing care. Osteoporosis risk factors should be identified and addressed.

⊕OOO STRONG



	Where available, measurement of BMD at initial diagnosis of POI is recommended for all women.	$\oplus \oplus \bigcirc \bigcirc$	STRONG
357			
	In case of a diagnosis of osteoporosis or low bone mass in women with POI, BMD measurement should be repeated within 5 years. A decrease in BMD should prompt review of estrogen replacement therapy and of other potential factors. Review by a specialist in osteoporosis may be appropriate.	€000	STRONG
858			
	If BMD is normal and adequate systemic estrogen replacement is commenced, the value of repeated DXA scan within 5 years is low.	0000	STRONG
9			
	Assessment of bone turnover markers can be considered as it may be useful in monitoring response and adherence to therapy.	0000	CONDITIONAL
	<i>Justification</i> Based on the evidence that women with POI have reduced BMD (see section V BMD measurement should be considered at POI diagnosis. Dual-Energy X-ray		•
3 1	the most reliable assessment for BMD and the amount of ionising radiation us optimal interval at which DXA should be repeated is unclear and intervals of s	-	

required based on the limitations of DXA for measuring small changes in BMD. However, repeat BMD

testing should be considered if the results will influence a management decision, i.e. change in

treatment. As in older postmenopausal women, bone turnover markers may be useful to assess

response or adherence to treatment, but evidence is limited in POI.

RAY



2369 VI.4. Muscle health


2370

2371

PICO QUESTION: WHAT ARE THE CONSEQUENCES OF POI FOR MUSCLE HEALTH?

2372 POI is likely to adversely affect muscle mass and function although this remains under-researched and 2373 poorly understood. Multiple factors have been identified as contributors to sarcopenia in older populations including genetic, nutritional, behavioural, co-morbidities, neurocognitive function, 2374 2375 microbiome, hormonal and aging (Figure 11). Sarcopenia is associated with increased morbidity and mortality in older populations (de Villiers and Goldstein, 2021). However, there is a lack of consensus 2376 2377 regarding sarcopenia definitions, diagnostic criteria, and treatment guidelines (Cruz-Jentoft and Sayer, 2378 2019, Chen et al., 2020, de Villiers and Goldstein, 2021). The prevalence and impact of sarcopenia in women with POI is unclear. 2379

FIGURE 12 FACTORS ASSOCIATED WITH DEVELOPMENT OF ADVERSE MUSCULOSKELETAL HEALTH OUTCOMES. ADAPTED FROM (KIRK *ET AL.*, 2020) AND USED WITH PERMISSION (OPEN ACCESS CREATIVE COMMONS CC BY LICENCE).



2383

2384 A 2023 systematic review of 6 observational studies (n=18291) reported lower muscle mass (DXA 2385 derived appendicular skeletal muscle mass (ASM)/BMI) in women with early menopause in two studies 2386 of Asian women compared with age of menopause >45 years (standardized mean difference (SMD) -2387 0.14 ± 0.03; 95% CI -0.20 to -0.07; p=0.001) (Divaris et al., 2023). There was insufficient data regarding muscle mass and POI. POI was associated with lower muscle strength as assessed by hand grip strength 2388 2389 (SMD -0.3; 95% CI -0.58, -0.01; p=0.04) and lower muscle performance as assessed by gait speed (SMD 2390 -0.13; 95% CI -0.23 to -0.04; p=0.004) compared with age of menopause >45 years (Divaris et al., 2023); 2391 however, only the difference in gait speed persisted after adjusting for age. Subgroup analysis indicated 2392 that women with non-iatrogenic POI, but not surgical POI (one study), had lower gait speed compared 2393 with menopause at usual age. In contrast, a study of USA women reported that bilateral oophorectomy 2394 before age 45 years (n=1365) was associated with a mean 2.86% reduction in DXA derived total lean 2395 mass compared to women without surgery (adjusted for age, race, BMI, parity, lifestyle factors, and 2396 post-surgery HRT use) (Karia et al., 2021).



2397 A case-control study of 240 Chinese women with idiopathic POI (mean age 31.6 years) compared to 240 2398 age matched controls and 520 peri/postmenopausal controls (mean age 45.5 and 50.1 years 2399 respectively) observed significantly decreased lower limb muscle strength in women with POI compared 2400 with controls but lower limb muscle strength was similar to perimenopausal women and increased 2401 compared with the postmenopausal group (Luo et al., 2018). Lower limb muscle mass (muscle 2402 distributing coefficient) was significantly lower in women with POI compared to all groups. Lower limb 2403 muscle strength was a significant predictor of femoral BMD in multivariate analysis adjusted for age and 2404 BMI (Luo et al., 2018). No difference in DXA derived lean mass indices was observed in a study of 70 2405 Brazilian women with normal karyotype POI (mean age 36.3 years), all using HRT for the past year, 2406 compared with age matched controls (Freitas et al., 2021). A recent cross-sectional study of 59 Chinese 2407 women with idiopathic POI (mean age 37 years; 75% using HRT) reported lower DXA derived 2408 appendicular skeletal muscle mass compared with 57 age matched controls (ASM/height² 5.71 \pm 0.64 2409 versus 6.15 \pm 0.62; BMI p < 0.001) (Li *et al.*, 2023b). This relationship persisted after adjusting for age, 2410 BMI, and lifestyle factors. The prevalence of low muscle mass (defined as ASM/height²<5.4 was greater 2411 in Chinese women with idiopathic POI compared with premenopausal controls (32.2% versus 8.77% 2412 kg/m²; p=0.002) (Li et al., 2023b). The Asian Working Group for Sarcopenia definition includes low muscle mass ASM/height² < 5.4 kg/m² (DXA-derived ASM) and reduced grip strength (< 18kg) (Chen et 2413 2414 al., 2020). Muscle strength/function was not assessed; however, based on the reported prevalence of 2415 low muscle mass, one-third of POI participants in this study could be considered "pre-sarcopenic" or "sarcopenic" depending on normal or reduced muscle strength respectively. Lower muscle mass was 2416 2417 observed in 60 women with spontaneous or iatrogenic POI versus 60 age matched controls (6.17 versus 6.15 versus 7.08 kg/m2 respectively; p<0.001) (Samad et al., 2022). In contrast, a prospective study 2418 showed no significant change in DXA derived lean body mass at two years follow-up in 54 women 2419 2420 following risk reducing BSO, at mean age 42 years, compared to 81 premenopausal controls, mean age 2421 40 years (Price et al., 2023).

Women with TS have lower lean body mass compared with age and BMI matched controls (Gravholt 2422 2423 and Backeljauw, 2017, Samad et al., 2020). A cross-sectional study of 54 Danish women with TS, mean 2424 age 42.5 years, reported reduced muscle mass, oxygen uptake, and physical activity versus 55 2425 premenopausal controls (Gravholt et al., 2006). Normal muscle force (Fmax) but reduced power (Pmax) 2426 was observed in a cross-sectional study of 60 adolescent TS girls compared with healthy controls 2427 (Soucek et al., 2015). There was no association with menarcheal stage, karyotype, or HRT duration 2428 (Soucek et al., 2015). Consistent with this, a study of 15 TS women (mean age 13.9 years) demonstrated 2429 greater anaerobic stress during exercise contributing to increased muscle fatigue compared with 16 2430 age, activity and BMI matched healthy controls (Wells et al., 2013).

2431 **Recommendations**

> Women with POI and HCPs should be aware that POI is associated with $\oplus \oplus \bigcirc \bigcirc$ lower muscle mass, strength, and performance.

STRONG

2432

The guideline group recommends that HCPs be aware that POI may be associated with an increased risk of sarcopenia.

GPP

2433

2434 **Justification**

2435 Limited evidence suggests that POI is associated with reduced muscle mass, strength and performance 2436 which may vary according to cause of POI and ethnicity. Women with POI may be at increased risk of



- sarcopenia. This has implications for morbidity, including bone and cardiometabolic health, andmortality. There is an urgent need for more research.
- 2439

2440 VI.5.Muscle protection and improvement

2441 **PICO QUESTION: WHAT ARE THE TREATMENT OPTIONS FOR MUSCLE PROTECTION AND** 2442 **IMPROVEMENT?**

Proposed lifestyle interventions for management of sarcopenia/osteosarcopenia incorporate adequate nutrition (including protein intake \geq 1.2g/kg/day), creatine supplementation 3-5g/day, and calcium and vitamin D supplementation if deficient (Kirk *et al.*, 2020, de Villiers and Goldstein, 2021). Increased lean body mass, muscle strength and performance with resistance exercise have been demonstrated in metaanalyses, although study quality varied (Thomas *et al.*, 2021, Sá *et al.*, 2023). Whole body vibration has shown benefits in regard to muscle strength in separate meta-analyses of postmenopausal and younger population (Samad *et al.*, 2020). There are no specific studies in women with POI.

Meta-analyses indicate a positive effect in postmenopausal women of HRT on muscle strength but not 2450 lean body mass (potentially reflecting variable study methodology, HRT regimens, time since 2451 menopause or prior HRT) (Greising et al., 2009, Javed et al., 2019). Although estrogen therapy is 2452 2453 important in bone health in women with POI (see VI.1. Skeletal health), data is lacking regarding muscle parameters and HRT exposure. A longitudinal analysis indicated that continued HRT use was associated 2454 with an increase in muscle mass (ALM/ height²+47.3 g/m²per year; 95% CI 25,4,69.23); whereas no 2455 change was seen in those with interrupted HRT (Samad et al., 2022). In contrast, no difference was 2456 2457 observed between HRT users and non-users in women with non-iatrogenic POI (Li et al., 2023b) or following RR BSO (Price et al.) which may reflect small sample sizes. A five-year RCT reported increased 2458 2459 lean mass in TS women taking high dose 4mg estradiol but not 2mg estradiol per day (Cleemann et al., 2460 2017).

A systematic review found no benefit in regard to lean body mass with testosterone therapy in postmenopausal women (Islam *et al.*, 2019a). A positive effect of testosterone therapy on lean body mass was observed in a pilot study of 14 women with TS (Zuckerman-Levin *et al.*, 2009).

There are no pharmacologic interventions approved by government regulatory agencies (e.g. FDA) for prevention/ treatment of sarcopenia. A small study in postmenopausal women, mean age 65 years, reported increased muscle strength and lean mass with denosumab but not with bisphosphonate or placebo therapy (Bonnet *et al.*, 2019).

The guideline group recommends that HCPs consider informing women with POI	
about muscle health.	

GPP

2469

2468

Recommendations

HCPs should identify modifiable risk factors for muscle health in women with POI. Maintaining a healthy lifestyle, involving adequate nutrition, regular exercise, avoidance of smoking, and maintenance of normal body weight is likely to benefit muscle health



women wi	pplementation of calcium and vitamin D may be required in th inadequate vitamin D status and/or calcium intake and it muscle health.	⊕⊕⊖⊖	CONDITIONAL
	training can be considered as it increases muscle mass, nd performance in other populations and is likely to be of POI	⊕000	CONDITIONAL
	of HT on muscle parameters in women with POI is uncertain lent may be of benefit and can be offered.	€000	CONDITIONAL
	of other therapies, including testosterone, on muscle health with POI is uncertain and they should not be offered.	⊕0000	STRONG
suggests tha and perform	nterventions for muscle health in women with POI are limited at t lifestyle interventions and HRT in non-POI populations may bene ance. There is an urgent need for more research. nitoring of muscle health		
suggests tha and perform VI.6. Mo	nterventions for muscle health in women with POI are limited and t lifestyle interventions and HRT in non-POI populations may bene ance. There is an urgent need for more research. nitoring of muscle health	efit muscle ma	ass, strength
suggests tha and perform VI.6. Mo PICO QUES The 2019 Eu	t lifestyle interventions and HRT in non-POI populations may bene ance. There is an urgent need for more research. nitoring of muscle health STION: HOW SHOULD MUSCLE HEALTH BE MONITORED IN WOI ropean Working Group on Sarcopenia in Older People (EWGSOP2 ed recommendations on definition and diagnosis of sarcopeni	efit muscle ma MEN WITH P 2) (Cruz-Jento	ol?
suggests tha and perform VI.6. Mo PICO QUES The 2019 Eur 2019) updat	Atterventions for muscle health in women with POL are limited at the tifestyle interventions and HRT in non-POI populations may bener ance. There is an urgent need for more research. Initoring of muscle health STION: HOW SHOULD MUSCLE HEALTH BE MONITORED IN WOI ropean Working Group on Sarcopenia in Older People (EWGSOP2 ed recommendations on definition and diagnosis of sarcopenia sarcopenia: Probable sarcopenia is identified by Criterion 1. Diagnosis is confirmed by additional documentation of Criterion 1.	efit muscle ma MEN WITH P 2) (Cruz-Jento a provide an terion 2.	ol?
suggests tha and perform VI.6. Mo PICO QUES The 2019 Eur 2019) updat	Anterventions for muscle health in women with POI are limited and t lifestyle interventions and HRT in non-POI populations may bene ance. There is an urgent need for more research. Initoring of muscle health STION: HOW SHOULD MUSCLE HEALTH BE MONITORED IN WOI ropean Working Group on Sarcopenia in Older People (EWGSOP2 ed recommendations on definition and diagnosis of sarcopeni sarcopenia. Probable sarcopenia is identified by Criterion 1. Diagnosis is confirmed by additional documentation of Cri If Criteria 1, 2 and 3 are all met, sarcopenia is considered so	efit muscle ma MEN WITH P 2) (Cruz-Jento a provide an terion 2.	ol?
Suggests tha and perform VI.6. Mo PICO QUES The 2019 Eur 2019) updat	Anterventions for muscle health in women with POI are limited at the tifestyle interventions and HRT in non-POI populations may bener ance. There is an urgent need for more research. Initoring of muscle health STION: HOW SHOULD MUSCLE HEALTH BE MONITORED IN WOI ropean Working Group on Sarcopenia in Older People (EWGSOP2 ed recommendations on definition and diagnosis of sarcopenia sarcopenia: Probable sarcopenia is identified by Criterion 1. Diagnosis is confirmed by additional documentation of Criteria 1, 2 and 3 are all met, sarcopenia is considered set	efit muscle ma MEN WITH P 2) (Cruz-Jento a provide an terion 2.	ol?
Suggests tha and perform VI.6. Mo PICO QUES The 2019 Eur 2019) updat	A tireventions for muscle health in women with POI are limited at tifestyle interventions and HRT in non-POI populations may bener ance. There is an urgent need for more research. Initoring of muscle health STION: HOW SHOULD MUSCLE HEALTH BE MONITORED IN WOIl ropean Working Group on Sarcopenia in Older People (EWGSOP2 ed recommendations on definition and diagnosis of sarcopenia sarcopenia: Probable sarcopenia is identified by Criterion 1. Diagnosis is confirmed by additional documentation of Cri If Criteria 1, 2 and 3 are all met, sarcopenia is considered sarcopenia considered sarcop	efit muscle ma MEN WITH P 2) (Cruz-Jento a provide an terion 2.	ol?

A variety of tools have been proposed to assess sarcopenia (Cruz-Jentoft and Sayer, 2019, Samad et al., 2487 2020). The EWGSOP2 recommended pathway for diagnosis of sarcopenia in clinical practice includes: (i) 2488 initial assessment of muscle strength via grip strength and/or chair stand test (ii) confirmation of low 2489 muscle mass via DXA derived total body or ASM, adjusted for BMI or height; and (iii) determine severity 2490 2491 via measurement of physical performance assessed via either gait speed, Timed Up and Go test or Short 2492 Physical Performance Battery. However, cut off points depend on the measurement technique and



population studied and there are no cut-off values for women aged <45 years (Samad *et al.*, 2020). In the absence of validated POI specific thresholds, current sarcopenia cut-off values (as used in publications referred to in VI.5.Muscle protection and improvement) (Cruz-Jentoft and Sayer, 2019, Chen *et al.*, 2020) could be used.

DXA is recommended for women with POI at diagnosis to assess bone health and this provides an opportunity to also assess muscle mass. Despite limitations (Cruz-Jentoft and Sayer, 2019, Samad *et al.*, 2020), DXA-derived total or ASM (adjusted for BMI or height) combined with grip strength and gait speed could potentially provide useful information regarding the presence of sarcopenia in women with POI. There are no data regarding whether or when these tests should be repeated.

2502 Recommendation

The guideline group recommends that HCPs consider assessment for sarcopenia at POI diagnosis.

GPP

2503 Justification

- Recommendations for screening, diagnosis and monitoring of sarcopenia exist for older populations; however, the best tools and relevant cut-off values for women with POI are lacking. Further research
- 2506 regarding muscle health and POI is need.
- 2507

2508 Conclusion

- 2509 Adverse effects of POI on BMD are well recognised although the impact on fracture requires further 2510 clarification. Risk factors for bone loss in women with POI have been identified and support the key 2511 role of HT in maintaining bone mass. Newer evidence has provided guidance regarding the estrogen doses/ regimens needed to prevent bone loss. The evidence regarding therapeutic options where HT is 2512 contraindicated is limited and referral to a bone specialist should be considered. DXA assessment of 2513 bone density provides osteoporosis risk stratification and information regarding muscle mass. Emerging 2514 2515 evidence indicates that POI may have an adverse effect on muscle health which has implications for 2516 cardiometabolic and bone health. Optimal strategies for assessing, monitoring, and managing muscle 2517 health in women with POI are unknown.
- 2518

2519 Research recommendation.

- Further research is required to (i) clarify fracture risk associated with POI and the effect of HT on this outcome; (ii) determine the best strategies for monitoring of bone health including screening interval, role of bone turnover markers and newer imaging modalities; (iii) investigate the effect of exercise on muscle parameters and bone density in women with POI; (iv) clarify the role bone specific agents in managing POI associated osteoporosis; (v) clarify the changes in muscle mass and function associated with POI; (vi) identify strategies for assessment and monitoring of muscle health in this population including defining
- 2526 sarcopenia; and (vii) examine the role of HT and other strategies to maintain muscle health.
- 2527



2528 VII. POI and cardiometabolic health

Early loss of ovarian function (i.e., POI, early menopause before the age of 45 years and surgical menopause) has emerged as a female-specific risk factor for cardiovascular disease (CVD). Since the end of the 1950's, it has been recognised that women undergoing premenopausal oophorectomy show increased cardiovascular morbidity (Robinson *et al.*, 1959, Parrish *et al.*, 1967). Indeed, all meta-analyses show that women with POI, surgical menopause and early menopause are at higher risk for CVD and death, probably due to the shorter exposure to cardioprotective endogenous estrogen.

Studies evaluating cardiovascular problems in women with POI or Turner Syndrome are summarised in the first part of this chapter. Whether cardiovascular disease and mortality may be prevented by estrogen replacement therapy or screening and monitoring of risk factors is explored in the second part of the chapter.

2539 VII.1. Impact of POI on cardiometabolic health

2540 PICO QUESTION: WHAT ARE THE CONSEQUENCES OF POI FOR THE CARDIOVASCULAR SYSTEM?

All published studies, consistently, have shown that women with POI have increased risk for earlier onset 2541 2542 of coronary artery disease (CAD) (Atsma et al., 2006) and increased cardiovascular disease (CVD) mortality (Zhu et al., 2019, Okoth et al., 2020). This increased risk is evident in women with POI, early 2543 menopause (at age 40-45 years) and surgical menopause. A meta-analysis with pooled data from 2544 2545 310329 women (derived from 32 observational studies), showed that women with early menopause had 2546 an increased risk for CAD, CVD mortality and CAD mortality compared to women who had menopause 2547 after the age of 45 years (RR 1.50; 95% CI 1.28 to 1.76, RR 1.19; 95% CI 1.08 to 1.31, and RR 1.11; 95% CI 1.03 to 1.20, respectively) (Muka et al., 2016). Interestingly, pooled individual-level data from 15 2548 2549 observational studies suggested that women with POI and early menopause had a substantially 2550 increased risk of a non-fatal cardiovascular disease event before the age of 60 years, but not after age 70 years, as compared with women who had menopause at the usual age of 50-51 years (Zhu et al., 2551 2552 2019). Lower premenopausal AMH levels and/or greater declines in AMH over the menopausal 2553 transition were found to be associated with greater atherosclerotic risk (El Khoudary et al., 2023).

The risk of stroke is also increased in women with early loss of ovarian function. A recent study involving 1.159,405 Korean postmenopausal women showed that women with POI have increased risk of myocardial infarction (HR 1.40; 95% CI 1.31 to 1.50), ischemic stroke (HR 1.24; 95% CI 1,17 to 1,31), and all-cause mortality (HR 1.19; 95% CI 1.14 to 1.24), compared with women with menopause in the normal age range (Lee *et al.*, 2023a).

2559 Initially, a systematic review of cohort studies published in English between 2006 and 2010 examined 2560 the risk of early lack of endogenous estrogen, through either surgical menopause or spontaneous 2561 ovarian cessation before the age of 50 years, on stroke and found that estrogen is protective for stroke in women younger than 50 years (Rocca et al., 2012a). Age at ovarian failure was more important than 2562 2563 type of estrogen loss, i.e., either natural or induced ovarian failure (Rocca et al., 2012a). A Korean 2564 population-based cohort study of 135575 women aged 40-49 years (median follow-up 7.9 years) 2565 showed that the risk of stroke was significantly higher in women with early hysterectomy before 45 2566 years of age (HR 1.31; 95% CI 1.12 to 1.53) (Yuk et al., 2023). Finally, a systematic review showed that 2567 hysterectomy with bilateral oophorectomy before the age of 45 years is associated with an increased risk of stroke (HR 1.20; 95% CI 1.10 to 1.31) and CVD (HR 1.18; 95% CI 1.11 to 1.25) (Hassan et al., 2024). 2568



These findings were confirmed by a recent meta-analysis of 20 cohort studies, which showed that women with POI or early menopause (at age 40-45 years) have a higher risk for CHD, ischemic and haemorrhagic stroke and total cardiovascular event compared to women with menopause at age > 45 years (Liu *et al.*, 2023b).

2573 In a cohort study (UK biobank) of 144260 postmenopausal women, POI was associated with increased 2574 risk for a composite cardiovascular outcome, that included CAD, heart failure, aortic stenosis, mitral 2575 regurgitation, atrial fibrillation, ischemic stroke, peripheral artery disease, and venous thromboembolism 2576 (Honigberg et al., 2019). The hazard ratio was 1.36 for non-iatrogenic POI and 1.87 for surgical premature menopause (Honigberg et al., 2019). The finding of increased risk of heart failure and atrial 2577 2578 fibrillation in women with POI was further confirmed in a cohort study of 1401175 Korean women (Shin 2579 et al., 2022). A recent meta-analysis of 9 cohort studies also found that women with POI or early 2580 menopause (before the age of 45 years) have a higher risk of heart failure and atrial fibrillation compared 2581 with women with menopause in the normal age range (Liu et al., 2023a).

- Women undergoing risk reducing bilateral oophorectomy before the age of 40 consistently showed an increased risk for cardiovascular disease (Lokkegaard *et al.*, 2006, Rocca *et al.*, 2006, Parker *et al.*, 2009b, Barrett-Connor, 2013, Honigberg *et al.*, 2019, Hassan *et al.*, 2024). Bilateral oophorectomy before the age of 45 is associated with a 2-fold increase in cardiovascular risk (Atsma *et al.*, 2006, Parker *et al.*, 2009b, Rivera *et al.*, 2009a, Ingelsson *et al.*, 2011). It should be pointed out that hysterectomy along with
- any oophorectomy (unilateral or bilateral) has also been associated with an increased risk of CVD (Farland *et al.*, 2023).
- 2589 Interestingly, a study of 130254 postmenopausal women showed that women with POI have a shorter
- leukocyte telomere length, a marker of cellular aging (Schuermans *et al.*, 2023). In that study, leukocyte
- telomere length and age of menopause were independently associated with CAD (Schuermans et al.,
- 2592 2023).

2593 Cardiovascular effects of spontaneous and surgical POI

Women with POI develop earlier signs of endothelial dysfunction (Kalantaridou *et al.*, 2004) and premature atherosclerosis (Clarkson, 2007). Surgical menopause in premenopausal women (aged 46-53 years) induced an increase in total, low-density lipoprotein cholesterol (LDL-C), and lipoprotein(a) within the next 2-3 months; HDL cholesterol decreased significantly for 3 months (Bruschi *et al.*, 1996).

A meta-analysis of 20 cohort studies showed that women with POI and early menopause have a higher risk of type 2 diabetes (RR 1.32; 95% CI 1.08 to 1.62 and RR 1.17; 95% CI 10.91 to 1.36, respectively), and hyperlipidaemia (RR 1.21; 95% CI 1.05 to 1.39 and RR 1.17; 95% CI 1.02 to 1.33, respectively), both aspects of metabolic syndrome, compared with women with usual age menopause (Liu *et al.*, 2023b). The prevalence of the metabolic syndrome increases with ovarian failure and may also contribute to the acceleration of CVD thereafter.

- The adverse effects of early loss of ovarian function in metabolic parameters has also been shown in the following studies: A small cross-sectional study of 118 Chinese Women with POI and 151 age-matched controls, showed that women with POI have significantly increased triglyceride levels, fasting glucose and insulin and HOMA-IR (Jin *et al.*, 2023). A recent meta-analysis of 21 studies, also showed that women with POI had significantly higher waist circumference, total cholesterol, LDL-C, triglycerides, and fasting glucose (Cai *et al.*, 2022).
- 2610 Alteration of haemostatic factors and markers of platelet function was observed in another group of
- 2611 premenopausal women 6 weeks after surgical menopause (Lip *et al.*, 1997). A smaller study in 26 females
- with POI and 31 healthy controls suggested that QT dynamicity is impaired in patients with POI despite
- the absence of overt cardiovascular involvement (Canpolat *et al.*, 2013).



2614 Turner Syndrome

2615 Women with Turner Syndrome (TS) have a 3-fold increased mortality risk compared with the general population, mainly due to cardiovascular disease (Gravholt et al., 2023). Women with TS have a higher 2616 2617 prevalence of congenital cardiac malformations such as aortic coarctation (11%) and bicuspid aortic valve (16%), thus being at higher risk for infective endocarditis and, over time, the bicuspid aortic valve 2618 2619 may deteriorate leading to clinically significant aortic stenosis or regurgitation (Bondy, 2008). A bicuspid aortic valve is also associated with aortic wall abnormalities including ascending aortic dilatation, 2620 2621 aneurysm formation, and aortic dissection. Women with TS have an increased risk of CVD, including arrythmia, CAD, hypertension, stroke, and hyperlipidaemia (Gravholt et al., 2023). A major concern in TS 2622 2623 remains the rare but often fatal aortic dilatation, dissection, or rupture in relatively young women. The 2624 prevalence of aortic dilatation increases with age but dilatation in TS can already be present in the second decade of life (Sharma et al., 2009). Women with TS present an increased risk of hypertension, 2625 2626 diabetes mellitus, celiac disease, osteoporosis and disorders of the thyroid and the parathyroid gland 2627 (Gravholt et al., 2023). The majority of girls with TS will require pubertal induction (see XIII. Puberty 2628 Induction). Cardiovascular health is of great importance, especially in pre-pregnancy assessment (see 2629 V.3. Pregnancy.

2630 *Recommendations*

HCPs should be aware that women with POI are at increased risk of cardiovascular disease, including coronary artery disease, heart failure and stroke. ⊕⊕⊕⊕⊖ STRONG

2631

The guideline group recommends that women with POI should be advised of cardiovascular risk factors that they can modify through behavioural change (e.g. by avoidance of smoking, heart healthy diet, regular exercise, and maintenance of normal body weight).

2632

All women diagnosed with Turner Syndrome should be evaluated by a		
cardiologist with expertise in congenital heart disease, especially prior	$\oplus \oplus \bigcirc \bigcirc$	STRONG
to and during pregnancy.		

2633 Justification

Women with POI are at greater risk of hypertension, diabetes and hyperlipidaemia and endothelial dysfunction contributing to premature atherosclerosis. They further show increased cardiovascular morbidity and mortality regardless of the cause of the ovarian insufficiency.

- 2637 Morbidity and mortality are increased in patients with TS compared with the general population, 2638 predominately due to an increased risk of cardiovascular disease including congenital heart disease.
- 2639



2641 VII.2 Hormone treatment for cardiovascular health

2642

2643 **PICO QUESTION: IS ESTROGEN REPLACEMENT CARDIO-PROTECTIVE?**

2644 Spontaneous and surgical POI

2645 Oophorectomy and early menopause are associated with a markedly increased incidence of CAD in 2646 young women (Manson, 1994). Premenopausal women with premature coronary artery disease have 2647 significantly lower plasma estradiol concentrations compared with controls (Hanke *et al.*, 1997). Recent 2648 findings indicate that lower premenopausal AMH levels and/or greater declines in AMH over the 2649 menopausal transition are associated with greater atherosclerotic.

- 2650 In women with spontaneous and surgical POI, estrogen has beneficial effects on vascular endothelium and lipid parameters (Kalantaridou et al., 2004). In experimental animals, the most robust inhibition of 2651 postmenopausal atherosclerotic progression was found in animals given contraceptive steroids 2652 premenopausally and subsequently given conjugated equine estrogens postmenopausally (Clarkson, 2653 2654 1994). There are inadequate prospective data regarding hormone therapy in women with POI. Most reports suggesting an increased risk of CVD in women with POI also suggest a protective effect of 2655 2656 hormone therapy . Existing data regarding hormone therapy in women experiencing menopause at the usual age should not be extrapolated to women experiencing POI and initiating hormone therapy at 2657 that time (Rees, 2008). The risks attributable to hormone therapy used by these young women are likely 2658 smaller and the benefits potentially greater than those in older women who commence hormone 2659 therapy beyond the usual age of menopause (Utian et al., 2008). Recent studies suggest that the 2660 increased CVD morbidity and mortality observed after the menopause cannot be fully explained by 2661 2662 changes in plasma lipoproteins only and support the concept that sudden ovarian hormone deprivation has a widespread impact on the cardiovascular system with a direct harmful effect on vessel wall 2663 physiology (Mercuro et al., 2004). Similarly, Kalantaridou and colleagues reported that young women 2664 with POI (age range 23-40 years) have significant endothelial dysfunction (Kalantaridou et al., 2004). 2665 Oral estrogen/progestogen cyclic treatment for 6 months restored endothelial function in these 2666 2667 patients. However, the risks and benefits of HT in women with POI have not been studied in long-term 2668 trials (Hendrix, 2005, Kalantaridou et al., 2006b).
- In the observational Danish female nurses' study, an increased risk of ischemic heart disease was found 2669 among women having their ovaries removed before the age of 40 compared with those having their 2670 2671 ovaries removed after the age of 45, as well as among women who had spontaneous menopause before age 40 compared with those after the age of 45 (Lokkegaard et al., 2006). For the group of women 2672 2673 experiencing menopause after bilateral oophorectomy, a threefold increase in ischemic heart disease 2674 was observed among never users compared to ever users of hormone therapy. However, this finding 2675 was based on few cases. The effect of hormone therapy was most pronounced for the subgroup of 2676 current users and among women who started treatment within 1 year of menopause.
- Estrogens have effects on ventricular myocyte contractile function (Ren *et al.*, 2003) and on intracellular Ca²⁺ kinetics in coronary endothelial cells thus having antiarrhythmic effects in cardiac myocytes (Nakajima *et al.*, 1999). There is also evidence that estrogen decrease insulin resistance (Sumino *et al.*, 2003) and protect against lipid peroxidation (Ayres *et al.*, 1998).
- During menopause, plasma lipids change in an unfavourable way to a more atherogenic pattern with increased total and LDL-cholesterol and decreased HDL cholesterol concentrations. There is evidence that short-term HRT beneficially affects plasma lipids and reverses some of these changes (Sack *et al.*, 1994, Rajman *et al.*, 1996, Darling *et al.*, 1997).



2685 Clinical and experimental data indicate that there may be different effects of hormone therapy in younger women (e.g. women with POI and healthy vessels without established atherosclerosis starting 2686 2687 HT), in comparison with older women (e.g. women with age of menopause over 50 years, starting treatment 10 years after their final menstrual period) (Clarkson, 1994, Atsma et al., 2006, Mikkola and 2688 Clarkson, 2006, Ouyang et al., 2006). In blood vessels with established atherosclerosis, oral estrogen 2689 administration has negative effects via its prothrombotic effects, thus contributing to plague instability 2690 2691 (Clarkson, 1994, Walsh et al., 2000). In comparison with a 12-month standard regimen (oral 2692 ethinylestradiol and norethisterone), physiological sex-steroid replacement therapy (transdermal 2693 estradiol 100 μ g + vaginal progesterone) in a randomized, controlled crossover study resulted in lower 2694 blood pressure, better renal function, and less activation of the renin-angiotensin system in 18 women 2695 aged 19-39 years with POI (Langrish et al., 2009).

2696 In a group of 25 young hypogonadal women (mean age 31.9 years; range 18.5-42.2), increasing doses 2697 of hormone therapy (17β-estradiol at 1 mg, 2 mg, and 4 mg) resulted in a reduction of carotid intima-2698 media thickness along with increased serum HDL and decreased plasma glucose (Ostberg *et al.*, 2007).

2699 Turner Syndrome

Almost all women with TS need appropriate HT until the age of natural menopause, following induction 2700 of puberty, i.e. approximately for 40 years. A Danish cohort study showed that women with TS treated 2701 2702 with HT had a significantly lower use of antihypertensives, antidiabetics, and thyroid hormones and 2703 significantly reduced hospitalization rates for stroke and osteoporotic fractures (Viuff et al., 2020). A 2704 small study showed that increasing doses of HT result in a reduction in carotid IMT and plasma glucose, along with increased serum HDL (Ostberg et al., 2007). Studies have shown no increased risk for 2705 2706 neoplasia in women with TS receiving HT, including breast cancer (Schoemaker et al., 2008, Larizza et al., 2016, Viuff et al., 2021). Women with spontaneous and surgical POI, as well as TS are not only 2707 estrogen deficient; they are also testosterone deficient (Kalantaridou et al., 2006a, Viuff et al., 2022, 2708 2709 Gravholt et al., 2023) However, there are no clinical studies showing the effect of testosterone addition 2710 to standard HT regarding CV health..

2711 **Recommendation**

Despite a lack of data from randomised controlled trials, hormone therapy with early initiation is recommended in women with POI to control future risk of cardiovascular disease. Hormone therapy should be continued at least until the usual age of menopause. \oplus

) STRONG

2712 Justification

Hormone therapy in POI has beneficial effects on plasma lipids, blood pressure, insulin resistance, and vascular endothelial function. There is a need for long-term randomized prospective studies to determine the optimal routes, doses, and regimens of HT. In the absence of long-term randomized prospective data, treatment should be individualized and carefully monitored.

- 2717 Research recommendation.
- 2718 There is a need for long-term randomized prospective studies to determine the optimal routes, doses, and
- 2719 regimens of HT. In the absence of long-term randomized prospective data, treatment should be 2720 individualized and carefully monitored.
- 2721



2722 VII.3. Monitoring of cardiovascular risk factors

2723 Premature estrogen deficiency is associated with increased risk of CAD, stroke, and overall CVD and 2724 increased CVD mortality, CAD mortality and all-cause mortality.

Starting hormone therapy soon after the diagnosis of POI and achieving a healthy lifestyle (i.e., not smoking, maintaining normal BMI, having regular exercise program, and a healthy diet) are important parameters and are associated with normal lipid profile and blood pressure and less progression of subclinical atherosclerosis (Mehta and Manson, 2024). Regular CVD follow-up is essential including cardiologist review according to individual needs and availability.

2730 **PICO QUESTION: SHOULD CARDIOVASCULAR RISK FACTORS BE MONITORED?**

2731 Spontaneous and surgical POI

Women with POI have an increased risk for CAD, heart failure, type 2 diabetes, hypertension, dyslipidaemia, and stroke. Clinical data has shown that hormone therapy reduces the risk for CAD, and stroke and improves insulin sensitivity and lowers glucose levels, thus decreasing the risk for type 2 diabetes in postmenopausal women (Mehta and Manson, 2024).

Annual follow-up is essential for monitoring HT, blood pressure (BP), BMI, and lipid and glucose levels.
 Because of the impact on CV risks, screening for thyroid function, by measuring TSH, should be
 performed according to individual needs. Regular cardiovascular follow-up is also important, which may

2739 require referral to a cardiologist. Achieving and maintaining a healthy lifestyle, along with transdermal

- HT until the usual age of menopause, will reduce the risk for CVD (Mehta and Manson, 2024) (see also
- 2741 XII.3. Lifestyle management options).

2742 Turner Syndrome

- In addition to the burden of congenital heart defects, women with TS have an excess of several
 cardiovascular risk factors including hypertension, obesity, impaired glucose tolerance, type 2 diabetes,
 and hyperlipidaemia.
- Women with Turner Syndrome have a 50% risk of developing impaired glucose tolerance and a fourfold increase in the relative risk of developing type 2 diabetes (Gravholt *et al.*, 1998). Impaired glucose tolerance is thought to result from a combination of insulin deficiency (Bakalov *et al.*, 2004) and insulin resistance (Salgin *et al.*, 2006), and both are independent of body composition although, if obesity is present, it will further aggravate insulin resistance. A more atherogenic lipid profile is usually found in women with TS compared with those who have a normal karyotype and POI (elevation of LDL and triglycerides).
- Annual screening for these risk factors should be performed and, if relevant, smoking cessation should be discussed. Standardized multidisciplinary evaluation is effective; girls with Turner Syndrome benefit from a careful transition to ongoing adult medical care (Freriks *et al.*, 2011).
- 2756 Close monitoring of CVD factors by specialized cardiologists is essential (Gravholt *et al.*, 2023).

2757 *Recommendations*

The guideline group recommends that cardiovascular risk should be assessed in women diagnosed with POI.

GPP



The guideline group recommends that all women with POI should have annual monitoring of blood pressure, weight and smoking status, and where available blood tests for lipid profile and diabetes screening. Other tests for assessing cardiovascular risk can be performed upon indication.

GPP

2759 Justification

- 2760 There are no validated tools for screening CVD risk in women with POI or Turner Syndrome.
- 2761 Conventional screening tools are not suitable for women with POI as they are at increased relative risk 2762 for cardiovascular disease as compared to age-matched healthy women. Estrogen deficiency at young 2763 age adds to the 'lifetime' risk for CVD.
- However, screening for cardiovascular risk factors at diagnosis may be indicated as lifestyle measures
 during pre-menopause improve health in later years.
- Women with POI including Turner Syndrome, have an excess of several cardiovascular risk factors, including hypertension, obesity, impaired glucose tolerance, and hyperlipidaemia. Therefore, annual screening for cardiovascular risk factors should be performed, and if present managed appropriately. A heart healthy lifestyle should be discussed including smoking cessation There are no clear recommendations on BP thresholds or targets for the treatment of hypertension in women with Turner Syndrome, but somewhat lower target values are believed to be desirable.
- 2772

JRAFFOR



2774 VIII. POI and psychological wellbeing

Psychological wellbeing is an essential component of quality of life (QoL) that is a key endpoint in 2775 2776 medical and health research. QoL is a broad concept measurable with multiple scales assessing an 2777 overall score and domain score, with no universal accepted definition. The WHO has created a scale 2778 with six domains: physical health, psychological state, levels of independence, social relationships, 2779 environmental features, and spiritual concerns. Any condition or intervention able to modify the 2780 individual status may influence one or more dimensions of QoL that are generally interconnected. 2781 Several conceptual and methodological challenges emerge in the literature, mostly related to 2782 definitions, theoretical backgrounds, and design of validated instruments (Haraldstad et al., 2019). 2783 Measures of health-related quality of life (HRQoL) take generally into account physical, psychological, and social dimensions contributing to wellbeing, and they are effective in clinical practice when retaining 2784 the ability to capture the specificity of health conditions or interventions under investigation in a 2785 2786 multidimensional perspective. In many circumstances, including menopause, the final goal is to 2787 understand individual feelings and behaviours associated with the health status and the level of intra-2788 personal and inter-personal distress in a specific socio-cultural context (Kotz et al., 2006).

2789

2790 VIII.1. Impact of POI on psychological wellbeing

2791 PICO QUESTION: WHAT ARE THE CONSEQUENCES OF POI ON PSYCHOLOGICAL WELLBEING AND
2792 QUALITY OF LIFE?

2793 General aspects

Over the years intensive research has been conducted on the most appropriate and validated 2794 2795 instruments to measure global, health and menopause related QoL regarding the impact of hormone therapy on symptoms and conditions that may variably affect women at this life stage. The main 2796 challenge associated with menopause is the assessment of QoL in a real multidimensional perspective 2797 that should consider several biopsychosocial modulators influencing the individual perception of a 2798 natural transition, not a disease (Utian and Woods, 2013). On the other hand, chronic illnesses 2799 2800 underlying iatrogenic POL may influence psychological wellbeing and QoL by itself, in addition to typical menopausal symptoms (Woods and Utian, 2018), which are generally more severe (Kotz et al., 2006). 2801

2802 Within the POI literature on QoL, few studies had set out to specifically and systematically examine QoL 2803 patterns and their physical and psychosocial predictors. A meta-analysis including only six studies with 2804 645 women with POI and 492 normal-ovarian control subjects under 40 years reports lower overall HRQoL and physical function in women with POI, whereas the impact on psychological and social 2805 2806 HRQoL seems to be small. Sexual function is affected, especially lubrication, with a high rate of variability (see IX. POI and sexuality). Collectively, the data suggest the importance of developing condition-2807 specific questionnaires based on POI-related constructs (Li et al., 2020b). A sample of Chinese women 2808 2809 with POI after hematopoietic stem cell transplantation (HSCT) for hematologic diseases showed milder 2810 symptoms in comparison with the norm group, but non-specific scales to assess QoL were used (Su et al., 2023). Recently, Golezar et al. developed and evaluated the psychometric properties of POI QoL 2811 2812 scale (POIQoL) which consists of six subscales including psychological effects, coping strategies, 2813 hormone therapy complications, fears and concerns, self-conception, and sexual function (Golezar et 2814 al., 2022).



2815 The criticism goes beyond the validity of the QoL measure used. POI is not a homogenous and fixed 2816 state, and most importantly is not natural because, even when a specific cause is not identified, it occurs 2817 early in the life course and assumes the characteristics of a chronic health problem requiring long-term care. It is currently unclear to what extent women with POI can be compared to other long-term medical 2818 2819 conditions associated with a higher prevalence of psychological and mental health difficulties (The 2820 British Psychological Society & The Royal College of Psychiatrists., 2010). With these limitations in mind, studies of varying quality and scale appear to point to a higher prevalence of psychological distress 2821 2822 (Nappi et al., 2019). Distinct aspects of POI such as the absence or presence of previous cancer 2823 diagnosis/risk increase, concurrent unrelated health problems, vasomotor symptoms, as well as current 2824 treatment (e.g. fertility treatment) may impact upon different QoL domains in distinctive ways. These 2825 effects may be mitigated by a number of variables, such as the absence or presence of a stable and 2826 satisfying relationship and/or children, and pre-POI mental health.

2827 Importantly, social, and economic status is associated with access to social privileges and can powerfully 2828 influence QoL domains, so that the confounding effects of education, occupation, and income may need 2829 to be controlled for. A fair example is a retrospective study with women who had undergone risk 2830 reducing salpingo-oophorectomy. The authors found that younger women were at a higher risk for 2831 poorer long-term wellbeing outcomes, and that sport participation and a stable weight had a protective effect (Touboul et al., 2011). However, the potential confounding effects of educational level and 2832 2833 executive occupation – markers of socio-economic success and privilege were measured and reported 2834 as results rather than considered for their potentially overriding influence on wellbeing outcome.

2835 Quality of Life and menopausal symptoms

The research on POI and QoL has not yet reached the stage of being able to map specific aspects of 2836 2837 POI across different dimensions of QoL, mainly because of the paucity of instruments specifically 2838 designed for these women (Li et al., 2020b). Generic HRQoL instruments may not appropriately assess the variety of biopsychosocial elements described in women with non-iatrogenic POI (Nappi et al., 2839 2019). In a non-clinic-based sample of members of a POI-specific support group, symptom scores did 2840 not substantially decrease with time since diagnosis or correlate with age at POI diagnosis. Of note, 2841 women with POI report many symptoms not adequately captured by the symptom checklists created 2842 2843 for age-appropriate postmenopausal women (Allshouse et al., 2015). For instance, iatrogenic POI, 2844 especially before the age of 41 years, is associated with a poor QoL namely in sexual and vasomotor domains (Gosset et al., 2022). On the other hand, research in menopause at usual age suggests there 2845 are important cognitive, emotional, and behavioural variations in vasomotor symptom experience and 2846 2847 reporting, so that their impact on women can be expected to be highly variable (Hunter and Mann, 2010). A total of 140 relatively healthy mid-aged women with vasomotor symptoms (at least ten hot 2848 2849 flushes/night sweats) report reduced HRQoL compared to age-matched normal subjects and a general 2850 sample of menopausal women. Poor HRQoL is associated with younger age, current psychosocial 2851 concerns, poor general health, and higher body mass index (Ayers and Hunter, 2013).

2852 Quality of Life and psychological wellbeing

2853 Poor female identity emerges in women with POI undergoing gualitative research (Moukhah et al., 2854 2023). Body image changes are also important factors to consider regarding adaptation to surgery with 2855 an impact on feminine perception (Pearce et al., 2014). A study that compared women who have 2856 experienced natural and surgical menopause for benign conditions found that HRQoL is worse for 2857 women who have had a surgical menopause (Bhattacharya and Jha, 2010), whereas risk reducing 2858 bilateral salpingo-oophorectomy (RRBSO) in women with pathogenic BRCA variants is not associated 2859 with significant changes in QoL, but with lower global health status, as compared with an expectant 2860 management (Zilski et al., 2023). Of note, in a non-randomized controlled trial risk reducing



2861 salpingectomy with delayed oophorectomy in premenopausal women who had completed childbearing 2862 is associated with better menopause-related QoL than with RRBSO, without significant differences in 2863 HRQoL (Steenbeek et al., 2021). Individual experiences of RRBSO are variable and influenced by multiple factors but psychosexual problems are common and often cause significant distress to the women with 2864 2865 POI and their partners (Hickey et al., 2021a). A recent review addresses the psychosocial impact of the decision-making process in women candidate to risk reducing surgery pointing to the need of 2866 methodological standards (Alves-Nogueira et al., 2023) to counteract the suboptimal clinical care after 2867 2868 premenopausal RRBSO in high-risk women (Nebgen et al., 2023).

- 2869 Also, the relationship between oophorectomy and depression may vary depending on the type of 2870 iatrogenic POI affecting the population of women and on the instruments used to assess psychological 2871 wellbeing. A large-scale telephone interview follow-up study of women who had undergone bilateral oophorectomy before the onset of menopause for a non-cancer indication shows the participants to be 2872 2873 at an increased long-term risk of depressive and anxiety symptoms compared to an age-matched referent group (Rocca et al., 2008). This report highlights that a reduction in psychological wellbeing is 2874 2875 not always accountable in terms of cancer diagnosis and risk. Different trajectories of depressive 2876 symptoms across menopause stages have been described in a large prospective longitudinal cohort of 2877 midlife women, including in those with surgical menopause and taking menopause hormone therapy 2878 (Hickey et al., 2016). In a recent retrospective cohort study performed using a national database in South Korea, menopause at an earlier age showed an increased risk of depression, as well the use of 2879 menopause hormone therapy for more than 5 years (Kim et al., 2023). A cross-sectional study conducted 2880 in the same country showed that suicidal ideation was present in middle-aged women with POI, 2881 2882 regardless of a positive diagnosis of major depressive disorder (Ryu et al., 2022)
- Women with iatrogenic POI are more affected in term of depression and anxiety as compared with non-2883 iatrogenic POI and controls (Deeks et al., 2011). Among women at an elevated risk of ovarian cancer, 2884 2885 the surgery did not increase self-reported depression and antidepressant use in a prospective study 2886 (Kotsopoulos et al., 2020), whereas in another study (using a validated instrument risk of depressive 2887 symptoms) depression doubled within 3 months of premenopausal RRBSO and remained elevated in the 3 to 12 months after RRBSO (Hickey et al., 2017). In a nationwide population-based cohort study 2888 using Danish National Registries including women after RRBSO for a family history of cancer (n=2002) 2889 2890 and an age-matched reference group (n=18 018), surgery was likely associated with the use of 2891 antidepressants, especially in women treated with hormone therapy (Bräuner et al., 2022). Interpretation 2892 of results should always consider that pre-existing mood disorders are associated with increased risk of bilateral oophorectomy in overall analyses and also in women \leq 45 years of age (Gazzuola Rocca et 2893 2894 al., 2019). Moreover, intrapersonal experiences, including adverse childhood and adult experiences, 2895 might play a role in the association between mental health and gynaecologic symptoms that eventually 2896 lead to bilateral oophorectomy (Rocca, et al., 2021).
- 2897 An early cross-sectional observational study using standardised questionnaires with 64 attendees at a 2898 POI clinic showed that women report higher levels of depression and perceived stress, and lower levels 2899 of self-esteem and life satisfaction, compared to normative data. Very important factors affecting the 2900 degree of reported distress were age, age at diagnosis, time since diagnosis, already having children, 2901 being in a long-term relationship, or having psychological treatment in the past or present (Liao et al., 2902 2000). Levels of psychological distress were high in women with POI in both users and non-users of 2903 hormone therapy, as shown in a cross-sectional study comparing women with Turner syndrome, POI 2904 women with normal karyotype and healthy controls. The psychosocial profile was similar with increased 2905 shyness, social anxiety, and depression, and decreased self-esteem (Schmidt et al., 2006). Non-2906 iatrogenic POI is associated with an increased lifetime risk for major depression, probably sharing a 2907 common vulnerability (Schmidt et al., 2011). A cross-sectional questionnaire-based study showed a high



2908 rate of negative impact on self-image and confidence in women with POI (Singer et al., 2011). Another 2909 cross-sectional opportunistic descriptive study involving clinic patients and support group members 2910 also suggested poorer psychosocial adjustment in women with POI and the presence of vasomotor 2911 symptoms explains only a small amount of the variance in psychosocial functioning (Mann et al., 2012). 2912 Other symptoms such as poor sleep quality and insomnia seemed to be linked to depression, but 2913 interpersonal factors (being married, having more children) seem to mediate this link (Ates et al., 2022). 2914 Lifestyle factors, for example smoking, may also play a mediator role. Indeed, in a sample of non-2915 hysterectomized 31435 women aged 45 and above, POI was positively associated with insomnia and 2916 depression and negatively associated with cognition, with a more significant association among those 2917 who consumed tobacco (Kundu and Acharya, 2023).

2918 A study found that scores on Illness Uncertainty, Purpose in Life and Stigma are significantly implicated 2919 in scores on Anxiety and Depression, whilst scores on Goal Reengagement and Purpose in Life are 2920 associated with scores on Positive Affect (Davis et al., 2010). A significant positive relationship between 2921 spiritual and functional wellbeing is evident in women with non-iatrogenic POI (Ventura et al., 2007). However, they perceive lower levels of social support (Orshan et al., 2009). A systematic review and 2922 2923 meta-analysis confirmed a high risk of depression and anxiety in women with POI (Xi et al., 2023). A 2924 gualitative study exploring factors affecting QoL of women with POL identified profound effects on different aspects of biopsychosocial health, including fears for short- and long-term consequences and 2925 2926 ambivalence towards hormone therapy. Distorted self-concept, mainly deriving from amenorrhea, changes in maternity expectations and signs of aging, is also a major topic (Golezar et al., 2020). A 2927 heterogeneous sample of midlife women diagnosed with early menopause at age 38 \pm 5 years 2928 2929 described the condition with words having negative connotations and referring to symptoms, especially hot flushes (36.8%), mood swings (20.5%), and infertility (16.8%) (Yeganeh et al., 2020a). 2930

2931 *Quality of Life and fertility concerns*

Fertility concerns were reported by 71% of a descriptive study sample involving clinic patients and 2932 support group members, but a strong relationship with self-reports of psychosocial functioning 2933 measures was not demonstrated (Mann et al., 2012). However, infertility is one of the most disturbing 2934 aspects of the "silent grief" of women with POI, with feelings of guilt and shame (Singer et al., 2011). In 2935 2936 a longitudinal investigation on 102 women with POI, avoidance to acknowledge stress deriving from 2937 infertility, regardless of parity status, seems the most important factor to negatively cope with the POI 2938 condition following 12 months (Driscoll et al., 2016). Difficulties in forming new relationships or fears of 2939 losing current partner, along with the awareness that a fundamental component of femininity is missing, 2940 make POI a very special form of infertility requiring comprehensive care (Singer, 2019). A case-control 2941 study showed that male partners of women with POI report significantly higher anxiety and depression, 2942 and experience worse marital relationship in several aspects. Most male partners had inadequate and 2943 inaccurate knowledge about their partners' disease, and this lack of understanding correlated with mood status and level of communication (Chu et al., 2021). 2944


A recent systematic scoping review of the literature on HRQoL in women with non-iatrogenic POI is extremely useful to identify relevant categorical themes and associated dimensions, as well as individual factors, interpersonal influences or healthcare system factors that can modulate the level of impairment of HRQoL and are important promoters of effective coping with a POI diagnosis (McDonald *et al.*, 2022)(Figure 12).

This updated review sets the stage for further development in providing adequate care to women with POI who very often report feelings of loneliness and experiences of negative interactions with health care providers (HCPs). Discontinuing of care, knowledge gaps and inadequate support are very relevant to psychosexual distress. All these themes (diagnostic odyssey, isolation and stigma, and ego integrity)



and associated dimensions should be targets of effective counselling to make informed choices in the management of the POI condition (McDonald *et al.*, 2022).

2956Figure 13 Themes and dimensions related to impaired health-related quality of life (HRQoL) in2957women with POI (McDonald *et al.*, 2022) (permission pending)



2958

2959Themes and dimensions related to impaired health-related quality of life (HR-QoL) in women with primary ovarian insufficiency2960(POI). Synthesizing the results of the scoping review identified potential targets for interventions to improve health-related quality of2961life (HR-QoL) in women with primary ovarian insufficiency (POI). (A) Three interacting themes (bold text in overlapping circles:2962diagnostic odyssey, isolation and stigma, ego integrity) contributed to impaired HR-QoL in women with POI (i.e. anxiety, depression,2963psychological distress, diminished health status). Dimensions for each theme are depicted by bullets. (B) Several mitigating factors2964were identified from the literature and are categorized at the individual, interpersonal and healthcare system levels. Protective factors2965are noted by bulleted points for each respective level. Dx, diagnosis.

2966 **Recommendations**

HCPs should be aware that a diagnosis of POI can have a significant impact on psychological wellbeing and quality of life

STRONG

2967

The guideline group recommends offering assessment of psychological health and	
quality of life to all women with POI.	GPP

2968 Justification

2969 Current evidence suggests that women with POI report lower levels of psychological wellbeing 2970 compared to women in the general population. However, it is far from certain whether this constitutes 2971 the psychological sequelae of having a chronic condition or is particular to POI per se. Several 2972 knowledge gaps in QoL are still present because of the difficulties in investigating the multifaceted



2973 impact of a chronic condition that it is very distinct from one woman to another, depending on the 2974 stage of life at diagnosis, type of POI, and intrapersonal and interpersonal characteristics able to 2975 modulate the psychological impact.

Authoritative data is needed to confidently inform service users and providers about the wellbeing trajectories of the key aspects of POI. Meanwhile, the use of doctor- and patient-friendly wellbeing screening tools may prompt discussion and signpost to supportive resources is a crucial aspect of clinical services for long term medical conditions in general and POI in particular, so that patient distress does not go unnoticed and unmanaged. Many simple and acceptable tools exist to facilitate an effective discussion and the hope is they can be implemented with the help of women suffering from POI of different aetiologies to guide tailored interventions.

- 2983 Research recommendation.
- 2984 QoL research is needed involving prospective studies with the use of comprehensive scale validated in 2985 women with spontaneous and iatrogenic POI.

2986 VIII.2. Management options

2987 **PICO QUESTION: WHAT ARE THE MANAGEMENT OPTIONS FOR REDUCED QUALITY OF LIFE** 2988 **ASSOCIATED WITH POI?**

A large variety of therapeutics are available to support women with POI and the crucial point is to understand how to investigate QoL outcomes following intervention. POI is a physical health condition that affects multiple body systems so that some impact on HRQoL may be expected at some time point. The effect may be mild or moderate, transient, or prolonged, depending on a wide range of variables. It should not be implied that every woman reporting a reduction in QoL should be medically or psychologically treated. Psychological distress in response to (aspects of) POI is normal. Coping with a level of adversity across the lifespan is intrinsic to human development.

- In some situations, a caring professional attitude may be the best form of clinical management. A telephone interview study based on findings from focus groups suggested that the manner in which women are informed about their diagnosis could significantly affect their level of distress, and they expressed a need for HCPs to spend more time with them and provide more information about their condition (Groff *et al.*, 2005).
- 3001 A recent review including 19 studies involving a total of 10856 participants with various chronic 3002 conditions points to the importance of personalised care planning (Coulter et al., 2015). Having a 3003 conversation, or series of conversations, in which patients and HCPs identify and discuss problems 3004 caused by or related to a given chronic condition leads to improvements in certain indicators of physical 3005 and psychological health status, and people's capability to self-manage their condition when compared 3006 to routine care (Coulter et al., 2015). Ideally, HCPs should be able to integrate personalised care planning 3007 into routine consultations to empower women with POI in the decision-making regarding their 3008 condition with the ultimate goal of enhancing QoL.

A very important aspect of empowering women with POI to take individual decisions on pharmacological and non-pharmacological strategies to improve QoL and psychological wellbeing is the development of co-designed instruments to help them to understand the condition and to facilitate the communication with HCPs (Yeganeh *et al.*, 2020b). A study in 2017 indicates the need for higherquality internet resources for women seeking information on early menopause (Aleksova *et al.*, 2017). A question prompt list -a structured list of questions- has been developed to assist women with early menopause in acquiring relevant information and facilitating communication with HCPs. Both women



- and HCPs found it useful to overcome communication difficulties related to sexual function (vaginal/urinary symptoms) and psychological impact (Yeganeh *et al.*, 2020c). A recent study using a codesigned early menopause digital resource shows an improvement in women's health-related empowerment, illness perception, menopause symptoms, risk perception, and knowledge (Yeganeh *et al.*, 2022). This approach has the potential to further improve QoL in women with POI that may feel part of a community as well as perceive a shared reality of their condition with HCPs.
- 3022 The guiding principle in daily practice should be individualized care (Figure 12).

3023 *Medical interventions*

- 3024 An early review that focused specifically on the effects of hormone interventions on QoL concluded that 3025 estrogen with or without testosterone may improve general wellbeing in some surgically menopausal 3026 women for whom the level of serum estrogen was within a premenopausal range. They further observed 3027 that adding testosterone to estrogen therapy may provide additional improvements in wellbeing in 3028 some women but only at supra-physiological levels of total testosterone and physiological levels of free 3029 testosterone (Kotz et al., 2006). A recent systematic review and meta-analysis (Gonçalves et al., 2022) 3030 assessing several endpoints of hormone therapy (HT) in women with POI included two RCTs evaluating QoL (Zuckerman-Levin et al., 2009, Guerrieri et al., 2014). These studies were designed to compare 3031 3032 groups treated with and without testosterone and showed that women with POI treated with estrogen 3033 plus progestogen had stability or improvement in the QoL scores after 1 year. One study (Zuckerman-Levin et al., 2009) was conducted in 14 young (age range: 17-27 years) women with Turner Syndrome 3034 treated with estrogen/progestogen replacement therapy and receiving oral 1.5 mg methyl testosterone 3035 or placebo for 1 year and the alternative for another year. QoL, including general health, coping with 3036 3037 stress, and sexual desire, were significantly improved by using androgen treatment, which was safe when 3038 given for 1 year. The other study was conducted in 128 women with 46,XX non-iatrogenic POI over a 3039 12-month period (Guerrieri et al., 2014). The research team concluded that augmentation of standard estrogen/progestogen therapy with physiologic low-dose testosterone (150-µg patch) in young women 3040 with POI did not change reported QoL or self-esteem and had minimal impact on mood. It was 3041 suggested that other pathways were likely to be involved in any mood alterations associated with POI. 3042 3043 Another study in adults with Turner Syndrome explored long-term psychological functioning after 3044 androgen exposure (oxandrolone) during childhood in terms of neurocognition, QoL and social-3045 emotional functioning (Freriks et al., 2015). Results suggest that early androgen treatment has long-3046 term effects on adult QoL (higher anxiety and depression levels) and social-emotional functioning (lower 3047 emotion perception for fearful faces without effect on interpersonal behaviour) (Freriks et al., 2015).
- A cross-sectional study of 61 women with POI receiving HT and 61 aga-matched women with preserved 3048 3049 ovarian function showed that women with POI receiving HT have poor sleep quality, take longer to fall 3050 asleep and have a higher fatigue index (Benetti-Pinto et al., 2019). The same research team showed that 3051 women with POI receiving HT have indexes of depression, anxiety, and stress similar to the population 3052 of women with preserved ovarian function (Menezes et al., 2020). However, the cross-sectional design 3053 of these studies does not allow cause and effect conclusions. A systematic review of studies considering 3054 patient-reported outcomes for psychological and sexual wellbeing in surgically menopausal women and 3055 women after BSO, but not POI, showed that estradiol may beneficially affect psychological symptoms 3056 and testosterone might improve sexual desire and overall sexual functioning (Stuursma et al., 2022).
- 3057 Vasomotor symptoms could be implicated in a reduction of QoL for some women. In a cohort study,
 3058 HT was reported to be associated with up to 80% reduction in the prevalence of hot flushes in POI
 3059 (Vermeulen *et al.*, 2017). Non-hormonal drugs including selective serotonin reuptake inhibitors (SSRIs)
 3060 and serotonin-norepinephrine reuptake inhibitor (SNRIs), clonidine, and gabapentin have produced
 3061 moderate reductions in hot flush and night sweat frequency, averaging 37% across trials, although they



3062 appear to have little effect on QoL measures (Rada et al., 2010). Escitalopram and venlafaxine used as a 3063 non-hormonal therapy for vasomotor symptoms were associated with improvement in psychosocial 3064 QoL in peri-postmenopausal women, but effects have not been specifically assessed in POI (Diem et al., 3065 2020) (see also XII.1. Non-hormonal therapies). Back in 2005, Utian (Utian, 2005) stated that in women 3066 who need or wish to avoid HT, additional targeted therapies, validated by results from controlled clinical 3067 trials that are safe, efficacious, cost-effective, and well tolerated by symptomatic women are needed. At 3068 present, there is some hope from the possible use of a new class of drugs (NK3R antagonists) that target 3069 the hypothalamic neuroendocrine mechanisms generating vasomotor symptoms (Menown and Tello, 3070 2021), but no data on their efficacy and safety are available in women with POI.

3071 *Psychological interventions*

3072 For some women diagnosed with POI, psychological wellbeing may be particularly compromised at 3073 specific time points, such as the time of diagnosis, when physical symptoms are most acute, when 3074 fertility treatments are being pursued, at the beginning or ending of an important relationship, or when 3075 a number of physical, psychosocial, and economic factors converge to exacerbate distress. The approach 3076 taken would depend on the presenting complaint, the therapeutic orientation of the HCP, and service constraints, bearing in mind that psychological interventions should be tailored to the specific needs of 3077 3078 women with POI (McDonald et al., 2022). To date however, there is no authoritative evaluative research of psychological interventions specific to a diagnosis of POI. This is partly because psychological 3079 interventions tend not to target medical diagnoses as such, but a psychological problem (e.g. health 3080 3081 anxiety), which may be related to an aspect or multiple aspects of a condition (e.g. infertility) rather than to the diagnosis per se (e.g. POI). Singer stated that practicing sensibly may help women with POI to 3082 3083 psychologically adjust to their situation. Even the involvement of the partner, when present, can help in understanding and communication (Singer, 2019). 3084

Nonmedical interventions mostly comprise cognitive behavioural therapy (CBT) with a primary focus on 3085 vasomotor symptoms and indirect effects on QoL. A brief CBT (four to six sessions), theory- and 3086 evidence-based, is acceptable to women and was shown to have benefits to QoL (Hunter, 2021). A 3087 systematic review and meta-analysis including 14 RCTs comprising 1618 patients focussing on 3088 vasomotor symptoms reported a moderate effect of CBT on QoL (Ye et al., 2022). Mindfulness-based 3089 3090 interventions can improve overall QoL of menopausal women (Chen et al., 2021). An Iranian randomized 3091 clinical study conducted in women with POI showed an improvement of QoL, but its methodology has been questioned (Pyri et al., 2021). 3092

Other approaches, including acupuncture, relaxation therapy, and exercise, have not been evaluated for
 effect on QoL. Studies focussing on vasomotor symptoms are discussed in section XII.2. Complementary
 therapies.

3096 Where infertility is centrally implicated in a significant reduction of wellbeing, routine psychosocial care 3097 is mandatory according to recommendations formulated for infertile couples (Gameiro et al., 2015, 3098 Romualdi et al., 2023). However, fostering wellbeing in women with POI implies a stronger promotion 3099 of active coping and identity integration to manage stigmatisation that can predispose to poorer mental 3100 health independently of the infertility burden (McDonald et al., 2022). Psychological distress in women 3101 with POI was negatively associated with goal re-engagement despite continued preoccupation with the 3102 loss (Davis et al., 2010). Whilst supportive counselling could be first line psychological input, for some 3103 women there may be a need to extend such input to help patients to renegotiate life goals successfully.

A wide range of psychological approaches for infertility have been described that may be relevant in supporting adjustment to the diagnosis of POI. An early review (Boivin, 2003) identified three categories of intervention: i) counselling; ii) focussed education (including sex therapy, coping training, support and stress reduction, autogenic training, and preparatory information); and iii) comprehensive



3108 educational programmes (including a mixed range of coping and relaxation techniques). Therapy 3109 offered was both short-term (1-2 weeks) and long-term (32 weeks) and formats varied including group, 3110 couple, and individual work. The author reported that on the whole, the interventions were more effective in reducing negative affect than in changing interpersonal functioning (e.g. social or marital 3111 3112 relationships), and that group interventions, which had an emphasis on education and skills training, 3113 were more effective across a range of outcomes than those that required more emotional expression 3114 of thoughts and feelings in relation to infertility. None of these studies were specific to women with a 3115 definitive diagnosis of POI or QoL as an outcome. However, the review was useful in signposting a need 3116 for all psychological interventions to be more clearly specified and accountable, rather than referred to 3117 as 'counselling' as a catch-all concept. It is important to bear in mind that for many diagnosed women, 3118 POI is not the only challenge to their wellbeing, or even the most important one. The influence of past 3119 and (con)current psychosocial vulnerabilities should not be overlooked. Therefore, where psychological 3120 distress is significant and prolonged, a potential referral to specialist psychological or mental health care 3121 pathways should be discussed.

At present, care models for POI are under development taking into account six key themes: stakeholder engagement, supporting integrated care, evidence-based care, defined outcomes and evaluation, incorporating behaviour change methodology and adaptability (Jones *et al.*, 2020). Engagement of patients is central to improve clinical and process outcomes, translate evidence into practice, and use resources more efficiently to deliver a multidisciplinary care for POI.

3127 Recommendation

Personalised care, including psychological support, should be accessible to women with POI STRONG

3128 Justification

A personalised care plan that considers how a woman approaches her situation is essential to improve 3129 3130 HR-QoL in women with POI. The best methodology to deliver high-guality care is still unclear and should consider both intrinsic and extrinsic factors, including physical health, current and past psychological 3131 health, age, parity, personal values and preferences, and access to social resources such as work, 3132 education, and supportive relationships. An offer of intervention should be based on a thorough and 3133 3134 holistic assessment of the presentation, and multi-disciplinary skills may be required. Once the hormone profile is adjusted, psychological interventions for problems that are associated with POI can lead to 3135 positive benefits on QoL, although validated, disease specific instruments to measure effectiveness are 3136 lacking. Contribution of patients is of paramount importance to fill the gaps still present in the POI 3137 3138 process of care.

- 3139 Research recommendation.
- 3140 The role of medical and psychological interventions in improving QoL should be implemented with the aid
- 3141 of adequate instruments developed in collaboration with women with POI of different aetiologies.
- 3142



3143 IX. POI and sexuality

3144 Sexual experiences and their interpretation and reporting are complex mind-body experiences. 3145 Observations within a purely biomedical knowledge framework are inevitably incomplete. POI may have 3146 direct or indirect effects on sexuality and the biopsychosocial model is essential to manage sexual 3147 consequences. Health-related quality of life (HRQoL), including sexual areas, is significantly impaired (Li 3148 et al., 2020b). However, patient-centred primary research is sparse in the clinical literature and more 3149 efforts are necessary to explore the role of underlining POI aetiologies and life stages in QoL. Available 3150 data do not allow a confident answer to questions on female sexuality and POI in ways that are helpful 3151 to affected women and close others. Targeted-interventions (McDonald et al., 2022) require detailed 3152 exploration of the potential sexuality effects of POI in a multidimensional perspective selecting relevant 3153 samples and using adequate instruments to assess and monitor bio-medical and/or psychosocial 3154 interventions.

3155 IX.1. Impact of POI on sexuality

3156 PICO QUESTION: WHAT ARE THE CONSEQUENCES OF POI FOR SEXUALITY?

3157 *General aspects*

Well-designed studies on sexuality in women with non-iatrogenic POI are limited and most data 3158 3159 addressing sexual concerns are part of the general assessment of menopausal symptomatology following the standard approach used for usual age menopause (Nappi et al., 2019). For instance, in a 3160 recent cross-sectional study involving 293 Chinese women with POI the use of the modified Kupperman 3161 Menopausal Index displays a high prevalence of menopausal symptoms, particularly related to 3162 psychological and sexual domains (Huang et al., 2021). On the other hand, the adverse health 3163 3164 consequences of early loss of ovarian function, including sexual consequences, are most studied in 3165 women experiencing iatrogenic POI [surgical treatment for benign gynaecologic disorders and risk 3166 reducing bilateral salpingo-oophorectomy (RRBSO) in women with BRCA mutations] (Kingsberg et al., 3167 2020). Less data on sexuality are available in survivors of childhood, adolescent, and young adult (AYA) cancer with POI (Lindau et al. 2015) and even genitourinary symptoms have not been investigated yet 3168 according to a recent systematic review (Gargus et al., 2018). However, despite many similarities, every 3169 3170 clinical scenario displays its own biopsychosocial peculiarities that introduce confounding variables (e.g., 3171 variable endocrine milieu, anatomical modifications of the vaginal canal, loss of sensitivity and the emotional sequelae of the threat of the illness that had necessitated different types of 3172 3173 surgery/treatments), rendering them at best partially comparable and generalizable to non-iatrogenic 3174 POI.

3175 As reported, POI is a life-altering diagnosis with several psychosocial ramifications encompassing 3176 multiple dimensions of womanhood (Rafigue et al., 2012) which significantly influence sexuality along 3177 with the primary effect of the physiological changes associated with early hormonal deprivation (Panay 3178 et al., 2020)(see also VIII. POI and psychological wellbeing). A qualitative focus on the perception and 3179 experience of women with POI regarding their sexual and reproductive health identifies four critical 3180 areas: endangerment of women's health, psychological agitation, disruption of social life and 3181 disturbance in sexual life (Moukhah et al., 2021). However, the lack of difference between sexual function 3182 and distress in women who are unaware that they have POI and in age-matched women with normal 3183 gonadal function offers a fair example (Aydin et al., 2017) that sexual effects of POI on women is far 3184 from straightforward. In reading the data on sexuality in women with POI, it is also important to consider 3185 that the hormonal challenge occurs at a younger age when distress associated with sexual complaints



is usually higher but age-dependent processes affecting the multi-systemic sexual response are lessimpaired in respect to women experiencing menopause at usual age.

3188 Common clinical conditions associated with sexual problems.

3189 The two most common clinical conditions associated with sexual problems in women with menopause 3190 at usual age are genitourinary syndrome of menopause (GSM) and low sexual desire with distress, 3191 named hypoactive sexual desire disorder (HSDD). Uncomfortable or painful intercourse from vaginal 3192 dryness is part of GSM, a chronic progressive condition associated with hormone- and age-dependent 3193 changes in urogenital tissues, which may influence all domains of the sexual response (desire, arousal, 3194 orgasm, satisfaction). HSDD is dependent on both hormonal changes, namely androgen decline, and 3195 other psychosocial aspects affecting intimacy and satisfaction with sex (Simon et al., 2018a). HSDD has 3196 been well described in women with surgical menopause, who are deprived early of sex hormones, but 3197 it may be present in women of any age even in the absence of low testosterone levels, which cannot be 3198 used to diagnose poor sexual function. A certain amount of controversy exists concerning the separation 3199 of sexual desire domain from arousal domain and a single condition termed female sexual interest and 3200 arousal disorder (FSIAD) has been proposed in the last Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) (Kingsberg and Simon, 2020). 3201

3202 Sexual function in women with POI

A study conducted in Turkey comparing surgically menopausal women with women undergoing 3203 menopause at usual age showed that surgery significantly affects sexual desire but not overall sexual 3204 performance (Bildircin et al., 2020). Another Turkish cohort of non-iatrogenic and iatrogenic menopause 3205 3206 reported no significant differences between the groups with respect to mean scores for desire, arousal, 3207 lubrication, orgasm, satisfaction, pain and sexual function measured by the Female Sexual Function 3208 Index (FSFI) (Gulbahar and Akgun Kavurmaci, 2022). Culture plays a crucial role in rebuilding individual feminine identity and sexual/marital relationship after surgical menopause, as shown by qualitative 3209 research conducted in Iran. Indeed, the main concern of women with surgical menopause is the 3210 emotional separation because of sexual changes after surgery (Abadi et al., 2018). 3211

Women with a BRCA1/2 mutation, who have undergone premenopausal RRBSO after completion of 3212 3213 childbearing to reduce their risk of ovarian cancer, show a decline in sexual functioning following 3.5 years post-surgery (Hall et al., 2019). However, a meta-analysis shows that decline of sexual function 3214 3215 after RRBSO is independent of menopausal status (Kershaw et al., 2021). Indeed, a recent large study 3216 demonstrated that the proportion of sexually active women (with premenopausal RRBSO more than 15 years ago is comparable with the proportion of sexually active women with a postmenopausal RRSO 3217 more than 15 years after premenopausal RRBSO. These same women with POI induced by risk reducing 3218 3219 surgery experience more vaginal dryness and more often have substantial sexual discomfort during 3220 sexual intercourse without reporting less pleasure with sexual activity (Terra et al., 2023). In a cross-3221 sectional study of breast cancer survivors, similar sexual function scores and QoL are present in women 3222 with RRBSO or not with a rate of sexual dysfunction and HSDD already very high before the surgery 3223 (Tucker et al., 2021). Recent systematic reviews and meta-analyses underline the importance of BSO in 3224 overall sexual function changes and the need of analysing predictors of sexual function change 3225 trajectories, especially different indications (Dedden et al., 2023) and profiles of risk (Morgan et al., 2023).

By using a general scale for menopausal symptomatology and QoL, a Chinese observational study of 215 women with POI after HSCT and 200 controls (menopausal women) showed no differences in scores related to sexual problems and vaginal dryness (Su *et al.*, 2020a). In young estrogen-replete women with spontaneous 46,XX POI, the Derogatis Interview for Sexual Function Self-Report (DISF-SR) indicated that sexual scores are lower, but still in the normal range, in comparison with regularly menstruating controls, and display a significant correlation with circulating testosterone levels. Women with POI with



3232 lower circulating testosterone showed a non-significant trend to lower sexual function scores 3233 (Kalantaridou et al., 2008). A case-control study evaluating sexual wellbeing concluded that women with 3234 POI have diminished general and sexual wellbeing and are less satisfied with their sexual lives than 3235 controls (van der Stege et al., 2008). In addition, they have fewer sexual fantasies and masturbated less 3236 frequently. Sexual contacts were associated with less sexual arousal, reduced lubrication, and increased 3237 genital pain. However, the frequency of desire to have sexual contact and the frequency of actual sexual 3238 contact with the partner did not differ between women with POI and control women and was primarily 3239 affected by the wish to have (more) children. Women with POI had lower levels of total testosterone, 3240 which has only a weak influence on sexual functioning, and used HT in 59% of the cases, without any 3241 difference in sexual wellbeing or satisfaction between users and non-users (van der Stege et al., 2008). 3242 A cross-sectional study comparing women with POI with an age-matched control group with normal 3243 ovarian function reported a diagnosis of sexual dysfunction (through cut-off score of the total FSFI) in 3244 62.1% and 37.8% respectively. They calculated a 2.8-fold increased risk of sexual dysfunction in POI and 3245 commented that desire was the only FSFI domain showing no difference with controls (de Almeida et al., 2011). In a subsequent study, the same research group reported that women with POI have impaired 3246 3247 sexual function, mainly due to changes in arousal and desire (Benetti-Pinto et al., 2015c). These data suggest an overall impact of POI on sexual function and point to the need to explore further the role of 3248 3249 hormonal milieu and intimacy-based stimuli in sexual desire and arousal, and in their connection with 3250 poor lubrication and sexual pain. A narrative review on the long-term effects of POI indicated that urogenital atrophy interferes significantly with sexual functioning (Podfigurna-Stopa et al., 2016). More 3251 3252 recently, a case-control study of 66Iranian women (with POI and 66 age-matched fertile controls showed 3253 an in impairment in all areas of sexual function and QoL. Sexual desire, arousal, satisfaction, and pain 3254 had the most impact on QoL in women with POI (Javadpour et al., 2021). A French cross-sectional 3255 observational study involving 88 women with POI showed a negative impact of GSM on QoL and sexual 3256 wellbeing by using validated guestionnaires [Day-to-Day Impact of Vaginal Aging (DIVA) and FSFI] (Gosset et al., 2023). An earlier study assessed the psychosexual wellness (as opposed to sexual function, 3257 3258 a more performance-based construct) in a group of women aged 19 to 40 with POI interviewed by post (Liao et al., 2000). Compared to normative data, women with POI reported lower scores on Sexual 3259 Esteem, Sexual Assertiveness, and Sexual Satisfaction, and higher on Sexual Anxiety and Sexual 3260 3261 Depression.

In a cross-sectional observational study comparing 302 women with Turner Syndrome (TS) and 53 3262 3263 women with karyotypically normal POI, age at first relationship and sexual debut were significantly higher in women with TS, with no difference on whether estrogen replacement was started before or 3264 3265 after 14 years of age. After adjusting for age and diagnosis, induction of puberty, as opposed to 3266 spontaneous puberty, was associated with a delay in the median age at first relationship and sexual 3267 debut, as well as with a reduced probability of having vaginal sexual intercourse (Cardona Attard et al., 3268 2020). Another cross-sectional study showed overall good sexual wellbeing and normal genital touch 3269 sensitivity in women born with differences of sex development or early loss of gonadal function 3270 (complete gonadal dysgenesis and POI) as compared to population-derived controls (Engberg et al., 3271 2022).

3272 Recommendations

HCPs should be aware that a diagnosis of POI can have a significant $\oplus \oplus \bigcirc \bigcirc$

STRONG

3273



The guideline group recommends that HCPs routinely enquire about sexual GPP wellbeing and sexual function in women with POI.

3274 Justification

Sexuality in women with POI may well be affected in the context of QoL aspects associated with the 3275 3276 condition (see VIII. POI and psychological wellbeing) and its own aetiology. Despite the 3277 multidimensional aspects characterizing sexual experience, there is a lack of inter-disciplinary approach 3278 in current literature that limits interpretation of available data on the sexual consequences of POI. Whilst 3279 most studies acknowledge multiple factors, from hormonal to spiritual, there is a lack of commitment 3280 to collect quality information from socially diverse samples within a coherent inter-disciplinary 3281 framework. It is highly unlikely that any finding is generalizable to women across age groups and cultural 3282 and socio-economic conditions. Gender-equality issues and women's ability to sexually self-determine 3283 will profoundly shape their sexual outlook in relation to POI and generally.

There is an urgent need to develop a process of care based on the most recent model available for 3284 3285 managing women's sexuality (Parish et al., 2019), taking into account the number of mechanisms and 3286 factors able to characterize the relationship between POI and multiple aspects of sexuality. Basic 3287 counselling should be provided to uncover the topic and offer the basis for a multidimensional clinical 3288 interview that could be adapted to different categories of women with POI, stratified by age, diagnosis, partnership, and fulfilment of reproductive goals, general menopausal symptoms, attitudes and 3289 3290 compliance to treatments, and any other relevant intra-personal and inter-personal variable. Core competences should include the identification of the most common sexual problems that cause distress, 3291 including low sexual desire, difficulty with sexual arousal and with orgasm, sexual pain/genito-pelvic 3292 3293 pain, penetration dysfunction, medication-induced symptoms, and relationship conflicts. A diagnostic algorithm (see Figure 12) will provide guidance in the treatment and will help to understand when a 3294 3295 referral to sexual medicine specialists for specific care is needed.

3296 *Research recommendation.*

3297 Studies conducted in a multidimensional perspective are needed to assess sexual changes in women with 3298 POI and the entity of distress.

3299 A process of care specifically developed for women with POI presenting sexual symptoms is warranted. 3300

3301 IX.2. Management options

3302 **PICO QUESTION: WHAT ARE THE MANAGEMENT OPTIONS FOR THE EFFECTS OF POI ON** 3303 **SEXUALITY?**

3304 *General aspects*

A number of known and potential factors contribute to sexuality and sexual experiences, rendering 3305 3306 sexual difficulties as much psychosocial as physical, hence the often-used description 'psychosexual'. 3307 The most recent standard process of care for management of sexual concerns and problems in women 3308 (Parish et al., 2019), including HSDD (Clayton et al., 2018), describes a therapeutic algorithm based on a 3309 multidisciplinary approach with pharmacologic and non-pharmacologic management. This separation 3310 is mainly for didactic purpose keeping in mind that, basically, acquired generalized sexual dysfunction 3311 firstly requires a biomedical approach, whereas lifelong or situational sexual dysfunction firstly needs a 3312 psychosexual approach. Brief counselling offers emotional relief, education, and empowerment, and 3313 provides very simple strategies to cope with sexual symptoms (Al-Azzawi et al., 2010); therefore, it can



represent a first-line treatment in postmenopausal women, including those with POI. By replacing hormonal deficiencies, medical treatments aim to restore the neuroendocrine balance, which drives sexual desire, mental arousal, and satisfaction, and to maintain the urogenital response (genital arousal, lubrication, and orgasm) to sexual stimulatory clues (Nappi *et al.*, 2019). Non-pharmacological management includes multimodal physical therapies and cognitive behavioural and sexual therapies, alone or in combination for those women who may benefit from this approach (Nappi *et al.*, 2023a).

3320 Systemic Estrogens

3321 Estrogens are important for the health and function of the genitourinary system and preventing dyspareunia will affect sexual function and desire. The treatments for GSM are reviewed in IX.3. 3322 3323 Treatment of genital-urinary symptoms. Systemic estrogens may also be relevant for other components 3324 that contribute to sexuality, possibly affecting peripheral as well as central neurotransmission and 3325 neurovascular modulators and should be the first choice in women with POI without contraindications 3326 (Nappi et al., 2021). Women receiving estrogen therapy after opphorectomy reported better global 3327 sexual function but may require higher doses of estradiol replacement (Zilio Rech et al., 2019). Even in women with POI, after RRBSO due to a BRCA mutation without personal history of breast cancer, the 3328 3329 use of estrogen therapy for 1 year minimizes menopausal symptoms and sexual discomfort (Vermeulen 3330 et al., 2017). Another prospective observational study of 73 premenopausal women at elevated risk of 3331 ovarian cancer planning RRBSO and 68 premenopausal controls at population risk of ovarian cancer confirmed the adverse impact of surgery on several aspects of sexual function (arousal, lubrication, 3332 3333 orgasm, and pain), which may be mitigated by the use of estrogen therapy (Islam et al., 2021). However, 3334 after 1-year, sexual desire and satisfaction were unchanged in the RRBSO group compared with controls. 3335 Indeed, according to another study investigating women with POI due to RRBSO, sexual symptoms 3336 profile (vaginal dryness and low sexual desire) does not always improve suggesting that HT may alleviate but not resolve sexual difficulties (Moss et al., 2022). That being so, factors other than estrogens may 3337 influence sexuality in women with POI. A small Brazilian case-control study of 36 sexually active women 3338 with non-iatrogenic POI aged 18 to 40 years shows that following 12 months of systemic HT women 3339 with POI display significantly lower FSFI domain scores, in comparison with age-matched women with 3340 3341 normal gonadal function, despite having similar vaginal tropism and vaginal flora (Pacello et al., 2014). 3342 More sexual pain and poorer lubrication are present in treated POI women that score less on the vaginal 3343 health index (VHI), a clinical tool assessing vaginal mucosa elasticity, epithelial integrity, fluid secretion, 3344 pH, and hydration (Benetti-Pinto et al., 2015b). The same group has recently compared the use of 3345 perineal electrotherapy sessions versus local estrogen therapy (LET) with low dose estriol vaginal cream 3346 in estrogen-replete women with POI showing an improvement in global sexual function, lubrication, 3347 and pain domains for both treatments. Of note, there was no pre-/posttreatment difference for the 3348 desire and arousal domains, whereas both orgasm and satisfaction improved with perineal stimulation 3349 (Benetti-Pinto et al., 2020).

3350 It is very important to underline that systemic HT has been mainly investigated in early menopausal 3351 women or in presence of menopausal symptoms with evidence of a small benefit on sexual function 3352 (Meziou et al., 2023). Types of molecules and their metabolites, dose, and route of administration have 3353 to be considered to minimize the relative androgen insufficiency induced by exogenous estrogens, 3354 which may variably affect sex hormone binding globulin (SHBG) and free testosterone circulating levels 3355 (Nappi et al., 2022b). When compared to oral formulations, transdermal estradiol improved lubrication 3356 and pain, measured by FSFI to a higher extent, with no significant difference in overall score of sexual 3357 function (Taylor et al., 2017). The type and dose of combined progestogens add a further element of 3358 complexity due to the impact on SHBG. However, in absence of any evidence that the different 3359 androgenicity of progestogens plays a role in modulating sexual function, tolerability and safety should 3360 guide treatment choice (Nappi et al., 2022b). It is important to underline also the lack of clear evidence



3361 on the impact of combined hormonal contraception on sexuality of women with POI. In general, 3362 available evidence indicates that a minority of women experience a change in sexual functioning with 3363 regard to general sexual response, desire, lubrication, orgasm, and relationship satisfaction when assuming hormonal contraception (Both et al., 2019). Natural estrogens in some oral contraceptives 3364 3365 have a lesser effect on SHBG levels and, thus, exert a milder impact on androgen milieu (Nappi et al., 3366 2019). However, there is insufficient evidence to draw a clear algorithm for the management of 3367 hormonal contraception-induced sexual dysfunction in healthy women and, therefore, in women with 3368 POI.

3369 Systemic Testosterone and other androgenic compounds

Clinical research has focused almost exclusively on the use of testosterone for low sexual desire, even though the relationship between the two is not certain. This is as true for women in general as for those diagnosed with POI. The rationale is rooted in the decline of androgens over time and under certain circumstances (iatrogenic or non-iatrogenic POI) (Davis *et al.*, 2019).

A series of randomised, placebo-controlled trials of testosterone patches have been carried out, using 3374 300µg, daily for 24 weeks, in the form of a twice weekly patch worn on the abdomen (Shifren et al., 3375 2000, Braunstein et al., 2005, Buster et al., 2005, Simon et al., 2005, Davis et al., 2006, Shifren et al., 2006. 3376 Davis et al., 2008, Panay et al., 2010). Some of these studies were part of the Phase III trial program that 3377 3378 induced the European Medical Agency (EMA) to approve transdermal testosterone in surgically 3379 menopausal women with HSDD, whereas others were conducted in estrogen-replete and non-replete 3380 women with usual age menopause, and at premenopause. Overall, the effectiveness was clinically 3381 meaningful for improved sexual function as assessed by self-reports on psychometric scales and sexual activity logs alike, over and above a large placebo effect (Kingsberg et al., 2007). A point of controversy 3382 is that all studies involved short-term treatment and follow-up. Moreover, the most intensively studied 3383 population was one of Caucasian (and presumably heterosexual) women, making the evidence not yet 3384 3385 applicable to other populations. Adverse events of testosterone patches were reported as mild or 3386 minimal, rarely resulting in trial withdrawal, and no important changes in the safety or tolerability profile 3387 were revealed with long-term use for up to 4 years in a cohort of otherwise healthy women after BSO with HSDD on concomitant estrogens (Nachtigall et al., 2011). However, long-term health and harm on 3388 3389 a large scale remains unknown because testosterone patches prescribed in the trials are no longer 3390 available. A special consideration should be given to the occurrence of pregnancy in young POI women 3391 under testosterone treatment, even though the virilization risk to the foetus is minimal and occurs only 3392 in a very high hyperandrogenic state (Nappi et al., 2019). A recent Global Consensus Position Statement 3393 provides clear clinical guidance on the use of testosterone therapy in women (Davis et al., 2019), aiming 3394 to: (i) identify women that might benefit from testosterone therapy, (ii) to recognize symptoms, signs, 3395 and conditions without evidence for prescribing testosterone, (iii) to explore areas of uncertainty, and 3396 (iv) to avoid prescribing practices that have the potential to cause harm. Recommendations regarding 3397 the benefits and risks of testosterone therapy are based on findings of meta-analyses, which included 3398 blinded placebo/ comparator RCTs, of at least 12 weeks duration (Islam, et al., 2019). Available data 3399 support a moderate therapeutic effect for HSDD, with insufficient data to support the use of 3400 testosterone for the treatment of any other symptom or clinical condition, or for disease prevention. 3401 The International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use 3402 of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women further provides standards 3403 for safe prescription including identification of appropriate patients, dosing, and monitoring (Parish et 3404 al., 2021). Shared decision-making involves comprehensive discussion of off-label use of one-tenth of 3405 a standard male dose of 1% transdermal testosterone or about 300 µg/day, as well as benefits and risks. 3406 Indeed, only in Australia is a transdermal 1% testosterone cream available by prescription, approved in



- 2020 by the Australian Register of Therapeutics Goods for treatment of HSDD in postmenopausalwomen.
- 3409 In agreement with The Fourth International Consultation of Sexual Medicine conducting studies of 3410 testosterone therapy for women with POI presenting with desire and other sexual problems is desirable 3411 (Davis et al., 2016) and will offer the possibility to explore also other effects on general health (see XI.5. 3412 Testosterone Therapy). A large number of exclusion criteria were deployed in previous research with 3413 testosterone patches, which may restrict the applicability of the findings within clinical practice, where 3414 women with POI may present with a range of issues that have been excluded. However, it seems 3415 reasonable to offer a trial of testosterone therapy for women with POI who experience HSDD despite 3416 adequate HT for at least 6 months, monitoring testosterone levels to avoid supra-physiological exposure 3417 (Davis, 2021).
- 3418 Other androgenic compounds have been poorly investigated. Tibolone is a selective tissue estrogenic 3419 activity regulator, with some androgenic properties, approved in many countries for treatment of 3420 menopausal symptoms and for osteoporosis prevention (Baber et al., 2016). A recent Cochrane review 3421 on synthetic steroids, including tibolone, did not show clear beneficial effects on sexual function 3422 advocating the need for high quality studies in the investigation of HT (Lara et al., 2023). In a randomized crossover study involving women with iatrogenic POI (ovarian surgery), there were some signals that 3423 tibolone may improve sexual desire (in sexual subscale of the Greene Climacteric Scale) more than 3424 3425 estrogen therapy alone (Somunkiran et al., 2007). Whether this may translate in a larger sexual 3426 therapeutic effect of tibolone in women with natural POI is unknown.
- In line with the Global Consensus Position Statement (Davis *et al.*, 2019), systemic dehydroepiandrosterone (DHEA) administration does not have consistent beneficial effects for menopausal symptoms, sexual function, cognition, or overall wellbeing in the general female population.

3431 *Psychosexual management*

- A range of dedicated professional services exists to provide assessment and treatment of sexual 3432 3433 difficulties reported by men and women in the general population. This mirrors a broad acknowledgement of the role of complex interactions between the anatomical, physiological, 3434 3435 psychological, and social factors in sexual preferences, activities, experiences, and their interpretations. 3436 Currently there is a significant amount of discussion on what type of intervention works best, for what, 3437 in what way, and for whom. The biopsychosocial lens suggests the need for combined therapy and a 3438 mix of approaches (Kingsberg et al., 2017) keeping in mind that some women might respond better to 3439 one type of intervention over the others.
- Knowledge needs to improve significantly to enable women with POI to make a truly informed choice. Indeed, sex therapy has received scanty scientific attention in women and couples affected by natural POI, whereas it often addresses psychosexual consequences of sexual pain and low distressing desire in usual age menopause (Simon *et al.*, 2018b). Psychosexual approaches aim to expand on patients' anatomical, physiological, and sexual knowledge and attitudes. Cognitive and behavioural strategies further assist sexually distressed patients to overcome unhelpful thoughts and feelings and encourage realistic goals to overcome problems or access preferred experiences (ter Kuile *et al.*, 2010).
- Sexual counselling educational programs are effective in improving sexual dysfunction in postmenopausal women when compared to routine care (Santos Silva *et al.*, 2022). Evidence based techniques in sex therapy include sensate focus, cognitive behavioural therapy (CBT) and mindfulness, that may be useful to improve all domains of sexuality, including sexual pain and HSDD (Kingsberg *et al.*, 2017). A randomised controlled trial in 66 women carriers of the BRCA1/2 mutation who developed



3452 at least two moderate-to-severe menopausal symptoms after RRBSO 8-week of mindfulness-based stress reduction improves menopause-related QoL, but not sexual functioning or distress (van Driel et 3453 3454 al., 2019a). Another randomized study with mindfulness versus education on sexuality and aging shows 3455 that women aged ≥45 years with low libido report a significant reduction of sexual distress with 3456 mindfulness and no significant changes in sexual function according to the type of sex therapy (Thomas 3457 et al., 2023). A novel sexual health intervention, integrating elements of cognitive behavioural therapy with sexual health education, was tested in a single-arm trial in iatrogenic menopause (Bober et al., 3458 3459 2015). Women with BRCA1/2 mutations who previously underwent RRBSO showed significant 3460 improvement in overall sexual functioning, as well as desire, arousal, satisfaction, and pain. Sexual self-3461 efficacy and sexual knowledge also improved significantly from baseline to post intervention and 3462 women are highly satisfied with the intervention content and report utilizing new skills to manage sexual 3463 dysfunction. As in the gynaecological cancer population, both cognitive behavioural therapy and 3464 psychoeducation about sexuality and relationships can improve symptoms and sexual satisfaction in 3465 women with iatrogenic POI (Alexandre et al., 2017).

3466	Recommendation		
	The guideline group recommends personalised management biopsychosocial model for the effects of POI on sexuality.	using the	GPP
3467			
	Where available, transdermal testosterone therapy at physiological premenopausal levels can be considered as it may improve HSDD and sexual function.	⊕⊕⊖⊖	CONDITIONAL
3468			
	HCPs should be aware that although short-term treatment with transdermal testosterone at physiological premenopausal levels is safe, longer term safety data are lacking.	⊕⊕⊖⊖	STRONG
3469			
	HCPs should be aware that hormone therapy prescribed to women with POI for other indications may improve sexual function, although the effect is generally small.	⊕000	STRONG
3470	V		

3471 Justification

3472 There is a lack of agreement on the best strategy to improve sexual function in women with POI and 3473 therapeutic management should be on individual basis. The diverse presentations of sexual dysfunction 3474 are unique for each woman suggesting the need for combined therapy and a mix of pharmacological 3475 and non-pharmacological strategies. Adequate estrogen replacement, with additional local treatment if 3476 necessary for dyspareunia, is essential in women with POI and sexual dysfunction (see IX.3. Treatment 3477 of genital-urinary symptoms). Partnered (especially Caucasian) women who are medically and 3478 psychologically uncomplicated, who prior to POI had a satisfying sexual life and are currently distressed 3479 about low sexual desire despite adequate estrogen replacement, may benefit from at least a 6-month 3480 short-term trial of transdermal testosterone with dosing to maintain testosterone levels in 3481 premenopausal physiological range. The international consensus on the use of testosterone therapy in 3482 women (Davis et al., 2019) should guide clinical practice, with the clear understanding that long-term 3483 risks are unknown.



- For those who are refractory to hormone therapies and other women who have expressed a preference for non-medical interventions, which are so far under researched, low risk approaches such as psychosexual therapies may be of value and be more acceptable to a significant number of women with or without partners.
- 3488 *Research recommendation.*
- 3489 A better understanding on the effects of different type and dose of systemic estrogens alone or in 3490 combination with specific progestogens on sexuality of POI is warranted.
- 3491 Studies should evaluate the safety of testosterone when applied for a longer period (more than 6 months)3492 to improve sexual function in POI.
- 3493 More research is needed to understand the difference between iatrogenic and non-iatrogenic POI in terms 3494 of testosterone levels and testosterone treatments.
- 3495

3496 IX.3. Treatment of genital-urinary symptoms

3497 PICO QUESTION: WHAT TREATMENTS ARE AVAILABLE FOR GENITAL-ORINARY SYMPTOMS IN
 3498 POI?

3499 General aspects

- Prolonged low levels of estrogens may lead to vulvovaginal atrophy (VVA), which is now part of genitourinary syndrome of menopause (GSM), a new definition encompassing a multitude of signs and symptoms related to genital, sexual and urinary health (Gandhi *et al.*, 2016). Even the decline of androgens plays a role given the presence of androgen receptors in the urogenital sinus and vaginal canal (Simon *et al.*, 2018b).
- The real epidemiology of genitourinary symptoms in non-iatrogenic POI has not been reported. A recent 3505 3506 systematic review (Mili et al., 2021) on the prevalence of GSM symptoms (range 13%-87%) and its treatment (range 13-78%) included only one Spanish study out of 27 in which menopausal women were 3507 3508 also under 40 years of age. This study reports up to 70% of postmenopausal women consulting the gynaecologist for GSM symptoms (vaginal dryness, irritation, itching, and dyspareunia) (Moral et al., 3509 3510 2018). latrogenic POI seems especially associated with a significantly higher rate of VVA/GSM (Kingsberg et al., 2020). A multitude of biopsychosocial factors is present in women after BSO, cancer 3511 3512 survivors and in those undergoing risk reducing surgery. However, the endocrine insult deriving from 3513 surgery or chemotherapy, or radiotherapy plays a crucial role in the adverse effects on genitourinary 3514 health (Crean-Tate et al., 2020). According to a recent systematic review, there is insufficient evidence 3515 to confirm that menopause is associated with urinary symptoms. The authors suggest that prospective 3516 studies of urinary symptoms after POI may help clarify the extent to which age or the endocrine changes 3517 of menopause contribute to urinary symptoms in this population (Christmas et al., 2023).
- 3518 A diagnosis of GSM combines the presence of subjective distressing symptoms with some objective 3519 signs that may be scored with validated scales to assess severity of the clinical condition and to monitor 3520 response to treatment. Despite available effective and safe treatments, research findings consistently 3521 show an unmet need in the management of VVA/GSM, requiring a proactive attitudes of health care 3522 providers (HCPs) to ensure compliance to chronic treatment (Shifren, 2018). More research is needed into the pathophysiology of VVA/GSM to explain variability of signs and symptoms across age groups 3523 3524 and in dependence of specific risk factors that may affect the genitourinary environment (e.g., 3525 microbiota, immune system) (Stabile et al., 2023).



3526 Data about therapies specifically investigated in women with non-iatrogenic POI and VVA/GSM are 3527 lacking and evidence for practice derived from menopause at usual age (Nappi et al., 2019) or from 3528 cancer survivors (Biglia et al., 2015). Whenever possible, women with POI should start systemic HT but this may not be enough to relieve genitourinary symptoms (Panay et al., 2020). In this case, vaginal non-3529 3530 hormonal and hormonal treatments, as well as other strategies may be added or selected with the 3531 specific purpose to alleviate symptoms and restore genitourinary tissues according to current 3532 international guidelines and local availability (Sturdee et al., 2010, The 2020 genitourinary syndrome of 3533 menopause position statement of The North American Menopause Society, 2020, Hirschberg et al., 3534 2021).

3535 Systemic therapy

Systemic hormone therapy (HT) relieves VVA/GSM symptoms in many postmenopausal women but not all. It has been calculated that in about 25% of them a combination of systemic and local therapy may be required initially to manage the condition (Sturdee *et al.*, 2010). In postmenopausal women with VVA/GSM on clinical examination, systemic HT reduced the incidence of urinary tract infections when compared with placebo (Marx *et al.*, 2004). However, systemic HT does not seem to improve urinary symptoms, including urinary (Christmas *et al.*, 2023) or faecal incontinence (Staller *et al.*, 2017).

A study including 149 patients with POI and 303 control women with similar age, BMI, and parity showed 3542 3543 that the prevalence of stress urinary incontinence (SUI) is quite high among patients with POI, without 3544 an influence of duration of POI and use of systemic HT. Although data do not support an association 3545 between SUI and POI, the study points to the need to increase awareness about the importance of urinary system health in QoL of women with POI (Tan et al., 2018). In a secondary analysis of a cross-3546 sectional study that aimed to study the prevalence of pelvic floor disorders in women with POI, systemic 3547 3548 HT did not modify pelvic floor muscle assessment scores but seems to improve some pelvic floor and urinary symptoms (Fante et al., 2020). 3549

POI is likely to occur in women following high dose chemotherapy and radiotherapy required for 3550 3551 haematopoietic stem cell transplantation (HSCT). If medically stable, they are candidate to systemic HT and to regular gynaecological follow-up to prevent severe clinical signs and genital tract malignancies 3552 (Brennan and Hickey, 2017). Graft-versus-host disease (GVHD) is the main complication of allogeneic 3553 3554 HSCT and can affect the genital tract causing vaginal bleeding, dyspareunia, synechia, and even 3555 complete vagina occlusion (Machado et al., 2022), overlapping with VVA/GSM symptoms. An early study of 31 women with POI after HSCT showed that 54% of them have symptoms of VVA (vaginal dryness, 3556 3557 burning sensation, and dyspareunia), 42% have urinary tract symptoms (dysuria, urinary frequency, mild urinary incontinence) and almost 100% display signs of genital atrophy. With systemic HT (various 3558 3559 preparations were used), there is a rapid improvement of vulvovaginal atrophy and resolution of 3560 associated symptoms in half of the study sample (Piccioni et al., 2004).

- 3561 Ospemifene (SERM)
- The use of a selective estrogen receptor modulators (SERMs), such as ospemifene, for relief of genitourinary symptoms in women with POI has not been studied (Palacios *et al.*, 2023b). In view of the absence of data, there is no indication for this treatment in women with POI (Nappi *et al.*, 2021).

3565 Local therapies

3566 Vaginal lubricants, moisturizers, and other substances

Vaginal lubricants and moisturizers are available over the counter, but their chemical composition can vary significantly in pH, osmolality, and additives. They should be body similar to avoid irritation and minimize the risk of epithelial damage. These strategies may be used when there is a need for local treatment where (i) systemic HT is contraindicated, as in iatrogenic POI, secondary to treatment for



3571 estrogen sensitive cancer (ii) in women who are averse to HT or (iii) still experience genitourinary 3572 symptoms despite an appropriate HT dose. Lubricants can either be water, silicone or oil-based and are 3573 used prior to intercourse. They have been shown to relieve symptomatology of vaginal dryness and 3574 dyspareunia but also to enhance overall sexual satisfaction (Palacios et al., 2023a). Moisturizers are 3575 longer lasting than lubricants and rehydrate tissues mimicking vaginal secretions (Cox and Panay, 2023). 3576 Hyaluronic acid-based moisturizers have been studied both in healthy and in high-risk women or 3577 survivors. Its strong water-binding properties provide lubricating and moisturizing effects, which 3578 contribute to maintaining a proper level of hydration and viscoelasticity in genitourinary tract. A review 3579 of available clinical data confirms its efficacy on signs and symptoms of VVA/GSM when regularly 3580 vaginally applied (Nappi et al., 2022a). Other substances (oxytocin, polycarbophil, probiotics, herbal 3581 products, phytoestrogens, and vitamins) have been tested in local products for GSM symptoms, but 3582 more research is needed (Cox and Panay, 2023, Farahat et al., 2023, Radnia et al., 2023). The use of 3583 topical 4% aqueous lidocaine applied for 3 minutes before vaginal intercourse may be particularly 3584 effective for dyspareunia related to introital pain as compared to placebo (Faubion et al., 2018).

3585 Local estrogen therapy

Local estrogen therapy (LET) includes many vaginally administered products approved with the 3586 indication to treat symptomatic VVA because GSM is a novel heterogeneous clinical entity. Different 3587 formulations (tablets, rings, capsules, pessaries, creams, gels, and ovules) and molecules (estradiol [E2], 3588 3589 estriol [E3], promestriene, conjugated equine estrogens [CEE] and estrone [E1]) are available displaying 3590 a class effect (Nappi et al., 2023b). Indeed, the last Cochrane review in 2016 concluded that approved LET are all similarly effective in relieving vaginal dryness and dyspareunia, thus the choice should 3591 3592 consider patient's preference (Lethaby et al., 2016). Low-dose and ultra-low-dose LET is the gold standard due to its minimal systemic absorption and should be continued at the appropriate dose to 3593 relieve symptoms for as long as needed. When needed, LET can be used in association with systemic 3594 HT (Sturdee et al., 2010). Long-term LET safety data show cardiovascular and oncological neutrality but 3595 3596 special attention should be paid to women with iatrogenic POI due to hormone-sensitive malignancies. 3597 At present, in terms of recurrence risk, particularly in breast cancer survivors, who may present with 3598 severe symptoms associated with the use of anti-estrogenic therapies, especially aromatase inhibitors, a tailored counselling and a shared decision with the oncologist represent the standard of care (Faubion 3599 et al., 2018). A recent systematic review and meta-analysis confirms caution related to cancer recurrence 3600 and points to the importance of keeping serum estradiol levels at the lowest possible concentration 3601 3602 with the use of low dose LET (Comini et al., 2023).

- LET improves dysuria, frequency, urge incontinence, stress incontinence, and recurrent urinary tract infections in menopausal women (Christmas *et al.*, 2023). Even though LET is not a "universal fix" in the urologic setting, it is the first step in managing many of the effects of GSM in the urinary tract (Wasserman and Rubin, 2023).
- In women with POI after allogeneic hematopoietic cell transplantation, early LET is effective in reducing
 in vaginal dryness, dyspareunia and prevent the occurrence of severe tissue consequences (Klasa *et al.*,
 2020).
- 3610 Local androgens
- Intravaginal DHEA, also known as prasterone, is approved with the indication to relieve signs and symptoms of moderate-severe VVA with some benefits to sexual function and urinary function. Being a pro-hormone with an intracrine estro-androgenic intracellular action and only a minimal amount of steroid metabolites entering the circulation, it has a safety profile potentially suitable for women at high cancer risk or even for cancer survivors but well conducted studies are needed (Crean-Tate *et al.*, 2020) with validated assessment tools to better establish the efficacy, safety and cost effectiveness of
- 3617 intravaginal DHEA (Kearley-Shiers et al., 2022). Use of local androgens are potential treatments in the



setting of concurrent aromatase inhibitors as aromatization to estradiol would be prevented In these patients, intravaginal testosterone cream shows efficacy to reduce dyspareunia and vaginal dryness and improve sexual function compared to placebo over a 24-week period, without significant changes in circulating sex steroids (Davis *et al.*, 2018).

3622 Physical therapy

Physical therapy may be useful for several pelvic conditions, such as VVA/GSM, prolapse, vaginal laxity, incontinence, and may be combined with psychosexual education and other sex therapies. It ranges from use of vaginal dilators in women with severe dyspareunia (Faubion *et al.*, 2018) to vibrators that may increase sensation and engorgement, and to muscle exercises that may reduce pelvic floor dysfunctions and GSM, improving both perfusion and tonicity of pelvic tissues (Mercier *et al.*, 2023).

3628 Lasers and other thermal energies

In recent years, energy-based therapies, including laser (micro ablative fractional CO₂ and non-ablative erbium laser) and radiofrequency technologies, have been proposed as an alternative to pharmacological treatment for GSM in healthy women and in women with contraindications to standard treatment, such as breast cancer survivors (Cucinella *et al.*, 2023). A recent pilot sham-controlled study with a novel home-use therapeutic ultrasound device for the treatment of vaginal dryness showed efficacy and safety, holding promise for postmenopausal women with VVA/GSM symptoms (Hickey *et al.*, 2023).

A systematic review and meta-analysis of RCTs found that vaginal laser treatment is associated with 3636 similar improvement in genitourinary symptoms as LET (Jang et al., 2022b). A RCT comparing 3637 intravaginal laser therapy and hyaluronic acid suppositories showed that both options are effective for 3638 3639 breast cancer women suffering from genitourinary symptoms with no differences between treatment regimens (Gold et al., 2023). However, among women with postmenopausal vaginal symptoms, 3640 3641 treatment with fractional CO₂ laser vs sham treatment did not significantly improve vaginal symptoms 3642 after 1 year (Li et al., 2021b). In another prospective double-blind sham controlled RCT with 6 months of follow-up, CO₂ laser treatment was found to be safe, but no statistically significant differences in 3643 3644 efficacy were observed between active therapy and sham laser therapy (Mension et al., 2023). Therefore, 3645 caution and points of controversies still exist on efficacy versus less invasive measures, long-term effects 3646 and costs, and laser technology cannot be recommended as a standard of practice.

3647 Other local approaches

In a small cohort bi-centric pilot study, multi-point vaginal intra-mucosal injections with a crosslinked 3648 hyaluronic acid may stimulate collagen formation improving VVA symptomatology and sexual function 3649 3650 without modifying the vaginal mucosal thickness (Berreni et al., 2021). Topical growth factors with the 3651 aim to activate collagen and elastin at a molecular level, and thus restore all vaginal functions such as 3652 secretion, absorption, elasticity, lubrication, and vaginal epithelium thickness deserve attention in well-3653 designed studies (Isaza, 2019). In the meantime, HCPs and women are waiting for bioengineering 3654 techniques in regenerative medicine with stem cells tested in the preclinical model (Francés-Herrero et 3655 al., 2022), all these approaches in female reproduction should still be considered experimental in the 3656 clinical setting.

3657 Recommendation

HCPs should offer local estrogen therapy (LET) to improve genital, ecological estrogen therapy (LET) estrogen

STRONG

3658



CONDITIONAL

3659

3660

The guideline group recommends that laser or thermal energy is not currently considered standard care for genitourinary syndrome of menopause (GSM) due to the lack of clear benefit in RCTs

GPP

3661 Justification

3662 Hypoestrogenism plays a crucial role in the clinical manifestation of genitourinary symptoms with a 3663 significant impact on QoL and sexual health. Symptoms are highly prevalent but the exact number of women with POI affected is not known. HCPs should be proactive in discussing genitourinary health 3664 because GSM is highly prevalent and undertreated, as women may not volunteer such symptoms. 3665 Vaginal lubricants, moisturizers, and menopause hormone therapy (both systemic and local) can be 3666 used to treat genitourinary symptoms. Vaginal lubricants and moisturizers may be used when there is a 3667 3668 need for local treatment and systemic treatment is contra-indicated, or if women still experience 3669 genitourinary symptoms despite an appropriate dose of hormone therapy. Women with POI have not been considered in clinical trials for investigating the effects of local and systemic menopause hormone 3670 3671 therapy on GSM.

3672 Research recommendation.

3673 More research conducted specifically in women with POI is needed on hormonal approaches for 3674 genitourinary symptoms.

- 3674 genitourinary symptoms.
- 3675 Studies should explore the efficacy and safety of laser therapy and other non-hormonal approaches to
- 3676 relief genitourinary symptoms in women with POI, especially in those with contraindications to vaginal
- 3677 *estrogen*.



3678 X. POI and neurological function

3679 Neurological function was defined for the purpose of this review as cognitive impairment and dementia, 3680 parkinsonism and Parkinson's disease, and restless leg syndrome. By contrast, stroke was discussed as part of cardiovascular health following POI (see VII. POI and cardiometabolic health). A rapidly growing 3681 3682 body of studies have directly investigated the long-term effects of both spontaneous and iatrogenic 3683 POI on neurological function. Many of these studies involved women who underwent premenopausal 3684 bilateral oophorectomy. Interestingly, bilateral salphingo-oophorectomy (BSO) was the most common 3685 cause of POI in a US study for the period 1988-2007 (Rocca et al., 2023). The same pattern is expected 3686 to hold for many other countries; however, a decline in the frequency of oophorectomy over time has 3687 been reported in recent years (Erickson et al., 2022).

- 3688 This chapter is not addressing neurological function in women who experience POI in the context of a 3689 genetic disorder because it remains unclear whether the neurological manifestations observed are related to the premature deprivation of ovarian hormones (POI per se) or to the underlying 3690 3691 chromosomal or genetic condition. In these genetic disorders, POI is only one of several manifestations of the disease. The neurological manifestations may precede, accompany, or follow the development of 3692 3693 POI and generally do not respond well to estrogen treatment. For example, women with Turner 3694 Syndrome may have characteristic neurocognitive and psychosocial differences, including visuo-spatial and perceptual changes that are relatively estrogen-resistant, whereas other neurocognitive effects may 3695 respond at least in part to estrogen. In women who are carriers of the Fragile X premutation, there is a 3696 risk of developing Fragile X-associated tremor/ataxia syndrome (FTAS), which may affect about 16% of 3697 3698 women. Readers are referred to specific literature and guidelines concerning neurological function and 3699 long-term sequelae in women affected by these genetic disorders (Ross et al., 2000, Hutaff-Lee et al., 3700 2019, Cabal-Herrera et al., 2020, Gravholt, 2024).
- The focus of this chapter is on the long-term sequelae of the hormonal deprivation caused by POI rather than on acute changes in cognitive function (e.g., memory) caused by iatrogenic POI.

3703 X.1. Impact of POI on neurological function

 3704
 PICO QUESTION: WHAT ARE THE CONSEQUENCES OF POI ON COGNITION/NEUROLOGICAL

 3705
 FUNCTION?

3706

3707 Cognitive impairment and dementia after non-iatrogenic POI

3708 A number of authors have investigated the association between earlier age of menopause and risk of 3709 dementia or cognitive impairment (measured by cognitive tests). A 2016 systematic review and meta-3710 analysis identified thirteen studies of adequate quality. (Georgakis et al., 2016). Unfortunately, the 3711 studies showed a wide variability in study design (case-control studies, cross-sectional studies, and 3712 cohort studies), in the outcome measured (clinically defined dementia, dementia on death certificates, 3713 clinically defined Alzheimer's disease, Alzheimer's disease on death certificates, and severe cognitive 3714 impairment measured by cognitive tests), and in the number of confounding variables considered (level 3715 of adjustment). Finally, and important for this chapter, the cut-off point used to separate earlier onset menopause from later onset menopause varied greatly. Only one study used the cut-off of \leq 40 year 3716 3717 that would directly relate to POI (Ryan et al., 2014). The authors contrasted later menopause to earlier 3718 menopause; therefore, the measures of association were reported in the opposite direction (decreased 3719 risk with later menopause rather than increased risk with younger menopause). Overall analyses did not 3720 show a significant decreased risk of dementia or of Alzheimer's disease in women who experienced a



3721 later menopause. However, the analyses showed a significant decrease in cognitive impairment3722 (Georgakis *et al.*, 2016).

A later systematic review focused on ten studies and used the cut-off of <45 vs. \geq 45 years. The authors reported a decreased risk of all-cause dementia for menopause at age \geq 45 years compared to <45 years. The association followed a linear trend by which the older the age of menopause, the lower was the risk of all-cause dementia. There was also a significant decrease in risk for Alzheimer's disease and vascular dementia considered separately. Finally, there was a decrease in risk of cognitive impairment (Fu *et al.*, 2022).

A 2022 study based on the UK Biobank reported an increased risk of all-cause dementia when comparing spontaneous menopause before age 47 years with spontaneous menopause at age 50 years (Gong *et al.*, 2022). A 2023 study based again on the UK Biobank provided more detailed analyses by age of menopause. The risk of all-cause dementia was increased both for premature spontaneous menopause (HR 1.4; 95% CI 1.0 to 1.8; age \leq 40 years) and for early spontaneous menopause (HR 1.2; 95% CI 1.0 to 1.4; age 41-45 years) compared to women with menopause at ages 46-50 years (Hao *et al.*, 2023).

In addition, a 2023 study from the Wisconsin Registry for Alzheimer Prevention reported imaging analyses suggesting that younger age of menopause compared with later age of menopause may be associated with higher regional tau deposition in the brains of women with elevated _β-amyloid deposition. The affected brain regions included medial and lateral regions of the temporal and occipital lobes. Women with both non-iatrogenic and iatrogenic menopause were included in that study

3741 (Coughlan *et al.*, 2023).

In summary, because of the age cut-off used in most studies, the relevance of these results to the question addressed in this chapter is limited. Only two studies used the age cut-off of \leq 40 years which is approximately equivalent to the definition of POI (<40 years) (Ryan *et al.*, 2014, Hao *et al.*, 2023).

3745 Cognitive impairment and dementia after iatrogenic POI

A 2019 systematic review and meta-analysis on cognitive outcomes after bilateral oophorectomy 3746 3747 identified eleven studies of adequate quality (Georgakis et al., 2019). The studies showed wide variability in the outcome measure used. Some studies considered dementia as an overall clinical diagnosis; other 3748 3749 studies measured cognitive performance on one or several cognitive tests cross-sectionally (at only one 3750 point in time during follow-up). Other studies followed women for a number of years and measured 3751 cognitive decline over time. Finally, one study considered neuropathologic lesions in women who died 3752 during the follow-up (senile plagues and global pathology score)(Bove et al., 2014). In addition, major 3753 heterogeneity across studies related to the timing of oophorectomy. When oophorectomy was 3754 considered at any age, there was no association with dementia; however, oophorectomy was associated 3755 with a decline in verbal memory, semantic memory, and processing speed. When analyses were 3756 restricted to women who underwent BSO at age 45 years or younger (corresponding to POI or early 3757 menopause), oophorectomy was associated with a 70% increased risk of dementia (HR 1.7; 95% CI 1.1 3758 to 2.7; based on two studies). In addition, oophorectomy was associated with a decline in global 3759 cognition and semantic memory (based on one study)(Georgakis et al., 2019). Several studies were 3760 published after the systematic review.

In 2021, a case-control study showed an increased risk of mild cognitive impairment (MCI) associated with bilateral oophorectomy performed at age 45 years or younger (OR 2.2; 95% CI 1.4 to 3.5)(Rocca *et al.*, 2021a). The association varied by surgical indication (stronger in women with a benign ovarian indication). In 2021, the same Mayo Clinic group also reported a cross-sectional study of bilateral oophorectomy and cognitive performance measured using nine cognitive tests in four cognitive domains. Bilateral oophorectomy at age 45 years or younger was associated with lower performance in



global cognition, attention, and executive function, and on a short test of mental status. The association
was particularly strong for women who had the oophorectomy before age 40 years (corresponding to
POI) (Rocca *et al.*, 2021a).

3770 In 2022, another study was published from the Danish Nurse Cohort Study. However, the study had 3771 limited power to test the association, and the relative risk for dementia was not statistically significant 3772 (Uldbjerg et al., 2022). A second case-control study of MCI was reported in 2022 from a collaboration 3773 of six countries in Latin America. Bilateral oophorectomy at any age was associated with increased risk 3774 of MCI (OR 1.6; 95% CI 1.1 to 2.2) (Blümel et al., 2022). A 2023 study based on the UK Biobank confirmed the increased risk of all-cause dementia and of Alzheimer's disease following bilateral oophorectomy at 3775 3776 age ≤40 years compared to age 46-50 years (Hao et al., 2023). Finally, a 2023 systematic review 3777 confirmed the association of bilateral oophorectomy before age 45 years with increased risk of dementia 3778 (Hassan et al., 2024).

- In summary, bilateral oophorectomy performed before menopause at age 45 years or younger is
 associated with an increased risk of cognitive decline (measured by cognitive tests), MCI, and dementia.
- 3781 However, the timing of oophorectomy is crucial in predicting the risk.

3782 Parkinsonism and Parkinson's disease after iatrogenic POI

Because Parkinson's disease is relatively uncommon, several studies have considered the broader group 3783 3784 of patients with parkinsonism (the syndrome including Parkinson's disease). We do not have a 3785 systematic review of the literature for premature or early bilateral oophorectomy and parkinsonism. 3786 However, a recent paper by Rocca and colleagues included a review of nine studies (Rocca et al., 2022). 3787 The studies used different methods and different definitions of the outcome. Five studies used the casecontrol design whereas the remaining four studies used a cohort study design. Five of the nine studies 3788 provided evidence in favour of an association but four did not. The reasons for the discrepant findings 3789 remain partly unclear (Rocca et al., 2022). A 2017 meta-analysis of reproductive risk factors for 3790 3791 Parkinson's disease did not focus on premature and early oophorectomy but rather on surgical 3792 menopause at any age (including both hysterectomy and BSO). The authors suggested that surgical 3793 menopause may be associated with a decreased risk of Parkinson's disease after adjusting for coffee 3794 intake or for smoking. However, the authors reported an increased risk of Parkinson's disease in studies 3795 that did not adjust for smoking (Ly et al., 2017). The timing of oophorectomy is crucial in predicting the 3796 risk. Not surprisingly, some studies that lumped hysterectomy and oophorectomy at all ages reported 3797 contradictory results,

- The 2022 study by Rocca and colleagues was a cohort study of 2,750 women with oophorectomy and 2749 referent women. In women who were age 43 years or younger at oophorectomy (first tertile) the risk was increased for both parkinsonism (HR 7.7; 95% CI 1.8 to 33.3) and Parkinson's disease (HR 5.0; 95% CI 1.1 to 22.7). The number needed to harm was 27 women for parkinsonism and 48 women for Parkinson's disease. In addition, there was a significant trend of increasing risk with younger age at oophorectomy for parkinsonism (Rocca *et al.*, 2022).
- Two studies were published after the review in the Rocca and colleagues' paper. In 2022, another casecontrol study from Egypt confirmed the association (Ibrahim *et al.*, 2022). Finally, in 2023, another cohort study from France confirmed the association (Pesce *et al.*, 2023).
- In summary, the evidence from a total of eleven studies is reasonably strong to support an association between premature or early oophorectomy and the risk of parkinsonism or Parkinson's disease. Out of a total of eleven studies, seven provided supporting evidence. However, some studies that grouped hysterectomy and oophorectomy at all ages, reported contradictory results.
- 3811



3812 Other neurological diseases after iatrogenic POI

In 2021, Huo and colleagues reported a significant association between bilateral oophorectomy before usual age menopause and restless leg syndrome (HR 1.4; 95% Cl 1.1 to 1.9)(Huo *et al.*, 2021). As of today, this association has not been replicated. Several studies investigated the long-term risk of stroke

3816 after POI or bilateral oophorectomy (Hassan *et al.*, 2024). However, the studies are discussed in chapter

3817 VII. POI and cardiometabolic health.

3818 **Recommendation**

HCPs should be aware that earlier age of menopause is associated with an increased risk of dementia.

3819

The guideline group recommends that HCPs implement appropriate preventive actions for the consequences of POI on neurological function

3820

The possible detrimental effect on cognition and the increased risk of dementia, parkinsonism, and other neurologic diseases should be discussed when planning a bilateral oophorectomy under the age of 45 years, especially for women at average risk of ovarian cancer. STRONG

3821

3822 Justification

Although the cut-off age used to separate early menopause from late menopause varied across studies, there is adequate evidence that younger age of menopause (either spontaneous or iatrogenic) is associated with increased risk of dementia, parkinsonism, and possibly other neurological diseases. These findings should apply also to POI.

3827

3828 X.2. Management options

3829

3830

PICO QUESTION: WHAT ARE THE MANAGEMENT OPTIONS FOR THE EFFECT OF **POI** ON COGNITION/NEUROLOGICAL FUNCTION?

3831 3832

Long-term estrogen replacement therapy for cognitive impairment and dementia afterPOI

There are no clinical trials examining the long-term effects of estrogen replacement therapy (ERT) on 3835 3836 neurological function after spontaneous or iatrogenic POI. The evidence available comes primarily from 3837 observational studies of women who underwent premenopausal bilateral oophorectomy. The 3838 systematic review by Georgakis and colleagues did not consider the effect of hormonal treatment. 3839 (Georgakis et al., 2019). In 2007, the Mayo Clinic Cohort Study of Oophorectomy and Aging showed a 3840 lower risk of cognitive impairment or dementia in women who underwent oophorectomy and received 3841 ERT (HR 0.8; 95% CI 0.3 to 2.5) compared to women who did not receive ERT (HR 1.9; 95% CI 1.3 to 2.8). 3842 Even though the difference was not statistically significant, it was clinically important (Rocca et al., 2007). 3843 This protective effect of ERT was confirmed seven years later by another US study. Longer duration of 3844 hormone use was associated with slower decline in global cognition when ERT was administered within 3845 the 5-year perimenopausal window (Bove et al., 2014). In 2014, the French Three-City Study showed a 3846 beneficial effect of ERT in women who underwent POI (defined as age ≤40 years). In that study, both



- spontaneous and iatrogenic POI were considered separately (Ryan *et al.*, 2014). Finally, in a 2023 study based on the UK Biobank, the women with spontaneous menopause at age \leq 45 years who did not receive ERT had a higher risk of all-cause dementia and Alzheimer's disease compared to women who received therapy. The difference was significant for Alzheimer's disease (Hao *et al.*, 2023).
- Some more recent studies focused on MCI. A 2021 case-control study of bilateral oophorectomy and risk of MCI did not show a significant effect of ERT therapy (Rocca *et al.*, 2021a). By contrast, ERT was beneficial for preventing MCI in the Latin America case-control study published in 2022 (Blümel *et al.*, 2022).
- 3855 The beneficial effect of ERT in women who experienced POI or early menopause is consistent with the 3856 timing hypothesis. The timing hypothesis is supported by observational clinical data, some clinical trial 3857 data, and by animal research data. The hypothesis suggests that the effects of estrogens are most beneficial when initiated around the usual age of menopause but may become neutral or detrimental if 3858 initiated further away from menopause (Rocca et al., 2014). The timing hypothesis was introduced to 3859 3860 explain the contradictory findings from the Women's Health Initiative randomized clinical trials as 3861 compared to findings from previous observational studies (Gleason et al., 2015, Henderson et al., 2016). 3862 However, the focus of the Women's Health Initiative trials was on the majority of women who underwent spontaneous menopause within the normal age range (approximately 45-54 years). For women who 3863 experienced POI or early menopause, both spontaneous and iatrogenic, the age at onset of ERT is 3864 shifted farther to younger ages (age <40 years or 40-44 years), and the protective effect is expected to 3865 3866 be more pronounced (Rocca et al., 2021b).
- 3867 Long-term estrogen replacement therapy for other neurologic diseases after POI
- The studies of the association between oophorectomy and parkinsonism or Parkinson's disease 3868 reviewed above did not have adequate power to test for differences in strata with and without ERT. The 3869 study by Rocca and colleagues reported a lower risk in women who underwent oophorectomy at age 3870 45 years or younger and received ERT compared to women who did not for both parkinsonism and 3871 3872 Parkinson's disease. However, the differences were not statistically significant (Rocca et al., 2022). The 3873 analyses for restless leg syndrome did not suggest a beneficial effect of ERT (Huo et al., 2021). In summary, the evidence for the effect of ERT on the long-term risk of other neurological diseases remains 3874 3875 inconclusive.
- 3876

Recommendations

3877

Hormone replacement therapy to reduce the possible risk of cognitive impairment and the risk of dementia, parkinsonism and other neurologic diseases is recommended in women with POI at least until the usual age of menopause.

3878

Hormone replacement therapy may be recommended for neurological function even in the absence of menopausal symptoms, as HRT is for cardiovascular and bone health.

3879

The guideline group recommends that women with POI should be advised to maintain a healthy lifestyle, involving exercise, healthy diet, avoidance of smoking, and maintenance of normal body weight to reduce possible risks for cognitive impairment.



3880

3881 Justification

Several long-term cohort studies or case-control studies suggest that women with POI caused by oophorectomy who did not receive ERT had accelerated cognitive decline and an increased risk for dementia and possibly other neurologic diseases compared to women who received ERT. Some of the inconsistent findings may be explained by differences in study design, quality of the data, lack of stratification by age at oophorectomy, inadequate length of follow-up to detect dementia or other diseases, or lack of data on hormone treatment. Two studies confirmed a protective effect of ERT also after non-iatrogenic POI.

The majority of these observational studies suggest that ERT until the approximate average age of spontaneous menopause may be beneficial for cognitive function and other neurologic outcomes in women who have undergone a premature or early menopause. By contrast, hormone treatment initiated at an older age (>60 years of age) may confer added risk for dementia and vascular disease (2022). Because the intention of treatment is to replace the hormones that have become prematurely insufficient, the treatment should be independent from the development of menopausal symptoms. Both women with and without menopausal symptoms should be treated.

There is no evidence of adverse effects on brain function of ERT therapy before the usual age of menopause, but this may not be true after the average age of spontaneous menopause. Hormone treatment should probably be part of a lifestyle change to reduce risk for vascular disorders associated with age-related cognitive impairment and dementia, such as lowering abdominal fat, hypertension, hyperlipidaemia, and insulin resistance risk in midlife by cessation of smoking, exercising, and eating a healthy diet (Clifford, 2009).

3902 Research recommendation.

3903 Research is needed to further clarify the pathogenetic mechanisms mediating the effects of POI, both non-

iatrogenic and iatrogenic, on adverse neurological outcomes including cognitive decline and dementia. In

addition, further research is needed to confirm the beneficial effects of ERT in women who underwent POI,

3906 both with and without menopausal symptoms.

3907



XI. POI Treatment: Hormone Therapy 3908

3909 This chapter focuses on treatment with sex steroids such as Hormone Replacement Therapy (HRT) and the Combined Oral Contraceptive Pill (COC) for women with POI. 3910

3911 A summary of the principles and indications for use of HT in POI is provided, with reference to other 3912 chapters where relevant. A review of possible risks and adverse effects of HT use in women with POI 3913 then follows. The next section reviews the options for existing preparations including details about 3914 regimens, routes of administration, dosage, and recommendations of treatment duration. The final parts 3915 of the chapter cover the role of testosterone therapy in POI, and specific considerations for hormone 3916 therapy in iatrogenic POI.

XI.1. Hormone therapy in POI – Principles and indications 3917

3918	Principles of HT					
3919	• The aim of HT is to approximate physiological replacement .					
3920	 If the uterus is present, combined therapy with estrogen with a proget 	stogen is require	ed.			
3921	• Non oral delivery of estrogen avoids first pass hepatic effects e.g., thr	ombotic effects.				
3922	• Estrogen doses required are usually higher than those for women at	usual age of mer	nopause,			
3923	reflecting the physiological environment in younger women and dose	-				
3924	mineral density (BMD)	·				
3925	Pragmatic aspects					
3926	• There are few prospective RCT data for specific HT regimens regard	ling symptom rel	ief, QOL			
3927	and prevention of bone loss.					
3928	 Doses of estrogen and progestogen (including progesterone) are usu 	• Doses of estrogen and progestogen (including progesterone) are usually decided based on the				
3929	basis of the principles of HT [as above] rather than good quality evidence.					
3930	• The availability and cost of HT regimens vary immensely from region to region and country to					
3931	country.	country.				
3932	• The choice of regimen often varies according to patient preference	• The choice of regimen often varies according to patient preference e.g., desire for pregnancy				
3933	versus contraception, to optimise adherence and peer friendliness	rather than evide	ence for			
3934	effectiveness and safety.					
3935	Indications for HT in POI					
3936	The sequelae of POI and the possible benefit of HT for each of them has been outlined in the respective					
3937	chapters and summarised in Table III Summary of Indications for HT in women with POI.					
3938	Recommendations					
	Women with POI should be advised that hormone therapy is recommended for the preservation of bone, cardiovascular and brain health.	⊕⊕OO st	RONG			
3939						
	Women with POI should be advised that hormone therapy is	⊕⊕⊖⊖ st	RONG			
	recommended for the treatment of symptoms due to low estrogen.					

3940



Hormone therapy should be continued until at least the usual age of menopause $\textcircled{\begin{tabular}{ll} \oplus \end{tabular}}$

STRONG

3941

3942 TABLE VI SUMMARY OF INDICATIONS FOR HORMONE THERAPY (HT) IN WOMEN WITH POI

Symptoms or Sequelae of POI	Indication for HT	Supporting recommendation
Vasomotor symptoms	YES	HT is indicated for the treatment of vasomotor symptoms in women with POI.
Genito-urinary symptoms	YES	Offer local estrogen therapy (LET) to improve genital, sexual and urinary symptoms. Women with POI may be offered LET if genitourinary syndrome of menopause (GSM)is not fully relieved by using systemic HT.
Life expectancy	YES	Women with POI should be offered HT at least until the usual age of menopause as primary prevention to reduce risk of overall morbidity and mortality
Skeletal health	YES	Estrogen replacement is recommended to maintain bone health and prevent osteoporosis; it is plausible that it will reduce the risk of fracture.
Muscle health	Uncertain	The effect of HRT on muscle parameters in women with POI is uncertain but may be of benefit.
Cardiovascular health	YES	Despite lack of data from randomised controlled trials, hormone therapy with early initiation is recommended in women with POI to control future risk of cardiovascular disease. HT should be continued at least until the usual age of menopause.
Quality of life	Uncertain	HT has a positive impact on quality of life in women at usual age of menopause. There are minimal data regarding women with POI, but HT may be of benefit
Sexual function	YES	Where HT has been prescribed for other indications to women with POI, it may ameliorate sexual function, acknowledging the effect is generally small.
Neurological function	YES	Hormone replacement therapy to reduce the possible risk of cognitive impairment and the risk of dementia, parkinsonism and other neurologic diseases should be recommended in women with POI at least until the usual age of menopause.
Fertility treatment	YES	HRT in higher doses creates a favourable hormonal environment for fertility intervention such as replacement of embryos in oocyte donation IVF.
Puberty Induction	YES	HT is indicated for normal pubertal development and skeletal maturation



3944 XI.2. Risks of hormone therapy

In this section, the evidence for risks of HT in women with POI is summarized and supplemented withapplicable data from women at usual age menopause (UAM) where evidence was scarce.

PICO QUESTION: WHAT ARE THE RISKS OF HORMONE THERAPY?

3948 Risk of breast cancer

- The incidence of breast cancer in women with POI has been poorly investigated. Modulating risk factors for breast cancer such as pregnancy and breast-feeding may not apply to women with POI. It has been reported that breast cancer risk increases with increasing age of menopause, and this risk seems lowest in women experiencing menopause before the age of 40 years.
- From a theoretical standpoint, women with POI taking HT with estradiol in physiological doses should not have a higher risk of breast cancer than women with normal ovarian estrogen production (Wu *et al.*, 2014).

3956 **Possible impact of HT on breast density**

- Higher breast density, as assessed by mammography, is associated with increased breast cancer risk (Boyd *et al.*, 2007). However, increased breast density due to HT is not thought to be as significant as familial/genetically pre-determined breast density.
- A report on 62 women with Turner syndrome described the effect of prolonged (> 25 years) use of combined HRT, commencing at the age of 11-19 years. Mammography was initiated from the age of 35-40 years. While high breast density was associated with increased breast cancer risk, none of these women had an increase in breast density. Furthermore, none of these women were diagnosed with breast cancer or a benign breast disorder (Bosze *et al.*, 2006).
- A study compared mammographic density between women with POI taking HRT and those with POI not taking HRT over a 5-year period (Benetti-Pinto *et al.*, 2014). They observed no significant difference in mammographic density between the groups and concluded that breast density in women with POI decreases across a period of 5 years, regardless of HRT use.
- 3969 The effect of different HRT types on breast density was compared in women with a high risk of breast 3970 cancer (familial risk +/- BRCA1/2 mutation). Women aged 30-50 years who had undergone risk reducing 3971 salpingo-oophorectomy were randomised to tibolone or conjugated estrogens with medroxyprogesterone acetate; there was also an untreated comparison group. Breast density decreased 3972 3973 by 46% in untreated women, 39% in tibolone treated women and 17% in CEE MPA treated women; the 3974 difference in the latter group versus the untreated group was significant (p=0.017) (van Barele et al., 3975 2021). If increase in breast density with HRT is regarded as a risk factor for breast cancer it could be 3976 argued that tibolone was the safer option in this study.

3977 Risk of breast cancer in women with POI

- 3978 It has been demonstrated that the risk of breast cancer is lower in women with untreated POI who have 3979 less estrogen exposure (RR 0.67; 95% CI 0.62 to 0.73) (Collaborative Group on Hormonal Factors in 3980 Breast Cancer., 2012), however the risks of many other conditions are increased if estrogen is not 3981 replaced.
- Wu and colleagues found a decreased incidence of breast cancer in Chinese women with POI due to diverse causes compared with women with usual age menopause (OR 0.59; 95% CI 0.38 to 0.91) after adjustment for confounding factors (Wu *et al.*, 2014).
- A Danish study identified no increased breast cancer risk in a cohort of 15,631 women using any form of HRT (non-systemic HRT not included), compared with 62,749 unexposed women. During a mean



- follow-up of 10 years, they found that breast cancer incidence was non-significantly lower among
 women exposed to HRT in the age groups 40-44 (RR 0.56; 95% CI 0.07 to 2.01) and 45-49 (RR 0.62; 95%
 CI 0.62 to 1.22) (Ewertz *et al.*, 2005).
- 3990 Observational data of breast cancer in women in early menopause demonstrate an excess risk RR 2.22 3991 (95% CI 1.96 to 2.52) in those on estrogen and progestogen HRT and of RR 1.33 (95% CI 1.19 to 1.48) 3992 in those on estrogen alone, for 5-14 years of current usage. However, the comparator group were never 3993 users of HRT, rather than age matched women with normal ovarian function (Collaborative Group on 3994 Hormonal Factors in Breast Cancer., 2019).

3995 **Risk of breast cancer in women with iatrogenic POI and a BRCA mutation**

- In iatrogenic POI due to surgery, breast cancer risk is decreased by at least 50% in BRCA1/2 carriers as
 well as in genetically uncharacterized women (Rebbeck *et al.*, 2009).
- In a cohort study, 178 379 women were recruited in 2006-2010. Self-reported data showed that HRT use was associated with a lower risk of breast cancer mortality following surgical menopause before 45 years (HR 0.17; 95% CI 0.08 to 0.36), at 45-49 years (HR 0.15; 95% CI 0.07 to 0.35) or at \geq 50 years (HR 0.28; 95% CI 0.13 to 0.63) (Xu *et al.*, 2022). The association between HRT use and the risk of breast cancer mortality did not differ by HRT use duration (<6 or 6-20 years). HRT use was also associated with a lower risk of breast cancer mortality following usual age menopause before 45 years (HR 0.59; 95% CI 0.36 to 0.95) or hysterectomy before 45 years (HR 0.49; 95% CI 0.32 to 0.74).
- A recent expert narrative review (Rozenberg *et al.*, 2021) advised that carriers of BRCA 1/2 mutation after risk reducing bilateral salpingo-oophorectomy (RRBSO), without a personal history of cancer, may be treated with HRT till the age of 50 based on the results of two systematic reviews and meta-analyses (Marchetti *et al.*, 2018, Gordhandas *et al.*, 2019). The data included both women with POI and with early menopause. Another systematic review and meta-analysis demonstrated similar findings, indicating the evidence is more favourable for estrogen alone therapy (Vermeulen *et al.*, 2019). These observations are repeated in recent review articles (Loizzi *et al.*, 2023a, Loizzi *et al.*, 2023b).
- Women who have had irradiation to the breast (e.g. mediastinal or total body irradiation) are at an increased risk of breast cancer. In theory, this risk may be reduced by the hypoestrogenic state of POI, but returned to the same level as those without POI by HT.


4015 HT Regimens and breast cancer risk

- A higher risk of breast cancer has been demonstrated with continuous combined estrogen-progestogen regimens compared with the sequential, in several large cohort studies of postmenopausal women (Lambrinoudaki, 2014, Collaborative Group on Hormonal Factors in Breast Cancer., 2019). However, since the risk of breast cancer for women with POI may be reduced compared to normal and, given that the little published data regarding the risks of various HRT regimens in the POI group is conflicting, extrapolation of evidence based on postmenopausal women may not be appropriate.
- There has been considerable debate on the effect of different progestogens on the risk of breast cancer (Stahlberg *et al.*, 2004, Seeger and Mueck, 2008). In theory, progesterone has a less proliferative and a more apoptotic effect than androgenic progestogens. However, the evidence is largely observational and relates to women with UAM; there are no data specific to POI (Vinogradova *et al.*, 2020).
- 4026 With regards to the combined oral contraceptive pill, there is a lack of data in the POI population but
- 4027 in those with normal ovarian function, a large, nested case-control study and meta-analysis indicates a
- small increase in breast cancer risk (OR 1.23; 95% CI 1.14 to1.32) (Fitzpatrick *et al.*, 2023).

4029 Recommendations



It is suggested that women with POI be informed that hormone therapy does not appear to increase the risk of breast cancer before the usual age of menopause compared to women without POI in the same age group.



STRONG

4030

Women with POI should be informed that hormone therapy is $\oplus \oplus \oplus \odot$ STRONG generally contra-indicated in breast cancer survivors.

4031

Women with BRCA1/2 mutations without a personal history of breast cancer should be advised that hormone therapy is an option after risk reducing bilateral salpingo-oophorectomy.

4032

4033 Justification

The evidence in terms of risks of HT in relation to breast cancer are reassuring for all women apart from breast cancer survivors. As such, recommendations on reassuring women with POI and women with

4036 BRCA1/2 mutations without a personal history of breast cancer were formulated, as in these women the

4037 benefits of HT outweigh the risks. This is not the case for breast cancer survivors and a recommendation

4038 against HT was formulated for these women.

4039 Risk of endometrial cancer and endometrial hyperplasia

Estrogen-only HT is associated with increased risk for endometrial hyperplasia and endometrial cancer in postmenopausal women . The effect of estrogen-only HRT on the endometrium of women with POI with an intact uterus has not been studied. However, because the association has been well-proven in postmenopausal women , only combined estrogen-progestogen therapy should be used in women with POI and an intact uterus.

According to the Cochrane Library review on oral HRT and endometrial hyperplasia, all doses of unopposed estrogen therapy led to a significant increase of approximately 50% for endometrial hyperplasia within three years. Regimens combining estrogens with continuous progestogens are not significantly different from placebo at two years (Furness *et al.*, 2012). Continuous progestogen HRT regimens appear to be safer that sequential HRT regimens for protecting the endometrium (Weiderpass *et al.*, 1999).

The combined oral contraceptive pill reduces the risk of endometrial hyperplasia and endometrial cancer in women with normally functioning ovaries, especially if administered continuously, and so it is reasonable to expect that it will have the same effect in women with POI (Michels *et al.*, 2018).

4054 Recommendations

Women with POI should be advised that progestogen should be given in combination with estrogen therapy to protect the endometrium in all women with an intact uterus.

4055



It is suggested that the dose of progestogen is increased when higher doses of estrogen therapy are used. \oplus

CONDITIONAL

4056 Justification

The dose of progestogen required for adequate endometrial protection is related to the dose of estrogen used. Given that the dose of estrogen used in HRT for POI is higher than used conventionally in postmenopausal women, it is important that adequate progestogen doses are used for endometrial protection (unless the woman has progestogen intolerance) (Hamoda, 2022).

4061 Risk of stroke

- 4062 No evidence was identified regarding the risk of stroke for women with POI treated with HT. The 4063 increased risk of stroke in women with POI or early menopause due to surgical menopause, was found 4064 to be reduced by HRT, suggesting that estrogen deprivation is involved in the association (Rocca *et al.*, 4065 2012b).
- 4066 Studies on the use of HRT in women with UAM have identified an increased risk of thrombotic stroke 4067 with HRT (maximum RR 1.47, increasing from 6 per 1000 in the control group to 8 per 1000 in the HRT 4068 group) (Marjoribanks *et al.*, 2012, Gu *et al.*, 2014) although this risk is not evident in women using 4069 standard or low dose transdermal estradiol (Renoux *et al.*, 2010).
- 4070 In young women using the combined oral contraceptive pill (i.e. menstruating women requiring 4071 contraception), the risk of stroke is roughly doubled although the absolute risk is extremely low (21.4 4072 per 100,000 person-years) (Lidegaard *et al.*, 2012).
- 4073 Recent studies suggest that an individual's genomic profile may modify the COC associated risk of 4074 ischaemic stroke (Lin *et al.*, 2023).

4075 *Risk of thromboembolic disease*

- 4076 Only one study on the risks of thromboembolism and HRT use for women with POI has been identified, 4077 and that was of a minority sub-group within the WHI clinical trials.
- This looked at venous thromboembolism (VTE) occurring in women on HRT (CEE+MPA) who had no history of VTE. Overall, the authors did not identify any significant relation between occurrence of first VTE event in relation to HRT use compared with placebo. Analyses restricted to non-procedure related VTE showed a U-shaped relationship between age of menopause: after adjustment for potential confounders, women who experienced menopause at 39 years or younger, or at 56 years or older had increased thrombotic risk as compared with women with age of menopause between 40 and 49 years (adjusted HR 1.8; 95% Cl 1.2 to 2.8) while using HRT (Canonico *et al.*, 2014).
- Evidence on VTE risk in women at UAM using oral HRT has shown increased risk, which becomes most apparent in the first year of HRT use: increased risk from 2 per 1000 to between 4 and 11 per 1000 with combined continuous HRT in otherwise healthy users (Marjoribanks *et al.*, 2017). However, most observational and case-controlled data in women with menopause at usual age have shown that the risk of VTE can be reduced or negated through the use of transdermal estradiol and micronized progesterone or dydrogesterone (Canonico *et al.*, 2006, Canonico *et al.*, 2007, Canonico *et al.*, 2008, Vinogradova *et al.*, 2020).
- 4092 A recent real-world survey data in women with UAM, showed a lower VTE risk of an oral combined 4093 estradiol / progesterone formulation compared to conjugated equine estrogen / medroxyprogesterone
- 4094 acetate formulations (Panay *et al.*, 2023).



- The risk of VTE in women (age 15-49) using an oral contraceptive pill is increased compared to nonusers: adjusted rate ratio (95% CI 2.65 to 3.01) (Lidegaard *et al.*, 2012).
- The evidence on VTE risk in COC users is relevant to women with POI using COC because they are in the same age group, albeit with exogenously suppressed ovarian function. The mechanism of VTE does not appear to be any different between women with normal ovarian function and those with POI.
- 4100 Known risk factors for VTE in COC users such as smoking, and obesity therefore can be applied to 4101 women with POI using the COC.

4102 It is possible that estradiol or estetrol delivering COCs are associated with a similar or even lower 4103 cardiovascular and VTE risk but there is very little clinical experience using these pills in POI, and no 4104 published data on safety issues in this population (Dinger *et al.*, 2016, Reed *et al.*, 2021)

4105 POI patients with potential higher risks of HT linked to comorbidities.

4106 Women with POI and endometriosis

- 4107 Endometriosis is defined as the presence of endometrial-like tissue outside the uterus. Medical or
- 4108 surgical ovarian suppression in women with endometriosis is effective in improving pain symptoms.
- 4109 Medical treatments prescribed for women with endometriosis (GnRH agonists) induce a temporary state
- 4110 of hypoestrogenism that is restored after discontinuation of treatment. Hysterectomy with bilateral
- 4111 oophorectomy should only be considered in women who no longer wish to conceive and failed to
- 4112 respond to more conservative treatments (Becker *et al.*, 2022) (lancu *et al.*, 2022). (
- 4113 As endometriosis is an estrogen-dependent disease, the use of estrogen therapy in women with
- 4114 endometriosis and POI (for instance after hysterectomy and BSO) could theoretically reactivate residual
- 4115 disease. A systematic review reported a small association between the treatment with HT and recurrence
- 4116 of endometriosis, but this conclusion was based on limited available data (Gemmell *et al.*, 2017).
- 4117 Malignant transformation was reported in only a few reports, and mostly related to unopposed estrogen 4118 treatment (Gemmell *et al.*, 2017).
- 4119 Despite a lack of good evidence, most experts recommend the use of continuous progestogen with 4120 estrogen in women thought to have residual disease after hysterectomy and BSO (Gemmell *et al.*, 2017).
- 4121 The question on how to treat vasomotor symptoms in women with endometriosis has also been
- 4122 discussed in the "ESHRE guideline: Endometriosis" (Becker *et al.*, 2022) and similar recommendations
- 4123 were formulated.
- 4124 **Recommendation**.¹¹

The guideline group recommends that HCPs treat women with a history of endometriosis after surgical menopause with combined estrogen-progestogen at least until the usual age of menopause

GPP

- 4125
- Further recommendations on treatment of women with endometriosis, including women after surgical
 menopause, is available in the "ESHRE guideline: Endometriosis" (Becker *et al.*, 2022).

¹¹ These recommendations were derived from the ESHRE Guideline Endometriosis, with minor changes to the formulation for consistency with the terminology used in this document.



4128 Women with POI and Migraine

- The main issues to consider regarding HT use in women with POI and migraine are the potential risk of ischaemic stroke and whether HT might affect the occurrence of migraine.
- 4131 A recent comprehensive review of the subject indicated that data on hormonal treatments in migraine
- 4132 are scarce and heterogeneous but suggest a good safety profile in women with menstrual migraine,
- 4133 especially if used with reduced or absent hormone free intervals (Nappi et al., 2022c).
- 4134 Good quality data on the effect of migraine and COC use on risk of ischaemic stroke are lacking although 4135 caution should be exercised in prescribing the COC in this group of women (Ornello *et al.*, 2020).
- 4136 No studies were identified for the dose, type, or route of administration of HRT in women with POI and
- 4137 migraine. Data for women at UAM, with migraine is also minimal and conflicting. Migraine with aura
- 4138 remains a contraindication for combined oral contraceptive pill use in women, including those with POI.
- 4139 In the absence of any data regarding the risks of HRT use for women with POI and migraine, it would
- 4140 seem reasonable to recommend it to protect against the consequences of estrogen deprivation, even
- 4141 in migraine sufferers.

Recommendation (1)

- 4142 Given that some migraine is provoked by estrogen (by high, low, or even changing levels), a migraine 4143 history should be sought and documented when commencing HRT in women with POI. Should
- 4144 migraines become more frequent whilst taking HRT, consideration should be given to whether the
- 4145 potentiating factor could be over- or under-replacement.
- 4146 Other causes should be considered as well as HRT if new migraine occurs during HT.
- Transdermal estrogen may have the advantage of providing a constant level of estrogen and may be
- 4148 associated with a lower risk of thrombosis (MacGregor, 2018, Nappi et al., 2022c).

	Migraine should not be seen as a contraindication to hormone therapy use by women with POI.	⊕⊕⊖⊖	STRONG
4150			
	HCPS should consider changing dose, route of administration or regimen if migraine worsens during hormone therapy.	⊕⊕⊖⊖	STRONG
4151			
	Women with POI and migraine with aura should be advised to use transdermal estrogen as this may be the lowest-risk route of administration	⊕000	STRONG

```
4152
```

4149

4153 Women with POI and other comorbidities

- 4154 An overview of the most common comorbidities in women with POI, the specific risks of HT in these 4155 women and the probability are listed in Table VIII. Where possible, the table also provides a suggested
- 4156 HT options for each comorbidity.

4157 **TABLE VII SUMMARY OF RECOMMENDATIONS FOR HT IN WOMEN WITH POI WITH POTENTIAL HIGHER (RISKS** 4158 LINKED TO COMORBIDITIES



Comorbidity	нт		Type of risk	Probabilit y	Proposed HT	
Breast cancer survivor	\mathbf{O}	Contra-indicated	Recurrence	High	n/a	
BRCA1/2 mutations after RRBSO, without a personal history of breast cancer	F	Can be considered	Developing BC	Low	TE/MP ¹	
Migraine	F	Can be considered	lschaemic stroke	Unclear	Dose/regimen/administr ation can be adapted in line with migraine symptoms	
Migraine with Aura		Can be considered	lschaemic stroke	Unclear	Transdermal estrogen (COC contraindicated ²)	
Hypertension	Fil	Can be considered	CVD/VTE	Low	TE/MP ¹	
Diabetes mellitus		Can be considered	CVD/VTE	Low	TE/MP ¹	
Obesity	F	Can be considered	CVD/VTE	Low	TE/MP ¹	
Endometriosis	F	Can be considered	Disease reactivation / malignancy	Low	combined estrogen- progestogen	
Prior VTE		Can be considered after haematologist review.	VTE/PE	High	TE/MP ¹ (COC contraindicated ²)	
Malabsorption		Recommended	Inadequate absorption of oral therapy	Unclear	Non-oral HT	
Known CVD	0	Relatively Contra-indicated	CVD	Unclear	TE/MP ¹	
Abnormal liver function	F	Can be considered	Worsening of liver function	Unclear	Transdermal estrogen	

4159 ¹ TE/MP: Transdermal estrogen, Micronized progestogen

4160 ² See https://www.cdc.gov/reproductivehealth/contraception/mmwr/mec/summary.html

4161



4162 XI.3. HT – treatment options

4163 **PICO QUESTION: WHAT ARE THE OPTIONS FOR HORMONE THERAPY?**

In contrast to women with UAM, the need for hormone therapy (HT) in younger women with POI extendsbeyond the need for symptom relief (the primary indication for HT in women with UAM.

As reviewed in the other chapters evidence suggests that HT is justified in women with POI to protect against serious morbidity and earlier mortality related to prolonged estrogen deficiency but should at the same time be prescribed safely to avoid or minimize potential risks (see also Table III Summary of Indications for HT in women with POI),

- In a retrospective chart review the authors stated that treatment should be initiated rapidly after
 confirmation of diagnosis, for the physical as well as emotional components of the condition, especially
 to preserve bone mineral density (Kanj *et al.*, 2018).
- 4173 This section reviews the HT options for women with POI: types of preparation, regimens and route of 4174 administration, doses, duration, monitoring, and adherence to therapy.
- 4175 Research on the optimal HT for women with POI is limited. On the other hand, there are numerous
- 4176 studies on the effect of regimens, route of administration, doses, and management of HRT in women at
- 4177 UAM, above the ages of 45-50 years. As a consequence of the sparse evidence, recommendations for
- 4178 HT in POI must necessarily be based on theoretical knowledge about physiology and endocrinology
- 4179 and extrapolated from the evidence of HRT in women with UAM.
- 4180 Thus, recommendations in this chapter are primarily based on "best clinical practice" supplemented by
- 4181 evidence where it exists. Patient preference and individualisation of regimens is important for adherence
- 4182 and must therefore be taken into consideration when prescribing.

4183 *Type of preparations: Estrogens and progestogens*

4184 *Estrogens*

- There are four types of estrogen that are available for hormone replacement: estradiol (the main ovarian estrogen 17 β -estradiol), ethinylestradiol (a synthetic estrogen) and conjugated equine estrogens (CEE derived from pregnant mare's urine) and the new estetrol products. At the time of writing only the estetrol/drospirenone COC was available but research was progressing to bring to market an HRT option.
- 4190 The main goal of hormone therapy for women with POI is to reproduce the normal physiological 4191 endocrinological environment to achieve estrogen replacement. Given current evidence, experts in 4192 management of POI recommend that the choice of hormone therapy should closely mimic normal 4193 ovarian steroid hormone production and provide sufficient levels of estradiol to reduce menopausal 4194 symptoms, maintain bone density, minimize psychological impacts of estrogen deficiency, and protect 4195 against early progression of cardiovascular disease and dementia. Hormone therapy is long-term in 4196 women with POI, and therefore it is essential that the risk benefit ratio is optimal to maximise longer 4197 term health (Sassarini et al., 2015, Sullivan et al., 2016).
- In a recent publication the authors proposed an "integrated and patient-based hormonal approach for
 women with POI, from puberty to late reproductive age" (Fruzzetti *et al.*, 2020). However, there is still
 lack of consistency in terms of what precisely is advised for hormone replacement in POI and largely
 depends on what is available in each country at any particular time.



4202 COC versus HRT

- In many countries the COC is free of charge and perceived as more "peer friendly" hence its popularity for HT in this group of young women if they do not wish to achieve a pregnancy (approx. 5% chance in non-iatrogenic POI). In an online survey of Australian health care providers, the combined oral contraceptive pill was reported as the first-line treatment for women with premature menopause (52% of respondents), (Yeganeh *et al.*, 2017)
- 4208 Most oral contraceptives contain the potent synthetic estrogen ethinylestradiol (EE), which in effect 4209 provides more steroid hormone than is needed for physiological replacement, with unfavourable effects 4210 on the lipid profile, on haemostatic factors and with an increased risk of thromboembolic events related 4211 to both the EE and progestogen, and the first pass hepatic effects.
- 4212 Some newer oral contraceptives now deliver estradiol and estetrol, but there is some concern as to 4213 whether the estrogen levels achieved are sufficient in women with POI.
- 4214 *Bone*: Evidence regarding HT and bone suggest that prompt initiation, continued use, adherence, and 4215 higher doses of estrogen are needed to optimise bone mineral density. Data regarding COC are 4216 conflicting with continuous use associated with better preserved BMD, versus conventional 4217 discontinuous use (Fine *et al.*, 2022). This is covered comprehensively in the bone chapter (*see* VI. POI 4218 and musculoskeletal health).
- 4219 *Cardiovascular*: With regards to metabolic effects, Langrish and colleagues found that a "physiological" 4220 HRT regimen led to lower mean blood pressure, reduced plasma angiotensin II and reduced serum-4221 creatinine without altering plasma aldosterone concentrations, compared with women with POI treated 4222 with COCs (Langrich et al. 2000)
- 4222 with COCs (Langrish *et al.*, 2009).
- A well conducted systematic review found that HRT reduced plasma cholesterol concentrations, avoided
 uterine atrophy and increased adult height in prepubertal girls with Turner Syndrome (Gonçalves *et al.*,
 2022).
- There are no comparative studies on the risks of VTE with the estradiol and estetrol COC preparations and so the indications for their use in women with POI should remain contraception, although more research is warranted to determine if these could provide the ideal balance between contraception and hormone therapy. These findings may have major implications for the future cardiovascular and bone health of young women with POI, who require long-term sex steroid replacement therapy.
- The need for better comparative data has been highlighted by the authors of a recent paper in which they described the POISE study (Premature Ovarian Insufficiency Study of Effectiveness of hormonal therapy) which has been designed to determine whether hormone therapy is superior to combined oral contraceptives on important clinical outcomes such a bone mineral density and cardiovascular risk markers, and patient-reported symptoms, based on the hypothesis that hormone therapy provides more physiological continuous hormone supplementation with natural estrogens (Upton *et al.*, 2021). The study is ongoing in the UK at the time of update of this guideline.

4238 Estrogen Choice in Turner Syndrome

4239 Most experts now prefer transdermal estradiol for puberty induction in Turner syndrome and advise 4240 against the use of conjugated estrogens or ethinylestradiol for metabolic reasons and to achieve good 4241 uterine growth (Klein *et al.*, 2018, Klein and Phillips, 2019) (see XIII. Puberty Induction for more details).

4242 Progestogens

Progestogens protect the endometrium from the mitogenic effect of estrogen. However, there is a lack of evidence on the effect and role of various progestogen preparations in HT for women with POI. Although all progestogens are progesterone receptor agonists, thus enabling their endometrial



- protective effect, binding to other steroid receptors also occurs which varies with the progestogen.
 These differing agonist and antagonist effects contribute to the variable adverse effects profile (for
 example, breast cancer or VTE as discussed below) and this should be considered when deciding on the
 HT regimen (Stanczyk *et al.*, 2013).
- 4250 Synthetic progestogens provide effective endometrial protection and cycle control but should not be 4251 used for endometrial preparation for embryo transfer (Fatemi *et al.*, 2007).
- 4252 Evidence from women with UAM, appears to favour micronized progesterone or dydrogesterone. These 4253 appear to have favourable cardiovascular and breast safety profiles when compared to androgenic 4254 progestogens (Mueck, 2012).
- 4255 Compounded "bio-identical" preparations of estrogen and progesterone are not recommended due to 4256 lack of data on efficacy and safety unless no alternative regimens are available.
- However, recently published data indicate that if the estrogen is delivered transdermally in HRT then haemostatic biomarkers do not differ significantly between micronized progesterone and androgenic progestogen (MPA) users (Mittal *et al.*, 2022).
- Also, as previously described, micronized progesterone and dydrogesterone may be preferred over other progestogens with regard to breast cancer risk (Davey, 2013, Vinogradova *et al.*, 2020).
- 4262 A randomised controlled trial demonstrated that in women with UAM, micronized progesterone given
- in an oral dose of 200mg/day for 12 days per 28-day cycle was as effective as the same regimen using
 10mg/day medroxyprogesterone acetate (MPA), or 2.5mg MPA every day, for protecting the
 endometrium from hyperplasia caused by 0.625mg/day conjugated equine estrogens (CEE) (The Writing
 Group for the PEPI, 1996).
- These data on the safety of progesterone on the endometrium were supported by a subsequent metaanalysis (Stute *et al.*, 2016) assuming the dose and duration of use is adequate.
- 4269 An RCT in women with UAM also demonstrated endometrial safety in a continuous combined oral 4270 estradiol and progesterone formulation (Mirkin *et al.*, 2020).
- 4271 A recent national French case control study found a significant increase in risk of meningioma with the 4272 progestogens, depot MPA, cyproterone acetate, nomegestrol, promegestone, medrogestone and 4273 chlormadinone acetate which are not usually used for endometrial protection in HT – no link was found 4274 with progesterone, dydrogesterone and the levonorgestrel intrauterine device and excess risk of 4275 meningioma (Roland *et al.*, 2024).

4276 HT Regimens

- 4277 Continuous estrogen replacement is required to avoid symptoms of estrogen deficiency and minimise 4278 risk of co-morbidities. Some women using the combined oral contraceptive pill for hormone therapy 4279 will be symptomatic during the pill-free (or inactive pill) week.
- Studies of women with UAM, have shown that use of sequential progestogen (progestogen for 10 days or more per month or 14 days up to every 12 weeks) lowers (but not eliminates) the risk of endometrial hyperplasia/cancer risk and is associated with a regular withdrawal bleed. Whereas, continuous combined estrogen-progestogen therapy, designed to omit the withdrawal bleed, may even prevent endometrial hyperplasia and cancer (see section *XI.2.b Risk of endometrial cancer and endometrial hyperplasia*)
- Long cycle HT (continuous estrogen combined with 14 days of progestogen every 12 weeks) is an option for some women with progestogen intolerance but is associated with an increased risk of endometrial



- 4288 hyperplasia. In this case, endometrial surveillance should be instituted with ultrasonography and 4289 hysteroscopy and endometrial biopsy where indicated.
- 4290 As per women with UAM, unscheduled breakthrough bleeding should be investigated even on 4291 conventional HT regimens.
- The incidence of endometrioid cancer of the ovary was increased in women with sequential but not with continuous combined estrogen-progestogen HRT in a Danish study (Mørch *et al.*, 2012).
- The atrophic effect on the endometrium of the contraceptive pill may also be a reason to avoid its use for HT in women with POI desiring of pregnancy, at least until after a period of treatment with a sequential combined HRT regimen (see V.1. Fertility and fertility treatments).
- 4297 Younger women are more likely to experience breakthrough bleeding with continuous combined HRT 4298 than women with UAM and should probably use sequential therapy for at least two years.
- 4299 Women with POI who desire bleed-free HRT (and contraception) may benefit from using the 52mg 4300 levonorgestrel intrauterine device with appropriate estrogen replacement which is licensed in many 4301 countries for endometrial protection and/or contraception.

4302 Route of administration

4303 Estrogens

- 4304 Systemic estrogen can be administered orally or through transdermal patches, spray, gels, and implants.
 4305 However, the availability of these different preparations varies within and between countries.
- 4306 Local estrogen treatment for treatment of vulvovaginal atrophy (VVA)/genitourinary syndrome of 4307 menopause can be administered in the form of an estrogen-releasing vaginal ring and estrogen-based 4308 vaginal creams and pessaries. Locally administered estrogen (Suckling *et al.*, 2006) is not believed to 4309 carry a risk of endometrial hyperplasia if used in the licensed dosage (Lethaby *et al.*, 2016) and a 4310 progestogen is not required.
- 4311 There is also a locally (vaginally) active selective estrogen receptor modulator (ospemifene) although 4312 there is little experience of using this in women with POI.
- The major advantage of transdermal estrogen is avoidance of first-pass metabolism in the liver and effect on VTE risk as previously discussed (Chetkowski *et al.*, 1986). A recent clinical trial in women with POI using transdermal estradiol (and either sequential oral micronized progesterone or medroxyprogesterone acetate for endometrial protection) confirmed absence of statistically significant changes in thrombin generation (Mittal *et al.*, 2022).
- 4318 Compared to oral administration, the transdermal route does not increase SHBG and can achieve higher 4319 plasma levels of circulating estradiol with a lower treatment dose and therefore fewer circulating 4320 estrogen metabolites than oral estradiol (which is metabolised to estrone), thereby more closely 4321 matching the normal premenopausal state (Goodman, 2012).
- There are now a large amount of data regarding the route-dependent effect of the metabolic actions of estrogen. However, most studies were conducted in women with UAM. A more general review of the cardiovascular impact of estrogen route is included in the CV chapter (VII. POI and cardiometabolic health).
- 4326 Practical aspects
- 4327 Transdermal patches may result in local skin irritation, although the smaller dot matrix patches are better 4328 tolerated, and some individuals find them difficult to keep in place. Advice on correct application and
 - Guideline POI DRAFT FOR REVIEW



- rotation of application sites may help. Younger women with POI may be reluctant to use a patch becauseof concerns that others might see it.
- 4331 Estradiol gel and sprays are available, but younger women may still prefer oral HRT (Davies and 4332 Cartwright, 2012).

Estradiol implants are not widely available in many countries. These have often been used for surgical menopause; a pellet can be inserted subcutaneously at the time of hysterectomy to prevent consequent severe vasomotor symptoms. Panay and colleagues found little clinical difference between 25mg and formg implants in a randomized double-blind trial in women after total abdominal hysterectomy and bilateral salpingo-oophorectomy although there is a dose response effect on bone density (Panay *et al.*, 2000).

4339 Given the paucity of evidence regarding the optimum route of administration for estrogen in women 4340 with POI, compliance with HRT is the main issue and patient preference is therefore currently the most 4341 important consideration (Stevenson *et al.*, 2021).

4342 Progestogens

- 4343 Progestogens can be administered via the oral, transdermal (as a patch), or intra-uterine routes for HRT.
- 4344 No studies have been identified comparing route of administration for synthetic progestogens as a
- 4345 component of combined HRT for women with POI. However, there is no reason to believe that their
- 4346 safety and effectiveness for endometrial protection would be any different to that for women with UAM,
- for which there are a considerable amount of safety data. Subdermal implants and intramuscular depot preparations are also available, but these are licensed as contraceptive devices, and no data exist for
- 4349 their use in HRT for endometrial protection.
- 4350 If the woman prefers a bleed-free regimen, local treatment with a 52mg progestogen-releasing intra-
- 4351 uterine system (IUD) will provide sufficient protection from endometrial hyperplasia (Ewies and Alfhaily,
- 4352 2012), usually with fewer side effects compared to systemic progestogen treatment (Pirimoglu et al.,
- 4353 2011). This is also licensed for contraception in many countries, in those that require it. (NB: Not licensed
- 4354 for endometrial protection in some countries e.g. US)
- 4355 Micronized progesterone preparations are available to use orally, vaginally, and as transdermal (cream) 4356 preparations. Only the oral route of administration is licensed for endometrial protection. Vaginal 4357 progesterone may have the benefit of achieving adequate endometrial protection whilst avoiding side 4358 effects such as drowsiness and low mood due to the absence of conversion to allopregnanolone. On 4359 the other hand, some women notice sleep and calming benefit with oral usage.
- 4360 Cyclical vaginal progesterone 100mg/day or 200mg/day had no significant effect on endometrial 4361 thickness as assessed by ultrasound scan and was associated with better compliance and therefore cycle 4362 control, than equivalent oral doses in an RCT of postmenopausal women using 50 µg estradiol patches 4363 (Di Carlo *et al.*, 2010). However, the trial did not assess the endometrium histologically and follow up 4364 was only for 1 year.
- Recent data in women with UAM, indicated that a 4% formulation of micronized progesterone gel administered intravaginally for 10 days with a low dose of estrogen (1mg estradiol) was insufficient to fully protect against endometrial hyperplasia (Sriprasert *et al.*, 2021). Caution should therefore be exercised in assuming that vaginal progesterone will always provide adequate endometrial protection and endometrial surveillance should be instituted when lower dose / reduced duration regimens are prescribed (Hamoda and Sharma, 2023).
- The evidence for oral and vaginal micronized progesterone usage is well summarised in a meta-analysis.(Stute *et al.*, 2016).



- In a study of 54 women with UAM, Vashisht and colleagues found that compounded transdermal natural
 progesterone cream in a continuous regimen was insufficient to fully attenuate the mitogenic effect of
- 4375 estrogen on the endometrium (Vashisht *et al.*, 2005) and should therefore not be used for this purpose.

4376 *Dose*

4377 Estrogen

Evidence indicates that a dose of at least 2 mg oral estradiol or 100 µg transdermal estradiol per day or equivalent is required to reliably prevent bone loss (Costa *et al.*, 2023) (also see VI. POI and musculoskeletal health). Low dose HT suitable for older postmenopausal women is not sufficient for women with POI to preserve bone mass.

- Titrating the dose against vasomotor symptoms may be helpful, although some women with POI have minimal symptoms despite being estrogen deficient. The dose required to treat vasomotor symptoms may not be the same as that required for bone protection or to achieve peak bone mass, for example.
- 4385 It is reasonable to aim for physiological estradiol levels as found in the serum of women with normal 4386 menstrual cycles of approximately 200-400pmol/l (Panay et al 2020 #2804). These levels can be achieved
- 4387 with 100µg estradiol patches or 2-4 pumps (or 2-3mg) of estrogen gel, or 2-3 estradiol sprays when
- 4388 given transdermally to women with POI (Steingold *et al.*, 1991, Popat *et al.*, 2008).
- 4389 Similar levels can be provided by oral estradiol in doses of 2 to 4 mg, but serum levels of estrone become
- 4390 supra-physiological, which is of uncertain clinical significance (Steingold et al., 1991). No data were
- 4391 identified to support the use of any particular dose for symptom relief in women with POI, although
- 4392 opinion was expressed that a transdermal dose of 100µg/day was usually sufficient (Nelson, 2009).
- 4393 In women who are minimally symptomatic or asymptomatic it is reasonable to start with lower doses to 4394 avoid adverse effects and then to increase the dose according to tolerance, estradiol levels and bone
- 4395 mineral density (Panay *et al.*, 2020).

4396 Progestogens

- 4397 Women with POI and an intact uterus taking estrogen replacement require progestogen therapy to 4398 protect against endometrial hyperplasia/ cancer as discussed previously.
- The dose of progestogen required depends on the dose of estrogen and the regimen (i.e. continuous combined or sequential). Continuous regimens require a minimum dose of 1mg of oral norethisterone (NETA) daily, 2.5mg medroxyprogesterone acetate (MPA), 5mg dydrogesterone or 100mg of micronized progesterone. The dose may need to be doubled with higher doses of estrogen. Sequential regimens require 2.5-5.0mg NETA, 5-10mg MPA, 10-20mg dydrogesterone for a minimum of 10 to 12 days per month, or 200-300mg micronized oral progesterone (Furness *et al.*, 2012, Hamoda, 2022).
- These regimens have been largely determined in women with UAM, on HRT based on pharmacokineticsand endometrial safety (see Table IX)

4407 XI.3.e Duration

- 4408 There is some evidence that the longer estrogen is used in POI the lower the risk of CVD although long 4409 term prospective randomised trial data are absent (Zhu *et al.*, 2019).
- 4410 In order to prevent the long-term health consequences of the loss of ovarian function, the consensus
- 4411 of the guideline group was that HT should be continued at least until the usual age of menopause
- 4412 (although this varies globally). This is in line with the recommendation of other organizations (Pitkin et
- 4413 *al.*, 2007, Vujovic *et al.*, 2010, Zhu *et al.*, 2019, Panay *et al.*).



- 4414 Subsequently, recommendations regarding the use of HT in women with UAM, can be followed, 4415 considering factors such as symptoms, bone density, cardiovascular and cognitive risks.
- 4416 Commencing HT as early as possible is particularly important for young women with POI in order to
- 4417 maximize peak bone mass (see VI. POI and musculoskeletal health). Similarly, cardiovascular risk factors
- 4418 may be minimized by early use of estrogen replacement (see VII. POI and cardiometabolic health).

4419 XI.3. Adherence to therapy

It is not possible or realistic to achieve 100% adherence with hormone therapy in POI although desirable unless there are contraindications. In a commercial database study, the cumulative rate of estrogen use at 36 months after surgical menopause was found to be only 79.1% (95% CI 76.9 to 81.1) in those aged 18-29 years, 75.9% (95% CI 74.5 to 77.3%) in those aged 30-34 years, 70.2% (95% CI 69.1 to 71.2%) in those aged 35-39 years (Suzuki *et al.*, 2022).

- 4425 Adherence with HT is crucial if the benefits are to be maintained and optimised. Very few studies have 4426 followed up the long-term use of HT. A cross sectional study demonstrated poor adherence to HRT in 4427 which 42.6% withdrew from treatment due to "lack of interest" or fears about breast cancer risks.
- 4428 In multivariate analysis, after adjustment by stepwise model selection on age (p=0.05), BMI (p=0.48), 4429 smoking use (p=0.22) and vitamin D deficiency (p = 0.69), and duration of POI (p=0.003); 4430 discontinuation of HRT over one year was always associated with significant loss of femoral BMD: -17 4431 mg/cm² versus -52 mg/cm² (p=0.022)(Bachelot *et al.*, 2016). At the vertebral level, they also found this 4432 non-significant trend -37 mg/cm² versus -45 mg/cm² (p=0.80).
- In a study of women with POI due to Fragile X premutation, 52% of women never took hormone therapy, started it years after POI diagnosis, or stopped it before 45 years of age (Hipp *et al.*, 2016).

4435 *Recommendation*

The guideline group recommends that women are advised that compounded "bioidentical" preparations of estrogen and progesterone are not recommended due to lack of data on efficacy and safety unless no alternative regimens are available.

GPP

4436

Women with POI should be advised that estradiol has advantages over ethinylestradiol and conjugated equine estrogens when used for $\oplus \oplus \oplus \oplus \oplus$ hormone therapy.

STRONG

4437

The guideline group recommends shared decision making when prescribing each component of hormone therapy with consideration of patient preference, GPP contraceptive needs, and presence of co-morbidities.

4438

Women with POI should be advised that adherence to hormone therapy is important to minimise long term health risks and therefore long term follow up is needed.

4439 Justification

4440 There have been very few studies comparing different types and regimens of estrogen replacement for

4441 women with POI.



- 4442 The little evidence there is suggests physiological sex steroid replacement regimens may be more beneficial than the combined oral contraceptive pill (COC) and the risks may be lower. 4443
- 4444 However, risks of using the COC in the general female population, though small, are well documented 4445 and are not dependent on the presence of functioning ovaries.
- 4446 There may also be additional health benefits to using the COC although most of these are in women 4447 with normally functioning ovaries (Coelingh Bennink et al., 2024).
- 4448 If adherence is improved with the use of the COC, then this is a reasonable alternative, or if contraception 4449 is required.

Conclusion 4450

- 4451 As with women at UAM the key to optimal HT prescribing in women with POI is personalisation, taking into account the individual benefit / risk balance, considering all available evidence, and empowering
- 4452
- 4453 women through the counselling process to make the choice that is right for them.
- 4454

urt Horen Heren He



4455 **TABLE VIII SUMMARY OF HORMONE THERAPY (HT) OPTIONS: STANDARD AND 'PREMATURE OVARIAN** 4456 INSUFFICIENCY (**POI**)' REGIMENS (**ADAPTED FROM (PANAY** *ET AL.*, **2020**), PERMISSION REQUESTED)

HT type	Sequential combined HT		Continuous combined HT		
<u>Per 24 hours or day</u>	Low/standard doses	Higher 'POI' doses	Low/standard doses	Higher 'POI' doses	
Estradiol type					
Patch (transdermal, µg/24h	25–50	75–100	25–50	75–100	
Gel sachet (transdermal, mg)	0.5–1.0	1.5–2.0	0.5–1.0	1.5–2.0	
Gel pump (1 metered dose = 0.75 mg)	1–2	3–4	1–2	3–4	
Spray (1.53mg per spray)	1-2	3-4	1-2	3-4	
Oral (mg)	1.0–2.0	3.0–4.0	1.0–2.0	3.0–4.0	
Progesterone/proges	stogen				
Micronized progesterone (oral/per vagina, mg)	100–200	≥ 200 (e.g. 300– 400)	100	≥ 200	
Dydrogesterone (oral, mg)	10	20	5.0	10	
Medroxyprogesterone acetate (oral, mg)	5.0	10	2.5	5.0	
Norethisterone acetate (oral, mg)	2.5–5.0	2.5-10	1.25–2.5*	5.0	
E2/progesterone com	nbined regimens				
E2/micronized progesterone (oral, mg)	1.0-2.0/100-200	> 2.0/> 200	1.0-2.0/100-200	3.0-4.0/300-400	
E2/norethisterone acetate (transdermal) (μg)	25–50/85–170	75–100/255–340	25–50/85–170	75–100/255–340	
E2/dydrogesterone (oral, mg)	1.0-2.0/10	3.0-4.0/20	0.5–1.0/2.5–5.0	3.0-4.0/7.5-10	
E2/norethisterone acetate (oral, mg)	1.0-2.0/1.0	3.0-4.0/2.0-4.0	0.1–2.0/0.5–1.0	3.0-4.0/1.5-2.0	
Levonorgestrel intrauterine system	n/a	n/a	20 μg/day sufficient (52mg L		

4457 The table does not show all available options globally. Licensed (in at least one country) types/doses/regimens of 4458 HT shown in bold; other regimens are achieved off-label by halving/doubling/combining regimens.

- Higher doses of estradiol usually required in POI but, to assess tolerance or in case of adverse effects, lower doses may be used initially.
- Variation globally as to what doses perceived as low, medium, and high, e.g. North America 0.5 mg E2 is low dose, 1 mg E2 is standard dose, and 2 mg E2 is high dose.
- Sequential regimens require 12-14 days progesterone/progestogen per cycle for endometrial protection –
 this may need modification depending on tolerance.
- Endometrial safety is less assured with micronized progesterone used for > 5 years¹.
- 4466 Progesterone/progestogen doses shown are the minimum effective for endometrial protection given current data².
- Endometrial safety data lacking for the minimum effective dose of progestogen/progesterone with higher
 estrogen doses.

4470 *A 1 mg dose of norethisterone acetate is adequate for standard-dose continuous combined HT, but not available

separately from E2, hence 1.25–2.5 mg doses (¹/₄ to ¹/₂ of a 5 mg tablet).



4472 XI.4.Monitoring HT

4473 Currently, there is no good evidence regarding the optimum HT monitoring strategy. Estrogen dosage 4474 should be titrated to achieve symptom control and adequate bone density. Although acknowledging 4475 limitations of estradiol assays, measurement of serum estradiol may be helpful in clinical practice where 4476 there is inadequate symptom relief, failure to achieve adequate bone protection or where there are 4477 adverse effects. Women being treated with hormone implants should have their estrogen levels checked 4478 to minimise the risk of tachyphylaxis.

Estradiol assays do not measure ethinylestradiol (in COCs) or estrone (the predominant estrogen produced by some oral HRT). There is no value in monitoring FSH levels, since they may not normalize due to dependence on inhibin as well as estradiol levels (Davies and Cartwright, 2012). Regular reviews are recommended, with the aim to assess adherence, satisfaction, side effects, and possible need for change of regimen or administration form. Adherence is improved with shared decision making, empowering and involving the woman in the discussion of treatment choice (Cartwright *et al.*, 2012, Panay *et al.*, 2020).

4486 *Mammography*

4487 As described previously, there is no evidence to suggest an increased risk of breast cancer in young 4488 women on HRT compared with age-matched normally menstruating/ovulating women. It is therefore 4489 appropriate to commence mammographic screening as per national screening programme at the age 4490 of 45 to 50 years in unless there are specific risk factors e.g. BRCA 1/2 mutation, previous chest 4491 irradiation.

4492 Bone density assessment

The importance of monitoring bone health in women with POI has been described in detail in Section VI. POI and musculoskeletal health. Measurement of bone mineral density (BMD) with Dual-Energy Xray Absorptiometry (DXA) should be performed at diagnosis of POI in all individuals where available, especially where other risk factors for osteoporosis are present. Optimal timing of repeat bone density measurement is unclear.

4498 Cardiovascular health

Women with POI (spontaneous and iatrogenic) are at increased risk of cardiovascular disease, including coronary artery disease, heart failure and stroke. As such assessment of cardiovascular risk factors is recommended in women with POI, with a suggestion for screening of blood pressure, lipid profile, diabetes screening (HbA1c), weight and smoking status at least annually, and more frequently or additional risk factors where indicated. Further information on Monitoring of Cardiovascular health is discussed in section VII.3. Monitoring of cardiovascular risk factors

4505 *Recommendation*


Women with POI should be advised to have a clinical review at least annually, addressing individualised risk review (specifically cardiovascular and bone health) and adherence to therapy.

4506

4507



4508 FIGURE 14. SUMMARY OF MONITORING OF WOMEN WITH POI FROM DIAGNOSIS TO USUAL AGE OF MENOPAUSE





4513 XI.5. Testosterone Therapy

4514 **PICO QUESTION: WHAT IS THE ROLE OF TESTOSTERONE THERAPY IN POI?**

The decision to treat with androgens in women with POI should be made as in women with UAM using a biopsychosocial approach (Davis *et al.*, 2019). The currently accepted indication is for hypoactive sexual desire disorder (HSDD) which is distressing low libido in women who are replete of systemic and local estrogen. Not all women with POI require androgens but all should be counselled about the possibility of using androgens if they have distressing symptoms not alleviated by conventional HRT.

Androgen concentrations fall with advancing age (Davison *et al.*, 2005). There is much debate whether the cessation of ovarian function (at any age) leads to a more rapid decline in androgen concentration. A systematic review and meta-analysis have shown that women with POI are at risk for decreased concentrations of androgens such as testosterone, dehydroepiandrosterone sulphate and androstenedione (Soman *et al.*, 2019).

A major pitfall in this research area is the lack of reliable testosterone assays. Although liquid 4525 4526 chromatography-tandem mass spectrometry (LCMS) seems most precise and sensitive for measuring the relatively low testosterone levels in women compared to men, most available studies on the 4527 incidence of androgen deficiency and the efficacy of androgen replacement therapy have applied less 4528 4529 reliable assays such as direct radioimmunoassay (Stanczyk, 2006, Janse et al., 2011). Moreover, there is 4530 large between-women variability, thereby making the diagnosis of hypoandrogenemia even more 4531 challenging (Shiraishi et al., 2008, Labrie et al., 2011). In women with non-iatrogenic POI, there is still debate whether androgen concentrations are different from those in age-matched cycling women 4532 (Janse et al., 2012). In contrast, women who underwent oophorectomy at a young age are probably 4533 hypo-androgenic due to the lack of ovarian androgen production, which makes up for 25% of the total 4534 production in premenopausal women (Longcope, 1986, Sluijmer et al., 1995, Burger, 2002, Fogle et al., 4535 4536 2007, Janse et al., 2012) and around 50% in postmenopausal women (Simon, 2002, Stanczyk et al., 2019).

4537 Despite all the uncertainties, it has become clear from previous chapters that women with POI, either 4538 spontaneous or iatrogenic, may suffer from long-term health consequences such as diminished sexual 4539 function, neurological complaints, and decreased bone density. It has been suggested that androgen 4540 replacement therapy may be used for these indications. This section provides an overview of the 4541 available evidence on indications for androgen replacement therapy, possible risks, and routes of 4542 administration.

4543 Indications

4544 Sexual function

4545 As was noted in IX. POI and sexuality, it is important to realize that not all women identified by medical 4546 researchers as presenting with hypoactive sexual desire disorder (HSDD) or female sexual disorder, 4547 actually have low testosterone levels, and no single testosterone level predicts low female sexual 4548 function (Schwenkhagen and Studd, 2009). However, according to the International Society for the 4549 Study of Women's Sexual Health clinical practice guideline for the use of systemic testosterone for HSDD 4550 in women, total testosterone and SHBG (to calculate the free androgen index) should be measured before initiating therapy and during testosterone therapy to avoid supra-physiological levels (Parish et 4551 4552 al., 2021). A series of randomised, placebo-controlled trials of testosterone patches in women after BSO have been carried out over the past years, using 300µg testosterone patches daily for 24 weeks, in the 4553 4554 form of a twice weekly patch worn on the abdomen (Shifren et al., 2000, Braunstein et al., 2005, Buster 4555 et al., 2005, Simon et al., 2005, Davis et al., 2006). Overall effectiveness is reported for improved sexual 4556 function as assessed by self-reports on psychometric scales and sexual activity logs alike, over and above



4557 a large placebo effect. All of the studies involved short-term treatment and follow-up and reported mild 4558 or minimal short-term adverse effects of treatment. The efficacy of transdermal testosterone 4559 replacement for sexual dysfunction seems to be similar in surgically and spontaneously postmenopausal women with and without estrogen therapy (Davis et al., 2006, Panay et al., 2010). The 4560 4561 recent global consensus position statement on the use of testosterone therapy for women clearly stated that total testosterone level should not be used to diagnose HSDD, and testosterone treatment should 4562 4563 only use formulations (transdermal) that achieve blood concentrations of testosterone that approximate 4564 premenopausal physiological concentrations (Davis et al., 2019). Systemic DHEA cannot be 4565 recommended for women with HSDD (Davis et al., 2019).

4566 Neurological function

4567 Studies on neurological function and the use of androgen replacement therapy in women with 4568 spontaneous or iatrogenic POI are scarce. An older study in women who underwent surgical menopause 4569 and received either a combined estrogen-androgen preparation, estrogen alone, or androgen alone 4570 indicated a protective role of these treatments on two tests of short-term memory, a test of long-term 4571 memory and a test of logical reasoning that were significantly impaired with placebo use (Sherwin, 4572 1988). Another study focussed on girls with Turner syndrome between 10 and 14 years old and not 4573 using estrogen replacement. In this study, the effect of androgen replacement therapy on neurological 4574 function, including verbal abilities, spatial cognition, executive function and working memory, was 4575 investigated. Oxandrolone-treated girls showed improved performance on the working memory 4576 domain score only after 2 years of treatment as compared to girls receiving placebo (Ross et al., 2003). Studies in the elderly (postmenopausal women and elderly men) have shown conflicting results, and 4577 only involved small samples, inducing supraphysiological levels of androgens and without control for 4578 confounders (Wisniewski et al., 2002, Davison et al., 2011, Kocoska-Maras et al., 2011). More recent 4579 4580 systematic reviews on the impact of testosterone on cognitive function in postmenopausal women have not shown a benefit ((Sultana et al., 2023a); more data are required in both POI and usual age 4581 4582 menopause. Similarly, a systematic review did not support a beneficial effect of DHEA therapy on cognitive performance in postmenopausal women (Sultana et al., 2023b). 4583

4584 Bone health

4585 The effect of testosterone on bone health has been discussed elsewhere (see Testosterone) showing 4586 mixed results in terms of benefit.

4587 Risks of androgen therapy

4588 Masculinising effects

4589 Supraphysiological and rogen concentrations may lead to acne, hirsutism, deepening of the voice and 4590 androgenic alopecia. However, these have not been described often in studies in which women receive 4591 physiological levels of testosterone of up to 5mg of testosterone per day. A study by Buster et al, also 4592 including 54 (10%) women with surgical POI, reported a non-significant increase of alopecia, acne, and 4593 voice deepening (5.3 vs 2.6%, 7.5 vs 4.1%, 3.0 vs 1.5%, respectively)(Buster et al., 2005). The most 4594 reported side effect of transdermal testosterone therapy was unwanted (non-scalp) hair growth (9% in 4595 the treatment group vs. 5.3% in the placebo group) (Simon et al., 2005). In the recent systematic review 4596 and meta-analysis of studies using physiological doses of testosterone replacement only the incidence 4597 of acne and excess hair growth were increased with no significant effect on alopecia, voice changes or 4598 clitoromegaly (Islam et al., 2019b).

4599 Endometrial effect

Theoretically, androgen therapy could lead to endometrial hypertrophy by peripheral aromatization of androgens to estrogen. However, the endometrium is thought to be devoid of aromatase and androgens are now believed to be associated with endometrial atrophy. In one large clinical study



- 4603 (APHRODITE) on transdermal testosterone therapy in postmenopausal women aged 20-70 years (of 4604 whom one quarter had surgical menopause) not using estrogen replacement, similar endometrial 4605 biopsy findings were identified between baseline and after 1-year use. The frequency of endometrial 4606 bleeding was increased in the group with higher dosage (300 compared to 150µg), along with an 4607 increased occurrence of endometrial atrophy on biopsy (Davis *et al.*, 2008).
- 4608 When using estrogen replacement along with testosterone treatment, it is advisable to also add 4609 progestogen therapy for endometrial safety, as was discussed in XI.2. Risks of hormone therapy. Long-4610 term follow-up data of the effect of androgen therapy on the endometrium is not available.

4611 Breast cancer risk

4612 None of the studies conducted to date showed an increased risk of breast cancer associated with the 4613 use of testosterone, but conclusive data on long-term safety are not yet available (Davis et al., 2012). The APHRODITE study, mentioned in the previous section on endometrial effects, observed no 4614 4615 differences in breast density between transdermal testosterone and placebo use (Davis et al., 2008). 4616 After using testosterone patches for over 1 year on average, no increase in breast cancer incidence 4617 compared with that of the Australian reference population was identified during a follow-up of six years 4618 (Davis et al., 2009). The combination of methyltestosterone with estrogen was associated with an increased risk of breast cancer (RR 2.48; 95% CI 1.53 to 4.0) in women included in the Nurses' Health 4619 4620 Study with a follow-up of 24 years (Tamimi et al., 2006) but this was not physiological replacement, and 4621 the estrogen could have had an effect. The data from the large meta-analysis by Islam et al showed no 4622 increase in risk of breast cancer but there were no RCT data for longer than 24 months (Islam et al., 4623 2019b).

4624 Routes of administration, dose, duration, monitoring

- 4625 Testosterone may be administered transdermally (gel/patch/cream), orally or through an implant. The patches are not commercially available and currently only a 1% testosterone cream is licensed for use 4626 in women with HSDD in Australia. A search for women with menopause at the usual age identified that 4627 oral administration may be associated with decreased high-density lipoprotein (HDL) cholesterol and 4628 other less-favourable lipid changes (Chiuve et al., 2004), while in transdermal administration this is not 4629 observed (Braunstein et al., 2005). Moreover, the transdermal route is the most investigated in women. 4630 4631 The major complaint in transdermal use of testosterone is application site effects such as excess hair 4632 growth and skin irritation with patches, leading to a discontinuation of the transdermal patches in 4% 4633 in a surgically postmenopausal group (Simon et al., 2005). Similar to estrogen and progestogen replacement, women's preferences need to be considered when deciding on the route of administration 4634 4635 of androgen replacement.
- Androgen replacement should not be given in the dosages prescribed for men, since these will lead to supraphysiological levels in women for which there are no data on safety and efficacy. One study in 447 women aged 24-70 years after BSO identified a 67%, statistically significant increase of sexual desire with a 300µg/day patch compared to placebo and 150 µg/day. The higher dosage of 450µg/day did not lead to a further increase of sexual desire.
- The optimal duration of treatment is unclear. Most studies have only prescribed androgen replacement for the duration of the trial, 6 to 12 months on average, and no RCT evidence on efficacy and safety is available after 24 months. No studies have been performed on the monitoring of androgen treatment. In the recent global consensus statement (Davis *et al.*, 2019) it was agreed that the baseline total testosterone concentration should be evaluated before treatment is started and continue to be measured every 3 to 6 months to avoid overdose, particularly with off label use of male gels. Adverse



4647 effects and the effect of the treatment should be evaluated and if no improvement of sexual function is4648 seen after a maximum of 6 months, treatment should be discontinued.

4649 *Recommendations*

4650

The guideline group recommends that women with POI are informed that there is limited data for androgen treatment for indications other than hypoactive sexual GPP desire disorder (HSDD), and that long-term health effects are unknown.

4651 Justification

Androgens decline with age and women with POI display lower circulating levels of androgens. The 4652 4653 methodological difficulties in accurately measuring testosterone in women in routine practice with reliable sensitive assays at low levels, coupled with the paucity of safe treatments, have significantly 4654 delayed clinical research on significant endpoints such as symptoms and conditions that may be 4655 4656 androgen dependent. Current knowledge is based on clinical trials, often with small sample sizes, short duration and follow-up, and conducted with a variety of products. These methodological limitations 4657 4658 indicate the need for a conservative approach to testosterone therapy. Transdermal route of 4659 administration of testosterone at the dose that mimics premenopausal circulating levels is safe and 4660 should be monitored every 3-6 months to avoid supra-physiologic levels. No adverse cardiovascular or oncologic effects have been documented with transdermal testosterone but data in women with POI 4661 4662 are lacking. The only evidence-based indication for testosterone therapy for women is for the treatment of postmenopausal women with low sexual desire with associated personal distress (HSDD). Other 4663 4664 health benefits, especially bone measures and cognitive function, should be evaluated in long-term 4665 well-designed trials.

4666



4667 XI.6. HT in women with latrogenic POI

4668

4669

4670

PICO QUESTION: What are the specific considerations for hormone replacement therapy in iatrogenic POI ?

4671 In contrast to HT regimens for women with UAM, HRT regimen for women with iatrogenic POI need to 4672 consider the impact of hormones on the primary disease. Different primary diseases convey different 4673 risks of HRT. There is a lack of data specific to the POI population in many instances and evidence in 4674 relation to older women is cited below.

4675 Breast Cancer

4676 In women with breast cancer, POI may occur secondary to chemotherapy or bilateral oophorectomy 4677 (discussed in section XI.2. Risks of hormone therapy). RCT studies of breast cancer survivors, predominately aged over 50 years, have shown that HRT may increase the risk of breast cancer 4678 recurrence (Kenemans et al., 2009, Bundred et al., 2012, Fahlen et al., 2013). The recurrence of breast 4679 4680 cancer is related to many factors, including family history, heredity, pathological type, stage, 4681 differentiation, extent of surgery, radiotherapy, chemotherapy, and endocrine therapy. The expression of hormone receptor (ER/PR) (Poggio et al., 2022) and BMI (Cui et al., 2014) are also important factors 4682 4683 for recurrence. Among non-breast cancer survivors, a retrospective study of Hodgkin lymphoma 4684 survivors showed that breast cancer risk increased linearly with radiation dose (Krul et al., 2017). However, HRT did not appear to increase breast cancer risk in Hodgkin survivors with premature 4685 menopause (Krul et al., 2017). 4686

4687 Gynaecological Cancers

- In terms of reproductive system cancers, vulvar, vaginal, and cervical squamous cell carcinoma are not
 hormone-dependent and can be treated with systemic or local HRT (Rees *et al.*, 2020).
- 4690 Cervical Cancer

Cervical cancer is more common in women under 40 years of age. Although most cervical cancer 4691 4692 survivors might need to consider HRT to relieve menopausal symptoms (Lee et al., 2022b), less than half of patients might be willing to use (Cotangco et al., 2020), counselled or prescribed HRT (Rauh et al., 4693 2017), or continue HRT beyond 5 years (Everhov Å et al., 2015). Women were more likely to be prescribed 4694 4695 HRT if younger age, fewer co-morbidities, earlier stage disease and longer follow-up duration (Rauh et 4696 al., 2017). HRT does not increase the risk of cervical squamous cell carcinoma (Vargiu et al., 2021). 4697 However, in addition to squamous cell carcinoma, cervical cancer also includes adenocarcinoma, 4698 adenosquamous carcinoma and other types. Meta-analysis showed that HRT may slightly increase the 4699 risk of recurrence in patients with cervical adenocarcinoma (Standardised incidence ratio 1.83; 95% CI 4700 1.24 to 2.59, 1 study, > 5 years of HRT) (Vargiu et al., 2021).

4701 Endometrial Cancer

The overall 5-year survival rate of endometrial cancer is approximately 86%, increasing to 97% if the disease is confined to the uterus (Edey *et al.*, 2018). Retrospective studies have shown that postoperative HRT does not increase the risk of recurrence in patients with early-stage, low-risk endometrial cancer (Suriano *et al.*, 2001). A randomized double-blind study in women, median age 57 years (<10% with POI), showed that the absolute recurrence rate was low (2.3% in ERT patients versus 1.9% in placebo group) with stage I or II endometrial cancer at median 36 months follow-up with no significant increased risk of recurrence or death versus placebo (Barakat *et al.*, 2006). A 2014 systematic review including one

4709 RCT and five observational studies (n=896 HRT users and 1079 nonusers) concluded that there was no



4710 evidence of an increased risk of endometrial cancer recurrence with HRT use (Shim *et al.*, 2014). Given

that the positive effect of HRT on quality of life in surgically postmenopausal patients may outweigh the risk of recurrence, systemic or vaginal estrogen may be considered in patients with low-grade, early detected endometrial cancer with low risk of recurrence, but the regimen needs to be individualized and discussed in full detail with the patient (Rees *et al.*, 2020).

4715 Ovarian cancer

4716 There is limited evidence regarding the risk of recurrence in patients with ovarian cancer treated with 4717 HRT after surgery. A retrospective study of patients with papillary serous ovarian cancer (SOC) showed 4718 that progression-free survival (PFS) in patients with SOC was mainly related to FIGO stage and whether 4719 cytoreductive surgery was adequate. HRT is not a prognostic factor for PFS in SOC patients (Zhang et 4720 al., 2016). Meta-analysis showed that HRT improved overall survival (HR 0.71; 95% CI 0.54 to 0.93) and 4721 had little or no effect on PFS (HR 0.76; 95% CI 0.57 to 1.07) in epithelial ovarian cancer patients, with 4722 very low rates of breast cancer, transient ischemic attack, cerebrovascular accident, and myocardial 4723 infarction (Saeaib et al., 2020).

4724 In general, malignant tumours with hormone dependence, such as uterine sarcoma, endometrioid 4725 carcinoma, ovarian clear cell carcinoma, ovarian granulosa cell tumour, sex cord-stromal tumours, 4726 require caution when considering hormone replacement therapy. Estrogen or progesterone receptor 4727 status is an important factor when considering the safety of HRT (O'Donnell *et al.*, 2016).

4728 Surgical Menopause

In patients who undergo surgical menopause, menopausal symptoms tend to be more severe than in spontaneously menopausal women due to sudden decline in hormone levels (O and Manyonda, 2022). HRT relieves symptoms associated with estrogen deficiency, and decreases risk of death, CVD, osteoporosis, and cognitive decline (refer to respective chapters) (Techatraisak *et al.*, 2021). In recent years, androgen deficiency in surgical postmenopausal patients has also attracted attention. Metaanalysis found that androgen supplementation in surgically menopausal patients might improve sexual desire, function, and satisfaction, but not mood (Stuursma *et al.*, 2022).

4736 Risk reducing bilateral oophorectomy.

- A large population-based retrospective study has shown that BRCA mutation positivity is an important 4737 4738 reason to choose risk reducing bilateral salpingo-oophorectomy (RRBSO). However, compared with 4739 other patients undergoing premature surgical menopause for medical reasons (such as endometriosis, 4740 or benign ovarian tumours), BRCA mutation-positive patients are more likely to opt for HRT after risk 4741 reducing surgery (Jang et al., 2020). These women chose RRBSO because of a family history of cancer, 4742 positive BRCA mutations, or other cancer risk. Prospective, multicentre, age-matched cohort studies 4743 show that most of these women experienced menopausal symptoms after surgery (Hickey et al., 2017), 4744 decreased bone density and strength (Jiang et al. 2021), depression and anxiety (Hickey et al., 2021b), 4745 increased cardiovascular and metabolic risk (Hickey et al., 2021d), and decreased quality of life (Hickey 4746 et al., 2021c).
- 4747 HRT should be considered as early as possible after RRBSO in women under 50 years old, especially 4748 under 46 years old, to reduce the incidence of estrogen deficiency related symptoms and co-4749 morbidities. In a large prospective study (n=872), estrogen-only therapy use is associated with reduced 4750 breast cancer risk in BRCA-1 mutation carriers undergoing RRBSO before 45 years of age (HR 0.24; 95% 4751 CI 0.06 to 0.98 for over 5 years of ERT use) (Kotsopoulos et al., 2018). In contrast, addition of a progestin 4752 is associated with increased risk of breast cancer (HR 1.78; 95% CI 1.17 to 9.73 for over 5 years of HRT) 4753 (Kotsopoulos et al., 2018). Consistent with this, a 2018 meta-analysis (three studies, n=1100) indicated 4754 no increased risk of breast cancer in BRCA1/2 mutation carriers receiving HRT post RRBSO (HR 0.98;



4755 95% CI 0.63 to 1.52) with possible greater benefit with estrogen-only therapy (Marchetti et al., 2018). 4756 The cumulative incidence of breast cancer among BRCA-mutation carriers was 12% with estrogen-only 4757 therapy. In contrast, the incidence of breast cancer was 22% with combined estrogen+progestogen therapy (Kotsopoulos, 2018). A systematic review concluded that HRT mitigates risks of premenopausal 4758 4759 RRBSO with evidence of safety for short term use in BRCA mutation carriers without breast cancer and 4760 recommends use after RRBSO until AUM (Gaba and Manchanda, 2020). Thus, BRCA mutation carriers undergoing hysterectomy with RRBSO can choose estrogen-only replacement therapy post-surgery. 4761 4762 However, for BRCA mutation carriers who retain their uterus, counselling with consideration of 4763 alternative treatment options may be needed (Gordhandas et al., 2019). Available studies suggest that 4764 HRT may not increase ovarian cancer risk in BRCA mutation carriers (Huber et al., 2021).

4765 *Hematopoietic stem cell transplantation*

4766 Hematopoietic stem cell transplantation (HSCT) is an important method for the treatment of 4767 haematological diseases, especially haematological malignancies, and some congenital or hereditary 4768 diseases. However, the myeloablative conditioning regimen (MAC) before transplantation will cause 4769 irreversible damage to the patient's ovaries. The resulting POI affects the health of multiple systems 4770 such as skeletal, cardiovascular, urogenital, and neurological systems, quality of life, and even reducing 4771 life expectancy (Gargus *et al.*, 2018). Prospective observational studies suggest that HRT is safe for 4772 patients with POI after HSCT. HRT can relieve menopausal symptoms and correct bone loss after HSCT

4773 (Ha et al., 2020), and does not increase the risk of recurrence of the primary disease (Yang et al., 2017).

4774 **Recommendations**

The guideline group recommends a personalised approach to risks and benefits of hormone therapy in women with iatrogenic POI after gynaecological/breast cancer

GPP

Hormon	e therapy does not increase the risk of recurrence of squamous		
	cinoma of the cervix and is recommended for women with	$\oplus \oplus \oplus \bigcirc$	STRONG
iatrogen	nic POI due to treatment of squamous cell carcinoma.		

4776

4775

Hormone therapy may be associated with a low risk of recurrence of		
cervical adenocarcinoma and a personalised approach considering	$\oplus \oplus \bigcirc \bigcirc$	STRONG
individualised hormone therapy risk and benefits is recommended.		

4777

HCPs could consider use of hormone therapy in women with early-		
stage low-risk endometrioid adenocarcinoma, as there is a low risk of	$\Theta \oplus OO$	CONDITIONAL
cancer recurrence with hormone therapy use		

4778

HCPs could consider hormone therapy in women with iatrogenic POI	$\oplus \oplus \oplus \bigcirc$	CONDITIONAL
due to epithelial ovarian cancer.		

4779

The effect of hormone therapy on the risk of recurrence of nonepithelial ovarian cancer is unclear and it is suggested that HCPs use CONDITIONAL



an individualised approach to prescribing hormone therapy including consideration of tumour hormone receptor status.		
Hormone therapy should be avoided in women with hormone dependent ovarian or uterine tumours including uterine sarcoma, endometrioid carcinoma, ovarian clear cell carcinoma, ovarian granulosa cell tumour, or sex cord-stromal tumours.	⊕⊕⊕⊖	STRON
Women should be informed of the risks of iatrogenic POI and risks and benefits of hormone therapy before risk reducing bilateral salpingo- oophorectomy.	⊕0000	STRON
Women with POI should be informed that hormone therapy is generally contra-indicated in breast cancer survivors.	⊕⊕⊕⊖	STRON
Women with BRCA1/2 mutations without a personal history of breast cancer should be advised that hormone therapy is an option after risk reducing bilateral salpingo-oophorectomy	⊕0000	STRON
It is recommended that individualised hormone therapy or pubertal induction be commenced in girls/women with POI following hematopoietic stem cell transplantation.	⊕⊕⊖⊖	STRON

4785 Justification

4786 While in general, HT is recommended in women with POI, for women with iatrogenic POI after cancer 4787 treatment, risks may outweigh the treatment benefits. Different recommendations were formulated for 4788 iatrogenic POI after gynaecological/breast cancer taking into consideration the possible risks of 4789 recurrence or reactivation of cancer, and other risk factors (see also Table X Summary of 4790 recommendations for POI linked to gynaecological/breast cancer.

4791



TABLE IX SUMMARY OF RECOMMENDATIONS FOR POI LINKED TO GYNECOLOGICAL/BREAST CANCER

Cancer/previous diagnosis		нт	Risk of recurrence with HT use	Other considerations
Squamous cell carcinoma	\checkmark	Recommended	Not increased	
Cervical adenocarcinoma	F	Consider after risk assessment	Low risk	
Early-stage low-risk endometrioid adenocarcinoma	F	Consider after risk assessment	Low risk	
Epithelial ovarian cancer	,	Consider after risk assessment	Z	
Non-epithelial ovarian cancer	,	Consider after risk assessment	Moderate risk	Tumour hormone receptor status.
Hormone dependent ovarian or uterine tumours (uterine sarcoma, endometrioid carcinoma, ovarian clear cell carcinoma, ovarian granulosa cell tumour, sex cord-stromal tumours)	0	Contra-indicated	High risk	
Breast cancer survivors.	0	Contra-indicated	High risk	
BRCA1/2 mutation carrier after RRBO, without a personal history of breast cancer	•	Can be considered	NA	Estrogen-only HRT has lower risk compared to combined estrogen/progestogen
POI following hematopoietic stem cell transplantation	\checkmark	Recommended	Not increased	Individualised HT / pubertal induction



XII. POI Treatment: Non-hormonal treatments, complementary treatments, and lifestyle interventions

Hormone therapy (HT) is preferentially used in women with POI to prevent or treat sequelae as detailed
in previous chapters. However, some women with POI may choose against HT, while for other women,
including those with hormone-sensitive malignancies, studies have shown severe adverse events and
HT may not be appropriate.

Both women and health professionals have increased interest in non-hormonal, complementary and
lifestyle alternatives to HT and are interested in both pharmacological and non-pharmacological options
to relieve menopausal symptoms and improve quality of life.

4805 XII.1. Non-hormonal therapies

In this section the evidence regarding non-hormonal therapies for symptom management in POI is presented. Indirect evidence from studies of peri- or postmenopausal women is also included. The 2023 nonhormone therapy position statement of The North American Menopause Society provides a useful overview of this topic in the non-POI population (2023). Non-hormonal therapies for urogenital symptoms are discussed in Section IX.3. Treatment of genital-urinary symptoms.

4811 **PICO QUESTION: WHAT NON-HORMONAL THERAPIES ARE AVAILABLE FOR POI?**

The systematic search of non-hormonal therapies included the following: antidepressants, clonidine, gabapentin, pregabalin, neurokinin receptor antagonists, oxybutynin, cognitive behavioural therapy (CBT), stellate ganglion blockade and hypnosis. Clinical outcomes included vasomotor symptoms and other menopause related symptoms, e.g. sleep, and quality of life.

4816 Women with POI

We did not identify any RCTs, cohort or case-control studies evaluating non-hormonal treatments in 4817 women with POI specifically, as defined in chapter 2. Several RCTs (Hummel et al., 2017) included women 4818 4819 with iatrogenic menopause aged over 18 years or aged under 50 years with menopause following risk reducing BSO (Bober et al., 2015), but did not specify POI. The following summary of the evidence relates 4820 to perimenopausal or postmenopausal women, including breast cancer survivors, and may be of 4821 4822 relevance to women with POI (Table). It is important to remember that many nonhormonal 4823 pharmacological therapies for vasomotor symptoms are not government approved for this indication in many countries and their use is considered "off label". 4824

4825 Pharmacologic therapies for vasomotor symptoms

4826 Antidepressants

4827 A 2022 systematic review of Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin-4828 Norepinephrine Reuptake Inhibitors (SNRIs) which included 36 RCTs (27 acceptable and nine low 4829 quality) involving 7347 healthy peri-/postmenopausal (studies involving women with cancer were 4830 excluded), concluded that the SSRIs escitalopram, paroxetine, and fluoxetine, and SNRIs, venlafaxine 4831 and desvenlafaxine, are effective in reducing vasomotor symptom frequency and severity (Azizi *et al.*, 4832 2022). Studies on the effectiveness of sertraline, citalopram, fluvoxamine, and duloxetine were limited 4833 in number or showed inconsistent results.



Data from the MS FLASH RCTs involving 899 peri-/postmenopausal women aged 40-62 years with prevalent hot flushes, reported 18-37% reductions in vasomotor symptom frequency with 10-20mg escitalopram, 75 mg venlafaxine and 0.5 mg oral estradiol at 8-12 weeks versus placebo (Joffe *et al.*, 2014, Guthrie *et al.*, 2015). Estradiol was associated with the greatest reduction in vasomotor symptoms.

Two previous meta-analysis of 5 RCTs (1482 postmenopausal women) with significant heterogeneity (Wei *et al.*, 2016, Riemma *et al.*, 2019), reported a significant reduction in hot flush frequency with paroxetine versus placebo at 12 weeks (mean difference 7.36 per week; 95% CI 4.25 to 10.46; P < 0.00001) (Wei *et al.*, 2016). Efficacy was observed with low dose paroxetine and in women with either natural or surgical menopause (Wei *et al.*, 2016).

- A recent RCT involving 91 symptomatic postmenopausal Mexican women, average age 54 years, comparing 20mg fluoxetine and 20mg citalopram observed reduction in the menopause rating scale scores for both agents at 3 months and citalopram at 6 months follow-up; however, citalopram was associated with greater improvement compared with fluoxetine with benefits observed for vasomotor, psychological, urogenital, libido and somatic subdomains (Rios-Espinosa *et al.*, 2022).
- A pharma sponsored RCT involving 1888 postmenopausal women aged 40-65 years reported decreased hot flush frequency and severity at 4 and 12 weeks with esmirtazepine compared to placebo (Birkhaeuser *et al.*, 2019).

4851 Gabapentanoids

Gabapentanoids are used for the management of seizures and neuropathic pain. A 2020 meta-analysis 4852 of gabapentin and pregabalin (19 RCTs and 2 randomized crossover trials, n= 3519 participants) 4853 4854 reported a reduction in hot flush frequency with gabapentin (mainly 900mg/day dosing) versus 4855 comparator with moderate quality evidence at four weeks and low-quality evidence at 12- and 24-weeks 4856 follow-up (Shan et al., 2020). A similar response was seen in women with and without breast cancer. 4857 Two crossover studies showed no difference between gabapentin and fluoxetine or venlafaxine in 4858 reducing hot flush severity. Gabapentin was less effective than estrogen therapy (2 RCTs) and was associated with a higher rate of dizziness and drowsiness (Shan et al., 2020). Similar findings were 4859 4860 reported in another meta-analysis (Yoon et al., 2020). Pregabalin was superior to placebo for hot flush frequency and severity (1 RCT) but inferior to Stellate ganglion block (1 RCT) (Shan et al., 2020). However, 4861 4862 pregabalin is a controlled substance in many countries due to the potential for abuse (North American 4863 Menopause Society)

4864 **Oxybutynin**

Oxybutynin, an antimuscarinic, anticholinergic agent, is used for the management of overactive bladder and urinary urge incontinence. A RCT of 148 healthy postmenopausal women (surgical menopause excluded) aged 40-65 years with moderate- severe vasomotor symptoms reported significant reduction in hot flush frequency with 15 mg daily extended-release oxybutynin versus placebo (mean change -9.48 and -4.69 hot flushes/day respectively) at 12 weeks follow up (Simon *et al.*, 2016). A significant reduction in severity of hot flushes with oxybutynin versus placebo was also observed.

4871 *Clonidine*

4872 Clonidine, a centrally acting alpha2 adrenergic antagonist, is used to treat hypertension. A 2010 4873 Cochrane review (Rada *et al.*) reported (on the basis of two RCTs using transdermal patch or oral 4874 clonidine; n=252) that clonidine significantly reduced the number and severity of hot flushes by 4875 approximately 20% compared with placebo. A subsequent RCT involving 102 women with breast cancer 4876 (Boekhout *et al.*, 2011) compared venlafaxine, clonidine and placebo and reported significantly lower 4877 hot flush scores in the clonidine versus placebo groups at 12 weeks follow-up. Clonidine is less effective 4878 compared to other pharmacological agents and is associated with adverse effects including dry mouth,



4879 hypotension, headache, and dizziness with sudden cessation resulting in elevation of blood pressure4880 (NAMS 2023 position statement)

4881 Neurokinin B receptor antagonists

4882 Fezolinetant, a neurokinin B3 receptor antagonist postulated to act on the hypothalamic KNDy neuron 4883 thermoregulatory system, was recently approved in Europe, North America, and Australia for the 4884 management of vasomotor symptoms in postmenopausal women (Morga et al., 2024). Phase 2 studies 4885 of elinzanetant (a dual neurokinin B 1 and 3 receptor antagonist) and phase 3/4 studies of fezolinetant 4886 in other populations are ongoing (Koysombat et al., 2024). The SKYLIGHT 1,2 and 4 RCTs involving 4887 ~1000 postmenopausal women, average age 54 years, demonstrated efficacy of fezolinetant at 12 and 4888 52 weeks versus placebo in reducing vasomotor symptoms(mean difference in hot flush frequency at 4889 12 weeks versus placebo -2.51 (95% CI -3.20 to -1.82) (Johnson et al., 2023, Lederman et al., 2023) 4890 (Santoro et al., 2024). Pooled 12-week data from Skylight 1 and 2 indicated efficacy across a range of 4891 intrinsic (age, BMI, ethnicity, baseline vasomotor symptom duration or severity) and extrinsic (lifestyle, 4892 geographic region, previous HT use) factors indicating efficacy in diverse populations (Santoro et al.). A 4893 recent systematic review of neurokinin B antagonists (fezolinetant, elinzanetant) included 6 RCTs and 4894 reported > 50% reduction in moderate-severe hot flush frequency by 12 weeks versus placebo with favourable safety profiles and low incidence of liver enzyme elevations (Cieri-Hutcherson et al., 2024). A 4895 4896 2024 Bayesian network meta-analysis (Morga et al., 2024) involving 2 fezolinetant RCTs and 23 4897 comparator studies reported that fezolinetant 45 mg reduced the frequency of moderate to severe 4898 vasomotor symptoms significantly more than placebo, paroxetine, desvenlafaxine or gabapentin with similar efficacy to low or usual dose HRT regimens at 12 weeks follow-up (Morga et al., 2024). 4899 4900 Fezolinetant significantly reduced vasomotor symptom severity compared with placebo or 50mg desvenlafaxine but was less effective compared to tibolone or conjugated estrogen/ bazedoxifene. 4901

4902 **Other**

4903 A phase 2 study of oral Q122 in 131 women aged 18-70 years with estrogen- receptor positive breast 4904 cancer demonstrated a significant reduction in vasomotor symptom severity compared to placebo 4905 (Vrselja et al., 2022). The effect of sulpiride, a neuroleptic which acts on dopaminergic and serotoninergic 4906 receptors, was investigated in a small RCT involving 29 postmenopausal Brazilian women (Borba et al., 2020). Reduction in hot flush severity and frequency at four- and eight-weeks follow-up was observed 4907 4908 with sulpiride compared with placebo. Suvorexant, a dual orexin receptor antagonist, reduced nighttime 4909 vasomotor symptoms and insomnia indices in a small RCT of 56 postmenopausal women (Rahman et 4910 al., 2022)

4911 Non-pharmacological therapies for vasomotor symptoms

4912 Cognitive behavioural therapy (CBT)

4913 A 2022 meta-analysis including 14 RCTs comprising 1618 women with and without breast cancer (six 4914 and eight studies respectively) investigated CBT in managing menopausal symptoms. In most studies, 4915 interventions were delivered face to face (both individual and group) with the remaining studies using 4916 web-based interventions (Ye et al., 2022). CBT intervention groups were compared to waitlist (n = 9), 4917 usual care (n = 3), or menopause education (n = 2) control groups and involved various settings 4918 including the workplace. CBT was associated with reductions in vasomotor symptom problem rating 4919 and frequency compared to controls which extended to a mean 23-week follow-up. However, women 4920 with treatment induced menopause displayed a smaller response to CBT compared to those with usual 4921 age menopause. Secondary analysis (Atema et al., 2020) of a RCT (Atema et al., 2019, Ye et al., 2022) 4922 indicated that breast cancer survivors with a high school/vocational training degree benefited most 4923 from an internet based CBT program for treatment-induced vasomotor symptoms and that the positive 4924 effects of the CBT program on vasomotor and overall menopausal symptom burden were mediated by



4925 the development of healthier beliefs regarding the ability to cope with and control vasomotor 4926 symptoms. Secondary analysis (Donegan et al., 2022) of a RCT (Green et al., 2019, Ye et al., 2022) 4927 included 51 peri-/postmenopausal women aged 40-65 who received weekly group CBT for 12 weeks or 4928 a wait-list control group. CBT participants reported greater improvements compared to controls in 4929 menopause-specific beliefs, dysfunctional attitudes, and menopause-specific behaviours (assessed 4930 using validated scales) at 12 weeks treatment and then at a further three-month follow-up. Economic 4931 analyses concluded that CBT was cost effective for menopausal symptoms in women with breast cancer 4932 (Mewes et al., 2015, Verbeek et al., 2019).

4933 *Hypnosis*

4934 Hypnosis, a mind-body therapy, uses mental imagery for coolness, deep hypnosis, and dissociation from 4935 hot flushes and positive imagery to alleviate vasomotor symptoms. RCTs in women with and without 4936 breast cancer have shown reduction in vasomotor symptoms (subjective and objective measures) with 4937 hypnosis compared with wait list or sham hypnosis controls (Elkins et al., 2008, Elkins et al., 2013b, 4938 Barton et al., 2017). Hypnosis was similarly effective in reducing vasomotor symptoms to comparators 4939 900mg/ day gabapentin or 75 mg venlafaxine in two small RCTs of breast cancer survivors (Maclaughlan 4940 David et al., 2013, Barton et al., 2017). A pilot study of thirteen women suggests that self-guided 4941 hypnosis may also be helpful (Elkins et al., 2013a).

4942 **Other**

- 4943 No benefit was observed with non-aerobic yoga, aerobic exercise, or 1.8 g/day omega-3 fatty acid 4944 supplementation in the MS-FLASH RCT (Guthrie *et al.*, 2015).
- A review of stellate ganglion blockade RCTs concluded that vasomotor symptom frequency was reduced with stellate ganglion blockade compared with sham in one American RCT (Lee *et al.*, 2022c). Similar findings were reported in a recent RCT of stellate ganglion blockade versus saline sham in 40 symptomatic perimenopausal Chinese women with a significant reduction in hot flush frequency and severity versus control at 4-, 8- and 12-weeks follow-up (Li *et al.*, 2023c). No difference was observed in two RCTs comparing paroxetine or pregabalin to stellate ganglion blockade in women with breast cancer (Lee *et al.*, 2022c).
- A systematic review and meta-analysis of 12 studies (including 6 studies of breast cancer survivors) with 4952 high heterogeneity involving 1019 postmenopausal women examined the effect of psychological 4953 4954 interventions including CBT (5 studies), behavioural therapy (4 studies) and mindfulness-based therapies 4955 (3 studies) on menopausal symptoms compared to controls (predominately wait list or usual care) (van 4956 Driel et al., 2019b). Web-based psychological interventions or RCTs involving yoga, hypnosis, exercise, 4957 meditation, awareness training breathing techniques as stand-alone therapies were excluded. Reduction 4958 in hot flush bother was observed with psychological interventions versus comparator but no difference 4959 was seen regarding hot flush frequency. Sub-group analysis showed similar benefits in women with 4960 natural or iatrogenic menopause. A recent Iranian study of 40 postmenopausal women indicated that 4961 an intervention involving predominately phone based cognitive behavioural counselling achieved 4962 similar vasomotor symptom benefits to an in-person intervention (Sadeghijoola et al., 2022).
- 4963

4964



4965 **TABLE X NONHORMONAL OPTIONS FOR MANAGEMENT OF VASOMOTOR SYMPTOMS (ADAPTED FROM (NORTH** 4966 **AMERICAN MENOPAUSE SOCIETY., 2023), PERMISSION REQUESTED)**

Agent	Dose	Comments
Pharmacological	-	
SNRIs	-	
Venlafaxine	37.5-150 mg/day	Commence with lowest dose then titrate upwards
Desvenlafaxine	100-150 mg/day	Commence with 50mg/day and titrate upwards
SSRIs	-	
Devenueting	7.5 mg/day*	Single dose, no nitration needed
Paroxetine	10-25 mg/day	
Escitalopram	10-20 mg/day	Commence with 5-10mg dose then titrate upwards
Citalopram	10-20 mg/day	
Other	-	
Gabapentin	900-2400 mg/day in three divided doses.	Commence with 100-300 mg nighttime dose.
Fezolinetant	45 mg/day*	Single dose no titration needed
Oxybutynin	2.5-5 mg twice daily	Commence with lowest dose then titrate upwards
Clonidine	50-150 μg/day in twice daily dosing*	Commence with 25 µg twice daily and titrate upwards.
Non-Pharmacological		
Cognitive behavioural therapy	2	
Hypnosis		

*Government approved in some countries for use for vasomotor symptoms

4967

4968 Non-hormonal therapies and the effect on other symptoms or quality of life

4969 A 2020 meta-analysis of seven RCTs (n=1949 peri-/postmenopausal women) investigating the effect of 4970 serotoninergic antidepressants on sleep indicated that these agents improved sleep quality compared with placebo but with small effect sizes (Cheng et al., 2020). Only 3/7 RCTs involving escitalopram, 4971 4972 citalopram, or venlafaxine, reported significant differences to the placebo groups. A sub-study of the MS-FLASH RCT (n=399) reported a small significant improvement in subjective sleep quality with low 4973 4974 dose estradiol but not venlafaxine versus placebo in peri-/postmenopausal women with vasomotor symptoms (Caan et al., 2015, Ensrud et al., 2015). Modest improvement in the insomnia index was 4975 4976 observed with venlafaxine versus placebo but did not reach significance with low dose estradiol. 4977 Addition of 5mg melatonin to fluoxetine resulted in greater improvements in sleep guality compared 4978 with fluoxetine alone in a Polish study of 64 postmenopausal women (Chojnacki et al., 2015).

4979 Although sleep quality indices improved in both groups, a RCT comparing 900mg/ day gabapentin to 4980 electroacupuncture administered as ten treatments over eight weeks in 58 predominately 4981 postmenopausal breast cancer survivors (age range 31-75 years) reported a significant between group 4982 difference in favour of electroacupuncture at eight weeks (Garland *et al.*, 2017). In contrast, 900mg/day 4983 gabapentin was associated with greater improvement in sleep quality index at 12 weeks follow-up 4984 compared with 60mg isoflavones in a RCT involving 50 Indian peri-/postmenopausal women, mean age 4985 50 years (Singhal and Shullai, 2016).



- 4986 Analysis of secondary outcomes indicated that stellate ganglion blockade was associated with a 4987 significant reduction in Kupperman index and sleep quality scores compared to sham (Li *et al.*, 2023c).
- Improvement in sleep indices was reported in 2/3 RCTs of 45mg fezolinetant which assessed sleep and
 two RCTs involving elinzanetant at doses>120 mg was reported in a systematic review of neurokinin B
 antagonists (Cieri-Hutcherson *et al.*, 2024). This review also reported improved quality of life scores with
 both agents.
- 4992 Sleep quality index, a secondary outcome, was significantly improved by hypnosis compared to 4993 structured attention controls in addition to vasomotor symptoms in a RCT of postmenopausal women 4994 (Elkins *et al.*, 2013b).
- The MS Flash study reported improved menopause related quality of life (MENQOL scale) with 75mg venlafaxine or 0.5mg estradiol versus placebo in women with prevalent vasomotor symptoms (Caan *et al.*, 2015, Azizi *et al.*, 2022).
- 4998 Evidence (RCTs and a 2022 meta-analysis) indicate that CBT is associated with improvement in 4999 depression, anxiety, stress, sleep, fatigue, and quality of life indices with small to medium effect sizes, 5000 compared to comparator (Abdelaziz *et al.*, 2021, Ye *et al.*, 2022). A RCT of 169 breast cancer survivors 5001 aged 18-65 years with sexual function problems demonstrated that weekly therapist guided internet-5002 based CBT for 24 weeks was associated with improvements in sexual function parameters, menopausal 5003 symptoms, body image and marital sexual satisfaction compared to wait-list controls (Hummel *et al.*, 5004 2017).
- A 2022 meta-analysis of 13 studies with significant heterogeneity, investigated the effect of mindfulness-based interventions including mindfulness, meditation, and yoga (n=1138 menopausal women without psychiatric disorder aged 40-70 years) (Liu *et al.*, 2022a). The authors reported reduced stress but no effect on anxiety or depression with a mindfulness intervention versus comparator (wait list, usual care, or education).
- 5010 Recommendation

Non-hormonal pharmacologic and non-pharmacologic therapies effective in peri-/postmenopausal women are likely to be helpful in women with POI although POI specific data is lacking

- 5011 Justification
- 5012 There is a lack of evidence specific to women with POI regarding the use of non-hormonal therapies.
- 5013 This is of particular concern regarding the large number of women with iatrogenic POI associated with
- 5014 breast cancer treatment where HT is usually contra-indicated. Research to address this gap is needed.
- 5015 It is likely that non-hormonal therapies shown to be effective in older peri-and postmenopausal women
- are effective in POI, but differences may exist and need to be identified.
- 5017



5018 XII.2. Complementary therapies

5019 The prevalence of use of complementary therapies in women in POI has not been reported. Use of 5020 natural products for menopause is around 13% (Gartoulla et al., 2015, Vanden Noven et al., 2023). Use 5021 of complementary therapies in breast cancer survivors is high, with research showing 45.5% of women 5022 with breast cancer use mind-body therapies, and 31.8% use natural health products and dietary 5023 therapies (Balneaves et al., 2016). Breast cancer survivors report inadequate access to information on 5024 the safety and efficacy of complementary therapies and have called for concise and credible information 5025 about complementary therapies in order to support them in making informed and safe decisions about 5026 using complementary therapies for menopausal symptom management (Balneaves et al., 2016). In one 5027 study, almost one third (29%) of Chinese breast cancer survivors were using traditional Chinese medicine 5028 (Yeo et al., 2020).

- 5029 The presence of menopausal symptoms such as vasomotor symptoms is associated with higher use of 5030 complementary therapies, both in natural and chemotherapy-induced menopause (Yeo *et al.*, 2020, 5031 Vanden Noven *et al.*, 2023).
- 5032 In this section the evidence on complementary therapies for relief of symptoms in POI is summarized.
- 5033 Indirect evidence on women after usual age menopause is added, where evidence in POI is absent.
- 5034

5035PICO QUESTION: WHAT COMPLEMENTARY TREATMENTS ARE EFFECTIVE FOR5036MANAGING THE SEQUELAE OF POI?

5037 Chinese herbal medicine (CHM)

5038 CHM + HT versus HT alone

A 2016 meta-analysis of Chinese herbal medicine (CHM) + HT compared to HT alone reported a mean 5039 5040 difference of -1.19 (95% CI -1.77 to -0.61; 3 trials; n=152; I² 63%; p<0.0001; low certainty evidence) in the Kupperman index (KI).¹² at end of treatment, favouring CHM + HT (Kou *et al.*, 2016). The included 5041 5042 trials used a variety of CHM formulae including Peikun pills, Yishenkangshuai decoction, and *Taijingkangshuai* decoction. Treatment duration ranged from 3 to 5 months and HT used in the control 5043 5044 groups included conjugated estrogen and medroxyprogesterone acetate, estradiol valerate and 5045 cyproterone, and estradiol valerate and dydrogesterone. We note that KI scores were low at end of treatment, ranging from 5 to 9 in the experimental and 10 to 12 in the control groups (i.e. scoring in the 5046 5047 mild range). Adverse events were not reported in the review. CHM + HT was reported to be more 5048 efficacious than HT alone for reducing FSH levels (MD -7.08; 95% CI -9.8 to -4.37; 17 trials; n=1352; I² 78%; p<0.00001) and increasing E2 levels (MD 3.45; 95% CI 2.11 to 4.79; 17 trials; n=1352; I² 72%; 5049 5050 p<0.00001) but not for LH (15 trials; n=1246).

A more recent network meta-analysis examined patent CHM + HT v HT alone (64 RCTs examining 12 oral patent medicines; n=5675) (Zhong *et al.*, 2022). For FSH, three patent medicines (*Kuntai* capsule, *Fuke Yangrong* capsule, *Liu Wei Di Huang Wan* capsule) + HT were more efficacious than HT alone (59 RCTs; n=5415). For LH, four patent medicines (*Guishen* pill, *Liu Wei Di Huang Wan* capsule, *Kuntai* capsule and *Fuke Yangrong* capsule) and for E2, three patent medicines (*Ziheche* capsule, *Fuke Yangrong* capsule and *Zuogui* pills) + HT were more efficacious than HT alone. Thirteen studies reported adverse effects. Only *Kuntai* capsule + HT resulted in fewer adverse effects compared to HT alone.

¹² Reflecting perimenopausal syndrome and symptoms



5058 Two meta-analyses examined a Chinese herbal medicine formula known as Kuntai capsule.¹³ + HT v HT alone (Liu et al., 2019, Ma et al., 2020). The analysis by Liu et al reported that Kuntai capsule + HT was 5059 5060 more effective than HT alone for some lipid parameters including triglycerides (WMD -0.55; 95% CI -5061 0.67 to -0.43; 3 studies; n=290; I² 0%; p<0.00001; low certainty evidence), total cholesterol (-0.63; 95% 5062 CI -0.74 to -0.52; 3 studies; I² 0%; P<0.00001; low certainty evidence), LDL cholesterol (WMD -0.62; 95% CI -0.75 to -0.49; 3 studies; I² 0%; p<0.00001; low certainty evidence) but not for HDL (very low certainty 5063 5064 evidence). The reviewers also report on findings from one RCT that found a mean difference of -5.99 in 5065 the KI between intervention and control (95% CI -8.04 to -3.94; n=100; p<0.00001). Kuntai capsule + HT 5066 was more efficacious than HT alone for LH (MD -3.47; 95% CI -5.68 to -1.26; 11 trials; n=1100; I² 92%; 5067 p=0.002), FSH (MD -8.15; 95% CI -10.44 to -5.86; 11 trials; n=1100; I² 83%; p<0.00001) and E2 (MD 17.21; 95% CI 10.16 to 24.26; 11 trials; n=1100; I² 98%; p<0.00001)(Liu et al., 2019). 5068

5069 Ma *et al* reported that *Kuntai* capsule + Climen was more effective than Climen alone for menopausal 5070 symptoms (KI) (MD -3.86; 95% CI -4.92 to -2.8; 5 trials; n=606; l² 83%; p<0.00001, very low certainty 5071 evidence). Mean endpoint scores in both groups for the KI ranged from 6 to 13 (i.e. in the mild range). 5072 *Kuntai* capsule + HT was more effective than HT alone for FSH (MD -8.987; 95% CI -11.94 to -6.12; 10 5073 trials; n=990; l² 74%; p<0.00001), LH (MD -7.01; 95% CI -10.77 to -3.24; 5 trials; n=460; l² 92%; p=0.0008) 5074 and E2 (MD 11.38; 95% CI 7.11 to 15.64; 10 trials; n=990; l² 87%; p<0.00001) (Ma *et al.*, 2020).

5075 CHM versus HT

5076 One meta-analysis examined Chinese herbal medicine formulae that are designed for the Chinese 5077 medicine functions of tonifying the kidney (bushen) and activating blood (huoxue) compared directly 5078 with HT (Li *et al.*, 2020a). CHM was more effective than HT for KI (SMD -0.78; 95% CI -1.24 to -0.31; 7 5079 trials; n=452; I² 81%; p=0.001; very low certainty evidence). KI scores ranged from 7.2 to 18.24. CHM 5080 was more efficacious than HT for E2 levels (SMD 0.70; 95% CI 0.14 to 1.26; 19 trials; n=1345; I² 95%; p < 5081 0.05)), and FSH (SMD -0.50; 95% CI -0.81 to -0.18; 19 trials; n=1345; I² 95%; p < 0.05) but not for LH.

5082 CHM versus placebo

A double-blind placebo controlled RCT (n=146) compared a Chinese herbal formula Yangyin Shugan 5083 5084 formula against matched placebo. The study reported significant reductions in the intervention group compared to placebo at 12 weeks for the total score of the Chinese MENQOL¹⁴ (38.64±5.69 vs 5085 5086 65.04±4.40) and for the different domains including the vasomotor, psychosocial, physical, and sexual 5087 domain (p<0.01 for all comparisons) (Cao et al., 2018). CHM was more efficacious than placebo for reducing FSH (10.11±4.63 vs 32.66±13.81), increasing AMH (1.76±2.11 vs 0.73±1.61) and AFC (6.97±3.35 5088 5089 vs 4.43±3.06), but not for E2 at endpoint. There were no differences between groups for whole blood 5090 counts, renal and liver function. No serious adverse events were reported in either group. One 5091 participant in the placebo group reported abdominal pain. One participant in the placebo group 5092 withdrew from the study. Compliance was excellent with all participants taking at least 95% of scheduled 5093 doses based on medication count (Cao et al., 2018)

5094 **CHM + acupuncture versus HT alone**

A meta-analysis examined the effectiveness of the combination of CHM and acupuncture compared with HT, placebo, or no treatment (Li *et al.*, 2020c). Only one trial reported on the outcomes of interest to this guideline. This trial (n=56) reported a lower KI in the acupuncture + CHM (*Bushen Nuan Chong Tang*) group compared to HT (EV + cycloprogesterone) after three months of treatment (KI 14.41 ± 2.97 vs 25.69 ± 3.25; p<0.05). The meta-analysis reported no difference between acupuncture + CHM and

¹³ Kuntai capsule is a formula containing *Rhizoma coptidis, Radix Paeoniae alba, Poria cocos, Radix scutellariae,* and *Rehmannia glutinosa*.

¹⁴ Chinese version Menopause-Specific Quality of Life questionnaire



- 5100 control for adverse events (RR 0.31; 95% Cl 0.04 to 2.54; 5 trials; n=387; l² 42%; p=0.28). Acupuncture +
- 5101 CHM was more efficacious than HT for reducing FSH (MD -2.88; 95% CI -5.00 to -0.76; 12 trials; n=778; 5102 I^2 0%; p=0.008), and normalisation of menstrual cycles (RR 2.06; 95% CI 1.62 to 2.61; 14 trials; n=1030;
- 102 = 100, p=0.000, and normalisation of mensular cycles (KK 2.00, 95% Ci 1.02 to 2.01, 14 thats, n=1050, 102 = 12260, p=0.0000) but not for LU
- 5103 l² 26%; p<0.00001) but not for LH.

5104 An RCT examined the effectiveness of acupuncture (*Tiaobu Chongren* style) and CHM (*Wenjing* 5105 decoction) compared with HT (Climen) (n=119) (Yi *et al.*, 2021). Participants were asked to rate how "hot 5106 and sweaty" they felt based on a 4-point Likert scale from 0-3 representing no symptoms, mild, 5107 moderate, and severe symptoms. Acupuncture + CHM resulted in lower scores at 3 months compared 5108 to the HT group (0.7 \pm 0.08 vs 1.45 \pm 0.12, p<0.05).

5109 Acupuncture and moxibustion.

5110 Acupuncture + HT (or CHM) versus HT alone.

5111 A 2015 meta-analysis included 3 RCTs comparing acupuncture + HT versus HT alone, and one RCT 5112 comparing acupuncture + CHM versus HT alone. (Jo et al., 2015). Two RCTs (n=125) used the KI as an outcome measure, but neither reported any difference in the KI at end of treatment between 5113 5114 acupuncture + HT and HT alone however there was a difference between groups at 6 months post end 5115 of treatment in one study. Acupuncture as an adjunct to HT/CHM was efficacious for lowering FSH (MD -11.40; 95% CI -19.61 to -3.2; 3 trials; n=161; l² 0%; p=0.006), resumption of menstruation (RR 1.20; 95% 5116 CI 1.03 to 1.39; 4 trials; n=233; l² 37%; p=0.02), lowering LH (MD - 19.81; 95% CI - 34.14 to -5.48; 2 trials; 5117 n=80; I² 0%; p=0.007) but not for improving E2 (3 trials, n=161). 5118

5119 Acupuncture versus HT

- 5120 The same 2015 meta-analysis included 4 trials comparing acupuncture with HT and found that
- acupuncture was more efficacious than HT for reducing FSH (MD -8.60; 95% CI -13.58 to -3.62; 3 trials,
- 5122 n=360; l² 23%; p=0.007), resumption of menstruation (RR 1.32; 95% Cl 1.10 to 1.59; 4 trials; n=381; l²
- 5123 62%; p=0.003), raising E2 (MD 42.61; 95% CI 6.4 to 78.83; 3 trials; n=318; l² 97%; p=0.02), but not for
- 5124 improving LH (2 trials; n=198) (Jo *et al.*, 2015).
- 5125 A 2017 RCT randomised 80 women to receive either electroacupuncture and moxibustion or HT (Climen)
- 5126 for 6 months and reported a lower night sweat score in the intervention group at end of treatment (1.17
- 5127 \pm 0.82 vs 1.53 \pm 0.65, p<0.05) where the night sweat score ranged from 0 to 4 with 0 being occasional
- 5128 fever and slight sweatiness, and 4 being intermittent fever with sweatiness and red face, interfering with
- 5129 attention and affecting sleep (Wxu and Tian, 2017).
- 5130 A 2014 case series reported on 31 women who received acupuncture for 3 months (Chen *et al.*, 2014).
- 5131 At the end of the 3-month period, there was a reduction in anxiety (Self-Rating Anxiety scale) from 54±6 5132 to 41±7 and in the KI from 18±4 to 12±2 (p=0.00 for both).
- 5133A 2022 umbrella review (Cao *et al.*, 2022) included two systematic reviews already described above (Jo5134*et al.*, 2015, Li *et al.*, 2020c).
- 5135 It should be noted that the total effective rate or effectiveness rate, a commonly used outcome measure
- 5136 in Chinese medicine trials, has not been considered as a relevant outcome measure for this guideline as
- it is aims to assess efficacy of treatment according to resolution of symptoms that are relevant in Chinesemedicine only.

5139 *Moxibustion + HT versus HT alone*

5140 Moxibustion is an acupuncture-related technique that involves burning of mugwort leaves near 5141 acupuncture points. One RCT (n=66) compared moxibustion with HT versus HT alone for 3 months and 5142 reported a higher AFC (3.06 ± 1.2 vs 2.33 ± 0.96), E2 (77.57 ± 9.21 vs 67.16 ± 9.95 pmol/L) and lower FSH



5143 (50.31±6.19 vs 59.12±6.82 IU/L) in the intervention group compared to control (p<0.05) (Wang *et al.*, 5144 2021)

5145 Korean medicine

5146 One case series reported on three women with POI (age range 26-39) treated with Korean herbal 5147 medicine, electroacupuncture and moxibustion, and placental acupuncture for at least 3 months (Jang 5148 *et al.*, 2022a). All patients experienced a decrease in FSH to < 40. One woman conceived 2 years after 5149 starting treatment. Two women had resolution of hot flushes while the third woman had not been 5150

5150 experiencing hot flushes at baseline.

5151 *Nutrients*

- 5152 Evidence on nutrient supplementation for POI is very limited due to lack of randomised controlled trials. 5153 We found only one RCT and one case report. The RCT (n=67) evaluated the efficacy of three months of 5154 a selenium and Vitamin E supplement against matched placebo. Improvements in AMH (MD 0.59; 95% 5155 CI 0.48 to 0.71; p<0.001), AFC (MD 5.08; 95% CI 4.36 to 5.08; p<0.001) and mean ovarian volume (MD 5156 2.17; 95% CI 1.87 to 2.47; P<0.001) were reported in the intervention group compared with placebo at
- 5157 12 months (Safiyeh *et al.*, 2021).
- A case report on the use of methylfolate in a 34-year-old woman with POI due to chemotherapy for non-Hodgkin's lymphoma, and a history recurrent pregnancy loss and homozygous for MTHFR C677T
- variant, reported natural conception after 3 months of methylfolate 800 mg daily with a B vitamin
- 5161 supplement (dose and ingredients unspecified). This was complicated by vanishing twin at 9 weeks and
- 5162 oligohydramnios and preeclampsia at 36 weeks. Delivery was by Caesarean section at 37 weeks due to
- 5163 oligohydramnios, preeclampsia, and breech presentation. A healthy male baby was delivered weighing
- 5164 2.69 kg (Goyco Ortiz *et al.*, 2019). Methylation is proposed to be an important process in DNA repair, 5165 gene expression regulation and epigenesis, with an impact on early and late embryogenesis, trophoblast
- 5165 gene expression regulation and epigenesis, with an impact on early and late embryogenesis, trophoblast 5166 development and implantation. Synthetic folic acid has poor capacity to form tetrahydrofolate and 5
- 5167 MTHF which is required for recycling of homocysteine.

5168 *Phytoestrogens: soy, red clover, and flaxseed*

- 5169 Phytoestrogens are plant substances that have similar effects to estrogen. Two groups of 5170 phytoestrogens, isoflavones and lignans, can be found in soybeans-red clover, and flaxseed, 5171 respectively.
- 5172 We did not identify studies evaluating phytoestrogens in women with POI. We report on data from RCTs 5173 of postmenopausal women.
- 5174 Cardiovascular health

5175 A 2022 meta-analysis of RCTs in postmenopausal women reported benefits from phytoestrogens 5176 (flaxseed, red clover, and soy) on lipid profiles. Flaxseed was associated with reductions in total 5177 cholesterol (TC) (weighted-mean difference (WMD) -0.26; 95% CI -0.38 to -0.13; 7 RCTs; n=452; I² 6%; p=0.0001) and low-density lipoprotein cholesterol (LDL-C) (WMD -0.19; 95% CI -0.30 to -0.08; 7 RCTs; 5178 5179 n=417; l² 0%; p=0.0006). However, flaxseed also resulted in an increase in high-density lipoprotein 5180 cholesterol (HDL-C) (WMD -0.06; 95% CI -0.11 to -0.01; 7 RCTs; n= 418; l² 0%; p=0.0150). Soy protein 5181 resulted in reductions in TC levels (WMD -0.15; 95% CI -0.25 to 0.05; 18 RCTs, n=1322; l² 26%; p=0.0048), LDL-C levels (WMD -0.15; 95% CI -0.25 to 0.05; 16 RCTs; n=1234; l² 17%; p=0.0067), as well as an increase 5182 in HDL-C levels (WMD 0.05; 95% CI 0.02 to 0.08; 18 RCTs; n=1322; I² 0%; p=0.0034). Red clover reduced 5183 TC levels (WMD -0.11; 95% CI -0.18to-0.04; 8 RCTs; n=884; I² 0%; p=0.0017) and increased HDL-C levels 5184 (WMD 0.04; 95% CI 0.01 to 0.07; 8 RCTs; n=884; I² 0%; p=0.0165) (Błaszczuk et al., 2022). 5185



5186 Vasomotor symptoms

- 5187 A meta-analysis of eight trials (ten comparisons) in postmenopausal women demonstrated a statistically
- 5188 significant reduction in hot flush frequency in women receiving red clover compared to those receiving
- 5189 placebo (WMD -1.73; 95% CI -3.28 to -0.18; 8 RCTs; n=751; 1² 87%; p=0.0292). The greatest benefit appears to
- 5190 be in women with \geq 5 hot flushes per day, a duration of >12 weeks, with an isoflavone dose of \geq 80
- 5191 mg/day, and when the formulations contained a higher proportion of biochanin A (Kanadys *et al.*, 2021).

5192 Sexual function

- 5193 A 2021 systematic review and meta-analysis reported no benefit of soy, red clover, or flaxseed on sexual
- 5194 function, however soy improved dyspareunia (1 RCT, n=37) (Najaf Najafi and Ghazanfarpour, 2018) .

5195 Black cohosh

- Black Cohosh is a plant native to North America widely used for the relief of vasomotor symptoms. A
 2012 Cochrane review reported no benefit from using black cohosh for vasomotor symptoms compared
 to placebo in postmenopausal women (Leach Matthew and Moore, 2012). No updated meta-analyses
- 5199 have been published.

5200 Other supplements

- 5201 Single trials have not demonstrated benefits from wild yam (*Dioscorea villosa*), dong quai (*Angelica sinensis*), or evening primrose oil (*Oenothera biennis*) for vasomotor symptoms (North American 5203 Menopause Society., 2023).
- A 2022 review on ginseng reported a reduction in menopausal symptoms, hot flushes, and quality of life but no benefit for sexual function (Lee *et al.*, 2022a). A 2021 review reported improvements in menopausal symptoms with fennel (Foeniculum vulgare Miller) compared to placebo, but no benefit for quality of life, psychological health, or sexual function. No serious adverse events were reported (Lee *et al.*, 2021).

5209 **Recommendations**

The guideline group recommends that HCPs should enquire about use of complementary therapies, and incorporate individual patient values and GPP preferences into shared decision making about their use

5210

Complementary treatments do not prevent the long-term sequalae of	$\oplus \bigcirc \bigcirc \bigcirc \bigcirc$	STRONG
POI and should therefore not be used to replace hormone therapy.	0000	STRONG

5211

Women who are considering the use of Chinese herbal medicine for the management of menopausal symptoms and metabolic risk should be informed that the evidence for benefit is limited but the intervention does not appear to cause significant harm in the short term.

5212

Women should be informed that there is limited evidence on the effectiveness of acupuncture for menopausal symptoms in POI and the evidence does not suggest a benefit from adding acupuncture to hormone therapy.

STRONG



Women who are considering using nutrient supplements for improving reproductive parameters in POI should be informed that the evidence is very limited with only one intervention (Vitamin E and selenium) studied in randomised controlled trials.



5214

Women who are considering using other nutrient supplements and herbal medicines should be informed that there is insufficient evidence to support their use.

€CCC STRONG

- 5215 Justification
- 5216 In general, evidence on the different complementary treatments is limited, both in terms of efficacy for 5217 relief of vasomotor symptoms and improving of fertility, as well as for possible side effects.
- 5218 Acknowledging that women with POI may seek complementary interventions to relief their symptoms
- 5219 or improve their fertility, emphasis was put on informing them that there is too little evidence of benefit
- 5220 to recommend the different treatments, as well as, for some interventions, too little evidence to consider
- 5221 them to be safe.
- 5222 Considering the data on efficacy and the different long-term consequences of estrogen deprivation in
- 5223 POI, the guideline group strongly recommends not to replace the recommended HT treatment with
- 5224 complementary therapies solely aimed to relief short term vasomotor symptoms. In women with
- 5225 vasomotor symptoms while taking HT, a revision of the HT regimen should be prioritised over
- 5226 complementary treatments.

ORAFIC



5227 XII.3. Lifestyle management options

5228 Given both the shorter-term symptoms and quality of life (QoL) impact of POI and the potential long-5229 term health implications, there is growing interest in identifying effective interventions to mitigate the 5230 adverse effects, improve the overall wellbeing and prevent long-term complications for women with 5231 this condition. Healthy lifestyle is routinely advocated for healthy ageing and mitigation of common 5232 preventable illnesses. This includes cardiovascular disease and osteoporosis. Prevention of these 5233 conditions is even more relevant in POI.

5234 In this section, the evidence regarding lifestyle interventions in menopausal women is summarized.

5235

5236 **PICO QUESTION: WHAT ARE THE LIFESTYLE MANAGEMENT OPTIONS FOR POI?**

5237 The systematic literature search included lifestyle intervention, diet, and physical activity/ exercise. The 5238 outcomes include relief of menopause symptoms, quality of life and cardiovascular outcomes. 5239 Osteoporosis and bone health outcomes are covered elsewhere in this guideline (VI. POI and 5240 musculoskeletal health).

5241 *Menopause symptoms*

- 5242 There is a lack of evidence specifically investigating the effects of lifestyle interventions on the relief of 5243 menopause symptoms in women with POI.
- A systematic review conducted by Noll et al. found inconclusive evidence regarding the association between dietary intake and the intensity of menopausal symptoms. Nevertheless, some studies have suggested that postmenopausal women who adhere to a high-quality diet, including consumption of vegetables, fruits, and whole grains, may experience lower intensity of menopausal symptoms (Noll *et al.*, 2021). Conversely, diets rich in processed foods, saturated fat, refined grains, fried foods, fatty meats, sweets, and sugar-sweetened beverages were associated with more severe psychological, vasomotor, and somatic symptoms (Noll *et al.*, 2021).
- Regarding exercise interventions, in a Cochrane review and meta-analysis, no significant difference was 5251 5252 found between exercise and control groups in frequency or intensity of vasomotor symptoms in symptomatic peri- and postmenopausal women (SMD -0.10; 95% CI -0.33 to 0.13; 3 studies; 454 5253 5254 women). Also, no significant differences were observed between exercise and yoga when two studies 5255 were pooled (SMD -0.03; 95% CI -0.45 to 0.38; 279 women). Also, one small trial found fewer frequency 5256 of hot flashes in hormone therapy group compared to the exercise group. Women involved in these 5257 studies were aged 40-63 years. All studies were of low quality (Daley et al., 2014). However, Liu (2022) 5258 found in a systematic review that exercise interventions significantly improved the severity of vasomotor 5259 symptoms compared to no-treatment control group (SMD 0.25; 95% CI 0.04 to 0.47, 10 studies), but no 5260 significant changes in vasomotor frequency were observed (SMD 0.14; 95% CI -0.03 to 0.31). Authors 5261 reported that further exploration is required to understand the potential impact of exercise on 5262 menopause symptoms based on the intensity and type of exercise (Liu et al., 2022b).

5263 *Quality of life*

5264 Several systematic reviews have examined the impact of exercise interventions on the QoL in 5265 menopausal women. However, there is no study assessing the effect of lifestyle interventions on the 5266 QoL of women with POI.

5267 A systematic review of 11 studies including 1548 peri- and post-menopausal women aimed to explore 5268 the impact of various exercise programs on sexual function and quality of sexual life related to



5269 menopausal symptoms. Mind-body exercises such as yoga showed the potential to improve 5270 menopausal symptoms, whereas the effectiveness of aerobic training was inconclusive and resistance 5271 training did not exhibit any significant improvements in this context (Carcelén-Fraile *et al.*, 2020).

5272 A systematic review of 23 studies focusing on perimenopausal women (n=1812) revealed that exercise-5273 based interventions and mind-body therapies have the potential to enhance QoL (SMD -0.67; 95% CI 5274 -1.29 to -0.05; 5 studies/6 interventions) and alleviate menopausal symptoms (SMD -1.32; 95% CI 5275 -1.72 to -0.91;10 studies) and depression (SMD -1.10; 95% CI: -1.73 to -0.47; 7 studies). However, the 5276 analysis did not find a significant intervention effect for mitigating hot flashes. The meta-analysis results 5277 showed high levels of heterogeneity among studies (Shorey *et al.*, 2020).

- 5278 Additionally, a systematic review of nine RCTs, explored the impact of exercise interventions including 5279 yoga, pelvic floor muscle training, aerobic training, walking and self-directed exercise programs (such 5280 as swimming, running, and cycling) on the QoL in 882 women experiencing menopausal symptoms. The 5281 meta-analysis revealed some positive effects of exercise on physical and psychological QoL scores, 5282 although the results were not statistically significant [(SMD 0.89; 95% CI -0.11 to 1.89; p=0.08; 5 studies; 5283 1² 97%) and (SMD 0.56; 95% CI -0.04 to 1.15; p=0.07; 7 studies; 1² 93%), respectively]. However, there 5284 was no conclusive evidence to indicate that exercise interventions had a significant effect on overall, social, and menopause specific QoL scores when compared to no active interventions. Among the 5285 5286 interventions studied, yoga and pelvic floor muscle training were the most commonly used interventions 5287 for women experiencing menopausal and urinary symptoms, respectively. Yoga significantly improved 5288 physical QoL, but its effects on overall, psychological, sexual, and vasomotor symptom QoL scores were not significant. Similarly, pelvic floor muscle training did not yield a significant effect on overall QoL 5289 5290 (Nguyen et al., 2020).
- A meta-analysis of five RCTs including 268 post-menopausal women (mean age 53-67 years) revealed that pelvic floor muscle training, commonly known as Kegel's exercise, significantly enhanced healthrelated QoL (HRQoL) in those experiencing urinary symptoms compared to non-Kegel's exercise or regular activity (SMD -0.95; 95% CI -1.35 to -0.54; 3 studies; I² 0%). However, there was no significant impact on HRQoL related to sexual symptoms (SMD 1.11; 95% CI -0.25 to 2.47; 2 studies; I² 94%). The Kegel's exercise programs in the included studies consisted of 8-12 sessions lasting 20-40 minutes, twice weekly. Most studies exhibited a low risk of bias (Nguyen *et al.*, 2024).
- 5298 A systematic review of 12 studies involving 925 menopausal women highlighted the effectiveness of 5299 exercise, phytoestrogen and isoflavone products and participating in educational programs in 5300 improving the QoL in menopausal women (Taebi *et al.*, 2018).
- 5301 The impact of aquatic exercises on postmenopausal women (n=594) was assessed in a systematic review 5302 and meta-analysis comprising 16 RCTs predominantly of moderate quality. The findings revealed 5303 significant improvements in lower limb strength (SMD 1.37; 95% CI 0.53 to 2.21; 11 studies), upper limb 5304 strength (SMD 1.86; 95% CI 0.55 to 3.16; 3 studies), agility (SMD -0.67; 95% CI -1.09 to -0.25; 16 studies) 5305 and overall QoL (SMD 1.04; 95% CI 0.06 to 2.03; 5 studies) among women engaging in aquatic exercises 5306 compared to those with no exercise. Furthermore, within the range of aquatic exercises, resistance 5307 exercise showed greater benefits in enhancing physical fitness and QoL than aerobic and 5308 multicomponent exercise. The positive effects on physical fitness were particularly evident in 5309 postmenopausal women under 65 years, while improvement in overall QoL were observed in women 5310 both under and over 65 years (Zhou et al., 2023).

5311 *Cardiovascular health*

5312 Two RCTs assessed the effect of a lifestyle intervention on cardiovascular fitness among cancer survivors. 5313 In a small trial involving 35 BRCA1/2+ breast cancer survivors (with a mean age of 46 years) who



- underwent risk reducing oophorectomy, a 12- month web-based lifestyle modification program improved body composition and bone health and successfully prevented a decline in cardiovascular fitness (Sturgeon *et al.*, 2017). In another study on 154 female cancer survivors (with a mean age of 52 years), a 12-month aerobic-resistance exercise intervention at a fitness centre yielded significantly better results in terms of cardiovascular fitness and metabolic risk factors compared to a home-based physical activity group (Knobf *et al.*, 2017).
- In a systematic review of 14 RCTs, most studies highlighted the significant benefits of physical activity/ exercise interventions on cardiorespiratory fitness and cardiovascular risk factors including lipid and glycemic metabolism, body composition, blood pressure, inflammatory index, and autonomic responses in both premenopausal and postmenopausal women. These interventions have been shown to increase maximum oxygen uptake or decrease inflammatory factors in women. It is worth noting that women of different ages (ranging from 18 to 77 years) participated in these studies (Ruiz-Rios and Maldonado-Martin, 2022).
- 5327 A systematic review encompassing 129 studies, including 7141 post-menopausal women with the mean 5328 age of 53-90 years indicates that exercise training boosts cardiorespiratory fitness (SMD 1.15; 95% CI 5329 0.87 to 1.42; 25 studies), lower-body muscular strength (SMD 1.06; 95% CI 0.90 to 1.22; 90 studies), 5330 upper-body muscular strength (SMD 1.11; 95% CI 0.91 to 1.31) and handgrip strength (weighted mean difference (WMD) 1.78 kg; 95% CI 1.24 to 2.32). However, there was a significant heterogeneity among 5331 5332 studies for all outcomes. Sub-group analysis shows a significant enhancement in cardiorespiratory 5333 fitness and muscle strength among both middle-aged and older individuals and women engaged in medium- and long-term interventions. Various types of exercise-such as aerobic, resistance, combined 5334 aerobic-resistance and water-based training were associated with significant increases in 5335 cardiorespiratory fitness levels and lower-body strength. Resistance exercise notably increased upper-5336 body strength, while both resistance and combined training enhanced handgrip strength. However, 5337 5338 aerobic training alone did not affect handgrip strength (Khalafi et al., 2023b).
- Exercise training was also found effective for improving body composition, leading to increased muscle 5339 mass (SMD 0.26; 95% CI 0.13 to 0.39; 1² 0%) and decreased fat mass (WMD -1.27 kg; 95% CI -1.93 to -5340 0.62; I² 56%) in post-menopausal women, as revealed in a meta-analysis on 101 RCTs (n=5697 women, 5341 5342 mean age 51-89 years). Specifically, aerobic training was found effective for fat loss, while resistance 5343 training contributed to muscle gain. Sub-group analysis further indicates that these favourable outcomes are observed predominantly among middle aged and older women, engaged in medium-5344 5345 and long-term interventions. Consequently, this study suggests incorporating a combination of aerobic 5346 and resistance exercises to promote overall health in postmenopausal women (Khalafi et al., 2023a).
- 5347 The effect of resistance training was assessed through a systematic review and meta-analysis including 5348 20 RCTs with a total of 742 overweight/ obese postmenopausal and older women. The findings 5349 demonstrate improvements in body composition and metabolic health, as well as reductions in 5350 inflammation, in both low-volume and high-volume resistance training interventions. However, high-5351 volume resistance training reveals superior efficacy in mitigating metabolic risk factors and inflammation than low-volume training when compared to the control group. This study suggests the 5352 5353 potential benefits of incorporating resistance training, particularly high-volume, into interventions 5354 targeting obesity and related metabolic disorders in this demographic (Nunes et al., 2023).
- 5355 In a systematic review of 13 studies (12 RCTs and one retrospective cohort, mostly with fair quality) 5356 involving 700 postmenopausal women, aerobic training and a combined aerobic-resistance training 5357 were found to enhance cardiorespiratory fitness and decrease arterial stiffness while also lowering pulse 5358 waive velocity. Of these approaches, the combined exercise program exhibited the greatest



effectiveness. Notably, the study included participants aged 47 to 88 years, reflecting a diverse range ofpostmenopausal women (Ferreira *et al.*, 2024).

A meta-analysis of 17 small RCTs (n=792 women) highlighted the significant benefits of exercise on body fat (SMD -0.34; 95% CI -0.60 to -0.08; 8 studies), waist circumference (SMD -0.39; 95% CI -0.68to -0.09; 5 studies), triglyceride levels (SMD -0.37; 95% CI -0.62 to -0.11; 7 studies), and bone mineral density (SMD 0.38; 95% CI 0.08 to 0.68; 5 studies) in menopausal women. The exercise interventions encompassed various modalities, such as aerobic exercise, resistance training, strength training, tai chi, high-impact training, and yoga (Yeh *et al.*, 2018).

- 5367 Resistance training was found effective in reducing lipid profile including total cholesterol (WMD -11.47 5368 mg/dl, 95% CI -18.55 to -4.39, n=686 women), triglyceride (WMD -6.61 mg/dl; 95% CI -13.03 to -0.19; 5369 n=741 women) and low-density lipoprotein cholesterol (WMD -8.48 mg/dl; 95% CI -15.05 to -1.91; 5370 n=721 women) compared with placebo, as revealed by a meta-analysis encompassing 19 RCTs (mostly 5371 with a good quality). However, significant heterogeneity was observed among studies. Although the 5372 impact of resistance training on reducing high-density lipoprotein was minimal overall, it was discernible in women with obesity. Notable, the effects of resistance training on the lipid levels were particularly 5373 5374 significant in short term interventions and among women with dyslipidaemia or obesity prior to trial 5375 enrolment (He et al., 2023).
- 5376 A meta-analysis of 63 RCTs revealed that exercise training (including aerobic, resistance or combined 5377 training) resulted in small but clinically relevant reductions in systolic blood pressure (MD –3.43 mm Hg; 5378 95% CI -5.16 to -1.71), diastolic blood pressure (MD –2.25 mm Hg; 95% CI -3.40 to -1.11) and mean 5379 arterial pressure (MD –3.48 mm Hg; 95% CI -5.84 to -1.11) in menopausal women. Combined training 5380 showed the highest reductions in blood pressure and mean arterial pressure. The included studies 5381 encompassed women aged between 50 and 85 years (Loaiza-Betancur *et al.*, 2021).
- 5382 Considering the menopause transition stage, a systematic review noted limited research on exercise 5383 and/or dietary interventions on women's body weight and composition. Out of 3 included studies in 5384 this review, one high quality RCT suggested that exercise combined with dietary interventions could 5385 potentially mitigate the increase in body adiposity. Additionally, two other studies with higher risk of 5386 bias indicated that exercise, including walking programs or circuit training, might help reduce weight 5387 gain and modify abdominal adiposity patterns during the menopause transition (Jull *et al.*, 2014).

5388 Recommendation

Women should be aware that a healthy lifestyle, including physical activity, has metabolic and heart benefits in the general population including postmenopausal women, although specific evidence on lifestyle interventions in POI is limited.

⊕⊕⊖⊖ STRONG

5389

The guideline group recommends women with POI should be encouraged to adopt a healthy lifestyle to improve their overall well-being and mitigate the risk of potential complications.

GPP

- 5390 Justification
- 5391 While there is limited research specifically assessing lifestyle interventions in women with POI, existing
- evidence suggests that exercise interventions have the potential to enhance QoL and alleviate physical
- and psychological menopause symptoms.



5394 Exercise training showed blood pressure reductions and positive impacts on cardiovascular fitness and 5395 body composition in menopausal women. However, more research is needed to explore the specific 5396 impact of exercise and dietary interventions during the menopause transition and post menopause 5397 stage, particularly in women with POI.

5398 To promote the overall wellbeing of women with POI, it is vital for them to adhere to general population 5399 healthy lifestyle guidelines. This entails adopting a healthy diet and engaging in regular physical activity. 5400 These practices offer a broad range of health benefits and are particularly important due to the 5401 increased risks associated with POI. By prioritizing a healthy lifestyle, women with POI can enhance their 5402 overall health and mitigate potential complications effectively.

- 5403 Research recommendation.
- 5404 Due to limited evidence available for POI, ongoing research is essential to explore the specific effect of 5405 lifestyle interventions on the features of menopause, QoL and cardiovascular outcomes for women with 5406 this condition.

ORAFIC



5407 XIII. Puberty Induction

There are many and all quite rare causes of POI that could need pubertal induction, including but not limited to galactosemia, , hypergonadotropic hypogonadism of different genesis, disorders of sex development (complete gonadal dysgenesis ovotesticular dysgenesis, female 45,X/46,XY and others), rare mutations like FSH receptor, LH receptor, FOXL2 and BMP15 mutations, and cancer survivors. (Nordenström *et al.*, 2022, Ke *et al.*, 2023). Most of the available literature on puberty induction in POI concerns studies of girls with Turner Syndrome (TS) (Nordenström *et al.*, 2022).

Five to 10% of girls with TS retain sufficient ovarian function for puberty to start spontaneously and among these patients AMH can be used as a future marker of appropriate ovarian function (Hagen *et al.*, 2010). Most girls show a progressive ovarian failure and need estrogen and progestogen treatment for complete pubertal development and withdrawal bleeding. The attainment of an optimal adult height with growth hormone (GH) therapy is also of importance, in some conditions like Turner syndrome and other conditions with poor linear growth. Lower estrogen doses may stimulate growth, but higher estrogen doses cause acceleration of bone maturation and result in decreased adult height.

It is important to educate the patient that estrogen replacement is usually required until the time of usual menopause to maintain feminization and prevent osteoporosis (Gravholt *et al.*, 2017). Still, recent studies have shown that a considerable percentage of TS patients discontinue therapy in adult life and are lost to follow-up (Ertl *et al.*, 2018, Bernard *et al.*, 2019, Cameron-Pimblett *et al.*, 2019, Viuff *et al.*, 2020). Therefore, the continuum of care through childhood and adolescence into adulthood is mandatory.

5427 **PICO QUESTION: HOW SHOULD PUBERTY BE INDUCED?**

5428 When to start estrogens?

During recent years consensus has evolved concerning the optimal age at which to begin puberty 5429 5430 induction. Although estrogens can accelerate bone maturation, and thus estrogen replacement was 5431 previously delayed, often until 15 or 16 years of age, to allow additional time for linear growth with growth hormone therapy in TS (Chernausek et al., 2000), there is now consensus that there are ample 5432 5433 reasons for starting therapy around 11-12 years of age in all patients with POI (Gravholt et al., 2017, Nordenström et al., 2022). The aims of induction of puberty at the same age as in peers is to achieve 5434 further growth, increase BMD, adult uterine and breast configuration, monthly withdrawal bleeds and 5435 5436 optimal neurocognitive development. More recently, studies have shown that beginning GH at a 5437 younger age in TS, thus providing a longer period of estrogen-free GH treatment, may allow initiation 5438 of estrogen therapy, at a low dose, at a more normal age (11-12 years) without loss of adult height 5439 (Gravholt et al., 2017, Nordenström et al., 2022). This approach can be considered for other causes of 5440 delayed or absent puberty when the condition is known from an early age. One study has also suggested 5441 that very early and very low dose estrogen may even be beneficial for growth, but this approach has so 5442 far not been included in usual clinical care (Ross et al., 2011).

5443 What preparations, mode of delivery and doses of estrogen should be used?

5444 Multiple forms of estrogen are available; oral estrogens have been the most widely used. However, 5445 conjugated equine estrogen preparations (CEE, Premarin®) contain multiple estrogens some of which 5446 are not found in humans and are not justified for use in children (Gravholt *et al.*, 2017, Nordenström *et 5447 al.*, 2022). Similarly, the oral contraceptive pill is best avoided, because the synthetic estrogen doses are 5448 too high and the typical synthetic progestin may interfere with optimal breast and uterine development 5449 (Gravholt *et al.*, 2017) and more patients seem to develop hypertension (Cameron-Pimblett *et al.*, 2019).



5450 Furthermore, the oral contraceptive pill is conventionally taken with a pill-free week, resulting in 3 5451 months of estrogen deficiency for each year of use.

5452 Oral ethinylestradiol is no longer recommended for puberty induction. Natural estrogens are 5453 metabolised in the liver and must be given either orally (Leung et al., 2004) or, to avoid the first pass 5454 effect, transdermally. Natural estrogens, i.e. 17β -estradiol, have less pronounced effects on coagulation 5455 factors, lipid profiles and blood pressure than synthetic estrogens and are recommended for use in TS 5456 (Gravholt et al., 2017) and other forms of hypogonadism (Nordenström et al., 2022), with oral or 5457 transdermal estradiol showing similar effects on metabolic parameters (Torres-Santiago et al., 2013). 5458 With 17β-estradiol transdermal (TD) patches or percutaneous gel, spontaneous pubertal hormonal 5459 changes are mimicked, and normal pubertal development is achieved (Ankarberg-Lindgren et al., 2019).

Puberty is a relatively slow process and the replacement therapy in the induction process should mimic this (Donaldson *et al.*, 2019). Although the appropriate starting dose has yet to be determined, estrogen replacement is usually begun at one-tenth to one-eighth of the adult replacement dose and then increased gradually over a period of 2 to 4 years (Donaldson *et al.*, 2019). To allow for normal breast and uterine development, it seems advisable to delay the addition of progestin at about 18-24 months after starting estrogen or until breakthrough bleeding occurs (Shim *et al.*, 2023).

5466 Based on these principles, suggested age-specific preparations and doses of estrogen substitution 5467 therapy in adolescence are listed in Table XII. This table is only a guide and individual tailoring of dose 5468 and timing will be required.

5469 **TABLE XI ESTROGEN SUBSTITUTION THERAPY IN ADOLESCENCE (ADAPTED FROM (GRAVHOLT** *ET AL.*, **2017, KLEIN** 5470 *ET AL.*, **2018**))

Age	Age-specific suggestions	Preparation/dose/comments
11 - 12 years	If no spontaneous development and FSH elevated, start low dose estrogens	17β-estradiol (E2) Transdermal: 6.25 μg/day ¹ E2 via patch Oral micronized E2: 5 μg/kg/day or 0.25 mg/day
11.5 – 13.5 years	Gradually increase E2 dose at 6-12 months interval over 2 - 3 years ² to adult dose	Transdermal E2: 12.5, 25, 37.5, 50, 75, 100μg/day. (<i>Adult dose: 100-200 μg/day</i>) Oral E2: 5, 7.5, 10, 15 μg/kg/day. (<i>Adult dose: 2-4 mg/day</i>)
13 – 15 years	Begin cyclic progestogen after 2 years of estrogen or when breakthrough bleeding occurs or use an IUD	Oral micronized progesterone 100-200 mg/day or dydrogesterone 5-10 mg/day during 12 – 14 days of the month. Levonorgestrel is used in IUD's.

¹ the lowest dose commercially available E2 transdermal patches deliver 25 or 50 μg/day; it is not established whether
 various means of dose fractionation (e.g., administering 1/8, 1/6, 1/4 patch overnight or daily or administering whole
 patches for 7-10 days per month) are equivalent.

² with concomitant GH therapy in Turner Syndrome, to achieve an optimal adult height the increase in E2 dose might
be relatively slow; while in cases of late diagnosis and for those girls in whom growth is not a consideration, E2 may
be started at somewhat higher doses and escalated more rapidly.

5477

In cases of later diagnosis of pubertal failure and for those girls in whom growth is not a consideration,
estrogens may be started at somewhat higher doses and escalated more rapidly (*Gravholt et al., 2017*, *Nordenström et al., 2022*). A proposed treatment could be a starting dose of 0.5 mg/day oral micronized
E2, or 12.5 µg/day transdermal estrogen. The starting dose of E2 should be increased at 3-6 months



interval over 2 years to adult dose. The starting dose and dose escalations are not evidence-based and
should be individualised with monitoring of breast development since too rapid breast development
may cause stretch marks and asymmetry. Ultrasound of the uterus can be used to guide the timing of
addition of progesterone, although the value of this approach has not been evaluated in prospective
setup.

5487 *Effects of estrogen therapy*

5488 Breast and pubic hair

Both oral and transdermal estrogens induce normal breast maturation in hypogonadal girls. Bannink and colleagues showed that with low, increasing doses of oral 17β-estradiol in 56 GH-treated TS girls without spontaneous start of pubertal development starting at mean age 12.7 (\pm 0.7) years, breast and pubic hair development were similar to that in normal Dutch girls up to Tanner stage B5 and P5 (adult stage), albeit with a 2-year delay (Bannink *et al.*, 2009). Nabhan and colleagues found no significant differences in breast development after 1 year of oral estrogen or transdermal estrogen in 12 GH-treated TS girls (Nabhan *et al.*, 2009).

5496 Uterine size

In the study of Nabhan and colleagues, 12 prepubertal GH-treated girls with TS were randomized to 5497 oral conjugated estrogen or transdermal estrogen for 1 year. Uterine growth was significantly greater 5498 in the transdermal 17 β -estradiol group (Nabhan *et al.*, 2009). In a study of 40 girls with TS receiving 17 β -5499 5500 estradiol with a dose escalation regime uterine growth was recorded after 6-12 month, although the 5501 size of the uterus was smaller than in age-matched girls (Obara-Moszynska et al., 2021). In another 5502 study uterine volume, length and shape of the TS girls were suboptimal at age 19.9 (±2.2) years, after 5503 on average 7.1 (± 2.2) years of oral estrogen therapy compared to women of the same age (Bannink et al., 2009), also reported in other studies also reported in other studies (Paterson et al., 2002, Snajderova 5504 5505 et al., 2003). In contrast, 18 GH-treated girls with TS (5 with spontaneous puberty and 13 receiving estrogen therapy from age 14.6 (± 2.2) years), all girls had normal uterine length and volume at final 5506 5507 assessment at age 17.1 (± 2.8) years (McDonnell et al., 2003). A study comparing transdermal 17βestradiol at a dose of 100 microgram versus oral 17β-estradiol at a dose of 2 mg found normal uterine 5508 5509 size in both groups comparable to normative data (Lindsay Mart et al., 2023). A study comparing 2 mg versus 4 mg 17β-estradiol orally, showed that more TS females in the high dose group achieved a 5510 5511 normal adult uterine size (Cleemann et al., 2011). A retrospective study using oral estradiol valerate 5512 using a standard protocol showed that after pubertal induction of TS girls (n=75) showed that in the 5513 subset that could be analysed many did not achieve a normal uterine size (Guo et al., 2019).

5514 One retrospective study of a mixed group of females (n=95) with TS, POI, and gonadotropin deficiency, 5515 all needing pubertal induction showed lower average uterine volume. Treatment for pubertal induction 5516 was mixed, with some being treated with oral contraceptive pill, some with transdermal E2 and some 5517 with low dose ethinyl estradiol, and no direct comparison was performed. A large proportion of patient 5518 had uterine size below the normal range after pubertal induction (Burt et al., 2019). Another recent 5519 retrospective study of a mixed group of females (n=95), including POI and hypogonadotropic 5520 hypogonadism of all causes, all receiving a standardized protocol with transdermal estrogen being 5521 increased at fixed times with similar dose increases, reported a reduced uterine volume in most of 5522 evaluated patients (27 out of 45). Determinants of low uterine volume was previous irradiation (47% 5523 had POI due to cancer treatment) and E2 dose at introduction of progestins (Rodari et al., 2023).

5524 *Metabolic actions and bone*

5525 Metabolic actions of oral versus transdermal estrogen in adolescents have been examined in 4 short-5526 term randomized trials. In one study aiming at comparing the metabolic effects of oral versus 5527 transdermal estrogen, it was concluded that the route of delivery does not adversely affect the metabolic



- effects of GH in young girls with TS (Mauras *et al.*, 2007). In another study, no significant differences in change of IGF-I, lipid profile, BMI SD score, fat mass, or fat free mass was found between oral and transdermal estradiol (Nabhan *et al.*, 2009), although spine BMD was affected more positively by transdermal treatment. In a third study comparing oral and transdermal 17β-estradiol, with E2 concentrations titrated to normal range in both groups, there were no difference after 12 months treatment in body composition, BMD, lipid oxidation, resting energy expenditure and metabolic parameters (Torres-Santiago *et al.*, 2013).
- 5535 A five-year study with 20 TS females around 15 years at start of treatment, using 2 and 4 mg of 17β -5536 estradiol given orally found similar BMD accrual, but more favourable lean body increments during 5537 higher dose treatment, which led to normalization of circulating estradiol levels (Cleemann *et al.*, 2017).

5538 Cardiovascular actions

5539 Cardiovascular risk, both due to congenital and acquired disease, is increased in TS, as well as other 5540 forms of POI and HRT is thought to decrease this risk. One epidemiological study show that treated 5541 compared with untreated TS have a lower risk of being prescribed antihypertensives, antidiabetics and 5542 thyroid medications, and stroke was also less frequent, results pointing towards a protective effect of 5543 HRT (Viuff *et al.*, 2020). A five-year prospective study with 20 TS females around 15 years at start of 5544 treatment, using 2 and 4 mg of 17β -estradiol given orally found similar development in blood pressure, 5545 irrespective of the 17β -estradiol dosing (Brun *et al.*, 2019).

5546 Cognitive function

5547 Cognitive challenges are frequent among females with TS, and can encompass domains such as attention, working memory, executive function/cognitive control, perceptual-motor and visual-spatial 5548 5549 skills, visual memory, language, motor function, social cognition, and academic achievement. Patients 5550 with TS receiving estradiol for pubertal induction seemed to have exhibit the expected maturational 5551 changes in brain development studied by MRI (Li et al., 2019, O'Donoghue et al., 2020). Whether such cognitive challenges apply to other groups of females needing pubertal induction is unknown. Likewise, 5552 it is unknown if age-appropriate 17β-estradiol treatment affects maturational brain development in a 5553 5554 similar manner.

5555 Monitoring

- 5556 It is important that pubertal induction mimics physiology as closely as possible to support linear growth 5557 and gradually induce puberty at an age and tempo within the normal range for peers. This is important 5558 for psychosocial wellbeing, bone health, uterine growth, future pregnancy prospects and possible 5559 neurocognitive benefits.
- 5560 We suggest monitoring biochemically with measurement of estradiol, FSH and LH at regular intervals 5561 during pubertal induction, for example every 3-6 month. At some point it will make sense to measure 5562 bone density with DXA and ultrasound scan of the uterus can be used to guide the timing of addition 5563 of progesterone.
- 1 5

5564 *Recommendations*

Puberty should be induced or progressed with 17 β -estradiol, starting with low dose at the age of 11 with a gradual increase over 2 to 3 years.

5565

In cases of late diagnosis and for those girls in whom growth is not a concern, a modified regimen of estradiol can be considered.

5566

STRONG



	Evidence for the optimum mode of administration (oral or transdermal) is inconclusive. Transdermal estradiol may result in more physiological estrogen levels and may therefore be preferred.	⊕000	CONDITIONAL
5567			
	The oral contraceptive pill should not be used for puberty induction.	000€	STRONG
5568			
	The guideline group recommends starting cyclical progestogens after about 2 years of estrogen therapy or when breakthrough bleeding occurs.		

- 5569 Justification
- 5570 Estrogen therapy should be started from the age of 11 years onwards when there has been no 5571 spontaneous start to puberty or progression of breast development.
- 5572 There are many options for HRT for puberty induction. However, systemic administration of increasing 5573 doses estradiol, preferably by transdermal application, is the most used form of therapy to achieve 5574 natural levels of estradiol in blood and mimic normal estradiol physiology in adolescence and adulthood
- 5575 (Ankarberg-Lindgren et al., 2019, Donaldson et al., 2019).
- 5576 It is suggested to use unopposed estradiol for at least 18-24 months before adding a progestogen to 5577 allow for regular menstrual periods (Gravholt *et al.*, 2017, Klein *et al.*, 2018).
- In cases of later diagnosis of pubertal failure and for those girls in whom growth is not a consideration,
 estrogens may be started at somewhat higher doses and escalated more rapidly (Gravholt *et al.*, 2017,
 Klein *et al.*, 2018).
- 5581 With increasing doses of oral and transdermal 17β -estradiol normal breast and pubic hair development 5582 can be achieved (Gravholt *et al.*, 2017, Klein *et al.*, 2018). With higher starting doses of E2 and/or more 5583 rapid dose escalation, breast development should be monitored for stretch marks and asymmetry.
- Almost all the literature concerning puberty induction deals with Turner syndrome and the recommendations are based on knowledge from this area. It is thought that one can extrapolate data from this arena, but the reader should of course be cautious that one may not be able to extrapolate all conclusions to other conditions with primary ovarian insufficiency. Suffice to say, more research is needed in other causes of POI.
- 5589 Research recommendation.
- Research concerning the optimal age for induction of puberty is still needed, with increased focus on cognitive function, sexual function, uterine development, cardiovascular status, development of a normal body composition including bone acquisition and other areas. Likewise, there is a need to establish the optimal route of delivery of first estradiol at escalating doses and then progesterone, when sequential therapy is needed. Establishing the long-term outcome of appropriate puberty induction using both a clinical and an epidemiological approach is also needed. The fundamental understanding of why POI develop in conditions like Turner syndrome remains an enigma and should also be investigated.
- 5597



5598 **References**

- 5599 The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. *Menopause* 5600 (*New York, NY*) 2020;27: 976-992.
- Abadi O, Cheraghi MA, Tirgari B, Nayeri ND, Rayyani M. Feeling an Invisible Wall: The Experience of Iranian Women's Marital
 Relationship After Surgical Menopause: A Qualitative Content Analysis Study. J Sex Marital Ther 2018;44: 627-640.
- 5603 Abdelaziz EM, Elsharkawy NB, Mohamed SM. Efficacy of Internet-based cognitive behavioral therapy on sleeping difficulties in 5604 menopausal women: A randomized controlled trial. *Perspectives in psychiatric care* 2021.
- ACOG. Committee opinion no. 605: primary ovarian insufficiency in adolescents and young women. *Obstetrics and gynecology* 2014;124: 193-197.
- Ağaçayak E, Yaman Görük N, Küsen H, Yaman Tunç S, Başaranoğlu S, İçen MS, Yıldızbakan A, Yüksel H, Kalkanlı S, Gül T. Role of
 inflammation and oxidative stress in the etiology of primary ovarian insufficiency. *Turkish journal of obstetrics and gynecology* 2016;13: 109-115.
- 5610Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological Profile for Polychlorinated Biphenyls (PCBs). . 2000.5611DepartmentofHealthandHumanServices,PublicHealthService.5612https://wwwn.cdc.gov/TSP/ToxProfiles/ToxProfiles.aspx?id=142&tid=26, Atlanta, GA: U.S. .HealthService.
- Akhavan Zanjani M, Rahmani S, Mehranfar S, Zarrin M, Bazyar H, Moradi Poodeh B, Zare Javid A, Hosseini SA, Sadeghian M.
 Soy Foods and the Risk of Fracture: A Systematic Review of Prospective Cohort Studies. *Complementary medicine research*2022;29: 172-181.
- 5616 Akhtar S, Youssef I, Soudy H, Elhassan TA, Rauf SM, Maghfoor I. Prevalence of menstrual cycles and outcome of 50 pregnancies
- after high-dose chemotherapy and auto-SCT in non-Hodgkin and Hodgkin lymphoma patients younger than 40 years. *Bone marrow transplantation* 2015;50: 1551-1556.
- Al-Azzawi F, Bitzer J, Brandenburg U, Castelo-Branco C, Graziottin A, Kenemans P, Lachowsky M, Mimoun S, Nappi RE, Palacios
 S *et al.* Therapeutic options for postmenopausal female sexual dysfunction. *Climacteric : the journal of the International Menopause Society* 2010;13: 103-120.
- Albright F, Smith PH, Fraser R. A syndrome characterized by primary ovarian insufficiency and decreased stature: report of 11
 cases with a digression on hormonal control of axillary and public hair. *Am J Med Sci* 1942;204: 625-648.
- Aleksova J, Kuczynska-Burggraf M, Ranasinha S, Vincent A. Information on early menopause: is the internet the place to search? *Climacteric : the journal of the International Menopause Society* 2017;20: 248-255.
- Alexandre M, Black J, Whicker M, Minkin MJ, Ratner E. The management of sexuality, intimacy, and menopause symptoms
 (SIMS) after prophylactic bilateral salpingo-oophorectomy: How to maintain sexual health in "previvors". *Maturitas* 2017;105:
 46-51.
- Allen EG, Charen K, Hipp HS, Shubeck L, Amin A, He W, Hunter JE, Sherman SL. Clustering of comorbid conditions among
 women who carry an FMR1 premutation. *Genetics in medicine : official journal of the American College of Medical Genetics*2020;22: 758-766.
- Allshouse AA, Semple AL, Santoro NF. Evidence for prolonged and unique amenorrhea-related symptoms in women with
 premature ovarian failure/primary ovarian insufficiency. *Menopause (New York, NY)* 2015;22: 166-174.
- Alvaro Mercadal B, Imbert R, Demeestere I, Englert Y, Delbaere A. Pregnancy outcome after oocyte donation in patients with Turner's syndrome and partial X monosomy. *Human reproduction (Oxford, England)* 2011;26: 2061-2068.
- Alves-Nogueira AC, Melo D, Carona C, Figueiredo-Dias M. The Psychosocial Impact of the Decision to Undergo Risk-Reducing
 Salpingo-Oophorectomy Surgery in BRCA Mutation Carriers and the Role of Physician-Patient Communication. *Current oncology (Toronto, Ont)* 2023;30: 2429-2440.
- Alzubaidi NH, Chapin HL, Vanderhoof VH, Calis KA, Nelson LM. Meeting the needs of young women with secondary
 amenorrhea and spontaneous premature ovarian failure. *Obstetrics and gynecology* 2002;99: 720-725.
- Anagnostis P, Siolos P, Gkekas NK, Kosmidou N, Artzouchaltzi AM, Christou K, Paschou SA, Potoupnis M, Kenanidis E, Tsiridis E
 et al. Association between age at menopause and fracture risk: a systematic review and meta-analysis. *Endocrine* 2019;63: 213-224.
- Anderson C, Engel SM, Mersereau JE, Black KZ, Wood WA, Anders CK, Nichols HB. Birth Outcomes Among Adolescent and
 Young Adult Cancer Survivors. *JAMA oncology* 2017a;3: 1078-1084.
- Anderson MS, Venanzi ES, Klein L, Chen Z, Berzins SP, Turley SJ, von Boehmer H, Bronson R, Dierich A, Benoist C *et al.* Projection
 of an immunological self shadow within the thymus by the aire protein. *Science* 2002;298: 1395-1401.
- Anderson RA, Amant F, Braat D, D'Angelo A, Chuva de Sousa Lopes SM, Demeestere I, Dwek S, Frith L, Lambertini M, Maslin C
 et al. ESHRE guideline: female fertility preservation. *Human reproduction open* 2020;2020: hoaa052.
- Anderson RA, Cameron D, Clatot F, Demeestere I, Lambertini M, Nelson SM, Peccatori F. Anti-Müllerian hormone as a marker
 of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review. *Human reproduction update* 2022a;28: 417-434.
- Anderson RA, Kelsey TW, Morrison DS, Wallace WHB. Family size and duration of fertility in female cancer survivors: a population-based analysis. *Fertility and sterility* 2022b;117: 387-395.
- Anderson RA, Kelsey TW, Perdrix A, Olympios N, Duhamel O, Lambertini M, Clatot F. Diagnostic and predictive accuracy of
 anti-mullerian hormone for ovarian function after chemotherapy in premenopausal women with early breast cancer. *Breast cancer research and treatment* 2022c;192: 273-282.



- 5658Anderson RA, Mansi J, Coleman RE, Adamson DJA, Leonard RCF. The utility of anti-Müllerian hormone in the diagnosis and5659prediction of loss of ovarian function following chemotherapy for early breast cancer. Eur J Cancer 2017b;87: 58-64.
- Ankarberg-Lindgren C, Gawlik A, Kriström B, Mazzanti L, Ruijgrok EJ, Sas TCJ. Estradiol matrix patches for pubertal induction:
 stability of cut pieces at different temperatures. *Endocrine connections* 2019;8: 360-366.
- Appiah D, Nwabuo CC, Ebong IA, Wellons MF, Winters SJ. Trends in Age at Natural Menopause and Reproductive Life Span
 Among US Women, 1959-2018. *Jama* 2021;325: 1328-1330.
- Arif S, Underhill JA, Donaldson P, Conway GS, Peakman M. Human leukocyte antigen-DQB1* genotypes encoding aspartate at
 position 57 are associated with 3beta-hydroxysteroid dehydrogenase autoimmunity in premature ovarian failure. *The Journal* of clinical endocrinology and metabolism 1999;84: 1056-1060.
- Atema V, van Leeuwen M, Kieffer JM, Oldenburg HSA, van Beurden M, Gerritsma MA, Kuenen MA, Plaisier PW, Lopes Cardozo
 AMF, van Riet YEA *et al.* Efficacy of Internet-Based Cognitive Behavioral Therapy for Treatment-Induced Menopausal
 Symptoms in Breast Cancer Survivors: Results of a Randomized Controlled Trial. *J Clin Oncol* 2019;37: 809-822.
- Atema V, van Leeuwen M, Kieffer JM, Oldenburg HSA, van Beurden M, Hunter MS, Aaronson NK. Internet-based cognitive
 behavioral therapy aimed at alleviating treatment-induced menopausal symptoms in breast cancer survivors: Moderators and
 mediators of treatment effects. *Maturitas* 2020;131: 8-13.
- 5673 Ates S, Aydın S, Ozcan P, Bakar RZ, Cetin C. Sleep, depression, anxiety and fatigue in women with premature ovarian 5674 insufficiency. *Journal of psychosomatic obstetrics and gynaecology* 2022: 1-6.
- 5675 Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk 5676 factors for cardiovascular disease: a meta-analysis. *Menopause (New York, NY)* 2006;13: 265-279.
- Aydin S, Ateş S, Arioğlu Aydin Ç, Batmaz G. The Role of Premature Ovarian Failure Awareness in Female Sexual Functions and
 Distress. J Sex Marital Ther 2017;43: 354-360.
- Ayers B, Hunter MS. Health-related quality of life of women with menopausal hot flushes and night sweats. *Climacteric : the journal of the International Menopause Society* 2013;16: 235-239.
- 5681Ayres S, Abplanalp W, Liu JH, Subbiah MT. Mechanisms involved in the protective effect of estradiol-17beta on lipid5682peroxidation and DNA damage. The American journal of physiology 1998;274: E1002-1008.
- Azizi M, Khani S, Kamali M, Elyasi F. The Efficacy and Safety of Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine Reuptake Inhibitors in the Treatment of Menopausal Hot Flashes: A Systematic Review of Clinical Trials. *Iran J Med Sci* 2022;47: 173-193.
- Baber RJ, Panay N, Fenton A. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy.
 Climacteric : the journal of the International Menopause Society 2016;19: 109-150.
- 5688Bachelot A, Nicolas C, Bidet M, Dulon J, Leban M, Golmard JL, Polak M, Touraine P. Long-term outcome of ovarian function in
women with intermittent premature ovarian insufficiency. *Clinical endocrinology* 2017;86: 223-228.
- 5690Bachelot A, Nicolas C, Gricourt S, Dulon J, Leban M, Golmard JL, Touraine P. Poor Compliance to Hormone Therapy and5691Decreased Bone Mineral Density in Women with Premature Ovarian Insufficiency. *PloS one* 2016;11: e0164638.
- Bachelot A, Rouxel A, Massin N, Dulon J, Courtillot C, Matuchansky C, Badachi Y, Fortin A, Paniel B, Lecuru F *et al.* Phenotyping
 and genetic studies of 357 consecutive patients presenting with premature ovarian failure. *Eur J Endocrinol* 2009;161: 179187.
- Badawy A, Goda H, Ragab A. Induction of ovulation in idiopathic premature ovarian failure: a randomized double-blind trial.
 Reprod Biomed Online 2007;15: 215-219.
- 5697 Bakalov VK, Anasti JN, Calis KA, Vanderhoof VH, Premkumar A, Chen S, Furmaniak J, Smith BR, Merino MJ, Nelson LM.
 5698 Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46,XX spontaneous premature ovarian failure.
 5699 Fertility and sterility 2005;84: 958-965.
- 5700 Bakalov VK, Cooley MM, Quon MJ, Luo ML, Yanovski JA, Nelson LM, Sullivan G, Bondy CA. Impaired insulin secretion in the 5701 Turner metabolic syndrome. *The Journal of clinical endocrinology and metabolism* 2004;89: 3516-3520.
- 5702 Baker V. Life plans and family-building options for women with primary ovarian insufficiency. *Seminars in reproductive* 5703 *medicine* 2011;29: 362-372.
- 5704 Bakhsh H, Dei M, Bucciantini S, Balzi D, Bruni V. Premature ovarian insufficiency in young girls: repercussions on uterine volume 5705 and bone mineral density. *Gynecol Endocrinol* 2015;31: 65-69.
- Balen AH, Harris SE, Chambers EL, Picton HM. Conservation of fertility and oocyte genetics in a young woman with mosaic
 Turner syndrome. *BJOG* 2010;117: 238-242.
- 5708 Balneaves LG, Panagiotoglou D, Brazier AS, Lambert LK, Porcino A, Forbes M, Van Patten C, Truant TL, Seely D, Stacey D.
 5709 Qualitative assessment of information and decision support needs for managing menopausal symptoms after breast cancer.
- 5710 Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2016;24: 4567-4575.
- 5711 Bannatyne P, Russell P, Shearman RP. Autoimmune oophoritis: a clinicopathologic assessment of 12 cases. *Int J Gynecol Pathol* 5712 1990;9: 191-207.
- 5713 Bannink EM, van Sassen C, van Buuren S, de Jong FH, Lequin M, Mulder PG, de Muinck Keizer-Schrama SM. Puberty induction 5714 in Turner syndrome: results of oestrogen treatment on development of secondary sexual characteristics, uterine dimensions 5715 and server horners a lowel. *Clinical and environmentation* 2000, 70: 2010, 201
- and serum hormone levels. *Clinical endocrinology* 2009;70: 265-273.
- 5716 Bansal N, Hazim CF, Badillo S, Shyam S, Wolfe D, Bortnick AE, Garcia MJ, Rodriguez CJ, Zhang L. Maternal Cardiovascular
 5717 Outcomes of Pregnancy in Childhood, Adolescent, and Young Adult Cancer Survivors. *Journal of cardiovascular development* 5718 *and disease* 2022;9.
- 5719 Bar J, Davidi O, Goshen Y, Hod M, Yaniv I, Hirsch R. Pregnancy outcome in women treated with doxorubicin for childhood cancer. *American journal of obstetrics and gynecology* 2003;189: 853-857.



- 5721 Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS. Randomized double-blind trial of estrogen replacement therapy versus 5722 placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. *J Clin Oncol* 2006;24: 587-592.
- Baronchelli S, Conconi D, Panzeri E, Bentivegna A, Redaelli S, Lissoni S, Saccheri F, Villa N, Crosti F, Sala E *et al.* Cytogenetics of
 premature ovarian failure: an investigation on 269 affected women. *Journal of biomedicine & biotechnology* 2011;2011:
 370195.
- 5726 Barrett-Connor E. Menopause, atherosclerosis, and coronary artery disease. *Current opinion in pharmacology* 2013;13: 186-5727 191.
- 5728 Barrientos-Rios R, Frias S, Velázquez-Aragón JA, Villaroel CE, Sánchez S, Molina B, Martínez A, Carnevale A, García-de-Teresa
- 5729 B, Bonilla E et al. Low bone mineral density and renal malformation in Mexican patients with Turner syndrome are associated
- 5730 with single nucleotide variants in vitamin D-metabolism genes. *Gynecol Endocrinol* 2019;35: 772-776.
- 5731 Barros F, Carvalho F, Barros A, Dória S. Premature ovarian insufficiency: clinical orientations for genetic testing and genetic 5732 counseling. *Porto biomedical journal* 2020;5: e62.
- 5733 Barton DL, Schroeder KCF, Banerjee T, Wolf S, Keith TZ, Elkins G. Efficacy of a biobehavioral intervention for hot flashes: a 5734 randomized controlled pilot study. *Menopause (New York, NY)* 2017;24: 774-782.
- 5735 Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel L, King K, Kvaskoff M, Nap A, Petersen K *et al.* ESHRE guideline:
 5736 endometriosis. *Human reproduction open* 2022;2022: hoac009.
- 5737 Beitl K, Rosta K, Poetsch N, Seifried M, Mayrhofer D, Soliman B, Marculescu R, Ott J. Autoimmunological serum parameters
 5738 and bone mass density in premature ovarian insufficiency: a retrospective cohort study. *Archives of gynecology and obstetrics*5739 2021;303: 1109-1115.
- 5740 Benetti-Pinto CL, Brancalion MF, Assis LH, Tinois E, Giraldo HP, Cabello C, Yela DA. Mammographic breast density in women 5741 with premature ovarian failure: a prospective analysis. *Menopause (New York, NY)* 2014;21: 933-937.
- 5742 Benetti-Pinto CL, Ferreira VB, Yela DA. Long-term follow-up of bone density in women with primary ovarian insufficiency.
 5743 *Menopause (New York, NY)* 2015a;22: 946-949.
- 5744 Benetti-Pinto CL, Giraldo HP, Giraldo AE, Mira TA, Yela DA. Interferential current: a new option for the treatment of sexual
- 5745 complaints in women with premature ovarian insufficiency using systemic hormone therapy: a randomized clinical trial.
 5746 *Menopause (New York, NY)* 2020;27: 519-525.
- 5747 Benetti-Pinto CL, Giraldo PC, Pacello PC, Soares PM, Yela DA. Vaginal epithelium and microflora characteristics in women with
 5748 premature ovarian failure under hormone therapy compared to healthy women. Archives of gynecology and obstetrics
 5749 2015b;292: 159-164.
- 5750 Benetti-Pinto CL, Menezes C, Yela DA, Cardoso TM. Sleep quality and fatigue in women with premature ovarian insufficiency 5751 receiving hormone therapy: a comparative study. *Menopause (New York, NY)* 2019;26: 1141-1145.
- 5752 Benetti-Pinto CL, Soares PM, Giraldo HP, Yela DA. Role of the different sexuality domains on the sexual function of women 5753 with premature ovarian failure. *The journal of sexual medicine* 2015c;12: 685-689.
- 5754 Bernard V, Donadille B, Le Poulennec T, Nedelcu M, Martinerie L, Christin-Maitre S. MANAGEMENT OF ENDOCRINE DISEASE:
 5755 Transition of care for young adult patients with Turner syndrome. *Eur J Endocrinol* 2019;180: R1-r7.
- 5756 Bernard V, Donadille B, Zenaty D, Courtillot C, Salenave S, Brac de la Perrière A, Albarel F, Fèvre A, Kerlan V, Brue T *et al.*5757 Spontaneous fertility and pregnancy outcomes amongst 480 women with Turner syndrome. *Human reproduction (Oxford, England)* 2016;31: 782-788.
- 5759 Berreni N, Salerno J, Chevalier T, Alonso S, Mares P. Evaluation of the effect of multipoint intra-mucosal vaginal injection of a
 5760 specific cross-linked hyaluronic acid for vulvovaginal atrophy: a prospective bi-centric pilot study. *BMC Womens Health*5761 2021;21: 322.
- 5762 Bestetti I, Barbieri C, Sironi A, Specchia V, Yatsenko SA, De Donno MD, Caslini C, Gentilini D, Crippa M, Larizza L et al. Targeted
- besteell, burden e, show a, sector a v, rate no sa, be bonno Mb, casim e, sentim b, enppa w, tanza e e a. raigetea
 whole exome sequencing and Drosophila modelling to unveil the molecular basis of primary ovarian insufficiency. *Human* reproduction (Oxford, England) 2021;36: 2975-2991.
- 5764 reproduction (Oxford, England) 2021;36: 2975-2991.
 5765 Betterle C, Coco G, Zanchetta R. Adrenal cortex autoantibodies in subjects with normal adrenal function. Best practice & research Clinical endocrinology & metabolism 2005;19: 85-99.
- 5767 Bhattacharya SM, Jha A. A comparison of health-related quality of life (HRQOL) after natural and surgical menopause.
 5768 *Maturitas* 2010;66: 431-434.
- 5769 Bidet M, Bachelot A, Bissauge E, Golmard JL, Gricourt S, Dulon J, Coussieu C, Badachi Y, Touraine P. Resumption of ovarian 5770 function and pregnancies in 358 patients with premature ovarian failure. *The Journal of clinical endocrinology and metabolism*
- **5771** 2011;96: 3864-3872.
- 5772 Biglia N, Bounous VE, Sgro LG, D'Alonzo M, Pecchio S, Nappi RE. Genitourinary Syndrome of Menopause in Breast Cancer
 5773 Survivors: Are We Facing New and Safe Hopes? *Clinical breast cancer* 2015;15: 413-420.
- 5774 Bildircin FD, Özdeş EK, Karlı P, Özdemir AZ, Kökçü A. Does Type of Menopause Affect the Sex Lives of Women? *Medical science* 5775 *monitor : international medical journal of experimental and clinical research* 2020;26: e921811.
- 5776 Birkebaek NH, Crüger D, Hansen J, Nielsen J, Bruun-Petersen G. Fertility and pregnancy outcome in Danish women with Turner 5777 syndrome. *Clinical genetics* 2002;61: 35-39.
- 5778 Birkhaeuser M, Bitzer J, Braat S, Ramos Y. Esmirtazapine treatment of postmenopausal vasomotor symptoms: two randomized controlled trials. *Climacteric : the journal of the International Menopause Society* 2019;22: 312-322.
- 5780 Błaszczuk A, Barańska A, Kanadys W, Malm M, Jach ME, Religioni U, Wróbel R, Herda J, Polz-Dacewicz M. Role of
 5781 Phytoestrogen-Rich Bioactive Substances (Linum usitatissimum L., Glycine max L., Trifolium pratense L.) in Cardiovascular
 5782 Disease Prevention in Postmenopausal Women: A Systematic Review and Meta-Analysis. *Nutrients* 2022;14.



- 5783 Blizzard RM, Chee D, Davis W. The incidence of adrenal and other antibodies in the sera of patients with idiopathic adrenal 5784 insufficiency (Addison's disease). *Clin Exp Immunol* 1967;2: 19-30.
- 5785 Blümel JE, Arteaga E, Vallejo MS, Ojeda E, Meza P, Martino M, Rodríguez-Vidal D, Ñañez M, Tserotas K, Rojas J *et al.* Association
 5786 of bilateral ophorectomy and menopause hormone therapy with mild cognitive impairment: the REDLINC X study. *Climacteric*5787 : the journal of the International Menopause Society 2022;25: 195-202.
- 5788 Bober SL, Recklitis CJ, Bakan J, Garber JE, Patenaude AF. Addressing sexual dysfunction after risk-reducing salpingo-5789 oophorectomy: effects of a brief, psychosexual intervention. *The journal of sexual medicine* 2015;12: 189-197.
- 5790 Bodri D, Vernaeve V, Figueras F, Vidal R, Guillen JJ, Coll O. Oocyte donation in patients with Turner's syndrome: a successful technique but with an accompanying high risk of hypertensive disorders during pregnancy. *Human reproduction (Oxford,*
- 5792 England) 2006;21: 829-832.
 5793 Boekhout AH, Vincent AD, Dalesio OB, van den Bosch J, Foekema-Tons JH, Adriaansz S, Sprangers S, Nuijen B, Beijnen JH,
- 5794 Schellens JH. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized,
- 5795 double-blind, placebo-controlled trial. J Clin Oncol 2011;29: 3862-3868.
- 5796 Boivin J. A review of psychosocial interventions in infertility. Social science & medicine 2003;57: 2325-2341.
- 5797 Bondy C. Pregnancy and cardiovascular risk for women with Turner syndrome. *Women's health (London, England)* 2014;10:
 5798 469-476.
- 5799 Bondy CA. Congenital cardiovascular disease in Turner syndrome. *Congenit Heart Dis* 2008;3: 2-15.
- 5800 Bondy CA, Turner Syndrome Study Group. Care of girls and women with Turner syndrome: a guideline of the Turner Syndrome 5801 Study Group. *The Journal of clinical endocrinology and metabolism* 2007;92: 10-25.
- 5802 Bonnet N, Bourgoin L, Biver E, Douni E, Ferrari S. RANKL inhibition improves muscle strength and insulin sensitivity and restores
 5803 bone mass. *The Journal of clinical investigation* 2019;129: 3214-3223.
- 5804 Borba CM, Ferreira CF, Ferreira FV, Pérez-López FR, Wender MCO. Effect of sulpiride on menopausal hot flashes: a randomized,
 5805 double-blind, placebo-controlled clinical trial. *Gynecol Endocrinol* 2020;36: 247-251.
- Borgstrom B, Hreinsson J, Rasmussen C, Sheikhi M, Fried G, Keros V, Fridstrom M, Hovatta O. Fertility preservation in girls with
 turner syndrome: prognostic signs of the presence of ovarian follicles. *The Journal of clinical endocrinology and metabolism* 2009;94: 74-80.
- 5809 Bosze P, Toth A, Torok M. Hormone replacement and the risk of breast cancer in Turner's syndrome. *N Engl J Med* 2006;355:
 5810 2599-2600.
- 5811 Both S, Lew-Starowicz M, Luria M, Sartorius G, Maseroli E, Tripodi F, Lowenstein L, Nappi RE, Corona G, Reisman Y et al.
- 5812Hormonal Contraception and Female Sexuality: Position Statements from the European Society of Sexual Medicine (ESSM).5813The journal of sexual medicine 2019;16: 1681-1695.
- 5814 Bove R, Secor E, Chibnik LB, Barnes LL, Schneider JA, Bennett DA, De Jager PL. Age at surgical menopause influences cognitive 5815 decline and Alzheimer pathology in older women. *Neurology* 2014;82: 222-229.
- 5816 Bowman MC, Saunders DM. Rates of aneuploidy in oocytes of older women: are equivocal findings of concern for postmenopausal embryo recipients? *Human reproduction (Oxford, England)* 1994;9: 1200-1201.
- 5818 Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jong RA, Hislop G, Chiarelli A, Minkin S *et al.* Mammographic density and the risk and detection of breast cancer. *N Engl J Med* 2007;356: 227-236.
- Brand J, Onland-Moret N, Eijkemans M, Tjønneland A, Roswall N, Overvad K, Fagherazzi G, Clavel-Chapelon F, Dossus L,
 Lukanova A. Diabetes and onset of natural menopause: results from the European Prospective Investigation into Cancer and
 Nutrition. *Human Reproduction* 2015;30: 1491-1498.
- 5823 Bräuner EV, Wilson LF, Koch T, Christensen J, Dehlendorff C, Duun-Henriksen AK, Priskorn L, Abildgaard J, Simonsen MK,
- 5824Jørgensen JT et al. The long-term association between bilateral oophorectomy and depression: a prospective cohort study.5825Menopause (New York, NY) 2022;29: 276-283.
- 5826 Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA, Bachman G, Aguirre OA, Lucas JD, Rodenberg C *et al.*5827 Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal
 5828 women: a randomized, placebo-controlled trial. *Archives of internal medicine* 2005;165: 1582-1589.
- 5829 Brennan A, Brennan D, Rees M, Hickey M. Management of menopausal symptoms and ovarian function preservation in women 5830 with gynecological cancer. *International Journal of Gynecologic Cancer* 2021;31.
- 5831 Brennan A, Hickey M. Gynaecological care after stem cell transplant: An overview. *Maturitas* 2017;105: 30-32.
- 5832 Broer SL, Eijkemans MJ, Scheffer GJ, van Rooij IA, de Vet A, Themmen AP, Laven JS, de Jong FH, Te Velde ER, Fauser BC et al.
- Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women. *The Journal of clinical endocrinology and metabolism* 2011;96: 2532-2539.
- 5835 BROOKS H. INVOLVEMENT OF THE OVARY IN EPIDEMIC PAROTITIS: WITH A REPORT OF TWO CASES. *Journal of the American* 5836 *Medical Association* 1913;60: 359-360.
- 5837 Brozzetti A, Alimohammadi M, Morelli S, Minarelli V, Hallgren Å, Giordano R, De Bellis A, Perniola R, Kämpe O, Falorni A.
 5838 Autoantibody response against NALP5/MATER in primary ovarian insufficiency and in autoimmune Addison's disease. *The* 5839 *Journal of clinical endocrinology and metabolism* 2015;100: 1941-1948.
- Brun S, Cleemann L, Holm K, Salskov G, Erlandsen M, Berglund A, Andersen NH, Gravholt CH. Five-Year Randomized Study
 Demonstrates Blood Pressure Increases in Young Women With Turner Syndrome Regardless of Estradiol Dose. *Hypertension*2019;73: 242-248.
- 5843 Bruschi F, Meschia M, Soma M, Perotti D, Paoletti R, Crosignani PG. Lipoprotein(a) and other lipids after oophorectomy and 5844 estrogen replacement therapy. *Obstetrics and gynecology* 1996;88: 950-954.



- 5845Bryman I, Sylven L, Berntorp K, Innala E, Bergstrom I, Hanson C, Oxholm M, Landin-Wilhelmsen K. Pregnancy rate and outcome5846in Swedish women with Turner syndrome. *Fertility and sterility* 2011;95: 2507-2510.
- 5847 Bullington BW, Edmonds A, Ramirez C, Rahangdale L, Neal-Perry G, Konkle-Parker D, Weiss DJ, Moran C, Golub ET, Cejtin H *et* 5848 *al.* Premature and early menopause among US women with or at risk for HIV. *Menopause (New York, NY)* 2022;29: 741-747.
- 5849 Bundred NJ, Kenemans P, Yip CH, Beckmann MW, Foidart JM, Sismondi P, Schoultz B, Vassilopoulou-Sellin R, Galta RE, Lieshout
- 5850 EV *et al.* Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE trial bone substudy.
 5851 *Breast Cancer Res* 2012;14: R13.
- 5852 Burger HG. Androgen production in women. *Fertility and sterility* 2002;77 Suppl 4: S3-5.
- Burgos N, Cintron D, Latortue-Albino P, Serrano V, Rodriguez Gutierrez R, Faubion S, Spencer-Bonilla G, Erwin PJ, Murad MH.
 Estrogen-based hormone therapy in women with primary ovarian insufficiency: a systematic review. *Endocrine* 2017;58: 413 425.
- 5856 Burt E, Davies MC, Yasmin E, Cameron-Pimblett A, Mavrelos D, Talaulikar V, Conway GS. Reduced uterine volume after 5857 induction of puberty in women with hypogonadism. *Clinical endocrinology* 2019;91: 798-804.
- Bustami M, Matalka KZ, Elyyan Y, Hussein N, Hussein N, Abu Safieh N, Thekrallah F, Mallah E, Abu-Qatouseh L, Arafat T. Age of
 Natural Menopause Among Jordanian Women and Factors Related to Premature and Early Menopause. *Risk management and healthcare policy* 2021;14: 199-207.
- 5861 Buster JE, Kingsberg SA, Aguirre O, Brown C, Breaux JG, Buch A, Rodenberg CA, Wekselman K, Casson P. Testosterone patch 5862 for low sexual desire in surgically menopausal women: a randomized trial. *Obstetrics and gynecology* 2005;105: 944-952.
- 5863 Caan B, LaCroix AZ, Joffe H, Guthrie KA, Larson JC, Carpenter JS, Cohen LS, Freeman EW, Manson JE, Newton K *et al.* Effects of
 5864 estrogen and venlafaxine on menopause-related quality of life in healthy postmenopausal women with hot flashes: a placebo5865 controlled randomized trial. *Menopause (New York, NY)* 2015;22: 607-615.
- 5866 Cabal-Herrera AM, Tassanakijpanich N, Salcedo-Arellano MJ, Hagerman RJ. Fragile X-Associated Tremor/Ataxia Syndrome 5867 (FXTAS): Pathophysiology and Clinical Implications. *Int J Mol Sci* 2020;21.
- 5868 Cabanes L, Chalas C, Christin-Maitre S, Donadille B, Felten ML, Gaxotte V, Jondeau G, Lansac E, Lansac J, Letur H *et al.* Turner
 syndrome and pregnancy: clinical practice. Recommendations for the management of patients with Turner syndrome before
 and during pregnancy. *European journal of obstetrics, gynecology, and reproductive biology* 2010;152: 18-24.
- 5871 Cai WY, Luo X, Wu W, Song J, Xie NN, Duan C, Wu XK, Xu J. Metabolic differences in women with premature ovarian insufficiency: a systematic review and meta-analysis. *Journal of ovarian research* 2022;15: 109.
- 5873 Cakiroglu Y, Saltik A, Yuceturk A, Karaosmanoglu O, Kopuk SY, Scott RT, Tiras B, Seli E. Effects of intraovarian injection of
 5874 autologous platelet rich plasma on ovarian reserve and IVF outcome parameters in women with primary ovarian insufficiency.
 5875 Aging 2020;12: 10211-10222.
- 5876 Cakmak E, Karakus S, Demirpence O, Demet Coskun B. Ovarian Reserve Assessment in Celiac Patients of Reproductive Age.
 5877 *Medical science monitor : international medical journal of experimental and clinical research* 2018;24: 1152-1157.
- 5878 Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST, Hurley DL, Kelly J, Lewiecki EM *et al.* AMERICAN
 5879 ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES
 5880 FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE. *Endocrine practice : official*5881 *journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists* 2020;26: 1-46.
- Cambray S, Dubreuil S, Tejedor I, Dulon J, Touraine P. Family building after diagnosis of premature ovarian insufficiency: a
 cross-sectional survey in 324 women. *Eur J Endocrinol* 2023;188.
- 5884 Cameron-Pimblett A, Davies MC, Burt E, Talaulikar VS, La Rosa C, King TFJ, Conway GS. Effects of Estrogen Therapies on
 5885 Outcomes in Turner Syndrome: Assessment of Induction of Puberty and Adult Estrogen Use. *The Journal of clinical* 5886 *endocrinology and metabolism* 2019;104: 2820-2826.
- 5887 Cameron DA, Douglas S, Brown JE, Anderson RA. Bone mineral density loss during adjuvant chemotherapy in pre-menopausal
 5888 women with early breast cancer: is it dependent on oestrogen deficiency? *Breast cancer research and treatment* 2010;123:
 5889 805-814.
- 5890 Cameron K, Sammel MD, Prewitt M, Gracia C. Differential Rates of Change in Measures of Ovarian Reserve in Young Cancer
 5891 Survivors Across the Reproductive Lifespan. *The Journal of clinical endocrinology and metabolism* 2019;104: 1813-1822.
- 5892 Canonico M, Oger E, Conard J, Meyer G, Levesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J, Scarabin PY *et al.* Obesity
 5893 and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of
 5894 estrogen administration. The ESTHER Study. *J Thromb Haemost* 2006;4: 1259-1265.
- 5895 Canonico M, Oger E, Plu-Bureau G, Conard J, Meyer G, Levesque H, Trillot N, Barrellier MT, Wahl D, Emmerich J *et al.* Hormone
 5896 therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and
 5897 progestogens: the ESTHER study. *Circulation* 2007;115: 840-845.
- 5898 Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. *BMJ* 2008;336: 1227-1231.
- 5900 Canonico M, Plu-Bureau G, O'Sullivan MJ, Stefanick ML, Cochrane B, Scarabin PY, Manson JE. Age at menopause, reproductive
 5901 history, and venous thromboembolism risk among postmenopausal women: the Women's Health Initiative Hormone Therapy
 5902 clinical trials. *Menopause (New York, NY)* 2014;21: 214-220.
- 5903 Canpolat U, Tokgozoglu L, Yorgun H, Baris Kaya E, Murat Gurses K, Sahiner L, Bozdag G, Kabakci G, Oto A, Aytemir K. The
- 5904 association of premature ovarian failure with ventricular repolarization dynamics evaluated by QT dynamicity. Europace :
- European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias,
 and cardiac cellular electrophysiology of the European Society of Cardiology 2013;15: 1657-1663.
 - Guideline POI DRAFT FOR REVIEW



- 5907 Cao M, Pan W, Shen X, Li C, Zhou J, Liu J. Urinary levels of phthalate metabolites in women associated with risk of premature 5908 ovarian failure and reproductive hormones. *Chemosphere* 2020;242: 125206.
- 5909 Cao X, Sun ML, Qin YN, Zhang JJ, Bai YF, Zhang Y, Ai YK, Liu J. Overview of the systematic reviews of premature ovarian 5910 insufficiency treated with acupuncture. *World Journal of Acupuncture - Moxibustion* 2022;32: 287-297.
- 5911 Cao XJ, Huang X, Liu J, Ma F, Zeng Y, Chen C, Wang JJ, Nie G, Wang XY. A randomized, double-blind, placebo-controlled trial of 5912 Chinese herbal medicine capsules for the treatment of premature ovarian insufficiency. *Menopause (New York, NY)* 2018;25:
- 5912 Chinese herbal medicine capsules for the treatment of premature ovarian insufficiency. *Menopause (New York, NY)* 2018;25: 5913 918-926.
- 5914 Carcelén-Fraile MDC, Aibar-Almazán A, Martínez-Amat A, Cruz-Díaz D, Díaz-Mohedo E, Redecillas-Peiró MT, Hita-Contreras F.
- 5915 Effects of Physical Exercise on Sexual Function and Quality of Sexual Life Related to Menopausal Symptoms in Peri- and
- 5916 Postmenopausal Women: A Systematic Review. *Int J Environ Res Public Health* 2020;17.
- 5917 Cardona Attard C, Cameron-Pimblett A, Puri D, Elliot J, Wilson JC, Talaulikar VS, Davies MC, Conway GS. Fracture rate in women
 5918 with oestrogen deficiency Comparison of Turner syndrome and premature ovarian insufficiency. *Clinical endocrinology* 5919 2019;91: 743-749.
- 5920 Cardona Attard C, Cameron-Pimblett A, Puri D, La Rosa C, Talaulikar VS, Davies MC, Learner HI, Liao LM, Conway GS.
 5921 Relationship and sexual experiences in women with early-onset oestrogen deficiency: Comparison between women with
 5922 Turner syndrome and premature ovarian insufficiency. *Clinical endocrinology* 2020;93: 473-481.
- 5923 Cartwright B, Holloway D, Grace J, Robinson J, Rymer J. A service evaluation of women attending the menopause/premature
 5924 ovarian failure clinic of a tertiary referral centre. *Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics* 5925 and Gynaecology 2012;32: 357-361.
- 5926 Cartwright B, Robinson J, Seed PT, Fogelman I, Rymer J. Hormone Replacement Therapy Versus the Combined Oral
 5927 Contraceptive Pill in Premature Ovarian Failure: A Randomized Controlled Trial of the Effects on Bone Mineral Density. *The*5928 Journal of clinical endocrinology and metabolism 2016;101: 3497-3505.
- 5929 Castaneda S, Carmona L, Carvajal I, Arranz R, Diaz A, Garcia-Vadillo A. Reduction of bone mass in women after bone marrow
 5930 transplantation. *Calcified tissue international* 1997;60: 343-347.
- Castronovo C, Rossetti R, Rusconi D, Recalcati MP, Cacciatore C, Beccaria E, Calcaterra V, Invernizzi P, Larizza D, Finelli P *et al.*Gene dosage as a relevant mechanism contributing to the determination of ovarian function in Turner syndrome. *Human reproduction (Oxford, England)* 2014;29: 368-379.
- 5934 Chaker L, Razvi S, Bensenor IM, Azizi F, Pearce EN, Peeters RP. Hypothyroidism. *Nature reviews Disease primers* 2022;8: 30.
- 5935 Chemaitilly W, Li Z, Krasin MJ, Brooke RJ, Wilson CL, Green DM, Klosky JL, Barnes N, Clark KL, Farr JB *et al.* Premature Ovarian
 5936 Insufficiency in Childhood Cancer Survivors: A Report From the St. Jude Lifetime Cohort. *The Journal of clinical endocrinology* 5937 and metabolism 2017;102: 2242-2250.
- 5938 Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, Jang HC, Kang L, Kim M, Kim S *et al.* Asian Working Group for
 5939 Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. *J Am Med Dir Assoc* 2020;21: 300-307 e302.
- 5940 Chen M, Jiang H, Zhang C. Selected Genetic Factors Associated with Primary Ovarian Insufficiency. Int J Mol Sci 2023;24.
- 5941 Chen S, Sawicka J, Betterle C, Powell M, Prentice L, Volpato M, Rees Smith B, Furmaniak J. Autoantibodies to steroidogenic 5942 enzymes in autoimmune polyglandular syndrome, Addison's disease, and premature ovarian failure. *The Journal of clinical*
- 5942 endocrinology and metabolism 1996;81: 1871-1876.
 5044 Chen TL Cheng CC, Wang LW, Sfferting end of mindfulness have distance from the filte and metabolism 1996;81: 1871-1876.
- 5944 Chen TL, Chang SC, Huang CY, Wang HH. Effectiveness of mindfulness-based interventions on quality of life and menopausal
 5945 symptoms in menopausal women: A meta-analysis. *Journal of psychosomatic research* 2021;147: 110515.
- 5946 Chen Y, Fang Y, Yang J, Wang F, Wang Y, Yang L. Effect of acupuncture on premature ovarian failure: a pilot study. *Evidence-* 5947 *based complementary and alternative medicine : eCAM* 2014;2014: 718675.
- 5948 Cheng YS, Sun CK, Yeh PY, Wu MK, Hung KC, Chiu HJ. Serotonergic antidepressants for sleep disturbances in perimenopausal
 and postmenopausal women: a systematic review and meta-analysis. *Menopause (New York, NY)* 2020;28: 207-216.
- Chernausek SD, Attie KM, Cara JF, Rosenfeld RG, Frane J. Growth hormone therapy of Turner syndrome: the impact of age of
 estrogen replacement on final height. Genentech, Inc., Collaborative Study Group. *The Journal of clinical endocrinology and metabolism* 2000;85: 2439-2445.
- 5953 Chetkowski RJ, Meldrum DR, Steingold KA, Randle D, Lu JK, Eggena P, Hershman JM, Alkjaersig NK, Fletcher AP, Judd HL.
 5954 Biologic effects of transdermal estradiol. *N Engl J Med* 1986;314: 1615-1620.
- 5955 Chevalier N, Letur H, Lelannou D, Ohl J, Cornet D, Chalas-Boissonnas C, Frydman R, Catteau-Jonard S, Greck-Chassain T,
- 5956 Papaxanthos-Roche A *et al.* Materno-fetal cardiovascular complications in Turner syndrome after oocyte donation: insufficient
 5957 prepregnancy screening and pregnancy follow-up are associated with poor outcome. *The Journal of clinical endocrinology and* 5958 *metabolism* 2011;96: E260-267.
- 5959 Chiuve SE, Martin LA, Campos H, Sacks FM. Effect of the combination of methyltestosterone and esterified estrogens
 5960 compared with esterified estrogens alone on apolipoprotein CIII and other apolipoproteins in very low density, low density,
 5961 and high density lipoproteins in surgically postmenopausal women. *The Journal of clinical endocrinology and metabolism*5962 2004;89: 2207-2213.
- 5963 Chojnacki C, Walecka-Kapica E, Klupinska G, Pawlowicz M, Blonska A, Chojnacki J. Effects of fluoxetine and melatonin on mood,
 5964 sleep quality and body mass index in postmenopausal women. *Journal of physiology and pharmacology : an official journal of* 5965 *the Polish Physiological Society* 2015;66: 665-671.
- 5966 Chow EJ, Stratton KL, Leisenring WM, Oeffinger KC, Sklar CA, Donaldson SS, Ginsberg JP, Kenney LB, Levine JM, Robison LL *et*
- 5967 *al.* Pregnancy after chemotherapy in male and female survivors of childhood cancer treated between 1970 and 1999: a report
 5968 from the Childhood Cancer Survivor Study cohort. *The Lancet Oncology* 2016;17: 567-576.
 - Guideline POI DRAFT FOR REVIEW



- 5969 Christin-Maitre S, Givony M, Albarel F, Bachelot A, Bidet M, Blanc JV, Bouvattier C, Brac de la Perrière A, Catteau-Jonard S,
 5970 Chevalier N *et al.* Position statement on the diagnosis and management of premature/primary ovarian insufficiency (except
 5971 Turner Syndrome). *Annales d'endocrinologie* 2021;82: 555-571.
- 5972 Christmas MM, Iyer S, Daisy C, Maristany S, Letko J, Hickey M. Menopause hormone therapy and urinary symptoms: a systematic review. *Menopause (New York, NY)* 2023;30: 672-685.
- 5974 Chu K, Wang Y, He Y, Tang Y, Gu J, Wu S, Zhang H, Sun N, Li Z, Zhang Q *et al.* The psychosocial impact of premature ovarian insufficiency on male partners and their perceptions of the disease. *Psychology, health & medicine* 2021;26: 1248-1257.
- 5976 Cieri-Hutcherson NE, Marji EK, Hutcherson TC. Systematic review of neurokinin-3 receptor antagonists for the management
- 5977 of vasomotor symptoms of menopause. *Menopause (New York, NY)* 2024;31: 342-354.
- 5978 Cintron D, Rodriguez-Gutierrez R, Serrano V, Latortue-Albino P, Erwin PJ, Murad MH. Effect of estrogen replacement therapy
 5979 on bone and cardiovascular outcomes in women with turner syndrome: a systematic review and meta-analysis. *Endocrine* 5980 2017;55: 366-375.
- Clarkson TB. Estrogens, progestins, and coronary heart disease in cynomolgus monkeys. *Fertility and sterility* 1994;62: 1475 151S.
- 5983 Clarkson TB. Estrogen effects on arteries vary with stage of reproductive life and extent of subclinical atherosclerosis 5984 progression. *Menopause (New York, NY)* 2007;14: 373-384.
- 5985 Clayton AH, Goldstein I, Kim NN, Althof SE, Faubion SS, Faught BM, Parish SJ, Simon JA, Vignozzi L, Christiansen K *et al.* The
 5986 International Society for the Study of Women's Sexual Health Process of Care for Management of Hypoactive Sexual Desire
 5987 Disorder in Women. *Mayo Clinic proceedings Mayo Clinic* 2018;93: 467-487.
- 5988 Cleemann L, Holm K, Fallentin E, Skouby SO, Smedegaard H, Møller N, Borch-Christensen H, Jeppesen EM, Wieslander SB,
 5989 Andersson AM *et al.* Uterus and ovaries in girls and young women with Turner syndrome evaluated by ultrasound and magnetic
 5990 resonance imaging. *Clinical endocrinology* 2011;74: 756-761.
- 5991 Cleemann L, Holm K, Kobbernagel H, Kristensen B, Skouby SO, Jensen AK, Gravholt CH. Dosage of estradiol, bone and body 5992 composition in Turner syndrome: a 5-year randomized controlled clinical trial. *Eur J Endocrinol* 2017;176: 233-242.
- 5993 Clifford A, Bandelow, S., Yesufu, A., Edwards, L., Hogervorst, E. . Maintaining cognitive health in elderly women: an invited 5994 review. *Women's Health* 2009;5: 655-670.
- 5995 Coccia ME, Rizzello F, Mariani G, Bulletti C, Palagiano A, Scarselli G. Ovarian surgery for bilateral endometriomas influences 5996 age at menopause. *Human reproduction (Oxford, England)* 2011;26: 3000-3007.
- 5997 Coelingh Bennink HJT, van Gennip FAM, Gerrits MGF, Egberts JFM, Gemzell-Danielsson K, Kopp-Kallner H. Health benefits of
 5998 combined oral contraceptives a narrative review. *The European journal of contraception & reproductive health care : the* 5999 official journal of the European Society of Contraception 2024: 1-13.
- 6000 Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual
 6001 participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. *The Lancet Oncology* 6002 2012;13: 1141-1151.
- 6003 Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast 6004 cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. *Lancet* 2019;394: 1159-1168.
- 6005 Comba C, Comba A, Yılmaz H, Erdogan SV, Demir O. Celiac disease does not influence markers of ovarian reserve in adolescent 6006 girls. *Archives of gynecology and obstetrics* 2020;302: 1263-1269.
- 6007 Comini ACM, Carvalho BM, Moreira MJB, Reis PCA, Colapietro L, Northern J, Batalini F. Safety and Serum Estradiol Levels in
 6008 Hormonal Treatments for Vulvovaginal Atrophy in Breast Cancer Survivors: A Systematic Review and Meta-Analysis. *Clinical* 6009 *breast cancer* 2023;23: 835-846.
- 6010 Conrad KP, von Versen-Höynck F, Baker VL. Potential role of the corpus luteum in maternal cardiovascular adaptation to pregnancy and preeclampsia risk. *American journal of obstetrics and gynecology* 2022;226: 683-699.
- 6012 Conway GS. Premature ovarian failure. *British medical bulletin* 2000;56: 643-649.
- 6013 Cooper AR, Baker VL, Sterling EW, Ryan ME, Woodruff TK, Nelson LM. The time is now for a new approach to primary ovarian 6014 insufficiency. *Fertility and sterility* 2011;95: 1890-1897.
- 6015 Costa GPO, Ferreira-Filho ES, Simoes RDS, Soares-Junior JM, Baracat EC, Maciel GAR. Impact of hormone therapy on the bone 6016 density of women with premature ovarian insufficiency: A systematic review. *Maturitas* 2023;167: 105-112.
- 6017 Cotangco K, Class QA, Johnson TP, Kothari R. Cervical cancer survivors' attitudes and understanding of menopause and 6018 hormone therapy. *Menopause (New York, NY)* 2020;27: 701-705.
- 6019 Coughlan GT, Betthauser TJ, Boyle R, Koscik RL, Klinger HM, Chibnik LB, Jonaitis EM, Yau WW, Wenzel A, Christian BT *et al.* 6020 Association of Age at Menopause and Hormone Therapy Use With Tau and β-Amyloid Positron Emission Tomography. *JAMA* 6021 *neurology* 2023;80: 462-473.
- 6022 Coulam CB. The prevalence of autoimmune disorders among patients with primary ovarian failure. *Am J Reprod Immunol* 6023 (*1980*) 1983;4: 63-66.
- 6024 Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. *Obstetrics and gynecology* 1986;67: 604-606.
- 6025 Coulam CB, Ryan RJ. Prevalence of circulating antibodies directed toward ovaries among women with premature ovarian 6026 failure. *Am J Reprod Immunol Microbiol* 1985;9: 23-24.
- 6027 Coulter A, Entwistle VA, Eccles A, Ryan S, Shepperd S, Perera R. Personalised care planning for adults with chronic or long-term
 6028 health conditions. *Cochrane Database Syst Rev* 2015;2015: CD010523.
- 6029 Cox P, Panay N. Non-hormonal treatments for managing vulvovaginal atrophy/genitourinary syndrome of menopause.
- 6030 *Climacteric : the journal of the International Menopause Society* 2023;26: 367-372.
 6031 Cramer DW, Xu H. Predicting age at menopause. *Maturitas* 1996;23: 319-326.



- 6032 Cramer DW, Xu H, Harlow BL. Family history as a predictor of early menopause. Fertility and sterility 1995;64: 740-745.
- 6033 Crean-Tate KK, Faubion SS, Pederson HJ, Vencill JA, Batur P. Management of genitourinary syndrome of menopause in female 6034 cancer patients: a focus on vaginal hormonal therapy. *American journal of obstetrics and gynecology* 2020;222: 103-113.
- 6035 Critchley HO, Wallace WH. Impact of cancer treatment on uterine function. *Journal of the National Cancer Institute* 6036 *Monographs* 2005: 64-68.
- 6037 Critchley HO, Wallace WH, Shalet SM, Mamtora H, Higginson J, Anderson DC. Abdominal irradiation in childhood; the potential 6038 for pregnancy. *British journal of obstetrics and gynaecology* 1992;99: 392-394.
- 6039 Crofton PM, Evans N, Bath LE, Warner P, Whitehead TJ, Critchley HO, Kelnar CJ, Wallace WH. Physiological versus standard sex
- 6040 steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover. *Clinical*
- 6041 endocrinology 2010;73: 707-714.
- 6042 Cruz-Jentoft AJ, Sayer AA. Sarcopenia. *Lancet* 2019;393: 2636-2646.
- 6043 Cucinella L, Tiranini L, Cassani C, Martella S, Nappi RE. Genitourinary Syndrome of Menopause in Breast Cancer Survivors:
 6044 Current Perspectives on the Role of Laser Therapy. *Int J Womens Health* 2023;15: 1261-1282.
- 6045 Cui J, Wang Y. Premature ovarian insufficiency: a review on the role of tobacco smoke, its clinical harm, and treatment. *Journal* 6046 of ovarian research 2024;17: 8.
- 6047 Cui Y, Deming-Halverson SL, Beeghly-Fadiel A, Lipworth L, Shrubsole MJ, Fair AM, Shu XO, Zheng W. Interactions of hormone
 6048 replacement therapy, body weight, and bilateral oophorectomy in breast cancer risk. *Clinical cancer research : an official*6049 *journal of the American Association for Cancer Research* 2014;20: 1169-1178.
- 6050 Cusimano MC, Chiu M, Ferguson SE, Moineddin R, Aktar S, Liu N, Baxter NN. Association of bilateral salpingo-oophorectomy 6051 with all cause and cause specific mortality: population based cohort study. *Bmj* 2021;375: e067528.
- 6052 Dal Pra C, Chen S, Furmaniak J, Smith BR, Pedini B, Moscon A, Zanchetta R, Betterle C. Autoantibodies to steroidogenic enzymes
 6053 in patients with premature ovarian failure with and without Addison's disease. *Eur J Endocrinol* 2003;148: 565-570.
- Daley A, Stokes-Lampard H, Thomas A, MacArthur C. Exercise for vasomotor menopausal symptoms. *Cochrane Database Syst Rev* 2014: Cd006108.
- 6056 Daly MB, Pal T, Berry MP, Buys SS, Dickson P, Domchek SM, Elkhanany A, Friedman S, Goggins M, Hutton ML. Genetic/familial
- high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology. *Journal of the National Comprehensive Cancer Network* 2021;19: 77-102.
- 6059 Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. *N Engl J Med* 1997;337: 595-601.
- bavey DA. HRT: some unresolved clinical issues in breast cancer, endometrial cancer and premature ovarian insufficiency.
 Womens Health (Lond Engl) 2013;9: 59-67.
- Davies MC, Cartwright B. What is the best management strategy for a 20-year-old woman with premature ovarian failure?
 Clinical endocrinology 2012;77: 182-186.
- bavis DD, Ruiz AL, Yanes LL, Iliescu R, Yuan K, Moulana M, Racusen LC, Reckelhoff JF. Testosterone supplementation in male
 obese Zucker rats reduces body weight and improves insulin sensitivity but increases blood pressure. *Hypertension* 2012;59:
 726-731.
- Davis M, Ventura JL, Wieners M, Covington SN, Vanderhoof VH, Ryan ME, Koziol DE, Popat VB, Nelson LM. The psychosocial transition associated with spontaneous 46,XX primary ovarian insufficiency: illness uncertainty, stigma, goal flexibility, and purpose in life as factors in emotional health. *Fertility and sterility* 2010;93: 2321-2329.
- 6071 Davis SR. Androgens in premenopausal women and women with premature ovarian insufficiency. *Climacteric : the journal of the International Menopause Society* 2021;24: 459-465.
- 6073 Davis SR, Baber R, Panay N, Bitzer J, Perez SC, Islam RM, Kaunitz AM, Kingsberg SA, Lambrinoudaki I, Liu J *et al.* Global Consensus
 6074 Position Statement on the Use of Testosterone Therapy for Women. *The Journal of clinical endocrinology and metabolism* 6075 2019;104: 4660-4666.
- 6076 Davis SR, Hirschberg AL, Wagner LK, Lodhi I, von Schoultz B. The effect of transdermal testosterone on mammographic density
 in postmenopausal women not receiving systemic estrogen therapy. *The Journal of clinical endocrinology and metabolism* 6078 2009;94: 4907-4913.
- 6079 Davis SR, Jane F. Sex and perimenopause. *Australian family physician* 2011;40: 274-278.
- Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M, Braunstein GD, Hirschberg AL, Rodenberg C, Pack S *et al.* Testosterone for low libido in postmenopausal women not taking estrogen. *N Engl J Med* 2008;359: 2005-2017.
- 6082 Davis SR, Robinson PJ, Jane F, White S, White M, Bell RJ. Intravaginal Testosterone Improves Sexual Satisfaction and Vaginal
- Symptoms Associated With Aromatase Inhibitors. *The Journal of clinical endocrinology and metabolism* 2018;103: 4146-4154.
 Davis SR, van der Mooren MJ, van Lunsen RH, Lopes P, Ribot C, Rees M, Moufarege A, Rodenberg C, Buch A, Purdie DW.
- bavis SR, van der Mooren MJ, van Lunsen RH, Lopes P, Ribot C, Rees M, Moufarege A, Rodenberg C, Buch A, Purdie DW.
 Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal
 women: a randomized, placebo-controlled trial. *Menopause (New York, NY)* 2006;13: 387-396.
- Davis SR, Worsley R, Miller KK, Parish SJ, Santoro N. Androgens and Female Sexual Function and Dysfunction--Findings From
 the Fourth International Consultation of Sexual Medicine. *The journal of sexual medicine* 2016;13: 168-178.
- 6089Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and6090oophorectomy. The Journal of clinical endocrinology and metabolism 2005;90: 3847-3853.
- bavison SL, Bell RJ, Gavrilescu M, Searle K, Maruff P, Gogos A, Rossell SL, Adams J, Egan GF, Davis SR. Testosterone improves
 verbal learning and memory in postmenopausal women: Results from a pilot study. *Maturitas* 2011;70: 307-311.
- 6093de Almeida DM, Benetti-Pinto CL, Makuch MY. Sexual function of women with premature ovarian failure. *Menopause (New York, NY)* 2011;18: 262-266.



- 6095 de Villiers TJ, Goldstein SR. Update on bone health: the International Menopause Society White Paper 2021. *Climacteric : the* 6096 *journal of the International Menopause Society* 2021;24: 498-504.
- 6097 De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. *Lancet* 2010;376: 911-921.
- 6098 Dedden SJ, Werner MA, Steinweg J, Lissenberg-Witte BI, Huirne JAF, Geomini P, Maas JWM. Hysterectomy and sexual function:
 a systematic review and meta-analysis. *The journal of sexual medicine* 2023;20: 447-466.
- 6100 Deeks AA, Gibson-Helm M, Teede H, Vincent A. Premature menopause: a comprehensive understanding of psychosocial aspects. *Climacteric : the journal of the International Menopause Society* 2011;14: 565-572.
- 6102 Del Pilar Larosa M, Chen S, Steinmaus N, Macrae H, Guo L, Masiero S, Garelli S, Costa MD, Bossowski A, Furmaniak J *et al.* A 6103 new ELISA for autoantibodies to steroid 21-hydroxylase. *Clinical chemistry and laboratory medicine* 2018;56: 933-938.
- 6104 Dendrinos ML, Smorgick N, Marsh CA, Smith YR, Quint EH. Occurrence of Gonadoblastoma in Patients with 45,X/46,XY 6105 Mosaicism. *Journal of pediatric and adolescent gynecology* 2015;28: 192-195.
- 6106 Dhakate M, Goswami D, Goswami R, Saha S, Kandasamy D, Arora M. Bone mineral density, vertebral fractures and trabecular 6107 bone score in primary ovarian insufficiency. *Journal of endocrinological investigation* 2023;46: 1865-1874.
- 6108 Di Carlo C, Tommaselli GA, Gargano V, Savoia F, Bifulco G, Nappi C. Transdermal estradiol and oral or vaginal natural 6109 progesterone: bleeding patterns. *Climacteric : the journal of the International Menopause Society* 2010;13: 442-446.
- Diem SJ, LaCroix AZ, Reed SD, Larson JC, Newton KM, Ensrud KE, Woods NF, Guthrie KA. Effects of pharmacologic and
 nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from
 four MsFLASH trials. *Menopause (New York, NY)* 2020;27: 1126-1136.
- 6113 Ding N, Harlow SD, Randolph JF, Calafat AM, Mukherjee B, Batterman S, Gold EB, Park SK. Associations of Perfluoroalkyl
 6114 Substances with Incident Natural Menopause: The Study of Women's Health Across the Nation. *The Journal of clinical*6115 *endocrinology and metabolism* 2020;105: e3169-3182.
- 6116 Dinger J, Do Minh T, Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives.
 6117 Contraception 2016;94: 328-339.
- 6118 Divaris E, Anagnostis P, Gkekas NK, Kouidi E, Goulis DG. Early menopause and premature ovarian insufficiency may increase 6119 the risk of sarcopenia: A systematic review and meta-analysis. *Maturitas* 2023;175: 107782.
- 6120 Donaldson M, Kriström B, Ankarberg-Lindgren C, Verlinde S, van Alfen-van der Velden J, Gawlik A, van Gelder M, Sas T. Optimal
 6121 Pubertal Induction in Girls with Turner Syndrome Using Either Oral or Transdermal Estradiol: A Proposed Modern Strategy.
 6122 Hormone research in paediatrics 2019;91: 153-163.
- 6123 Donegan E, Frey BN, McCabe RE, Streiner DL, Fedorkow DM, Furtado M, Green SM. Impact of the CBT-Meno protocol on
- 6124 menopause-specific beliefs, dysfunctional attitudes, and coping behaviors. *Menopause (New York, NY)* 2022;29: 963-972.
- 6125 Donnenfeld AE, Icke KV, Pargas C, Dowman C. Biochemical screening for aneuploidy in ovum donor pregnancies. *American* 6126 *journal of obstetrics and gynecology* 2002;187: 1222-1225.
- Dorman JS, Steenkiste AR, Foley TP, Strotmeyer ES, Burke JP, Kuller LH, Kwoh CK. Menopause in type 1 diabetic women: is it
 premature? *Diabetes* 2001;50: 1857-1862.
- 6129 Doulgeraki T, Papageorgopoulou M, Iliodromiti S. The genetic background of female reproductive disorders: a systematic 6130 review. *Current opinion in obstetrics & gynecology* 2023;35: 426-433.
- 6131 Driscoll MA, Davis MC, Aiken LS, Yeung EW, Sterling EW, Vanderhoof V, Calis KA, Popat V, Covington SN, Nelson LM.
 6132 Psychosocial Vulnerability, Resilience Resources, and Coping with Infertility: A Longitudinal Model of Adjustment to Primary
- 6133 Ovarian Insufficiency. Annals of behavioral medicine : a publication of the Society of Behavioral Medicine 2016;50: 272-284.
- 6134 Duley L, Meher S, Hunter KE, Seidler AL, Askie LM. Antiplatelet agents for preventing pre-eclampsia and its complications.
 6135 *Cochrane Database Syst Rev* 2019;2019.
- 6136 Dunlop CE, Jack SA, Telfer EE, Zahra S, Anderson RA. Clinical pregnancy in Turner syndrome following re-implantation of 6137 cryopreserved ovarian cortex. *Journal of assisted reproduction and genetics* 2023;40: 2385-2390.
- 6138 Dutta D, Dharmshaktu P, Aggarwal A, Gaurav K, Bansal R, Devru N, Garga UC, Kulshreshtha B. Severity and pattern of bone
- 6139 mineral loss in endocrine causes of osteoporosis as compared to age-related bone mineral loss. *Journal of postgraduate* 6140 *medicine* 2016;62: 162-169.
- 6141 Eastell R, O'Neill TW, Hofbauer LC, Langdahl B, Reid IR, Gold DT, Cummings SR. Postmenopausal osteoporosis. *Nature reviews* 6142 *Disease primers* 2016;2: 16069.
- 6143 Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological Management of Osteoporosis in
- 6144 Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline. *The Journal of clinical endocrinology and* 6145 *metabolism* 2019;104: 1595-1622.
- 6146 Ebeling PR, Nguyen HH, Aleksova J, Vincent AJ, Wong P, Milat F. Secondary Osteoporosis. *Endocrine reviews* 2022;43: 240-313.
- 6147 Edey KA, Rundle S, Hickey M. Hormone replacement therapy for women previously treated for endometrial cancer. *Cochrane* 6148 *Database Syst Rev* 2018;5: Cd008830.
- 6149 Ehrhardt MJ, Leerink JM, Mulder RL, Mavinkurve-Groothuis A, Kok W, Nohria A, Nathan PC, Merkx R, de Baat E, Asogwa OA et
- 6150 *al.* Systematic review and updated recommendations for cardiomyopathy surveillance for survivors of childhood, adolescent,
- and young adult cancer from the International Late Effects of Childhood Cancer Guideline Harmonization Group. *The Lancet*
- 6152 Oncology 2023;24: e108-e120.
- 6153 El Khoudary SR, Chen X, Qi M, Derby CA, Brooks MM, Thurston RC, Janssen I, Crawford S, Lee JS, Jackson EA *et al.* The 6154 independent associations of anti-Müllerian hormone and estradiol levels over the menopause transition with 6155 lipids/lipoproteins: The Study of Women's health Across the Nation. *Journal of clinical lipidology* 2023;17: 157-167.
- 6156 Elkins G, Johnson A, Fisher W, Sliwinski J, Keith T. A pilot investigation of guided self-hypnosis in the treatment of hot flashes
- 6150 among postmenopausal women. The International journal of clinical and experimental hypnosis 2013a;61: 342-350.



- 6158 Elkins G, Marcus J, Stearns V, Perfect M, Rajab MH, Ruud C, Palamara L, Keith T. Randomized trial of a hypnosis intervention 6159 for treatment of hot flashes among breast cancer survivors. *J Clin Oncol* 2008;26: 5022-5026.
- 6160 Elkins GR, Fisher WI, Johnson AK, Carpenter JS, Keith TZ. Clinical hypnosis in the treatment of postmenopausal hot flashes: a 6161 randomized controlled trial. *Menopause (New York, NY)* 2013b;20: 291-298.
- 6162 Engberg H, Strandqvist A, Berg E, Nordenskjöld A, Nordenström A, Frisén L, Hirschberg AL. Sexual Function in Women With
- **6163** Differences of Sex Development or Premature Loss of Gonadal Function. *The journal of sexual medicine* 2022;19: 249-256.
- 6164 Ensrud KE, Guthrie KA, Hohensee C, Caan B, Carpenter JS, Freeman EW, LaCroix AZ, Landis CA, Manson J, Newton KM *et al.*
- 6165 Effects of estradiol and venlafaxine on insomnia symptoms and sleep quality in women with hot flashes. *Sleep* 2015;38: 97-6166 108.
- 6167 Erickson Z, Rocca WA, Smith CY, Gazzuola Rocca L, Stewart EA, Laughlin-Tommaso SK, Mielke MM. Time Trends in Unilateral
- and Bilateral Oophorectomy in a Geographically Defined American Population. *Obstetrics and gynecology* 2022;139: 724-734.
- 6169 Ertl DA, Gleiss A, Schubert K, Culen C, Hauck P, Ott J, Gessl A, Haeusler G. Health status, quality of life and medical care in adult 6170 women with Turner syndrome. *Endocrine connections* 2018;7: 534-543.
- 6171 Eskenazi S, Bachelot A, Hugon-Rodin J, Plu-Bureau G, Gompel A, Catteau-Jonard S, Molina-Gomes D, Dewailly D, Dodé C,
 6172 Christin-Maitre S *et al.* Next Generation Sequencing Should Be Proposed to Every Woman With "Idiopathic" Primary Ovarian
 6173 Insufficiency. *Journal of the Endocrine Society* 2021;5: bvab032.
- 6174 Everhov Å H, Nyberg T, Bergmark K, Citarella A, Rådestad AF, Hirschberg AL, Smedby KE. Hormone therapy after uterine cervical 6175 cancer treatment: a Swedish population-based study. *Menopause (New York, NY)* 2015;22: 633-639.
- 6176 Ewertz M, Mellemkjaer L, Poulsen AH, Friis S, Sørensen HT, Pedersen L, McLaughlin JK, Olsen JH. Hormone use for menopausal
 6177 symptoms and risk of breast cancer. A Danish cohort study. *British journal of cancer* 2005;92: 1293-1297.
- 6178 Ewies AA, Alfhaily F. Use of levonorgestrel-releasing intrauterine system in the prevention and treatment of endometrial 6179 hyperplasia. *Obstetrical & gynecological survey* 2012;67: 726-733.
- Fahlen M, Fornander T, Johansson H, Johansson U, Rutqvist LE, Wilking N, von Schoultz E. Hormone replacement therapy after
 breast cancer: 10 year follow up of the Stockholm randomised trial. *Eur J Cancer* 2013;49: 52-59.
- Faienza MF, Brunetti G, Ventura A, Piacente L, Messina MF, De Luca F, Ciccarelli M, Oranger A, Mori G, Natale MP *et al.*Mechanisms of enhanced osteoclastogenesis in girls and young women with Turner's Syndrome. *Bone* 2015;81: 228-236.
- **6184** Falorni A, Brozzetti A, Aglietti MC, Esposito R, Minarelli V, Morelli S, Sbroma Tomaro E, Marzotti S. Progressive decline of residual follicle pool after clinical diagnosis of autoimmune ovarian insufficiency. *Clinical endocrinology* 2012;77: 453-458.
- Falorni A, Laureti S, Candeloro P, Perrino S, Coronella C, Bizzarro A, Bellastella A, Santeusanio F, De Bellis A. Steroid-cell
 autoantibodies are preferentially expressed in women with premature ovarian failure who have adrenal autoimmunity. *Fertility and sterility* 2002;78: 270-279.
- Fante JF, Brito LGO, Teatin-Juliato CR, Benetti-Pinto CL. Can hormone therapy modify pelvic floor muscle assessment and symptoms within women with premature ovarian insufficiency? *European journal of obstetrics, gynecology, and reproductive biology* 2020;252: 624-625.
- 6192 Farahat RA, Salamah HM, Mahmoud A, Hamouda E, Hashemy M, Hamouda H, Samir A, Chenfouh I, Marey A, Awad DM et al.
- 6192 The efficacy of oxytocin gel in postmenopausal women with vaginal atrophy: an updated systematic review and meta-analysis.
 6194 BMC Womens Health 2023;23: 494.
- Farland LV, Rice MS, Degnan WJ, 3rd, Rexrode KM, Manson JE, Rimm EB, Rich-Edwards J, Stewart EA, Cohen Rassier SL,
 Robinson WR *et al.* Hysterectomy With and Without Oophorectomy, Tubal Ligation, and Risk of Cardiovascular Disease in the
 Nurses' Health Study II. J Womens Health (Larchmt) 2023;32: 747-756.
- Fatemi HM, Camus M, Kolibianakis EM, Tournaye H, Papanikolaou EG, Donoso P, Devroey P. The luteal phase of recombinant
 follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation
 with progesterone or progesterone and estradiol. *Fertility and sterility* 2007;87: 504-508.
- Faubion SS, Larkin LC, Stuenkel CA, Bachmann GA, Chism LA, Kagan R, Kaunitz AM, Krychman ML, Parish SJ, Partridge AH *et al.*Management of genitourinary syndrome of menopause in women with or at high risk for breast cancer: consensus
 recommendations from The North American Menopause Society and The International Society for the Study of Women's
 Sexual Health. *Menopause (New York, NY)* 2018;25: 596-608.
- Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, Baughman KL, Kasper EK. Underlying causes and
 long-term survival in patients with initially unexplained cardiomyopathy. *N Engl J Med* 2000;342: 1077-1084.
- Ferrari S, Bianchi ML, Eisman JA, Foldes AJ, Adami S, Wahl DA, Stepan JJ, de Vernejoul MC, Kaufman JM. Osteoporosis in young adults: pathophysiology, diagnosis, and management. *Osteoporosis international : a journal established as result of*
- 6209 cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
 6210 2012;23: 2735-2748.
- Ferreira L, Abrantes C, Alves ME, Moreira C, Moreira H. Effects of exercise programs on cardiorespiratory fitness and arterial
 stiffness on postmenopausal women: A systematic review study. *Maturitas* 2024;181: 107917.
- Ferreri J, Fàbregues F, Calafell JM, Solernou R, Borrás A, Saco A, Manau D, Carmona F. Drug-free in-vitro activation of follicles
 and fresh tissue autotransplantation as a therapeutic option in patients with primary ovarian insufficiency. *Reprod Biomed Online* 2020;40: 254-260.
- 6216 Fine A, Busza A, Allen LM, Kelly C, Wolfman W, Jacobson M, Lega IC. Comparing estrogen-based hormonal contraceptives and
- 6217 hormone therapy on bone mineral density in women with premature ovarian insufficiency: a systematic review. *Menopause*
- 6218 (New York, NY) 2022;29: 351-359.



- 6219 Fiot E, Alauze B, Donadille B, Samara-Boustani D, Houang M, De Filippo G, Bachelot A, Delcour C, Beyler C, Bois E *et al*. Turner
- syndrome: French National Diagnosis and Care Protocol (NDCP; National Diagnosis and Care Protocol). Orphanet journal of
 rare diseases 2022;17: 261.
- 6222 Fitzpatrick D, Pirie K, Reeves G, Green J, Beral V. Combined and progestagen-only hormonal contraceptives and breast cancer 6223 risk: A UK nested case-control study and meta-analysis. *PLoS medicine* 2023;20: e1004188.
- 6224 Fogle RH, Stanczyk FZ, Zhang X, Paulson RJ. Ovarian androgen production in postmenopausal women. *The Journal of clinical* 6225 *endocrinology and metabolism* 2007;92: 3040-3043.
- Forges T, Monnier-Barbarino P, Faure GC, Bene MC. Autoimmunity and antigenic targets in ovarian pathology. *Human reproduction update* 2004;10: 163-175.
- 6228 Fosså SD, Magelssen H, Melve K, Jacobsen AB, Langmark F, Skjaerven R. Parenthood in survivors after adulthood cancer and 6229 perinatal health in their offspring: a preliminary report. *Journal of the National Cancer Institute Monographs* 2005: 77-82.
- 6230 Foudila T, Soderstrom-Anttila V, Hovatta O. Turner's syndrome and pregnancies after oocyte donation. *Human reproduction* 6231 (*Oxford, England*) 1999;14: 532-535.
- 6232 Fraison E, Crawford G, Casper G, Harris V, Ledger W. Pregnancy following diagnosis of premature ovarian insufficiency: a 6233 systematic review. *Reprod Biomed Online* 2019;39: 467-476.
- França MM, Funari MFA, Lerario AM, Santos MG, Nishi MY, Domenice S, Moraes DR, Costalonga EF, Maciel GAR, Maciel-Guerra
 AT *et al.* Screening of targeted panel genes in Brazilian patients with primary ovarian insufficiency. *PloS one* 2020;15:
 e0240795.
- França MM, Mendonca BB. Genetics of ovarian insufficiency and defects of folliculogenesis. *Best practice & research Clinical endocrinology & metabolism* 2022;36: 101594.
- 6239 Francés-Herrero E, Lopez R, Hellström M, de Miguel-Gómez L, Herraiz S, Brännström M, Pellicer A, Cervelló I. Bioengineering 6240 trends in female reproduction: a systematic review. *Human reproduction update* 2022;28: 798-837.
- 6241 Frederick AB, Zinsli AM, Carlock G, Conneely K, Fridovich-Keil JL. Presentation, progression, and predictors of ovarian 6242 insufficiency in classic galactosemia. *Journal of inherited metabolic disease* 2018;41: 785-790.
- Freeman EW, Sammel MD, Lin H, Gracia CR. Anti-mullerian hormone as a predictor of time to menopause in late reproductive age women. *The Journal of clinical endocrinology and metabolism* 2012;97: 1673-1680.
- Freeman JR, Whitcomb BW, Purdue-Smithe AC, Manson JE, Langton CR, Hankinson SE, Rosner BA, Bertone-Johnson ER. Is Alcohol Consumption Associated With Risk of Early Menopause? *American journal of epidemiology* 2021;190: 2612-2617.
- Freitas ATA, Donovan Giraldo AE, Pravatta Rezende G, Yela DA, Jales RM, Benetti-Pinto CL. Body composition in women with
 premature ovarian insufficiency using hormone therapy and the relation to cardiovascular risk markers: A case-control study.
 Clinical endocrinology 2021;94: 111-118.
- Freriks K, Timmermans J, Beerendonk CC, Verhaak CM, Netea-Maier RT, Otten BJ, Braat DD, Smeets DF, Kunst DH, Hermus AR
 et al. Standardized multidisciplinary evaluation yields significant previously undiagnosed morbidity in adult women with Turner
 syndrome. *The Journal of clinical endocrinology and metabolism* 2011;96: E1517-1526.
- Freriks K, Verhaak CM, Sas TC, Menke LA, Wit JM, Otten BJ, de Muinck Keizer-Schrama SM, Smeets DF, Netea-Maier RT, Hermus
 AR *et al.* Long-term effects of oxandrolone treatment in childhood on neurocognition, quality of life and social-emotional
 functioning in young adults with Turner syndrome. *Hormones and behavior* 2015;69: 59-67.
- Fruzzetti F, Palla G, Gambacciani M, Simoncini T. Tailored hormonal approach in women with premature ovarian insufficiency.
 Climacteric : the journal of the International Menopause Society 2020;23: 3-8.
- 6258 Fu C, Hao W, Shrestha N, Virani SS, Mishra SR, Zhu D. Association of reproductive factors with dementia: A systematic review 6259 and dose-response meta-analyses of observational studies. *eClinicalMedicine* 2022;43.
- 6260 Fukami M. Ovarian dysfunction in women with Turner syndrome. *Frontiers in endocrinology* 2023;14: 1160258.
- Furness S, Roberts H, Marjoribanks J, Lethaby A. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. *Cochrane Database Syst Rev* 2012;2012: Cd000402.
- 6263 Gaba F, Manchanda R. Systematic review of acceptability, cardiovascular, neurological, bone health and HRT outcomes 6264 following risk reducing surgery in BRCA carriers. *Best practice & research Clinical obstetrics & gynaecology* 2020;65: 46-65.
- 6265 Gameiro S, Boivin J, Dancet E, de Klerk C, Emery M, Lewis-Jones C, Thorn P, Van den Broeck U, Venetis C, Verhaak CM et al.
- 6266 ESHRE guideline: routine psychosocial care in infertility and medically assisted reproduction-a guide for fertility staff. *Human* 6267 *reproduction (Oxford, England)* 2015;30: 2476-2485.
- 6268 Gameiro S, Sousa-Leite M, Vermeulen N. Dissemination, implementation and impact of the ESHRE evidence-based guidelines. 6269 *Human reproduction open* 2019;2019: hoz011.
- 6270 Gandhi J, Chen A, Dagur G, Suh Y, Smith N, Cali B, Khan SA. Genitourinary syndrome of menopause: an overview of clinical 6271 manifestations, pathophysiology, etiology, evaluation, and management. *American journal of obstetrics and gynecology*
- **6272** 2016;215: 704-711.
- 6273 Gao J, Jiao X, Dang Y, Li J, Li G, Han T, Liu Y, Qin Y, Chen ZJ. Identification of patients with primary ovarian insufficiency caused 6274 by autoimmunity. *Reprod Biomed Online* 2017;35: 475-479.
- 6275 Garelli S, Dalla Costa M, Sabbadin C, Barollo S, Rubin B, Scarpa R, Masiero S, Fierabracci A, Bizzarri C, Crinò A *et al.* Autoimmune 6276 polyendocrine syndrome type 1: an Italian survey on 158 patients. *Journal of endocrinological investigation* 2021;44: 2493-6277 2510.
- 6278 Gargus E, Deans R, Anazodo A, Woodruff TK. Management of Primary Ovarian Insufficiency Symptoms in Survivors of 6279 Childhood and Adolescent Cancer. *Journal of the National Comprehensive Cancer Network : JNCCN* 2018;16: 1137-1149.



- 6280 Garland SN, Xie SX, Li Q, Seluzicki C, Basal C, Mao JJ. Comparative effectiveness of electro-acupuncture versus gabapentin for
 6281 sleep disturbances in breast cancer survivors with hot flashes: a randomized trial. *Menopause (New York, NY)* 2017;24: 517 6282 523.
- 6283 Gartoulla P, Davis SR, Worsley R, Bell RJ. Use of complementary and alternative medicines for menopausal symptoms in 6284 Australian women aged 40-65 years. *The Medical journal of Australia* 2015;203: 146, 146e 141-146.
- 6285 Gayete-Lafuente S, Turan V, Oktay KH. Oocyte cryopreservation with in vitro maturation for fertility preservation in girls at risk 6286 for ovarian insufficiency. *Journal of assisted reproduction and genetics* 2023;40: 2777-2785.
- 6287 Gazzuola Rocca L, Smith CY, Bobo WV, Grossardt BR, Stewart EA, Laughlin-Tommaso SK, Rocca WA. Mental health conditions
 6288 diagnosed before bilateral oophorectomy: a population-based case-control study. *Menopause (New York, NY)* 2019;26: 13956289 1404.
- 6290 Gemmell LC, Webster KE, Kirtley S, Vincent K, Zondervan KT, Becker CM. The management of menopause in women with a 6291 history of endometriosis: a systematic review. *Human reproduction update* 2017;23: 481-500.
- 6292 Georgakis MK, Beskou-Kontou T, Theodoridis I, Skalkidou A, Petridou ET. Surgical menopause in association with cognitive 6293 function and risk of dementia: A systematic review and meta-analysis. *Psychoneuroendocrinology* 2019;106: 9-19.
- 6294 Georgakis MK, Kalogirou EI, Diamantaras AA, Daskalopoulou SS, Munro CA, Lyketsos CG, Skalkidou A, Petridou ET. Age at 6295 menopause and duration of reproductive period in association with dementia and cognitive function: A systematic review and 6296 meta-analysis. *Psychoneuroendocrinology* 2016;73: 224-243.
- 6297 Gibson-Helm M, Teede H, Vincent A. Symptoms, health behavior and understanding of menopause therapy in women with 6298 premature menopause. *Climacteric : the journal of the International Menopause Society* 2014;17: 666-673.
- 6299 Gierach GL, Pfeiffer RM, Patel DA, Black A, Schairer C, Gill A, Brinton LA, Sherman ME. Long-term overall and disease-specific 6300 mortality associated with benign gynecologic surgery performed at different ages. *Menopause (New York, NY)* 2014;21: 592-6301 601.
- 6302 Gill J. The effects of moderate alcohol consumption on female hormone levels and reproductive function. *Alcohol and alcoholism (Oxford, Oxfordshire)* 2000;35: 417-423.
- 6304 Giri R, Vincent AJ. Prevalence and Risk Factors of Premature Ovarian Insufficiency/Early Menopause. *Seminars in reproductive* 6305 *medicine* 2020;38: 237-246.
- 6306 Gleason CE, Dowling NM, Wharton W, Manson JE, Miller VM, Atwood CS, Brinton EA, Cedars MI, Lobo RA, Merriam GR *et al.*6307 Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized,
 6308 Controlled KEEPS-Cognitive and Affective Study. *PLoS medicine* 2015;12: e1001833; discussion e1001833.
- 6309 Goh M, Nguyen HH, Khan NN, Milat F, Boyle JA, Vincent AJ. Identifying and addressing osteoporosis knowledge gaps in women
- with premature ovarian insufficiency and early menopause: A mixed-methods study. *Clinical endocrinology* 2019;91: 498-507.
 Gold D, Nicolay L, Avian A, Greimel E, Balic M, Pristauz-Telsnigg G, Tamussino K, Trutnovsky G. Vaginal laser therapy versus
- 6312 hyaluronic acid suppositories for women with symptoms of urogenital atrophy after treatment for breast cancer: A
 6313 randomized controlled trial. *Maturitas* 2023;167: 1-7.
- 6314 Gold EB, Crawford SL, Avis NE, Crandall CJ, Matthews KA, Waetjen LE, Lee JS, Thurston R, Vuga M, Harlow SD. Factors related 6315 to age at natural menopause: longitudinal analyses from SWAN. *American journal of epidemiology* 2013;178: 70-83.
- 6316 Goldenberg RL, Grodin JM, Rodbard D, Ross GT. Gonadotropins in women with amenorrhea. The use of plasma follicle 6317 stimulating hormone to differentiate women with and without ovarian follicles. *American journal of obstetrics and gynecology* 6318 1973;116: 1003-1012.
- 6319 Golezar S, Keshavarz Z, Ramezani Tehrani F, Ebadi A. An exploration of factors affecting the quality of life of women with 6320 primary ovarian insufficiency: a qualitative study. *BMC Womens Health* 2020;20: 163.
- 6321 Golezar S, Keshavarz Z, Ramezani Tehrani F, Ebadi A, Zayeri F, Golezar MH. Primary ovarian insufficiency quality of life scale 6322 (POIQOLS): development and psychometric properties. *BMC Womens Health* 2022;22: 481.
- 6323 Golezar S, Ramezani Tehrani F, Khazaei S, Ebadi A, Keshavarz Z. The global prevalence of primary ovarian insufficiency and 6324 early menopause: a meta-analysis. *Climacteric : the journal of the International Menopause Society* 2019;22: 403-411.
- 6325 Gonçalves CR, Vasconcellos AS, Rodrigues TR, Comin FV, Reis FM. Hormone therapy in women with premature ovarian insufficiency: a systematic review and meta-analysis. *Reprod Biomed Online* 2022;44: 1143-1157.
- 6327 Gong D, Sun J, Zhou Y, Zou C, Fan Y. Early age at natural menopause and risk of cardiovascular and all-cause mortality: A meta-6328 analysis of prospective observational studies. *International journal of cardiology* 2016;203: 115-119.
- 6329 Gong J, Harris K, Peters SAE, Woodward M. Reproductive factors and the risk of incident dementia: A cohort study of UK 6330 Biobank participants. *PLoS medicine* 2022;19: e1003955.
- Goodman MP. Are all estrogens created equal? A review of oral vs. transdermal therapy. J Womens Health (Larchmt) 2012;21:
 161-169.
- Gordhandas S, Norquist BM, Pennington KP, Yung RL, Laya MB, Swisher EM. Hormone replacement therapy after risk reducing
 salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits. *Gynecol Oncol* 2019;153: 192-200.
- Gordon CM, Ackerman KE, Berga SL, Kaplan JR, Mastorakos G, Misra M, Murad MH, Santoro NF, Warren MP. Functional
 Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline. *The Journal of clinical endocrinology and metabolism* 2017;102: 1413-1439.
- 6339 Gosden RG, Treloar SA, Martin NG, Cherkas LF, Spector TD, Faddy MJ, Silber SJ. Prevalence of premature ovarian failure in 6340 monozygotic and dizygotic twins. *Human reproduction (Oxford, England)* 2007;22: 610-615.
- 6341 Gosset A, Claeys JM, Huyghe E, Tremollieres F. Sexual function and quality of life in women with idiopathic premature ovarian 6342 insufficiency. *The journal of sexual medicine* 2023;20: 626-632.



- 6343 Gosset A, Susini M, Vidal F, Tanguy-Le-Gac Y, Chantalat E, Genre L, Trémollières F. Quality of life of patients with bilateral 6344 oophorectomy before the age of 45 for the treatment of endometriosis. *Maturitas* 2022;162: 52-57.
- 6345 Goswami D, Conway GS. Premature ovarian failure. *Human reproduction update* 2005;11: 391-410.
- 6346 Gottschalk MS, Eskild A, Hofvind S, Bjelland EK. The relation of number of childbirths with age at natural menopause: a 6347 population study of 310147 women in Norway. *Human reproduction (Oxford, England)* 2022;37: 333-340.
- 6348 Gottschalk MS, Eskild A, Hofvind S, Gran JM, Bjelland EK. Temporal trends in age at menarche and age at menopause: a population study of 312656 women in Norway. *Human reproduction (Oxford, England)* 2020;35: 464-471.
- 6350 Gottschau M, Rosthøj S, Settnes A, Aalborg GL, Viuff JH, Munk C, Jensen A, Kjær SK, Mellemkjær L. Long-Term Health 6351 Consequences After Ovarian Removal at Benign Hysterectomy : A Nationwide Cohort Study. *Annals of internal medicine* 6352 2023;176: 596-604.
- 6353 Goyco Ortiz LE, Servy EJ, Menezo YJR. A successful treatment with 5 methyltetrahydrofolate of a 677 TT MTHFR woman 6354 suffering premature ovarian insufficiency post a NHL (non-Hodgkin's lymphoma) and RPL (repeat pregnancy losses). *Journal* 6355 *of assisted reproduction and genetics* 2019;36: 65-67.
- 6356 Gravholt CH. Clinical Practice Guidelines for the Care of Girls and Women with Turner Syndrome. Proceedings from the 2023 6357 Aarhus International Turner Syndrome Meeting. *In publication* 2024.
- Gravholt CH, Andersen NH, Conway GS, Dekkers OM, Geffner ME, Klein KO, Lin AE, Mauras N, Quigley CA, Rubin K *et al.* Clinical
 practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International
 Turner Syndrome Meeting. *Eur J Endocrinol* 2017;177: G1-g70.
- 6361 Gravholt CH, Backeljauw P. New international Turner syndrome guideline: a multi-society feat. *Eur J Endocrinol* 2017;177: E1-6362 e2.
- 6363 Gravholt CH, Hjerrild BE, Mosekilde L, Hansen TK, Rasmussen LM, Frystyk J, Flyvbjerg A, Christiansen JS. Body composition is
- distinctly altered in Turner syndrome: relations to glucose metabolism, circulating adipokines, and endothelial adhesion
 molecules. *Eur J Endocrinol* 2006;155: 583-592.
- 6366 Gravholt CH, Juul S, Naeraa RW, Hansen J. Morbidity in Turner syndrome. *Journal of clinical epidemiology* 1998;51: 147-158.
- 6367 Gravholt CH, Viuff M, Just J, Sandahl K, Brun S, van der Velden J, Andersen NH, Skakkebaek A. The Changing Face of Turner 6368 Syndrome. *Endocrine reviews* 2023;44: 33-69.
- 6369 Green SM, Donegan E, Frey BN, Fedorkow DM, Key BL, Streiner DL, McCabe RE. Cognitive behavior therapy for menopausal 6370 symptoms (CBT-Meno): a randomized controlled trial. *Menopause (New York, NY)* 2019;26: 972-980.
- 6371 Greising SM, Baltgalvis KA, Lowe DA, Warren GL. Hormone therapy and skeletal muscle strength: a meta-analysis. *The journals* 6372 of gerontology Series A, Biological sciences and medical sciences 2009;64: 1071-1081.
- 6373 Grindler NM, Allsworth JE, Macones GA, Kannan K, Roehl KA, Cooper AR. Persistent organic pollutants and early menopause 6374 in U.S. women. *PloS one* 2015;10: e0116057.
- 6375 Groff AA, Covington SN, Halverson LR, Fitzgerald OR, Vanderhoof V, Calis K, Nelson LM. Assessing the emotional needs of women with spontaneous premature ovarian failure. *Fertility and sterility* 2005;83: 1734-1741.
- 6377 Grossmann B, Saur S, Rall K, Pecher AC, Hubner S, Henes J, Henes M. Prevalence of autoimmune disease in women with 6378 premature ovarian failure. *The European journal of contraception & reproductive health care : the official journal of the* 6379 *European Society of Contraception* 2020;25:72-75.
- 6380 Grynberg M, Jacquesson L, Sifer C. In vitro maturation of oocytes for preserving fertility in autoimmune premature ovarian 6381 insufficiency. *Fertility and sterility* 2020;114: 848-853.
- 6382 Gu H, Zhao X, Zhao X, Yang Y, Lv X. Risk of stroke in healthy postmenopausal women during and after hormone therapy: a 6383 meta-analysis. *Menopause (New York, NY)* 2014;21: 1204-1210.
- 6384 Guerrieri GM, Martinez PE, Klug SP, Haq NA, Vanderhoof VH, Koziol DE, Popat VB, Kalantaridou SN, Calis KA, Rubinow DR *et al.*6385 Effects of physiologic testosterone therapy on quality of life, self-esteem, and mood in women with primary ovarian
 6386 insufficiency. *Menopause (New York, NY)* 2014;21: 952-961.
- Gulbahar A, Akgun Kavurmaci S. Comparison of sexual function between women with iatrogenic and natural menopause.
 Revista internacional de andrologia 2022;20: 121-127.
- 6389 Guo S, Zhang J, Li Y, Ma H, Chen Q, Chen H, Du M. The pubertal development mode of Chinese girls with turner syndrome 6390 undergoing hormone replacement therapy. *BMC Endocr Disord* 2019;19: 72.
- Guthrie KA, LaCroix AZ, Ensrud KE, Joffe H, Newton KM, Reed SD, Caan B, Carpenter JS, Cohen LS, Freeman EW *et al.* Pooled
 Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms. *Obstetrics and gynecology* 2015;126: 413-422.
- Ha J, Park SS, Park S, Yoon JH, Baek KH, Kim HJ, Lee S, Kim MR, Kang MI, Lee JW. Effects of Hormone Replacement Therapy on
 Bone Mass After Allogeneic Hematopoietic Stem Cell Transplantation. *The Journal of clinical endocrinology and metabolism*2020;105.
- Hadnott TN, Gould HN, Gharib AM, Bondy CA. Outcomes of spontaneous and assisted pregnancies in Turner syndrome: the
 U.S. National Institutes of Health experience. *Fertility and sterility* 2011;95: 2251-2256.
- Hagen CP, Aksglaede L, Sorensen K, Main KM, Boas M, Cleemann L, Holm K, Gravholt CH, Andersson AM, Pedersen AT *et al.*Serum levels of anti-Mullerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and
 in 172 Turner syndrome patients. *The Journal of clinical endocrinology and metabolism* 2010;95: 5003-5010.
- Hagen CP, Vestergaard S, Juul A, Skakkebaek NE, Andersson AM, Main KM, Hjollund NH, Ernst E, Bonde JP, Anderson RA et al.
- 6403 Low concentration of circulating antimullerian hormone is not predictive of reduced fecundability in young healthy women: a
 6404 prospective cohort study. *Fertility and sterility* 2012;98: 1602-1608 e1602.



- Hagerman R, Hagerman P. Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated
 tremor/ataxia syndrome. *Lancet neurology* 2013;12: 786-798.
- Hagman A, Loft A, Wennerholm UB, Pinborg A, Bergh C, Aittomaki K, Nygren KG, Bente Romundstad L, Hazekamp J,
 Soderstrom-Anttila V. Obstetric and neonatal outcome after oocyte donation in 106 women with Turner syndrome: a Nordic cohort study. *Human reproduction (Oxford, England)* 2013;28: 1598-1609.
- Hall E, Finch A, Jacobson M, Rosen B, Metcalfe K, Sun P, Narod SA, Kotsopoulos J. Effects of bilateral salpingo-oophorectomy
 on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation. *Gynecol Oncol* 2019;152:
 145-150.
- 6413 Hamoda H. British Menopause Society tools for clinicians: Progestogens and endometrial protection. *Post Reprod Health* 2022;28: 40-46.
- Hamoda H, Sharma A. Premature ovarian insufficiency, early menopause, and induced menopause. *Best practice & research Clinical endocrinology & metabolism* 2023: 101823.
- Hanke H, Hanke S, Ickrath O, Lange K, Bruck B, Muck AO, Seeger H, Zwirner M, Voisard R, Haasis R *et al.* Estradiol concentrations
 in premenopausal women with coronary heart disease. *Coronary artery disease* 1997;8: 511-515.
- Hansen S, Brixen K, Gravholt CH. Compromised trabecular microarchitecture and lower finite element estimates of radius and
 tibia bone strength in adults with turner syndrome: a cross-sectional study using high-resolution-pQCT. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research* 2012;27: 1794-1803.
- 6422 Hao W, Fu C, Dong C, Zhou C, Sun H, Xie Z, Zhu D. Age at menopause and all-cause and cause-specific dementia: a prospective 6423 analysis of the UK Biobank cohort. *Human reproduction (Oxford, England)* 2023;38: 1746-1754.
- Haraldstad K, Wahl A, Andenaes R, Andersen JR, Andersen MH, Beisland E, Borge CR, Engebretsen E, Eisemann M, Halvorsrud
 L et al. A systematic review of quality of life research in medicine and health sciences. Quality of life research : an international
 journal of quality of life aspects of treatment, care and rehabilitation 2019;28: 2641-2650.
- Hardy R, Kuh D, Wadsworth M. Smoking, body mass index, socioeconomic status and the menopausal transition in a British
 national cohort. *International journal of epidemiology* 2000;29: 845-851.
- Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, Sherman S, Sluss PM, de Villiers TJ. Executive summary of the Stages of
 Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. *The Journal of clinical endocrinology and metabolism* 2012;97: 1159-1168.
- Hartnett KP, Mertens AC, Kramer MR, Lash TL, Spencer JB, Ward KC, Howards PP. Pregnancy after cancer: Does timing of
 conception affect infant health? *Cancer* 2018;124: 4401-4407.
- Hassan H, Allen I, Sofianopoulou E, Walburga Y, Turnbull C, Eccles DM, Tischkowitz M, Pharoah P, Antoniou AC. Long-term
 outcomes of hysterectomy with bilateral salpingo-oophorectomy: a systematic review and meta-analysis. *American journal of*obstetrics and gynecology 2024;230: 44-57.
- He M, Hu S, Wang J, Wang J, Găman MA, Hariri Z, Tian Y. Effect of resistance training on lipid profile in postmenopausal women:
 A systematic review and meta-analysis of randomized controlled trials. *European journal of obstetrics, gynecology, and*reproductive biology 2023;288: 18-28.
- Heddar A, Ogur C, Da Costa S, Braham I, Billaud-Rist L, Findlinki N, Beneteau C, Reynaud R, Mahmoud K, Legrand S *et al.* Genetic
 landscape of a large cohort of Primary Ovarian Insufficiency: New genes and pathways and implications for personalized
 medicine. *EBioMedicine* 2022;84: 104246.
- Henderson VW, St John JA, Hodis HN, McCleary CA, Stanczyk FZ, Shoupe D, Kono N, Dustin L, Allayee H, Mack WJ. Cognitive
 effects of estradiol after menopause: A randomized trial of the timing hypothesis. *Neurology* 2016;87: 699-708.
- Hendrix SL. Bilateral oophorectomy and premature menopause. *The American journal of medicine* 2005;118 Suppl 12B: 131-135.
- Herlihy N, Cakiroglu Y, Whitehead C, Reig A, Klimczak A, Scott R, Tiras B, Seli E. O-065 A multi-center randomized controlled
 trial of intraovarian injection of platelet rich plasma for women with poor ovarian response. *Human Reproduction* 2023;38.
- Hickey I, Jha S, Wyld L. The psychosexual effects of risk-reducing bilateral salpingo-oophorectomy in female BRCA1/2 mutation
 carriers: A systematic review of qualitative studies. *Gynecol Oncol* 2021a;160: 763-770.
- Hickey M, Baber R, Eden J, Brennan J, Bateson D, Goldman M, Rockweiler H, Dreon D. Safety and effectiveness of a novel home-use therapeutic ultrasound device for the treatment of vaginal dryness in postmenopausal women: a pilot study.
 Menopause (New York, NY) 2023;30: 383-392.
- Hickey M, Basu P, Sassarini J, Stegmann ME, Weiderpass E, Nakawala Chilowa K, Yip CH, Partridge AH, Brennan DJ. Managing
 menopause after cancer. *Lancet* 2024;403: 984-996.
- Hickey M, Moss KM, Brand A, Wrede CD, Domchek SM, Meiser B, Mishra GD, Joffe H. What happens after menopause?
 (WHAM): A prospective controlled study of depression and anxiety up to 12 months after premenopausal risk-reducing
 bilateral salpingo-oophorectomy. *Gynecol Oncol* 2021b;161: 527-534.
- Hickey M, Moss KM, Krejany EO, Wrede CD, Brand A, Kirk J, Symecko HL, Domchek SM, Tejada-Berges T, Trainer A *et al*. What
 happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality
 of life 12 months after premenopausal risk-reducing salpingo-oophorectomy. *Gynecol Oncol* 2021c;163: 148-154.
- Hickey M, Moss KM, Mishra GD, Krejany EO, Domchek SM, Wark JD, Trainer A, Wild RA. What Happens After Menopause?
 (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing
 bilateral salpingo-oophorectomy. *Gynecol Oncol* 2021d;162: 88-96.
- 6465 Hickey M, Schoenaker DA, Joffe H, Mishra GD. Depressive symptoms across the menopause transition: findings from a large 6466 population-based cohort study. *Menopause (New York, NY)* 2016;23: 1287-1293.



- Hickey M, Trainer A, Braat S, Davey MA, Krejany E, Wark J. What Happens After Menopause? (WHAM): protocol for a prospective, multicentre, age-matched cohort trial of risk-reducing bilateral salpingo-oophorectomy in high-risk
 premenopausal women. *BMJ open* 2017;7: e018758.
- 6470 Hill EL, Graham ML, Shelley JM. Hysterectomy trends in Australia--between 2000/01 and 2004/05. *The Australian & New Zealand journal of obstetrics & gynaecology* 2010;50: 153-158.
- 6472 Hipp HS, Charen KH, Spencer JB, Allen EG, Sherman SL. Reproductive and gynecologic care of women with fragile X primary 6473 ovarian insufficiency (FXPOI). *Menopause (New York, NY)* 2016;23: 993-999.
- Hirschberg AL, Bitzer J, Cano A, Ceausu I, Chedraui P, Durmusoglu F, Erkkola R, Goulis DG, Kiesel L, Lopes P *et al.* Topical estrogens and non-hormonal preparations for postmenopausal vulvovaginal atrophy: An EMAS clinical guide. *Maturitas* 2021;148: 55-61.
- Hoek A, Schoemaker J, Drexhage HA. Premature ovarian failure and ovarian autoimmunity. *Endocrine reviews* 1997;18: 107134.
- Hogan RG, Wang AY, Li Z, Hammarberg K, Johnson L, Mol BW, Sullivan EA. Oocyte donor age has a significant impact on oocyte
 recipients' cumulative live-birth rate: a population-based cohort study. *Fertility and sterility* 2019;112: 724-730.
- Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE. Serum TSH, T(4), and thyroid
 antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). *The*Journal of clinical endocrinology and metabolism 2002;87: 489-499.
- Honigberg MC, Zekavat SM, Aragam K, Finneran P, Klarin D, Bhatt DL, Januzzi JL, Jr., Scott NS, Natarajan P. Association of
 Premature Natural and Surgical Menopause With Incident Cardiovascular Disease. *Jama* 2019;322: 2411-2421.
- 6486 Howell SJ, Berger G, Adams JE, Shalet SM. Bone mineral density in women with cytotoxic-induced ovarian failure. *Clinical* 6487 *endocrinology* 1998;49: 397-402.
- Hsieh Y-T, Ho JYP. Thyroid autoimmunity is associated with higher risk of premature ovarian insufficiency—a nationwide Health
 Insurance Research Database study. *Human Reproduction* 2021;36: 1621-1629.
- Huan L, Deng X, He M, Chen S, Niu W. Meta-analysis: Early Age at Natural Menopause and Risk for All-Cause and Cardiovascular
 Mortality. *BioMed research international* 2021;2021: 6636856.
- Huang Y, Qi T, Ma L, Li D, Li C, Lan Y, Chu K, Chen P, Xu W, Cao Y *et al.* Menopausal symptoms in women with premature ovarian insufficiency: prevalence, severity, and associated factors. *Menopause (New York, NY)* 2021;28: 529-537.
- Huber D, Seitz S, Kast K, Emons G, Ortmann O. Hormone replacement therapy in BRCA mutation carriers and risk of ovarian,
 endometrial, and breast cancer: a systematic review. J Cancer Res Clin Oncol 2021;147: 2035-2045.
- Hudson MM. Reproductive outcomes for survivors of childhood cancer. *Obstetrics and gynecology* 2010;116: 1171-1183.
- Hummel SB, van Lankveld J, Oldenburg HSA, Hahn DEE, Kieffer JM, Gerritsma MA, Kuenen MA, Bijker N, Borgstein PJ, Heuff G
 et al. Efficacy of Internet-Based Cognitive Behavioral Therapy in Improving Sexual Functioning of Breast Cancer Survivors:
 Results of a Randomized Controlled Trial. *J Clin Oncol* 2017;35. 1328-1340.
- Hunter JE., Berry-Kravis E., Hipp H., al. e. FMR1 Disorders. 1998 Jun 16 [Updated 2019 Nov 21]. In Adam MP FJ, Mirzaa GM, et al., editors. (ed) *GeneReviews®* [Internet] 2019. Available from: <u>https://www.ncbi.nlm.nih.gov/books/NBK1384/</u>, Seattle (WA): University of Washington, Seattle; 1993-2024.
- Hunter MS. Cognitive behavioral therapy for menopausal symptoms. *Climacteric : the journal of the International Menopause Society* 2021;24: 51-56.
- Hunter MS, Mann E. A cognitive model of menopausal hot flushes and night sweats. *Journal of psychosomatic research*2010;69: 491-501.
- Huo N, Smith CY, Gazzuola Rocca L, Rocca WA, Mielke MM. Association of Premenopausal Bilateral Oophorectomy With
 Restless Legs Syndrome. JAMA Netw Open 2021;4: e2036058.
- Huong DL, Amoura Z, Duhaut P, Sbai A, Costedoat N, Wechsler B, Piette JC. Risk of ovarian failure and fertility after intravenous
 cyclophosphamide. A study in 84 patients. *The Journal of rheumatology* 2002;29: 2571-2576.
- Husebye ES, Anderson MS, Kampe O. Autoimmune Polyendocrine Syndromes. N Engl J Med 2018;378: 1132-1141.
- 6512 Husebye ES, Pearce SH, Krone NP, Kämpe O. Adrenal insufficiency. *Lancet* 2021;397: 613-629.
- Hutaff-Lee C, Bennett E, Howell S, Tartaglia N. Clinical developmental, neuropsychological, and social-emotional features of
 Turner syndrome. American journal of medical genetics Part C, Seminars in medical genetics 2019;181: 126-134.
- Hynes JS, Kuller JA, Goldstein SA, Ward CC, Muasher SJ. Increased Risk of Aortic Dissection Associated With Pregnancy in
 Women With Turner Syndrome: A Systematic Review. *Obstetrical & gynecological survey* 2020;75: 566-575.
- Iancu AM, Murji A, Chow O, Shapiro J, Cipolla A, Shirreff L. Avoidable bilateral salpingo-oophorectomy at hysterectomy: a large
 retrospective study. *Menopause (New York, NY)* 2022;29: 523-530.
- Ibarra-Ramírez M, Campos-Acevedo LD, Martínez de Villarreal LE. Chromosomal Abnormalities of Interest in Turner Syndrome:
 An Update. *Journal of pediatric genetics* 2023;12: 263-272.
- Ibrahim AA, Abdelazim IA, Hagras AM. The risk of Parkinson's disease in women who underwent hysterectomy before the age
 of menopause. *Przeglad menopauzalny = Menopause review* 2022;21: 185-190.
- Ingelsson E, Lundholm C, Johansson AL, Altman D. Hysterectomy and risk of cardiovascular disease: a population-based cohort
 study. *Eur Heart J* 2011;32: 745-750.
- International Society for Clinical Densitometry. International Society for Clinical Densitometry position statement.
 <u>https://wwwiscdorg/official-positions/2019-iscd-official-positions-adult</u> 2019.
- 6527 Irvine WJ, Chan MM, Scarth L, Kolb FO, Hartog M, Bayliss RI, Drury MI. Immunological aspects of premature ovarian failure
 6528 associated with idiopathic Addison's disease. *Lancet* 1968;2: 883-887.
- 6529 Isaza PG. Use of Growth Factors for Vulvo/Vaginal Bio-Stimulation. Surgical technology international 2019;34: 269-273.



- Ishizuka B. Current Understanding of the Etiology, Symptomatology, and Treatment Options in Premature Ovarian
 Insufficiency (POI). Frontiers in endocrinology 2021;12: 626924.
- **6532** Islam RM, Bell RJ, Green S, Davis SR. Effects of testosterone therapy for women: a systematic review and meta-analysis protocol. *Systematic reviews* 2019a;8: 19.
- **6534** Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and metaanalysis of randomised controlled trial data. *The lancet Diabetes & endocrinology* 2019b;7: 754-766.
- 6536 Islam RM, Davis SR, Bell RJ, Tejada-Berges T, Wrede CD, Domchek SM, Meiser B, Kirk J, Krejany EO, Hickey M. A prospective
- 6537 controlled study of sexual function and sexually related personal distress up to 12 months after premenopausal risk-reducing
 6538 bilateral salpingo-oophorectomy. *Menopause (New York, NY)* 2021;28: 748-755.
- Iwase A, Asada Y, Sugishita Y, Osuka S, Kitajima M, Kawamura K, from the subcommittee "Survey of Amh measurement in
 Japan" in Reproductive Endocrinology Committee JSoO, Gynecology. Anti-Mullerian hormone for screening, diagnosis,
 evaluation, and prediction: A systematic review and expert opinions. *The journal of obstetrics and gynaecology research*2024;50: 15-39.
- Jacob S, Koc M. Autoimmune oophoritis: a rarely encountered ovarian lesion. *Indian J Pathol Microbiol* 2015;58: 249-251.
- 544 Jacoby VL, Grady D, Wactawski-Wende J, Manson JE, Allison MA, Kuppermann M, Sarto GE, Robbins J, Phillips L, Martin LW et
- 6545 *al.* Oophorectomy vs ovarian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women's
 6546 Health Initiative Observational Study. *Archives of internal medicine* 2011;171: 760-768.
- Jacquemont S, Hagerman RJ, Hagerman PJ, Leehey MA. Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome:
 two faces of FMR1. *Lancet neurology* 2007;6: 45-55.
- Jang JH, Arora N, Kwon JS, Hanley GE. Hormone Therapy Use After Premature Surgical Menopause Based on Prescription
 Records: A Population-Based Study. *Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie* du Canada : JOGC 2020;42: 1511-1517.
- Jang S, Kim MS, Kim PW, Kim S. Korean medicine treatment for premature ovarian failure: Three case reports. *Explore (New York, NY)* 2022a.
- 6554Jang YC, Leung CY, Huang HL. Comparison of Severity of Genitourinary Syndrome of Menopause Symptoms After Carbon6555Dioxide Laser vs Vaginal Estrogen Therapy: A Systematic Review and Meta-analysis. JAMA Netw Open 2022b;5: e2232563.
- Janse F, Eijkemans MJ, Goverde AJ, Lentjes EG, Hoek A, Lambalk CB, Hickey TE, Fauser BC, Norman RJ. Assessment of androgen
 concentration in women: liquid chromatography-tandem mass spectrometry and extraction RIA show comparable results. *Eur J Endocrinol* 2011;165: 925-933.
- **6559** Janse F, Tanahatoe SJ, Eijkemans MJ, Fauser BC. Testosterone concentrations, using different assays, in different types of ovarian insufficiency: a systematic review and meta-analysis. *Human reproduction update* 2012;18: 405-419.
- **6561** Javadpour S, Sharifi N, Mosallanezhad Z, Rasekhjahromi A, Jamali S. Assessment of premature menopause on the sexual function and quality of life in women. *Gynecol Endocrinol* 2021;37: 307-311.
- Javed AA, Mayhew AJ, Shea AK, Raina P. Association Between Hormone Therapy and Muscle Mass in Postmenopausal Women:
 A Systematic Review and Meta-analysis. *JAMA Netw Open* 2019;2: e1910154.
- Ji J, Sundquist J, Sundquist K. Stillbirth and neonatal death among female cancer survivors: A national cohort study.
 International journal of cancer Journal international du cancer 2016;139: 1046-1052.
- Jiang H, Robinson DL, Lee PVS, Krejany EO, Yates CJ, Hickey M, Wark JD. Loss of bone density and bone strength following
 premenopausal risk-reducing bilateral salpingo-oophorectomy: a prospective controlled study (WHAM Study). Osteoporosis
 international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the
 National Osteoporosis Foundation of the USA 2021;32: 101-112.
- Jiao X, Zhang H, Ke H, Zhang J, Cheng L, Liu Y, Qin Y, Chen ZJ. Premature Ovarian Insufficiency: Phenotypic Characterization
 Within Different Etiologies. *The Journal of clinical endocrinology and metabolism* 2017;102: 2281-2290.
- Jin J, Ruan X, Hua L, Mueck AO. Prevalence of metabolic syndrome and its components in Chinese women with premature
 ovarian insufficiency. *Gynecol Endocrinol* 2023;39: 2254847.
- Jo J, Lee YJ, Lee H. Effectiveness of Acupuncture for Primary Ovarian Insufficiency: A Systematic Review and Meta-Analysis.
 Evidence-based complementary and alternative medicine : eCAM 2015;2015: 842180.
- Joffe H, Guthrie KA, LaCroix AZ, Reed SD, Ensrud KE, Manson JE, Newton KM, Freeman EW, Anderson GL, Larson JC *et al.* Lowdose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized
 clinical trial. *JAMA internal medicine* 2014;174: 1058-1066.
- Johnson KA, Martin N, Nappi RE, Neal-Perry G, Shapiro M, Stute P, Thurston RC, Wolfman W, English M, Franklin C *et al.* Efficacy
 and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT. *The Journal of clinical endocrinology and metabolism* 2023;108: 1981-1997.
- Jolly A, Bayram Y, Turan S, Aycan Z, Tos T, Abali ZY, Hacihamdioglu B, Coban Akdemir ZH, Hijazi H, Bas S *et al.* Exome Sequencing
 of a Primary Ovarian Insufficiency Cohort Reveals Common Molecular Etiologies for a Spectrum of Disease. *The Journal of clinical endocrinology and metabolism* 2019;104: 3049-3067.
- 6586Jones AR, Tay CT, Melder A, Vincent AJ, Teede H. What Are Models of Care? A Systematic Search and Narrative Review to6587Guide Development of Care Models for Premature Ovarian Insufficiency. Seminars in reproductive medicine 2020;38: 323-330.
- 588 Jull J, Stacey D, Beach S, Dumas A, Strychar I, Ufholz LA, Prince S, Abdulnour J, Prud'homme D. Lifestyle interventions targeting
- body weight changes during the menopause transition: a systematic review. *Journal of obesity* 2014;2014: 824310.
- Jungari SB, Chauhan BG. Prevalence and Determinants of Premature Menopause among Indian Women: Issues and Challenges
 Ahead. *Health & social work* 2017;42: 79-86.



- Kalantaridou SN, Calis KA, Vanderhoof VH, Bakalov VK, Corrigan EC, Troendle JF, Nelson LM. Testosterone deficiency in young
 women with 46,XX spontaneous premature ovarian failure *Fertility and sterility*. 2006a, pp. 1475-1482.
- Kalantaridou SN, Naka KK, Bechlioulis A, Makrigiannakis A, Michalis L, Chrousos GP. Premature ovarian failure, endothelial
 dysfunction and estrogen-progestogen replacement. *Trends in endocrinology and metabolism: TEM* 2006b;17: 101-109.
- 6596 Kalantaridou SN, Naka KK, Papanikolaou E, Kazakos N, Kravariti M, Calis KA, Paraskevaidis EA, Sideris DA, Tsatsoulis A, Chrousos
- 6597 GP *et al.* Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy.
 6598 *The Journal of clinical endocrinology and metabolism* 2004;89: 3907-3913.
- 6599 Kalantaridou SN, Vanderhoof VH, Calis KA, Corrigan EC, Troendle JF, Nelson LM. Sexual function in young women with 6600 spontaneous 46,XX primary ovarian insufficiency. *Fertility and sterility* 2008;90: 1805-1811.
- Kalra R, Cameron M, Stern C. Female fertility preservation in DSD. *Best practice & research Clinical endocrinology & metabolism* 2019;33: 101289.
- Kanadys W, Baranska A, Blaszczuk A, Polz-Dacewicz M, Drop B, Kanecki K, Malm M. Evaluation of Clinical Meaningfulness of
 Red Clover (Trifolium pratense L.) Extract to Relieve Hot Flushes and Menopausal Symptoms in Peri- and Post-Menopausal
 Women: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Nutrients* 2021;13.
- 6606 Kanis JA, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in 6607 postmenopausal women. Osteoporosis international : a journal established as result of cooperation between the European 6608 Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2019;30: 3-44.
- 6609 Kanj RV, Ofei-Tenkorang NA, Altaye M, Gordon CM. Evaluation and Management of Primary Ovarian Insufficiency in 6610 Adolescents and Young Adults. *Journal of pediatric and adolescent gynecology* 2018;31: 13-18.
- Karia PS, Joshu CE, Visvanathan K. Association of Oophorectomy and Fat and Lean Body Mass: Evidence from a Population-Based Sample of U.S. Women. *Cancer Epidemiol Biomarkers Prev* 2021;30: 1424-1432.
- Kato I, Toniolo P, Akhmedkhanov A, Koenig KL, Shore R, Zeleniuch-Jacquotte A. Prospective study of factors influencing the onset of natural menopause. *Journal of clinical epidemiology* 1998;51: 1271-1276.
- 6615 Katsifis GE, Tzioufas AG. Ovarian failure in systemic lupus erythematosus patients treated with pulsed intravenous 6616 cyclophosphamide. *Lupus* 2004;13: 673-678.
- Kaunitz AM, Kapoor E, Faubion S. Treatment of Women After Bilateral Salpingo oophorectomy Performed Prior to Natural
 Menopause. *Jama* 2021;326: 1429-1430.
- Kawamura K, Kawamura N, Hsueh AJ. Activation of dormant follicles: a new treatment for premature ovarian failure? *Current opinion in obstetrics & gynecology* 2016;28: 217-222.
- Ke H, Tang S, Guo T, Hou D, Jiao X, Li S, Luo W, Xu B, Zhao S, Li G *et al.* Landscape of pathogenic mutations in premature ovarian
 insufficiency. *Nat Med* 2023;29: 483-492.
- 6623 Kearley-Shiers K, Holloway D, Janice R, Bruce D. Intravaginal dehydroepiandrosterone for genitourinary symptoms of the 6624 menopause: Is the evidence sufficient? *Post Reprod Health* 2022;28: 237-243.
- Kelkar RL, Meherji PK, Kadam SS, Gupta SK, Nandedkar TD. Circulating auto-antibodies against the zona pellucida and thyroid
 microsomal antigen in women with premature ovarian failure. *Journal of reproductive immunology* 2005;66: 53-67.
- Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts
 M *et al.* Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non inferiority trial. *The Lancet Oncology* 2009;10: 135-146.
- Kershaw V, Hickey I, Wyld L, Jha S. The impact of risk reducing bilateral salpingo-oophorectomy on sexual function in BRCA1/2
 mutation carriers and women with Lynch syndrome: A systematic review and meta-analysis. *European journal of obstetrics, gynecology, and reproductive biology* 2021;265: 7-17.
- Keukens A, van Wely M, van der Meulen C, Mochtar MH. Pre-eclampsia in pregnancies resulting from oocyte donation, natural
 conception or IVF: a systematic review and meta-analysis. *Human reproduction (Oxford, England)* 2022;37: 586-599.
- 6635 Khalafi M, Habibi Maleki A, Sakhaei MH, Rosenkranz SK, Pourvaghar MJ, Ehsanifar M, Bayat H, Korivi M, Liu Y. The effects of 6636 exercise training on body composition in postmenopausal women: a systematic review and meta-analysis. *Frontiers in*
- 6637 endocrinology 2023a;14: 1183765.
 6638 Khalafi M, Sakhaei MH, Habibi Maleki A, Rosenkranz SK, Pourvaghar MJ, Fang Y, Korivi M. Influence of exercise type and duration on cardiorespiratory fitness and muscular strength in post-menopausal women: a systematic review and meta-
- 6640 analysis. Frontiers in cardiovascular medicine 2023b;10: 1190187.
- 6641 Khastgir G, Abdalla H, Studd JW. The case against ovarian biopsy for the diagnosis of premature menopause. *British journal of* 6642 *obstetrics and gynaecology* 1994;101: 96-98.
- 6643 Khizroeva J, Nalli C, Bitsadze V, Lojacono A, Zatti S, Andreoli L, Tincani A, Shoenfeld Y, Makatsariya A. Infertility in women with 6644 systemic autoimmune diseases. *Best practice & research Clinical endocrinology & metabolism* 2019;33: 101369.
- Kim C, Cleary PA, Cowie CC, Braffett BH, Dunn RL, Larkin ME, Gatcomb PM, Wessells HB, Nathan DM, Sarma AV. Effect of
 glycemic treatment and microvascular complications on menopause in women with type 1 diabetes in the Diabetes Control
 and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) cohort. *Diabetes care*2014;37: 701-708.
- 6649 Kim H, Jung JH, Han K, Lee DY, Fava M, Mischoulon D, Jeon HJ. Ages at menarche and menopause, hormone therapy, and the 6650 risk of depression. *General hospital psychiatry* 2023;83: 35-42.
- 6651 Kingsberg S, Shifren J, Wekselman K, Rodenberg C, Koochaki P, Derogatis L. Evaluation of the clinical relevance of benefits
- associated with transdermal testosterone treatment in postmenopausal women with hypoactive sexual desire disorder. *The journal of sexual medicine* 2007;4: 1001-1008.



- Kingsberg SA, Althof S, Simon JA, Bradford A, Bitzer J, Carvalho J, Flynn KE, Nappi RE, Reese JB, Rezaee RL *et al.* Female Sexual
 Dysfunction-Medical and Psychological Treatments, Committee 14. *The journal of sexual medicine* 2017;14: 1463-1491.
- Kingsberg SA, Larkin LC, Liu JH. Clinical Effects of Early or Surgical Menopause. *Obstetrics and gynecology* 2020;135: 853-868.
 Kingsberg SA, Simon JA. Female Hypoactive Sexual Desire Disorder: A Practical Guide to Causes, Clinical Diagnosis, and
 Treatment. *J Womens Health (Larchmt)* 2020;29: 1101-1112.
- Kiriakova V, Cooray SD, Yeganeh L, Somarajah G, Milat F, Vincent AJ. Management of bone health in women with premature
 ovarian insufficiency: Systematic appraisal of clinical practice guidelines and algorithm development. *Maturitas* 2019;128: 7080.
- Kirk B, Zanker J, Duque G. Osteosarcopenia: epidemiology, diagnosis, and treatment-facts and numbers. *Journal of cachexia, sarcopenia and muscle* 2020;11: 609-618.
- 6664 Kirshenbaum M, Orvieto R. Premature ovarian insufficiency (POI) and autoimmunity-an update appraisal. *Journal of assisted* 6665 *reproduction and genetics* 2019;36: 2207-2215.
- Klasa Ł, Sadowska-Klasa A, Piekarska A, Wydra D, Zaucha JM. The management of gynecological complications in long-term
 survivors after allogeneic hematopoietic cell transplantation-a single-center real-life experience. *Annals of hematology*2020;99: 1361-1368.
- 6669 Klein KO, Phillips SA. Review of Hormone Replacement Therapy in Girls and Adolescents with Hypogonadism. *Journal of* 6670 *pediatric and adolescent gynecology* 2019;32: 460-468.
- Klein KO, Rosenfield RL, Santen RJ, Gawlik AM, Backeljauw PF, Gravholt CH, Sas TCJ, Mauras N. Estrogen Replacement in Turner
 Syndrome: Literature Review and Practical Considerations. *The Journal of clinical endocrinology and metabolism* 2018;103:
 1790-1803.
- Knauff EA, Eijkemans MJ, Lambalk CB, ten Kate-Booij MJ, Hoek A, Beerendonk CC, Laven JS, Goverde AJ, Broekmans FJ,
 Themmen AP *et al.* Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure. *The*
- 6676 Journal of clinical endocrinology and metabolism 2009;94: 786-792.
- 6677 Knobf MT, Jeon S, Smith B, Harris L, Thompson S, Stacy MR, Insogna K, Sinusas AJ. The Yale Fitness Intervention Trial in female 6678 cancer survivors: Cardiovascular and physiological outcomes. *Heart & lung : the journal of critical care* 2017;46: 375-381.
- Kobayashi M, Nakashima A, Yoshino O, Yoshie M, Ushijima A, Ito M, Ono Y, Shima T, Kawamura K, Ishizuka B *et al.* Decreased
 effector regulatory T cells and increased activated CD4(+) T cells in premature ovarian insufficiency. *American journal of reproductive immunology (New York, NY : 1989)* 2019;81: e13125.
- Kocoska-Maras L, Zethraeus N, Radestad AF, Ellingsen T, von Schoultz B, Johannesson M, Hirschberg AL. A randomized trial of
 the effect of testosterone and estrogen on verbal fluency, verbal memory, and spatial ability in healthy postmenopausal
 women. *Fertility and sterility* 2011;95: 152-157.
- 6685 Kokcu A. Premature ovarian failure from current perspective. *Gynecol Endocrinol* 2010;26: 555-562.
- 6686 Kotsopoulos J. BRCA Mutations and Breast Cancer Prevention. *Cancers* 2018;10.
- Kotsopoulos J, Gronwald J, Karlan BY, Huzarski T, Tung N, Moller P, Armel S, Lynch HT, Senter L, Eisen A *et al.* Hormone
 Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers. *JAMA oncology* 2018;4:
 1059-1065.
- Kotsopoulos J, Gronwald J, Lubinski J, McCuaig J, Lynch HT, Neuhausen SL, Foulkes WD, Weitzel JN, Senter L, Tung N *et al.* Does
 preventive oophorectomy increase the risk of depression in BRCA mutation carriers? *Menopause (New York, NY)* 2020;27:
 156-161.
- 6693 Kotz K, Alexander JL, Dennerstein L. Estrogen and androgen hormone therapy and well-being in surgically postmenopausal 6694 women. J Womens Health (Larchmt) 2006;15: 898-908.
- Kotze LMS. Gynecologic and Obstetric Findings Related to Nutritional Status and Adherence to a Gluten-Free Diet in Brazilian
 Patients with Celiac Disease. *Journal of Clinical Gastroenterology* 2004;38: 567-574.
- Kou MJ, Ding XF, Chen JX, Liu Y, Liu YY. TRADITIONAL CHINESE MEDICINE COMBINED WITH HORMONE THERAPY TO TREAT
 PREMATURE OVARIAN FAILURE: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. *African journal of traditional, complementary, and alternative medicines : AJTCAM* 2016;13: 160-169.
- Koysombat K, McGown P, Nyunt S, Abbara A, Dhillo WS. New advances in menopause symptom management. *Best practice & research Clinical endocrinology & metabolism* 2024;38: 101774.
- Krailo MD, Pike MC. Estimation of the distribution of age at natural menopause from prevalence data. *American journal of epidemiology* 1983;117: 356-361.
- 6704 Kramer MG, Reiter RC. Hysterectomy: indications, alternatives and predictors. *American family physician* 1997;55: 827-834.
- 6705 Krul IM, Opstal-van Winden AWJ, Aleman BMP, Janus CPM, van Eggermond AM, De Bruin ML, Hauptmann M, Krol ADG,
- 6706 Schaapveld M, Broeks A *et al.* Breast Cancer Risk After Radiation Therapy for Hodgkin Lymphoma: Influence of Gonadal 6707 Hormone Exposure. *International journal of radiation oncology, biology, physics* 2017;99: 843-853.
- Kundu S, Acharya SS. Linkage of premature and early menopause with psychosocial well-being: a moderated multiple
 mediation approach. *BMC psychology* 2023;11: 228.
- La Marca A, Brozzetti A, Sighinolfi G, Marzotti S, Volpe A, Falorni A. Primary ovarian insufficiency: autoimmune causes. *Current opinion in obstetrics & gynecology* 2010;22: 277-282.
- La Marca A, Marzotti S, Brozzetti A, Stabile G, Artenisio AC, Bini V, Giordano R, De Bellis A, Volpe A, Falorni A *et al.* Primary
 ovarian insufficiency due to steroidogenic cell autoimmunity is associated with a preserved pool of functioning follicles. *The*
- 6714 Journal of clinical endocrinology and metabolism 2009;94: 3816-3823.
- 6715 La Marca A, Mastellari E. Fertility preservation for genetic diseases leading to premature ovarian insufficiency (POI). *Journal of* 6716 *assisted reproduction and genetics* 2021;38: 759-777.



- 6717 Labrie F, Martel C, Balser J. Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal
- 6718 women: role of the ovary? *Menopause (New York, NY)* 2011;18: 30-43.
- Lambrinoudaki I. Progestogens in postmenopausal hormone therapy and the risk of breast cancer. *Maturitas* 2014;77: 311-317.
- 6721 Langrish JP, Mills NL, Bath LE, Warner P, Webb DJ, Kelnar CJ, Critchley HO, Newby DE, Wallace WH. Cardiovascular effects of
- 6722 physiological and standard sex steroid replacement regimens in premature ovarian failure. *Hypertension* 2009;53: 805-811.
- Langton CR, Whitcomb BW, Purdue-Smithe AC, Sievert LL, Hankinson SE, Manson JE, Rosner BA, Bertone-Johnson ER.
 Association of Parity and Breastfeeding With Risk of Early Natural Menopause. *JAMA Netw Open* 2020;3: e1919615.
- 6724 Association of Parity and Bleastreeding with Nsk of Early Natural Menopause. JANA Netw Open 2020, 5: e1919615.
 6725 Lara LA, Cartagena-Ramos D, Figueiredo JB, Rosa ESACJ, Ferriani RA, Martins WP, Fuentealba-Torres M. Hormone therapy for
- 6726 sexual function in perimenopausal and postmenopausal women. *Cochrane Database Syst Rev* 2023;8: Cd009672.
- Larizza D, Albanesi M, De Silvestri A, Accordino G, Brazzelli V, Maffè GC, Calcaterra V. Neoplasia in Turner syndrome. The
 importance of clinical and screening practices during follow-up. *European journal of medical genetics* 2016;59: 269-273.
- 6729 Larsen EC, Loft A, Holm K, Muller J, Brocks V, Andersen AN. Oocyte donation in women cured of cancer with bone marrow
- 6730 transplantation including total body irradiation in adolescence. *Human reproduction (Oxford, England)* 2000;15: 1505-1508.
- 6731 Lasa JS, Zubiaurre I, Soifer LO. Risk of infertility in patients with celiac disease: a meta-analysis of observational studies. *Arquivos* 6732 *de gastroenterologia* 2014;51: 144-150.
- Lau NM, Huang JY, MacDonald S, Elizur S, Gidoni Y, Holzer H, Chian RC, Tulandi T, Tan SL. Feasibility of fertility preservation in
 young females with Turner syndrome. *Reprod Biomed Online* 2009;18: 290-295.
- 6735 Leach Matthew J, Moore V. Black cohosh (Cimicifuga spp.) for menopausal symptoms *Cochrane Database of Systematic* 6736 *Reviews*. 2012. John Wiley & Sons, Ltd.
- 6737 Lederman S, Ottery FD, Cano A, Santoro N, Shapiro M, Stute P, Thurston RC, English M, Franklin C, Lee M et al. Fezolinetant
- for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised
 controlled study. *Lancet* 2023;401: 1091-1102.
- 6740 Lee GB, Nam GE, Kim W, Han B, Cho KH, Kim SM, Choi YS, Kim DH, Park YG, Jung JH et al. Association Between Premature
- 6741 Menopause and Cardiovascular Diseases and All-Cause Mortality in Korean Women. *Journal of the American Heart Association* 6742 2023a: e030117.
- 6743 Lee HW, Ang L, Kim E, Lee MS. Fennel (Foeniculum vulgare Miller) for the management of menopausal women's health: A
 6744 systematic review and meta-analysis. *Complementary therapies in clinical practice* 2021;43: 101360.
- 6745 Lee HW, Ang L, Lee MS. Using ginseng for menopausal women's health care: A systematic review of randomized placebo-6746 controlled trials. *Complementary therapies in clinical practice* 2022a;48: 101615.
- 6747 Lee JS, Wasim AM, Karreman E, Al-Hayki M. Hormone Therapy Use Among Young Patients with Cervical Cancer in Southern
 6748 Saskatchewan. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC
 6749 2022b;44: 757-761.
- 6750 Lee YJ, Kim JS, Jo JC, Kim Y, Im HS, Kim H, Koh S, Min YJ, Park SH, Ahn JW. Risk factors of menopause after allogeneic 6751 hematopoietic cell transplantation in premenopausal adult women. *European journal of haematology* 2023b;111: 449-457.
- Lee YS, Wie C, Pew S, Kling JM. Stellate ganglion block as a treatment for vasomotor symptoms: Clinical application. *Cleveland Clinic journal of medicine* 2022c;89: 147-153.
- 6754 Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. *Cochrane Database Syst* 6755 *Rev* 2016;2016: Cd001500.
- Leung KC, Johannsson G, Leong GM, Ho KK. Estrogen regulation of growth hormone action. *Endocrine reviews* 2004;25: 693 721.
- 6758 Li C, Cao M, Ma L, Ye X, Song Y, Pan W, Xu Z, Ma X, Lan Y, Chen P *et al.* Pyrethroid Pesticide Exposure and Risk of Primary
 6759 Ovarian Insufficiency in Chinese Women. *Environmental science & technology* 2018;52: 3240-3248.
- Li C, Cao M, Qi T, Ye X, Ma L, Pan W, Luo J, Chen P, Liu J, Zhou J. The association of bisphenol A exposure with premature ovarian insufficiency: a case-control study. *Climacteric : the journal of the International Menopause Society* 2021a;24: 95-100.
 Li F, Lu H, Huang Y, Wang X, Zhang Q, Li X, Qiang L, Yang Q. A systematic review and meta-analysis of the association between
- Hashimoto's thyroiditis and ovarian reserve. *Int Immunopharmacol* 2022;108: 108670.
- 6764 Li FG, Maheux-Lacroix S, Deans R, Nesbitt-Hawes E, Budden A, Nguyen K, Lim CY, Song S, McCormack L, Lyons SD *et al.* Effect
 6765 of Fractional Carbon Dioxide Laser vs Sham Treatment on Symptom Severity in Women With Postmenopausal Vaginal
 6766 Symptoms: A Randomized Clinical Trial. *Jama* 2021b;326: 1381-1389.
- Li HF, Shen QH, Chen WJ, Chen WM, Feng ZF, Yu LY. Efficacy of Traditional Chinese Medicine Tonifying Kidney (Bushen) and
 Activating Blood (Huoxue) Prescription for Premature Ovarian Insufficiency: A Systematic Review and Meta-Analysis. *Evidence- based Complementary and Alternative Medicine* 2020a;2020: 1789304.
- 6770 Li M, Zhao C, Xie S, Liu X, Zhao Q, Zhang Z, Gong G. Effects of hypogonadism on brain development during adolescence in girls
 6771 with Turner syndrome. *Human brain mapping* 2019;40: 4901-4911.
- 6772 Li M, Zhu Y, Wei J, Chen L, Chen S, Lai D. The global prevalence of premature ovarian insufficiency: a systematic review and
 6773 meta-analysis. *Climacteric : the journal of the International Menopause Society* 2023a;26: 95-102.
- 6774 Li S, Ma L, Huang H, Lou Z, Qi T, Huang Y, Zou Y, Zhou J. Loss of muscle mass in women with premature ovarian insufficiency
 6775 as compared with healthy controls. *Menopause (New York, NY)* 2023b;30: 122-127.
- 6776 Li XT, Li PY, Liu Y, Yang HS, He LY, Fang YG, Liu J, Liu BY, Chaplin JE. Health-related quality-of-life among patients with premature
- 6777 ovarian insufficiency: a systematic review and meta-analysis. *Quality of life research : an international journal of quality of life*
- 6778 *aspects of treatment, care and rehabilitation* 2020b;29: 19-36.



- 6779 Li Y, Chang J, Shi G, Zhang W, Wang H, Wei L, Liu X, Zhang W. Effects of stellate ganglion block on perimenopausal hot flashes:
 6780 a randomized controlled trial. *Frontiers in endocrinology* 2023c;14: 1293358.
- 6781 Li Y, Xia G, Tan Y, Shuai J. Acupoint stimulation and Chinese herbal medicines for the treatment of premature ovarian 6782 insufficiency: A systematic review and meta-analysis. *Complementary therapies in clinical practice* 2020c;41: 101244.
- Li Y, Zhao D, Wang M, Sun JY, Liu J, Qi Y, Hao YC, Deng QJ, Liu J, Liu J *et al.* Combined effect of menopause and cardiovascular risk factors on death and cardiovascular disease: a cohort study. *BMC cardiovascular disorders* 2021c;21: 109.
- 6785 Liao KL, Wood N, Conway GS. Premature menopause and psychological well-being. *Journal of psychosomatic obstetrics and gynaecology* 2000;21: 167-174.
- 6787 Lidegaard Ø, Løkkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal
 6788 contraception. *N Engl J Med* 2012;366: 2257-2266.
- 6789 Lin F, Tomppo L, Gaynor B, Ryan K, Cole JW, Mitchell BD, Putaala J, Kittner SJ. Genomic risk scores and oral contraceptive-6790 associated ischemic stroke risk: a call for collaboration. *Frontiers in stroke* 2023;2.
- Lindau ST, Abramsohn EM, Matthews AC. A manifesto on the preservation of sexual function in women and girls with cancer.
 American journal of obstetrics and gynecology 2015;213: 166-174.
- Lindsay Mart F, Gutmark-Little I, Streich-Tilles T, Trout AT, Khoury J, Bowers K, Casnellie L, Backeljauw P. Current
 Recommended Estrogen Dosing for Pubertal Induction in Turner Syndrome Results in Normal Uterine Growth. *The Journal of clinical endocrinology and metabolism* 2023.
- 6796 Lip GY, Blann AD, Jones AF, Beevers DG. Effects of hormone-replacement therapy on hemostatic factors, lipid factors, and
 6797 endothelial function in women undergoing surgical menopause: implications for prevention of atherosclerosis. *American heart* 6798 *journal* 1997;134: 764-771.
- Liu H, Cai K, Wang J, Zhang H. The effects of mindfulness-based interventions on anxiety, depression, stress, and mindfulness
 in menopausal women: A systematic review and meta-analysis. *Frontiers in public health* 2022a;10: 1045642.
- Liu J, Jin X, Chen W, Wang L, Feng Z, Huang J. Early menopause is associated with increased risk of heart failure and atrial
 fibrillation: A systematic review and meta-analysis. *Maturitas* 2023a;176: 107784.
- 6802 fibrillation: A systematic review and meta-analysis. *Maturitas* 2023a;176: 107784.
 6803 Liu J, Jin X, Liu W, Chen W, Wang L, Feng Z, Huang J. The risk of long-term cardiometabolic disease in women with premature
 6804 or early menopause: A systematic review and meta-analysis. *Frontiers in cardiovascular medicine* 2023b;10: 1131251.
- **6805** Liu T, Chen S, Mielke GI, McCarthy AL, Bailey TG. Effects of exercise on vasomotor symptoms in menopausal women: a systematic review and meta-analysis. *Climacteric : the journal of the International Menopause Society* 2022b;25: 552-561.
- Liu W, Nguyen TN, Tran Thi TV, Zhou S. Kuntai Capsule plus Hormone Therapy vs. Hormone Therapy Alone in Patients with
 Premature Ovarian Failure: A Systematic Review and Meta-Analysis. *Evidence-based Complementary and Alternative Medicine* 2019;2019: 2085804.
- 6810 Loaiza-Betancur AF, Chulvi-Medrano I, Díaz-López VA, Gómez-Tomás C. The effect of exercise training on blood pressure in
- 6811 menopause and postmenopausal women: A systematic review of randomized controlled trials. *Maturitas* 2021;149: 40-55.
- Loizzi V, Dellino M, Cerbone M, Arezzo F, Cazzato G, Damiani GR, Pinto V, Silvestris E, Kardhashi A, Cicinelli E *et al.* The Role of
 Hormonal Replacement Therapy in BRCA Mutated Patients: Lights and Shadows. *Int J Mol Sci* 2023a;24.
- Loizzi V, Dellino M, Cerbone M, Arezzo F, Chiariello G, Lepera A, Cazzato G, Cascardi E, Damiani GR, Cicinelli E *et al.* Hormone
 replacement therapy in BRCA mutation carriers: how shall we do no harm? *Hormones (Athens, Greece)* 2023b;22: 19-23.
- Lokkegaard E, Jovanovic Z, Heitmann BL, Keiding N, Ottesen B, Pedersen AT. The association between early menopause and
 risk of ischaemic heart disease: influence of Hormone Therapy. *Maturitas* 2006;53: 226-233.
- Long P, Wang L, Tan H, Quan R, Hu Z, Zeng M, Deng Z, Huang H, Greenbaum J, Deng H *et al.* Oligogenic basis of premature ovarian insufficiency: an observational study. *Journal of ovarian research* 2024;17: 32.
- 6820 Longcope C. Adrenal and gonadal androgen secretion in normal females. *Clin Endocrinol Metab* 1986;15: 213-228.
- Luborsky J, Llanes B, Davies S, Binor Z, Radwanska E, Pong R. Ovarian autoimmunity: greater frequency of autoantibodies in
 premature menopause and unexplained infertility than in the general population. *Clinical immunology* 1999;90: 368-374.
- Luborsky JL, Meyer P, Sowers MF, Gold EB, Santoro N. Premature menopause in a multi-ethnic population study of the
 menopause transition. *Human reproduction (Oxford, England)* 2003;18: 199-206.
- Luo W, Ke H, Tang S, Jiao X, Li Z, Zhao S, Zhang F, Guo T, Qin Y. Next-generation sequencing of 500 POI patients identified novel
 responsible monogenic and oligogenic variants. *Journal of ovarian research* 2023;16: 39.
- Luo X, Cheng R, Zhang J, Ma Y, Zhang J, Luo Y, Xu L. Evaluation of body composition in POF and its association with bone mineral
 density and sex steroid levels. *Gynecol Endocrinol* 2018;34: 1027-1030.
- Lutjen P, Trounson A, Leeton J, Findlay J, Wood C, Renou P. The establishment and maintenance of pregnancy using in vitro
 fertilization and embryo donation in a patient with primary ovarian failure. *Nature* 1984;307: 174-175.
- **6831** Lv M, Zhang Y, Chen GC, Li G, Rui Y, Qin L, Wan Z. Reproductive factors and risk of Parkinson's disease in women: A meta-**6832** analysis of observational studies. *Behavioural brain research* 2017;335: 103-110.
- 6833 Ma L, Chen G, Xu W, Chen P, Lan Y, Huang Y, Li C, Zhou J. The relationship between vitamin E level and premature ovarian 6834 insufficiency. *The journal of obstetrics and gynaecology research* 2021;47: 1481-1486.
- 6835 Ma L, Li X, Li C, Chen P, Lan Y, Huang Y, Xu W, Zhou J. Association of Coenzyme Q10 with Premature Ovarian Insufficiency.
 6836 *Reproductive sciences (Thousand Oaks, Calif)* 2023;30: 1548-1554.
- 6837 Ma Q, Tan Y, Mo G. Effectiveness of Cotreatment with Kuntai Capsule and Climen for Premature Ovarian Failure: A Meta-
- Analysis. Evidence-based complementary and alternative medicine : eCAM 2020;2020: 4367359.
- 6839 Ma X, Pan W, Zhu Z, Ye X, Li C, Zhou J, Liu J. A case-control study of thallium exposure with the risk of premature ovarian 6840 insufficiency in women. *Archives of environmental & occupational health* 2022;77: 468-477.
- 6841 MacGregor EA. Migraine, menopause and hormone replacement therapy. *Post Reprod Health* 2018;24: 11-18.



- 6842 Machado AMN, Rodrigues M, Malvezzi H, de Azevedo Piccinato C, Hamerschlak N, Podgaec S. Graft-versus-host disease in the 6843 female genital tract: a prospective cohort study. *Archives of gynecology and obstetrics* 2022;305: 1551-1558.
- Maclaughlan David S, Salzillo S, Bowe P, Scuncio S, Malit B, Raker C, Gass JS, Granai CO, Dizon DS. Randomised controlled trial
 comparing hypnotherapy versus gabapentin for the treatment of hot flashes in breast cancer survivors: a pilot study. *BMJ open* 2013;3: e003138.
- Madanat-Harjuoja LM, Lähteenmäki PM, Dyba T, Gissler M, Boice JD, Jr., Malila N. Stillbirth, early death and neonatal morbidity
 among offspring of female cancer survivors. *Acta oncologica* 2013;52: 1152-1159.
- 6849 Mamsen LS, Charkiewicz K, Anderson RA, Telfer EE, McLaughlin M, Kelsey TW, Kristensen SG, Gook DA, Ernst E, Andersen CY.
- 6850 Characterization of follicles in girls and young women with Turner syndrome who underwent ovarian tissue cryopreservation.
 6851 *Fertility and sterility* 2019;111: 1217-1225 e1213.
- 6852 Mamsen LS, Kelsey TW, Ernst E, Macklon KT, Lund AM, Andersen CY. Cryopreservation of ovarian tissue may be considered in 6853 young girls with galactosemia. *Journal of assisted reproduction and genetics* 2018;35: 1209-1217.
- 6854 Mann E, Singer D, Pitkin J, Panay N, Hunter MS. Psychosocial adjustment in women with premature menopause: a cross-6855 sectional survey. *Climacteric : the journal of the International Menopause Society* 2012;15: 481-489.
- 6856 Manson JE. Postmenopausal hormone therapy and atherosclerotic disease. American heart journal 1994;128: 1337-1343.
- Manson JE, Aragaki AK, Bassuk SS, Chlebowski RT, Anderson GL, Rossouw JE, Howard BV, Thomson CA, Stefanick ML, Kaunitz
 AM *et al.* Menopausal Estrogen-Alone Therapy and Health Outcomes in Women With and Without Bilateral Oophorectomy:
 A Randomized Trial. *Annals of internal medicine* 2019;171: 406-414.
- Marchetti C, De Felice F, Boccia S, Sassu C, Di Donato V, Perniola G, Palaia I, Monti M, Muzii L, Tombolini V *et al.* Hormone
 replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2
 mutation carriers: A meta-analysis. *Critical reviews in oncology/hematology* 2018;132: 111-115.
- 6863 Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal 6864 women. *Cochrane Database Syst Rev* 2012: Cd004143.
- 6865 Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for perimenopausal and postmenopausal 6866 women. *Cochrane Database Syst Rev* 2017;1: Cd004143.
- 6867 Martyn F, O'Brien YM, Wingfield M. Review of clinical indicators, including serum anti-Müllerian hormone levels, for 6868 identification of women who should consider egg freezing. *International journal of gynaecology and obstetrics: the official* 6869 *organ of the International Federation of Gynaecology and Obstetrics* 2017;138: 37-41.
- 6870 Marx P, Schade G, Wilbourn S, Blank S, Moyer DL, Nett R. Low-dose (0.3 mg) synthetic conjugated estrogens A is effective for 6871 managing atrophic vaginitis. *Maturitas* 2004;47: 47-54.
- Matsumoto F, Matsuyama S, Matsui F, Yazawa K, Matsuoka K. Variation of Gonadal Dysgenesis and Tumor Risk in Patients
 With 45,X/46,XY Mosaicism. *Urology* 2020;137: 157-160.
- 6874 Matthijs G, Souche E, Alders M, Corveleyn A, Eck S, Feenstra I, Race V, Sistermans E, Sturm M, Weiss M *et al.* Guidelines for diagnostic next-generation sequencing. *European journal of human genetics : EJHG* 2016;24: 2-5.
- 6876 Matura LA, Ho VB, Rosing DR, Bondy CA. Aortic dilatation and dissection in Turner syndrome. *Circulation* 2007;116: 1663-1670.
 6877 Mauras N, Shulman D, Hsiang HY, Balagopal P, Welch S. Metabolic effects of oral versus transdermal estrogen in growth hormone-treated girls with turner syndrome. *The Journal of clinical endocrinology and metabolism* 2007;92: 4154-4160.
- 6879 McDonald IR, Welt CK, Dwyer AA. Health-related quality of life in women with primary ovarian insufficiency: a scoping review
 6880 of the literature and implications for targeted interventions. *Human reproduction (Oxford, England)* 2022.
- 6881 McDonnell CM, Coleman L, Zacharin MR. A 3-year prospective study to assess uterine growth in girls with Turner's syndrome 6882 by pelvic ultrasound. *Clinical endocrinology* 2003;58: 446-450.
- 6883 McKinlay SM, Bifano NL, McKinlay JB. Smoking and age at menopause in women. *Annals of internal medicine* 1985;103: 350-6884 356.
- 6885 Mehta JM, Manson JE. The menopausal transition period and cardiovascular risk. *Nature reviews Cardiology* 2024;21: 203-6886 211.
- 6887 Melin J, Heinävaara S, Malila N, Tiitinen A, Gissler M, Madanat-Harjuoja L. Risk factors for preterm delivery among early onset
 6888 cancer survivors: A Finnish register-based study. *International journal of cancer Journal international du cancer* 2019;144:
 6889 1954-1961.
- 6890 Mendoza M, Bonacina E, Garcia-Manau P, López M, Caamiña S, Vives À, Lopez-Quesada E, Ricart M, Maroto A, de Mingo L *et al.* Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized
 6892 Clinical Trial. *Jama* 2023;329: 542-550.
- 6893 Menezes C, Pravata GR, Yela DA, Benetti-Pinto CL. Women with premature ovarian failure using hormone therapy do not
 6894 experience increased levels of depression, anxiety and stress compared to controls. *Journal of affective disorders* 2020;273:
 6895 562-566.
- 6896 Menown SJ, Tello JA. Neurokinin 3 Receptor Antagonists Compared With Serotonin Norepinephrine Reuptake Inhibitors for
 6897 Non-Hormonal Treatment of Menopausal Hot Flushes: A Systematic Qualitative Review. *Advances in therapy* 2021;38: 5025 6898 5045.
- Mension E, Alonso I, Anglès-Acedo S, Ros C, Otero J, Villarino Á, Farré R, Saco A, Vega N, Castrejón N *et al.* Effect of Fractional
 Carbon Dioxide vs Sham Laser on Sexual Function in Survivors of Breast Cancer Receiving Aromatase Inhibitors for
 Genitourinary Syndrome of Menopause: The LIGHT Randomized Clinical Trial. *JAMA Netw Open* 2023;6: e2255697.
- 6902 Mercier J, Dumoulin C, Carrier-Noreau G. Pelvic floor muscle rehabilitation for genitourinary syndrome of menopause: why,
- 6903 how and when? Climacteric : the journal of the International Menopause Society 2023;26: 302-308.



- 6904 Mercuro G, Zoncu S, Saiu F, Mascia M, Melis GB, Rosano GM. Menopause induced by oophorectomy reveals a role of ovarian 6905 estrogen on the maintenance of pressure homeostasis. *Maturitas* 2004;47: 131-138.
- Mewes JC, Steuten LM, Duijts SF, Oldenburg HS, van Beurden M, Stuiver MM, Hunter MS, Kieffer JM, van Harten WH, Aaronson
 NK. Cost-effectiveness of cognitive behavioral therapy and physical exercise for alleviating treatment-induced menopausal
 symptoms in breast cancer patients. *Journal of cancer survivorship : research and practice* 2015;9: 126-135.
- 6909 Meziou N, Scholfield C, Taylor CA, Armstrong HL. Hormone therapy for sexual function in perimenopausal and postmenopausal 6910 women: a systematic review and meta-analysis update. *Menopause (New York, NY)* 2023;30: 659-671.
- 6911 Michels KA, Brinton LA, Pfeiffer RM, Trabert B. Oral Contraceptive Use and Risks of Cancer in the NIH-AARP Diet and Health 6912 Study. *American journal of epidemiology* 2018;187: 1630-1641.
- 6913 Michelsen TM, Rosland TE, Åsvold BO, Pripp AH, Liavaag AH, Johansen N. All-cause and cardiovascular mortality after
- 6914 hysterectomy and oophorectomy in a large cohort (HUNT2). *Acta obstetricia et gynecologica Scandinavica* 2023;102: 465-472.
- 6915 Mikkola TS, Clarkson TB. Coronary heart disease and postmenopausal hormone therapy: conundrum explained by timing? J
 6916 Womens Health (Larchmt) 2006;15: 51-53.
- 6917 Mili N, Paschou SA, Armeni A, Georgopoulos N, Goulis DG, Lambrinoudaki I. Genitourinary syndrome of menopause: a 6918 systematic review on prevalence and treatment. *Menopause (New York, NY)* 2021;28: 706-716.
- 6919 Minaković I, Zvekić-Svorcan J, Janković T, Vuksanović M, Mikić D, Bošković K. Early Menopause and Risk of Fractures-A 6920 Preventable Gap. *Iranian journal of public health* 2023;52: 534-541.
- 6921 Mirkin S, Goldstein SR, Archer DF, Pickar JH, Graham S, Bernick B. Endometrial safety and bleeding profile of a 17β-6922 estradiol/progesterone oral softgel capsule (TX-001HR). *Menopause (New York, NY)* 2020;27: 410-417.
- Mishra GD, Chung HF, Cano A, Chedraui P, Goulis DG, Lopes P, Mueck A, Rees M, Senturk LM, Simoncini T *et al.* EMAS position
 statement: Predictors of premature and early natural menopause. *Maturitas* 2019;123: 82-88.
 Mishra GD, Pandeya N, Dobson AJ, Chung HF, Anderson D, Kuh D, Sandin S, Giles GG, Bruinsma F, Hayashi K *et al.* Early
- Mishra GD, Pandeya N, Dobson AJ, Chung HF, Anderson D, Kuh D, Sandin S, Giles GG, Bruinsma F, Hayashi K *et al.* Early
 menarche, nulliparity and the risk for premature and early natural menopause. *Human reproduction (Oxford, England)*2017;32: 679-686.
- Mittal M, McEniery C, Supramaniam PR, Cardozo L, Savvas M, Panay N, Hamoda H. Impact of micronised progesterone and
 medroxyprogesterone acetate in combination with transdermal oestradiol on cardiovascular markers in women diagnosed
 with premature ovarian insufficiency or an early menopause: a randomised pilot trial. *Maturitas* 2022;161: 18-26.
- Moncayo H, Moncayo R, Benz R, Wolf A, Lauritzen C. Ovarian failure and autoimmunity. Detection of autoantibodies directed
 against both the unoccupied luteinizing hormone/human chorionic gonadotropin receptor and the hormone-receptor
 complex of bovine corpus luteum. *The Journal of clinical investigation* 1989;84: 1857-1865.
- Monteleone P, Parrini D, Faviana P, Carletti E, Casarosa E, Uccelli A, Cela V, Genazzani AR, Artini PG. Female infertility related
 to thyroid autoimmunity: the ovarian follicle hypothesis. *American journal of reproductive immunology (New York, NY : 1989)*2011;66: 108-114.
- 6937 Moral E, Delgado JL, Carmona F, Caballero B, Guillán C, González PM, Suárez-Almarza J, Velasco-Ortega S, Nieto C.
 6938 Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study.
 6939 *Climacteric : the journal of the International Menopause Society* 2018;21: 167-173.
- 6940 Mørch LS, Løkkegaard E, Andreasen AH, Kjær SK, Lidegaard Ø. Hormone therapy and ovarian borderline tumors: a national cohort study. *Cancer causes & control : CCC* 2012;23: 113-120.
- Morga A, Ajmera M, Gao E, Patterson-Lomba O, Zhao A, Mancuso S, Siddiqui E, Kagan R. Systematic review and network meta analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor
 symptoms due to menopause. *Menopause (New York, NY)* 2024;31: 68-76.
- 6945 Morgan O, Belda R, Schnur J, Montgomery G, Parmar S, Chirivella I, Cano A. Prophylactic mastectomy and bilateral salpingo 6946 oophorectomy in patients with breast cancer: a systematic review of postsurgical sexual function and menopausal hormone
 6947 therapy symptom mitigation. *Sexual medicine reviews* 2023;12: 3-13.
- 6948 Morris DH, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ. Familial concordance for age at natural menopause: results 6949 from the Breakthrough Generations Study. *Menopause (New York, NY)* 2011;18: 956-961.
- Morrison JC, Givens JR, Wiser WL, Fish SA. Mumps oophoritis: a cause of premature menopause. *Fertility and sterility* 1975;26:
 655-659.
- 6952 Moses-Kolko EL, Berga SL, Kalro B, Sit DK, Wisner KL. Transdermal estradiol for postpartum depression: a promising treatment
 6953 option. *Clinical obstetrics and gynecology* 2009;52: 516-529.
- 6954 Moss KM, Mishra GD, Krejany EO, Hickey M. What happens after menopause? (WHAM): A prospective controlled study of 6955 symptom profiles up to 12 months after pre-menopausal risk-reducing salpingo-oophorectomy. *Gynecol Oncol* 2022.
- 6956 Moukhah S, Ghorbani B, Behboodi-Moghadam Z, Zafardoust S. Perceptions and experiences of women with premature ovarian 6957 insufficiency about sexual health and reproductive health. *BMC Womens Health* 2021;21: 54.
- Moukhah S, Ghorbani B, Behboodi Moghadam Z, Zafardoust S, Haji Parvaneh A, Alinaghi E, Moukhah R. Perception of Female
 Identity in Women with Premature Ovarian Insufficiency: A Qualitative Study. *Journal of reproduction & infertility* 2023;24: 4957.
- Mueck AO. Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and
 micronized progesterone. *Climacteric : the journal of the International Menopause Society* 2012;15 Suppl 1: 11-17.
- 6963 Muka T, Oliver-Williams C, Kunutsor S, Laven JS, Fauser BC, Chowdhury R, Kavousi M, Franco OH. Association of Age at Onset
- 6964 of Menopause and Time Since Onset of Menopause With Cardiovascular Outcomes, Intermediate Vascular Traits, and All 6965 Cause Mortality: A Systematic Review and Meta-analysis. JAMA cardiology 2016;1: 767-776.



- 6966 Mytton J, Evison F, Chilton PJ, Lilford RJ. Removal of all ovarian tissue versus conserving ovarian tissue at time of hysterectomy 6967 in premenopausal patients with benign disease: study using routine data and data linkage. *BMJ* 2017;356: j372.
- Nabhan ZM, Dimeglio LA, Qi R, Perkins SM, Eugster EA. Conjugated oral versus transdermal estrogen replacement in girls with
 Turner syndrome: a pilot comparative study. *The Journal of clinical endocrinology and metabolism* 2009;94: 2009-2014.
- 6970 Nachtigall L, Casson P, Lucas J, Schofield V, Melson C, Simon JA. Safety and tolerability of testosterone patch therapy for up to
 6971 4 years in surgically menopausal women receiving oral or transdermal oestrogen. *Gynecol Endocrinol* 2011;27: 39-48.
- 6972 Nadesapillai S, van der Velden J, van der Coelen S, Schleedoorn M, Sedney A, Spath M, Schurink M, Oerlemans A, IntHout J,
- Beerendonk I *et al.* TurnerFertility trial: fertility preservation in young girls with Turner syndrome by freezing ovarian cortex
 tissue-a prospective intervention study. *Fertility and sterility* 2023;120: 1048-1060.
- 6975 Naessén S, Bergström I, Ljungman P, Landgren BM. Long-term follow-up of bone density, general and reproductive health in 6976 female survivors after treatment for haematological malignancies. *European journal of haematology* 2014;93: 137-142.
- 6976 female survivors after treatment for haematological malignancies. *European journal of haematology* 2014;93: 137-142.
 6977 Najaf Najafi M, Ghazanfarpour M. Effect of phytoestrogens on sexual function in menopausal women: a systematic review and
 6978 meta-analysis. *Climacteric : the journal of the International Menopause Society* 2018;21: 437-445.
- Nakajima T, Iwasawa K, Oonuma H, Morita T, Goto A, Wang Y, Hazama H. Antiarrhythmic effect and its underlying ionic
 mechanism of 17beta-estradiol in cardiac myocytes. *British journal of pharmacology* 1999;127: 429-440.
- Nakamura T, Tsuburai T, Tokinaga A, Nakajima I, Kitayama R, Imai Y, Nagata T, Yoshida H, Hirahara F, Sakakibara H. Efficacy of
 estrogen replacement therapy (ERT) on uterine growth and acquisition of bone mass in patients with Turner syndrome. *Endocrine journal* 2015;62: 965-970.
- Naletto L, Frigo AC, Ceccato F, Sabbadin C, Scarpa R, Presotto F, Dalla Costa M, Faggian D, Plebani M, Censi S *et al.* The natural
 history of autoimmune Addison's disease from the detection of autoantibodies to development of the disease: a long-term
 follow-up study on 143 patients. *Eur J Endocrinol* 2019;180: 223-234.
- Naleway AL, Mittendorf KF, Irving SA, Henninger ML, Crane B, Smith N, Daley MF, Gee J. Primary Ovarian Insufficiency and
 Adolescent Vaccination. *Pediatrics* 2018;142.
- 6989 Nappi RE, Cucinella L, Martini E, Cassani C. The role of hormone therapy in urogenital health after menopause. *Best practice* 6990 & *research Clinical endocrinology & metabolism* 2021;35: 101595.
- Nappi RE, Cucinella L, Martini E, Rossi M, Tiranini L, Martella S, Bosoni D, Cassani C. Sexuality in premature ovarian insufficiency.
 Climacteric : the journal of the International Menopause Society 2019;22: 289-295.
- Nappi RE, Martella S, Albani F, Cassani C, Martini E, Landoni F. Hyaluronic Acid: A Valid Therapeutic Option for Early
 Management of Genitourinary Syndrome of Menopause in Cancer Survivors? *Healthcare (Basel, Switzerland)* 2022a;10.
- Nappi RE, Tiranini L, Cucinella L, Martini E, Bosoni D, Righi A, Cassani C, Gardella B. Pharmacotherapy for female sexual dysfunctions (FSDs): what is on the market and where is this field heading? *Expert opinion on pharmacotherapy* 2023a;24: 135-143.
- 6998 Nappi RE, Tiranini L, Martini E, Bosoni D, Cassani C, Cucinella L. Different local estrogen therapies for a tailored approach to 6999 GSM. *Climacteric : the journal of the International Menopause Society* 2023b;26: 361-366.
- Nappi RE, Tiranini L, Martini E, Bosoni D, Righi A, Cucinella L. Medical Treatment of Female Sexual Dysfunction. *The Urologic clinics of North America* 2022b;49: 299-307.
- 7002 Nappi RE, Tiranini L, Sacco S, De Matteis E, De Icco R, Tassorelli C. Role of Estrogens in Menstrual Migraine. *Cells* 2022c;11.
- 7003 Nash Z, Davies M. Premature ovarian insufficiency. *Bmj* 2024;384: e077469.
- Nebgen DR, Domchek SM, Kotsopoulos J, de Hullu JA, Crosbie EJ, Paramanandam VS, Brood-van Zanten MMA, Norquist BM,
 Guise T, Rozenberg S *et al.* Care after premenopausal risk-reducing salpingo-oophorectomy in high-risk women: Scoping
 review and international consensus recommendations. *Bjog* 2023;130: 1437-1450.
- 7007 Nelson LM. Clinical practice. Primary ovarian insufficiency. *N Engl J Med* 2009;360: 606-614.
- 7008 Nelson SM, Davis SR, Kalantaridou S, Lumsden MA, Panay N, Anderson RA. Anti-Müllerian hormone for the diagnosis and prediction of menopause: a systematic review. *Human reproduction update* 2023;29: 327-346.
- Nguyen HH, Wong P, Strauss BJ, Ebeling PR, Milat F, Vincent A. A Cross-Sectional and Longitudinal Analysis of Trabecular Bone
 Score in Adults With Turner Syndrome. *The Journal of clinical endocrinology and metabolism* 2018;103: 3792-3800.
- Nguyen HH, Wong P, Strauss BJ, Jones G, Ebeling PR, Milat F, Vincent A. Delay in estrogen commencement is associated with
 lower bone mineral density in Turner syndrome. *Climacteric : the journal of the International Menopause Society* 2017;20:
 436-441.
- Nguyen TM, Do TTT, Tran TN, Kim JH. Exercise and Quality of Life in Women with Menopausal Symptoms: A Systematic Review
 and Meta-Analysis of Randomized Controlled Trials. *Int J Environ Res Public Health* 2020;17.
- 7017 Nguyen TTB, Hsu YY, Sari YP. The Effect of Pelvic Floor Muscle Training on Health-Related Quality of Life in Postmenopausal
 7018 Women With Genitourinary Syndrome: A Systematic Review and Meta-Analysis. *The journal of nursing research : JNR* 2024;32:
 7019 e316.
- NICE. Menopause: diagnosis and management. NICE guideline [NG23] <u>https://wwwniceorguk/quidance/ng23</u> 2015;Published:
 12 November 2015 Last updated: 05 December 2019.
- NICE. Summary of evidence for 2019 surveillance of menopause (2015) NICE guideline NG23.
 <u>https://wwwniceorguk/consultations/672/10/diagnosing-and-managing-premature-ovarian-insufficiency#diagnosing-and-managing-premature-ovarian-insufficiency</u> 2019.
- 7025 NICE clinical Guideline. Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. 2010.
- Nielsen BF, Schmidt AA, Mulvihill JJ, Frederiksen K, Tawn EJ, Stovall M, Johansen C, Boice JD, Jr., Winther JF. Chromosomal
 Abnormalities in Offspring of Young Cancer Survivors: A Population-Based Cohort Study in Denmark. J Natl Cancer Inst
 2018;110: 534-538.



- Nolan M, Oikonomou EK, Silversides CK, Hines MR, Thompson KA, Campbell BA, Amir E, Maxwell C, Thavendiranathan P. Impact
 of Cancer Therapy-Related Cardiac Dysfunction on Risk of Heart Failure in Pregnancy. *JACC CardioOncology* 2020;2: 153-162.
- Noll P, Campos CAS, Leone C, Zangirolami-Raimundo J, Noll M, Baracat EC, Júnior JMS, Sorpreso ICE. Dietary intake and
 menopausal symptoms in postmenopausal women: a systematic review. *Climacteric : the journal of the International Menopause Society* 2021;24: 128-138.
- Nordenström A, Ahmed SF, van den Akker E, Blair J, Bonomi M, Brachet C, Broersen LHA, Claahsen-van der Grinten HL, Dessens
 AB, Gawlik A *et al.* Pubertal induction and transition to adult sex hormone replacement in patients with congenital pituitary or
 gonadal reproductive hormone deficiency: an Endo-ERN clinical practice guideline. *Eur J Endocrinol* 2022;186: G9-g49.
- 7037 North American Menopause Society. Management of osteoporosis in postmenopausal women: the 2021 position statement
 7038 of The North American Menopause Society. *Menopause (New York, NY)* 2021;28: 973-997.
- 7039 North American Menopause Society. The 2022 hormone therapy position statement of The North American Menopause 7040 Society. *Menopause (New York, NY)* 2022;29: 767-794.
- North American Menopause Society. The 2023 nonhormone therapy position statement of The North American Menopause
 Society. *Menopause (New York, NY)* 2023;30: 573-590.
- Novosad JA, Kalantaridou SN, Tong ZB, Nelson LM. Ovarian antibodies as detected by indirect immunofluorescence are
 unreliable in the diagnosis of autoimmune premature ovarian failure: a controlled evaluation. *BMC Womens Health* 2003;3:
 2.
- Nunes PRP, Castro ESP, de Oliveira AA, Camilo BF, Cristina-Souza G, Vieira-Souza LM, Carneiro M. Effect of resistance training
 volume on body adiposity, metabolic risk, and inflammation in postmenopausal and older females: Systematic review and
 meta-analysis of randomized controlled trials. *Journal of sport and health science* 2023.
- 7049 O'Donnell RL, Clement KM, Edmondson RJ. Hormone replacement therapy after treatment for a gynaecological malignancy.
 7050 *Current opinion in obstetrics & gynecology* 2016;28: 32-41.
- O'Donnell RL, Warner P, Lee RJ, Walker J, Bath LE, Kelnar CJ, Wallace WH, Critchley HO. Physiological sex steroid replacement
 in premature ovarian failure: randomized crossover trial of effect on uterine volume, endometrial thickness and blood flow,
 compared with a standard regimen. *Human reproduction (Oxford, England)* 2012;27: 1130-1138.
- O'Donoghue S, Green T, Ross JL, Hallmayer J, Lin X, Jo B, Huffman LC, Hong DS, Reiss AL. Brain Development in School-Age and
 Adolescent Girls: Effects of Turner Syndrome, Estrogen Therapy, and Genomic Imprinting. *Biological psychiatry* 2020;87: 113 122.
- 7057 O CP, Manyonda I. The surgical menopause. Best practice & research Clinical obstetrics & gynaecology 2022;81: 111-118.
- 7058 Obara-Moszynska M, Dzialach L, Rabska-Pietrzak B, Niedziela M, Kapczuk K. Uterine Development During Induced Puberty in 7059 Girls with Turner Syndrome. *Frontiers in endocrinology* 2021;12: 707031.
- 7060 Okoth K, Chandan JS, Marshall T, Thangaratinam S, Thomas GN, Nirantharakumar K, Adderley NJ. Association between the 7061 reproductive health of young women and cardiovascular disease in later life: umbrella review. *Bmj* 2020;371: m3502.
- 7062 Okumura A, Kondo E, Kubo-Kaneda M, Yoshida K, Ikeda T. Efficacy of minodronic acid for the prevention of osteoporosis in
 7063 premenopausal women with gynaecologic disease who undergo bilateral oophorectomy: a single-centre, non-randomised
 7064 controlled, experimental study. *Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and* 7065 *Gynaecology* 2022;42: 3591-3599.
- 7066 Ornello R, Frattale I, Caponnetto V, Pistoia F, Sacco S. Cerebral vascular reactivity and the migraine-stroke relationship: A 7067 narrative review. *Journal of the neurological sciences* 2020;414: 116887.
- 7068 Orshan SA, Ventura JL, Covington SN, Vanderhoof VH, Troendle JF, Nelson LM. Women with spontaneous 46,XX primary
 7069 ovarian insufficiency (hypergonadotropic hypogonadism) have lower perceived social support than control women. *Fertility* 7070 *and sterility* 2009;92: 688-<u>6</u>93.
- 7071 Ostberg JE, Storry C, Donald AE, Attar MJ, Halcox JP, Conway GS. A dose-response study of hormone replacement in young 7072 hypogonadal women: effects on intima media thickness and metabolism. *Clinical endocrinology* 2007;66: 557-564.
- 7073 Osuka S, Iwase A, Goto M, Takikawa S, Nakamura T, Murase T, Kato N, Kotani T, Kikkawa F. Thyroid Autoantibodies do not
 7074 Impair the Ovarian Reserve in Euthyroid Infertile Women: A Cross-Sectional Study. *Hormone and metabolic research =* 7075 *Hormon- und Stoffwechselforschung = Hormones et metabolisme* 2018;50: 537-542.
- 7076 Otero UB, Chor D, Carvalho MS, Faerstein E, Lopes Cde S, Werneck GL. Lack of association between age at menarche and age 7077 at menopause: Pro-Saude Study, Rio de Janeiro, Brazil. *Maturitas* 2010;67: 245-250.
- 7078 Otsuka N, Tong ZB, Vanevski K, Tu W, Cheng MH, Nelson LM. Autoimmune oophoritis with multiple molecular targets mitigated
 7079 by transgenic expression of mater. *Endocrinology* 2011;152: 2465-2473.
- 7080 Ouyang P, Michos ED, Karas RH. Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions. *Journal of the American College of Cardiology* 2006;47: 1741-1753.
- 7082 Oyesanya OA, Olufowobi O, Ross W, Sharif K, Afnan M. Prognosis of oocyte donation cycles: a prospective comparison of the
 7083 in vitro fertilization-embryo transfer cycles of recipients who used shared oocytes versus those who used altruistic donors.
 7084 *Fertility and sterility* 2009;92: 930-936.
- 7085 Özbek MN, Demirbilek H, Baran RT, Baran A. Bone Mineral Density in Adolescent Girls with Hypogonadotropic and
 7086 Hypergonadotropic Hypogonadism. *Journal of clinical research in pediatric endocrinology* 2016;8: 163-169.
- Pacello PC, Yela DA, Rabelo S, Giraldo PC, Benetti-Pinto CL. Dyspareunia and lubrication in premature ovarian failure using
 hormonal therapy and vaginal health. *Climacteric : the journal of the International Menopause Society* 2014;17: 342-347.
- Palacios S, Hood S, Abakah-Phillips T, Savania N, Krychman M. A randomized trial on the effectiveness and safety of 5 water based personal lubricants. *The journal of sexual medicine* 2023a;20: 498-506.



- 7091 Palacios S, Nappi RE, Cancelo MJ, Sánchez S, Simoncini T. Expert opinion on the treatment of vulvovaginal atrophy with 7092 ospemifene based on new evidence. Climacteric : the journal of the International Menopause Society 2023b;26: 388-391.
- 7093 Pan ML, Chen LR, Tsao HM, Chen KH. Polycystic ovarian syndrome and the risk of subsequent primary ovarian insufficiency: a 7094 nationwide population-based study. Menopause (New York, NY) 2017;24: 803-809.
- 7095 Pan W, Ye X, Yin S, Ma X, Li C, Zhou J, Liu W, Liu J. Selected persistent organic pollutants associated with the risk of primary 7096 ovarian insufficiency in women. Environment international 2019;129: 51-58.
- 7097 Pan W, Ye X, Zhu Z, Li C, Zhou J, Liu J. A case-control study of arsenic exposure with the risk of primary ovarian insufficiency in 7098 women. Environmental science and pollution research international 2020;27: 25220-25229.
- 7099 Pan W, Ye X, Zhu Z, Li C, Zhou J, Liu J. Urinary cadmium concentrations and risk of primary ovarian insufficiency in women: a 7100 case-control study. Environmental geochemistry and health 2021;43: 2025-2035.
- 7101 Panay N, Al-Azzawi F, Bouchard C, Davis SR, Eden J, Lodhi I, Rees M, Rodenberg CA, Rymer J, Schwenkhagen A et al. 7102 Testosterone treatment of HSDD in naturally menopausal women: the ADORE study. Climacteric : the journal of the 7103 International Menopause Society 2010;13: 121-131.
- 7104 Panay N, Anderson RA, Nappi RE, Vincent AJ, Vujovic S, Webber L, Wolfman W. Premature ovarian insufficiency: an 7105 International Menopause Society White Paper. Climacteric : the journal of the International Menopause Society 2020;23: 426-7106 446.
- 7107 Panay N, Nappi RE, Stute P, Palacios S, Paszkowski T, Kagan R, Archer DF, Héroux J, Boolell M. Oral estradiol/micronized 7108 progesterone may be associated with lower risk of venous thromboembolism compared with conjugated equine 7109 estrogens/medroxyprogesterone acetate in real-world practice. Maturitas 2023;172: 23-31.
- 7110 Panay N, Versi E, Savvas M. A comparison of 25 mg and 50 mg oestradiol implants in the control of climacteric symptoms 7111
- following hysterectomy and bilateral salpingo-oophorectomy. *BJOG* 2000;107: 1012-1016. Parish SJ, Hahn SR, Goldstein SW, Giraldi A, Kingsberg SA, Larkin L, Minkin MJ, Brown V, Christiansen K, Hartzell-Cushanick R 7112 et al. The International Society for the Study of Women's Sexual Health Process of Care for the Identification of Sexual Concerns 7113
- 7114
- and Problems in Women. *Mayo Clinic proceedings Mayo Clinic* 2019;94: 842-856. Parish SJ, Simon JA, Davis SR, Giraldi A, Goldstein I, Goldstein SW, Kim NN, Kingsberg SA, Morgentaler A, Nappi RE *et al.* 7115 7116 International Society for the Study of Women's Sexual Health Clinical Practice Guideline for the Use of Systemic Testosterone 7117 for Hypoactive Sexual Desire Disorder in Women. The journal of sexual medicine 2021;18: 849-867.
- 7118 Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, Shoupe D, Berek JS, Hankinson S, Manson JE. Ovarian 7119 conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstetrics and 7120 gynecology 2009a;113: 1027-1037.
- 7121 Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM, Berek JS, Manson JE. Long-term mortality associated 7122 with oophorectomy compared with ovarian conservation in the nurses' health study. Obstetrics and gynecology 2013;121: 7123 709-716.
- Parker WH, Jacoby V, Shoupe D, Rocca W. Effect of bilateral oophorectomy on women's long-term health. Womens Health 7124 7125 (Lond Engl) 2009b;5: 565-576.
- Parrish HM, Carr CA, Hall DG, King TM. Time interval from castration in premenopausal women to development of excessive 7126 7127 coronary atherosclerosis. American journal of obstetrics and gynecology 1967;99: 155-162.
- 7128 Paterson WF, Hollman AS, Donaldson MD. Poor uterine development in Turner syndrome with oral oestrogen therapy. Clinical 7129 endocrinology 2002;56: 359-365.
- 7130 Patiño LC, Beau I, Carlosama C, Buitrago JC, González R, Suárez CF, Patarroyo MA, Delemer B, Young J, Binart N et al. New 7131 mutations in non-syndromic primary ovarian insufficiency patients identified via whole-exome sequencing. Human 7132 reproduction (Oxford, England) 2017;32: 1512-1520.
- 7133 Patricia Wodi A, Marquez P, Mba-Jonas A, Barash F, Nguon K, Moro PL. Spontaneous reports of primary ovarian insufficiency 7134 after vaccination: A review of the vaccine adverse event reporting system (VAERS). Vaccine 2023;41: 1616-1622.
- 7135 Pearce G, Thøgersen-Ntoumani C, Duda JL, McKenna J. Changing Bodies: Experiences of Women Who Have Undergone a 7136 Surgically Induced Menopause. Qualitative health research 2014;24: 738-748.
- 7137 Pellicer N, Cozzolino M, Diaz-García C, Galliano D, Cobo A, Pellicer A, Herraiz S. Ovarian rescue in women with premature 7138 ovarian insufficiency: facts and fiction. Reprod Biomed Online 2023;46: 543-565.
- 7139 Persani L, Cools M, Ioakim S, Faisal Ahmed S, Andonova S, Avbelj-Stefanija M, Baronio F, Bouligand J, Bruggenwirth HT, Davies 7140 JH et al. The genetic diagnosis of rare endocrine disorders of sex development and maturation: a survey among Endo-ERN 7141 centres. Endocrine connections 2022;11.
- 7142 Persani L, Rossetti R, Cacciatore C, Bonomi M. Primary Ovarian Insufficiency: X chromosome defects and autoimmunity. Journal 7143 of autoimmunity 2009;33: 35-41.
- 7144 Pesce G, Artaud F, Roze E, Degaey I, Portugal B, Nguyen TTH, Fournier A, Boutron-Ruault MC, Severi G, Elbaz A et al. 7145 Reproductive characteristics, use of exogenous hormones and Parkinson disease in women from the E3N study. Brain : a 7146 journal of neurology 2023;146: 2535-2546.
- 7147 Peycheva D, Sullivan A, Hardy R, Bryson A, Conti G, Ploubidis G. Risk factors for natural menopause before the age of 45: 7148 evidence from two British population-based birth cohort studies. BMC Womens Health 2022;22: 438.
- 7149 Piccioni P, Scirpa P, D'Emilio I, Sora F, Scarciglia M, Laurenti L, De Matteis S, Sica S, Leone G, Chiusolo P. Hormonal replacement 7150 therapy after stem cell transplantation. Maturitas 2004;49: 327-333.
- 7151 Pires ES, Khole VV. A block in the road to fertility: autoantibodies to heat-shock protein 90-beta in human ovarian 7152 autoimmunity. Fertility and sterility 2009;92: 1395-1409.



- 7153 Pirimoglu ZM, Ozyapi AG, Kars B, Buyukbayrak EE, Solak Y, Karsidag AY, Unal O, Turan MC. Comparing the effects of intrauterine
- progestin system and oral progestin on health-related quality of life and Kupperman index in hormone replacement therapy.
 The journal of obstetrics and gynaecology research 2011;37: 1376-1381.
- 7156 Pitkin J, Rees MC, Gray S, Lumsden MA, Marsden J, Stevenson JC, Williamson J. Management of premature menopause. 7157 *Menopause international* 2007;13: 44-45.
- 7158 Podfigurna-Stopa A, Czyzyk A, Grymowicz M, Smolarczyk R, Katulski K, Czajkowski K, Meczekalski B. Premature ovarian 7159 insufficiency: the context of long-term effects. *Journal of endocrinological investigation* 2016;39: 983-990.
- Podfigurna A, Maciejewska-Jeske M, Nadolna M, Mikolajska-Ptas P, Szeliga A, Bilinski P, Napierala P, Meczekalski B. Impact of
 Hormonal Replacement Therapy on Bone Mineral Density in Premature Ovarian Insufficiency Patients. *Journal of clinical*
- 7161 Hormonal Replace 7162 *medicine* 2020;9.
- 7163 Poggio F, Del Mastro L, Bruzzone M, Ceppi M, Razeti MG, Fregatti P, Ruelle T, Pronzato P, Massarotti C, Franzoi MA *et al.* Safety
- 7164 of systemic hormone replacement therapy in breast cancer survivors: a systematic review and meta-analysis. *Breast cancer*
- **7165** *research and treatment* 2022;191: 269-275.
- Pokoradi AJ, Iversen L, Hannaford PC. Factors associated with age of onset and type of menopause in a cohort of UK women.
 American journal of obstetrics and gynecology 2011;205: 34 e31-13.
- 7168 Popat VB, Calis KA, Kalantaridou SN, Vanderhoof VH, Koziol D, Troendle JF, Reynolds JC, Nelson LM. Bone mineral density in
- 7169 young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological 7170 transdermal estradiol and testosterone replacement. *The Journal of clinical endocrinology and metabolism* 2014;99: 3418-
- 7171 3426.
- Popat VB, Calis KA, Vanderhoof VH, Cizza G, Reynolds JC, Sebring N, Troendle JF, Nelson LM. Bone mineral density in estrogen deficient young women. *The Journal of clinical endocrinology and metabolism* 2009;94: 2277-2283.
- Popat VB, Vanderhoof VH, Calis KA, Troendle JF, Nelson LM. Normalization of serum luteinizing hormone levels in women with
 46,XX spontaneous primary ovarian insufficiency *Fertility and sterility*. 2008, pp. 429-433.
- 7176 Poppe K, Velkeniers B, Glinoer D. The role of thyroid autoimmunity in fertility and pregnancy. *Nature clinical practice* 7177 *Endocrinology & metabolism* 2008;4: 394-405.
- 7178 Practice Committee of American Society For Reproductive Medicine. Increased maternal cardiovascular mortality associated 7179 with pregnancy in women with Turner syndrome. *Fertility and sterility* 2012;97: 282-284.
- Price SAL, Finch S, Krejany E, Jiang H, Kale A, Domchek S, Wrede D, Wark JD, Hickey M. WHAM-A Prospective Study of Weight
 and Body Composition After Risk-Reducing Bilateral Salpingo-oophorectomy. *The Journal of clinical endocrinology and*
- 7182 *metabolism* 2023;109: e397-e405.
- Prince C, Sharp GC, Howe LD, Fraser A, Richmond RC. The relationships between women's reproductive factors: a Mendelian
 randomisation analysis. *BMC medicine* 2022;20: 103.
- Pyri F, Abedi P, Maraghi E, Jefreh MG. The Effect of Mindfulness on Quality of Life among Women with Premature Ovarian
 Insufficiency: A Randomized Clinical Trial. *Journal of mid-life health* 2021;12: 116-121.
- Rada G, Capurro D, Pantoja T, Corbalan J, Moreno G, Letelier LM, Vera C. Non-hormonal interventions for hot flushes in women
 with a history of breast cancer. *Cochrane Database Syst Rev* 2010: CD004923.
- Radnia N, Hosseini ST, Vafaei SY, Pirdehghan A, Mehrabadi NL. The effect of conjugated estrogens vaginal cream and a combined vaginal cream of vitamins D and E in the treatment of genitourinary syndrome. *Journal of family medicine and primary care* 2023;12: 507-516.
- 7192 Raffi F, Metwally M, Amer S. The impact of excision of ovarian endometrioma on ovarian reserve: a systematic review and 7193 meta-analysis. *The Journal of clinical endocrinology and metabolism* 2012;97: 3146-3154.
- Rafique S, Sterling EW, Nelson LM. A new approach to primary ovarian insufficiency. *Obstetrics and gynecology clinics of North America* 2012;39: 567-586.
- 7196 Rahal I, Galambrun C, Bertrand Y, Garnier N, Paillard C, Frange P, Pondarré C, Dalle JH, de Latour RP, Michallet M et al. Late
- 7197 effects after hematopoietic stem cell transplantation for β-thalassemia major: the French national experience. *Haematologica* 7198 2018;103: 1143-1149.
- Rahman R, Panay N. Diagnosis and management of premature ovarian insufficiency. Best practice & research Clinical
 endocrinology & metabolism 2021;35: 101600.
- Rahman SA, Nathan MD, Wiley A, Crawford S, Cohn AY, Harder JA, Grant LK, Erickson A, Srivastava A, McCormick K *et al.* A
 double-blind, randomized, placebo-controlled trial of suvorexant for the treatment of vasomotor symptom-associated
 insomnia disorder in midlife women. *Sleep* 2022;45.
- Rajman I, Lip GY, Cramb R, Maxwell SR, Zarifis J, Beevers DG, Kendall MJ. Adverse change in low-density lipoprotein
 subfractions profile with oestrogen-only hormone replacement therapy. *QJM : monthly journal of the Association of Physicians*1996;89: 771-778.
- 7207 Ratcliffe MA, Lanham SA, Reid DM, Dawson AA. Bone mineral density (BMD) in patients with lymphoma: the effects of chemotherapy, intermittent corticosteroids and premature menopause. *Hematological oncology* 1992;10: 181-187.
- Rauh LA, Pannone AF, Cantrell LA. Hormone replacement therapy after treatment for cervical cancer: Are we adhering to standard of care? *Gynecol Oncol* 2017;147: 597-600.
- 7211 Reato G, Morlin L, Chen S, Furmaniak J, Smith BR, Masiero S, Albergoni MP, Cervato S, Zanchetta R, Betterle C. Premature 7212 ovarian failure in patients with autoimmune Addison's disease: clinical, genetic, and immunological evaluation. *The Journal of*
- 7213 *clinical endocrinology and metabolism* 2011;96: E1255-1261.
- Rebar RW, Connolly HV. Clinical features of young women with hypergonadotropic amenorrhea. *Fertility and sterility* 1990;53:
 804-810.



- Rebbeck TR, Mitra N, Domchek SM, Wan F, Chuai S, Friebel TM, Panossian S, Spurdle A, Chenevix-Trench G, Singer CF *et al.* Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. *Cancer Res* 2009;69: 5801-5810.
- 7219 Reed S, Koro C, DiBello J, Becker K, Bauerfeind A, Franke C, Heinemann K. Prospective controlled cohort study on the safety of
- 7220 a monophasic oral contraceptive containing nomegestrol acetate (2.5mg) and 17β-oestradiol (1.5mg) (PRO-E2 study): risk of 7221 venous and arterial thromboembolism. *The European journal of contraception & reproductive health care : the official journal*
- 7222 of the European Society of Contraception 2021;26: 439-446.
- Rees M, Angioli R, Coleman RL, Glasspool R, Plotti F, Simoncini T, Terranova C. European Menopause and Andropause Society
 (EMAS) and International Gynecologic Cancer Society (IGCS) position statement on managing the menopause after
 gynecological cancer: focus on menopausal symptoms and osteoporosis. *Maturitas* 2020;134: 56-61.
- 7226 Rees MC. Premature menopause: Hormone replacement therapy is indeed indicated. *BMJ* 2008;336: 1148.
- 7227 Rehm HL, Bale SJ, Bayrak-Toydemir P, Berg JS, Brown KK, Deignan JL, Friez MJ, Funke BH, Hegde MR, Lyon E. ACMG clinical
- 7228 laboratory standards for next-generation sequencing. *Genetics in medicine : official journal of the American College of Medical* 7229 *Genetics* 2013;15: 733-747.
- Ren J, Hintz KK, Roughead ZK, Duan J, Colligan PB, Ren BH, Lee KJ, Zeng H. Impact of estrogen replacement on ventricular
 myocyte contractile function and protein kinase B/Akt activation. *American journal of physiology Heart and circulatory physiology* 2003;284: H1800-1807.
- Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a populationbased study. *J Thromb Haemost* 2010;8: 979-986.
- 7235 Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E et al. Standards and guidelines
- 7236 for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics
- and Genomics and the Association for Molecular Pathology. *Genetics in medicine : official journal of the American College of Medical Genetics* 2015;17: 405-424.
- Richardson A, Haridass SA, Ward E, Ayres J, Baskind NE. Investigation and treatment of premature ovarian insufficiency: A
 multi-disciplinary review of practice. *Post Reprod Health* 2018;24: 155-162.
- Riemma G, Schiattarella A, La Verde M, Zarobbi G, Garzon S, Cucinella G, Calagna G, Labriola D, De Franciscis P. Efficacy of
 Low-Dose Paroxetine for the Treatment of Hot Flushes in Surgical and Physiological Postmenopausal Women: Systematic
 Review and Meta-Analysis of Randomized Trials. *Medicina (Kaunas, Lithuania)* 2019;55.
- 7244 Rios-Espinosa A, Cruz-Luna M, Garmendia-Gallardo C, Hernández-Castañón MY, Hernández-Hernández VY, Sánchez-Tinoco
- PM, Bajonero-Domínguez A, Vergara Lope-Núñez JA, Álvarez-Pérez MA, González-Quiroz JL *et al.* Citalopram improves
 vasomotor syndrome and urogenital syndrome of menopause in Mexican women: a randomized clinical trial. *Archives of gynecology and obstetrics* 2022;306: 2035-2045.
- 7248 Rivera CM, Grossardt BR, Rhodes DJ, Brown RD, Jr., Roger VL, Melton LJ, 3rd, Rocca WA. Increased cardiovascular mortality 7249 after early bilateral oophorectomy. *Menopause (New York, NY)* 2009a;16: 15-23.
- Rivera CM, Grossardt BR, Rhodes DJ, Rocca WA. Increased mortality for neurological and mental diseases following early
 bilateral oophorectomy. *Neuroepidemiology* 2009b;33: 32-40.
- Robinson RW, Higano N, Cohen WD. Increased incidence of coronary heart disease in women castrated prior to the menopause. *Archives of internal medicine* 1959;104: 908-913.
- Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, Melton LJ, 3rd. Increased risk of cognitive
 impairment or dementia in women who underwent oophorectomy before menopause. *Neurology* 2007;69: 1074-1083.
- 7256 Rocca WA, Faubion SS. Estrogen and dementia. *Maturitas* 2022;165: 120-121.
- 7257 Rocca WA, Gazzuola Rocca L, Smith CY, Kapoor E, Faubion SS, Stewart EA. Frequency and type of premature or early 7258 menopause in a geographically defined American population. *Maturitas* 2023;170: 22-30.
- 7259 Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ, 3rd. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. *The Lancet Oncology* 2006;7: 821-828.
- 7261 Rocca WA, Grossardt BR, Geda YE, Gostout BS, Bower JH, Maraganore DM, de Andrade M, Melton LJ, 3rd. Long-term risk of 7262 depressive and anxiety symptoms after early bilateral oophorectomy. *Menopause (New York, NY)* 2008;15: 1050-1059.
- Rocca WA, Grossardt BR, Miller VM, Shuster LT, Brown RD, Jr. Premature menopause or early menopause and risk of ischemic
 stroke. *Menopause (New York, NY)* 2012a;19: 272-277.
- Rocca WA, Grossardt BR, Shuster LT. Oophorectomy, estrogen, and dementia: a 2014 update. *Molecular and cellular endocrinology* 2014;389: 7-12.
- 7267 Rocca WA, Grossardt BR, Shuster LT, Stewart EA. Hysterectomy, oophorectomy, estrogen, and the risk of dementia. *Neuro-*7268 *degenerative diseases* 2012b;10: 175-178.
- Rocca WA, Lohse CM, Smith CY, Fields JA, Machulda MM, Mielke MM. Association of Premenopausal Bilateral Oophorectomy
 With Cognitive Performance and Risk of Mild Cognitive Impairment. JAMA Netw Open 2021a;4: e2131448.
- 7271 Rocca WA, Mielke MM, Gazzuola Rocca L, Stewart EA. Premature or early bilateral oophorectomy: a 2021 update. *Climacteric* 7272 : the journal of the International Menopause Society 2021b;24: 466-473.
- Rocca WA, Smith CY, Gazzuola Rocca L, Savica R, Mielke MM. Association of Premenopausal Bilateral Oophorectomy With Parkinsonism and Parkinson Disease. *JAMA Netw Open* 2022;5: e2238663.
- 7275 Rodari G, Federici S, Todisco T, Ubertini G, Cattoni A, Pagano M, Giacchetti F, Profka E, Citterio V, Messetti D et al. Towards an
- individualized management of pubertal induction in girls with hypogonadism: insight into the best replacement outcomes
 from a large multicentre registry. *Eur J Endocrinol* 2023;188: 467-476.



- Roland N, Neumann A, Hoisnard L, Duranteau L, Froelich S, Zureik M, Weill A. Use of progestogens and the risk of intracranial
 meningioma: national case-control study. *Bmj* 2024;384: e078078.
- 7280 Roman Lay AA, do Nascimento CF, Horta BL, Dias Porto Chiavegatto Filho A. Reproductive factors and age at natural 7281 menopause: A systematic review and meta-analysis. *Maturitas* 2020;131: 57-64.
- Romualdi D, Ata B, Bhattacharya S, Bosch E, Costello M, Gersak K, Homburg R, Mincheva M, Norman RJ, Piltonen T *et al.*Evidence-based guideline: unexplained infertility[†]. *Human reproduction (Oxford, England)* 2023;38: 1881-1890.
- Rosario R, Anderson RA. Novel approaches to fertility restoration in women with premature ovarian insufficiency. *Climacteric : the journal of the International Menopause Society* 2021;24: 491-497.
- 7286 Ross J, Zinn A, McCauley E. Neurodevelopmental and psychosocial aspects of Turner syndrome. *Mental retardation and developmental disabilities research reviews* 2000;6: 135-141.
- Ross JL, Quigley CA, Cao D, Feuillan P, Kowal K, Chipman JJ, Cutler GB, Jr. Growth hormone plus childhood low-dose estrogen
 in Turner's syndrome. N Engl J Med 2011;364: 1230-1242.
- Ross JL, Roeltgen D, Stefanatos GA, Feuillan P, Kushner H, Bondy C, Cutler Jr GB, Jr. Androgen-responsive aspects of cognition
 in girls with Turner syndrome. *The Journal of clinical endocrinology and metabolism* 2003;88: 292-296.
- Rossetti R, Moleri S, Guizzardi F, Gentilini D, Libera L, Marozzi A, Moretti C, Brancati F, Bonomi M, Persani L. Targeted Next Generation Sequencing Indicates a Frequent Oligogenic Involvement in Primary Ovarian Insufficiency Onset. *Frontiers in endocrinology* 2021;12: 664645.
- 7295 Rozenberg S, Di Pietrantonio V, Vandromme J, Gilles C. Menopausal hormone therapy and breast cancer risk. *Best practice* & 7296 *research Clinical endocrinology* & *metabolism* 2021;35: 101577.
- 7297 Ruiz-Rios M, Maldonado-Martin S. Physical activity on cardiorespiratory fitness and cardiovascular risk in premenopausal and
- 7298 postmenopausal women: a systematic review of randomized controlled trials. *Menopause (New York, NY)* 2022;29: 1222-1229.
- Ruth KS, Day FR, Hussain J, Martínez-Marchal A, Aiken CE, Azad A, Thompson DJ, Knoblochova L, Abe H, Tarry-Adkins JL *et al.*Genetic insights into biological mechanisms governing human ovarian ageing. *Nature* 2021;596: 393-397.
- Ruth KS, Perry JR, Henley WE, Melzer D, Weedon MN, Murray A. Events in Early Life are Associated with Female Reproductive
 Ageing: A UK Biobank Study. *Scientific reports* 2016;6: 24710.
- Ryan J, Scali J, Carrière I, Amieva H, Rouaud O, Berr C, Ritchie K, Ancelin ML. Impact of a premature menopause on cognitive
 function in later life. *Bjog* 2014;121: 1729-1739.
- 7305 Ryan MM, Jones HR, Jr. Myasthenia gravis and premature ovarian failure. *Muscle & nerve* 2004;30: 231-233.
- Ryu KJ, Park H, Jeong Y, Nam S, Jeong HG, Kim T. Age at Menopause and Suicidal Ideation in Menopausal Women: A Study of
 Korea National Health and Nutrition Examination Survey Data. *J Korean Med Sci* 2022;37: e330.
- 7308Sá KMM, da Silva GR, Martins UK, Colovati MES, Crizol GR, Riera R, Pacheco RL, Martimbianco ALC. Resistance training for7309postmenopausal women: systematic review and meta-analysis. *Menopause (New York, NY)* 2023;30: 108-116.
- 7310 Saari V, Holopainen E, Mäkitie O, Laakso S. Pubertal development and premature ovarian insufficiency in patients with APECED.
 7311 *Eur J Endocrinol* 2020;183: 513-520.
- 7312 Sack MN, Rader DJ, Cannon RO, 3rd. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. *Lancet* 1994;343: 269-270.
- Sadeghijoola N, Afshari P, Jofreh MG, Haghighizadeh MH, Abedi P. Comparing the effects of face-to-face versus phone counseling based on cognitive-behavioral therapy for vasomotor symptoms in postmenopausal women: a randomized controlled trial. *Postepy psychiatrii neurologii* 2022;31: 114-120.
- 7317 Sadrzadeh S, Painter RC, van Kasteren YM, Braat DD, Lambalk CB. Premature ovarian insufficiency and perinatal parameters:
 7318 A retrospective case-control study. *Maturitas* 2017;96: 72-76.
- 7319 Saeaib N, Peeyananjarassri K, Liabsuetrakul T, Buhachat R, Myriokefalitaki E. Hormone replacement therapy after surgery for 7320 epithelial ovarian cancer. *Cochrane Database Syst Rev* 2020;1: Cd012559.
- 7321 Safiyeh FD, Mojgan M, Parviz S, Sakineh MA, Behnaz SO. The effect of selenium and vitamin E supplementation on anti7322 Mullerian hormone and antral follicle count in infertile women with occult premature ovarian insufficiency: A randomized
 7323 controlled clinical trial. *Complementary therapies in medicine* 2021;56: 102533.
- Salgin B, Amin R, Yuen K, Williams RM, Murgatroyd P, Dunger DB. Insulin resistance is an intrinsic defect independent of fat mass in women with Turner's syndrome. *Horm Res* 2006;65: 69-75.
- 7326 Samad N, Nguyen HH, Ebeling PR, Milat F. Musculoskeletal Health in Premature Ovarian Insufficiency. Part Two: Bone.
 7327 Seminars in reproductive medicine 2020;38: 289-301.
- Samad N, Nguyen HH, Hashimura H, Pasco J, Kotowicz M, Strauss BJ, Ebeling PR, Milat F, Vincent AJ. Abnormal Trabecular
 Bone Score, Lower Bone Mineral Density and Lean Mass in Young Women With Premature Ovarian Insufficiency Are Prevented
 by Oestrogen Replacement. *Frontiers in endocrinology* 2022;13: 860853.
- Sanders JE, Hawley J, Levy W, Gooley T, Buckner CD, Deeg HJ, Doney K, Storb R, Sullivan K, Witherspoon R *et al.* Pregnancies
 following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow
 transplantation. *Blood* 1996;87: 3045-3052.
- Santoro N, Nappi RE, Neal-Perry G, English M, King DD, Yamaguchi Y, Ottery FD. Fezolinetant treatment of moderate-to-severe
 vasomotor symptoms due to menopause: effect of intrinsic and extrinsic factors in two phase 3 studies (SKYLIGHT 1 and 2).
- 7336 *Menopause (New York, NY)* 2024;31: 247-257.
- 7337 Santos Silva IM, Paula Pinto M, Gonçalves D. Educational Programs and Sexual Counselling for Postmenopausal Sexual
 7338 Dysfunction: A Systematic Review and Meta-Analysis. *The journal of sexual medicine* 2022;19: 54-63.
- 7339 Sassarini J, Lumsden MA, Critchley HO. Sex hormone replacement in ovarian failure new treatment concepts. *Best practice* 7340 & *research Clinical endocrinology & metabolism* 2015;29: 105-114.



- 7341 Sauer MV. Spontaneous pregnancy in women awaiting oocyte donation. J Reprod Med 1995;40: 630-632.
- Sauer MV, Paulson RJ, Ary BA, Lobo RA. Three hundred cycles of oocyte donation at the University of Southern California:
 assessing the effect of age and infertility diagnosis on pregnancy and implantation rates. *Journal of assisted reproduction and genetics* 1994;11: 92-96.
- 7345 Scalco R, Trarbach E, Albuquerque EVA, Homma TK, Inoue-Lima TH, Nishi MY, Mendonca BB, Jorge AAL. ESR1 polymorphism
- (rs2234693) influences femoral bone mass in patients with Turner syndrome. *Endocrine connections* 2019;8: 1513-1519.
- 7347 Schmidt PJ, Cardoso GM, Ross JL, Haq N, Rubinow DR, Bondy CA. Shyness, social anxiety, and impaired self-esteem in Turner
 7348 syndrome and premature ovarian failure. *Jama* 2006;295: 1374-1376.
- 7349 Schmidt PJ, Luff JA, Haq NA, Vanderhoof VH, Koziol DE, Calis KA, Rubinow DR, Nelson LM. Depression in women with 7350 spontaneous 46, XX primary ovarian insufficiency. *The Journal of clinical endocrinology and metabolism* 2011;96: E278-287.
- 7351 Schneider A, Summers S, Tassone F, Seritan A, Hessl D, Hagerman P, Hagerman R. Women with Fragile X-associated 7352 Tremor/Ataxia Syndrome. *Mov Disord Clin Pract* 2020;7: 910-919.
- Schoemaker MJ, Swerdlow AJ, Higgins CD, Wright AF, Jacobs PA. Cancer incidence in women with Turner syndrome in Great
 Britain: a national cohort study. *The Lancet Oncology* 2008;9: 239-246.
- 7355 Schoenaker DA, Jackson CA, Rowlands JV, Mishra GD. Socioeconomic position, lifestyle factors and age at natural menopause:
- 7356 a systematic review and meta-analyses of studies across six continents. *International journal of epidemiology* 2014;43: 1542 7357 1562.
- 7358 Schreiber K, Frishman M, Russell MD, Dey M, Flint J, Allen A, Crossley A, Gayed M, Hodson K, Khamashta M *et al.* British Society 7359 for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in
- 7360 rheumatology practice. *Rheumatology (Oxford, England)* 2023;62: e89-e104.
- 7361 Schuermans A, Nakao T, Uddin MM, Hornsby W, Ganesh S, Shadyab AH, Liu S, Haring B, Shufelt CL, Taub MA *et al.* Age at
- Menopause, Leukocyte Telomere Length, and Coronary Artery Disease in Postmenopausal Women. *Circulation research* 2023;133: 376-386.
- Schwenkhagen A, Studd J. Role of testosterone in the treatment of hypoactive sexual desire disorder. *Maturitas* 2009;63: 152-7365
 159.
- 7366 Scottish Intercollegiate Guidelines Network (SIGN). Long term follow up of survivors of childhood cancer. Edinburgh: SIGN;
 7367 2013
- 7368 (SIGN publication no 132) 2013;Available from URL: http://www.sign.ac.uk.
- 7369 Sedmak DD, Hart WR, Tubbs RR. Autoimmune oophoritis: a histopathologic study of involved ovaries with immunologic 7370 characterization of the mononuclear cell infiltrate. *Int J Gynecol Pathol* 1987;6: 73-81.
- 7371 Seeger H, Mueck AO. Are the progestins responsible for breast cancer risk during hormone therapy in the postmenopause?
 7372 Experimental vs. clinical data. *The Journal of steroid biochemistry and molecular biology* 2008;109: 11-15.
- 7373 Shan D, Zou L, Liu X, Shen Y, Cai Y, Zhang J. Efficacy and safety of gabapentin and pregabalin in patients with vasomotor 7374 symptoms: a systematic review and meta-analysis. *American journal of obstetrics and gynecology* 2020;222: 564-579.e512.
- 7375 Shapiro CL, Halabi S, Hars V, Archer L, Weckstein D, Kirshner J, Sikov W, Winer E, Burstein HJ, Hudis C *et al.* Zoledronic acid 7376 preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final
- 7377 results from CALGB trial 79809. *Eur J Cancer* 2011;47: 683-689.
- 7378 Sharma J, Friedman D, Dave-Sharma S, Harbison M. Aortic distensibility and dilation in Turner's syndrome. *Cardiology in the* 7379 *young* 2009;19: 568-572.
- 7380 Shea AK, Buwembo A, Mayhew A, Sohel N, Griffith LE, Raina P. The association between primary ovarian insufficiency and osteoporosis in the Canadian Longitudinal Study on Aging. *Menopause (New York, NY)* 2021;28: 693-698.
- 7382 Shea AK, Wolfman W. The role of hormone therapy in the management of severe postpartum depression in patients with Turner syndrome. *Menopause (New York, NY)* 2017;24: 1309-1312.
- 7384 Shekari S, Stankovic S, Gardner EJ, Hawkes G, Kentistou KA, Beaumont RN, Mörseburg A, Wood AR, Prague JK, Mishra GD *et* 7385 *al.* Penetrance of pathogenic genetic variants associated with premature ovarian insufficiency. *Nat Med* 2023;29: 1692-1699.
- 7386 Shen J, Qu D, Gao Y, Sun F, Xie J, Sun X, Wang D, Ma X, Cui Y, Liu J et al. Genetic etiologic analysis in 74 Chinese Han women
- with idiopathic premature ovarian insufficiency by combined molecular genetic testing. *Journal of assisted reproduction and genetics* 2021;38: 965-978.
- 7389 Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women.
 7390 *Psychoneuroendocrinology* 1988;13: 345-357.
- 7391 Shifren JL. Genitourinary Syndrome of Menopause. *Clinical obstetrics and gynecology* 2018;61: 508-516.
- 7392 Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP, Burki RE, Ginsburg ES, Rosen RC, Leiblum SR *et al.*7393 Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. *N Engl J Med* 2000;343:
 7394 682-688.
- Shifren JL, Davis SR, Moreau M, Waldbaum A, Bouchard C, DeRogatis L, Derzko C, Bearnson P, Kakos N, O'Neill S *et al.*Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the
 INTIMATE NM1 Study. *Menopause (New York, NY)* 2006;13: 770-779.
- Shim S, Streich-Tilles T, Gutmark-Little I, Yao M, Shafer J, Breech L, Casnellie L, Backeljauw P. Abnormal Uterine Bleeding during
 Pubertal Induction with Transdermal Estrogen in Individuals with Turner Syndrome. *Journal of pediatric and adolescent qynecology* 2023;36: 358-362.
- Shim SH, Lee SJ, Kim SN. Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors:
 a meta-analysis. *Eur J Cancer* 2014;50: 1628-1637.



- Shin J, Han K, Jung JH, Park HJ, Kim W, Huh Y, Kim YH, Kim DH, Kim SM, Choi YS *et al.* Age at menopause and risk of heart failure and atrial fibrillation: a nationwide cohort study. *Eur Heart J* 2022;43: 4148-4157.
- 7405 Shiraishi S, Lee PW, Leung A, Goh VH, Swerdloff RS, Wang C. Simultaneous measurement of serum testosterone and dihydrotestosterone by liquid chromatography-tandem mass spectrometry. *Clin Chem* 2008;54: 1855-1863.
- Shorey S, Ang L, Lau Y. Efficacy of mind-body therapies and exercise-based interventions on menopausal-related outcomes
 among Asian perimenopause women: A systematic review, meta-analysis, and synthesis without a meta-analysis. *Journal of advanced nursing* 2020;76: 1098-1110.
- 7410 Signorello LB, Mulvihill JJ, Green DM, Munro HM, Stovall M, Weathers RE, Mertens AC, Whitton JA, Robison LL, Boice JD, Jr.
- 7411 Stillbirth and neonatal death in relation to radiation exposure before conception: a retrospective cohort study. *Lancet* 7412 2010;376: 624-630.
- 7413 Silva CA, Yamakami LY, Aikawa NE, Araujo DB, Carvalho JF, Bonfa E. Autoimmune primary ovarian insufficiency. *Autoimmunity* 7414 *reviews* 2014;13: 427-430.
- 7415 Silvén H, Savukoski SM, Pesonen P, Pukkala E, Gissler M, Suvanto E, Niinimäki M. Incidence and familial risk of premature
- 7416 ovarian insufficiency in the Finnish female population. *Human reproduction (Oxford, England)* 2022;37: 1030-1036.
- Silven H, Savukoski SM, Pesonen P, Pukkala E, Ojaniemi M, Gissler M, Suvanto E, Niinimaki M. Association of genetic disorders
 and congenital malformations with premature ovarian insufficiency: a nationwide register-based study. *Human reproduction*(*Oxford, England*) 2023;38: 1224-1230.
- Simon J, Braunstein G, Nachtigall L, Utian W, Katz M, Miller S, Waldbaum A, Bouchard C, Derzko C, Buch A *et al.* Testosterone
 patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. *The Journal*of clinical endocrinology and metabolism 2005;90: 5226-5233.
- Simon JA. Estrogen replacement therapy: effects on the endogenous androgen milieu. *Fertility and sterility* 2002;77 Suppl 4:
 S77-82.
- Simon JA, Davis SR, Althof SE, Chedraui P, Clayton AH, Kingsberg SA, Nappi RE, Parish SJ, Wolfman W. Sexual well-being after
 menopause: An International Menopause Society White Paper. *Climacteric : the journal of the International Menopause Society* 2018a;21: 415-427.
- 7428 Simon JA, Gaines T, LaGuardia KD. Extended-release oxybutynin therapy for vasomotor symptoms in women: a randomized clinical trial. *Menopause (New York, NY)* 2016;23: 1214-1221.
- Simon JA, Goldstein I, Kim NN, Davis SR, Kellogg-Spadt S, Lowenstein L, Pinkerton JV, Stuenkel CA, Traish AM, Archer DF *et al.* The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study
- of Women's Sexual Health (ISSWSH) expert consensus panel review. *Menopause (New York, NY)* 2018b;25: 837-847.
 - 7433 Singer D. Managing the psychological sequelae of POI. Post Reprod Health 2019;25: 150-155.
 - Singer D, Mann E, Hunter MS, Pitkin J, Panay N. The silent grief: psychosocial aspects of premature ovarian failure. *Climacteric : the journal of the International Menopause Society* 2011;14: 428-437.
 - 7436 Singh P, Arora S, Lal S, Strand TA, Makharia GK. Celiac Disease in Women With Infertility: A Meta-Analysis. *J Clin Gastroenterol* 7437 2016;50: 33-39.
 - 7438 Singhal SR, Shullai WK. Comparative study of gabapentin and isoflavone in menopausal vasomotor symptoms. *Journal of mid-* 7439 *life health* 2016;7: 132-139.
- Sjöberg L, Pitkäniemi J, Harjutsalo V, Haapala L, Tiitinen A, Tuomilehto J, Kaaja R. Menopause in women with type 1 diabetes.
 Menopause (New York, NY) 2011;18: 158-163.
- 7442 Sluijmer AV, Heineman MJ, De Jong FH, Evers JL. Endocrine activity of the postmenopausal ovary: the effects of pituitary down-7443 regulation and oophorectomy. *The Journal of clinical endocrinology and metabolism* 1995;80: 2163-2167.
- 7444 Smith JA, Vitale S, Reed GF, Grieshaber SA, Goodman LA, Vanderhoof VH, Calis KA, Nelson LM. Dry eye signs and symptoms in 7445 women with premature ovarian failure. *Archives of ophthalmology* 2004;122: 151-156.
- Snajderova M, Mardesic T, Lebl J, Gerzova H, Teslik L, Zapletalova J, Czech National Study Group for HRTOiP, Adolescent E,
 Gynaecology. The uterine length in women with Turner syndrome reflects the postmenarcheal daily estrogen dose. *Horm Res*2003;60: 198-204.
- Soman M, Huang LC, Cai WH, Xu JB, Chen JY, He RK, Ruan HC, Xu XR, Qian ZD, Zhu XM. Serum androgen profiles in women
 with premature ovarian insufficiency: a systematic review and meta-analysis. *Menopause (New York, NY)* 2019;26: 78-93.
- 7451 Somigliana E, Berlanda N, Benaglia L, Vigano P, Vercellini P, Fedele L. Surgical excision of endometriomas and ovarian reserve:
 7452 a systematic review on serum antimullerian hormone level modifications. *Fertility and sterility* 2012;98: 1531-1538.
- 7453 Somunkiran A, Erel CT, Demirci F, Senturk ML. The effect of tibolone versus 17beta-estradiol on climacteric symptoms in 7454 women with surgical menopause: a randomized, cross-over study. *Maturitas* 2007;56: 61-68.
- Soucek O, Lebl J, Matyskova J, Snajderova M, Kolouskova S, Pruhova S, Hlavka Z, Sumnik Z. Muscle function in Turner syndrome:
 normal force but decreased power. *Clinical endocrinology* 2015;82: 248-253.
- 7457 Sriprasert I, Mert M, Mack WJ, Hodis HN, Shoupe D. Use of oral estradiol plus vaginal progesterone in healthy postmenopausal
 7458 women. *Maturitas* 2021;154: 13-19.
- 7459 Stabile G, Topouzova GA, De Seta F. The role of microbiota in the management of genitourinary syndrome of menopause.
 7460 *Climacteric : the journal of the International Menopause Society* 2023;26: 353-360.
- 7461 Stahlberg C, Pedersen AT, Lynge E, Andersen ZJ, Keiding N, Hundrup YA, Obel EB, Ottesen B. Increased risk of breast cancer
- following different regimens of hormone replacement therapy frequently used in Europe. International journal of cancer
- 7463 Journal international du cancer 2004;109: 721-727.



- 7464 Staller K, Townsend MK, Khalili H, Mehta R, Grodstein F, Whitehead WE, Matthews CA, Kuo B, Chan AT. Menopausal Hormone
- Therapy Is Associated With Increased Risk of Fecal Incontinence in Women After Menopause. *Gastroenterology* 2017;152:
 1915-1921.e1911.
- 7467 Stanczyk FZ. Measurement of androgens in women. *Seminars in reproductive medicine* 2006;24: 78-85.
- 7468 Stanczyk FZ, Chaikittisilpa S, Sriprasert I, Rafatnia A, Nadadur M, Mishell DR, Jr. Circulating androgen levels before and after
 7469 oophorectomy in premenopausal and postmenopausal women. *Climacteric : the journal of the International Menopause* 7470 Society 2019;22: 169-174.
- 7471 Stanczyk FZ, Hapgood JP, Winer S, Mishell DR, Jr. Progestogens used in postmenopausal hormone therapy: differences in their 7472 pharmacological properties, intracellular actions, and clinical effects. *Endocrine reviews* 2013;34: 171-208.
- 7473 Stathopoulos IP, Liakou CG, Katsalira A, Trovas G, Lyritis GG, Papaioannou NA, Tournis S. The use of bisphosphonates in women 7474 prior to or during pregnancy and lactation. *Hormones (Athens, Greece)* 2011;10: 280-291.
- Stavraka C, Maclaran K, Gabra H, Agarwal R, Ghaem-Maghami S, Taylor A, Dhillo WS, Panay N, Blagden SP. A study to evaluate
 the cause of bone demineralization in gynecological cancer survivors. *The oncologist* 2013;18: 423-429.
- Steenbeek MP, Harmsen MG, Hoogerbrugge N, de Jong MA, Maas A, Prins JB, Bulten J, Teerenstra S, van Bommel MHD, van
 Doorn HC *et al.* Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of
 Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial. *JAMA oncology* 2021;7: 1203-1212.
- 7479 Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Than, JANIA Dicology 2021;7: 1203-1212.
 7480 Steiner AZ, Pritchard D, Stanczyk FZ, Kesner JS, Meadows JW, Herring AH, Baird DD. Association Between Biomarkers of Ovarian
- 7481 Reserve and Infertility Among Older Women of Reproductive Age. Jama 2017;318: 1367-1376.
- Steingold KA, Matt DW, DeZiegler D, Sealey JE, Fratkin M, Reznikov S. Comparison of transdermal to oral estradiol
 administration on hormonal and hepatic parameters in women with premature ovarian failure *The Journal of clinical endocrinology and metabolism*. 1991, pp. 275-280.
- 7485 Steinmacher S, Brucker SY, Kölle A, Krämer B, Schöller D, Rall K. Malignant Germ Cell Tumors and Their Precursor Gonadal
 7486 Lesions in Patients with XY-DSD: A Case Series and Review of the Literature. *Int J Environ Res Public Health* 2021;18.
- 7487 Stevenson JC, Collins P, Hamoda H, Lambrinoudaki I, Maas A, Maclaran K, Panay N. Cardiometabolic health in premature 7488 ovarian insufficiency. *Climacteric : the journal of the International Menopause Society* 2021;24: 474-480.
- 7489 Storgaard M, Loft A, Bergh C, Wennerholm UB, Söderström-Anttila V, Romundstad LB, Aittomaki K, Oldereid N, Forman J,
 7490 Pinborg A. Obstetric and neonatal complications in pregnancies conceived after oocyte donation: a systematic review and
 7491 meta-analysis. *Bjog* 2017;124: 561-572.
- 7492 Stuenkel CA. Menopause, hormone therapy and diabetes. *Climacteric : the journal of the International Menopause Society* 7493 2017;20: 11-21.
- 7494 Sturdee DW, Panay N, International Menopause Society Writing G. Recommendations for the management of 7495 postmenopausal vaginal atrophy. *Climacteric : the journal of the International Menopause Society* 2010;13: 509-522.
- 7496 Sturgeon KM, Dean LT, Heroux M, Kane J, Bauer T, Palmer E, Long J, Lynch S, Jacobs L, Sarwer DB et al. Commercially available
- 7497 lifestyle modification program: randomized controlled trial addressing heart and bone health in BRCA1/2+ breast cancer
- survivors after risk-reducing salpingo-oophorectomy. *Journal of cancer survivorship : research and practice* 2017;11: 246-255.
 Stute P, Neulen J, Wildt L. The impact of micronized progesterone on the endometrium: a systematic review. *Climacteric : the journal of the International Menopause Society* 2016;19: 316-328.
- Stuursma A, Lanjouw L, Idema DL, de Bock GH, Mourits MJE. Surgical Menopause and Bilateral Oophorectomy: Effect of
 Estrogen-Progesterone and Testosterone Replacement Therapy on Psychological Well-being and Sexual Functioning; A
 Systematic Literature Review. *The journal of sexual medicine* 2022.
- Su H, Li H, Yang X, Wang C, Zhao Y. Assessment of menopausal symptoms and quality of life in women with premature ovarian
 failure after hematopoietic stem-cell transplantation for hematologic diseases. *Menopause (New York, NY)* 2020a;28: 65-69.
- 7506 Su H, Li H, Zhang H, Yang X, Wang C. Menopausal symptoms and quality of life in female survivors treated with hematopoietic 7507 stem cell transplantation. *Frontiers in psychiatry* 2023;14: 1050959.
- Su HI, Kwan B, Whitcomb BW, Shliakhsitsava K, Dietz AC, Stark SS, Martinez E, Sluss PM, Sammel MD, Natarajan L. Modeling
 Variation in the Reproductive Lifespan of Female Adolescent and Young Adult Cancer Survivors Using AMH. *The Journal of clinical endocrinology and metabolism* 2020b;105: 2740-2751.
- 7511 Suckling J, Lethaby A, Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. *Cochrane Database Syst Rev* 7512 2006: Cd001500.
- 7513 Suh YL. Autoimmune oophoritis--a case report. J Korean Med Sci 1992;7: 284-290.
- Sullivan SD, Sarrel PM, Nelson LM. Hormone replacement therapy in young women with primary ovarian insufficiency and
 early menopause. *Fertility and sterility* 2016;106: 1588-1599.
- 7516 Sultana F, Davis SR, Bell RJ, Taylor S, Islam RM. Association between testosterone and cognitive performance in postmenopausal women: a systematic review of observational studies. *Climacteric : the journal of the International* 7518 *Menopause Society* 2023a;26: 5-14.
- 7519 Sultana F, Davis SR, Islam RM. Effect of dehydroepiandrosterone therapy on cognitive performance among postmenopausal
 7520 women: a systematic review of randomized clinical trial data. *Menopause (New York, NY)* 2023b;30: 1167-1173.
- Sumino H, Ichikawa S, Itoh H, Utsugi T, Ohyama Y, Umeda M, Nakamura T, Kanda T, Mizunuma H, Tomono S *et al.* Hormone
 replacement therapy decreases insulin resistance and lipid metabolism in Japanese postmenopausal women with impaired
 and normal glucose tolerance. *Horm Res* 2003;60: 134-142.
- Sundblad V, Bussmann L, Chiauzzi VA, Pancholi V, Charreau EH. Alpha-enolase: a novel autoantigen in patients with premature
 ovarian failure. *Clinical endocrinology* 2006;65: 745-751.



- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates
 of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians* 2021;71: 209-249.
- Sung L, Bustillo M, Mukherjee T, Booth G, Karstaedt A, Copperman AB. Sisters of women with premature ovarian failure may
 not be ideal ovum donors. *Fertility and sterility* 1997;67: 912-916.
- 7530 Suriano KA, McHale M, McLaren CE, Li KT, Re A, DiSaia PJ. Estrogen replacement therapy in endometrial cancer patients: a matched control study. *Obstetrics and gynecology* 2001;97: 555-560.
- 7532 Suzuki Y, Huang Y, Melamed A, Clair CMS, Hou JY, Khoury-Collado F, Gockley A, Accordino M, Hershman DL, Wright JD. Use of
- 7533 Estrogen Therapy After Surgical Menopause in Women Who Are Premenopausal. *Obstetrics and gynecology* 2022;139: 756 7534 763.
- 7535 Szabo R, Marino J, Hickey M. Managing menopausal symptoms after cancer. *Climacteric : the journal of the International* 7536 *Menopause Society* 2019;22: 572-578.
- 7537 Szegda KL, Whitcomb BW, Purdue-Smithe AC, Boutot ME, Manson JE, Hankinson SE, Rosner BA, Bertone-Johnson ER. Adult 7538 adiposity and risk of early menopause. *Human reproduction (Oxford, England)* 2017;32: 2522-2531.
- 7539 Taebi M, Abdolahian S, Ozgoli G, Ebadi A, Kariman N. Strategies to improve menopausal quality of life: A systematic review.
 7540 *Journal of education and health promotion* 2018;7: 93.
- 7541 Takamizawa S, Shibahara H, Shibayama T, Suzuki M. Detection of antizona pellucida antibodies in the sera from premature 7542 ovarian failure patients by a highly specific test. *Fertility and sterility* 2007;88: 925-932.
- 7543 Tamimi RM, Hankinson SE, Chen WY, Rosner B, Colditz GA. Combined estrogen and testosterone use and risk of breast cancer 7544 in postmenopausal women. *Archives of internal medicine* 2006;166: 1483-1489.
- 7545Tan R, Pu D, Cao J, Ge H, Chang X, Ye G, Wu J. Prevalence of Stress Urinary Incontinence in Women with Premature Ovarian7546Insufficiency. J Womens Health (Larchmt) 2018;27: 1508-1512.
- 7547 Taneri PE, Kiefte-de Jong JC, Bramer WM, Daan NM, Franco OH, Muka T. Association of alcohol consumption with the onset
 7548 of natural menopause: a systematic review and meta-analysis. *Human reproduction update* 2016;22: 516-528.
- 7549 Tang VW, Faiman C. Premature ovarian failure: a search for circulating factors against gonadotropin receptors. *American* 7550 *journal of obstetrics and gynecology* 1983;146: 816-821.
- 7551 Tańska K, Gietka-Czernel M, Glinicki P, Kozakowski J. Thyroid autoimmunity and its negative impact on female fertility and 7552 maternal pregnancy outcomes. *Frontiers in endocrinology* 2023;13: 1049665.
- Tao X, Jiang A, Yin L, Li Y, Tao F, Hu H. Body mass index and age at natural menopause: a meta-analysis. *Menopause (New York, NY)* 2015;22: 469-474.
- **7555** Tao XY, Zuo AZ, Wang JQ, Tao FB. Effect of primary ovarian insufficiency and early natural menopause on mortality: a metaanalysis. *Climacteric : the journal of the International Menopause Society* 2016;19: 27-36.
- 7557 Tarín JJ, García-Pérez MA, Cano A. Obstetric and offspring risks of women's morbid conditions linked to prior anticancer 7558 treatments. *Reproductive biology and endocrinology : RB&E* 2016;14: 37.
- Tartagni M, Cicinelli E, De Pergola G, De Salvia MA, Lavopa C, Loverro G. Effects of pretreatment with estrogens on ovarian
 stimulation with gonadotropins in women with premature ovarian failure: a randomized, placebo-controlled trial. *Fertility and sterility* 2007;87: 858-861.
- Tassone F, Protic D, Allen EG, Archibald AD, Baud A, Brown TW, Budimirovic DB, Cohen J, Dufour B, Eiges R *et al.* Insight and
 Recommendations for Fragile X-Premutation-Associated Conditions from the Fifth International Conference on FMR1
 Premutation. *Cells* 2023;12.
- Tata LJ, Card TR, Logan RF, Hubbard RB, Smith CJ, West J. Fertility and pregnancy-related events in women with celiac disease:
 a population-based cohort study. *Gastroenterology* 2005;128: 849-855.
- Tatang C, Arredondo Bisonó T, Bergamasco A, Salvo F, Costa Clemens SA, Moride Y. Human Papillomavirus Vaccination and
 Premature Ovarian Failure: A Disproportionality Analysis Using the Vaccine Adverse Event Reporting System. *Drugs real world outcomes* 2022;9: 79-90.
- 7570 Tauchmanovà L, De Simone G, Musella T, Orio F, Ricci P, Nappi C, Lombardi G, Colao A, Rotoli B, Selleri C. Effects of various
- antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation.
 Bone marrow transplantation 2006;37: 81-88.
- 7573 Taylor AE, Adams JM, Mulder JE, Martin KA, Sluss PM, Crowley WF, Jr. A randomized, controlled trial of estradiol replacement
 7574 therapy in women with hypergonadotropic amenorrhea. *The Journal of clinical endocrinology and metabolism* 1996;81: 3615 7575 3621.
- 7576 Taylor HS, Tal A, Pal L, Li F, Black DM, Brinton EA, Budoff MJ, Cedars MI, Du W, Hodis HN *et al.* Effects of Oral vs Transdermal
 7577 Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study
 7578 (KEEPS). JAMA internal medicine 2017;177: 1471-1479.
- 7579 Techatraisak K, Angsuwathana S, Rattanachaiyanont M, Tanmahasumut P, Indhavivadhana S, Wongwananurak T, Leerasiri P,
 7580 Jirakittidul P. Compliance and health consequences of menopausal hormonal therapy after surgical menopause: A
 7581 retrospective study in Thailand. *The journal of obstetrics and gynaecology research* 2021;47: 208-215.
- 7582 Teh WT, Stern C, Chander S, Hickey M. The impact of uterine radiation on subsequent fertility and pregnancy outcomes.
 7583 *BioMed research international* 2014;2014: 482968.
- 7584 Templeton A, Morris JK, Parslow W. Factors that affect outcome of in-vitro fertilisation treatment. *Lancet* 1996;348: 1402-1406.
- ter Kuile MM, Both S, van Lankveld JJ. Cognitive behavioral therapy for sexual dysfunctions in women. *The Psychiatric clinics* of North America 2010;33: 595-610.



- 7588 Terra L, Beekman MJ, Engelhardt EG, Heemskerk-Gerritsen BAM, van Beurden M, Roeters van Lennep JE, van Doorn HC, de
 7589 Hullu JA, Van Dorst EBL, Mom CH *et al.* Sexual functioning more than 15 years after premenopausal risk-reducing salpingo7590 oophorectomy. *American journal of obstetrics and gynecology* 2023;228: 440.e441-440.e420.
- The British Psychological Society & The Royal College of Psychiatrists. *Depression in Adults with a Chronic Physical Health Problem: Treatment and Management*, 2010. The British Psychological Society & The Royal College of Psychiatrists., Leicester
 UK.
- 7594 The ESHRE Guideline Group On Ovarian Stimulation, Bosch E, Broer S, Griesinger G, Grynberg M, Humaidan P, Kolibianakis E,
- Kunicki M, La Marca A, Lainas G *et al.* ESHRE guideline: ovarian stimulation for IVF/ICSI(†). *Human reproduction open* 2020;2020: hoaa009.
- 7597 The Writing Group for the PEPI. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. *Jama* 1996;276: 1389-1396.
- 7599 Thomas E, Gentile A, Lakicevic N, Moro T, Bellafiore M, Paoli A, Drid P, Palma A, Bianco A. The effect of resistance training
 7600 programs on lean body mass in postmenopausal and elderly women: a meta-analysis of observational studies. *Aging Clin Exp* 7601 *Res* 2021;33: 2941-2952.
- Thomas HN, Brotto LA, de Abril Cameron F, Yabes J, Thurston RC. A virtual, group-based mindfulness intervention for midlife
 and older women with low libido lowers sexual distress in a randomized controlled pilot study. *The journal of sexual medicine* 2023;20: 1060-1068.
- Thong EP, Codner E, Laven JSE, Teede H. Diabetes: a metabolic and reproductive disorder in women. *The lancet Diabetes & endocrinology* 2020;8: 134-149.
- Tinjić S, Abazović D, Ljubić D, Vojvodić D, Božanović T, Ibrišimović M, Marković S, Ljubić A. Influence of Autologous In Vitro
 Activation of Ovaries by Stem Cells and Growth Factors on Endocrine and Reproductive Function of Patients with Ovarian
 Insufficiency-A Clinical Trial Study. *International journal of fertility & sterility* 2021;15: 178-188.
- Tokmak A, Yıldırım G, Sarıkaya E, Çınar M, Boğdaycıoğlu N, Yılmaz FM, Yılmaz N. Increased oxidative stress markers may be a
 promising indicator of risk for primary ovarian insufficiency: a cross-sectional case control study. *Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia* 2015;37: 411-416.
- Torella M, Marrapodi MM, Ronsini C, Ruffolo AF, Braga A, Frigerio M, Amabile E, Vastarella MG, Rossi F, Riemma G. Risk of
 Premature Ovarian Insufficiency after Human Papilloma Virus Vaccination: A PRISMA Systematic Review and Meta-Analysis of
 Current Evidence. *Vaccines* 2023;11.
- Torres-Santiago L, Mericq V, Taboada M, Unanue N, Klein KO, Singh R, Hossain J, Santen RJ, Ross JL, Mauras N. Metabolic
 effects of oral versus transdermal 17beta-estradiol (E(2)): a randomized clinical trial in girls with Turner syndrome. *The Journal* of clinical endocrinology and metabolism 2013;98: 2716-2724.
- Touboul C, Uzan C, Ichante JL, Caron O, Dunant A, Dauchy S, Gouy S, de Paillerets BB, Morice P, Delaloge S. Factors associated
 with altered long-term well-being after prophylactic salpingo-oophorectomy among women at increased hereditary risk for
 breast and ovarian cancer. *The oncologist* 2011;16: 1250-1257.
- Tsigkou A, Marzotti S, Borges L, Brozzetti A, Reis F, Candeloro P, Luisa Bacosi M, Bini V, Petraglia F, Falorni A. High serum inhibin
 concentration discriminates autoimmune oophoritis from other forms of primary ovarian insufficiency. *The Journal of clinical endocrinology and metabolism* 2008;93: 1263-1269.
- Tsuburai T, Nakamura T, Yoshikata H, Miyagi E, Sakakibara H. Eldecalcitol increases bone mass in patients with Turner
 syndrome who have insufficient bone mass acquisition after estrogen replacement therapy. *Endocrine journal* 2018;65: 629638.
- Tucker PE, Cohen PA, Bulsara MK, Jeffares S, Saunders C. The impact of bilateral salpingo-oophorectomy on sexuality and
 quality of life in women with breast cancer. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer* 2021;29: 369-375.
- Tuesley KM, Protani MM, Webb PM, Dixon-Suen SC, Wilson LF, Stewart LM, Jordan SJ. Hysterectomy with and without
 oophorectomy and all-cause and cause-specific mortality. *American journal of obstetrics and gynecology* 2020;223: 723.e721 723.e716.
- 7634 Uldbjerg CS, Wilson LF, Koch T, Christensen J, Dehlendorff C, Priskorn L, Abildgaard J, Simonsen MK, Lim YH, Jørgensen JT *et al.* Oophorectomy and rate of dementia: a prospective cohort study. *Menopause (New York, NY)* 2022;29: 514-522.
- 7636 Upton CE, Daniels JP, Davies MC. Premature ovarian insufficiency: the need for evidence on the effectiveness of hormonal 7637 therapy. *Climacteric : the journal of the International Menopause Society* 2021;24: 453-458.
- 7638 Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. *Health* 7639 *and quality of life outcomes* 2005;3: 47.
- 7640 Utian WH, Archer DF, Bachmann GA, Gallagher C, Grodstein F, Heiman JR, Henderson VW, Hodis HN, Karas RH, Lobo RA *et al.*7641 Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause
 7642 Society. *Menopause (New York, NY)* 2008;15: 584-602.
- 7643 Utian WH, Woods NF. Impact of hormone therapy on quality of life after menopause. *Menopause (New York, NY)* 2013;20:7644 1098-1105.
- 7645 Vallotton MB, Forbes AP. Antibodies to cytoplasm of ova. *Lancet* 1966;2: 264-265.
- 7646 van Barele M, Buis CCM, Brood-van Zanten MMA, van Doorn HLC, Gaarenstroom KN, Heemskerk-Gerritsen BAM, Hooning MJ,
- de Hullu J, Mourits MJ, Burger CW. The effect of hormone therapy on breast density following risk-reducing salpingooophorectomy in women with an increased risk for breast and ovarian cancer. *Menopause (New York, NY)* 2021;28: 13071312.
 - Guideline POI DRAFT FOR REVIEW



- 7650 van de Loo L, van den Berg MH, Overbeek A, van Dijk M, Damen L, Lambalk CB, Ronckers CM, van den Heuvel-Eibrink MM, 7651 Kremer LCM, van der Pal HJ et al. Uterine function, pregnancy complications, and pregnancy outcomes among female 7652 childhood cancer survivors. Fertility and sterility 2019;111: 372-380.
- 7653 Van Der Kelen A, Okutman Ö, Javey E, Serdarogullari M, Janssens C, Ghosh MS, Dequeker BJH, Perold F, Kastner C, Kieffer E et 7654 al. A systematic review and evidence assessment of monogenic gene-disease relationships in human female infertility and 7655 differences in sex development. Human reproduction update 2023;29: 218-232.
- 7656 van der Kooi ALF, Brewster DH, Wood R, Nowell S, Fischbacher C, van den Heuvel-Eibrink MM, Laven JSE, Wallace WHB, 7657 Anderson RA. Perinatal risks in female cancer survivors: A population-based analysis. PloS one 2018;13: e0202805.
- 7658 van der Kooi ALF, Kelsey TW, van den Heuvel-Eibrink MM, Laven JSE, Wallace WHB, Anderson RA. Perinatal complications in 7659 female survivors of cancer: a systematic review and meta-analysis. Eur J Cancer 2019;111: 126-137.
- 7660 van der Stege JG, Groen H, van Zadelhoff SJ, Lambalk CB, Braat DD, van Kasteren YM, van Santbrink EJ, Apperloo MJ, Weijmar 7661 Schultz WC, Hoek A. Decreased androgen concentrations and diminished general and sexual well-being in women with 7662 premature ovarian failure. Menopause (New York, NY) 2008;15: 23-31.
- 7663 van Dorp W, Haupt R, Anderson RA, Mulder RL, van den Heuvel-Eibrink MM, van Dulmen-den Broeder E, Su HI, Winther JF, 7664 Hudson MM, Levine JM et al. Reproductive Function and Outcomes in Female Survivors of Childhood, Adolescent, and Young 7665 Adult Cancer: A Review. J Clin Oncol 2018;36: 2169-2180.
- 7666 van Driel C, de Bock GH, Schroevers MJ, Mourits MJ. Mindfulness-based stress reduction for menopausal symptoms after risk-7667 reducing salpingo-oophorectomy (PURSUE study): a randomised controlled trial. Bjog 2019a;126: 402-411.
- 7668 van Driel CM, Stuursma A, Schroevers MJ, Mourits MJ, de Bock GH. Mindfulness, cognitive behavioural and behaviour-based 7669 therapy for natural and treatment-induced menopausal symptoms: a systematic review and meta-analysis. Bjog 2019b;126: 7670 330-339.
- van Kasteren YM, Hundscheid RD, Smits AP, Cremers FP, van Zonneveld P, Braat DD. Pamilial diopathic premature ovarian 7671 7672 failure: an overrated and underestimated genetic disease? Human reproduction (Oxford, England) 1999;14: 2455-2459.
- van Kasteren YM, Schoemaker J. Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian 7673 7674
- function and achieve pregnancy. Human reproduction update 1999;5: 483-492.
- 7675 van Noord PA, Dubas JS, Dorland M, Boersma H, te Velde E. Age at natural menopause in a population-based screening cohort: 7676 the role of menarche, fecundity, and lifestyle factors. Fertility and sterility 1997;68: 95-102.
- 7677 Van Ommen CE, King EM, Murray MCM. Age at menopause in women living with HIV: a systematic review. Menopause (New 7678 York, NY) 2021;28: 1428-1436.
- 7679 Vanden Noven ML, Larson M, Lee E, Reilly C, Tracy MF, Keller-Ross ML. Perceptions, Benefits, and Use of Complementary and 7680 Integrative Therapies to Treat Menopausal Symptoms: A Pilot Study. Women's health reports (New Rochelle, NY) 2023;4: 136-7681 147.
- Vargiu V, Amar ID, Rosati A, Dinoi G, Turco LC, Capozzi VA, Scambia G, Villa P. Hormone replacement therapy and cervical 7682 7683 cancer: a systematic review of the literature. Climacteric: the journal of the International Menopause Society 2021;24: 120-7684 127.
- 7685 Vashisht A, Wadsworth F, Carey A, Carey B, Studd J. Bleeding profiles and effects on the endometrium for women using a 7686 novel combination of transdermal oestradiol and natural progesterone cream as part of a continuous combined hormone 7687 replacement regime. Bjog 2005;112: 1402-1406.
- 7688 Ventura JL, Fitzgerald OR, Koziol DE, Covington SN, Vanderhoof VH, Calis KA, Nelson LM. Functional well-being is positively 7689 correlated with spiritual well-being in women who have spontaneous premature ovarian failure. Fertility and sterility 2007;87: 7690 584-590.
- 7691 Verbeek JGE, Atema V, Mewes JC, van Leeuwen M, Oldenburg HSA, van Beurden M, Hunter MS, van Harten WH, Aaronson 7692 NK, Retèl VP. Cost-utility, cost-effectiveness, and budget impact of Internet-based cognitive behavioral therapy for breast 7693 cancer survivors with treatment-induced menopausal symptoms. Breast cancer research and treatment 2019;178: 573-585.
- 7694 Verma P, A KS, Shankar H, Sharma A, Rao DN. Role of Trace Elements, Oxidative Stress and Immune System: a Triad in 7695 Premature Ovarian Failure. Biological trace element research 2018;184: 325-333.
- 7696 Vermeulen N, Le Clef N, Mcheik S, D'Angelo A, Tilleman K, Veleva Z, Nelen N. Manual for ESHRE Guideline Development. 2020. 7697 ESHRE, https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Guideline-development-process.
- 7698 Vermeulen RFM, Beurden MV, Kieffer JM, Bleiker EMA, Valdimarsdottir HB, Massuger L, Mourits MJE, Gaarenstroom KN, van 7699 Dorst EBL, van der Putten H et al. Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises 7700 endocrine and sexual problems: A prospective study. Eur J Cancer 2017;84: 159-167.
- 7701 Vermeulen RFM, Korse CM, Kenter GG, Brood-van Zanten MMA, Beurden MV. Safety of hormone replacement therapy 7702 following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines. Climacteric : the journal of the 7703 International Menopause Society 2019;22: 352-360.
- 7704 Verrilli L, Johnstone E, Welt C, Allen-Brady K. Primary ovarian insufficiency has strong familiality: results of a multigenerational 7705 genealogical study. Fertility and sterility 2023;119: 128-134.
- 7706 Vessey MP, Villard-Mackintosh L, McPherson K, Coulter A, Yeates D. The epidemiology of hysterectomy: findings in a large 7707 cohort study. British journal of obstetrics and gynaecology 1992;99: 402-407.
- 7708 Vincent AJ, Johnston-Ataata K, Flore J, Kokanović R, Hickey M, Boyle JA, Teede HJ. A qualitative study of work and early 7709 menopause: 'On-the job' experiences and career trajectories. Maturitas 2024;182: 107920.
- 7710 Vinogradova Y, Coupland C, Hippisley-Cox J. Use of hormone replacement therapy and risk of breast cancer: nested case-7711 control studies using the QResearch and CPRD databases. BMJ 2020;371: m3873.



- Viuff MH, Berglund A, Juul S, Andersen NH, Stochholm K, Gravholt CH. Sex Hormone Replacement Therapy in Turner
 Syndrome: Impact on Morbidity and Mortality. *The Journal of clinical endocrinology and metabolism* 2020;105.
- Viuff MH, Just J, Brun S, Dam TV, Hansen M, Melgaard L, Hougaard DM, Lappe M, Gravholt CH. Women With Turner Syndrome
 Are Both Estrogen and Androgen Deficient: The Impact of Hormone Replacement Therapy. *The Journal of clinical endocrinology and metabolism* 2022;107: 1983-1993.
- Viuff MH, Stochholm K, Lin A, Berglund A, Juul S, Gravholt CH. Cancer occurrence in Turner syndrome and the effect of sex
 hormone substitution therapy. *Eur J Endocrinol* 2021;184: 79-88.
- 7719 Vogt EC, Bratland E, Berland S, Berentsen R, Lund A, Bjornsdottir S, Husebye E, Oksnes M. Improving diagnostic precision in
- primary ovarian insufficiency using comprehensive genetic and autoantibody testing. *Human reproduction (Oxford, England)*
- **7721** 2024;39: 177-189.
- Vogt EC, Breivik L, Røyrvik EC, Grytaas M, Husebye ES, Øksnes M. Primary Ovarian Insufficiency in Women With Addison's
 Disease. *The Journal of clinical endocrinology and metabolism* 2021;106: e2656-e2663.
- 7724 Vogt EC, Real FG, Husebye ES, Björnsdottir S, Benediktsdottir B, Bertelsen RJ, Demoly P, Franklin KA, de Aja Gallastegui LS,
- González FJC et al. Premature menopause and autoimmune primary ovarian insufficiency in two international multi-center
- cohorts. *Endocrine connections* 2022;11.
- Volozonoka L, Miskova A, Kornejeva L, Kempa I, Bargatina V, Gailite L. A systematic review and standardized clinical validity
 assessment of genes involved in female reproductive failure. *Reproduction* 2022;163: 351-363.
- Vrselja A, Latifi A, Baber RJ, Stuckey BGA, Walker MG, Stearns V, Hickey M, Davis SR. Q-122 as a novel, non-hormonal, oral
 treatment for vasomotor symptoms in women taking tamoxifen or an aromatase inhibitor after breast cancer: a phase 2,
 randomised, double-blind, placebo-controlled trial. *Lancet* 2022;400: 1704-1711.
- 7732 Vujovic S, Brincat M, Erel T, Gambacciani M, Lambrinoudaki I, Moen MH, Schenck-Gustafsson K, Tremollieres F, Rozenberg S,
- 7733 Rees M *et al.* EMAS position statement: Managing women with premature ovarian failure. *Maturitas* 2010;67: 91-93.
- Walker MD, Zylberberg HM, Green PHR, Katz MS. Endocrine complications of celiac disease: a case report and review of the
 literature. *Endocrine research* 2019;44: 27-45.
- Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DA, Anderson PW. The effects of hormone replacement therapy and
 raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. *The Journal of clinical endocrinology and metabolism* 2000;85: 214-218.
- Wang H, Chen H, Qin Y, Shi Z, Zhao X, Xu J, Ma B, Chen ZJ. Risks associated with premature ovarian failure in Han Chinese women. *Reprod Biomed Online* 2015;30: 401-407.
- Wang QW, Tian Y, Qiu HX, Mo J, Zhang XY. Premature ovarian failure treated with mild moxibustion and western medication.
 World journal of acupuncture moxibustion 2021;31: 291 295.
- Wang Y, Li Y, Liang J, Zhang N, Yang Q. Chemotherapy-Induced Amenorrhea and Its Prognostic Significance in Premenopausal
 Women With Breast Cancer: An Updated Meta-Analysis. *Front Oncol* 2022;12: 859974.
- Wonten With Dicast current. An opparted Micra Analysis (*Font Oncol* 2022)12: 055574.
 Waqas K, Lima Ferreira J, Tsourdi E, Body JJ, Hadji P, Zillikens MC. Updated guidance on the management of cancer treatmentinduced bone loss (CTIBL) in pre- and postmenopausal women with early-stage breast cancer. *Journal of bone oncology*
- 7747 2021;28: 100355.
 7748 Warren BD, Kinsey WK, McGinnis LK, Christenson LK, Jasti S, Stevens AM, Petroff BK, Petroff MG. Ovarian autoimmune disease:
- clinical concepts and animal models. *Cell Mol Immunol* 2014;11: 510-521.
- Wasserman H, Backeljauw PF, Khoury JC, Kalkwarf HJ, Gordon CM. Bone fragility in Turner syndrome: Fracture prevalence and risk factors determined by a national patient survey. *Clinical endocrinology* 2018;89: 46-55.
- Wasserman MC, Rubin RS. Urologic view in the management of genitourinary syndrome of menopause. *Climacteric : the journal of the International Menopause Society* 2023;26: 329-335.
- Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B, Cifkova R, de Muinck Keizer-Schrama S, Hogervorst E, Janse
 F *et al.* ESHRE Guideline: management of women with premature ovarian insufficiency. *Human reproduction (Oxford, England)* 2016;31: 926-937.
- Weghofer A, Barad D, Li J, Gleicher N. Aneuploidy rates in embryos from women with prematurely declining ovarian function:
 a pilot study. *Fertility and sterility* 2007;88: 90-94.
- Wei D, Chen Y, Wu C, Wu Q, Yao L, Wang Q, Wang XQ, Yang KH. Effect and safety of paroxetine for vasomotor symptoms:
 systematic review and meta-analysis. *Bjog* 2016;123: 1735-1743.
- Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergström R, Lindgren A, Correia N, Persson I. Risk of endometrial cancer
 following estrogen replacement with and without progestins. *J Natl Cancer Inst* 1999;91: 1131-1137.
- Wells GD, O'Gorman CS, Rayner T, Caterini J, Thompson S, Bradley T, Hamilton J. Skeletal muscle abnormalities in girls and
 adolescents with Turner syndrome. *The Journal of clinical endocrinology and metabolism* 2013;98: 2521-2527.
- Welt CK. Primary ovarian insufficiency: a more accurate term for premature ovarian failure. *Clinical endocrinology* 2008;68:499-509.
- Welt CK, Falorni A, Taylor AE, Martin KA, Hall JE. Selective theca cell dysfunction in autoimmune oophoritis results in multifollicular development, decreased estradiol, and elevated inhibin B levels. *The Journal of clinical endocrinology and metabolism* 2005;90: 3069-3076.
- 7770 Wheatcroft NJ, Toogood AA, Li TC, Cooke ID, Weetman AP. Detection of antibodies to ovarian antigens in women with 7771 premature ovarian failure. *Clin Exp Immunol* 1994;96: 122-128.
- 7772 Whitcomb BW, Purdue-Smithe A, Hankinson SE, Manson JE, Rosner BA, Bertone-Johnson ER. Menstrual Cycle Characteristics
- in Adolescence and Early Adulthood Are Associated With Risk of Early Natural Menopause. *The Journal of clinical endocrinology*
- 7774 and metabolism 2018a;103: 3909-3918.



- Whitcomb BW, Purdue-Smithe AC, Szegda KL, Boutot ME, Hankinson SE, Manson JE, Rosner B, Willett WC, Eliassen AH,
 Bertone-Johnson ER. Cigarette Smoking and Risk of Early Natural Menopause. *American journal of epidemiology* 2018b;187:
 696-704.
- 7778 Wilson LF, Pandeya N, Byles J, Mishra GD. Hysterectomy status and all-cause mortality in a 21-year Australian population-7779 based cohort study. *American journal of obstetrics and gynecology* 2019;220: 83.e81-83.e11.
- Winqvist O, Gebre-Medhin G, Gustafsson J, Ritzén EM, Lundkvist O, Karlsson FA, Kämpe O. Identification of the main gonadal autoantigens in patients with adrenal insufficiency and associated ovarian failure. *The Journal of clinical endocrinology and metabolism* 1995;80: 1717-1723.
- 7783 Winther JF, Olsen JH, Wu H, Shyr Y, Mulvihill JJ, Stovall M, Nielsen A, Schmiegelow M, Boice JD, Jr. Genetic disease in the 7784 children of Danish survivors of childhood and adolescent cancer. *J Clin Oncol* 2012;30: 27-33.
- Wisner KL, Sit DK, Moses-Kolko EL, Driscoll KE, Prairie BA, Stika CS, Eng HF, Dills JL, Luther JF, Wisniewski SR. Transdermal
 Estradiol Treatment for Postpartum Depression: A Pilot, Randomized Trial. *Journal of clinical psychopharmacology* 2015;35:
 389-395.
- Wisniewski AB, Nguyen TT, Dobs AS. Evaluation of high-dose estrogen and high-dose estrogen plus methyltestosterone
 treatment on cognitive task performance in postmenopausal women. *Horm Res* 2002;58: 150-155.
- Woods NF, Utian W. Quality of life, menopause, and hormone therapy: an update and recommendations for future research.
 Menopause (New York, NY) 2018;25: 713-720.
- Wu J, Ning Y, Tan L, Chen Y, Huang X, Zhuo Y. Characteristics of the vaginal microbiome in women with premature ovarian
 insufficiency. *Journal of ovarian research* 2021;14: 172.
- Wu X, Cai H, Kallianpur A, Li H, Yang G, Gao J, Xiang YB, Ji BT, Yu T, Zheng W *et al.* Impact of Premature Ovarian Failure on
 Mortality and Morbidity among Chinese Women. *PloS one* 2014;9: e89597.
- Wxu MB, Tian HY. Comparative observation of the effect of electroacupuncture combined with heat-sensitive moxibustion
 and western medicine for premature ovarian failure. *World journal of acupuncture moxibustion* 2017;27: 9 14.
- Xi D, Chen B, Tao H, Xu Y, Chen G. The risk of depressive and anxiety symptoms in women with premature ovarian insufficiency:
 a systematic review and meta-analysis. *Archives of women's mental health* 2023;26: 1-10.
- Xing Z, Alman AC, Kirby RS. Premature Menopause and All-Cause Mortality and Life Span Among Women Older Than 40 Years
 in the NHANES I Epidemiologic Follow-Up Study: Propensity Score Matching Analysis. J Womens Health (Larchmt) 2023;32:
 950-959.
- 7803 Xiong J, Tan R, Wang W, Wang H, Pu D, Wu J. Evaluation of CD4(+)CD25(+)FOXP3(+) regulatory T cells and FOXP3 mRNA in premature ovarian insufficiency. *Climacteric : the journal of the International Menopause Society* 2020;23: 267-272.
- Xu X, Jones M, Mishra GD. Age at natural menopause and development of chronic conditions and multimorbidity: results from
 an Australian prospective cohort. *Human reproduction (Oxford, England)* 2020;35: 203-211.
- Xu Z, Chung HF, Dobson AJ, Wilson LF, Hickey M, Mishra GD. Menopause, hysterectomy, menopausal hormone therapy and cause-specific mortality: cohort study of UK Biobank participants. *Human reproduction (Oxford, England)* 2022;37: 2175-2185.
 Yang Q, Mumusoglu S, Qin Y, Sun Y, Hsueh AJ. A kaleidoscopic view of ovarian genes associated with premature ovarian insufficiency and senescence. *FASEB journal* : official publication of the Federation of American Societies for Experimental *Biology* 2021;35: e21753.
- Yang X, Touraine P, Desai S, Humphreys G, Jiang H, Yatsenko A, Rajkovic A. Gene variants identified by whole-exome sequencing in 33 French women with premature ovarian insufficiency. *Journal of assisted reproduction and genetics* 2019;36: 39-45.
- Yang X, Wang C, He X, Wei J, Wang Y, Li X, Xu LP. Hormone therapy for premature ovarian insufficiency patients with malignant
 hematologic diseases. *Climacteric : the journal of the International Menopause Society* 2017;20: 268-273.
- Yarde F, van der Schouw YT, de Valk HW, Franx A, Eijkemans MJ, Spiering W, Broekmans FJ. Age at menopause in women with
 type 1 diabetes mellitus: the OVADIA study. *Human reproduction (Oxford, England)* 2015;30: 441-446.
- 7819 Yaron Y, Ochshorn Y, Amit A, Yovel I, Kogosowki A, Lessing JB. Patients with Turner's syndrome may have an inherent 7820 endometrial abnormality affecting receptivity in oocyte donation. *Fertility and sterility* 1996;65: 1249-1252.
- 7821 Ye M, Shou M, Zhang J, Hu B, Liu C, Bi C, Lv T, Luo F, Zhang Z, Liang S *et al.* Efficacy of cognitive therapy and behavior therapy 7822 for menopausal symptoms: a systematic review and meta-analysis. *Psychol Med* 2022;52: 433-445.
- Yeganeh L, Boyle J, Teede H, Vincent A. Knowledge and attitudes of health professionals regarding menopausal hormone
 therapies. *Climacteric : the journal of the International Menopause Society* 2017;20: 348-355.
- Yeganeh L, Boyle JA, Gibson-Helm M, Teede H, Vincent AJ. Women's perspectives of early menopause: development of a word
 cloud. *Climacteric : the journal of the International Menopause Society* 2020a;23: 417-420.
- Yeganeh L, Boyle JA, Johnston-Ataata K, Flore J, Hickey M, Kokanović R, Teede H, Vincent AJ. Positive impact of a co-designed digital resource for women with early menopause. *Menopause (New York, NY)* 2022;29: 671-679.
- Yeganeh L, Johnston-Ataata K, Vincent AJ, Flore J, Kokanović R, Teede H, Boyle JA. Co-designing an Early Menopause Digital
 Resource: Model for Interdisciplinary Knowledge Translation. *Seminars in reproductive medicine* 2020b;38: 315-322.
- 7831 Yeganeh L, Khan NN, Boyle JA, Gibson-Helm M, Teede H, Vincent AJ. Development and evaluation of an early menopause 7832 question prompt list. *Menopause (New York, NY)* 2020c;27: 102-109.
- 7833 Yeh ML, Liao RW, Hsu CC, Chung YC, Lin JG. Exercises improve body composition, cardiovascular risk factors and bone mineral
- 7834 density for menopausal women: A systematic review and meta-analysis of randomized controlled trials. *Applied nursing* 7835 *research : ANR* 2018;40: 90-98.



- Yeo W, Pang E, Liem GS, Suen JJS, Ng RYW, Yip CCH, Li L, Yip CHW, Mo FKF. Menopausal symptoms in relationship to breast cancer-specific quality of life after adjuvant cytotoxic treatment in young breast cancer survivors. *Health and quality of life outcomes* 2020;18: 24.
- Yi A, Qin X, Du Z, Wang T, Liu F. Clinical Observation on the Improvement of Serum Sex Hormone and Ovarian Function in
 Premature Ovarian Failure Patients with Deficiency-Cold Syndrome by Combining Wenjing Decoction with Tiaobu Chongren
 Acupuncture and Moxibustion. *Evidence-based complementary and alternative medicine* 2021;2021.
- 7842 Yldrm G, Tokmak A, Kokanal MK, Sarkaya E, Züngün C, İnal HA, Ylmaz FM, Ylmaz N. Association between some inflammatory 7843 markers and primary ovarian insufficiency. *Menopause (New York, NY)* 2015;22: 1000-1005.
- Yoon SH, Lee JY, Lee C, Lee H, Kim SN. Gabapentin for the treatment of hot flushes in menopause: a meta-analysis. *Menopause* (*New York, NY*) 2020;27: 485-493.
- 7846 Yuk JS, Kim BG, Lee BK, Seo J, Kim GS, Min K, Lee HY, Byun YS, Kim BO, Yang SW *et al.* Association of Early Hysterectomy With 7847 Risk of Cardiovascular Disease in Korean Women. *JAMA Netw Open* 2023;6: e2317145.
- Zaiem F, Alahdab F, Al Nofal A, Murad MH, Javed A. ORAL VERSUS TRANSDERMAL ESTROGEN IN TURNER SYNDROME: A
 SYSTEMATIC REVIEW AND META-ANALYSIS. *Endocrine practice : official journal of the American College of Endocrinology and* the American Association of Clinical Endocrinologists 2017;23: 408-421.
- 7851 Zajicek M, Volodarsky-Perel A, Shai D, Dick-Necula D, Raanani H, Gruber N, Karplus G, Kassif E, Weisz B, Meirow D. Evaluation
 7852 of ovarian reserve in young females with non-iatrogenic ovarian insufficiency to establish criteria for ovarian tissue
- 7853 cryopreservation. *Reprod Biomed Online* 2023;47: 102-109.
 7854 Zhai T, Diergaarde B, Wilson DO, Kang H, Sood A, Bayliss SH, Yuan JM, Picchi MA, Lan Q, Belinsky SA *et al.* Early natural
- menopause is associated with poor lung health and increased mortality among female smokers. *American journal of obstetrics* and gynecology 2022.
- Zhang S, Tan R, Pan R, Xiong J, Tian Y, Wu J, Chen L. Association of Perfluoroalkyl and Polyfluoroalkyl Substances With
 Premature Ovarian Insufficiency in Chinese Women. *The Journal of clinical endocrinology and metabolism* 2018;103: 2543 2551.
- Zhang S, Zhu D, Mei X, Li Z, Li J, Xie M, Xie HJW, Wang S, Cheng K. Advances in biomaterials and regenerative medicine for
 primary ovarian insufficiency therapy. *Bioactive materials* 2021;6: 1957-1972.
- Zhang YL, Chen JH, Lu W, Li BL, Zhu QY, Wan XP. Efficacy of Postoperative Hormone Replacement Therapy on Prognosis of
 Patients with Serous Ovarian Carcinoma. *Chin Med J (Engl)* 2016;129: 1316-1321.
- Zhong HZ, Li MY, Yin XL, Bin CL, Zhou SY, Wei SB. Chinese patent medicines combined with hormone replacement therapy for
 premature ovarian failure: A Bayesian network meta-analysis. *Front Med (Lausanne)* 2022;9: 1043390.
- 7866 Zhou WS, Mao SJ, Zhang SK, Xu H, Li WL. Effects of aquatic exercises on physical fitness and quality of life in postmenopausal
 7867 women: an updated systematic review and meta-analysis. Frontiers in public health 2023;11: 1126126.
- Zhu C, Luo W, Li Z, Zhang X, Hu J, Zhao S, Jiao X, Qin Y. New theca-cell marker insulin-like factor 3 is associated with premature ovarian insufficiency. *Fertility and sterility* 2021;115: 455-462.
- Zhu D, Chung HF, Dobson AJ, Pandeya N, Giles GG, Bruinsma F, Brunner EJ, Kuh D, Hardy R, Avis NE *et al.* Age at natural
 menopause and risk of incident cardiovascular disease: a pooled analysis of individual patient data. *The Lancet Public health* 2019;4: e553-e564.
- Zhu D, Chung HF, Pandeya N, Dobson AJ, Cade JE, Greenwood DC, Crawford SL, Avis NE, Gold EB, Mitchell ES *et al.* Relationships
 between intensity, duration, cumulative dose, and timing of smoking with age at menopause: A pooled analysis of individual
 data from 17 observational studies. *PLoS medicine* 2018a;15: e1002704.
- 7876 Zhu D, Chung HF, Pandeya N, Dobson AJ, Kuh D, Crawford SL, Gold EB, Avis NE, Giles GG, Bruinsma F *et al.* Body mass index
 7877 and age at natural menopause: an international pooled analysis of 11 prospective studies. *European journal of epidemiology* 7878 2018b;33: 699-710.
- 7879 Zhu L, Jiang X, Sun Y, Shu W. Effect of hormone therapy on the risk of bone fractures: a systematic review and meta-analysis 7880 of randomized controlled trials. *Menopause (New York, NY)* 2016;23: 461-470.
- Zhu X, Liu M, Dong R, Gao L, Hu J, Zhang X, Wu X, Fan B, Chen C, Xu W. Mechanism Exploration of Environmental Pollutants
 on Premature Ovarian Insufficiency: a Systematic Review and Meta-analysis. *Reproductive sciences (Thousand Oaks, Calif)*2024;31: 99-106.
- Zilio Rech CM, Clapauch R, Bouskela E. Sexual Function Under Adequate Estrogen Therapy in Women After Oophorectomy
 Versus Natural Menopause. J Womens Health (Larchmt) 2019;28: 1124-1132.
- 7886 Zilski N, Speiser D, Bartley J, Roehle R, Blohmer JU, Keilholz U, Goerling U. Quality of life after risk-reducing salpingo-7887 oophorectomy in women with a pathogenic BRCA variant. *The journal of sexual medicine* 2023;21: 33-39.
- 7888 Zuckerman-Levin N, Frolova-Bishara T, Militianu D, Levin M, Aharon-Peretz J, Hochberg Z. Androgen replacement therapy in 7889 Turner syndrome: a pilot study. *The Journal of clinical endocrinology and metabolism* 2009;94: 4820-4827.
- Zugna D, Richiardi L, Akre O, Stephansson O, Ludvigsson JF. A nationwide population-based study to determine whether coeliac
 disease is associated with infertility. *Gut* 2010;59: 1471-1475.
- 7892

7893



7894 Annex 1 Guideline group.

7895 This guideline was developed by the ESHRE POI Guideline Development Group (GDG).

Chairs of the guideline group **Nick Panay Amanda Vincent** *Guideline group members* **Richard Anderson** FORRENIEN **Marcelle Cedars Melanie Davies Carolyn Ee Claus Højbjerg Gravholt** Sophia Kalantaridou Amanda Kallen **Micheline Misrahi Rossella Nappi** Walter A. Rocca **Xiangyan Ruan Helena Teede Elinor Vogt Patient representatives Amy Bennie Kimberly Kim** Methodological support **Nathalie Vermeulen** Additional contributors **Rinky Giri** Ladan Yeganeh

7896

7897



7898 Annex 2 Abbreviations.

21OH-Ab	21-hydroxylase antibodies	HSCT	Hematopoietic stem cell transplantation
AFC	low antral follicle count	HSDD	hypoactive sexual desire disorder
AMH	Anti-Müllerian hormone	HT	Hormone therapy
AOA	anti-ovarian autoantibodies	Hx	Hysterectomy
AOR	adjusted odds ratio	LDL-C	low-density lipoprotein cholesterol
APS-1	autoimmune polyendocrine syndrome	LET	local estrogen therapy
ART	Assisted reproduction technologies	LVEJ	left ventricular ejaculatory function
ASI	aortic size index	MAC	Myeloablative conditioning regimen
ASM	appendicular skeletal muscle mass	MAR	Medically assisted reproduction
BMD	bone mineral density	MCI	mild cognitive impairment
BMI	body mass index	MD	mean difference
BP	Blood pressure	MPA	medroxyprogesterone acetate
BPA	bisphenol A	MRI	magnetic resonance imaging
BSO	bilateral salpingo-oophorectomy	NGS	Next generation sequencing
BTM	bone turnover markers	OR	Odds ratio
CAD	coronary artery disease	PCBs	polychlorinated biphenyls
CBT		PCBS	Polymerase Chain Reaction
CDI	cognitive behavioural therapy	PCK	
CEE	Conjugated equine estrogens	PFASs	perfluoroalkyl and polyfluoroalkyl substances
COC	combined oral contraceptive pil	PFS	progression-free survival
CVD	cardiovascular disease	POI	Premature ovarian Insufficiency
DDT	dichlorodiphenyltrichloroethane	POPs	Persistent organic pollutants
DHEA	Dehydroepiandrosterone	PR	progesterone receptor
DOR	diminished ovarian reserve	QoL	quality of life
DXA	Dual-Energy X-ray Absorptiometry	RCT	RCT
E2	estradiol	RIA	Radio-Ligand Binding Assay
EDC	endocrine disrupting chemicals	RR	Relative risk
EE	estrogen ethinylestradiol	RRBSO	Risk reducing BSO
ELISA	Enzyme-linked immunosorbent assay	RT	radiotherapy
EMBx	endomyocardial biopsy	SCA	Steroid-cell autoantibodies
ER	estrogen receptor	SERMs	Selective estrogen receptor modulato
ERT	estrogen replacement therapy	SHBG	
	Fragile X mental retardation 1 gene		sex hormone binding globulin
FMR1		SLE	systemic lupus erythematosus
FRAX	Fragile X premutation	SMD	Standardised mean difference
FSFI	Female Sexual Function Index	SNRIs	serotonin-norepinephrine reuptake inhibitor
FSH	Follicle stimulating hormone	SOC	serous ovarian cancer
FSIAD	female sexual interest and arousal disorder	SSRIs	selective serotonin reuptake inhibitors
FTAS	Fragile X-associated tremor/ataxia syndrome	SUI	stress urinary incontinence (SUI)
FXPOI	Fragile X-associated POI	ТС	total cholesterol
TXI OI	Fragile X syndrome	TPO Abs	Thyroid peroxidase autoantibodies
FXTAS	Fragile X-associated tremor/ataxia	TS	Turner Syndrome
~~~	syndrome	TVC	Tripple V augurant-
GH	growth hormone	TXS	Tripple X syndrome
SSM	genitourinary syndrome of menopause	UAM	Usual age of menopause
HCP	health care providers	VHI	vaginal health index
HDL-C	high-density lipoprotein cholesterol	VVA	vulvovaginal atrophy
HOMA-IR	Homeostatic Model Assessment of Insulin Resistance	WES	whole exome sequencing
HPV	human papillomavirus	WGS	whole genome sequencing
HR	Hazard ratio	WHO	World Health Organization
HRQoL	health-related quality of life	WMD	weighted-mean difference
HRT	hormone replacement therapy		



## 7899 Annex 3 List of research recommendations.

7900 Risk factor, diagnosis and causation.

- Further research is required to (i) identify and clarify risk factors for POI, in addition to those related
   to early menopause, especially the role of socio-economic factors, lifestyle and environmental
   chemicals; and (ii) identify and quantify strategies that may mitigate modifiable risk factors.
- 79042.Further research is required to establish the optimal FSH criteria for the diagnosis of POI or a7905sensitive and specific alternative biomarker that is readily available.
- 7906 3. Ongoing research both in animal models and humans is required to identify additional genes
  7907 involved in POI and to allow uncovering of molecular defects in non-coding regions of known genes,
  7908 copy number variations and structural variations.
- 7909 4. Exploration of how genetic variants combine with environmental factors to determine the clinical
  7910 phenotype is also needed. This will markedly enhance the positivity of genetic testing, availability
  7911 of genetic testing and development of novel management strategies.
- 79125.Improvements in genetic sequencing techniques and interpretive approaches may provide a more7913precise determination of the mechanisms underlying ovarian dystunction, facilitate screening,7914diagnosis, and cost-effectiveness.
- 79156.Research into methods for reliable prediction of POI and monitoring of ovarian function in relatives7916of women with non-iatrogenic POI is needed. Further research into the outcomes of fertility7917preservation in the specific group of women with a family history of POI is indicated.

7918 Management

- Further research is required to (i) clarify fracture risk associated with POI and the effect of HT on 7919 7. this outcome; (ii) determine the best strategies for monitoring of bone health including screening 7920 7921 interval, role of bone turnover markers and newer imaging modalities; (iii) investigate the effect of exercise on muscle parameters and bone density in women with POI; (iv) clarify the role bone 7922 specific agents in managing POL associated osteoporosis; (v) clarify the changes in muscle mass and 7923 function associated with PQF, (vi) identify strategies for assessment and monitoring of muscle health 7924 in this population including defining sarcopenia; and (vii) examine the role of HT and other 7925 7926 strategies to maintain muscle health.
- 79278.There is a need for long term randomized prospective studies to determine the optimal routes,7928doses, and regimens of HT. In the absence of long-term randomized prospective data, treatment7929should be individualized and carefully monitored.
- 7930 9. QoL research is needed involving prospective studies with the use of comprehensive scale validated
  7931 in women with spontaneous and iatrogenic POI.
- 793210.The role of medical and psychological interventions in improving QoL should be implemented with7933the aid of adequate instruments developed in collaboration with women with POI of different7934aetiologies.
- 7935 11. Studies conducted in a multidimensional perspective are needed to assess sexual changes in women
  7936 with POI and the entity of distress.
- 793712. A process of care specifically developed for women with POI presenting sexual symptoms is7938warranted.
- 793913. A better understanding on the effects of different type and dose of systemic estrogens alone or in7940combination with specific progestogens on sexuality of POI is warranted.
- 794114.Studies should evaluate the safety of testosterone when applied for a longer period (more than 67942months) to improve sexual function in POI.



- 794315.More research is needed to understand the difference between iatrogenic and non-iatrogenic POI7944in terms of testosterone levels and testosterone treatments.
- 794516.More research conducted specifically in women with POI is needed on hormonal approaches for7946genitourinary symptoms.
- 7947 17. Studies should explore the efficacy and safety of laser therapy and other non-hormonal approaches
  7948 to relief genitourinary symptoms in women with POI, especially in those with contraindications to
  7949 vaginal estrogen.
- Research is needed to further clarify the pathogenetic mechanisms mediating the effects of POI,
  both non-iatrogenic and iatrogenic, on adverse neurological outcomes including cognitive decline
  and dementia. In addition, further research is needed to confirm the beneficial effects of ERT in
  women who underwent POI, both with and without menopausal symptoms.
- 795419.Due to limited evidence available for POI, ongoing research is essential to explore the specific effect7955of lifestyle interventions on the features of menopause, QoL and cardiovascular outcomes for7956women with this condition.
- 7957 Research concerning the optimal age for induction of puberty is still needed, with increased focus 20. on cognitive function, sexual function, uterine development, cardiovascular status, development of 7958 a normal body composition including bone acquisition and other areas. Likewise, there is a need to 7959 7960 establish the optimal route of delivery of first estradiol at escalating doses and then progesterone, when sequential therapy is needed. Establishing the long-term outcome of appropriate puberty 7961 induction using both a clinical and an epidemiological approach is also needed. The fundamental 7962 understanding of why POI develop in conditions like Turner syndrome remains an enigma and 7963 7964 should also be investigated.

RAFTEC

7965



## 7966 Annex 4 Methodology.

## 7967 Guideline development

European Society of Human Reproduction and Embryology (ESHRE) guidelines are developed based on the Manual for ESHRE guideline development (Vermeulen *et al.*, 2020), which can be consulted at the ESHRE website (www.eshre.eu/guidelines). The principal aim of this manual is to provide stepwise advice on ESHRE guideline development for members of ESHRE guideline development groups. The manual describes a 12-step procedure for writing clinical management guidelines by the guideline development group, supported by the ESHRE methodological expert (see Figure 12 Guideline development: 12-step procedure).

### 7975 **FIGURE 15 GUIDELINE DEVELOPMENT: 12-STEP PROCEDURE**



### 7976

The current guideline was developed with support of ESHRE, CREWhiRL, ASRM and IMS. The associations covered expenses associated with the guideline meetings (travel, hotel, and catering expenses) associated with the literature searches (library costs, costs associated with the retrieval of papers) and with the implementation of the guideline (printing, publication costs). Except for reimbursement of their travel expenses, guideline group members did not receive any payment for their participation in the guideline development process.

Once the ESHRE Executive Committee approved the guideline application and the guideline's scope, deliberations took place regarding the composition of the guideline group. Professionals with comprehensive expertise and diverse perspectives from ESHRE, CREWhiRL, ASRM and IMS were included in the guideline group, as well as patient representative. The ultimate goal was to achieve a well-rounded composition that encompassed a balanced representation of expertise, gender, and geographical location.

## 7989 Key Questions

- A meeting of the guideline development group was organised to discuss the key questions and redefine them through the PICO process (patients – interventions – comparison – outcome). The key questions drafted for the 2015/2016 guideline were re-used but modified according to progressive understanding and recent developments with regards to interventions for POI.
- The current guideline is structured around 38 key questions.

## 7995 Evidence search and synthesis.

Based on the defined key words for each of the key questions, literature searches were performed by the methodological expert (N. Vermeulen). Key words were sorted to importance and used for searches



in PUBMED/MEDLINE and the Cochrane library. We searched the databases from inception up toJanuary 30th, 2024.

8000 Literature searches were performed as an iterative process. In a first step, systematic reviews and meta-8001 analyses were collected. If no results were found, the search was extended to randomised controlled 8002 trials, and further to cohort studies and case reports, following the hierarchy of the levels of evidence. 8003 References were selected or excluded by the methodological expert and expert guideline group 8004 member based on title and abstract and knowledge of the existing literature. If necessary, additional 8005 searches were performed to get the final list of papers. The quality of the selected papers was assessed 8006 by means of the quality assessment checklist, defined in the ESHRE guideline manual. Next, the evidence 8007 was collected and summarised in an evidence table. The quality assessment and completion of evidence 8008 tables were performed by the expert guideline group members.

8009 Summary of findings tables are usually prepared according to the GRADE approach for all interventions 8010 with at least two studies (RCTs) per outcome. For the interventions in the current guideline, such 8011 evidence is not available, and hence no summary of findings tables were produced.

## 8012 **Recommendations**

8013 Guideline group meetings were organised to discuss the draft recommendations and the supporting 8014 evidence and to reach consensus on the final formulation of the recommendations.

8015 For each recommendation, it is mentioned whether it is strong or weak and what the quality of the 8016 supporting evidence was.



In the justification section, more data are provided on the interpretation of the supporting evidence and how other factors (i.e., balance between desirable and undesirable effects, certainty of the evidence of effects, certainty in how people value the outcome, and acceptability) were considered. Costs and resource impact were only discussed where relevant.

In a final step, all evidence and recommendations were combined in the ESHRE guideline: "Premature Ovarian Insufficiency".

### Implications of recommendations

We labelled the recommendations as either "strong" or "weak" according to the GRADE approach, with appropriate wording for each option. Suggested interpretation of strong and weak recommendations by patients, clinicians and health care policy makers is described in Figure 3.

8033 Good practice points (GPPs) are used to emphasize the importance of patient participation in decision 8034 making about specific procedure, provide advice on the management of specific surgical procedures 8035 for which there is an evidence-based recommendation, or advise caution where there is perceived risk 8036 of harm but no available direct evidence of such harms.

- 8037
- 8038
- 8039



#### 8040 **FIGURE 16 IMPLICATIONS OF THE STRENGTH OF THE RECOMMENDATIONS**



GOOD PRACTICE POINT Information of the advice of the GDG regarding a certain recommendation.

OTHER

RECOMMENDATIONS

#### RESEARCH-ONLY RECOMMENDATION

The test or intervention should only be considered within the setting of a research trial for which appropriate approvals and safety precautions have been established

#### 8041

## 8042 **Review of the Guideline draft**

After finalisation of the guideline draft, the review process was initiated. The draft guideline was published on the ESHRE website, accompanied by the reviewers' comments form and a short explanation of the review process. The guideline was open for review between 17 April and 27 May 2024.

## 8047 Guideline Implementation strategy

- 8048 The standard dissemination procedure for all ESHRE guidelines comprises publishing and 8049 announcement.
- Each guideline is published on the ESHRE Website. A summary of the recommendations will be published in Human Reproduction Open, and simultaneously in Fertility & Sterility and Climateric. Translation and resource development will be led by CRE WHIRL and modelled on the example of the
- 8053 international PCOS guideline (https://www.monash.edu/medicine/mchri/pcos/guideline).

## 8054 Schedule for updating the guideline.

- The current guideline will be considered for revision in 2028 (four years after publication). An intermediate search for new evidence will be performed two years after publication, which will inform the guideline group of the necessity of an update.
- Every care is taken to ensure that this publication is correct in every detail at the time of publication. However, in the event of errors or omissions, corrections will be published in the web version of this document, which is the definitive version at all times. This version can be found at www.eshre.eu/quidelines.
- 8062 For more details on the methodology of ESHRE guidelines, visit www.eshre.eu/guidelines





8093 Copyright © European Society of Human Reproduction and Embryology - All rights reserved The 8094 content of these ESHRE guidelines has been published for personal and educational use only. No 8095 commercial use is authorised. No part of the ESHRE guidelines may be translated or reproduced in any 8096 form without prior written permission of the ESHRE communications manager.